[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fkMfx-_d3Y6qqBXNUqppcKkP3Oyta_3aI1toSu63bphI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":88,"rows":95},"Bayer",[4],1664,false,85,322,24903250,72,119,[14,17,20,23,26,28,31,34],{"name":15,"count":16},"Contraception",81,{"name":18,"count":19},"Sunscreening Agents",52,{"name":21,"count":22},"Atrial Fibrillation",51,{"name":24,"count":25},"Hemophilia A",48,{"name":27,"count":25},"Erectile Dysfunction",{"name":29,"count":30},"Neoplasms",44,{"name":32,"count":33},"Chronic Kidney Disease",33,{"name":35,"count":36},"Multiple Sclerosis",31,[38,43,48,53,58,63,68,73,78,83],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT02185560","Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib","2020-02-27","Sorafenib",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT02562235","Riociguat in Children With Pulmonary Arterial Hypertension (PAH)","2020-03-07","Riociguat",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT05587296","A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer","2024-01-29","Elinzanetant",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT02637687","A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children","2024-07-20","Larotrectinib",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT06608212","An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States","2025-03-31","Finerenone",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT05059236","A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.","2025-05-30","Darolutamide",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT04597125","RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)","2025-11-21","Radium-223 dichloride",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT06117891","An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery","2025-12-10","Atezolizumab",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT05705258","A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)","2026-02-06","Aflibercept",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT05614102","A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors","2026-05-21","BAY2965501",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,329,364,387,700,982,1080,1252,1340,1375,1397,1433,1458,1476,1775,1812,1892,1918,1976,2001,2026,2050,2075,2093,2111,2137,2161,2580,2613,2643,2661,2687,2713,2731,2749,2767,2790,2808,2832,2859,2885,2903,3318,3392,3541,4465,4528,4561,5041,5156,5218,5285,5319,5349,5381,5426,5456,5484,5506,5534,5559,5580,5604,5622,5640,5663,5689,5712,5730,5748,5766,5784,5802,5897,5953,6016,6054,6098,6132,6177,6209,6255,6293,6331,6369,6409,6453,6478,6509,6545,6579,6606,6639,6664,6699,6723,6746,6764,6786,6804,6827,6851,6869,6893,6915,6938,6956,6983,7001,7026,7044,7067,7089,7107,7130,7148,7171,7196,7214,7232,7256,7278,7296,7318,7343,7361,7379,7401,7419,7442,7465,7483,7508,7526,7544,7567,7585,7603,7625,7643,7661,7679,7697,7715,7733,7751,7873,7939,8002,8063,8125,8177,8228,8273,8308,8363,8399,8438,8488,8530,8567,8605,8631,8681,8707,8736,8758,8790,8812,8834,8863,8896,8925,8947,8978,9009,9043,9070,9100,9129,9161,9193,9226,9255,9277,9305,9332,9350,9374,9392,9414,9437,9455,9480,9498,9516,9538,9556,9574,9595,9613,9631,9649,9674,9700,9718,9736,9758,9779,9801,9819,9840,9863,9881,9903,9921,9942,9967,9985,10010,10032,10050,10073,10097,10115,10133,10151,10176,10194,10217,10235,10260,10281,10304,10322,10340,10358,10376,10394,10416,10434,10452,10470,10488,10511,10529,10547,10571,10589,10611,10629,10652,10670,10688,10706,10724,10742,10768,10786,10804,10828,10846,10864,10882,10900,10925,10943,10965,10987,11005,11028,11050,11068,11086,11111,11129,11152,11170,11188,11206,11224,11247,11265,11283,11306,11324,11347,11365,11390,11414,11439,11457,11475,11493,11511,11529,11552,11575,11593,11611,11633,11657,11675,11697,11715,11737,11760,11778,11800,11823,11846,11870,11888,11906,11924,11942,11960,11984,12002,12027,12045,12063,12085,12103,12121,12139,12165,12190,12208,12230,12248,12266,12288,12312,12330,12353,12376,12394,12412,12430,12448,12475,12493,12617,12705,12763,12824,12871,12920,12977,13028,13077,13120,13174,13216,13265,13299,13334,13370,13412,13453,13494,13535,13572,13614,13656,13695,13723,13745,13767,13795,13825,13853,13875,13905,13935,13964,13991,14021,14050,14080,14102,14132,14154,14177,14195,14213,14231,14249,14271,14289,14307,14332,14353,14382,14400,14418,14436,14454,14472,14490,14508,14526,14544,14567,14588,14609,14635,14653,14671,14689,14711,14729,14751,14776,14794,14817,14839,14860,14883,14901,14919,14937,14955,14976,14994,15016,15034,15052,15079,15100,15121,15139,15163,15187,15210,15228,15246,15264,15287,15308,15326,15351,15369,15390,15415,15433,15458,15476,15500,15518,15536,15558,15582,15606,15628,15646,15669,15687,15705,15723,15741,15759,15783,15807,15825,15847,15865,15888,15906,15927,15948,15971,15989,16012,16030,16048,16066,16088,16111,16135,16153,16171,16189,16207,16225,16246,16273,16291,16312,16336,16359,16377,16398,16422,16440,16462,16486,16504,16522,16543,16570,16588,16606,16624,16642,16666,16684,16702,16720,16738,16756,16778,16800,16859,16906,16959,16993,17036,17078,17116,17147,17183,17218,17254,17287,17317,17349,17371,17398,17427,17459,17491,17524,17546,17568,17600,17622,17644,17670,17692,17722,17749,17787,17815,17846,17868,17898,17921,17939,17957,17975,17998,18016,18039,18062,18080,18098,18122,18140,18158,18176,18198,18216,18237,18258,18281,18299,18323,18345,18363,18381,18399,18424,18447,18465,18483,18507,18532,18550,18572,18590,18608,18626,18648,18674,18692,18710,18728,18753,18771,18789,18812,18830,18848,18866,18890,18911,18934,18952,18970,18991,19009,19032,19050,19068,19089,19107,19128,19146,19172,19190,19208,19231,19249,19273,19300,19318,19341,19359,19377,19407,19425,19443,19461,19479,19497,19515,19533,19551,19576,19594,19612,19630,19648,19666,19687,19711,19729,19754,19772,19790,19812,19834,19862,19880,19898,19916,19934,19952,19976,19994,20012,20030,20048,20066,20084,20106,20124,20142,20168,20186,20208,20226,20248,20266,20284,20307,20325,20349,20367,20390,20408,20426,20444,20462,20480,20498,20516,20534,20557,20575,20601,20619,20637,20655,20677,20695,20717,20742,20760,20778,20804,20822,20840,20864,20882,20900,20921,20944,20968,20986,21004,21022,21040,21058,21076,21094,21116,21134,21158,21176,21200,21218,21240,21261,21284,21308,21332,21354,21372,21390,21408,21432,21450,21474,21492,21513,21535,21553,21571,21594,21615,21638,21659,21677,21700,21718,21736,21754,21772,21790,21808,21826,21847,21870,21888,21913,21931,21949,21967,21991,22009,22027,22045,22063,22081,22099,22121,22139,22160,22178,22196,22219,22237,22255,22280,22298,22316,22334,22355,22382,22400,22418,22436,22454,22479,22497,22519,22537,22561,22582,22841,23071,23263,23430,23612,23772,23909,24039,24147,24223,24324,24410,24504,24572,24662,24759,24845,24924,25001,25082,25165,25232,25302,25379,25431,25502,25553,25620,25674,25730,25784,25818,25870,25916,25962,26006,26064,26120,26150,26193,26227,26268,26308,26339,26376,26406,26432,26475,26511,26551,26577,26615,26656,26699,26731,26765,26803,26825,26850,26872,26903,26935,26957,26979,27001,27023,27050,27075,27097,27126,27161,27185,27207,27240,27267,27294,27321,27352,27381,27408,27436,27466,27496,27525,27547,27570,27588,27606,27624,27642,27665,27688,27706,27727,27745,27763,27784,27807,27829,27852,27873,27891,27916,27934,27957,27978,28001,28019,28041,28059,28077,28095,28113,28136,28154,28177,28195,28218,28236,28254,28272,28290,28308,28334,28352,28370,28388,28406,28429,28452,28475,28498,28524,28548,28570,28595,28620,28638,28656,28674,28696,28718,28743,28764,28782,28800,28818,28842,28860,28885,28903,28921,28939,28957,28975,28993,29011,29029,29047,29071,29093,29115,29138,29164,29186,29207,29228,29252,29270,29294,29312,29334,29357,29375,29393,29415,29443,29461,29479,29497,29515,29533,29551,29575,29599,29621,29639,29662,29680,29702,29723,29745,29768,29786,29808,29830,29852,29875,29896,29914,29937,29959,29977,30001,30021,30045,30069,30087,30110,30133,30151,30174,30196,30218,30242,30267,30297,30315,30333,30351,30369,30387,30409,30427,30445,30463,30485,30509,30533,30556,30574,30596,30617,30635,30653,30671,30693,30716,30738,30756,30774,30795,30813],{"intervention":67,"totalTrials":97,"cells":98},20,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":129,"PHASE3":176,"PHASE4":221,"NA":234},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[104,117],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"primaryCompletion":109,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":115},"NCT03724747","Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer","COMPLETED",[90],"2022-08-25","2024-10-31","2018-12-18",63,[114],"Metastatic Castration Resistant Prostate Cancer (mCRPC)",[116,67],"BAY2315497",{"nctId":118,"briefTitle":119,"status":107,"phases":120,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":125,"interventions":127},"NCT03704519","Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers.",[90],"2019-10-01","2019-11-05","2018-10-23",26,[126],"Cerebrovascular Circulation",[67,128],"Enzalutamide",{"trials":130,"activeCount":175,"soonestReadout":66},[131,140,153,164],{"nctId":64,"briefTitle":65,"status":132,"phases":133,"primaryCompletion":66,"completion":134,"start":135,"enrollment":136,"conditions":137,"interventions":139},"ACTIVE_NOT_RECRUITING",[91],"2026-06-05","2021-11-04",223,[138],"Metastatic Hormone-sensitive Prostate Cancer",[67],{"nctId":141,"briefTitle":142,"status":143,"phases":144,"primaryCompletion":145,"completion":146,"start":147,"enrollment":148,"conditions":149,"interventions":151},"NCT07450599","A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.","RECRUITING",[91],"2028-06-15","2030-10-15","2026-04-27",250,[150],"High-Risk Localized Prostate Cancer",[67,152],"ADT",{"nctId":154,"briefTitle":155,"status":156,"phases":157,"primaryCompletion":158,"completion":158,"start":159,"enrollment":160,"conditions":161,"interventions":163},"NCT04157088","Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)","TERMINATED",[91],"2022-07-08","2019-12-17",30,[162],"Prostatic Cancer, Castration-Resistant",[67,128],{"nctId":165,"briefTitle":166,"status":107,"phases":167,"primaryCompletion":168,"completion":169,"start":170,"enrollment":171,"conditions":172,"interventions":174},"NCT05526248","A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide",[91],"2024-08-20","2024-12-04","2022-12-19",28,[173],"Biochemically Recurrent Prostate Cancer",[67,128],2,{"trials":177,"activeCount":175,"soonestReadout":205},[178,189,201,211],{"nctId":179,"briefTitle":180,"status":107,"phases":181,"primaryCompletion":182,"completion":183,"start":184,"enrollment":185,"conditions":186,"interventions":188},"NCT04736199","Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer",[92],"2024-06-07","2026-01-23","2021-02-23",669,[187],"Prostatic Neoplasms",[67],{"nctId":190,"briefTitle":191,"status":107,"phases":192,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":197,"interventions":200},"NCT02200614","Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer",[92],"2018-09-03","2021-06-14","2014-09-12",1509,[198,199],"Prostate Cancer Non-Metastatic","Castration-Resistant",[67],{"nctId":202,"briefTitle":203,"status":132,"phases":204,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":209,"interventions":210},"NCT05794906","A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies",[92],"2027-07-30","2030-03-29","2023-04-03",985,[173],[67],{"nctId":212,"briefTitle":213,"status":132,"phases":214,"primaryCompletion":215,"completion":215,"start":216,"enrollment":217,"conditions":218,"interventions":220},"NCT04464226","Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer",[92],"2028-06-26","2020-10-20",402,[219],"Cancer",[67],{"trials":222,"activeCount":233,"soonestReadout":227},[223],{"nctId":224,"briefTitle":225,"status":143,"phases":226,"primaryCompletion":227,"completion":227,"start":228,"enrollment":229,"conditions":230,"interventions":232},"NCT05348876","A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)",[93],"2027-04-29","2022-08-03",50,[231],"Non-metastatic Castration-resistant Prostate Cancer",[67],1,{"trials":235,"activeCount":328,"soonestReadout":283},[236,248,259,269,279,289,299,309,319],{"nctId":237,"briefTitle":238,"status":132,"phases":239,"primaryCompletion":240,"completion":241,"start":242,"enrollment":243,"conditions":244,"interventions":246},"NCT07344779","A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice",[],"2027-12-31","2030-06-30","2026-01-29",1600,[245],"Metastatic Hormone-Sensitive Prostate Cancer",[67,152,247],"Docetaxel",{"nctId":249,"briefTitle":250,"status":251,"phases":252,"primaryCompletion":253,"completion":254,"start":255,"enrollment":256,"conditions":257,"interventions":258},"NCT07538843","An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT Treatment","NOT_YET_RECRUITING",[],"2029-11-01","2030-01-30","2026-06-01",800,[231],[67,152],{"nctId":260,"briefTitle":261,"status":107,"phases":262,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":266,"interventions":267},"NCT05362149","An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings",[],"2023-06-30","2022-04-04",870,[231],[67,128,268],"Apalutamide",{"nctId":270,"briefTitle":271,"status":107,"phases":272,"primaryCompletion":273,"completion":273,"start":274,"enrollment":275,"conditions":276,"interventions":278},"NCT06204302","An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States",[],"2024-04-04","2024-01-05",1800,[277,231],"Non-metastatic Prostate Cancer",[67,128,268],{"nctId":280,"briefTitle":281,"status":143,"phases":282,"primaryCompletion":283,"completion":283,"start":284,"enrollment":285,"conditions":286,"interventions":287},"NCT07406282","A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics",[],"2026-05-31","2025-07-22",1400,[187,245],[67,288,128,268],"Abiraterone acetate",{"nctId":290,"briefTitle":291,"status":143,"phases":292,"primaryCompletion":293,"completion":294,"start":295,"enrollment":296,"conditions":297,"interventions":298},"NCT06334120","An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea",[],"2028-03-31","2028-06-30","2024-09-25",600,[231,138],[67],{"nctId":300,"briefTitle":301,"status":107,"phases":302,"primaryCompletion":303,"completion":303,"start":304,"enrollment":305,"conditions":306,"interventions":308},"NCT05202301","A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely",[],"2025-07-15","2022-01-15",13779,[307],"Prostate Cancer",[67,128,268],{"nctId":310,"briefTitle":311,"status":107,"phases":312,"primaryCompletion":313,"completion":314,"start":315,"enrollment":316,"conditions":317,"interventions":318},"NCT06013475","An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings",[],"2024-06-28","2024-10-28","2023-08-31",1375,[231],[268,67,128],{"nctId":320,"briefTitle":321,"status":132,"phases":322,"primaryCompletion":323,"completion":323,"start":324,"enrollment":325,"conditions":326,"interventions":327},"NCT04122976","A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described",[],"2026-12-30","2020-01-30",805,[307],[67],5,{"intervention":330,"totalTrials":175,"cells":331},"Acoramidis",{"EARLY_PHASE1":332,"PHASE1":334,"PHASE2":336,"PHASE3":338,"PHASE4":340,"NA":351},{"trials":333,"activeCount":101},[],{"trials":335,"activeCount":101},[],{"trials":337,"activeCount":101},[],{"trials":339,"activeCount":101},[],{"trials":341,"activeCount":233,"soonestReadout":346},[342],{"nctId":343,"briefTitle":344,"status":143,"phases":345,"primaryCompletion":346,"completion":346,"start":347,"enrollment":229,"conditions":348,"interventions":350},"NCT07298044","A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis",[93],"2027-12-25","2026-02-13",[349],"Transthyretin Amyloid Cardiomyopathy",[330],{"trials":352,"activeCount":233,"soonestReadout":357},[353],{"nctId":354,"briefTitle":355,"status":143,"phases":356,"primaryCompletion":357,"completion":358,"start":359,"enrollment":360,"conditions":361,"interventions":363},"NCT07235462","A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting",[],"2028-04-30","2028-07-03","2025-10-29",2000,[362],"Transthyretin Amyloid Cardiomyopathy (ATTR-CM)",[330],{"intervention":365,"totalTrials":233,"cells":366},"ARPI therapy",{"EARLY_PHASE1":367,"PHASE1":369,"PHASE2":371,"PHASE3":373,"PHASE4":375,"NA":385},{"trials":368,"activeCount":101},[],{"trials":370,"activeCount":101},[],{"trials":372,"activeCount":101},[],{"trials":374,"activeCount":101},[],{"trials":376,"activeCount":233,"soonestReadout":71},[377],{"nctId":69,"briefTitle":70,"status":132,"phases":378,"primaryCompletion":71,"completion":379,"start":380,"enrollment":381,"conditions":382,"interventions":384},[93],"2026-10-12","2020-11-09",654,[383],"Metastatic Castrate Resistant Prostate Cancer (mCRPC)",[72,365],{"trials":386,"activeCount":101},[],{"intervention":72,"totalTrials":160,"cells":388},{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":426,"PHASE3":554,"PHASE4":598,"NA":604},{"trials":390,"activeCount":101},[],{"trials":392,"activeCount":101},[393,404,414],{"nctId":394,"briefTitle":395,"status":107,"phases":396,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":401,"interventions":403},"NCT04521361","A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones",[90],"2023-10-10","2025-08-27","2020-11-16",46,[402],"Bone Metastatic Castration-resistant Prostate Cancer",[72],{"nctId":405,"briefTitle":406,"status":107,"phases":407,"primaryCompletion":408,"completion":409,"start":410,"enrollment":411,"conditions":412,"interventions":413},"NCT01565746","Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients",[90],"2012-10","2016-04","2012-03",19,[187],[72,72,72],{"nctId":415,"briefTitle":416,"status":156,"phases":417,"primaryCompletion":418,"completion":419,"start":420,"enrollment":421,"conditions":422,"interventions":424},"NCT03996473","Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases",[90],"2021-04-14","2023-01-30","2020-03-06",8,[423],"Carcinoma, Non-Small-Cell Lung",[72,425],"Pembrolizumab",{"trials":427,"activeCount":101},[428,440,452,461,474,483,494,503,513,525,535,544],{"nctId":429,"briefTitle":430,"status":107,"phases":431,"primaryCompletion":432,"completion":433,"start":434,"enrollment":435,"conditions":436,"interventions":439},"NCT00667199","BAY88-8223, Does Response Study in HRPC Patients",[91],"2008-04-01","2009-10-06","2005-05-30",100,[437,438],"Hormone Refractory Prostate Cancer","Bone Metastases",[72],{"nctId":441,"briefTitle":442,"status":107,"phases":443,"primaryCompletion":444,"completion":445,"start":446,"enrollment":447,"conditions":448,"interventions":450},"NCT00459654","A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer",[91],"2006-05","2007-05","2004-02",64,[307,449],"Neoplasm Metastasis",[72,451],"Saline",{"nctId":453,"briefTitle":454,"status":107,"phases":455,"primaryCompletion":456,"completion":456,"start":457,"enrollment":458,"conditions":459,"interventions":460},"NCT01929655","Japanese BAY88-8223 Monotherapy Phase II Study",[91],"2017-05-16","2013-09-30",49,[187],[72],{"nctId":462,"briefTitle":463,"status":464,"phases":465,"primaryCompletion":466,"completion":467,"start":468,"enrollment":101,"conditions":469,"interventions":471},"NCT02605356","Phase 1b\u002F2 Study Testing Radium-223 Dichloride\u002FBortezomib\u002FDexamethasone Combination in Relapsed Multiple Myeloma","WITHDRAWN",[90,91],"2019-11","2021-07","2016-10",[470],"Multiple Myeloma",[72,472,473],"Bortezomib","Dexamethasone",{"nctId":475,"briefTitle":476,"status":156,"phases":477,"primaryCompletion":478,"completion":478,"start":479,"enrollment":480,"conditions":481,"interventions":482},"NCT02928029","Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma",[90,91],"2019-03-20","2017-02-10",7,[470],[72,472,473],{"nctId":484,"briefTitle":485,"status":107,"phases":486,"primaryCompletion":487,"completion":488,"start":489,"enrollment":490,"conditions":491,"interventions":492},"NCT02034552","A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)",[91],"2016-07-15","2018-06-26","2014-03-07",68,[187],[72,288,493,128],"Prednisone",{"nctId":495,"briefTitle":496,"status":107,"phases":497,"primaryCompletion":498,"completion":499,"start":444,"enrollment":500,"conditions":501,"interventions":502},"NCT00337155","BAY88-8223, Dose Finding Study in Patients With HRPC",[91],"2008-12","2009-12",122,[307,449],[72],{"nctId":504,"briefTitle":505,"status":107,"phases":506,"primaryCompletion":507,"completion":508,"start":509,"enrollment":510,"conditions":511,"interventions":512},"NCT01934790","Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases",[90,91],"2015-06-04","2017-04-12","2013-12-22",45,[187],[72],{"nctId":514,"briefTitle":515,"status":107,"phases":516,"primaryCompletion":517,"completion":518,"start":507,"enrollment":519,"conditions":520,"interventions":522},"NCT02258451","Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer",[91],"2020-01-22","2022-10-28",283,[521],"Breast Neoplasms",[72,523,524],"Exemestane","Everolimus",{"nctId":526,"briefTitle":527,"status":107,"phases":528,"primaryCompletion":529,"completion":530,"start":531,"enrollment":532,"conditions":533,"interventions":534},"NCT02023697","Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone",[91],"2017-03-01","2018-08-09","2014-03-10",391,[187],[72],{"nctId":536,"briefTitle":537,"status":156,"phases":538,"primaryCompletion":539,"completion":539,"start":540,"enrollment":541,"conditions":542,"interventions":543},"NCT02258464","Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer",[91],"2019-08-13","2015-03-02",99,[521],[72],{"nctId":545,"briefTitle":546,"status":107,"phases":547,"primaryCompletion":548,"completion":548,"start":549,"enrollment":550,"conditions":551,"interventions":553},"NCT01106352","A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)",[90,91],"2015-06","2010-07",70,[438,552],"Castration-Resistant Prostate Cancer",[72,247],{"trials":555,"activeCount":101},[556,567,576,588],{"nctId":557,"briefTitle":558,"status":107,"phases":559,"primaryCompletion":560,"completion":561,"start":562,"enrollment":563,"conditions":564,"interventions":565},"NCT00699751","A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases",[92],"2011-07-15","2014-02-13","2008-06-12",921,[437,438],[72,566],"Best standard of care",{"nctId":568,"briefTitle":569,"status":107,"phases":570,"primaryCompletion":571,"completion":571,"start":572,"enrollment":573,"conditions":574,"interventions":575},"NCT01810770","Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis",[92],"2017-09-25","2013-03-26",243,[187],[72],{"nctId":577,"briefTitle":578,"status":107,"phases":579,"primaryCompletion":580,"completion":581,"start":582,"enrollment":583,"conditions":584,"interventions":585},"NCT02043678","Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms",[92],"2018-02-15","2024-02-08","2014-03-30",806,[187],[72,586,587],"Abiraterone","Prednisone\u002FPrednisolone",{"nctId":589,"briefTitle":590,"status":107,"phases":591,"primaryCompletion":592,"completion":593,"start":594,"enrollment":595,"conditions":596,"interventions":597},"NCT01618370","Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases",[92],"2014-08-13","2016-02-28","2012-07-22",705,[187],[72],{"trials":599,"activeCount":233,"soonestReadout":71},[600],{"nctId":69,"briefTitle":70,"status":132,"phases":601,"primaryCompletion":71,"completion":379,"start":380,"enrollment":381,"conditions":602,"interventions":603},[93],[383],[72,365],{"trials":605,"activeCount":101},[606,617,628,636,645,654,663,674,684,691],{"nctId":607,"briefTitle":608,"status":107,"phases":609,"primaryCompletion":610,"completion":610,"start":611,"enrollment":612,"conditions":613,"interventions":615},"NCT04256993","PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn",[],"2021-06-01","2020-02-15",1434,[614],"Metastatic Castration-Resistant Prostate Cancer",[72,616],"Other standard care",{"nctId":618,"briefTitle":619,"status":107,"phases":620,"primaryCompletion":621,"completion":622,"start":623,"enrollment":624,"conditions":625,"interventions":627},"NCT02141438","Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer",[],"2024-08-02","2024-10-24","2014-08-20",1472,[626],"Metastatic Castration-resistant Prostate Cancer",[72],{"nctId":629,"briefTitle":630,"status":156,"phases":631,"primaryCompletion":632,"completion":263,"start":633,"enrollment":421,"conditions":634,"interventions":635},"NCT05301062","A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels",[],"2023-04-28","2022-09-15",[626,438],[72],{"nctId":637,"briefTitle":638,"status":107,"phases":639,"primaryCompletion":640,"completion":640,"start":641,"enrollment":642,"conditions":643,"interventions":644},"NCT04281147","Study to Gather Information About the Use of Healthcare Services and the Way the Disease is Cared for in Canadian Patients With Prostate Gland Cancer Which Spread Throughout the Body",[],"2021-06-22","2020-02-24",4301,[307],[72],{"nctId":646,"briefTitle":647,"status":107,"phases":648,"primaryCompletion":649,"completion":649,"start":650,"enrollment":651,"conditions":652,"interventions":653},"NCT02518698","Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population",[],"2017-09-30","2015-08-31",1163,[307],[72],{"nctId":655,"briefTitle":656,"status":107,"phases":657,"primaryCompletion":658,"completion":658,"start":659,"enrollment":660,"conditions":661,"interventions":662},"NCT04516161","EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)",[],"2021-03-31","2020-08-03",1180,[114],[72],{"nctId":664,"briefTitle":665,"status":107,"phases":666,"primaryCompletion":667,"completion":668,"start":669,"enrollment":670,"conditions":671,"interventions":673},"NCT02803437","Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases",[],"2022-01-06","2024-12-18","2016-07-21",334,[672],"Prostatic Neoplasms, Castration-Resistant",[72],{"nctId":675,"briefTitle":676,"status":107,"phases":677,"primaryCompletion":678,"completion":678,"start":679,"enrollment":680,"conditions":681,"interventions":683},"NCT04232761","Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone",[],"2024-04-29","2020-07-07",194,[682],"Castration-resistant Prostate Cancer",[72],{"nctId":685,"briefTitle":686,"status":687,"phases":688,"conditions":689,"interventions":690},"NCT01516762","Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases","NO_LONGER_AVAILABLE",[],[187],[72],{"nctId":692,"briefTitle":693,"status":107,"phases":694,"primaryCompletion":695,"completion":696,"start":697,"enrollment":8,"conditions":698,"interventions":699},"NCT03315260","Treatment Satisfaction With Ra-223 in Japan",[],"2022-12-01","2023-03-20","2019-04-11",[187],[72],{"intervention":62,"totalTrials":701,"cells":702},27,{"EARLY_PHASE1":703,"PHASE1":705,"PHASE2":727,"PHASE3":762,"PHASE4":856,"NA":867},{"trials":704,"activeCount":101},[],{"trials":706,"activeCount":101},[707,718],{"nctId":708,"briefTitle":709,"status":107,"phases":710,"primaryCompletion":711,"completion":712,"start":713,"enrollment":701,"conditions":714,"interventions":717},"NCT04881994","A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution",[90],"2014-09-16","2014-12-08","2014-03-25",[715,716],"Worsening Chronic Heart Failure","Diabetic Nephropathy",[62],{"nctId":719,"briefTitle":720,"status":107,"phases":721,"primaryCompletion":722,"completion":723,"start":724,"enrollment":33,"conditions":725,"interventions":726},"NCT04908436","A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution",[90],"2011-05-05","2012-01-27","2010-10-27",[715,32],[62],{"trials":728,"activeCount":101},[729,741,751],{"nctId":730,"briefTitle":731,"status":107,"phases":732,"primaryCompletion":733,"completion":734,"start":735,"enrollment":736,"conditions":737,"interventions":739},"NCT01807221","Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone",[91],"2014-11-11","2014-12-09","2013-06-17",1066,[738],"Heart Failure",[62,740],"Inspra",{"nctId":742,"briefTitle":743,"status":107,"phases":744,"primaryCompletion":745,"completion":745,"start":746,"enrollment":747,"conditions":748,"interventions":750},"NCT05013008","An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants",[91],"2021-12-31","2021-08-18",951,[32,749],"Type 2 Diabetes Mellitus",[62],{"nctId":752,"briefTitle":753,"status":107,"phases":754,"primaryCompletion":755,"completion":756,"start":757,"enrollment":758,"conditions":759,"interventions":761},"NCT01874431","Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy",[91],"2014-07-09","2014-08-07","2013-06-12",823,[760],"Diabetic Nephropathies",[62],{"trials":763,"activeCount":855,"soonestReadout":768},[764,775,786,798,809,819,827,837,845],{"nctId":765,"briefTitle":766,"status":143,"phases":767,"primaryCompletion":768,"completion":769,"start":770,"enrollment":771,"conditions":772,"interventions":774},"NCT05196035","A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria",[92],"2027-07-31","2027-08-31","2022-03-28",219,[32,773],"Proteinuria",[62],{"nctId":776,"briefTitle":777,"status":107,"phases":778,"primaryCompletion":779,"completion":780,"start":781,"enrollment":782,"conditions":783,"interventions":785},"NCT05901831","A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes",[92],"2025-08-20","2025-09-15","2024-02-26",241,[32,784],"Type 1 Diabetes Mellitus",[62],{"nctId":787,"briefTitle":788,"status":143,"phases":789,"primaryCompletion":790,"completion":791,"start":792,"enrollment":793,"conditions":794,"interventions":797},"NCT07188805","A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction",[92],"2029-11-30","2029-12-30","2025-11-19",111,[795,796],"Left Ventricular Systolic Dysfunction","Heart Failure (Pediatric)",[62],{"nctId":799,"briefTitle":800,"status":107,"phases":801,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":806,"interventions":808},"NCT05047263","A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease",[92],"2025-12-31","2026-02-02","2021-09-21",1584,[807],"Non-diabetic Chronic Kidney Disease",[62],{"nctId":810,"briefTitle":811,"status":107,"phases":812,"primaryCompletion":813,"completion":813,"start":814,"enrollment":815,"conditions":816,"interventions":818},"NCT02545049","Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease",[92],"2021-02-02","2015-09-17",7352,[817],"Diabetic Kidney Disease",[62],{"nctId":820,"briefTitle":821,"status":107,"phases":822,"primaryCompletion":823,"completion":823,"start":814,"enrollment":824,"conditions":825,"interventions":826},"NCT02540993","Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease",[92],"2020-04-14",5734,[32],[62],{"nctId":828,"briefTitle":829,"status":143,"phases":830,"primaryCompletion":831,"completion":832,"start":833,"enrollment":435,"conditions":834,"interventions":836},"NCT05457283","A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria",[92],"2029-01-28","2029-02-27","2022-11-08",[32,773,835],"Children",[62],{"nctId":838,"briefTitle":839,"status":251,"phases":840,"primaryCompletion":841,"completion":841,"start":255,"enrollment":842,"conditions":843,"interventions":844},"NCT07192952","A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction",[92],"2030-12-30",117,[795,796],[62],{"nctId":846,"briefTitle":847,"status":107,"phases":848,"primaryCompletion":849,"completion":850,"start":851,"enrollment":852,"conditions":853,"interventions":854},"NCT04435626","Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%",[92],"2024-05-15","2024-06-14","2020-09-14",6016,[738],[62],4,{"trials":857,"activeCount":101},[858],{"nctId":859,"briefTitle":860,"status":107,"phases":861,"primaryCompletion":862,"completion":862,"start":863,"enrollment":864,"conditions":865,"interventions":866},"NCT05705271","A Study to Learn How Safe the Study Drug Finerenone is and How Well it Works in Indian People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 2 Diabetes Mellitus",[93],"2025-07-03","2023-02-08",200,[32,749],[62],{"trials":868,"activeCount":328,"soonestReadout":61},[869,877,887,896,905,914,927,936,947,954,961,970],{"nctId":870,"briefTitle":871,"status":251,"phases":872,"primaryCompletion":873,"completion":873,"start":283,"enrollment":874,"conditions":875,"interventions":876},"NCT07554469","An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score",[],"2029-04-30",500,[32,749],[62],{"nctId":878,"briefTitle":879,"status":107,"phases":880,"primaryCompletion":881,"completion":881,"start":882,"enrollment":883,"conditions":884,"interventions":885},"NCT05552339","A Study Called SMART-Finder to Look for People With Increased Amounts of Albumin in the Urine (UACR Level) in a Group of Type 2 Diabetes Mellitus Patients",[],"2025-11-18","2023-08-18",348,[749,32],[62,886],"Type 2 DM drugs",{"nctId":888,"briefTitle":889,"status":107,"phases":890,"primaryCompletion":891,"completion":891,"start":892,"enrollment":893,"conditions":894,"interventions":895},"NCT05703880","An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions",[],"2024-10-01","2023-06-01",15948,[32,749],[62],{"nctId":897,"briefTitle":898,"status":107,"phases":899,"primaryCompletion":900,"completion":900,"start":901,"enrollment":902,"conditions":903,"interventions":904},"NCT07124039","An Observational Study Called FIRST-2.0 China to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions in a Chinese Population.",[],"2026-02-28","2025-07-16",6537,[32,749],[62],{"nctId":906,"briefTitle":907,"status":107,"phases":908,"primaryCompletion":909,"completion":909,"start":910,"enrollment":550,"conditions":911,"interventions":913},"NCT04795726","A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR)",[94],"2021-06-30","2021-03-10",[912],"Diabetic Retinopathy",[62],{"nctId":915,"briefTitle":916,"status":107,"phases":917,"primaryCompletion":918,"completion":918,"start":919,"enrollment":920,"conditions":921,"interventions":922},"NCT05526157","An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice",[],"2024-09-05","2022-10-01",50000,[32,749],[62,923,924,925,926],"Sodium-glucose cotransporter 2 inhibitors","Glucagon-like peptide-1 receptor agonists","Steroidal mineral corticoid receptor antagonists","Non-steroidal mineral corticoid receptor antagonists",{"nctId":928,"briefTitle":929,"status":132,"phases":930,"primaryCompletion":931,"completion":931,"start":932,"enrollment":933,"conditions":934,"interventions":935},"NCT06763146","An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice",[],"2026-06-30","2025-09-22",1200,[32,749],[62],{"nctId":937,"briefTitle":938,"status":107,"phases":939,"primaryCompletion":940,"completion":940,"start":941,"enrollment":942,"conditions":943,"interventions":945},"NCT05640180","An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results",[],"2023-12-20","2022-11-23",17847,[32,944],"Type 2 Diabetes",[62,946],"Sodium-glucose cotransporter-2 inhibitors",{"nctId":948,"briefTitle":949,"status":143,"phases":950,"primaryCompletion":951,"completion":951,"start":849,"enrollment":920,"conditions":952,"interventions":953},"NCT06278207","An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions",[],"2026-09-30",[32,749],[62],{"nctId":59,"briefTitle":60,"status":132,"phases":955,"primaryCompletion":61,"completion":931,"start":956,"enrollment":957,"conditions":958,"interventions":959},[],"2024-10-09",150000,[32,749],[62,960],"Others except finerenone",{"nctId":962,"briefTitle":963,"status":107,"phases":964,"primaryCompletion":965,"completion":965,"start":966,"enrollment":967,"conditions":968,"interventions":969},"NCT04477707","A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)",[],"2021-06-25","2020-07-23",206,[912],[62],{"nctId":971,"briefTitle":972,"status":143,"phases":973,"primaryCompletion":974,"completion":975,"start":976,"enrollment":977,"conditions":978,"interventions":980},"NCT07379840","A Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South Korea",[],"2026-12-31","2027-09-30","2025-12-23",300,[979],"Chronic Heart Failure",[981],"finerenone",{"intervention":425,"totalTrials":421,"cells":983},{"EARLY_PHASE1":984,"PHASE1":986,"PHASE2":1045,"PHASE3":1058,"PHASE4":1076,"NA":1078},{"trials":985,"activeCount":101},[],{"trials":987,"activeCount":175,"soonestReadout":86},[988,1000,1012,1020,1024,1035],{"nctId":989,"briefTitle":990,"status":107,"phases":991,"primaryCompletion":992,"completion":993,"start":994,"enrollment":995,"conditions":996,"interventions":998},"NCT04095273","Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug",[90],"2022-11-24","2023-04-11","2019-09-30",56,[997],"Advanced Solid Tumors",[999,425],"Elimusertib",{"nctId":1001,"briefTitle":1002,"status":107,"phases":1003,"primaryCompletion":1004,"completion":1005,"start":1006,"enrollment":1007,"conditions":1008,"interventions":1010},"NCT03347292","Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC",[90],"2020-12-17","2022-09-06","2018-06-18",58,[1009],"Carcinoma, Hepatocellular",[1011,425],"Regorafenib",{"nctId":84,"briefTitle":85,"status":132,"phases":1013,"primaryCompletion":86,"completion":1014,"start":1015,"enrollment":1016,"conditions":1017,"interventions":1018},[90],"2027-04-14","2022-11-04",284,[997],[87,425,1019],"Platinum-based Chemotherapy",{"nctId":415,"briefTitle":416,"status":156,"phases":1021,"primaryCompletion":418,"completion":419,"start":420,"enrollment":421,"conditions":1022,"interventions":1023},[90],[423],[72,425],{"nctId":1025,"briefTitle":1026,"status":132,"phases":1027,"primaryCompletion":1028,"completion":1029,"start":1030,"enrollment":1031,"conditions":1032,"interventions":1033},"NCT05537740","A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors",[90],"2027-04-30","2027-05-04","2022-10-11",129,[997],[1034,425],"BAY3375968",{"nctId":1036,"briefTitle":1037,"status":156,"phases":1038,"primaryCompletion":313,"completion":1039,"start":1040,"enrollment":1041,"conditions":1042,"interventions":1043},"NCT04999202","A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults",[90],"2025-01-20","2021-08-30",47,[997],[1044,1044,425],"BAY2416964",{"trials":1046,"activeCount":101},[1047],{"nctId":1048,"briefTitle":1049,"status":107,"phases":1050,"primaryCompletion":1051,"completion":1052,"start":1053,"enrollment":1054,"conditions":1055,"interventions":1057},"NCT04696055","Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1\u002FPD-L1 Immune Checkpoint Inhibitors",[91],"2022-05-05","2024-04-23","2021-02-03",95,[1056],"Hepatocellular Carcinoma",[425,1011],{"trials":1059,"activeCount":233,"soonestReadout":1064},[1060],{"nctId":1061,"briefTitle":1062,"status":143,"phases":1063,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":1067,"conditions":1068,"interventions":1071},"NCT06452277","A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)",[92],"2027-10-28","2029-06-27","2024-08-28",444,[1069,1070],"Advanced Non-small Cell Lung Cancer","HER2 Mutation",[1072,425,1073,1074,1075],"Sevabertinib","Cisplatin","Carboplatin","Pemetrexed",{"trials":1077,"activeCount":101},[],{"trials":1079,"activeCount":101},[],{"intervention":52,"totalTrials":1081,"cells":1082},16,{"EARLY_PHASE1":1083,"PHASE1":1085,"PHASE2":1185,"PHASE3":1209,"PHASE4":1248,"NA":1250},{"trials":1084,"activeCount":101},[],{"trials":1086,"activeCount":101},[1087,1096,1106,1116,1127,1136,1145,1156,1166,1174],{"nctId":1088,"briefTitle":1089,"status":107,"phases":1090,"primaryCompletion":1091,"completion":1091,"start":1092,"enrollment":36,"conditions":1093,"interventions":1095},"NCT05071729","A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally",[90],"2022-10-19","2021-10-14",[1094],"Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men",[52],{"nctId":1097,"briefTitle":1098,"status":107,"phases":1099,"primaryCompletion":1100,"completion":1100,"start":1101,"enrollment":447,"conditions":1102,"interventions":1104},"NCT06219902","A Study to Learn if Elinzanetant Affects the Ability to Drive and Brain Function in Healthy Women",[90],"2024-04-15","2024-01-08",[1094,1103],"Hot Flashes",[52,1105],"Zopiclone",{"nctId":1107,"briefTitle":1108,"status":107,"phases":1109,"primaryCompletion":1110,"completion":1111,"start":1112,"enrollment":1081,"conditions":1113,"interventions":1114},"NCT04889287","A Study to Learn How Much Rosuvastatin Gets Into the Blood When Taken With or Without Elinzanetant and to Learn About the Safety of Elinzanetant in Healthy Participants",[90],"2021-07-23","2021-09-29","2021-05-26",[1094],[52,1115],"Rosuvastatin",{"nctId":1117,"briefTitle":1118,"status":107,"phases":1119,"primaryCompletion":1120,"completion":1121,"start":1122,"enrollment":97,"conditions":1123,"interventions":1125},"NCT05471817","A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants",[90],"2022-09-20","2022-11-14","2022-08-05",[1094,1103,1124],"Healthy Volunteers",[52,1126],"Dabigatran etexilate",{"nctId":1128,"briefTitle":1129,"status":107,"phases":1130,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":1133,"conditions":1134,"interventions":1135},"NCT04981431","A Study to Learn How Safe Elinzanetant is, How it Affects the Body, and How it Moves Into, Through and Out of the Body After Single and Multiple Doses in Japanese Healthy Female Adults",[90],"2022-03-13","2021-08-11",62,[1094],[52],{"nctId":1137,"briefTitle":1138,"status":107,"phases":1139,"primaryCompletion":1140,"completion":632,"start":1141,"enrollment":22,"conditions":1142,"interventions":1143},"NCT05481528","A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy Participants",[90],"2023-02-07","2022-08-19",[1094,1103,1124],[1144,52],"Moxifloxacin",{"nctId":1146,"briefTitle":1147,"status":107,"phases":1148,"primaryCompletion":1149,"completion":1150,"start":1151,"enrollment":1081,"conditions":1152,"interventions":1153},"NCT05028608","A Study to Learn What Happens to Elinzanetant in the Body When Taken With or Without Carbamazepine, and How Safe it is in Healthy Men and Women Aged 18 to 60 Years.",[90],"2021-10-31","2022-01-20","2021-09-06",[1094],[52,1154,1155],"Midazolam","Carbamazepine",{"nctId":1157,"briefTitle":1158,"status":107,"phases":1159,"primaryCompletion":1160,"completion":1161,"start":1162,"enrollment":1163,"conditions":1164,"interventions":1165},"NCT05351892","A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants",[90],"2022-06-09","2022-06-20","2022-05-04",18,[1094,1103,1124],[52],{"nctId":1167,"briefTitle":1168,"status":107,"phases":1169,"primaryCompletion":1170,"completion":1170,"start":1171,"enrollment":1081,"conditions":1172,"interventions":1173},"NCT05381142","A Study to Learn More About How the Study Treatment Elinzanetant (or BAY3427080) Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body After Taking Single and Multiple Doses in Healthy Women Aged 40 to 65 Years",[90],"2022-07-11","2022-05-23",[1094,1103,1124],[52],{"nctId":1175,"briefTitle":1176,"status":107,"phases":1177,"primaryCompletion":1178,"completion":1179,"start":1180,"enrollment":1181,"conditions":1182,"interventions":1183},"NCT05061563","A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults",[90],"2021-12-09","2022-02-23","2021-09-30",14,[1094,1103],[52,1184],"Esomeprazole",{"trials":1186,"activeCount":101},[1187,1198],{"nctId":1188,"briefTitle":1189,"status":107,"phases":1190,"primaryCompletion":1191,"completion":1191,"start":1192,"enrollment":1193,"conditions":1194,"interventions":1197},"NCT03596762","A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms",[91],"2019-11-21","2018-11-20",199,[1195,1103,1196],"Menopause","Night Waking",[52],{"nctId":1199,"briefTitle":1200,"status":107,"phases":1201,"primaryCompletion":1202,"completion":1203,"start":1204,"enrollment":1205,"conditions":1206,"interventions":1208},"NCT06112756","A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause",[91],"2024-08-22","2024-11-07","2023-11-08",110,[1207],"Sleep Disturbances Associated With Menopause",[52],{"trials":1210,"activeCount":233,"soonestReadout":51},[1211,1219,1229,1239],{"nctId":49,"briefTitle":50,"status":132,"phases":1212,"primaryCompletion":51,"completion":1213,"start":1214,"enrollment":1215,"conditions":1216,"interventions":1218},[92],"2028-06-05","2022-10-14",474,[1217,1103],"Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer",[52],{"nctId":1220,"briefTitle":1221,"status":107,"phases":1222,"primaryCompletion":1223,"completion":397,"start":1224,"enrollment":1225,"conditions":1226,"interventions":1228},"NCT05099159","A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)",[92],"2023-06-13","2021-10-29",400,[1227,1103],"Vasomotor Symptoms Associated With Menopause",[52],{"nctId":1230,"briefTitle":1231,"status":107,"phases":1232,"primaryCompletion":1233,"completion":1234,"start":1235,"enrollment":1236,"conditions":1237,"interventions":1238},"NCT05030584","A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause",[92],"2023-03-29","2024-02-12","2021-08-27",628,[1227,1103],[52],{"nctId":1240,"briefTitle":1241,"status":107,"phases":1242,"primaryCompletion":1243,"completion":1244,"start":1235,"enrollment":1245,"conditions":1246,"interventions":1247},"NCT05042362","A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause",[92],"2023-07-25","2023-11-27",396,[1227,1103],[52],{"trials":1249,"activeCount":101},[],{"trials":1251,"activeCount":101},[],{"intervention":1073,"totalTrials":480,"cells":1253},{"EARLY_PHASE1":1254,"PHASE1":1256,"PHASE2":1294,"PHASE3":1320,"PHASE4":1336,"NA":1338},{"trials":1255,"activeCount":101},[],{"trials":1257,"activeCount":101},[1258,1270,1282],{"nctId":1259,"briefTitle":1260,"status":107,"phases":1261,"primaryCompletion":1262,"completion":1263,"start":1264,"enrollment":1265,"conditions":1266,"interventions":1268},"NCT02639091","Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors",[90],"2018-05-23","2019-10-17","2016-02-03",36,[1267],"Medical Oncology",[1269,1075,1073],"BAY 94-9343",{"nctId":1271,"briefTitle":1272,"status":107,"phases":1273,"primaryCompletion":1274,"completion":1275,"start":1276,"enrollment":1277,"conditions":1278,"interventions":1279},"NCT03102320","Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors",[90],"2020-09-16","2021-07-26","2017-05-26",173,[29],[1073,1280,1281],"Gemcitabine","Anetumab ravtansine",{"nctId":1283,"briefTitle":1284,"status":107,"phases":1285,"primaryCompletion":1286,"completion":1287,"start":1288,"enrollment":229,"conditions":1289,"interventions":1290},"NCT01460537","Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer",[90],"2015-07-20","2015-12-18","2011-11-18",[29],[1280,1291,1073,1292,1293],"BAY80-6946","NaCl","BAY80-6964 fixed dose",{"trials":1295,"activeCount":101},[1296,1309],{"nctId":1297,"briefTitle":1298,"status":156,"phases":1299,"primaryCompletion":1300,"completion":1301,"start":1302,"enrollment":1303,"conditions":1304,"interventions":1306},"NCT01573338","Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)",[90,91],"2016-03-25","2016-06-23","2013-02-25",43,[1305],"Small Cell Lung Carcinoma",[1307,1308,1073,1074],"Roniciclib","Etoposide",{"nctId":1310,"briefTitle":1311,"status":107,"phases":1312,"primaryCompletion":1313,"completion":1314,"start":1315,"enrollment":124,"conditions":1316,"interventions":1318},"NCT00359359","A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer",[90,91],"2009-03","2009-08","2006-07",[1317],"Carcinoma, Small Cell",[1319,1073],"Sagopilone",{"trials":1321,"activeCount":233,"soonestReadout":1064},[1322,1332],{"nctId":1323,"briefTitle":1324,"status":107,"phases":1325,"primaryCompletion":1326,"completion":1327,"start":1328,"enrollment":1329,"conditions":1330,"interventions":1331},"NCT00449033","A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)",[92],"2010-04","2011-06","2007-02",904,[423],[42,1280,1073],{"nctId":1061,"briefTitle":1062,"status":143,"phases":1333,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":1067,"conditions":1334,"interventions":1335},[92],[1069,1070],[1072,425,1073,1074,1075],{"trials":1337,"activeCount":101},[],{"trials":1339,"activeCount":101},[],{"intervention":1074,"totalTrials":1341,"cells":1342},3,{"EARLY_PHASE1":1343,"PHASE1":1345,"PHASE2":1359,"PHASE3":1365,"PHASE4":1371,"NA":1373},{"trials":1344,"activeCount":101},[],{"trials":1346,"activeCount":101},[1347],{"nctId":1348,"briefTitle":1349,"status":107,"phases":1350,"primaryCompletion":1351,"completion":1352,"start":1315,"enrollment":33,"conditions":1353,"interventions":1355},"NCT01069328","Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)",[90],"2011-09","2011-10",[423,1354],"Lung Cancer",[1356,1356,1357,1357,1357,1357,1358,1074],"Nexavar","Bevacizumab","Paclitaxel",{"trials":1360,"activeCount":101},[1361],{"nctId":1297,"briefTitle":1298,"status":156,"phases":1362,"primaryCompletion":1300,"completion":1301,"start":1302,"enrollment":1303,"conditions":1363,"interventions":1364},[90,91],[1305],[1307,1308,1073,1074],{"trials":1366,"activeCount":233,"soonestReadout":1064},[1367],{"nctId":1061,"briefTitle":1062,"status":143,"phases":1368,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":1067,"conditions":1369,"interventions":1370},[92],[1069,1070],[1072,425,1073,1074,1075],{"trials":1372,"activeCount":101},[],{"trials":1374,"activeCount":101},[],{"intervention":1075,"totalTrials":175,"cells":1376},{"EARLY_PHASE1":1377,"PHASE1":1379,"PHASE2":1385,"PHASE3":1387,"PHASE4":1393,"NA":1395},{"trials":1378,"activeCount":101},[],{"trials":1380,"activeCount":101},[1381],{"nctId":1259,"briefTitle":1260,"status":107,"phases":1382,"primaryCompletion":1262,"completion":1263,"start":1264,"enrollment":1265,"conditions":1383,"interventions":1384},[90],[1267],[1269,1075,1073],{"trials":1386,"activeCount":101},[],{"trials":1388,"activeCount":233,"soonestReadout":1064},[1389],{"nctId":1061,"briefTitle":1062,"status":143,"phases":1390,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":1067,"conditions":1391,"interventions":1392},[92],[1069,1070],[1072,425,1073,1074,1075],{"trials":1394,"activeCount":101},[],{"trials":1396,"activeCount":101},[],{"intervention":1398,"totalTrials":175,"cells":1399},"Medroxyprogesterone acetate",{"EARLY_PHASE1":1400,"PHASE1":1402,"PHASE2":1404,"PHASE3":1406,"PHASE4":1429,"NA":1431},{"trials":1401,"activeCount":101},[],{"trials":1403,"activeCount":101},[],{"trials":1405,"activeCount":101},[],{"trials":1407,"activeCount":233,"soonestReadout":1412},[1408,1419],{"nctId":1409,"briefTitle":1410,"status":143,"phases":1411,"primaryCompletion":1412,"completion":1412,"start":1413,"enrollment":1414,"conditions":1415,"interventions":1417},"NCT06904274","Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months",[92],"2027-10-01","2025-11-24",207,[1416],"Endometrial Hyperplasia",[1418,1398],"BAY865028",{"nctId":1420,"briefTitle":1421,"status":107,"phases":1422,"primaryCompletion":1423,"completion":1423,"start":1315,"enrollment":1424,"conditions":1425,"interventions":1427},"NCT00360490","Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)",[92],"2008-06",165,[1426],"Menorrhagia",[1428,1398],"Levonorgestrel IUS",{"trials":1430,"activeCount":101},[],{"trials":1432,"activeCount":101},[],{"intervention":1434,"totalTrials":233,"cells":1435},"BAY3723113",{"EARLY_PHASE1":1436,"PHASE1":1438,"PHASE2":1440,"PHASE3":1442,"PHASE4":1454,"NA":1456},{"trials":1437,"activeCount":101},[],{"trials":1439,"activeCount":101},[],{"trials":1441,"activeCount":101},[],{"trials":1443,"activeCount":233,"soonestReadout":1448},[1444],{"nctId":1445,"briefTitle":1446,"status":132,"phases":1447,"primaryCompletion":1448,"completion":1449,"start":1450,"enrollment":1265,"conditions":1451,"interventions":1453},"NCT07023341","A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy",[92],"2026-08-31","2028-05-30","2025-06-30",[1452],"Obstructive Hypertrophic Cardiomyopathy",[1434],{"trials":1455,"activeCount":101},[],{"trials":1457,"activeCount":101},[],{"intervention":1418,"totalTrials":233,"cells":1459},{"EARLY_PHASE1":1460,"PHASE1":1462,"PHASE2":1464,"PHASE3":1466,"PHASE4":1472,"NA":1474},{"trials":1461,"activeCount":101},[],{"trials":1463,"activeCount":101},[],{"trials":1465,"activeCount":101},[],{"trials":1467,"activeCount":233,"soonestReadout":1412},[1468],{"nctId":1409,"briefTitle":1410,"status":143,"phases":1469,"primaryCompletion":1412,"completion":1412,"start":1413,"enrollment":1414,"conditions":1470,"interventions":1471},[92],[1416],[1418,1398],{"trials":1473,"activeCount":101},[],{"trials":1475,"activeCount":101},[],{"intervention":47,"totalTrials":160,"cells":1477},{"EARLY_PHASE1":1478,"PHASE1":1480,"PHASE2":1555,"PHASE3":1652,"PHASE4":1704,"NA":1726},{"trials":1479,"activeCount":101},[],{"trials":1481,"activeCount":101},[1482,1493,1502,1513,1528,1538,1546],{"nctId":1483,"briefTitle":1484,"status":107,"phases":1485,"primaryCompletion":1486,"completion":1487,"start":1488,"enrollment":36,"conditions":1489,"interventions":1491},"NCT02159326","Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women",[90],"2015-03","2015-07","2014-06",[1490],"Drug Interactions",[1492,47],"Microgynon",{"nctId":1494,"briefTitle":1495,"status":107,"phases":1496,"primaryCompletion":1314,"completion":1497,"start":1498,"enrollment":480,"conditions":1499,"interventions":1501},"NCT00680654","Interaction Study in Patients With Pulmonary Hypertension and Stable Treatment of Sildenafil 20 mg TID",[90],"2009-11","2008-10",[1500],"Hypertension, Pulmonary",[47],{"nctId":1503,"briefTitle":1504,"status":107,"phases":1505,"primaryCompletion":1506,"completion":1507,"start":1508,"enrollment":1509,"conditions":1510,"interventions":1512},"NCT01489488","Relative Bioavailability and Food Effect Study",[90],"2012-04","2012-05","2012-01",32,[1511],"Pharmacology, Clinical",[47,47,47,47,47],{"nctId":1514,"briefTitle":1515,"status":107,"phases":1516,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":1519,"conditions":1520,"interventions":1522},"NCT02556268","Interaction With HIV Antiretroviral Agents",[90],"2016-12-07","2016-02-23",40,[1521],"HIV-DDI",[47,1523,1524,1525,1526,1527],"ATRIPLA","COMPLERA","STRIBILD","TRIUMEQ","Antiretroviral protease inhibitor",{"nctId":1529,"briefTitle":1530,"status":107,"phases":1531,"primaryCompletion":1532,"completion":1533,"start":1534,"enrollment":1509,"conditions":1535,"interventions":1537},"NCT04366622","Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight",[90],"2011-04-28","2011-09-15","2010-04-14",[1536],"Clinical Pharmacology",[47],{"nctId":1539,"briefTitle":1540,"status":107,"phases":1541,"primaryCompletion":1542,"completion":1543,"start":1488,"enrollment":25,"conditions":1544,"interventions":1545},"NCT02159313","Relative Bioavailability Study",[90],"2014-09","2015-01",[1124],[47],{"nctId":1547,"briefTitle":1548,"status":107,"phases":1549,"primaryCompletion":1550,"completion":1551,"start":1552,"enrollment":1519,"conditions":1553,"interventions":1554},"NCT04364464","Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight",[90],"2011-03-17","2011-09-20","2010-02-19",[1536],[47],{"trials":1556,"activeCount":101},[1557,1565,1573,1581,1592,1603,1614,1625,1634,1643],{"nctId":1558,"briefTitle":1559,"status":156,"phases":1560,"primaryCompletion":408,"completion":408,"start":549,"enrollment":1561,"conditions":1562,"interventions":1564},"NCT01172756","A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction",[91],39,[1500,1563],"Ventricular Dysfunction, Left",[47,47,47],{"nctId":1566,"briefTitle":1567,"status":156,"phases":1568,"primaryCompletion":1569,"completion":1569,"start":1570,"enrollment":233,"conditions":1571,"interventions":1572},"NCT01065051","Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics",[91],"2011-01","2010-11",[1500,1563],[47],{"nctId":1574,"briefTitle":1575,"status":464,"phases":1576,"primaryCompletion":1577,"completion":1577,"start":1507,"enrollment":101,"conditions":1578,"interventions":1580},"NCT01165931","Coronary Vasomotor Response After Riociguat Exposure",[91],"2013-01",[1579],"Coronary Artery Disease",[47],{"nctId":1582,"briefTitle":1583,"status":107,"phases":1584,"primaryCompletion":1585,"completion":1586,"start":1587,"enrollment":1163,"conditions":1588,"interventions":1590},"NCT01179334","Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.",[91],"2012-06","2013-05","2010-08",[1589],"Pulmonary Hypertension",[47,1591],"Sildenafil",{"nctId":1593,"briefTitle":1594,"status":156,"phases":1595,"primaryCompletion":1596,"completion":1597,"start":1598,"enrollment":1599,"conditions":1600,"interventions":1602},"NCT02170025","Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients",[91],"2017-01-17","2017-09-22","2014-09-30",21,[1601],"Cystic Fibrosis",[47],{"nctId":1604,"briefTitle":1605,"status":107,"phases":1606,"primaryCompletion":1607,"completion":1608,"start":1609,"enrollment":1610,"conditions":1611,"interventions":1613},"NCT02283762","Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis",[91],"2017-12-15","2019-03-28","2015-01-15",121,[1612],"Scleroderma, Systemic",[47],{"nctId":1615,"briefTitle":1616,"status":156,"phases":1617,"primaryCompletion":1618,"completion":1619,"start":1620,"enrollment":1621,"conditions":1622,"interventions":1624},"NCT02138825","Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)",[91],"2016-05-05","2016-09-14","2014-06-04",147,[1623],"Idiopathic Interstitial Pneumonias \u002F Hypertension,Pulmonary",[47],{"nctId":1626,"briefTitle":1627,"status":107,"phases":1628,"primaryCompletion":1488,"completion":1488,"start":1629,"enrollment":1630,"conditions":1631,"interventions":1633},"NCT01926847","Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator",[91],"2013-10",23,[1632],"Raynaud Disease",[47],{"nctId":1635,"briefTitle":1636,"status":107,"phases":1637,"primaryCompletion":1638,"completion":1639,"start":1534,"enrollment":1640,"conditions":1641,"interventions":1642},"NCT01065454","A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction",[91],"2012-06-06","2025-07-23",202,[1500,1563],[47,47,47],{"nctId":1644,"briefTitle":1645,"status":107,"phases":1646,"primaryCompletion":1647,"completion":1542,"start":1648,"enrollment":1649,"conditions":1650,"interventions":1651},"NCT00454558","An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension",[91],"2014-07","2007-01",75,[1500],[47],{"trials":1653,"activeCount":233,"soonestReadout":46},[1654,1663,1672,1679,1688,1697],{"nctId":1655,"briefTitle":1656,"status":107,"phases":1657,"primaryCompletion":1658,"completion":1658,"start":1659,"enrollment":1660,"conditions":1661,"interventions":1662},"NCT00910429","BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension",[92],"2019-08-19","2009-07-01",237,[1589],[47],{"nctId":1664,"briefTitle":1665,"status":107,"phases":1666,"primaryCompletion":1667,"completion":1667,"start":1668,"enrollment":1669,"conditions":1670,"interventions":1671},"NCT02007629","Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor",[92],"2016-12-29","2014-02-18",61,[1500],[47],{"nctId":1673,"briefTitle":1674,"status":107,"phases":1675,"primaryCompletion":1658,"completion":1658,"start":1676,"enrollment":1245,"conditions":1677,"interventions":1678},"NCT00863681","BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension",[92],"2009-03-12",[1500],[47],{"nctId":1680,"briefTitle":1681,"status":107,"phases":1682,"primaryCompletion":1683,"completion":1683,"start":1684,"enrollment":1685,"conditions":1686,"interventions":1687},"NCT00855465","A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.",[92],"2012-06-27","2009-02-23",262,[1589],[47],{"nctId":1689,"briefTitle":1690,"status":107,"phases":1691,"primaryCompletion":1692,"completion":1692,"start":1693,"enrollment":1694,"conditions":1695,"interventions":1696},"NCT00810693","A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)",[92],"2012-05-14","2008-12-17",445,[1589],[47,47],{"nctId":44,"briefTitle":45,"status":132,"phases":1698,"primaryCompletion":46,"completion":1699,"start":1700,"enrollment":1701,"conditions":1702,"interventions":1703},[92],"2027-08-03","2015-10-29",24,[1500],[47],{"trials":1705,"activeCount":101},[1706,1718],{"nctId":1707,"briefTitle":1708,"status":107,"phases":1709,"primaryCompletion":1710,"completion":1711,"start":1712,"enrollment":1713,"conditions":1714,"interventions":1716},"NCT02891850","Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy",[93],"2020-01-29","2020-03-03","2017-01-11",225,[1715],"Pulmonary Arterial Hypertension",[47,1591,1717],"Tadalafil",{"nctId":1719,"briefTitle":1720,"status":107,"phases":1721,"primaryCompletion":1722,"completion":1722,"start":1723,"enrollment":1649,"conditions":1724,"interventions":1725},"NCT02191137","Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)",[93],"2016-07-16","2014-09-23",[1500],[47],{"trials":1727,"activeCount":101},[1728,1737,1747,1757,1766],{"nctId":1729,"briefTitle":1730,"status":107,"phases":1731,"primaryCompletion":207,"completion":1732,"start":1733,"enrollment":1734,"conditions":1735,"interventions":1736},"NCT02117791","Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH )",[],"2023-09-20","2014-07-16",1298,[1500],[47],{"nctId":1738,"briefTitle":1739,"status":107,"phases":1740,"primaryCompletion":1741,"completion":1742,"start":1743,"enrollment":1744,"conditions":1745,"interventions":1746},"NCT02545465","A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice",[],"2016-05-31","2016-08-31","2015-09-15",125,[1500],[47],{"nctId":1748,"briefTitle":1749,"status":107,"phases":1750,"primaryCompletion":1751,"completion":1752,"start":1753,"enrollment":1754,"conditions":1755,"interventions":1756},"NCT02092818","EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension",[],"2018-03-31","2018-06-29","2014-05-31",1316,[1500],[47],{"nctId":1758,"briefTitle":1759,"status":107,"phases":1760,"primaryCompletion":1761,"completion":1732,"start":1762,"enrollment":1763,"conditions":1764,"interventions":1765},"NCT02428985","Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH)",[],"2023-04-17","2015-06-29",882,[1500],[47],{"nctId":1767,"briefTitle":1768,"status":107,"phases":1769,"primaryCompletion":1770,"completion":1771,"start":1772,"enrollment":874,"conditions":1773,"interventions":1774},"NCT04813926","A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)",[],"2024-10-19","2025-02-03","2021-07-16",[1715],[47],{"intervention":1072,"totalTrials":1341,"cells":1776},{"EARLY_PHASE1":1777,"PHASE1":1779,"PHASE2":1793,"PHASE3":1795,"PHASE4":1801,"NA":1803},{"trials":1778,"activeCount":101},[],{"trials":1780,"activeCount":101},[1781],{"nctId":1782,"briefTitle":1783,"status":107,"phases":1784,"primaryCompletion":1785,"completion":1785,"start":1786,"enrollment":1163,"conditions":1787,"interventions":1792},"NCT07102095","A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose",[90],"2025-12-03","2025-07-24",[1788,1789,1790,1791],"Hepatic Insufficiency","Liver Diseases","Pharmacokinetics","Drug Metabolism",[1072],{"trials":1794,"activeCount":101},[],{"trials":1796,"activeCount":233,"soonestReadout":1064},[1797],{"nctId":1061,"briefTitle":1062,"status":143,"phases":1798,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":1067,"conditions":1799,"interventions":1800},[92],[1069,1070],[1072,425,1073,1074,1075],{"trials":1802,"activeCount":101},[],{"trials":1804,"activeCount":101},[1805],{"nctId":1806,"briefTitle":1807,"status":1808,"phases":1809,"conditions":1810,"interventions":1811},"NCT06761976","Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation","AVAILABLE",[],[1069,219],[1072],{"intervention":57,"totalTrials":480,"cells":1813},{"EARLY_PHASE1":1814,"PHASE1":1816,"PHASE2":1828,"PHASE3":1836,"PHASE4":1838,"NA":1840},{"trials":1815,"activeCount":101},[],{"trials":1817,"activeCount":101},[1818],{"nctId":1819,"briefTitle":1820,"status":107,"phases":1821,"primaryCompletion":1822,"completion":1823,"start":1824,"enrollment":1649,"conditions":1825,"interventions":1827},"NCT02122913","A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer",[90],"2017-02-01","2021-04-09","2014-05-04",[1826],"Solid Tumors Harboring NTRK Fusion",[57],{"trials":1829,"activeCount":233,"soonestReadout":56},[1830],{"nctId":54,"briefTitle":55,"status":132,"phases":1831,"primaryCompletion":56,"completion":951,"start":1832,"enrollment":1833,"conditions":1834,"interventions":1835},[90,91],"2015-12-16",154,[1826],[57],{"trials":1837,"activeCount":101},[],{"trials":1839,"activeCount":101},[],{"trials":1841,"activeCount":175,"soonestReadout":1846},[1842,1852,1863,1875,1884],{"nctId":1843,"briefTitle":1844,"status":143,"phases":1845,"primaryCompletion":1846,"completion":1847,"start":1848,"enrollment":435,"conditions":1849,"interventions":1851},"NCT04945330","NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes",[],"2029-06-30","2029-12-31","2021-11-05",[1850],"Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion",[57],{"nctId":1853,"briefTitle":1854,"status":143,"phases":1855,"primaryCompletion":790,"completion":1856,"start":1857,"enrollment":1858,"conditions":1859,"interventions":1861},"NCT04142437","Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body",[],"2030-03-31","2020-04-03",150,[1860],"Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion",[1862],"larotrectinib",{"nctId":1864,"briefTitle":1865,"status":107,"phases":1866,"primaryCompletion":1867,"completion":1867,"start":1868,"enrollment":1869,"conditions":1870,"interventions":1873},"NCT05236257","A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database",[],"2022-09-13","2022-03-10",93,[1871,1872],"Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion","Infantile Fibrosarcoma",[57,1874],"Standard of Care",{"nctId":1876,"briefTitle":1877,"status":107,"phases":1878,"primaryCompletion":315,"completion":315,"start":1879,"enrollment":1880,"conditions":1881,"interventions":1882},"NCT05192642","A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice",[],"2021-12-03",368,[1826],[57,1883],"Data on other treatments",{"nctId":1885,"briefTitle":1886,"status":1887,"phases":1888,"conditions":1889,"interventions":1891},"NCT03025360","Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion","APPROVED_FOR_MARKETING",[],[1890],"Tumors Harboring NTRK Fusion",[57],{"intervention":152,"totalTrials":1341,"cells":1893},{"EARLY_PHASE1":1894,"PHASE1":1896,"PHASE2":1898,"PHASE3":1904,"PHASE4":1906,"NA":1908},{"trials":1895,"activeCount":101},[],{"trials":1897,"activeCount":101},[],{"trials":1899,"activeCount":233,"soonestReadout":145},[1900],{"nctId":141,"briefTitle":142,"status":143,"phases":1901,"primaryCompletion":145,"completion":146,"start":147,"enrollment":148,"conditions":1902,"interventions":1903},[91],[150],[67,152],{"trials":1905,"activeCount":101},[],{"trials":1907,"activeCount":101},[],{"trials":1909,"activeCount":175,"soonestReadout":240},[1910,1914],{"nctId":237,"briefTitle":238,"status":132,"phases":1911,"primaryCompletion":240,"completion":241,"start":242,"enrollment":243,"conditions":1912,"interventions":1913},[],[245],[67,152,247],{"nctId":249,"briefTitle":250,"status":251,"phases":1915,"primaryCompletion":253,"completion":254,"start":255,"enrollment":256,"conditions":1916,"interventions":1917},[],[231],[67,152],{"intervention":1919,"totalTrials":328,"cells":1920},"BAY2927088",{"EARLY_PHASE1":1921,"PHASE1":1923,"PHASE2":1959,"PHASE3":1970,"PHASE4":1972,"NA":1974},{"trials":1922,"activeCount":101},[],{"trials":1924,"activeCount":101},[1925,1935,1943,1952],{"nctId":1926,"briefTitle":1927,"status":107,"phases":1928,"primaryCompletion":1929,"completion":1929,"start":1930,"enrollment":160,"conditions":1931,"interventions":1933},"NCT06348888","A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants",[90],"2024-06-12","2024-04-10",[1069,1932,1070,1124],"EGFR Mutation",[1919,1934,1155],"Itraconazole",{"nctId":1936,"briefTitle":1937,"status":107,"phases":1938,"primaryCompletion":1939,"completion":1939,"start":1940,"enrollment":1599,"conditions":1941,"interventions":1942},"NCT06378658","A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants",[90],"2024-06-11","2024-03-29",[1069,1932,1070,1124],[1919,1184],{"nctId":1944,"briefTitle":1945,"status":107,"phases":1946,"primaryCompletion":1947,"completion":1947,"start":1948,"enrollment":1949,"conditions":1950,"interventions":1951},"NCT06329895","A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants",[90],"2024-06-10","2024-03-25",15,[1069,1932,1070,1124],[1919,1126,1115],{"nctId":1953,"briefTitle":1954,"status":107,"phases":1955,"primaryCompletion":313,"completion":313,"start":1956,"enrollment":1949,"conditions":1957,"interventions":1958},"NCT06360211","A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants",[90],"2024-04-17",[1069,1932,1070,1124],[1919,1154],{"trials":1960,"activeCount":233,"soonestReadout":1965},[1961],{"nctId":1962,"briefTitle":1963,"status":143,"phases":1964,"primaryCompletion":1965,"completion":1966,"start":1967,"enrollment":793,"conditions":1968,"interventions":1969},"NCT06760819","A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)",[91],"2027-02-03","2027-10-25","2025-02-13",[997,1070],[1919],{"trials":1971,"activeCount":101},[],{"trials":1973,"activeCount":101},[],{"trials":1975,"activeCount":101},[],{"intervention":1977,"totalTrials":233,"cells":1978},"BAY 3713372",{"EARLY_PHASE1":1979,"PHASE1":1981,"PHASE2":1983,"PHASE3":1995,"PHASE4":1997,"NA":1999},{"trials":1980,"activeCount":101},[],{"trials":1982,"activeCount":101},[],{"trials":1984,"activeCount":233,"soonestReadout":1989},[1985],{"nctId":1986,"briefTitle":1987,"status":143,"phases":1988,"primaryCompletion":1989,"completion":1989,"start":1990,"enrollment":1991,"conditions":1992,"interventions":1994},"NCT06914128","A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors",[90,91],"2029-06-17","2025-03-21",370,[1993],"MTAP-deleted Solid Tumors",[1977],{"trials":1996,"activeCount":101},[],{"trials":1998,"activeCount":101},[],{"trials":2000,"activeCount":101},[],{"intervention":2002,"totalTrials":233,"cells":2003},"AB-1005",{"EARLY_PHASE1":2004,"PHASE1":2006,"PHASE2":2008,"PHASE3":2020,"PHASE4":2022,"NA":2024},{"trials":2005,"activeCount":101},[],{"trials":2007,"activeCount":101},[],{"trials":2009,"activeCount":233,"soonestReadout":2014},[2010],{"nctId":2011,"briefTitle":2012,"status":251,"phases":2013,"primaryCompletion":2014,"completion":2015,"start":2016,"enrollment":421,"conditions":2017,"interventions":2019},"NCT07566429","A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease",[91],"2028-12-15","2032-06-15","2026-07-27",[2018],"Parkinson Disease",[2002],{"trials":2021,"activeCount":101},[],{"trials":2023,"activeCount":101},[],{"trials":2025,"activeCount":101},[],{"intervention":2027,"totalTrials":233,"cells":2028},"BAY2599023",{"EARLY_PHASE1":2029,"PHASE1":2031,"PHASE2":2033,"PHASE3":2044,"PHASE4":2046,"NA":2048},{"trials":2030,"activeCount":101},[],{"trials":2032,"activeCount":101},[],{"trials":2034,"activeCount":233,"soonestReadout":2039},[2035],{"nctId":2036,"briefTitle":2037,"status":132,"phases":2038,"primaryCompletion":2039,"completion":2039,"start":2040,"enrollment":2041,"conditions":2042,"interventions":2043},"NCT03588299","Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a \"Shuttle\"",[90,91],"2026-11-03","2018-11-07",11,[24],[2027],{"trials":2045,"activeCount":101},[],{"trials":2047,"activeCount":101},[],{"trials":2049,"activeCount":101},[],{"intervention":2051,"totalTrials":233,"cells":2052},"BAY2927088_formulation A",{"EARLY_PHASE1":2053,"PHASE1":2055,"PHASE2":2057,"PHASE3":2069,"PHASE4":2071,"NA":2073},{"trials":2054,"activeCount":101},[],{"trials":2056,"activeCount":101},[],{"trials":2058,"activeCount":233,"soonestReadout":2063},[2059],{"nctId":2060,"briefTitle":2061,"status":132,"phases":2062,"primaryCompletion":2063,"completion":974,"start":2064,"enrollment":1991,"conditions":2065,"interventions":2066},"NCT05099172","First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and\u002For Human Epidermal Growth Factor Receptor 2 (HER2)",[90,91],"2026-11-30","2021-10-25",[1069,1932,1070],[2051,2067,2068],"BAY2927088_formulation B_1","BAY2927088_formulation B_2",{"trials":2070,"activeCount":101},[],{"trials":2072,"activeCount":101},[],{"trials":2074,"activeCount":101},[],{"intervention":2067,"totalTrials":233,"cells":2076},{"EARLY_PHASE1":2077,"PHASE1":2079,"PHASE2":2081,"PHASE3":2087,"PHASE4":2089,"NA":2091},{"trials":2078,"activeCount":101},[],{"trials":2080,"activeCount":101},[],{"trials":2082,"activeCount":233,"soonestReadout":2063},[2083],{"nctId":2060,"briefTitle":2061,"status":132,"phases":2084,"primaryCompletion":2063,"completion":974,"start":2064,"enrollment":1991,"conditions":2085,"interventions":2086},[90,91],[1069,1932,1070],[2051,2067,2068],{"trials":2088,"activeCount":101},[],{"trials":2090,"activeCount":101},[],{"trials":2092,"activeCount":101},[],{"intervention":2068,"totalTrials":233,"cells":2094},{"EARLY_PHASE1":2095,"PHASE1":2097,"PHASE2":2099,"PHASE3":2105,"PHASE4":2107,"NA":2109},{"trials":2096,"activeCount":101},[],{"trials":2098,"activeCount":101},[],{"trials":2100,"activeCount":233,"soonestReadout":2063},[2101],{"nctId":2060,"briefTitle":2061,"status":132,"phases":2102,"primaryCompletion":2063,"completion":974,"start":2064,"enrollment":1991,"conditions":2103,"interventions":2104},[90,91],[1069,1932,1070],[2051,2067,2068],{"trials":2106,"activeCount":101},[],{"trials":2108,"activeCount":101},[],{"trials":2110,"activeCount":101},[],{"intervention":2112,"totalTrials":233,"cells":2113},"Oxymetazoline HCl 0.05% nasal gel",{"EARLY_PHASE1":2114,"PHASE1":2116,"PHASE2":2118,"PHASE3":2131,"PHASE4":2133,"NA":2135},{"trials":2115,"activeCount":101},[],{"trials":2117,"activeCount":101},[],{"trials":2119,"activeCount":233,"soonestReadout":2124},[2120],{"nctId":2121,"briefTitle":2122,"status":143,"phases":2123,"primaryCompletion":2124,"completion":2124,"start":2125,"enrollment":2126,"conditions":2127,"interventions":2130},"NCT07582328","A Study to Learn More About How Well Oxymetazoline HCl 0.05% Nasal Gel Works and How Safe It Is in Healthy Adults",[91],"2026-08-07","2026-04-20",120,[2128,2129],"Nasal Congestion","Nasal Obstruction",[2112],{"trials":2132,"activeCount":101},[],{"trials":2134,"activeCount":101},[],{"trials":2136,"activeCount":101},[],{"intervention":2138,"totalTrials":233,"cells":2139},"BAY 3401016",{"EARLY_PHASE1":2140,"PHASE1":2142,"PHASE2":2144,"PHASE3":2155,"PHASE4":2157,"NA":2159},{"trials":2141,"activeCount":101},[],{"trials":2143,"activeCount":101},[],{"trials":2145,"activeCount":233,"soonestReadout":2150},[2146],{"nctId":2147,"briefTitle":2148,"status":143,"phases":2149,"primaryCompletion":2150,"completion":2150,"start":792,"enrollment":2151,"conditions":2152,"interventions":2154},"NCT07211685","BAY3401016; Biomarker Study Alport",[91],"2028-07-27",60,[2153],"Alport Syndrome",[2138],{"trials":2156,"activeCount":101},[],{"trials":2158,"activeCount":101},[],{"trials":2160,"activeCount":101},[],{"intervention":1011,"totalTrials":510,"cells":2162},{"EARLY_PHASE1":2163,"PHASE1":2165,"PHASE2":2294,"PHASE3":2351,"PHASE4":2411,"NA":2429},{"trials":2164,"activeCount":101},[],{"trials":2166,"activeCount":101},[2167,2179,2183,2192,2205,2216,2225,2234,2244,2251,2260,2267,2277,2285],{"nctId":2168,"briefTitle":2169,"status":107,"phases":2170,"primaryCompletion":2171,"completion":2172,"start":2173,"enrollment":1133,"conditions":2174,"interventions":2176},"NCT02085148","A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy",[90],"2019-05-05","2024-03-13","2014-04-11",[2175],"Pediatric Oncology",[1011,2177,2178],"Vincristine","Irinotecan",{"nctId":1001,"briefTitle":1002,"status":107,"phases":2180,"primaryCompletion":1004,"completion":1005,"start":1006,"enrollment":1007,"conditions":2181,"interventions":2182},[90],[1009],[1011,425],{"nctId":2184,"briefTitle":2185,"status":107,"phases":2186,"primaryCompletion":2187,"completion":2187,"start":2188,"enrollment":2189,"conditions":2190,"interventions":2191},"NCT01339104","Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity",[90],"2013-08","2011-04",53,[29],[1011],{"nctId":2193,"briefTitle":2194,"status":107,"phases":2195,"primaryCompletion":2196,"completion":2197,"start":2198,"enrollment":2199,"conditions":2200,"interventions":2201},"NCT01287598","BAY73-4506 Probe Substrate Study",[90],"2018-07-03","2018-07-30","2011-08-02",41,[29],[1011,2202,2203,1154,2204],"Warfarin","Omeprazole","Rosiglitazone",{"nctId":2206,"briefTitle":2207,"status":107,"phases":2208,"primaryCompletion":2209,"completion":2210,"start":2211,"enrollment":2212,"conditions":2213,"interventions":2214},"NCT01973868","Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination",[90],"2017-01-31","2018-04-03","2013-11-21",42,[29],[1011,2215],"Cetuximab",{"nctId":2217,"briefTitle":2218,"status":107,"phases":2219,"primaryCompletion":2220,"completion":2221,"start":1659,"enrollment":1949,"conditions":2222,"interventions":2224},"NCT00960258","Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors.",[90],"2010-04-26","2013-11-11",[2223],"Tumors",[1011],{"nctId":2226,"briefTitle":2227,"status":107,"phases":2228,"primaryCompletion":2229,"completion":2229,"start":2230,"enrollment":701,"conditions":2231,"interventions":2232},"NCT02001909","Effect of Neomycin on the Pharmacokinetics of Regorafenib",[90],"2014-04","2013-12",[29],[1011,2233],"Neomycin",{"nctId":2235,"briefTitle":2236,"status":107,"phases":2237,"primaryCompletion":2238,"completion":2239,"start":2240,"enrollment":2212,"conditions":2241,"interventions":2242},"NCT02106845","Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.",[90],"2015-04-27","2018-06-12","2014-04-22",[29],[2243,1115,1011],"Digoxin",{"nctId":2245,"briefTitle":2246,"status":107,"phases":2247,"primaryCompletion":1506,"completion":1506,"start":1314,"enrollment":510,"conditions":2248,"interventions":2250},"NCT00934882","Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI",[90],[2249],"Colorectal Neoplasms",[1011],{"nctId":2252,"briefTitle":2253,"status":107,"phases":2254,"primaryCompletion":2255,"completion":2255,"start":2256,"enrollment":1701,"conditions":2257,"interventions":2259},"NCT01002378","The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib",[90],"2010-02","2009-10",[2258,1790],"Dietary Fats",[1011,1011,1011],{"nctId":2261,"briefTitle":2262,"status":107,"phases":2263,"primaryCompletion":2264,"completion":2264,"start":549,"enrollment":33,"conditions":2265,"interventions":2266},"NCT01096030","Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors",[90],"2012-11",[29],[1011],{"nctId":2268,"briefTitle":2269,"status":156,"phases":2270,"primaryCompletion":2271,"completion":2272,"start":2273,"enrollment":97,"conditions":2274,"interventions":2275},"NCT02168777","Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer",[90],"2015-10-23","2016-04-05","2014-06-23",[29],[2276,1011],"Refametinib",{"nctId":2278,"briefTitle":2279,"status":107,"phases":2280,"primaryCompletion":1487,"completion":2281,"start":2282,"enrollment":1701,"conditions":2283,"interventions":2284},"NCT01853046","Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment",[90],"2015-11","2013-06",[29],[1011],{"nctId":2286,"briefTitle":2287,"status":107,"phases":2288,"primaryCompletion":2281,"completion":2289,"start":2290,"enrollment":1163,"conditions":2291,"interventions":2293},"NCT02398513","Regorafenib Phase I Study in Mainland Chinese Patients",[90],"2016-06","2015-04",[2292],"Oncology",[1011],{"trials":2295,"activeCount":233,"soonestReadout":2314},[2296,2300,2310,2320,2330,2340],{"nctId":1048,"briefTitle":1049,"status":107,"phases":2297,"primaryCompletion":1051,"completion":1052,"start":1053,"enrollment":1054,"conditions":2298,"interventions":2299},[91],[1056],[425,1011],{"nctId":2301,"briefTitle":2302,"status":107,"phases":2303,"primaryCompletion":2304,"completion":2305,"start":2306,"enrollment":2307,"conditions":2308,"interventions":2309},"NCT02465502","Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer",[91],"2017-05-02","2017-12-11","2015-07-21",59,[2249],[1011],{"nctId":2311,"briefTitle":2312,"status":132,"phases":2313,"primaryCompletion":2314,"completion":2314,"start":2315,"enrollment":2316,"conditions":2317,"interventions":2319},"NCT06246643","A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies",[91],"2028-04-27","2024-01-24",13,[2318],"Solid Malignant Tumors",[1011],{"nctId":2321,"briefTitle":2322,"status":107,"phases":2323,"primaryCompletion":2324,"completion":2325,"start":2326,"enrollment":458,"conditions":2327,"interventions":2329},"NCT00664326","A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC",[91],"2009-05-31","2019-04-02","2008-04-30",[2328],"Carcinoma, Renal Cell",[1011],{"nctId":2331,"briefTitle":2332,"status":107,"phases":2333,"primaryCompletion":2334,"completion":770,"start":2335,"enrollment":550,"conditions":2336,"interventions":2338},"NCT04126733","Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)",[91],"2020-11-11","2019-10-14",[2337],"Colorectal Cancer",[1011,2339],"Nivolumab",{"nctId":2341,"briefTitle":2342,"status":107,"phases":2343,"primaryCompletion":410,"completion":1488,"start":2344,"enrollment":2345,"conditions":2346,"interventions":2347},"NCT01289821","First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib",[91],"2011-02",54,[2249],[1011,2348,2349,2350],"Oxaliplatin","Folinic acid","5-FU",{"trials":2352,"activeCount":101},[2353,2362,2372,2382,2391,2402],{"nctId":2354,"briefTitle":2355,"status":107,"phases":2356,"primaryCompletion":2357,"completion":2358,"start":2359,"enrollment":435,"conditions":2360,"interventions":2361},"NCT01853319","Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy",[92],"2015-04-24","2018-06-11","2013-07-24",[2249],[1011],{"nctId":2363,"briefTitle":2364,"status":107,"phases":2365,"primaryCompletion":2366,"completion":2367,"start":1326,"enrollment":2368,"conditions":2369,"interventions":2371},"NCT01103323","Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy",[92],"2011-07","2014-01",760,[2370],"Metastatic Colorectal Cancer",[1011],{"nctId":2373,"briefTitle":2374,"status":107,"phases":2375,"primaryCompletion":2376,"completion":2377,"start":2378,"enrollment":2379,"conditions":2380,"interventions":2381},"NCT01774344","Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma",[92],"2016-02-29","2019-07-05","2013-05-14",573,[1009],[1011],{"nctId":2383,"briefTitle":2384,"status":156,"phases":2385,"primaryCompletion":2386,"completion":2386,"start":2387,"enrollment":2388,"conditions":2389,"interventions":2390},"NCT01939223","Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo-Controlled Phase-III STudy",[92],"2016-08-29","2013-12-02",25,[2249],[1011],{"nctId":2392,"briefTitle":2393,"status":107,"phases":2394,"primaryCompletion":2395,"completion":2396,"start":2397,"enrollment":1193,"conditions":2398,"interventions":2400},"NCT01271712","Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)",[92],"2012-01-26","2019-04-15","2011-01-04",[2399],"Gastrointestinal Stromal Tumors",[1011,2401],"Best supportive care",{"nctId":2403,"briefTitle":2404,"status":107,"phases":2405,"primaryCompletion":2406,"completion":2407,"start":1506,"enrollment":2408,"conditions":2409,"interventions":2410},"NCT01584830","Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy",[92],"2013-11","2016-01",204,[2249],[1011],{"trials":2412,"activeCount":101},[2413,2420],{"nctId":2414,"briefTitle":2415,"status":107,"phases":2416,"primaryCompletion":696,"completion":2417,"start":2197,"enrollment":435,"conditions":2418,"interventions":2419},"NCT03564938","Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).",[93],"2023-12-01",[2370],[1011],{"nctId":2421,"briefTitle":2422,"status":156,"phases":2423,"primaryCompletion":2424,"completion":2425,"start":733,"enrollment":1630,"conditions":2426,"interventions":2428},"NCT02287025","A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?",[93],"2016-02-26","2016-04-08",[2427],"Physician Education",[1011],{"trials":2430,"activeCount":101},[2431,2437,2448,2456,2466,2477,2485,2493,2501,2510,2516,2525,2532,2543,2551,2560,2574],{"nctId":2432,"briefTitle":2433,"status":687,"phases":2434,"conditions":2435,"interventions":2436},"NCT01646593","Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy",[],[2399],[1011],{"nctId":2438,"briefTitle":2439,"status":107,"phases":2440,"primaryCompletion":2441,"completion":2441,"start":2442,"enrollment":2443,"conditions":2444,"interventions":2446},"NCT05839951","An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions",[],"2025-04-30","2023-04-24",818,[2445],"Metastatic Colorectal Cancer (mCRC)",[1011,2447,1357],"TAS-102",{"nctId":2449,"briefTitle":2450,"status":107,"phases":2451,"primaryCompletion":2452,"completion":1224,"start":2453,"enrollment":11,"conditions":2454,"interventions":2455},"NCT01933958","Regorafenib Post-marketing Surveillance in Japan",[],"2021-03-29","2013-09-04",[2399],[1011],{"nctId":2457,"briefTitle":2458,"status":107,"phases":2459,"primaryCompletion":2460,"completion":2461,"start":2462,"enrollment":2463,"conditions":2464,"interventions":2465},"NCT01843400","Regorafenib Post-marketing Surveillance",[],"2016-09-12","2016-11-14","2013-04-22",1301,[2249],[1011],{"nctId":2467,"briefTitle":2468,"status":107,"phases":2469,"primaryCompletion":2470,"completion":2471,"start":2472,"enrollment":2473,"conditions":2474,"interventions":2476},"NCT01959269","Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy",[],"2017-03-31","2017-07-07","2013-10-31",483,[2475],"Colorectal Neoplasm",[1011],{"nctId":2478,"briefTitle":2479,"status":107,"phases":2480,"primaryCompletion":2481,"completion":2481,"start":2482,"enrollment":1225,"conditions":2483,"interventions":2484},"NCT02656524","Stivarga Real Life Evidence in Hungary",[],"2017-02-15","2016-07-01",[2249],[1011],{"nctId":2486,"briefTitle":2487,"status":107,"phases":2488,"primaryCompletion":2489,"completion":2489,"start":2490,"enrollment":2388,"conditions":2491,"interventions":2492},"NCT02347852","Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer",[],"2016-09-08","2015-01-20",[2249],[1011],{"nctId":2494,"briefTitle":2495,"status":156,"phases":2496,"primaryCompletion":2497,"completion":994,"start":2498,"enrollment":1341,"conditions":2499,"interventions":2500},"NCT03644511","Use of Sorafenib and\u002For Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment",[],"2019-07-18","2019-01-24",[1056],[1011,42],{"nctId":2502,"briefTitle":2503,"status":107,"phases":2504,"primaryCompletion":2505,"completion":2505,"start":2506,"enrollment":2507,"conditions":2508,"interventions":2509},"NCT03386825","Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib",[],"2018-05-01","2018-01-31",76,[2249],[1011],{"nctId":2511,"briefTitle":2512,"status":687,"phases":2513,"conditions":2514,"interventions":2515},"NCT01538680","Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy",[],[2249],[1011],{"nctId":2517,"briefTitle":2518,"status":107,"phases":2519,"primaryCompletion":2520,"completion":2520,"start":2521,"enrollment":2522,"conditions":2523,"interventions":2524},"NCT02106858","Stivarga Regulatory Post-Marketing Surveillance Study in Korea",[],"2019-05-07","2014-06-25",316,[2249],[1011],{"nctId":2526,"briefTitle":2527,"status":107,"phases":2528,"primaryCompletion":61,"completion":61,"start":2529,"enrollment":1610,"conditions":2530,"interventions":2531},"NCT06137170","A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of Treatment",[],"2024-03-01",[2370],[1011],{"nctId":2533,"briefTitle":2534,"status":107,"phases":2535,"primaryCompletion":2536,"completion":2537,"start":2538,"enrollment":2539,"conditions":2540,"interventions":2542},"NCT03289273","Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)",[],"2022-01-31","2022-06-21","2017-09-13",1010,[2541],"Liver Neoplasms",[1011],{"nctId":2544,"briefTitle":2545,"status":107,"phases":2546,"primaryCompletion":2547,"completion":2547,"start":315,"enrollment":2548,"conditions":2549,"interventions":2550},"NCT06029010","An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States",[],"2025-01-27",2326,[2370],[1011],{"nctId":2552,"briefTitle":2553,"status":107,"phases":2554,"primaryCompletion":2555,"completion":2555,"start":2529,"enrollment":2556,"conditions":2557,"interventions":2559},"NCT06321055","An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States",[],"2024-05-01",136,[2558],"Advanced Gastrointestinal Stromal Tumor",[1011],{"nctId":2561,"briefTitle":2562,"status":107,"phases":2563,"primaryCompletion":2564,"completion":2564,"start":2565,"enrollment":2566,"conditions":2567,"interventions":2571},"NCT05594147","An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib",[],"2023-04-21","2022-10-31",4103,[2568,2569,2570],"Malignant Solid Tumors","Coronavirus Disease 2019 (COVID-19)","SARS-CoV-2 Infection",[2572,2573,1011,42],"Non-TKIs","Other TKIs",{"nctId":2575,"briefTitle":2576,"status":687,"phases":2577,"conditions":2578,"interventions":2579},"NCT01689376","Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)",[],[2399],[1011],{"intervention":2581,"totalTrials":175,"cells":2582},"Nurandociguat",{"EARLY_PHASE1":2583,"PHASE1":2585,"PHASE2":2605,"PHASE3":2607,"PHASE4":2609,"NA":2611},{"trials":2584,"activeCount":101},[],{"trials":2586,"activeCount":233,"soonestReadout":2591},[2587,2597],{"nctId":2588,"briefTitle":2589,"status":251,"phases":2590,"primaryCompletion":2591,"completion":2591,"start":2592,"enrollment":1265,"conditions":2593,"interventions":2595},"NCT07431294","A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease",[90],"2027-05-07","2026-10-01",[2594],"Stable Coronary Artery Disease",[2596,2581],"Nitroglycerin spray",{"nctId":2598,"briefTitle":2599,"status":464,"phases":2600,"primaryCompletion":2601,"completion":2601,"start":2602,"enrollment":101,"conditions":2603,"interventions":2604},"NCT07515339","A Study to Learn More About How Safe Nurandociguat is and How it Affects the Way the Body Processes Rosuvastatin and Dabigatran in Healthy Adults",[90],"2026-06-26","2026-04-08",[32],[2581,1115,1126],{"trials":2606,"activeCount":101},[],{"trials":2608,"activeCount":101},[],{"trials":2610,"activeCount":101},[],{"trials":2612,"activeCount":101},[],{"intervention":2215,"totalTrials":175,"cells":2614},{"EARLY_PHASE1":2615,"PHASE1":2617,"PHASE2":2635,"PHASE3":2637,"PHASE4":2639,"NA":2641},{"trials":2616,"activeCount":101},[],{"trials":2618,"activeCount":233,"soonestReadout":2627},[2619,2623],{"nctId":2206,"briefTitle":2207,"status":107,"phases":2620,"primaryCompletion":2209,"completion":2210,"start":2211,"enrollment":2212,"conditions":2621,"interventions":2622},[90],[29],[1011,2215],{"nctId":2624,"briefTitle":2625,"status":143,"phases":2626,"primaryCompletion":2627,"completion":2628,"start":2629,"enrollment":2630,"conditions":2631,"interventions":2633},"NCT07535112","A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation",[90],"2029-07-27","2030-07-09","2026-04-07",130,[2632],"Advanced\u002FMetastatic Colorectal Adenocarcinoma",[2634,2215],"BAY 3771249",{"trials":2636,"activeCount":101},[],{"trials":2638,"activeCount":101},[],{"trials":2640,"activeCount":101},[],{"trials":2642,"activeCount":101},[],{"intervention":2596,"totalTrials":233,"cells":2644},{"EARLY_PHASE1":2645,"PHASE1":2647,"PHASE2":2653,"PHASE3":2655,"PHASE4":2657,"NA":2659},{"trials":2646,"activeCount":101},[],{"trials":2648,"activeCount":233,"soonestReadout":2591},[2649],{"nctId":2588,"briefTitle":2589,"status":251,"phases":2650,"primaryCompletion":2591,"completion":2591,"start":2592,"enrollment":1265,"conditions":2651,"interventions":2652},[90],[2594],[2596,2581],{"trials":2654,"activeCount":101},[],{"trials":2656,"activeCount":101},[],{"trials":2658,"activeCount":101},[],{"trials":2660,"activeCount":101},[],{"intervention":2662,"totalTrials":233,"cells":2663},"BAY3389934",{"EARLY_PHASE1":2664,"PHASE1":2666,"PHASE2":2679,"PHASE3":2681,"PHASE4":2683,"NA":2685},{"trials":2665,"activeCount":101},[],{"trials":2667,"activeCount":233,"soonestReadout":2672},[2668],{"nctId":2669,"briefTitle":2670,"status":143,"phases":2671,"primaryCompletion":2672,"completion":2673,"start":2674,"enrollment":1265,"conditions":2675,"interventions":2678},"NCT06854640","A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy",[90],"2026-12-25","2027-02-15","2025-03-12",[2676,2677],"Sepsis","Coagulopathy",[2662],{"trials":2680,"activeCount":101},[],{"trials":2682,"activeCount":101},[],{"trials":2684,"activeCount":101},[],{"trials":2686,"activeCount":101},[],{"intervention":2688,"totalTrials":233,"cells":2689},"BAY3498264",{"EARLY_PHASE1":2690,"PHASE1":2692,"PHASE2":2705,"PHASE3":2707,"PHASE4":2709,"NA":2711},{"trials":2691,"activeCount":101},[],{"trials":2693,"activeCount":233,"soonestReadout":2698},[2694],{"nctId":2695,"briefTitle":2696,"status":143,"phases":2697,"primaryCompletion":2698,"completion":2699,"start":2700,"enrollment":2701,"conditions":2702,"interventions":2704},"NCT06659341","A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation",[90],"2027-01-11","2027-05-31","2024-11-08",104,[2703],"Advanced Solid Tumors Harboring KRAS G12C Mutation",[2688],{"trials":2706,"activeCount":101},[],{"trials":2708,"activeCount":101},[],{"trials":2710,"activeCount":101},[],{"trials":2712,"activeCount":101},[],{"intervention":2634,"totalTrials":233,"cells":2714},{"EARLY_PHASE1":2715,"PHASE1":2717,"PHASE2":2723,"PHASE3":2725,"PHASE4":2727,"NA":2729},{"trials":2716,"activeCount":101},[],{"trials":2718,"activeCount":233,"soonestReadout":2627},[2719],{"nctId":2624,"briefTitle":2625,"status":143,"phases":2720,"primaryCompletion":2627,"completion":2628,"start":2629,"enrollment":2630,"conditions":2721,"interventions":2722},[90],[2632],[2634,2215],{"trials":2724,"activeCount":101},[],{"trials":2726,"activeCount":101},[],{"trials":2728,"activeCount":101},[],{"trials":2730,"activeCount":101},[],{"intervention":87,"totalTrials":233,"cells":2732},{"EARLY_PHASE1":2733,"PHASE1":2735,"PHASE2":2741,"PHASE3":2743,"PHASE4":2745,"NA":2747},{"trials":2734,"activeCount":101},[],{"trials":2736,"activeCount":233,"soonestReadout":86},[2737],{"nctId":84,"briefTitle":85,"status":132,"phases":2738,"primaryCompletion":86,"completion":1014,"start":1015,"enrollment":1016,"conditions":2739,"interventions":2740},[90],[997],[87,425,1019],{"trials":2742,"activeCount":101},[],{"trials":2744,"activeCount":101},[],{"trials":2746,"activeCount":101},[],{"trials":2748,"activeCount":101},[],{"intervention":1019,"totalTrials":233,"cells":2750},{"EARLY_PHASE1":2751,"PHASE1":2753,"PHASE2":2759,"PHASE3":2761,"PHASE4":2763,"NA":2765},{"trials":2752,"activeCount":101},[],{"trials":2754,"activeCount":233,"soonestReadout":86},[2755],{"nctId":84,"briefTitle":85,"status":132,"phases":2756,"primaryCompletion":86,"completion":1014,"start":1015,"enrollment":1016,"conditions":2757,"interventions":2758},[90],[997],[87,425,1019],{"trials":2760,"activeCount":101},[],{"trials":2762,"activeCount":101},[],{"trials":2764,"activeCount":101},[],{"trials":2766,"activeCount":101},[],{"intervention":2768,"totalTrials":233,"cells":2769},"BAY 3389934",{"EARLY_PHASE1":2770,"PHASE1":2772,"PHASE2":2782,"PHASE3":2784,"PHASE4":2786,"NA":2788},{"trials":2771,"activeCount":101},[],{"trials":2773,"activeCount":233,"soonestReadout":2778},[2774],{"nctId":2775,"briefTitle":2776,"status":143,"phases":2777,"primaryCompletion":2778,"completion":2778,"start":932,"enrollment":1081,"conditions":2779,"interventions":2781},"NCT07176728","A Study to Assess the Safety and Effects of Different Doses of an Investigational Drug, BAY 3389934, in Healthy Japanese Volunteers.",[90],"2026-06-02",[2780],"Sepsis Associated Disseminated Intravascular Coagulation (DIC)",[2768],{"trials":2783,"activeCount":101},[],{"trials":2785,"activeCount":101},[],{"trials":2787,"activeCount":101},[],{"trials":2789,"activeCount":101},[],{"intervention":1034,"totalTrials":233,"cells":2791},{"EARLY_PHASE1":2792,"PHASE1":2794,"PHASE2":2800,"PHASE3":2802,"PHASE4":2804,"NA":2806},{"trials":2793,"activeCount":101},[],{"trials":2795,"activeCount":233,"soonestReadout":1028},[2796],{"nctId":1025,"briefTitle":1026,"status":132,"phases":2797,"primaryCompletion":1028,"completion":1029,"start":1030,"enrollment":1031,"conditions":2798,"interventions":2799},[90],[997],[1034,425],{"trials":2801,"activeCount":101},[],{"trials":2803,"activeCount":101},[],{"trials":2805,"activeCount":101},[],{"trials":2807,"activeCount":101},[],{"intervention":2809,"totalTrials":233,"cells":2810},"BAY3546828",{"EARLY_PHASE1":2811,"PHASE1":2813,"PHASE2":2824,"PHASE3":2826,"PHASE4":2828,"NA":2830},{"trials":2812,"activeCount":101},[],{"trials":2814,"activeCount":233,"soonestReadout":2819},[2815],{"nctId":2816,"briefTitle":2817,"status":132,"phases":2818,"primaryCompletion":2819,"completion":2820,"start":1732,"enrollment":2821,"conditions":2822,"interventions":2823},"NCT06052306","A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)",[90],"2027-06-08","2031-08-10",232,[626],[2809],{"trials":2825,"activeCount":101},[],{"trials":2827,"activeCount":101},[],{"trials":2829,"activeCount":101},[],{"trials":2831,"activeCount":101},[],{"intervention":2833,"totalTrials":233,"cells":2834},"225Ac-PSMA-Trillium",{"EARLY_PHASE1":2835,"PHASE1":2837,"PHASE2":2851,"PHASE3":2853,"PHASE4":2855,"NA":2857},{"trials":2836,"activeCount":101},[],{"trials":2838,"activeCount":233,"soonestReadout":2843},[2839],{"nctId":2840,"briefTitle":2841,"status":143,"phases":2842,"primaryCompletion":2843,"completion":2844,"start":2845,"enrollment":2846,"conditions":2847,"interventions":2850},"NCT06217822","First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)",[90],"2028-11-26","2032-05-28","2024-03-07",198,[2848,2849],"Advanced Metastatic Castration-resistant Prostate Cancer","Prostate Specific Membrane Antigen (PSMA) Expression",[2833],{"trials":2852,"activeCount":101},[],{"trials":2854,"activeCount":101},[],{"trials":2856,"activeCount":101},[],{"trials":2858,"activeCount":101},[],{"intervention":2860,"totalTrials":233,"cells":2861},"BAY 3547926",{"EARLY_PHASE1":2862,"PHASE1":2864,"PHASE2":2877,"PHASE3":2879,"PHASE4":2881,"NA":2883},{"trials":2863,"activeCount":101},[],{"trials":2865,"activeCount":233,"soonestReadout":2870},[2866],{"nctId":2867,"briefTitle":2868,"status":143,"phases":2869,"primaryCompletion":2870,"completion":2871,"start":2872,"enrollment":2873,"conditions":2874,"interventions":2875},"NCT06764316","A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer",[90],"2029-07-31","2031-08-31","2025-02-28",148,[1056],[2860,2876],"BAY 3547922",{"trials":2878,"activeCount":101},[],{"trials":2880,"activeCount":101},[],{"trials":2882,"activeCount":101},[],{"trials":2884,"activeCount":101},[],{"intervention":2876,"totalTrials":233,"cells":2886},{"EARLY_PHASE1":2887,"PHASE1":2889,"PHASE2":2895,"PHASE3":2897,"PHASE4":2899,"NA":2901},{"trials":2888,"activeCount":101},[],{"trials":2890,"activeCount":233,"soonestReadout":2870},[2891],{"nctId":2867,"briefTitle":2868,"status":143,"phases":2892,"primaryCompletion":2870,"completion":2871,"start":2872,"enrollment":2873,"conditions":2893,"interventions":2894},[90],[1056],[2860,2876],{"trials":2896,"activeCount":101},[],{"trials":2898,"activeCount":101},[],{"trials":2900,"activeCount":101},[],{"trials":2902,"activeCount":101},[],{"intervention":82,"totalTrials":2212,"cells":2904},{"EARLY_PHASE1":2905,"PHASE1":2907,"PHASE2":2909,"PHASE3":2911,"PHASE4":2995,"NA":3055},{"trials":2906,"activeCount":101},[],{"trials":2908,"activeCount":101},[],{"trials":2910,"activeCount":101},[],{"trials":2912,"activeCount":101},[2913,2925,2935,2946,2955,2964,2975,2985],{"nctId":2914,"briefTitle":2915,"status":107,"phases":2916,"primaryCompletion":2917,"completion":2918,"start":2919,"enrollment":2920,"conditions":2921,"interventions":2923},"NCT01482910","VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)",[92],"2014-03","2014-08","2011-12",304,[2922],"Macular Degeneration",[82,2924],"Visudyne",{"nctId":2926,"briefTitle":2927,"status":107,"phases":2928,"primaryCompletion":2929,"completion":2930,"start":2931,"enrollment":2932,"conditions":2933,"interventions":2934},"NCT02540954","Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)",[92],"2019-12-24","2020-06-04","2015-09-29",336,[2922],[82],{"nctId":2936,"briefTitle":2937,"status":107,"phases":2938,"primaryCompletion":2939,"completion":2940,"start":2941,"enrollment":1081,"conditions":2942,"interventions":2944},"NCT03639675","Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied",[92],"2019-02-14","2019-03-14","2018-10-03",[2943],"Glaucoma, Neovascular",[82,2945],"Topical IOP-lowering drugs",{"nctId":2947,"briefTitle":2948,"status":107,"phases":2949,"primaryCompletion":1486,"completion":1486,"start":2950,"enrollment":2951,"conditions":2952,"interventions":2954},"NCT01783886","Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement",[92],"2013-02",381,[2953],"Macular Edema",[82,82],{"nctId":2956,"briefTitle":2957,"status":107,"phases":2958,"primaryCompletion":2344,"completion":2959,"start":2256,"enrollment":2960,"conditions":2961,"interventions":2963},"NCT01012973","Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)",[92],"2012-02",177,[2962],"Retinal Vein Occlusion",[82],{"nctId":2965,"briefTitle":2966,"status":107,"phases":2967,"primaryCompletion":2968,"completion":2969,"start":2970,"enrollment":2971,"conditions":2972,"interventions":2973},"NCT00637377","Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)",[92],"2010-09","2011-08","2008-04",1240,[2922],[2974,82,82,82],"Ranibizumab",{"nctId":2976,"briefTitle":2977,"status":107,"phases":2978,"primaryCompletion":2979,"completion":2980,"start":2981,"enrollment":2982,"conditions":2983,"interventions":2984},"NCT02818998","Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)",[92],"2018-11-13","2019-09-24","2016-11-16",463,[2953],[82],{"nctId":2986,"briefTitle":2987,"status":107,"phases":2988,"primaryCompletion":2989,"completion":2990,"start":2991,"enrollment":2345,"conditions":2992,"interventions":2993},"NCT02396316","Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients",[92],"2016-06-16","2016-09-06","2015-04-02",[2943],[82,2994],"Sham",{"trials":2996,"activeCount":101},[2997,3006,3016,3027,3037,3046],{"nctId":2998,"briefTitle":2999,"status":156,"phases":3000,"primaryCompletion":3001,"completion":3001,"start":3002,"enrollment":1341,"conditions":3003,"interventions":3005},"NCT05473715","A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment",[93],"2023-07-11","2023-04-25",[3004],"Neovascular (Wet) Age-related Macular Degeneration",[82],{"nctId":3007,"briefTitle":3008,"status":107,"phases":3009,"primaryCompletion":3010,"completion":2471,"start":3011,"enrollment":3012,"conditions":3013,"interventions":3015},"NCT02120950","Aflibercept in Polypoidal Choroidal Vasculopathy",[93],"2016-08-12","2014-05-29",333,[3014],"Neovascular Macular Degeneration",[82],{"nctId":3017,"briefTitle":3018,"status":107,"phases":3019,"primaryCompletion":3020,"completion":3021,"start":3022,"enrollment":3023,"conditions":3024,"interventions":3026},"NCT02305238","Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration",[93],"2016-12-22","2017-12-20","2014-12-19",288,[3025],"Wet Macular Degeneration",[82],{"nctId":3028,"briefTitle":3029,"status":107,"phases":3030,"primaryCompletion":3031,"completion":3031,"start":3032,"enrollment":3033,"conditions":3034,"interventions":3036},"NCT02800642","Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO",[93],"2019-07-31","2016-06-10",162,[3035],"Central Retinal Vein Occlusion",[82],{"nctId":3038,"briefTitle":3039,"status":107,"phases":3040,"primaryCompletion":3041,"completion":3041,"start":3042,"enrollment":435,"conditions":3043,"interventions":3045},"NCT05511038","A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema",[93],"2024-04-16","2022-08-26",[3044],"Diabetic Macular Edema",[82],{"nctId":3047,"briefTitle":3048,"status":107,"phases":3049,"primaryCompletion":3050,"completion":3050,"start":3051,"enrollment":22,"conditions":3052,"interventions":3054},"NCT06591598","A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration",[93],"2025-10-14","2024-09-02",[3044,3053],"Neovascular Age-related Macular Degeneration",[82],{"trials":3056,"activeCount":855,"soonestReadout":81},[3057,3067,3077,3087,3096,3106,3115,3125,3134,3143,3151,3161,3170,3180,3190,3199,3208,3217,3226,3237,3245,3254,3263,3271,3280,3289,3299,3309],{"nctId":3058,"briefTitle":3059,"status":132,"phases":3060,"primaryCompletion":205,"completion":205,"start":3061,"enrollment":3062,"conditions":3063,"interventions":3066},"NCT06929143","A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema",[],"2025-04-14",3000,[3064,3065],"Neovascular Age-related Macular Degeneration (nAMD)","Diabetic Macular Edema (DME)",[82],{"nctId":3068,"briefTitle":3069,"status":107,"phases":3070,"primaryCompletion":3071,"completion":3072,"start":3073,"enrollment":171,"conditions":3074,"interventions":3076},"NCT04524910","A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV)",[],"2022-10-17","2022-11-11","2021-06-16",[3075],"Myopic Choroidal Neovascularization",[82],{"nctId":3078,"briefTitle":3079,"status":107,"phases":3080,"primaryCompletion":3081,"completion":3082,"start":3083,"enrollment":3084,"conditions":3085,"interventions":3086},"NCT01756248","EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan",[],"2018-12-31","2019-05-20","2012-12-26",3872,[2922],[82],{"nctId":3088,"briefTitle":3089,"status":107,"phases":3090,"primaryCompletion":3091,"completion":3092,"start":3093,"enrollment":217,"conditions":3094,"interventions":3095},"NCT02924311","Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema",[],"2019-08-12","2019-12-06","2016-09-21",[912],[82],{"nctId":3097,"briefTitle":3098,"status":107,"phases":3099,"primaryCompletion":3100,"completion":3101,"start":3102,"enrollment":3103,"conditions":3104,"interventions":3105},"NCT02040220","Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO)",[],"2018-06-01","2018-11-09","2014-01-24",385,[2962],[82],{"nctId":3107,"briefTitle":3108,"status":107,"phases":3109,"primaryCompletion":2470,"completion":2470,"start":3110,"enrollment":3111,"conditions":3112,"interventions":3114},"NCT01914380","Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration",[],"2013-07-29",988,[3113],"Wet Age-related Macular Degeneration",[82],{"nctId":3116,"briefTitle":3117,"status":107,"phases":3118,"primaryCompletion":3119,"completion":3119,"start":3120,"enrollment":3121,"conditions":3122,"interventions":3124},"NCT02811692","Study for Collection of Aflibercept Data in Routine Practice",[],"2017-11-27","2016-09-30",425,[3123],"Eye Diseases",[82],{"nctId":79,"briefTitle":80,"status":132,"phases":3126,"primaryCompletion":81,"completion":3127,"start":3128,"enrollment":1649,"conditions":3129,"interventions":3133},[],"2027-03-30","2023-03-27",[3130,3131,3132],"Retinopathy of Prematurity","Newborns","Infants",[82],{"nctId":3135,"briefTitle":3136,"status":107,"phases":3137,"primaryCompletion":571,"completion":3138,"start":3139,"enrollment":3140,"conditions":3141,"interventions":3142},"NCT02540369","To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.",[],"2018-01-26","2015-12-14",2150,[3025],[82],{"nctId":3144,"briefTitle":3145,"status":107,"phases":3146,"primaryCompletion":3081,"completion":3081,"start":3147,"enrollment":3148,"conditions":3149,"interventions":3150},"NCT01783925","Eylea Post Marketing Surveillance(PMS)",[],"2014-04-29",3206,[2922],[82],{"nctId":3152,"briefTitle":3153,"status":143,"phases":3154,"primaryCompletion":3155,"completion":294,"start":3156,"enrollment":3157,"conditions":3158,"interventions":3160},"NCT04519619","Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)",[],"2027-06-30","2020-11-27",480,[3159],"Neovascular Glaucoma",[82],{"nctId":3162,"briefTitle":3163,"status":107,"phases":3164,"primaryCompletion":1608,"completion":3165,"start":3166,"enrollment":3167,"conditions":3168,"interventions":3169},"NCT02289924","Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy",[],"2019-07-08","2015-01-09",912,[3025],[82],{"nctId":3171,"briefTitle":3172,"status":107,"phases":3173,"primaryCompletion":3174,"completion":3175,"start":3176,"enrollment":3177,"conditions":3178,"interventions":3179},"NCT02321241","Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD",[],"2017-01-18","2017-08-18","2016-02-01",236,[3025],[82],{"nctId":3181,"briefTitle":3182,"status":107,"phases":3183,"primaryCompletion":3184,"completion":3185,"start":3186,"enrollment":3187,"conditions":3188,"interventions":3189},"NCT03161912","A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and\u002For Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease",[],"2021-09-14","2021-12-17","2017-11-24",2481,[2953],[82],{"nctId":3191,"briefTitle":3192,"status":107,"phases":3193,"primaryCompletion":3194,"completion":3194,"start":3195,"enrollment":3196,"conditions":3197,"interventions":3198},"NCT02279537","Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD",[],"2019-04-17","2014-01-02",593,[3025],[82],{"nctId":3200,"briefTitle":3201,"status":107,"phases":3202,"primaryCompletion":3203,"completion":3204,"start":3083,"enrollment":3205,"conditions":3206,"interventions":3207},"NCT01756261","EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan",[],"2016-07-20","2017-02-27",757,[2922],[82],{"nctId":3209,"briefTitle":3210,"status":107,"phases":3211,"primaryCompletion":3212,"completion":3212,"start":3213,"enrollment":3214,"conditions":3215,"interventions":3216},"NCT02645747","Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion",[],"2017-12-23","2016-01-21",126,[2962],[82],{"nctId":3218,"briefTitle":3219,"status":107,"phases":3220,"primaryCompletion":3101,"completion":3221,"start":3222,"enrollment":3223,"conditions":3224,"interventions":3225},"NCT03382587","Observational Study to Assess Intravitreal Aflibercept Injections Used in a \"Treat and Extend\" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients",[],"2018-11-27","2017-12-05",163,[3113],[82],{"nctId":3227,"briefTitle":3228,"status":107,"phases":3229,"primaryCompletion":3230,"completion":3231,"start":3232,"enrollment":3233,"conditions":3234,"interventions":3236},"NCT04137120","Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice",[],"2022-08-17","2023-02-01","2021-02-19",73,[3235],"Retinal Disease",[82],{"nctId":3238,"briefTitle":3239,"status":107,"phases":3240,"primaryCompletion":3241,"completion":539,"start":2490,"enrollment":3242,"conditions":3243,"interventions":3244},"NCT02425501","Special Drug Use Investigation of EYLEA for Diabetic Macular Edema",[],"2019-04-26",646,[2953],[82],{"nctId":3246,"briefTitle":3247,"status":107,"phases":3248,"primaryCompletion":3249,"completion":3249,"start":3250,"enrollment":3251,"conditions":3252,"interventions":3253},"NCT04641234","A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD).",[],"2021-06-09","2020-12-11",330,[3053],[82],{"nctId":3255,"briefTitle":3256,"status":107,"phases":3257,"primaryCompletion":3258,"completion":3259,"start":2482,"enrollment":12,"conditions":3260,"interventions":3262},"NCT02821247","Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece",[],"2019-07-10","2019-12-13",[3261,2922],"Choroidal Neovascularization",[82],{"nctId":3264,"briefTitle":3265,"status":107,"phases":3266,"primaryCompletion":3267,"completion":3268,"start":2939,"enrollment":435,"conditions":3269,"interventions":3270},"NCT03290794","Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice",[],"2022-11-25","2023-05-26",[3113],[82],{"nctId":3272,"briefTitle":3273,"status":107,"phases":3274,"primaryCompletion":3275,"completion":3276,"start":3277,"enrollment":11,"conditions":3278,"interventions":3279},"NCT02541084","Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan",[],"2016-03-30","2016-07-30","2015-08-18",[3025],[82],{"nctId":3281,"briefTitle":3282,"status":107,"phases":3283,"primaryCompletion":3284,"completion":3284,"start":3285,"enrollment":3286,"conditions":3287,"interventions":3288},"NCT03278262","The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting",[],"2017-12-31","2017-09-01",2312,[3025],[82],{"nctId":3290,"briefTitle":3291,"status":107,"phases":3292,"primaryCompletion":3293,"completion":3294,"start":3295,"enrollment":3296,"conditions":3297,"interventions":3298},"NCT02260687","Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization",[],"2018-04-02","2018-08-22","2014-12-05",353,[3261],[82],{"nctId":3300,"briefTitle":3301,"status":107,"phases":3302,"primaryCompletion":3303,"completion":3304,"start":3305,"enrollment":3306,"conditions":3307,"interventions":3308},"NCT03939767","Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease",[],"2023-07-07","2023-10-17","2019-05-12",1563,[3113],[82],{"nctId":3310,"briefTitle":3311,"status":143,"phases":3312,"primaryCompletion":3313,"completion":1028,"start":3314,"enrollment":864,"conditions":3315,"interventions":3317},"NCT06315556","An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)",[],"2027-03-31","2024-03-05",[3130,3316],"Preterm Infants",[82],{"intervention":3319,"totalTrials":480,"cells":3320},"Damoctocog alfa pegol",{"EARLY_PHASE1":3321,"PHASE1":3323,"PHASE2":3325,"PHASE3":3327,"PHASE4":3340,"NA":3350},{"trials":3322,"activeCount":101},[],{"trials":3324,"activeCount":101},[],{"trials":3326,"activeCount":101},[],{"trials":3328,"activeCount":101},[3329],{"nctId":3330,"briefTitle":3331,"status":107,"phases":3332,"primaryCompletion":3333,"completion":3334,"start":3335,"enrollment":1265,"conditions":3336,"interventions":3339},"NCT05147662","A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood",[92],"2024-01-04","2025-06-25","2022-03-23",[3337,3338,24,835],"Treatment of Bleeding","Prophylaxis of Bleeding",[3319],{"trials":3341,"activeCount":101},[3342],{"nctId":3343,"briefTitle":3344,"status":107,"phases":3345,"primaryCompletion":3346,"completion":3042,"start":3347,"enrollment":1509,"conditions":3348,"interventions":3349},"NCT04085458","Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation)",[93],"2022-05-20","2019-09-23",[24],[3319],{"trials":3351,"activeCount":855,"soonestReadout":974},[3352,3360,3367,3377,3385],{"nctId":3353,"briefTitle":3354,"status":132,"phases":3355,"primaryCompletion":974,"completion":3313,"start":3356,"enrollment":3357,"conditions":3358,"interventions":3359},"NCT03932201","Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A",[],"2019-10-21",371,[24],[3319],{"nctId":3361,"briefTitle":3362,"status":132,"phases":3363,"primaryCompletion":3313,"completion":3155,"start":3364,"enrollment":1133,"conditions":3365,"interventions":3366},"NCT04461639","Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent Bleeding",[],"2021-05-14",[24],[3319],{"nctId":3368,"briefTitle":3369,"status":107,"phases":3370,"primaryCompletion":3371,"completion":3372,"start":3373,"enrollment":3374,"conditions":3375,"interventions":3376},"NCT04091386","Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study)",[],"2024-05-07","2024-07-05","2021-06-10",10,[24],[3319],{"nctId":3378,"briefTitle":3379,"status":251,"phases":3380,"primaryCompletion":1847,"completion":3381,"start":3382,"enrollment":1519,"conditions":3383,"interventions":3384},"NCT07088458","An Observational Study to Learn More About How Well Damoctocog Alfa Pegol Works in Previously Treated Children With Hemophilia A",[],"2030-03-01","2026-05-29",[24],[3319],{"nctId":3386,"briefTitle":3387,"status":132,"phases":3388,"primaryCompletion":3313,"completion":3155,"start":3389,"enrollment":33,"conditions":3390,"interventions":3391},"NCT05643560","An Observational Study Called JOIHA to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A.",[],"2022-12-29",[24,3338],[3319],{"intervention":3393,"totalTrials":1949,"cells":3394},"Vericiguat",{"EARLY_PHASE1":3395,"PHASE1":3397,"PHASE2":3445,"PHASE3":3466,"PHASE4":3468,"NA":3481},{"trials":3396,"activeCount":101},[],{"trials":3398,"activeCount":101},[3399,3407,3417,3427,3435],{"nctId":3400,"briefTitle":3401,"status":107,"phases":3402,"primaryCompletion":3403,"completion":3404,"start":1733,"enrollment":701,"conditions":3405,"interventions":3406},"NCT04722562","A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Liver Disease and in Age-, Weight- and Gender-matched Healthy Participants",[90],"2015-01-21","2015-04-30",[738],[3393],{"nctId":3408,"briefTitle":3409,"status":107,"phases":3410,"primaryCompletion":3411,"completion":3412,"start":3413,"enrollment":3414,"conditions":3415,"interventions":3416},"NCT03504982","Study to Evaluate the QT \u002F QTc Interval Prolongation Potential of Vericiguat",[90],"2018-11-29","2019-02-26","2018-05-17",74,[1579],[3393,1144],{"nctId":3418,"briefTitle":3419,"status":107,"phases":3420,"primaryCompletion":3421,"completion":3422,"start":3423,"enrollment":1265,"conditions":3424,"interventions":3425},"NCT02617550","Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients",[90],"2016-05-18","2016-08-11","2015-11-18",[1579],[3393,3426],"Nitroglycerin",{"nctId":3428,"briefTitle":3429,"status":107,"phases":3430,"primaryCompletion":3431,"completion":3431,"start":3432,"enrollment":1561,"conditions":3433,"interventions":3434},"NCT04722484","A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Kidney Disease and in Age-, Weight- and Gender-matched Healthy Participants",[90],"2015-01-22","2014-06-12",[738],[3393],{"nctId":3436,"briefTitle":3437,"status":107,"phases":3438,"primaryCompletion":3439,"completion":3440,"start":3441,"enrollment":2199,"conditions":3442,"interventions":3443},"NCT03255512","Vericiguat Drug-drug Interaction Study With Isosorbite Mononitrate in Stable Coronary Artery Disease Patients",[90],"2018-02-07","2018-03-23","2017-08-17",[1579],[3393,3444],"Isosorbide mononitrate",{"trials":3446,"activeCount":101},[3447,3457],{"nctId":3448,"briefTitle":3449,"status":107,"phases":3450,"primaryCompletion":3451,"completion":3452,"start":3453,"enrollment":3454,"conditions":3455,"interventions":3456},"NCT01951625","Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)",[91],"2015-05-14","2015-06-09","2013-11-29",456,[738],[3393,3393],{"nctId":3458,"briefTitle":3459,"status":107,"phases":3460,"primaryCompletion":3277,"completion":3461,"start":3462,"enrollment":3463,"conditions":3464,"interventions":3465},"NCT01951638","Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)",[91],"2015-09-16","2013-11-06",477,[738],[3393,3393],{"trials":3467,"activeCount":101},[],{"trials":3469,"activeCount":101},[3470],{"nctId":3471,"briefTitle":3472,"status":107,"phases":3473,"primaryCompletion":3474,"completion":3474,"start":3475,"enrollment":3476,"conditions":3477,"interventions":3480},"NCT05658458","A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian Participants After Worsening of a Long-term Heart Condition in Which the Left Side of the Heart Does Not Pump Blood as Well as it Should (Chronic Heart Failure With Reduced Ejection Fraction)",[93],"2024-09-19","2022-12-16",205,[3478,3479],"Chronic Heart Failure With Reduced Ejection Fraction","Worsening Heart Failure",[3393],{"trials":3482,"activeCount":1341,"soonestReadout":931},[3483,3490,3498,3508,3515,3523,3532],{"nctId":3484,"briefTitle":3485,"status":107,"phases":3486,"primaryCompletion":3487,"completion":3487,"start":3372,"enrollment":874,"conditions":3488,"interventions":3489},"NCT06486844","An Observational Study Called ROVER to Learn More About How Well Vericiguat Works in People Who Were Newly Treated With Vericiguat in Routine Medical Care in Germany",[],"2025-08-31",[3478],[3393],{"nctId":3491,"briefTitle":3492,"status":107,"phases":3493,"primaryCompletion":359,"completion":3494,"start":3002,"enrollment":3495,"conditions":3496,"interventions":3497},"NCT05728502","An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China",[],"2025-12-26",2400,[3478],[3393,1874],{"nctId":3499,"briefTitle":3500,"status":107,"phases":3501,"primaryCompletion":3502,"completion":3502,"start":3503,"enrollment":3504,"conditions":3505,"interventions":3506},"NCT06697353","An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan",[],"2025-09-19","2024-11-01",4936,[979,3478],[3507],"vericiguat",{"nctId":3509,"briefTitle":3510,"status":107,"phases":3511,"primaryCompletion":3512,"completion":3512,"start":1930,"enrollment":285,"conditions":3513,"interventions":3514},"NCT06363110","An Observational Study to Learn More About Vericiguat Treatment Patterns and Its Safety in People With Chronic Heart Failure With Reduced Ejection Fraction in Routine Medical Care in the United States",[],"2024-06-24",[3478],[3393],{"nctId":3516,"briefTitle":3517,"status":132,"phases":3518,"primaryCompletion":931,"completion":931,"start":3519,"enrollment":3520,"conditions":3521,"interventions":3522},"NCT06632483","An Observational Study to Learn More About How Safe Vericiguat is and How Well it Works in Indian People With Chronic Heart Failure With Reduced Ejection Fraction and Worsening Chronic Heart Failure Under Real World Conditions",[],"2025-09-08",604,[3478,715],[3393],{"nctId":3524,"briefTitle":3525,"status":143,"phases":3526,"primaryCompletion":769,"completion":3527,"start":3528,"enrollment":3529,"conditions":3530,"interventions":3531},"NCT06148935","An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Setting",[],"2027-10-31","2023-11-30",1350,[3478],[3393],{"nctId":3533,"briefTitle":3534,"status":143,"phases":3535,"primaryCompletion":240,"completion":3536,"start":3537,"enrollment":285,"conditions":3538,"interventions":3539},"NCT05666518","A Study to Learn More About the Safety of the Drug Vericiguat in Japanese People With Chronic Heart Failure Who Will be Receiving Vericiguat Under Real-world Conditions",[],"2028-12-31","2022-08-31",[979],[3393,3540],"Standard of care",{"intervention":3542,"totalTrials":541,"cells":3543},"Rivaroxaban",{"EARLY_PHASE1":3544,"PHASE1":3546,"PHASE2":3612,"PHASE3":3709,"PHASE4":3884,"NA":3886},{"trials":3545,"activeCount":101},[],{"trials":3547,"activeCount":101},[3548,3555,3563,3572,3580,3590,3597,3605],{"nctId":3549,"briefTitle":3550,"status":107,"phases":3551,"primaryCompletion":2917,"completion":2229,"start":2367,"enrollment":1519,"conditions":3552,"interventions":3554},"NCT02537457","Bioequivalence Study of Rivaroxaban",[90],[3553],"Embolism, Atrial Fibrillation and Venous Thrombosis",[3542,3542],{"nctId":3556,"briefTitle":3557,"status":107,"phases":3558,"primaryCompletion":1487,"completion":1487,"start":1570,"enrollment":2307,"conditions":3559,"interventions":3562},"NCT01145859","Rivaroxaban Pharmacokinetics\u002FPharmacodynamics (PK\u002FPD) Study in Pediatric Subjects",[90],[3560,3561],"Venous Thrombosis","Pediatrics",[3542],{"nctId":3564,"briefTitle":3565,"status":107,"phases":3566,"primaryCompletion":1497,"completion":1497,"start":3567,"enrollment":3568,"conditions":3569,"interventions":3570},"NCT01507051","Switching Study From Warfarin to Rivaroxaban",[90],"2008-11",96,[3560],[2202,3542,3571],"Vitamin K",{"nctId":3573,"briefTitle":3574,"status":107,"phases":3575,"primaryCompletion":3576,"completion":3576,"start":1314,"enrollment":171,"conditions":3577,"interventions":3579},"NCT01436526","Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban",[90],"2009-09",[3578],"Therapeutic Equivalency",[3542,3542],{"nctId":3581,"briefTitle":3582,"status":107,"phases":3583,"primaryCompletion":3584,"completion":3585,"start":3586,"enrollment":160,"conditions":3587,"interventions":3589},"NCT04720092","A Trial to Learn How a New Liquid Form of Rivaroxaban Behaves and How Safe it is Compared to the Current Tablet Form of Rivaroxaban in Healthy Male Participants",[90],"2017-08-28","2017-10-27","2017-07-05",[3588],"Thromboembolic Disorders",[3542,3542],{"nctId":3591,"briefTitle":3592,"status":107,"phases":3593,"primaryCompletion":2290,"completion":548,"start":3594,"enrollment":1163,"conditions":3595,"interventions":3596},"NCT02367027","Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions",[90],"2015-02",[1790],[3542,3542,3542,3542],{"nctId":3598,"briefTitle":3599,"status":107,"phases":3600,"primaryCompletion":3601,"completion":2187,"start":1586,"enrollment":1181,"conditions":3602,"interventions":3604},"NCT01853800","Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet",[90],"2013-07",[3603],"Biological Availability",[3542],{"nctId":3606,"briefTitle":3607,"status":107,"phases":3608,"primaryCompletion":2917,"completion":2229,"start":3609,"enrollment":1519,"conditions":3610,"interventions":3611},"NCT02537405","Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects",[90],"2014-02",[3553],[3542,3542],{"trials":3613,"activeCount":101},[3614,3623,3634,3643,3653,3663,3672,3681,3694,3701],{"nctId":3615,"briefTitle":3616,"status":107,"phases":3617,"primaryCompletion":3618,"completion":1327,"start":3619,"enrollment":2388,"conditions":3620,"interventions":3622},"NCT00786422","Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer",[91],"2011-05","2009-05",[3560,3621],"Deep Vein Thrombosis",[3542],{"nctId":3624,"briefTitle":3625,"status":107,"phases":3626,"primaryCompletion":3627,"completion":3627,"start":3628,"enrollment":3629,"conditions":3630,"interventions":3632},"NCT00396786","Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement",[91],"2005-07","2004-11",877,[3631],"Venous Thromboembolism",[3542,3542,3542,3542,3542,3633],"Enoxaparin",{"nctId":3635,"briefTitle":3636,"status":107,"phases":3637,"primaryCompletion":3638,"completion":3638,"start":3639,"enrollment":3374,"conditions":3640,"interventions":3642},"NCT02564718","Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates",[90,91],"2017-12-18","2015-11-19",[3641],"Thromboembolism",[3542],{"nctId":3644,"briefTitle":3645,"status":107,"phases":3646,"primaryCompletion":3647,"completion":3647,"start":3648,"enrollment":447,"conditions":3649,"interventions":3650},"NCT01684423","Oral Rivaroxaban in Children With Venous Thrombosis",[91],"2016-09-01","2013-02-19",[3560],[3542,3651,3652],"Active comparator","Rivaroxaban (BAY59-7939) suspension",{"nctId":3654,"briefTitle":3655,"status":107,"phases":3656,"primaryCompletion":3657,"completion":3657,"start":3658,"enrollment":3659,"conditions":3660,"interventions":3662},"NCT00839826","ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial",[91],"2003-11","2002-12",641,[3641,3661],"Prevention",[3542,3633],{"nctId":3664,"briefTitle":3665,"status":107,"phases":3666,"completion":3667,"start":3668,"enrollment":3669,"conditions":3670,"interventions":3671},"NCT00398905","Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement",[91],"2004-09","2004-01",726,[3631],[3542,3542,3542,3542,3542,3633],{"nctId":3673,"briefTitle":3674,"status":107,"phases":3675,"primaryCompletion":3628,"completion":3628,"start":446,"enrollment":3676,"conditions":3677,"interventions":3678},"NCT00402467","An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study",[91],613,[3631],[3542,3679,3679,3679,3680,3680],"Rivaroxaban,","Enoxaparine",{"nctId":3682,"briefTitle":3683,"status":107,"phases":3684,"primaryCompletion":3685,"completion":3686,"start":3687,"enrollment":3688,"conditions":3689,"interventions":3691},"NCT01442792","Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention",[91],"2013-01-29","2013-03-04","2011-10-12",108,[3690,1579],"Cardiovascular Disease",[3692,3542,3542,3693],"UFH","Rivaroxaban (Xarelto, BAY59-7939) and UFH",{"nctId":3695,"briefTitle":3696,"status":107,"phases":3697,"primaryCompletion":3698,"completion":3698,"start":1609,"enrollment":400,"conditions":3699,"interventions":3700},"NCT02309411","EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis",[91],"2017-04-05",[3631],[3542],{"nctId":3702,"briefTitle":3703,"status":107,"phases":3704,"primaryCompletion":3705,"completion":3705,"start":3706,"enrollment":1265,"conditions":3707,"interventions":3708},"NCT00779064","BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status",[91],"2005-06","2004-07",[21],[3542,3542],{"trials":3710,"activeCount":101},[3711,3719,3728,3736,3746,3753,3764,3774,3783,3789,3797,3805,3814,3823,3830,3837,3852,3858,3869,3877],{"nctId":3712,"briefTitle":3713,"status":107,"phases":3714,"primaryCompletion":1629,"completion":2406,"start":2959,"enrollment":1519,"conditions":3715,"interventions":3717},"NCT01516814","Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients",[92],[3716],"Pulmonary Embolism",[3542,3718,2202],"Unfractionated heparin",{"nctId":3720,"briefTitle":3721,"status":107,"phases":3722,"primaryCompletion":445,"completion":3723,"start":3724,"enrollment":3725,"conditions":3726,"interventions":3727},"NCT00332020","Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement",[92],"2007-06","2006-02",2457,[3661,3631],[3542,3633],{"nctId":3729,"briefTitle":3730,"status":107,"phases":3731,"primaryCompletion":3732,"completion":3733,"start":2187,"enrollment":2151,"conditions":3734,"interventions":3735},"NCT01839357","Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial\u002FLeft Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter",[92],"2014-11","2014-12",[21],[3542],{"nctId":3737,"briefTitle":3738,"status":156,"phases":3739,"primaryCompletion":580,"completion":580,"start":3740,"enrollment":3741,"conditions":3742,"interventions":3744},"NCT02313909","Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)",[92],"2014-12-23",7213,[3743],"Stroke",[3542,3745],"Acetylsalicylic acid",{"nctId":3747,"briefTitle":3748,"status":107,"phases":3749,"primaryCompletion":1314,"completion":3576,"start":1328,"enrollment":3750,"conditions":3751,"interventions":3752},"NCT00439725","Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study",[92],1197,[3631],[3542],{"nctId":3754,"briefTitle":3755,"status":156,"phases":3756,"primaryCompletion":3221,"completion":3221,"start":1832,"enrollment":3757,"conditions":3758,"interventions":3760},"NCT02556203","Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes",[92],1653,[3759],"Transcatheter Aortic Valve Replacement",[3542,3761,3762,3542,3763],"Acetylsalicylic Acid","Clopidogrel","Vitamin K antagonist",{"nctId":3765,"briefTitle":3766,"status":107,"phases":3767,"primaryCompletion":1587,"completion":1570,"start":3768,"enrollment":3769,"conditions":3770,"interventions":3771},"NCT00571649","Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients",[92],"2007-12",8101,[3631],[3542,3633,3772,3773],"Rivaroxaban placebo","Enoxaparin placebo",{"nctId":3775,"briefTitle":3776,"status":107,"phases":3777,"primaryCompletion":1326,"completion":1326,"start":3778,"enrollment":3779,"conditions":3780,"interventions":3781},"NCT00440193","Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study",[92],"2007-03",3449,[3560],[3542,3782],"Enoxaparin followed by VKA",{"nctId":3784,"briefTitle":3785,"status":107,"phases":3786,"primaryCompletion":2230,"completion":2367,"start":410,"enrollment":2151,"conditions":3787,"interventions":3788},"NCT01516840","Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients",[92],[3621],[3542,3542,3718,2202],{"nctId":3790,"briefTitle":3791,"status":107,"phases":3792,"primaryCompletion":3618,"completion":1327,"start":3793,"enrollment":3794,"conditions":3795,"interventions":3796},"NCT01206972","Dose-confirmatory Bridging Study in Total Knee Replacement",[92],"2010-10",302,[3631],[3542,3542,3542,3633],{"nctId":3798,"briefTitle":3799,"status":107,"phases":3800,"primaryCompletion":1351,"completion":2919,"start":3778,"enrollment":3801,"conditions":3802,"interventions":3803},"NCT00439777","Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study",[92],4833,[3716],[3542,3804],"Enoxaparin overlapping with and followed by VKA",{"nctId":3806,"briefTitle":3807,"status":107,"phases":3808,"primaryCompletion":499,"completion":3809,"start":3723,"enrollment":3810,"conditions":3811,"interventions":3812},"NCT00494871","Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation",[92],"2010-01",1280,[21],[3542,2202,3772,3813],"Warfarin placebo",{"nctId":3815,"briefTitle":3816,"status":107,"phases":3817,"primaryCompletion":1648,"completion":3818,"start":3819,"enrollment":3820,"conditions":3821,"interventions":3822},"NCT00362232","Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.",[92],"2008-01","2006-06",3148,[3631],[3542,3633],{"nctId":3824,"briefTitle":3825,"status":107,"phases":3826,"primaryCompletion":2367,"completion":2367,"start":408,"enrollment":3827,"conditions":3828,"interventions":3829},"NCT01674647","Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion",[92],1504,[21],[3542,3763],{"nctId":3831,"briefTitle":3832,"status":107,"phases":3833,"primaryCompletion":1648,"completion":1648,"start":3724,"enrollment":3834,"conditions":3835,"interventions":3836},"NCT00361894","Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.",[92],2531,[3661,3631],[3542,3633],{"nctId":3838,"briefTitle":3839,"status":107,"phases":3840,"primaryCompletion":3841,"completion":3842,"start":3843,"enrollment":3844,"conditions":3845,"interventions":3847},"NCT01776424","Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease",[92],"2017-07-21","2021-06-15","2013-02-28",27395,[3846],"Prevention & Control",[3542,3542,3848,3849,3772,3850,3851],"Aspirin","Aspirin placebo","Pantoprazole","Pantoprazole placebo",{"nctId":3853,"briefTitle":3854,"status":107,"phases":3855,"primaryCompletion":1327,"completion":2969,"start":2968,"enrollment":217,"conditions":3856,"interventions":3857},"NCT01205932","Dose-confirmatory Bridging Study in Total Hip Replacement",[92],[3631],[3542,3542,3542,3633],{"nctId":3859,"briefTitle":3860,"status":107,"phases":3861,"primaryCompletion":3862,"completion":3863,"start":3277,"enrollment":3864,"conditions":3865,"interventions":3867},"NCT02504216","Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities",[92],"2019-11-27","2020-01-09",6564,[3866],"Peripheral Artery Disease",[3542,3868],"Rivaroxaban-Placebo",{"nctId":3870,"briefTitle":3871,"status":107,"phases":3872,"primaryCompletion":3873,"completion":3873,"start":3874,"enrollment":874,"conditions":3875,"interventions":3876},"NCT02234843","EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis",[92],"2019-01-30","2014-11-13",[3631],[3542,3542,1874],{"nctId":3878,"briefTitle":3879,"status":107,"phases":3880,"primaryCompletion":3778,"completion":3778,"start":3724,"enrollment":3881,"conditions":3882,"interventions":3883},"NCT00329628","Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin",[92],4541,[3631],[3542,3633],{"trials":3885,"activeCount":101},[],{"trials":3887,"activeCount":175,"soonestReadout":931},[3888,3901,3912,3922,3934,3944,3954,3965,3975,3985,3993,4003,4014,4024,4034,4043,4054,4062,4073,4083,4091,4102,4112,4123,4131,4140,4147,4156,4165,4174,4183,4192,4199,4209,4219,4229,4239,4246,4254,4262,4272,4281,4288,4297,4307,4316,4326,4333,4344,4352,4362,4371,4384,4393,4402,4412,4420,4427,4437,4447,4456],{"nctId":3889,"briefTitle":3890,"status":107,"phases":3891,"primaryCompletion":3892,"completion":3892,"start":3893,"enrollment":3894,"conditions":3895,"interventions":3898},"NCT04979780","Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort",[],"2022-03-31","2021-07-20",3708,[3896,3897],"Treatment of Venous Thromboembolism in Cancer Patients","Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients",[3542,3899,3900],"Low molecular weight heparin","Direct Oral Anticoagulants",{"nctId":3902,"briefTitle":3903,"status":107,"phases":3904,"primaryCompletion":3905,"completion":3905,"start":3906,"enrollment":3907,"conditions":3908,"interventions":3909},"NCT05150938","A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)",[],"2023-02-28","2022-03-18",5737,[3896],[3542,3899,3910,3911],"vitamin K antagonist","other NOACs",{"nctId":3913,"briefTitle":3914,"status":107,"phases":3915,"primaryCompletion":3916,"completion":3916,"start":3917,"enrollment":3918,"conditions":3919,"interventions":3920},"NCT04444804","Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany",[],"2021-04-30","2020-07-31",22153,[3631],[3542,3921],"LMWH and Phenprocoumon",{"nctId":3923,"briefTitle":3924,"status":107,"phases":3925,"primaryCompletion":3926,"completion":3927,"start":3928,"enrollment":977,"conditions":3929,"interventions":3933},"NCT04298567","Study to Learn More About the Safety and Effectiveness of Rivaroxaban (Xarelto) When Given Together With Acetylsalicylic Acid to Indian People With Narrowing of the Arteries of the Heart (CAD) and\u002For With Reduced Blood Flow in the Arteries of the Legs and Arms With Symptoms (Symptomatic PAD)",[],"2024-03-28","2024-06-06","2022-02-25",[3930,3931,3932],"Prevention of Atherothrombotic Events","Coronary Artery Disease (CAD)","Symptomatic Peripheral Artery Disease (Symptomatic PAD)",[3542,3745],{"nctId":3935,"briefTitle":3936,"status":107,"phases":3937,"primaryCompletion":3938,"completion":3938,"start":3939,"enrollment":3940,"conditions":3941,"interventions":3942},"NCT05461807","An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins (Venous Thromboembolism)",[],"2022-10-05","2022-07-14",2437,[3896,3631,219],[3542,3943],"Apixaban",{"nctId":3945,"briefTitle":3946,"status":132,"phases":3947,"primaryCompletion":931,"completion":974,"start":3948,"enrollment":1669,"conditions":3949,"interventions":3953},"NCT06193863","An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who Had a Heart Surgery Called the Fontan Procedure",[],"2024-06-18",[3950,3951,3952,835],"Prevention of Venous Thromboembolism","Congenital Heart Disease","Fontan Procedure",[3542],{"nctId":3955,"briefTitle":3956,"status":107,"phases":3957,"primaryCompletion":3958,"completion":3958,"start":3959,"enrollment":3960,"conditions":3961,"interventions":3962},"NCT03563937","Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon",[],"2019-12-10","2018-06-15",64920,[21],[3963,3943,3542,3964],"Phenprocoumon","Edoxaban",{"nctId":3966,"briefTitle":3967,"status":107,"phases":3968,"primaryCompletion":3969,"completion":3969,"start":3970,"enrollment":3971,"conditions":3972,"interventions":3974},"NCT04923139","A Study to Learn About Venous Thromboembolism (VTE) Treatment With Rivaroxaban in Japanese Patients Using a Claims Database",[],"2022-12-31","2022-01-24",2627,[3973],"Treatment of Venous Thromboembolism",[3542],{"nctId":3976,"briefTitle":3977,"status":156,"phases":3978,"primaryCompletion":3979,"completion":3979,"start":3980,"enrollment":3981,"conditions":3982,"interventions":3984},"NCT03715725","A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.",[],"2020-01-20","2018-10-31",70000,[3983],"Non-valvular Atrial Fibrillation",[3542,3943,1126,2202],{"nctId":3986,"briefTitle":3987,"status":107,"phases":3988,"primaryCompletion":3989,"completion":3733,"start":3601,"enrollment":3990,"conditions":3991,"interventions":3992},"NCT01855139","Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism",[],"2014-10",106,[21],[3542],{"nctId":3994,"briefTitle":3995,"status":107,"phases":3996,"primaryCompletion":3997,"completion":3997,"start":3998,"enrollment":3999,"conditions":4000,"interventions":4001},"NCT04249401","Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)",[],"2023-09-30","2020-03-01",134897,[21],[3542,3943,4002,2202],"Dabigatran",{"nctId":4004,"briefTitle":4005,"status":107,"phases":4006,"primaryCompletion":4007,"completion":4007,"start":4008,"enrollment":4009,"conditions":4010,"interventions":4012},"NCT04297072","Study to Gather Information on the Kidney Function of Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) Treated With Rivaroxaban or Vitamin K Antagonists",[],"2021-02-28","2020-05-01",25000,[4011],"Non-Valvular Atrial Fibrillation",[3542,4013],"VKAs",{"nctId":4015,"briefTitle":4016,"status":107,"phases":4017,"primaryCompletion":4018,"completion":4019,"start":4020,"enrollment":4021,"conditions":4022,"interventions":4023},"NCT02558465","Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)",[],"2021-04-01","2021-05-31","2015-11-13",2540,[3631],[3542],{"nctId":4025,"briefTitle":4026,"status":107,"phases":4027,"primaryCompletion":4028,"completion":4029,"start":2979,"enrollment":4030,"conditions":4031,"interventions":4033},"NCT03746275","Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid",[],"2021-06-08","2021-07-13",5798,[4032],"Atherosclerosis",[3542,3745],{"nctId":4035,"briefTitle":4036,"status":107,"phases":4037,"primaryCompletion":2187,"completion":1647,"start":1352,"enrollment":4038,"conditions":4039,"interventions":4042},"NCT01444586","Russian Non-Interventional Study on Compliance of Venous Thromboembolism (VTE)",[],2293,[4040,4041],"Arthroplasty, Replacement, Hip","Arthroplasty, Replacement, Knee",[3542],{"nctId":4044,"briefTitle":4045,"status":107,"phases":4046,"primaryCompletion":4047,"completion":4048,"start":4049,"enrollment":4050,"conditions":4051,"interventions":4053},"NCT03746301","Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation",[],"2021-07-28","2021-12-15","2018-12-03",924,[4052],"Non-valvular Atrial Fibrillation (NVAF)",[3542],{"nctId":4055,"briefTitle":4056,"status":107,"phases":4057,"primaryCompletion":4058,"completion":4058,"start":3422,"enrollment":4059,"conditions":4060,"interventions":4061},"NCT02876718","Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study",[],"2018-01-09",253,[21],[3542],{"nctId":4063,"briefTitle":4064,"status":107,"phases":4065,"primaryCompletion":4066,"completion":4066,"start":4067,"enrollment":4068,"conditions":4069,"interventions":4071},"NCT02485873","Real-Life Evidence on Stroke Prevention in SPAF",[],"2015-09","2015-05",8607,[4070],"Atrial Fibrillation (Prevention of Stroke)",[3542,4072],"Vitamin K antagonists",{"nctId":4074,"briefTitle":4075,"status":107,"phases":4076,"primaryCompletion":4077,"completion":4078,"start":4079,"enrollment":4080,"conditions":4081,"interventions":4082},"NCT03284762","Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation",[],"2019-08-09","2019-11-20","2017-09-11",1216,[21],[3542],{"nctId":4084,"briefTitle":4085,"status":107,"phases":4086,"primaryCompletion":1486,"completion":2407,"start":499,"enrollment":4087,"conditions":4088,"interventions":4089},"NCT01029743","Xarelto Regulatory Post-Marketing Surveillance",[],3388,[3631],[3542,4090],"Pharmacologic agents",{"nctId":4092,"briefTitle":4093,"status":107,"phases":4094,"primaryCompletion":3081,"completion":4095,"start":4096,"enrollment":4097,"conditions":4098,"interventions":4100},"NCT02468102","Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)",[],"2020-09-30","2015-06-15",99999,[4099,3560,3716,21],"Acute Coronary Syndrome",[3542,4101],"Standard of care drugs",{"nctId":4103,"briefTitle":4104,"status":107,"phases":4105,"primaryCompletion":4106,"completion":4106,"start":4107,"enrollment":4108,"conditions":4109,"interventions":4110},"NCT03359876","Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction",[],"2019-03-29","2017-12-01",16000,[21],[3542,4111],"Warfarin sodium",{"nctId":4113,"briefTitle":4114,"status":107,"phases":4115,"primaryCompletion":4116,"completion":4116,"start":4117,"enrollment":4118,"conditions":4119,"interventions":4121},"NCT03965741","Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners",[],"2020-11-30","2019-05-30",97765,[4120],"Venous Thromboembolism (VTE)",[3542,3943,4122],"Pradaxa",{"nctId":4124,"briefTitle":4125,"status":107,"phases":4126,"primaryCompletion":4127,"completion":4127,"start":2489,"enrollment":4097,"conditions":4128,"interventions":4129},"NCT02864758","Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France",[],"2018-09-30",[21],[3542,4072,4130],"dabigatran",{"nctId":4132,"briefTitle":4133,"status":107,"phases":4134,"primaryCompletion":4135,"completion":2980,"start":4136,"enrollment":4137,"conditions":4138,"interventions":4139},"NCT02784717","Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study",[],"2019-02-21","2016-05-11",3055,[3743],[3542],{"nctId":4141,"briefTitle":4142,"status":107,"phases":4143,"primaryCompletion":1542,"completion":3989,"start":2367,"enrollment":4144,"conditions":4145,"interventions":4146},"NCT02090543","BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies",[],647,[21],[3963,3542],{"nctId":4148,"briefTitle":4149,"status":251,"phases":4150,"primaryCompletion":1846,"completion":1846,"start":4151,"enrollment":4152,"conditions":4153,"interventions":4155},"NCT05900388","A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)",[],"2026-09-01",850,[3631,4154],"Children Under 2 Years",[3542,3540],{"nctId":4157,"briefTitle":4158,"status":107,"phases":4159,"primaryCompletion":4160,"completion":4160,"start":4107,"enrollment":4161,"conditions":4162,"interventions":4164},"NCT03374540","Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients",[],"2019-08-30",78517,[4163],"Nonvalvular Atrial Fibrillation",[3542,3763],{"nctId":4166,"briefTitle":4167,"status":107,"phases":4168,"primaryCompletion":4169,"completion":4169,"start":4170,"enrollment":4171,"conditions":4172,"interventions":4173},"NCT01750788","Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia",[],"2015-10-12","2013-01-13",2297,[21],[3542],{"nctId":4175,"briefTitle":4176,"status":107,"phases":4177,"primaryCompletion":4178,"completion":2470,"start":4179,"enrollment":4180,"conditions":4181,"interventions":4182},"NCT01598051","Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan",[],"2016-06-09","2012-05-31",741,[4052],[3542],{"nctId":4184,"briefTitle":4185,"status":107,"phases":4186,"primaryCompletion":263,"completion":4187,"start":4188,"enrollment":4189,"conditions":4190,"interventions":4191},"NCT04401761","A Study to Collect Data on the Treatment Pattern of Xarelto + Acetylsalicylic Acid in the Routine Clinical Practice in Patients Who Are Suffering From a Condition That Narrows the Blood Vessels Supplying the Heart and \u002F or a Condition That Most Commonly Narrows the Blood Vessel in the Legs",[],"2023-09-29","2020-05-28",3189,[1579,3866],[3542,3745],{"nctId":4193,"briefTitle":4194,"status":107,"phases":4195,"primaryCompletion":3594,"completion":4067,"start":3989,"enrollment":4196,"conditions":4197,"interventions":4198},"NCT02262676","Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain",[],2251,[21],[3542],{"nctId":4200,"briefTitle":4201,"status":107,"phases":4202,"primaryCompletion":4203,"completion":4203,"start":4204,"enrollment":4205,"conditions":4206,"interventions":4207},"NCT02690155","Real-world Comparative Effectiveness of Rivaroxaban Versus VKA",[],"2016-03-01","2016-02-12",38831,[21],[3542,4208],"VKA",{"nctId":4210,"briefTitle":4211,"status":107,"phases":4212,"primaryCompletion":4213,"completion":4214,"start":4215,"enrollment":4216,"conditions":4217,"interventions":4218},"NCT04356989","Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in the Non-central Nervous System Due to Irregular Heartbeat in Taiwanese Patients Suffering From Decreased Renal Function",[],"2022-11-15","2023-01-16","2020-05-13",493,[4052],[3542],{"nctId":4220,"briefTitle":4221,"status":107,"phases":4222,"primaryCompletion":4223,"completion":4224,"start":4225,"enrollment":4226,"conditions":4227,"interventions":4228},"NCT01800006","Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region",[],"2016-01-16","2016-06-20","2013-01-14",2101,[21],[3542],{"nctId":4230,"briefTitle":4231,"status":107,"phases":4232,"primaryCompletion":3042,"completion":3042,"start":4233,"enrollment":4234,"conditions":4235,"interventions":4236},"NCT05112666","A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK)",[],"2021-12-02",2601,[3896],[3542,4237,4238],"other DOACs","LMWH",{"nctId":4240,"briefTitle":4241,"status":107,"phases":4242,"primaryCompletion":4203,"completion":4203,"start":4204,"enrollment":4243,"conditions":4244,"interventions":4245},"NCT03242278","Real-world Dosing Patterns of Rivaroxaban in the United States",[],12507,[21],[3542],{"nctId":4247,"briefTitle":4248,"status":107,"phases":4249,"primaryCompletion":1543,"completion":1486,"start":4250,"enrollment":4251,"conditions":4252,"interventions":4253},"NCT01805531","Satisfaction\u002FQuality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication",[],"2013-04",411,[21],[3542],{"nctId":4255,"briefTitle":4256,"status":107,"phases":4257,"primaryCompletion":4095,"completion":4095,"start":4258,"enrollment":4259,"conditions":4260,"interventions":4261},"NCT01947959","Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)",[],"2011-12-22",665533,[3560,3716,21,4099],[3542,3540],{"nctId":4263,"briefTitle":4264,"status":107,"phases":4265,"primaryCompletion":4266,"completion":1608,"start":4267,"enrollment":4268,"conditions":4269,"interventions":4271},"NCT02742623","A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer",[],"2018-11-30","2016-10-11",528,[4270],"Venous Thrombosis and Pulmonary Embolism",[3542],{"nctId":4273,"briefTitle":4274,"status":107,"phases":4275,"primaryCompletion":4276,"completion":4276,"start":4277,"enrollment":4278,"conditions":4279,"interventions":4280},"NCT03462446","Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events",[],"2016-05-01","2015-06-01",249,[21],[3542,4072],{"nctId":4282,"briefTitle":4283,"status":107,"phases":4284,"primaryCompletion":3732,"completion":3733,"start":3601,"enrollment":4285,"conditions":4286,"interventions":4287},"NCT01855100","Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT)",[],131,[3560],[3542],{"nctId":4289,"briefTitle":4290,"status":107,"phases":4291,"primaryCompletion":1327,"completion":4250,"start":4292,"enrollment":4293,"conditions":4294,"interventions":4295},"NCT00831714","Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty",[],"2009-02",19076,[3631],[3542,4296],"Standard care treatment for VTE prophylaxis",{"nctId":4298,"briefTitle":4299,"status":107,"phases":4300,"primaryCompletion":4301,"completion":4302,"start":4303,"enrollment":4304,"conditions":4305,"interventions":4306},"NCT01606995","Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation",[],"2015-03-06","2015-03-31","2012-06-12",6784,[21],[3542],{"nctId":4308,"briefTitle":4309,"status":107,"phases":4310,"primaryCompletion":4311,"completion":4311,"start":4312,"enrollment":4313,"conditions":4314,"interventions":4315},"NCT04509193","A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes",[],"2021-07-31","2020-08-21",116049,[21],[3542,2202],{"nctId":4317,"briefTitle":4318,"status":107,"phases":4319,"primaryCompletion":4320,"completion":4321,"start":4322,"enrollment":4323,"conditions":4324,"interventions":4325},"NCT02975453","Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban",[],"2020-03-18","2020-08-26","2016-12-05",1481,[21],[3542],{"nctId":4327,"briefTitle":4328,"status":107,"phases":4329,"primaryCompletion":1486,"completion":1487,"start":1585,"enrollment":4330,"conditions":4331,"interventions":4332},"NCT01619007","Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy",[],5145,[3621,3560],[3542,3540],{"nctId":4334,"briefTitle":4335,"status":107,"phases":4336,"primaryCompletion":4337,"completion":4338,"start":4339,"enrollment":4340,"conditions":4341,"interventions":4343},"NCT01582737","Xarelto [SPAF] Post-marketing Surveillance in Japan",[],"2019-03-31","2020-01-17","2012-05-30",11310,[4342],"Brain Ischemia",[3542],{"nctId":4345,"briefTitle":4346,"status":107,"phases":4347,"primaryCompletion":4348,"completion":4348,"start":4349,"enrollment":4097,"conditions":4350,"interventions":4351},"NCT02960880","Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists",[],"2016-12-31","2016-10-15",[21],[3542,3963],{"nctId":4353,"briefTitle":4354,"status":107,"phases":4355,"primaryCompletion":4356,"completion":4357,"start":4358,"enrollment":4359,"conditions":4360,"interventions":4361},"NCT03887780","A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)",[],"2023-12-23","2024-12-16","2019-10-03",504,[4052],[3542],{"nctId":4363,"briefTitle":4364,"status":107,"phases":4365,"primaryCompletion":4366,"completion":4366,"start":4367,"enrollment":4368,"conditions":4369,"interventions":4370},"NCT05022758","A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin",[],"2022-10-24","2021-10-06",45000,[4052],[3542,2202],{"nctId":4372,"briefTitle":4373,"status":107,"phases":4374,"primaryCompletion":4375,"completion":4376,"start":4377,"enrollment":4378,"conditions":4379,"interventions":4382},"NCT02210819","Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy",[],"2016-11-03","2017-01-20","2014-06-27",1987,[4380,4381],"Deep Vein Thrombosis (DVT)","Pulmonary Embolism (PE)",[3542,4383],"Recommended VTE pharmacological treatments according to international guidelines",{"nctId":4385,"briefTitle":4386,"status":107,"phases":4387,"primaryCompletion":4388,"completion":4389,"start":4390,"enrollment":3023,"conditions":4391,"interventions":4392},"NCT03410706","Xarelto for Real Life Anticoagulation in Pulmonary Embolism (PE) in China",[],"2021-07-29","2021-12-24","2018-02-01",[3716],[3542],{"nctId":4394,"briefTitle":4395,"status":107,"phases":4396,"primaryCompletion":4397,"completion":4397,"start":4398,"enrollment":4399,"conditions":4400,"interventions":4401},"NCT03847181","Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice",[],"2020-10-31","2019-02-28",45164,[21],[3542,3943,2202],{"nctId":4403,"briefTitle":4404,"status":464,"phases":4405,"primaryCompletion":4406,"completion":4406,"start":3989,"enrollment":101,"conditions":4407,"interventions":4411},"NCT01523418","Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement)",[],"2016-11",[4408,4409,4410],"Prophylaxis, Thromboembolism, Venous","Total Knee Replacement","Total Hip Replacement",[3542],{"nctId":4413,"briefTitle":4414,"status":107,"phases":4415,"primaryCompletion":4095,"completion":4095,"start":4258,"enrollment":4416,"conditions":4417,"interventions":4418},"NCT01947998","Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)",[],50299,[3560,3716,21,4099],[3542,2202,4419],"Antiplatelet drugs",{"nctId":4421,"briefTitle":4422,"status":107,"phases":4423,"primaryCompletion":2290,"completion":548,"start":1586,"enrollment":4424,"conditions":4425,"interventions":4426},"NCT01805544","Satisfaction\u002FQuality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication",[],113,[3560],[3542],{"nctId":4428,"briefTitle":4429,"status":107,"phases":4430,"primaryCompletion":4431,"completion":4432,"start":4433,"enrollment":4434,"conditions":4435,"interventions":4436},"NCT03455439","Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)",[],"2021-07-17","2022-01-11","2018-03-16",552,[738],[3542],{"nctId":4438,"briefTitle":4439,"status":107,"phases":4440,"primaryCompletion":4441,"completion":4442,"start":4443,"enrollment":4444,"conditions":4445,"interventions":4446},"NCT03119116","Use of Direct Oral Anticoagulants in UK",[],"2017-10-16","2019-04-16","2017-05-15",31336,[3743],[3542,4002,3943],{"nctId":4448,"briefTitle":4449,"status":107,"phases":4450,"primaryCompletion":4451,"completion":4452,"start":3958,"enrollment":4453,"conditions":4454,"interventions":4455},"NCT04174859","Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment",[],"2022-06-30","2022-12-12",812,[3983],[3542],{"nctId":4457,"briefTitle":4458,"status":107,"phases":4459,"primaryCompletion":4460,"completion":4460,"start":4461,"enrollment":4462,"conditions":4463,"interventions":4464},"NCT03214172","Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban",[],"2017-09-15","2017-07-15",1000,[3631],[3542],{"intervention":3540,"totalTrials":4466,"cells":4467},9,{"EARLY_PHASE1":4468,"PHASE1":4470,"PHASE2":4472,"PHASE3":4474,"PHASE4":4480,"NA":4482},{"trials":4469,"activeCount":101},[],{"trials":4471,"activeCount":101},[],{"trials":4473,"activeCount":101},[],{"trials":4475,"activeCount":101},[4476],{"nctId":3870,"briefTitle":3871,"status":107,"phases":4477,"primaryCompletion":3873,"completion":3873,"start":3874,"enrollment":874,"conditions":4478,"interventions":4479},[92],[3631],[3542,3542,1874],{"trials":4481,"activeCount":101},[],{"trials":4483,"activeCount":175,"soonestReadout":240},[4484,4495,4499,4503,4507,4511,4520,4524],{"nctId":4485,"briefTitle":4486,"status":107,"phases":4487,"primaryCompletion":4488,"completion":4488,"start":4489,"enrollment":4490,"conditions":4491,"interventions":4493},"NCT03684395","Accessibility to New Drugs Versus SOC in Sweden",[],"2017-06-30","2016-06-15",68056,[4492],"Anticoagulation",[4494,3540],"DOACs: Rivaroxaban, Dabigatran, Apixaban",{"nctId":3491,"briefTitle":3492,"status":107,"phases":4496,"primaryCompletion":359,"completion":3494,"start":3002,"enrollment":3495,"conditions":4497,"interventions":4498},[],[3478],[3393,1874],{"nctId":4148,"briefTitle":4149,"status":251,"phases":4500,"primaryCompletion":1846,"completion":1846,"start":4151,"enrollment":4152,"conditions":4501,"interventions":4502},[],[3631,4154],[3542,3540],{"nctId":1864,"briefTitle":1865,"status":107,"phases":4504,"primaryCompletion":1867,"completion":1867,"start":1868,"enrollment":1869,"conditions":4505,"interventions":4506},[],[1871,1872],[57,1874],{"nctId":4255,"briefTitle":4256,"status":107,"phases":4508,"primaryCompletion":4095,"completion":4095,"start":4258,"enrollment":4259,"conditions":4509,"interventions":4510},[],[3560,3716,21,4099],[3542,3540],{"nctId":4512,"briefTitle":4513,"status":107,"phases":4514,"primaryCompletion":3081,"completion":4095,"start":4515,"enrollment":4516,"conditions":4517,"interventions":4518},"NCT01947985","Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)",[],"2012-02-01",208958,[3560,3716,21,4099],[4519,3540],"Rivaroxoban",{"nctId":4327,"briefTitle":4328,"status":107,"phases":4521,"primaryCompletion":1486,"completion":1487,"start":1585,"enrollment":4330,"conditions":4522,"interventions":4523},[],[3621,3560],[3542,3540],{"nctId":3533,"briefTitle":3534,"status":143,"phases":4525,"primaryCompletion":240,"completion":3536,"start":3537,"enrollment":285,"conditions":4526,"interventions":4527},[],[979],[3393,3540],{"intervention":4529,"totalTrials":175,"cells":4530},"Kerendia",{"EARLY_PHASE1":4531,"PHASE1":4533,"PHASE2":4535,"PHASE3":4537,"PHASE4":4539,"NA":4541},{"trials":4532,"activeCount":101},[],{"trials":4534,"activeCount":101},[],{"trials":4536,"activeCount":101},[],{"trials":4538,"activeCount":101},[],{"trials":4540,"activeCount":101},[],{"trials":4542,"activeCount":175,"soonestReadout":4555},[4543,4551],{"nctId":4544,"briefTitle":4545,"status":143,"phases":4546,"primaryCompletion":975,"completion":4547,"start":4548,"enrollment":874,"conditions":4549,"interventions":4550},"NCT07232537","An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea",[],"2028-01-28","2025-11-20",[32,749],[4529],{"nctId":4552,"briefTitle":4553,"status":132,"phases":4554,"primaryCompletion":4555,"completion":4556,"start":4557,"enrollment":4558,"conditions":4559,"interventions":4560},"NCT05348733","A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting",[],"2027-09-01","2027-12-15","2022-06-13",4613,[32,749],[4529],{"intervention":42,"totalTrials":2307,"cells":4562},{"EARLY_PHASE1":4563,"PHASE1":4565,"PHASE2":4631,"PHASE3":4764,"PHASE4":4872,"NA":4874},{"trials":4564,"activeCount":101},[],{"trials":4566,"activeCount":101},[4567,4575,4583,4592,4601,4608,4616,4623],{"nctId":4568,"briefTitle":4569,"status":107,"phases":4570,"completion":4571,"start":3705,"enrollment":1509,"conditions":4572,"interventions":4574},"NCT00119639","Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006",[90],"2005-12",[4573],"Kidney Diseases",[42],{"nctId":4576,"briefTitle":4577,"status":107,"phases":4578,"primaryCompletion":1313,"completion":1313,"start":4579,"enrollment":4580,"conditions":4581,"interventions":4582},"NCT00562523","Sorafenib\u002FDocetaxel Dose Escalation Trial",[90],"2007-11",17,[29],[42],{"nctId":4584,"briefTitle":4585,"status":107,"phases":4586,"primaryCompletion":4587,"completion":4587,"start":4588,"enrollment":510,"conditions":4589,"interventions":4591},"NCT00829231","Hepatic Impairment Study",[90],"2009-07","2009-01",[4590],"Liver Disease",[42,42,42],{"nctId":4593,"briefTitle":4594,"status":107,"phases":4595,"primaryCompletion":4596,"completion":1326,"start":4597,"enrollment":2316,"conditions":4598,"interventions":4600},"NCT00663741","Sorafenib Gastric Cancer Asian Phase I Study",[90],"2010-03","2008-05",[4599],"Gastric Cancer",[42,42,42],{"nctId":4602,"briefTitle":4603,"status":107,"phases":4604,"primaryCompletion":548,"completion":4066,"start":3594,"enrollment":2388,"conditions":4605,"interventions":4606},"NCT02332031","Sorafenib Drug Drug Interaction Study in Healthy Male Subjects",[90],[1490],[42,4607],"Levothyroxine",{"nctId":4609,"briefTitle":4610,"status":107,"phases":4611,"primaryCompletion":1328,"completion":4612,"start":4613,"enrollment":2189,"conditions":4614,"interventions":4615},"NCT00259129","Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients",[90],"2008-03","2005-08",[29],[42],{"nctId":4617,"briefTitle":4618,"status":156,"phases":4619,"primaryCompletion":3793,"completion":1570,"start":4597,"enrollment":4620,"conditions":4621,"interventions":4622},"NCT00622479","Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.",[90],12,[2328],[42],{"nctId":4624,"briefTitle":4625,"status":107,"phases":4626,"primaryCompletion":4066,"completion":4066,"start":4627,"enrollment":1519,"conditions":4628,"interventions":4629},"NCT01585870","Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination",[90],"2012-07",[29],[42,4630],"Eribulin",{"trials":4632,"activeCount":101},[4633,4643,4653,4662,4671,4679,4687,4696,4703,4711,4717,4724,4732,4740,4746,4755],{"nctId":4634,"briefTitle":4635,"status":107,"phases":4636,"primaryCompletion":4637,"completion":4638,"start":4639,"enrollment":1163,"conditions":4640,"interventions":4642},"NCT02114658","Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients",[91],"2015-02-23","2016-08-02","2014-04-15",[4641],"Thyroid Carcinoma",[42],{"nctId":4644,"briefTitle":4645,"status":107,"phases":4646,"primaryCompletion":1423,"completion":4647,"start":4648,"enrollment":4649,"conditions":4650,"interventions":4652},"NCT00492297","A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma",[91],"2008-07","2005-04",83,[4651],"Melanoma",[42],{"nctId":4654,"briefTitle":4655,"status":107,"phases":4656,"primaryCompletion":2366,"completion":4657,"start":3567,"enrollment":4658,"conditions":4659,"interventions":4661},"NCT00791778","Comparison of Nexavar\u002FPlacebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer",[91],"2012-12",246,[4660],"Ovarian Neoplasms",[42],{"nctId":4663,"briefTitle":4664,"status":107,"phases":4665,"primaryCompletion":4666,"completion":4612,"start":4648,"enrollment":4667,"conditions":4668,"interventions":4669},"NCT00110994","Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma",[91],"2006-10",101,[219,4651],[42,4670],"Dacarbazine",{"nctId":4672,"briefTitle":4673,"status":107,"phases":4674,"primaryCompletion":4675,"completion":3818,"start":446,"enrollment":2345,"conditions":4676,"interventions":4678},"NCT00101400","BAY43-9006 - Phase II in Advanced Breast Cancer",[91],"2006-01",[521,4677],"Breast Cancer",[42],{"nctId":4680,"briefTitle":4681,"status":107,"phases":4682,"primaryCompletion":1506,"completion":1506,"start":3567,"enrollment":1133,"conditions":4683,"interventions":4685},"NCT00785226","RDEA119 and Sorafenib Combination Dose Escalation Study",[90,91],[4684],"Advanced Cancer",[4686,42],"RDEA119",{"nctId":4688,"briefTitle":4689,"status":107,"phases":4690,"primaryCompletion":4691,"completion":4691,"start":4692,"enrollment":4693,"conditions":4694,"interventions":4695},"NCT00044512","A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma",[91],"2008-02","2002-08",137,[1009],[42],{"nctId":4697,"briefTitle":4698,"status":107,"phases":4699,"primaryCompletion":4700,"completion":1569,"start":4691,"enrollment":4649,"conditions":4701,"interventions":4702},"NCT00618982","Sorafenib Dose Escalation in Renal Cell Carcinoma",[91],"2009-04",[2328],[42],{"nctId":4704,"briefTitle":4705,"status":107,"phases":4706,"primaryCompletion":3705,"completion":2970,"start":4707,"enrollment":19,"conditions":4708,"interventions":4710},"NCT00101413","BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)",[91],"2004-04",[219,4709],"Carcinoma, Non-Small Cell Lung",[42],{"nctId":4712,"briefTitle":4713,"status":107,"phases":4714,"primaryCompletion":1569,"completion":2959,"start":1313,"enrollment":2846,"conditions":4715,"interventions":4716},"NCT00865709","Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects",[91],[2370],[42],{"nctId":4718,"briefTitle":4719,"status":107,"phases":4720,"primaryCompletion":2366,"completion":2950,"start":1313,"enrollment":4721,"conditions":4722,"interventions":4723},"NCT00855218","A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).",[91],307,[1009],[42],{"nctId":4725,"briefTitle":4726,"status":107,"phases":4727,"completion":1648,"start":4728,"enrollment":4729,"conditions":4730,"interventions":4731},"NCT00079612","Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer",[91],"2002-09",501,[2328],[42],{"nctId":4733,"briefTitle":4734,"status":156,"phases":4735,"primaryCompletion":4736,"completion":4736,"start":2970,"enrollment":1081,"conditions":4737,"interventions":4738},"NCT00678288","A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.",[91],"2009-06",[2328],[42,4739],"Sorafenib (Nexavar, BAY43-9006) + Interferon",{"nctId":4741,"briefTitle":4742,"status":107,"phases":4743,"primaryCompletion":1423,"completion":4647,"start":4571,"enrollment":1054,"conditions":4744,"interventions":4745},"NCT00586495","Long-term Extension From RCC Phase II (11515)",[91],[2328],[42],{"nctId":4747,"briefTitle":4748,"status":107,"phases":4749,"primaryCompletion":4750,"completion":1313,"start":3705,"enrollment":4751,"conditions":4752,"interventions":4753},"NCT00117637","BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and\u002For Metastatic Renal Cell Carcinoma",[91],"2006-09",189,[2328],[42,4754],"Interferon",{"nctId":4756,"briefTitle":4757,"status":107,"phases":4758,"primaryCompletion":4759,"completion":4760,"start":4761,"enrollment":1181,"conditions":4762,"interventions":4763},"NCT01915602","Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)",[91],"2015-07-29","2017-02-08","2013-09-27",[1009],[2276,42],{"trials":4765,"activeCount":101},[4766,4775,4779,4785,4793,4801,4812,4823,4832,4840,4847,4857,4865],{"nctId":4767,"briefTitle":4768,"status":107,"phases":4769,"primaryCompletion":4750,"completion":4588,"start":4770,"enrollment":4771,"conditions":4772,"interventions":4773},"NCT00111007","A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma",[92],"2005-05",270,[4651],[42,4774],"Carboplatin\u002FPaclitaxel",{"nctId":1323,"briefTitle":1324,"status":107,"phases":4776,"primaryCompletion":1326,"completion":1327,"start":1328,"enrollment":1329,"conditions":4777,"interventions":4778},[92],[423],[42,1280,1073],{"nctId":4780,"briefTitle":4781,"status":107,"phases":4782,"primaryCompletion":4597,"completion":4597,"start":4571,"enrollment":1561,"conditions":4783,"interventions":4784},"NCT00586105","Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)",[92],[2328],[42],{"nctId":4786,"briefTitle":4787,"status":107,"phases":4788,"primaryCompletion":3778,"completion":4587,"start":4789,"enrollment":4790,"conditions":4791,"interventions":4792},"NCT00492752","A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma",[92],"2005-10",226,[1009],[42],{"nctId":4794,"briefTitle":4795,"status":107,"phases":4796,"primaryCompletion":4797,"completion":4797,"start":4798,"enrollment":967,"conditions":4799,"interventions":4800},"NCT00625378","Sorafenib Long Term Extension Program",[92],"2021-09-24","2007-12-21",[29],[42],{"nctId":4802,"briefTitle":4803,"status":107,"phases":4804,"primaryCompletion":4805,"completion":4806,"start":4807,"enrollment":4808,"conditions":4809,"interventions":4810},"NCT01234337","Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer",[92],"2014-05-12","2017-10-20","2011-02-21",537,[4677],[42,4811],"Capecitabine",{"nctId":4813,"briefTitle":4814,"status":107,"phases":4815,"primaryCompletion":4816,"completion":4817,"start":4818,"enrollment":4819,"conditions":4820,"interventions":4822},"NCT00984282","Nexavar® Versus Placebo in Locally Advanced\u002FMetastatic RAI-Refractory Differentiated Thyroid Cancer",[92],"2012-08-31","2017-08-30","2009-10-15",417,[4821],"Thyroid Neoplasms",[42],{"nctId":4824,"briefTitle":4825,"status":107,"phases":4826,"primaryCompletion":410,"completion":4250,"start":4700,"enrollment":4827,"conditions":4828,"interventions":4831},"NCT00863746","A 3rd\u002F4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).",[92],703,[4829,4830],"Carcinoma","Non-Small-Cell Lung",[42],{"nctId":4833,"briefTitle":4834,"status":107,"phases":4835,"primaryCompletion":3567,"completion":3567,"start":4836,"enrollment":4837,"conditions":4838,"interventions":4839},"NCT00105443","A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma",[92],"2005-03",602,[1009],[42],{"nctId":4841,"briefTitle":4842,"status":107,"phases":4843,"primaryCompletion":4750,"completion":1326,"start":3657,"enrollment":4844,"conditions":4845,"interventions":4846},"NCT00073307","Study of BAY43-9006 in Patients With Unresectable and\u002For Metastatic Renal Cell Cancer",[92],903,[2328],[42],{"nctId":4848,"briefTitle":4849,"status":107,"phases":4850,"primaryCompletion":4851,"completion":1262,"start":4852,"enrollment":4853,"conditions":4854,"interventions":4855},"NCT00901901","Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma",[92],"2012-04-17","2009-05-21",732,[1009],[42,4856],"Erlotinib",{"nctId":4858,"briefTitle":4859,"status":107,"phases":4860,"primaryCompletion":4587,"completion":1570,"start":4861,"enrollment":4862,"conditions":4863,"interventions":4864},"NCT00494299","Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)",[92],"2006-04",458,[1009],[42],{"nctId":4866,"briefTitle":4867,"status":107,"phases":4868,"primaryCompletion":3723,"completion":1498,"start":3705,"enrollment":4869,"conditions":4870,"interventions":4871},"NCT00111020","Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma",[92],2567,[2328],[42],{"trials":4873,"activeCount":101},[],{"trials":4875,"activeCount":233,"soonestReadout":41},[4876,4884,4891,4899,4904,4912,4916,4922,4930,4938,4947,4956,4963,4970,4978,4988,4996,5007,5014,5022,5028,5037],{"nctId":4877,"briefTitle":4878,"status":107,"phases":4879,"primaryCompletion":1543,"completion":4880,"start":3576,"enrollment":4881,"conditions":4882,"interventions":4883},"NCT01012011","Regulatory Post Marketing Surveillance Study on Nexavar®",[],"2015-08",2845,[1009,2328],[42],{"nctId":4885,"briefTitle":4886,"status":107,"phases":4887,"primaryCompletion":2367,"completion":3594,"start":2959,"enrollment":4888,"conditions":4889,"interventions":4890},"NCT01539681","Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy",[],234,[1056],[42],{"nctId":4892,"briefTitle":4893,"status":107,"phases":4894,"primaryCompletion":4895,"completion":1667,"start":4896,"enrollment":3794,"conditions":4897,"interventions":4898},"NCT01839630","Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China",[],"2016-08-06","2013-05-30",[1009],[42],{"nctId":39,"briefTitle":40,"status":132,"phases":4900,"primaryCompletion":41,"completion":951,"start":4377,"enrollment":4901,"conditions":4902,"interventions":4903},[],453,[4641],[42],{"nctId":4905,"briefTitle":4906,"status":107,"phases":4907,"primaryCompletion":4908,"completion":593,"start":4909,"enrollment":842,"conditions":4910,"interventions":4911},"NCT01412671","Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program",[],"2011-09-21","2008-02-27",[2328],[42],{"nctId":2494,"briefTitle":2495,"status":156,"phases":4913,"primaryCompletion":2497,"completion":994,"start":2498,"enrollment":1341,"conditions":4914,"interventions":4915},[],[1056],[1011,42],{"nctId":4917,"briefTitle":4918,"status":107,"phases":4919,"primaryCompletion":2230,"completion":2230,"start":4627,"enrollment":97,"conditions":4920,"interventions":4921},"NCT01508364","Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma",[],[2328],[42],{"nctId":4923,"briefTitle":4924,"status":107,"phases":4925,"primaryCompletion":2209,"completion":4926,"start":4927,"enrollment":1669,"conditions":4928,"interventions":4929},"NCT01982097","Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma",[],"2017-12-07","2014-01-10",[2328],[42],{"nctId":4931,"briefTitle":4932,"status":107,"phases":4933,"completion":1570,"start":1423,"enrollment":4934,"conditions":4935,"interventions":4937},"NCT00771147","A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ®",[],71,[2328,4936],"Carcinoma, Renal Cell (Advanced)",[42],{"nctId":4939,"briefTitle":4940,"status":107,"phases":4941,"primaryCompletion":4942,"completion":4943,"start":4944,"enrollment":2151,"conditions":4945,"interventions":4946},"NCT01728948","Sorafenib in Elderly mRCC",[],"2016-01-04","2017-01-16","2013-01-06",[2328],[42],{"nctId":4948,"briefTitle":4949,"status":107,"phases":4950,"primaryCompletion":4951,"completion":4952,"start":4953,"enrollment":3476,"conditions":4954,"interventions":4955},"NCT01557127","Nexavar Dosing in Renal Cancer Patients in \"Real-life\" Setting",[],"2014-05-16","2016-03-31","2011-11-01",[2328],[42],{"nctId":4957,"briefTitle":4958,"status":107,"phases":4959,"primaryCompletion":1629,"completion":2229,"start":2970,"enrollment":4960,"conditions":4961,"interventions":4962},"NCT00792350","INSIGHT - Post Marketing Surveillance",[],791,[1009],[42],{"nctId":4964,"briefTitle":4965,"status":107,"phases":4966,"primaryCompletion":2917,"completion":3594,"start":3619,"enrollment":4967,"conditions":4968,"interventions":4969},"NCT01411436","Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan",[],1637,[1009],[42],{"nctId":4971,"briefTitle":4972,"status":107,"phases":4973,"primaryCompletion":4348,"completion":4974,"start":4975,"enrollment":3990,"conditions":4976,"interventions":4977},"NCT01751763","Sorafenib for Residue Disease After Resection With Curative Intent",[],"2017-09-08","2013-07-09",[1009],[42],{"nctId":4979,"briefTitle":4980,"status":107,"phases":4981,"primaryCompletion":4982,"completion":4983,"start":4984,"enrollment":4985,"conditions":4986,"interventions":4987},"NCT01933945","Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib",[],"2017-07-22","2017-11-10","2013-10-28",1676,[1009],[42],{"nctId":4989,"briefTitle":4990,"status":464,"phases":4991,"primaryCompletion":4992,"completion":4993,"start":3733,"enrollment":101,"conditions":4994,"interventions":4995},"NCT01353794","Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer",[],"2017-09","2018-04",[2328],[42],{"nctId":4997,"briefTitle":4998,"status":107,"phases":4999,"primaryCompletion":5000,"completion":5001,"start":5002,"enrollment":5003,"conditions":5004,"interventions":5005},"NCT02303444","An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors",[],"2020-06-10","2020-07-24","2015-04-08",667,[4821],[42,5006],"Other Multikinase inhibitors",{"nctId":5008,"briefTitle":5009,"status":107,"phases":5010,"primaryCompletion":1506,"completion":1506,"start":4588,"enrollment":5011,"conditions":5012,"interventions":5013},"NCT00812175","Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib",[],3371,[1009],[42],{"nctId":5015,"briefTitle":5016,"status":156,"phases":5017,"primaryCompletion":5018,"completion":4816,"start":5019,"enrollment":2041,"conditions":5020,"interventions":5021},"NCT01195649","Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy",[],"2012-06-08","2010-12-13",[2328],[42],{"nctId":5023,"briefTitle":5024,"status":107,"phases":5025,"primaryCompletion":548,"completion":4066,"start":2187,"enrollment":411,"conditions":5026,"interventions":5027},"NCT01908322","Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety",[],[1009],[42],{"nctId":5029,"briefTitle":5030,"status":107,"phases":5031,"primaryCompletion":5032,"completion":593,"start":5033,"enrollment":5034,"conditions":5035,"interventions":5036},"NCT01411423","Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan",[],"2012-03-16","2008-04-18",3305,[2328],[42],{"nctId":2561,"briefTitle":2562,"status":107,"phases":5038,"primaryCompletion":2564,"completion":2564,"start":2565,"enrollment":2566,"conditions":5039,"interventions":5040},[],[2568,2569,2570],[2572,2573,1011,42],{"intervention":5042,"totalTrials":2041,"cells":5043},"Molidustat",{"EARLY_PHASE1":5044,"PHASE1":5046,"PHASE2":5065,"PHASE3":5097,"PHASE4":5143,"NA":5145},{"trials":5045,"activeCount":101},[],{"trials":5047,"activeCount":101},[5048,5055],{"nctId":5049,"briefTitle":5050,"status":107,"phases":5051,"primaryCompletion":2950,"completion":3601,"start":5052,"enrollment":458,"conditions":5053,"interventions":5054},"NCT01679587","Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY85-3934 in Subjects With Chronic Kidney Disease (CKD)",[90],"2012-09",[4573],[5042],{"nctId":5056,"briefTitle":5057,"status":107,"phases":5058,"primaryCompletion":5059,"completion":5060,"start":5061,"enrollment":1519,"conditions":5062,"interventions":5064},"NCT02312973","To Investigate Pharmacokinetics (Absorption, Distribution, Elimination), Safety and Tolerability of a Single Oral Dose of 75 mg Molidustat Tablet in Male and Female Subjects Requiring Hemo- or Peritoneal Dialysis Compared to Healthy Subjects",[90],"2015-12-02","2016-06-01","2015-01-14",[5063],"Renal Insufficiency, Chronic",[5042,5042],{"trials":5066,"activeCount":101},[5067,5077,5088],{"nctId":5068,"briefTitle":5069,"status":107,"phases":5070,"primaryCompletion":2271,"completion":5071,"start":4984,"enrollment":5072,"conditions":5073,"interventions":5075},"NCT01975818","Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa \u002F Beta Treatment Versus BAY85-3934",[91],"2015-12-15",201,[5074,5063],"Anemia",[5042,5076],"Epoetin alfa\u002Fbeta",{"nctId":5078,"briefTitle":5079,"status":107,"phases":5080,"primaryCompletion":5081,"completion":5082,"start":5083,"enrollment":5084,"conditions":5085,"interventions":5086},"NCT02055482","Long-term Pre-dialysis Extension in Europe and Asia Pacific",[91],"2016-11-15","2016-12-12","2014-06-24",166,[5074,5063],[5042,5087],"Darbepoetin",{"nctId":5089,"briefTitle":5090,"status":107,"phases":5091,"primaryCompletion":5092,"completion":2981,"start":5093,"enrollment":5094,"conditions":5095,"interventions":5096},"NCT02064426","Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa \u002F Beta Treatment Versus BAY85-3934",[91],"2016-10-19","2014-03-13",88,[5074,5063],[5042,5076],{"trials":5098,"activeCount":101},[5099,5106,5115,5125,5134],{"nctId":5100,"briefTitle":5101,"status":107,"phases":5102,"primaryCompletion":123,"completion":1192,"start":5103,"enrollment":2388,"conditions":5104,"interventions":5105},"NCT03351166","A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects",[92],"2018-01-22",[5074,5063],[5042],{"nctId":5107,"briefTitle":5108,"status":107,"phases":5109,"primaryCompletion":5110,"completion":5111,"start":5112,"enrollment":22,"conditions":5113,"interventions":5114},"NCT03418168","A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects",[92],"2019-07-25","2019-07-29","2018-02-22",[5074,5063],[5042],{"nctId":5116,"briefTitle":5117,"status":107,"phases":5118,"primaryCompletion":2377,"completion":5119,"start":5120,"enrollment":5121,"conditions":5122,"interventions":5123},"NCT03350347","A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects",[92],"2019-11-28","2017-12-13",164,[5074,5063],[5042,5124],"Darbepoetin alfa",{"nctId":5126,"briefTitle":5127,"status":107,"phases":5128,"primaryCompletion":5129,"completion":2929,"start":5130,"enrollment":5131,"conditions":5132,"interventions":5133},"NCT03543657","Maintenance Treatment of Renal Anemia in Dialysis Subjects",[92],"2019-08-07","2018-06-23",229,[5074,5063],[5042,5124],{"nctId":5135,"briefTitle":5136,"status":107,"phases":5137,"primaryCompletion":5138,"completion":5139,"start":5140,"enrollment":3033,"conditions":5141,"interventions":5142},"NCT03350321","A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects",[92],"2019-05-17","2019-10-11","2017-12-12",[5074,5063],[5042,5124],{"trials":5144,"activeCount":101},[],{"trials":5146,"activeCount":233,"soonestReadout":3155},[5147],{"nctId":5148,"briefTitle":5149,"status":132,"phases":5150,"primaryCompletion":3155,"completion":975,"start":5151,"enrollment":5152,"conditions":5153,"interventions":5155},"NCT04899661","A Study to Learn More About the Long-term Safety and Effectiveness of Molidustat as a Treatment for Japanese Men and Women With Renal Anemia",[],"2021-08-06",1081,[5154],"Renal Anemia",[5042],{"intervention":128,"totalTrials":3374,"cells":5157},{"EARLY_PHASE1":5158,"PHASE1":5160,"PHASE2":5166,"PHASE3":5180,"PHASE4":5182,"NA":5184},{"trials":5159,"activeCount":101},[],{"trials":5161,"activeCount":101},[5162],{"nctId":118,"briefTitle":119,"status":107,"phases":5163,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":5164,"interventions":5165},[90],[126],[67,128],{"trials":5167,"activeCount":101},[5168,5172,5176],{"nctId":484,"briefTitle":485,"status":107,"phases":5169,"primaryCompletion":487,"completion":488,"start":489,"enrollment":490,"conditions":5170,"interventions":5171},[91],[187],[72,288,493,128],{"nctId":154,"briefTitle":155,"status":156,"phases":5173,"primaryCompletion":158,"completion":158,"start":159,"enrollment":160,"conditions":5174,"interventions":5175},[91],[162],[67,128],{"nctId":165,"briefTitle":166,"status":107,"phases":5177,"primaryCompletion":168,"completion":169,"start":170,"enrollment":171,"conditions":5178,"interventions":5179},[91],[173],[67,128],{"trials":5181,"activeCount":101},[],{"trials":5183,"activeCount":101},[],{"trials":5185,"activeCount":233,"soonestReadout":283},[5186,5190,5202,5206,5210,5214],{"nctId":260,"briefTitle":261,"status":107,"phases":5187,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":5188,"interventions":5189},[],[231],[67,128,268],{"nctId":5191,"briefTitle":5192,"status":107,"phases":5193,"primaryCompletion":5194,"completion":5195,"start":5196,"enrollment":5197,"conditions":5198,"interventions":5200},"NCT03896984","Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).",[],"2020-06-08","2020-12-14","2019-03-18",346,[5199],"Metastatic Castration-resistant Prostate Cancer (mCRPC)",[5201,586,128],"Radium-223",{"nctId":270,"briefTitle":271,"status":107,"phases":5203,"primaryCompletion":273,"completion":273,"start":274,"enrollment":275,"conditions":5204,"interventions":5205},[],[277,231],[67,128,268],{"nctId":280,"briefTitle":281,"status":143,"phases":5207,"primaryCompletion":283,"completion":283,"start":284,"enrollment":285,"conditions":5208,"interventions":5209},[],[187,245],[67,288,128,268],{"nctId":300,"briefTitle":301,"status":107,"phases":5211,"primaryCompletion":303,"completion":303,"start":304,"enrollment":305,"conditions":5212,"interventions":5213},[],[307],[67,128,268],{"nctId":310,"briefTitle":311,"status":107,"phases":5215,"primaryCompletion":313,"completion":314,"start":315,"enrollment":316,"conditions":5216,"interventions":5217},[],[231],[268,67,128],{"intervention":5219,"totalTrials":5220,"cells":5221},"Nifurtimox",6,{"EARLY_PHASE1":5222,"PHASE1":5224,"PHASE2":5261,"PHASE3":5263,"PHASE4":5274,"NA":5276},{"trials":5223,"activeCount":101},[],{"trials":5225,"activeCount":101},[5226,5235,5244,5252],{"nctId":5227,"briefTitle":5228,"status":107,"phases":5229,"primaryCompletion":5230,"completion":1542,"start":2406,"enrollment":5231,"conditions":5232,"interventions":5234},"NCT01927224","Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients",[90],"2014-05",37,[5233],"Chagas Disease",[5219,5219,5219],{"nctId":5236,"briefTitle":5237,"status":107,"phases":5238,"primaryCompletion":5239,"completion":5240,"start":5241,"enrollment":25,"conditions":5242,"interventions":5243},"NCT03350295","Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg",[90],"2018-09-18","2018-12-14","2018-06-14",[5233],[5219],{"nctId":5245,"briefTitle":5246,"status":107,"phases":5247,"primaryCompletion":409,"completion":5248,"start":5249,"enrollment":1265,"conditions":5250,"interventions":5251},"NCT02606864","Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients",[90],"2016-08","2015-12",[5233],[5219],{"nctId":5253,"briefTitle":5254,"status":107,"phases":5255,"primaryCompletion":5256,"completion":1710,"start":5257,"enrollment":1265,"conditions":5258,"interventions":5260},"NCT03334838","Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study",[90],"2019-11-07","2019-06-10",[5259],"Chagas' Disease",[5219],{"trials":5262,"activeCount":101},[],{"trials":5264,"activeCount":101},[5265],{"nctId":5266,"briefTitle":5267,"status":107,"phases":5268,"primaryCompletion":5269,"completion":5270,"start":5271,"enrollment":3251,"conditions":5272,"interventions":5273},"NCT02625974","A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi",[92],"2018-07-25","2021-08-10","2016-01-27",[5233],[5219],{"trials":5275,"activeCount":101},[],{"trials":5277,"activeCount":233,"soonestReadout":5282},[5278],{"nctId":5279,"briefTitle":5280,"status":251,"phases":5281,"primaryCompletion":5282,"completion":5282,"start":931,"enrollment":229,"conditions":5283,"interventions":5284},"NCT05477953","An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health",[],"2032-01-31",[5233],[5219],{"intervention":268,"totalTrials":328,"cells":5286},{"EARLY_PHASE1":5287,"PHASE1":5289,"PHASE2":5291,"PHASE3":5293,"PHASE4":5295,"NA":5297},{"trials":5288,"activeCount":101},[],{"trials":5290,"activeCount":101},[],{"trials":5292,"activeCount":101},[],{"trials":5294,"activeCount":101},[],{"trials":5296,"activeCount":101},[],{"trials":5298,"activeCount":233,"soonestReadout":283},[5299,5303,5307,5311,5315],{"nctId":260,"briefTitle":261,"status":107,"phases":5300,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":5301,"interventions":5302},[],[231],[67,128,268],{"nctId":270,"briefTitle":271,"status":107,"phases":5304,"primaryCompletion":273,"completion":273,"start":274,"enrollment":275,"conditions":5305,"interventions":5306},[],[277,231],[67,128,268],{"nctId":280,"briefTitle":281,"status":143,"phases":5308,"primaryCompletion":283,"completion":283,"start":284,"enrollment":285,"conditions":5309,"interventions":5310},[],[187,245],[67,288,128,268],{"nctId":300,"briefTitle":301,"status":107,"phases":5312,"primaryCompletion":303,"completion":303,"start":304,"enrollment":305,"conditions":5313,"interventions":5314},[],[307],[67,128,268],{"nctId":310,"briefTitle":311,"status":107,"phases":5316,"primaryCompletion":313,"completion":314,"start":315,"enrollment":316,"conditions":5317,"interventions":5318},[],[231],[268,67,128],{"intervention":1357,"totalTrials":1341,"cells":5320},{"EARLY_PHASE1":5321,"PHASE1":5323,"PHASE2":5329,"PHASE3":5331,"PHASE4":5333,"NA":5335},{"trials":5322,"activeCount":101},[],{"trials":5324,"activeCount":101},[5325],{"nctId":1348,"briefTitle":1349,"status":107,"phases":5326,"primaryCompletion":1351,"completion":1352,"start":1315,"enrollment":33,"conditions":5327,"interventions":5328},[90],[423,1354],[1356,1356,1357,1357,1357,1357,1358,1074],{"trials":5330,"activeCount":101},[],{"trials":5332,"activeCount":101},[],{"trials":5334,"activeCount":101},[],{"trials":5336,"activeCount":233,"soonestReadout":76},[5337,5341],{"nctId":2438,"briefTitle":2439,"status":107,"phases":5338,"primaryCompletion":2441,"completion":2441,"start":2442,"enrollment":2443,"conditions":5339,"interventions":5340},[],[2445],[1011,2447,1357],{"nctId":74,"briefTitle":75,"status":132,"phases":5342,"primaryCompletion":76,"completion":5343,"start":1244,"enrollment":977,"conditions":5344,"interventions":5346},[],"2026-12-10",[5345],"Unresectable Hepatocellular Carcinoma",[77,1357,5347,5348],"Durvalumab","Tremelimumab,",{"intervention":247,"totalTrials":1341,"cells":5350},{"EARLY_PHASE1":5351,"PHASE1":5353,"PHASE2":5355,"PHASE3":5361,"PHASE4":5373,"NA":5375},{"trials":5352,"activeCount":101},[],{"trials":5354,"activeCount":101},[],{"trials":5356,"activeCount":101},[5357],{"nctId":545,"briefTitle":546,"status":107,"phases":5358,"primaryCompletion":548,"completion":548,"start":549,"enrollment":550,"conditions":5359,"interventions":5360},[90,91],[438,552],[72,247],{"trials":5362,"activeCount":101},[5363],{"nctId":5364,"briefTitle":5365,"status":107,"phases":5366,"primaryCompletion":2064,"completion":993,"start":5367,"enrollment":5368,"conditions":5369,"interventions":5370},"NCT02799602","Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer",[92],"2016-11-30",1306,[138],[5371,5372,247],"BAY1841788 \u002F darolutamide","Standard ADT",{"trials":5374,"activeCount":101},[],{"trials":5376,"activeCount":233,"soonestReadout":240},[5377],{"nctId":237,"briefTitle":238,"status":132,"phases":5378,"primaryCompletion":240,"completion":241,"start":242,"enrollment":243,"conditions":5379,"interventions":5380},[],[245],[67,152,247],{"intervention":5382,"totalTrials":1341,"cells":5383},"Betaseron",{"EARLY_PHASE1":5384,"PHASE1":5386,"PHASE2":5388,"PHASE3":5399,"PHASE4":5401,"NA":5403},{"trials":5385,"activeCount":101},[],{"trials":5387,"activeCount":101},[],{"trials":5389,"activeCount":101},[5390],{"nctId":5391,"briefTitle":5392,"status":107,"phases":5393,"completion":5394,"start":5395,"enrollment":4934,"conditions":5396,"interventions":5398},"NCT00893217","BEYOND Pilot Study",[91],"2003-06","2002-11",[35,5397],"Relapsing-Remitting",[5382,5382],{"trials":5400,"activeCount":101},[],{"trials":5402,"activeCount":101},[],{"trials":5404,"activeCount":233,"soonestReadout":951},[5405,5413],{"nctId":5406,"briefTitle":5407,"status":107,"phases":5408,"primaryCompletion":5409,"completion":5409,"start":3809,"enrollment":5410,"conditions":5411,"interventions":5412},"NCT01031459","Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.",[],"2010-12",176,[35],[5382],{"nctId":5414,"briefTitle":5415,"status":132,"phases":5416,"primaryCompletion":951,"completion":951,"start":5417,"enrollment":855,"conditions":5418,"interventions":5420},"NCT06053749","An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden",[],"2024-03-20",[5419],"Multiple Sclerosis (MS)",[5421,5422,5423,5382,5424,5425],"Avonex","Rebif","Extavia","Plegridy","MS disease modifying drugs",{"intervention":5427,"totalTrials":175,"cells":5428},"Damoctocog-alfa-pegol",{"EARLY_PHASE1":5429,"PHASE1":5431,"PHASE2":5442,"PHASE3":5444,"PHASE4":5446,"NA":5448},{"trials":5430,"activeCount":101},[],{"trials":5432,"activeCount":101},[5433],{"nctId":5434,"briefTitle":5435,"status":107,"phases":5436,"primaryCompletion":5437,"completion":1710,"start":5438,"enrollment":1163,"conditions":5439,"interventions":5440},"NCT04015492","Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII)",[90],"2019-10-25","2019-08-08",[24],[5427,5441],"Rurioctocog alfa pegol",{"trials":5443,"activeCount":101},[],{"trials":5445,"activeCount":101},[],{"trials":5447,"activeCount":101},[],{"trials":5449,"activeCount":233,"soonestReadout":293},[5450],{"nctId":5451,"briefTitle":5452,"status":143,"phases":5453,"primaryCompletion":293,"completion":293,"start":2315,"enrollment":97,"conditions":5454,"interventions":5455},"NCT06222697","A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia A",[],[24,3338,3337],[5427],{"intervention":5422,"totalTrials":175,"cells":5457},{"EARLY_PHASE1":5458,"PHASE1":5460,"PHASE2":5462,"PHASE3":5464,"PHASE4":5466,"NA":5478},{"trials":5459,"activeCount":101},[],{"trials":5461,"activeCount":101},[],{"trials":5463,"activeCount":101},[],{"trials":5465,"activeCount":101},[],{"trials":5467,"activeCount":101},[5468],{"nctId":5469,"briefTitle":5470,"status":107,"phases":5471,"primaryCompletion":2970,"completion":2970,"start":5472,"enrollment":5473,"conditions":5474,"interventions":5476},"NCT00317941","Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif",[93],"2006-03",220,[5475],"Relapsing-remitting Multiple Sclerosis",[5477,5422,5477],"Betaferon\u002FBetaseron",{"trials":5479,"activeCount":233,"soonestReadout":951},[5480],{"nctId":5414,"briefTitle":5415,"status":132,"phases":5481,"primaryCompletion":951,"completion":951,"start":5417,"enrollment":855,"conditions":5482,"interventions":5483},[],[5419],[5421,5422,5423,5382,5424,5425],{"intervention":288,"totalTrials":175,"cells":5485},{"EARLY_PHASE1":5486,"PHASE1":5488,"PHASE2":5490,"PHASE3":5496,"PHASE4":5498,"NA":5500},{"trials":5487,"activeCount":101},[],{"trials":5489,"activeCount":101},[],{"trials":5491,"activeCount":101},[5492],{"nctId":484,"briefTitle":485,"status":107,"phases":5493,"primaryCompletion":487,"completion":488,"start":489,"enrollment":490,"conditions":5494,"interventions":5495},[91],[187],[72,288,493,128],{"trials":5497,"activeCount":101},[],{"trials":5499,"activeCount":101},[],{"trials":5501,"activeCount":233,"soonestReadout":283},[5502],{"nctId":280,"briefTitle":281,"status":143,"phases":5503,"primaryCompletion":283,"completion":283,"start":284,"enrollment":285,"conditions":5504,"interventions":5505},[],[187,245],[67,288,128,268],{"intervention":77,"totalTrials":175,"cells":5507},{"EARLY_PHASE1":5508,"PHASE1":5510,"PHASE2":5522,"PHASE3":5524,"PHASE4":5526,"NA":5528},{"trials":5509,"activeCount":101},[],{"trials":5511,"activeCount":101},[5512],{"nctId":5513,"briefTitle":5514,"status":107,"phases":5515,"primaryCompletion":1772,"completion":5516,"start":5517,"enrollment":5231,"conditions":5518,"interventions":5520},"NCT03473756","Phase 1b\u002F2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma",[90],"2024-07-10","2018-05-15",[5519],"Urothelial Carcinoma",[5521,77],"Rogaratinib",{"trials":5523,"activeCount":101},[],{"trials":5525,"activeCount":101},[],{"trials":5527,"activeCount":101},[],{"trials":5529,"activeCount":233,"soonestReadout":76},[5530],{"nctId":74,"briefTitle":75,"status":132,"phases":5531,"primaryCompletion":76,"completion":5343,"start":1244,"enrollment":977,"conditions":5532,"interventions":5533},[],[5345],[77,1357,5347,5348],{"intervention":5535,"totalTrials":233,"cells":5536},"Darolutamide (BAY1841788) + docetaxel + ADT",{"EARLY_PHASE1":5537,"PHASE1":5539,"PHASE2":5541,"PHASE3":5543,"PHASE4":5545,"NA":5547},{"trials":5538,"activeCount":101},[],{"trials":5540,"activeCount":101},[],{"trials":5542,"activeCount":101},[],{"trials":5544,"activeCount":101},[],{"trials":5546,"activeCount":101},[],{"trials":5548,"activeCount":233,"soonestReadout":5553},[5549],{"nctId":5550,"briefTitle":5551,"status":143,"phases":5552,"primaryCompletion":5553,"completion":2871,"start":5554,"enrollment":435,"conditions":5555,"interventions":5558},"NCT06661122","A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer",[],"2031-03-31","2024-11-18",[5556,5557],"Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","Low-volume Metastasis",[5535],{"intervention":5560,"totalTrials":233,"cells":5561},"Octocog alfa",{"EARLY_PHASE1":5562,"PHASE1":5564,"PHASE2":5566,"PHASE3":5568,"PHASE4":5570,"NA":5572},{"trials":5563,"activeCount":101},[],{"trials":5565,"activeCount":101},[],{"trials":5567,"activeCount":101},[],{"trials":5569,"activeCount":101},[],{"trials":5571,"activeCount":101},[],{"trials":5573,"activeCount":233,"soonestReadout":975},[5574],{"nctId":5575,"briefTitle":5576,"status":251,"phases":5577,"primaryCompletion":975,"completion":975,"start":4151,"enrollment":33,"conditions":5578,"interventions":5579},"NCT07446010","Post Approval Observational Study to Learn More About How Safe Octocog Alfa is and How Well it Works in Patients With Severe Hemophilia A in India",[],[24],[5560],{"intervention":5581,"totalTrials":233,"cells":5582},"Hydrotalcite",{"EARLY_PHASE1":5583,"PHASE1":5585,"PHASE2":5587,"PHASE3":5589,"PHASE4":5591,"NA":5593},{"trials":5584,"activeCount":101},[],{"trials":5586,"activeCount":101},[],{"trials":5588,"activeCount":101},[],{"trials":5590,"activeCount":101},[],{"trials":5592,"activeCount":101},[],{"trials":5594,"activeCount":233,"soonestReadout":5599},[5595],{"nctId":5596,"briefTitle":5597,"status":143,"phases":5598,"primaryCompletion":5599,"completion":5599,"start":881,"enrollment":5600,"conditions":5601,"interventions":5603},"NCT07291700","Study on Hydrotalcite for Relief of Acid Symptoms Due to Acid Rebound After Stopping Long-Term PPI Therapy",[],"2026-10-31",167,[5602],"Gastroesophageal Reflux",[5581],{"intervention":5347,"totalTrials":233,"cells":5605},{"EARLY_PHASE1":5606,"PHASE1":5608,"PHASE2":5610,"PHASE3":5612,"PHASE4":5614,"NA":5616},{"trials":5607,"activeCount":101},[],{"trials":5609,"activeCount":101},[],{"trials":5611,"activeCount":101},[],{"trials":5613,"activeCount":101},[],{"trials":5615,"activeCount":101},[],{"trials":5617,"activeCount":233,"soonestReadout":76},[5618],{"nctId":74,"briefTitle":75,"status":132,"phases":5619,"primaryCompletion":76,"completion":5343,"start":1244,"enrollment":977,"conditions":5620,"interventions":5621},[],[5345],[77,1357,5347,5348],{"intervention":5348,"totalTrials":233,"cells":5623},{"EARLY_PHASE1":5624,"PHASE1":5626,"PHASE2":5628,"PHASE3":5630,"PHASE4":5632,"NA":5634},{"trials":5625,"activeCount":101},[],{"trials":5627,"activeCount":101},[],{"trials":5629,"activeCount":101},[],{"trials":5631,"activeCount":101},[],{"trials":5633,"activeCount":101},[],{"trials":5635,"activeCount":233,"soonestReadout":76},[5636],{"nctId":74,"briefTitle":75,"status":132,"phases":5637,"primaryCompletion":76,"completion":5343,"start":1244,"enrollment":977,"conditions":5638,"interventions":5639},[],[5345],[77,1357,5347,5348],{"intervention":5641,"totalTrials":233,"cells":5642},"anti-VEGF medication",{"EARLY_PHASE1":5643,"PHASE1":5645,"PHASE2":5647,"PHASE3":5649,"PHASE4":5651,"NA":5653},{"trials":5644,"activeCount":101},[],{"trials":5646,"activeCount":101},[],{"trials":5648,"activeCount":101},[],{"trials":5650,"activeCount":101},[],{"trials":5652,"activeCount":101},[],{"trials":5654,"activeCount":233,"soonestReadout":974},[5655],{"nctId":5656,"briefTitle":5657,"status":143,"phases":5658,"primaryCompletion":974,"completion":974,"start":5659,"enrollment":920,"conditions":5660,"interventions":5662},"NCT07308639","DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.",[],"2026-03-03",[5661],"Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)",[5641],{"intervention":5664,"totalTrials":233,"cells":5665},"Aflibercept 8 mg",{"EARLY_PHASE1":5666,"PHASE1":5668,"PHASE2":5670,"PHASE3":5672,"PHASE4":5674,"NA":5676},{"trials":5667,"activeCount":101},[],{"trials":5669,"activeCount":101},[],{"trials":5671,"activeCount":101},[],{"trials":5673,"activeCount":101},[],{"trials":5675,"activeCount":101},[],{"trials":5677,"activeCount":233,"soonestReadout":975},[5678],{"nctId":5679,"briefTitle":5680,"status":132,"phases":5681,"primaryCompletion":975,"completion":5682,"start":5683,"enrollment":5684,"conditions":5685,"interventions":5688},"NCT06075147","The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema",[],"2028-01-31","2024-02-15",2500,[5686,3064,5687],"Visual Impairment","Diabetic Macula Edema (DME)",[5664],{"intervention":5690,"totalTrials":233,"cells":5691},"darolutamide plus ADT treatment",{"EARLY_PHASE1":5692,"PHASE1":5694,"PHASE2":5696,"PHASE3":5698,"PHASE4":5700,"NA":5702},{"trials":5693,"activeCount":101},[],{"trials":5695,"activeCount":101},[],{"trials":5697,"activeCount":101},[],{"trials":5699,"activeCount":101},[],{"trials":5701,"activeCount":101},[],{"trials":5703,"activeCount":233,"soonestReadout":5708},[5704],{"nctId":5705,"briefTitle":5706,"status":143,"phases":5707,"primaryCompletion":5708,"completion":5708,"start":5709,"enrollment":874,"conditions":5710,"interventions":5711},"NCT07395804","How Darolutamide Plus Hormone Therapy Works for Men With Advanced Prostate Cancer in Everyday Medical Practice in Germany",[],"2031-02-15","2026-04-14",[5556],[5690],{"intervention":5421,"totalTrials":233,"cells":5713},{"EARLY_PHASE1":5714,"PHASE1":5716,"PHASE2":5718,"PHASE3":5720,"PHASE4":5722,"NA":5724},{"trials":5715,"activeCount":101},[],{"trials":5717,"activeCount":101},[],{"trials":5719,"activeCount":101},[],{"trials":5721,"activeCount":101},[],{"trials":5723,"activeCount":101},[],{"trials":5725,"activeCount":233,"soonestReadout":951},[5726],{"nctId":5414,"briefTitle":5415,"status":132,"phases":5727,"primaryCompletion":951,"completion":951,"start":5417,"enrollment":855,"conditions":5728,"interventions":5729},[],[5419],[5421,5422,5423,5382,5424,5425],{"intervention":5423,"totalTrials":233,"cells":5731},{"EARLY_PHASE1":5732,"PHASE1":5734,"PHASE2":5736,"PHASE3":5738,"PHASE4":5740,"NA":5742},{"trials":5733,"activeCount":101},[],{"trials":5735,"activeCount":101},[],{"trials":5737,"activeCount":101},[],{"trials":5739,"activeCount":101},[],{"trials":5741,"activeCount":101},[],{"trials":5743,"activeCount":233,"soonestReadout":951},[5744],{"nctId":5414,"briefTitle":5415,"status":132,"phases":5745,"primaryCompletion":951,"completion":951,"start":5417,"enrollment":855,"conditions":5746,"interventions":5747},[],[5419],[5421,5422,5423,5382,5424,5425],{"intervention":5424,"totalTrials":233,"cells":5749},{"EARLY_PHASE1":5750,"PHASE1":5752,"PHASE2":5754,"PHASE3":5756,"PHASE4":5758,"NA":5760},{"trials":5751,"activeCount":101},[],{"trials":5753,"activeCount":101},[],{"trials":5755,"activeCount":101},[],{"trials":5757,"activeCount":101},[],{"trials":5759,"activeCount":101},[],{"trials":5761,"activeCount":233,"soonestReadout":951},[5762],{"nctId":5414,"briefTitle":5415,"status":132,"phases":5763,"primaryCompletion":951,"completion":951,"start":5417,"enrollment":855,"conditions":5764,"interventions":5765},[],[5419],[5421,5422,5423,5382,5424,5425],{"intervention":5425,"totalTrials":233,"cells":5767},{"EARLY_PHASE1":5768,"PHASE1":5770,"PHASE2":5772,"PHASE3":5774,"PHASE4":5776,"NA":5778},{"trials":5769,"activeCount":101},[],{"trials":5771,"activeCount":101},[],{"trials":5773,"activeCount":101},[],{"trials":5775,"activeCount":101},[],{"trials":5777,"activeCount":101},[],{"trials":5779,"activeCount":233,"soonestReadout":951},[5780],{"nctId":5414,"briefTitle":5415,"status":132,"phases":5781,"primaryCompletion":951,"completion":951,"start":5417,"enrollment":855,"conditions":5782,"interventions":5783},[],[5419],[5421,5422,5423,5382,5424,5425],{"intervention":960,"totalTrials":233,"cells":5785},{"EARLY_PHASE1":5786,"PHASE1":5788,"PHASE2":5790,"PHASE3":5792,"PHASE4":5794,"NA":5796},{"trials":5787,"activeCount":101},[],{"trials":5789,"activeCount":101},[],{"trials":5791,"activeCount":101},[],{"trials":5793,"activeCount":101},[],{"trials":5795,"activeCount":101},[],{"trials":5797,"activeCount":233,"soonestReadout":61},[5798],{"nctId":59,"briefTitle":60,"status":132,"phases":5799,"primaryCompletion":61,"completion":931,"start":956,"enrollment":957,"conditions":5800,"interventions":5801},[],[32,749],[62,960],{"intervention":5803,"totalTrials":421,"cells":5804},"Naproxen Sodium",{"EARLY_PHASE1":5805,"PHASE1":5807,"PHASE2":5833,"PHASE3":5857,"PHASE4":5870,"NA":5895},{"trials":5806,"activeCount":101},[],{"trials":5808,"activeCount":101},[5809,5817,5824],{"nctId":5810,"briefTitle":5811,"status":107,"phases":5812,"primaryCompletion":4691,"completion":4612,"start":3818,"enrollment":1509,"conditions":5813,"interventions":5815},"NCT00692016","Fast & Fed Pharmacokinetic (PK) Study",[90],[5814],"Bioavailability",[5816,5816],"Naproxen sodium",{"nctId":5818,"briefTitle":5819,"status":107,"phases":5820,"primaryCompletion":4067,"completion":4067,"start":3594,"enrollment":842,"conditions":5821,"interventions":5823},"NCT02229461","Naproxen Sodium\u002FASA Platelet Study",[90],[5822],"Hematology",[5803,3761],{"nctId":5825,"briefTitle":5826,"status":107,"phases":5827,"primaryCompletion":2959,"completion":410,"start":1508,"enrollment":1509,"conditions":5828,"interventions":5830},"NCT01666678","Compare Pharmacokinetic (PK) Profiles of Naproxen Sodium, Diphenhydramine Hydrochloride, and Naproxen Sodium and Diphenhydramine Hydrochloride Combination",[90],[5829],"Therapeutic Equivalence",[5831,5803,5832,5831],"BAY98-7111","Diphenhydramine HCl",{"trials":5834,"activeCount":101},[5835,5847],{"nctId":5836,"briefTitle":5837,"status":107,"phases":5838,"primaryCompletion":5839,"completion":1711,"start":5840,"enrollment":5841,"conditions":5842,"interventions":5844},"NCT04132336","Study to Find Out the Optimal Dose of Caffeine in the Combination Tablet of Naproxen Sodium and Caffeine in Patients Experiencing Moderate to Severe Pain After Having Wisdom Teeth Removed",[91],"2020-03-02","2019-11-12",193,[5843],"Pain, Postoperative",[5845,5816,5846],"Naproxen sodium\u002FCaffeine","Caffeine",{"nctId":5848,"briefTitle":5849,"status":107,"phases":5850,"primaryCompletion":5851,"completion":5851,"start":1752,"enrollment":2199,"conditions":5852,"interventions":5854},"NCT03570554","A Pilot Study Assessing the Treatment Responsiveness of a Novel Osteoarthritis Stiffness Scale",[91],"2019-06-14",[5853],"Osteoarthritis, Knee",[5803,5855,5856],"Acetaminophen ER","Celecoxib",{"trials":5858,"activeCount":101},[5859],{"nctId":5860,"briefTitle":5861,"status":107,"phases":5862,"primaryCompletion":5863,"completion":51,"start":5864,"enrollment":5865,"conditions":5866,"interventions":5868},"NCT05485805","A Study to Learn How Well a Single Dose of the Study Treatment Naproxen Sodium and Caffeine Combined in One Tablet (Fixed-dose Combination) Works to Relieve Pain After Dental Surgeries Compared to the Single Ingredients and to Placebo",[92],"2024-01-25","2022-09-21",541,[5867],"Postoperative Dental Pain",[5869,5816,5846],"Naproxen sodium and caffeine",{"trials":5871,"activeCount":101},[5872,5884],{"nctId":5873,"briefTitle":5874,"status":107,"phases":5875,"primaryCompletion":5876,"completion":5877,"start":5878,"enrollment":5879,"conditions":5880,"interventions":5882},"NCT04307940","Study to Collect Information on How Well the Study Drug Naproxen Sodium Tablets Works Compared to Hydrocodone\u002FAcetaminophen Tablets in Order to Relieve Pain in Participants Experiencing Moderate to Severe Pain After Having Their Wisdom Teeth Removed",[93],"2020-10-02","2020-10-05","2020-03-12",221,[5881],"Pain",[5803,5883],"Hydrocodone\u002FAcetaminophen",{"nctId":5885,"briefTitle":5886,"status":107,"phases":5887,"primaryCompletion":5888,"completion":5889,"start":5890,"enrollment":5891,"conditions":5892,"interventions":5893},"NCT03404206","A Trial to Compare the Duration of Analgesic Efficacy and Safety of Naproxen Sodium Tablets and Ibuprofen Tablets in Postsurgical Dental Pain",[93],"2018-07-06","2018-07-10","2018-02-12",387,[5843],[5803,5894],"Ibuprofen",{"trials":5896,"activeCount":101},[],{"intervention":1492,"totalTrials":328,"cells":5898},{"EARLY_PHASE1":5899,"PHASE1":5901,"PHASE2":5927,"PHASE3":5929,"PHASE4":5940,"NA":5951},{"trials":5900,"activeCount":101},[],{"trials":5902,"activeCount":101},[5903,5907,5920],{"nctId":1483,"briefTitle":1484,"status":107,"phases":5904,"primaryCompletion":1486,"completion":1487,"start":1488,"enrollment":36,"conditions":5905,"interventions":5906},[90],[1490],[1492,47],{"nctId":5908,"briefTitle":5909,"status":107,"phases":5910,"primaryCompletion":5911,"completion":5912,"start":5913,"enrollment":4934,"conditions":5914,"interventions":5916},"NCT03210246","Drug-drug Interaction Study: Influence of Vilaprisan on Pharmacodynamics (PD) and Pharmacokinetics (PK) of a Combined Oral Contraceptive (COC)",[90],"2018-06-21","2019-01-23","2017-07-17",[5915],"Clinical Trial ,Phase I",[5917,5918,1492,5919],"Vilaprisan","Vilaprisan Placebo","Microgynon Placebo",{"nctId":5921,"briefTitle":5922,"status":107,"phases":5923,"primaryCompletion":3733,"completion":1486,"start":1488,"enrollment":1081,"conditions":5924,"interventions":5925},"NCT02170038","Clinical Study Investigating the Conversion of the Contraceptive Compound Norethisterone Within the Body Towards the Contraceptive Compound Ethinylestradiol",[90],[1790],[1492,5926],"Noristerat",{"trials":5928,"activeCount":101},[],{"trials":5930,"activeCount":101},[5931],{"nctId":5932,"briefTitle":5933,"status":107,"phases":5934,"primaryCompletion":549,"completion":549,"start":4588,"enrollment":5935,"conditions":5936,"interventions":5938},"NCT00764881","Effects of SH T00658ID on Libido",[92],217,[15,5937],"Libido",[5939,1492],"EV\u002FDNG",{"trials":5941,"activeCount":101},[5942],{"nctId":5943,"briefTitle":5944,"status":107,"phases":5945,"completion":5946,"start":5394,"enrollment":1303,"conditions":5947,"interventions":5949},"NCT00651846","Investigate Impact of Yasmin vs Microgynon on Hemostasis Parameters in Healthy Women",[93],"2005-02",[5948],"Healthy",[5950,1492],"Yasmin",{"trials":5952,"activeCount":101},[],{"intervention":5954,"totalTrials":328,"cells":5955},"Loratadine",{"EARLY_PHASE1":5956,"PHASE1":5958,"PHASE2":5969,"PHASE3":5982,"PHASE4":5993,"NA":6014},{"trials":5957,"activeCount":101},[],{"trials":5959,"activeCount":101},[5960],{"nctId":5961,"briefTitle":5962,"status":107,"phases":5963,"primaryCompletion":2407,"completion":5964,"start":5249,"enrollment":2345,"conditions":5965,"interventions":5967},"NCT02593747","To Assess Bioequivalence of Loratadine Oral Solution\u002FSyrup Versus Claritin Peach Syrup",[90],"2016-03",[5966],"Histamine H1 Antagonists, Non-Sedating",[5968,5954],"Loratadine oral solution",{"trials":5970,"activeCount":101},[5971],{"nctId":5972,"briefTitle":5973,"status":107,"phases":5974,"primaryCompletion":3618,"completion":1327,"start":5975,"enrollment":5976,"conditions":5977,"interventions":5980},"NCT01330017","Effects of Phenylephrine on Nasal Congestion in Participants With Seasonal Allergic Rhinitis (P08156 AM2)(Completed)",[91],"2011-03",539,[5978,5979],"Rhinitis","Seasonal Rhinitis",[5981,5954],"Phenylephrine HCl",{"trials":5983,"activeCount":101},[5984],{"nctId":5985,"briefTitle":5986,"status":107,"phases":5987,"primaryCompletion":1352,"completion":1352,"start":2969,"enrollment":5988,"conditions":5989,"interventions":5991},"NCT01413958","Effects of Phenylephrine Extended-Release Tablets on Allergy-Related Nasal Congestion (P08498 AM1)",[92],575,[5990],"Seasonal Allergic Rhinitis",[5992,5954],"Phenylephrine",{"trials":5994,"activeCount":101},[5995,6005],{"nctId":5996,"briefTitle":5997,"status":107,"phases":5998,"primaryCompletion":5999,"completion":5999,"start":1352,"enrollment":6000,"conditions":6001,"interventions":6002},"NCT01469234","A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712)",[93],"2011-11",255,[5978],[6003,6004],"loratadine","fexofenadine",{"nctId":6006,"briefTitle":6007,"status":107,"phases":6008,"primaryCompletion":6009,"completion":6009,"start":5840,"enrollment":6010,"conditions":6011,"interventions":6013},"NCT04162795","A Study to Evaluate Cooling Sensation of an Allergy Product in Adults With a History of Allergies",[93],"2019-11-13",468,[6012],"Allergic Rhinitis",[5954],{"trials":6015,"activeCount":101},[],{"intervention":1591,"totalTrials":855,"cells":6017},{"EARLY_PHASE1":6018,"PHASE1":6020,"PHASE2":6022,"PHASE3":6028,"PHASE4":6030,"NA":6052},{"trials":6019,"activeCount":101},[],{"trials":6021,"activeCount":101},[],{"trials":6023,"activeCount":101},[6024],{"nctId":1582,"briefTitle":1583,"status":107,"phases":6025,"primaryCompletion":1585,"completion":1586,"start":1587,"enrollment":1163,"conditions":6026,"interventions":6027},[91],[1589],[47,1591],{"trials":6029,"activeCount":101},[],{"trials":6031,"activeCount":101},[6032,6036,6044],{"nctId":1707,"briefTitle":1708,"status":107,"phases":6033,"primaryCompletion":1710,"completion":1711,"start":1712,"enrollment":1713,"conditions":6034,"interventions":6035},[93],[1715],[47,1591,1717],{"nctId":6037,"briefTitle":6038,"status":107,"phases":6039,"completion":4666,"start":5946,"enrollment":112,"conditions":6040,"interventions":6042},"NCT00461565","FDA Phase IV - Commitment - Retinal Function Study",[93],[6041],"Safety",[1591,6043],"Vardenafil",{"nctId":6045,"briefTitle":6046,"status":107,"phases":6047,"primaryCompletion":3819,"completion":3819,"start":6048,"enrollment":864,"conditions":6049,"interventions":6050},"NCT00655590","Assess the Effect of Daily Treatment of Vardenafil 20mg or Sildenafil 100mg and Placebo on Sperm Function",[93],"2005-01",[27],[6051,1591],"Levitra",{"trials":6053,"activeCount":101},[],{"intervention":5950,"totalTrials":855,"cells":6055},{"EARLY_PHASE1":6056,"PHASE1":6058,"PHASE2":6060,"PHASE3":6062,"PHASE4":6090,"NA":6096},{"trials":6057,"activeCount":101},[],{"trials":6059,"activeCount":101},[],{"trials":6061,"activeCount":101},[],{"trials":6063,"activeCount":101},[6064,6071,6082],{"nctId":6065,"briefTitle":6066,"status":107,"phases":6067,"completion":6068,"start":3658,"enrollment":5879,"conditions":6069,"interventions":6070},"NCT00367276","Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 mg\u002FDRSP 3 mg) on Quality of Life.",[92],"2004-05",[5948],[5950],{"nctId":6072,"briefTitle":6073,"status":107,"phases":6074,"primaryCompletion":6075,"completion":6076,"start":6077,"enrollment":6078,"conditions":6079,"interventions":6080},"NCT01254292","LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study",[92],"2013-01-08","2014-05-28","2011-01-06",567,[15],[6081,5950],"Levonorgestrel IUD",{"nctId":6083,"briefTitle":6084,"status":107,"phases":6085,"primaryCompletion":5472,"completion":5472,"start":3657,"enrollment":6086,"conditions":6087,"interventions":6088},"NCT00185419","A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception",[92],842,[15],[5950,6089],"Marvelon",{"trials":6091,"activeCount":101},[6092],{"nctId":5943,"briefTitle":5944,"status":107,"phases":6093,"completion":5946,"start":5394,"enrollment":1303,"conditions":6094,"interventions":6095},[93],[5948],[5950,1492],{"trials":6097,"activeCount":101},[],{"intervention":1717,"totalTrials":1341,"cells":6099},{"EARLY_PHASE1":6100,"PHASE1":6102,"PHASE2":6104,"PHASE3":6106,"PHASE4":6117,"NA":6130},{"trials":6101,"activeCount":101},[],{"trials":6103,"activeCount":101},[],{"trials":6105,"activeCount":101},[],{"trials":6107,"activeCount":101},[6108],{"nctId":6109,"briefTitle":6110,"status":107,"phases":6111,"primaryCompletion":6112,"completion":6112,"start":6113,"enrollment":6114,"conditions":6115,"interventions":6116},"NCT00668109","Assessment of Efficacy of Vardenafil in Subjects With Erectile Dysfunction and Diabetes, Hypertension or Hyperlipidemia",[92],"2004-06","2003-12",614,[27],[6051,1717],{"trials":6118,"activeCount":101},[6119,6123],{"nctId":1707,"briefTitle":1708,"status":107,"phases":6120,"primaryCompletion":1710,"completion":1711,"start":1712,"enrollment":1713,"conditions":6121,"interventions":6122},[93],[1715],[47,1591,1717],{"nctId":6124,"briefTitle":6125,"status":107,"phases":6126,"primaryCompletion":3706,"completion":3706,"start":4707,"enrollment":6127,"conditions":6128,"interventions":6129},"NCT00663130","Evaluating the Efficacy Vardenafil 10 mg vs Tadalafil 10 mg in in Subjects With Erectile Dysfunction (ED)",[93],759,[27],[6051,1717],{"trials":6131,"activeCount":101},[],{"intervention":6133,"totalTrials":1341,"cells":6134},"Acetaminophen",{"EARLY_PHASE1":6135,"PHASE1":6137,"PHASE2":6139,"PHASE3":6141,"PHASE4":6163,"NA":6175},{"trials":6136,"activeCount":101},[],{"trials":6138,"activeCount":101},[],{"trials":6140,"activeCount":101},[],{"trials":6142,"activeCount":101},[6143,6152],{"nctId":6144,"briefTitle":6145,"status":156,"phases":6146,"primaryCompletion":6147,"completion":6147,"start":6148,"enrollment":4466,"conditions":6149,"interventions":6151},"NCT01552798","Efficacy of a Single Dose of Aspirin vs. Acetaminophen in Tension Type Headache",[92],"2012-06-04","2012-03-12",[6150],"Headache",[3745,6133],{"nctId":6153,"briefTitle":6154,"status":107,"phases":6155,"primaryCompletion":6156,"completion":6156,"start":6157,"enrollment":6158,"conditions":6159,"interventions":6161},"NCT01420094","Evaluate Onset of Action of a Fast Release Aspirin",[92],"2011-09-08","2011-06-16",510,[6160],"Healthy Subjects",[6162,6133],"Acetylsalicyclic acid",{"trials":6164,"activeCount":101},[6165],{"nctId":6166,"briefTitle":6167,"status":107,"phases":6168,"primaryCompletion":6169,"completion":6169,"start":6170,"enrollment":5072,"conditions":6171,"interventions":6173},"NCT03448536","A Study to Assess Menstrual Cramp Pain Associated With Primary Dysmenorrhea",[93],"2018-09-05","2018-04-05",[6172],"Dysmenorrhea",[6174,6133],"Naproxen Sodium,",{"trials":6176,"activeCount":101},[],{"intervention":5846,"totalTrials":1341,"cells":6178},{"EARLY_PHASE1":6179,"PHASE1":6181,"PHASE2":6183,"PHASE3":6189,"PHASE4":6195,"NA":6207},{"trials":6180,"activeCount":101},[],{"trials":6182,"activeCount":101},[],{"trials":6184,"activeCount":101},[6185],{"nctId":5836,"briefTitle":5837,"status":107,"phases":6186,"primaryCompletion":5839,"completion":1711,"start":5840,"enrollment":5841,"conditions":6187,"interventions":6188},[91],[5843],[5845,5816,5846],{"trials":6190,"activeCount":101},[6191],{"nctId":5860,"briefTitle":5861,"status":107,"phases":6192,"primaryCompletion":5863,"completion":51,"start":5864,"enrollment":5865,"conditions":6193,"interventions":6194},[92],[5867],[5869,5816,5846],{"trials":6196,"activeCount":101},[6197],{"nctId":6198,"briefTitle":6199,"status":107,"phases":6200,"primaryCompletion":6201,"completion":6201,"start":6202,"enrollment":6203,"conditions":6204,"interventions":6206},"NCT00781586","Efficacy of ONE A DAY Weightsmart Advanced Versus Caffeine and Placebo on Energy Expenditure, Thermogenesis and Perceived Energy Levels in Women.",[93],"2008-04-21","2007-10-02",22,[6205],"Energy Expenditure",[5846],{"trials":6208,"activeCount":101},[],{"intervention":6210,"totalTrials":1341,"cells":6211},"Naproxen Sodium 440 mg",{"EARLY_PHASE1":6212,"PHASE1":6214,"PHASE2":6216,"PHASE3":6218,"PHASE4":6239,"NA":6253},{"trials":6213,"activeCount":101},[],{"trials":6215,"activeCount":101},[],{"trials":6217,"activeCount":101},[],{"trials":6219,"activeCount":101},[6220,6231],{"nctId":6221,"briefTitle":6222,"status":107,"phases":6223,"primaryCompletion":1569,"completion":2344,"start":3793,"enrollment":6224,"conditions":6225,"interventions":6226},"NCT01280591","Evaluate Analgesic\u002FSedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain",[92],712,[5843],[6227,6228,6229,6230],"Naproxen sodium 440 mg \u002F DPH 50 mg","Naproxen sodium 220 mg \u002F DPH 50 mg","Naproxen sodium 440 mg","DPH 50 mg",{"nctId":6232,"briefTitle":6233,"status":107,"phases":6234,"primaryCompletion":2959,"completion":2959,"start":2919,"enrollment":6235,"conditions":6236,"interventions":6237},"NCT01495858","Evaluate Analgesic \u002F Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain",[92],267,[5843],[6238,6210,6230],"Naproxen Sodium 440 mg \u002F DPH 25 mg",{"trials":6240,"activeCount":101},[6241],{"nctId":6242,"briefTitle":6243,"status":107,"phases":6244,"primaryCompletion":4691,"completion":4691,"start":3818,"enrollment":3033,"conditions":6245,"interventions":6247},"NCT01118273","Evaluate Analgesic\u002FSedative Efficacy of Naproxen Sodium and Diphenhydramine",[93],[6246],"Sleep",[6248,6210,6249,6250,6251,6252],"Naproxen Sodium 440 mg (BAYH6689) \u002F DPH 50mg","Naproxen Sodium 220 mg (BAYH6689) \u002F DPH 50mg","Naproxen Sodium 220 mg","DPH 50mg","Ibuprofen 400 mg \u002F Diphenhydramine citrate 76 mg",{"trials":6254,"activeCount":101},[],{"intervention":5894,"totalTrials":1341,"cells":6256},{"EARLY_PHASE1":6257,"PHASE1":6259,"PHASE2":6261,"PHASE3":6263,"PHASE4":6275,"NA":6291},{"trials":6258,"activeCount":101},[],{"trials":6260,"activeCount":101},[],{"trials":6262,"activeCount":101},[],{"trials":6264,"activeCount":101},[6265],{"nctId":6266,"briefTitle":6267,"status":107,"phases":6268,"completion":6269,"start":6270,"enrollment":6271,"conditions":6272,"interventions":6274},"NCT01028079","Placebo and Active Controlled, Double Dummy Study to Prove Efficacy of Aspirin in Treatment of Acute Low Back Pain",[92],"2006-12","2005-11",338,[6273],"Low Back Pain",[3761,5894],{"trials":6276,"activeCount":101},[6277,6287],{"nctId":6278,"briefTitle":6279,"status":107,"phases":6280,"completion":6281,"start":3668,"enrollment":6282,"conditions":6283,"interventions":6286},"NCT01464983","Placebo and Active Controlled, Double Dummy Study to Compare Efficacy of Aspirin and Ibuprofen in Treatment of Episodic Tension-type Headache",[93],"2004-08",1115,[6150,6284,6285],"Tension-Type Headache","Tension-Type Headache (Episodic)",[3745,3745,5894,5894],{"nctId":5885,"briefTitle":5886,"status":107,"phases":6288,"primaryCompletion":5888,"completion":5889,"start":5890,"enrollment":5891,"conditions":6289,"interventions":6290},[93],[5843],[5803,5894],{"trials":6292,"activeCount":101},[],{"intervention":6294,"totalTrials":1341,"cells":6295},"Dexpanthenol",{"EARLY_PHASE1":6296,"PHASE1":6298,"PHASE2":6307,"PHASE3":6309,"PHASE4":6311,"NA":6329},{"trials":6297,"activeCount":101},[],{"trials":6299,"activeCount":101},[6300],{"nctId":6301,"briefTitle":6302,"status":107,"phases":6303,"primaryCompletion":3619,"completion":3619,"start":4700,"enrollment":33,"conditions":6304,"interventions":6305},"NCT00885937","Comparative Safety Study of New Sinecort Formulation Versus Positive Control",[90],[5948],[6294,6306],"Positive control, Na-laurylsulfat-solution",{"trials":6308,"activeCount":101},[],{"trials":6310,"activeCount":101},[],{"trials":6312,"activeCount":101},[6313,6321],{"nctId":6314,"briefTitle":6315,"status":107,"phases":6316,"primaryCompletion":6317,"completion":6317,"start":3778,"enrollment":171,"conditions":6318,"interventions":6320},"NCT02734628","Pilot Study to Assess Number of Patients for Main Trial",[93],"2007-04",[6319],"Wound Healing",[6294],{"nctId":6322,"briefTitle":6323,"status":107,"phases":6324,"primaryCompletion":4292,"completion":1313,"start":4292,"enrollment":1949,"conditions":6325,"interventions":6328},"NCT00859196","Study to Assess on a Molecular Level the Influence of a 5 % Dexpanthenol Ointment in Subjects With Superficial Injuries",[93],[6319,6326,6327],"Cell Proliferation","Gene Expression",[6294],{"trials":6330,"activeCount":101},[],{"intervention":6332,"totalTrials":1341,"cells":6333},"Menostar",{"EARLY_PHASE1":6334,"PHASE1":6336,"PHASE2":6338,"PHASE3":6340,"PHASE4":6357,"NA":6367},{"trials":6335,"activeCount":101},[],{"trials":6337,"activeCount":101},[],{"trials":6339,"activeCount":101},[],{"trials":6341,"activeCount":101},[6342,6350],{"nctId":6343,"briefTitle":6344,"status":107,"phases":6345,"completion":3723,"start":446,"enrollment":874,"conditions":6346,"interventions":6348},"NCT00310531","3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women",[92],[6347],"Osteopenia",[6332,6349],"Raloxifene",{"nctId":6351,"briefTitle":6352,"status":107,"phases":6353,"primaryCompletion":6354,"completion":6354,"start":3627,"enrollment":1424,"conditions":6355,"interventions":6356},"NCT00185237","Treatment of Hot Flushes in Asian Women With Ultra-low Dose Estradiol Patch",[92],"2006-11",[1103],[6332],{"trials":6358,"activeCount":101},[6359],{"nctId":6360,"briefTitle":6361,"status":107,"phases":6362,"completion":3724,"start":6363,"enrollment":3121,"conditions":6364,"interventions":6365},"NCT00206622","Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes",[93],"2004-12",[1103],[6366,6332],"Climara PRO",{"trials":6368,"activeCount":101},[],{"intervention":6370,"totalTrials":1341,"cells":6371},"Cipro XR",{"EARLY_PHASE1":6372,"PHASE1":6374,"PHASE2":6376,"PHASE3":6378,"PHASE4":6390,"NA":6407},{"trials":6373,"activeCount":101},[],{"trials":6375,"activeCount":101},[],{"trials":6377,"activeCount":101},[],{"trials":6379,"activeCount":101},[6380],{"nctId":6381,"briefTitle":6382,"status":107,"phases":6383,"completion":4675,"start":6384,"enrollment":6385,"conditions":6386,"interventions":6388},"NCT00668122","Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections",[92],"2004-03",212,[6387],"Urinary Tract Infection",[6370,6389],"Cipro IR",{"trials":6391,"activeCount":101},[6392,6400],{"nctId":6393,"briefTitle":6394,"status":107,"phases":6395,"completion":6396,"start":6068,"enrollment":874,"conditions":6397,"interventions":6399},"NCT00481689","Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens",[93],"2005-09",[6398],"Urinary Tract Infections",[6370],{"nctId":6401,"briefTitle":6402,"status":107,"phases":6403,"completion":3668,"start":5394,"enrollment":6404,"conditions":6405,"interventions":6406},"NCT00676533","Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections",[93],276,[6387],[6370],{"trials":6408,"activeCount":101},[],{"intervention":6410,"totalTrials":1341,"cells":6411},"Loratadine + Pseudoephedrine sulfate",{"EARLY_PHASE1":6412,"PHASE1":6414,"PHASE2":6433,"PHASE3":6435,"PHASE4":6437,"NA":6451},{"trials":6413,"activeCount":101},[],{"trials":6415,"activeCount":101},[6416,6424],{"nctId":6417,"briefTitle":6418,"status":107,"phases":6419,"primaryCompletion":6420,"completion":6420,"start":6421,"enrollment":19,"conditions":6422,"interventions":6423},"NCT03517930","A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects",[90],"2018-07-20","2018-04-17",[1536],[6410,6410],{"nctId":6425,"briefTitle":6426,"status":107,"phases":6427,"primaryCompletion":6428,"completion":6428,"start":6429,"enrollment":6430,"conditions":6431,"interventions":6432},"NCT03517943","A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects",[90],"2018-08-30","2018-04-24",29,[1536],[6410,6410],{"trials":6434,"activeCount":101},[],{"trials":6436,"activeCount":101},[],{"trials":6438,"activeCount":101},[6439],{"nctId":6440,"briefTitle":6441,"status":107,"phases":6442,"primaryCompletion":6443,"completion":6443,"start":6444,"enrollment":6445,"conditions":6446,"interventions":6448},"NCT03443843","A Study to Evaluate Changes in Nasal Airflow of Loratadine\u002FPseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure",[93],"2018-05-11","2018-02-21",82,[6447],"Rhinitis, Allergic",[6449,6450],"loratadine + pseudoephedrine sulfate","Fluticasone Propionate",{"trials":6452,"activeCount":101},[],{"intervention":6174,"totalTrials":175,"cells":6454},{"EARLY_PHASE1":6455,"PHASE1":6457,"PHASE2":6466,"PHASE3":6468,"PHASE4":6470,"NA":6476},{"trials":6456,"activeCount":101},[],{"trials":6458,"activeCount":101},[6459],{"nctId":6460,"briefTitle":6461,"status":107,"phases":6462,"primaryCompletion":3619,"completion":3619,"start":4700,"enrollment":171,"conditions":6463,"interventions":6464},"NCT00969449","Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and Naprelan",[90],[1790],[6174,6465],"Naprelan,",{"trials":6467,"activeCount":101},[],{"trials":6469,"activeCount":101},[],{"trials":6471,"activeCount":101},[6472],{"nctId":6166,"briefTitle":6167,"status":107,"phases":6473,"primaryCompletion":6169,"completion":6169,"start":6170,"enrollment":5072,"conditions":6474,"interventions":6475},[93],[6172],[6174,6133],{"trials":6477,"activeCount":101},[],{"intervention":6479,"totalTrials":175,"cells":6480},"Estradiol\u002FDRSP",{"EARLY_PHASE1":6481,"PHASE1":6483,"PHASE2":6485,"PHASE3":6487,"PHASE4":6497,"NA":6507},{"trials":6482,"activeCount":101},[],{"trials":6484,"activeCount":101},[],{"trials":6486,"activeCount":101},[],{"trials":6488,"activeCount":101},[6489],{"nctId":6490,"briefTitle":6491,"status":107,"phases":6492,"primaryCompletion":6493,"completion":6493,"start":444,"enrollment":4278,"conditions":6494,"interventions":6496},"NCT00356447","Safety\u002FEfficacy Study of Drospirenone\u002FEstradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.",[92],"2007-10",[6495],"Vasomotor Symptoms",[6479],{"trials":6498,"activeCount":101},[6499],{"nctId":6500,"briefTitle":6501,"status":107,"phases":6502,"completion":6269,"start":6396,"enrollment":6503,"conditions":6504,"interventions":6506},"NCT00185328","Efficacy and Tolerability of Angeliq in Thai Women",[93],55,[6505],"Postmenopause",[6479],{"trials":6508,"activeCount":101},[],{"intervention":6510,"totalTrials":175,"cells":6511},"Amoxicillin\u002FClavulanate",{"EARLY_PHASE1":6512,"PHASE1":6514,"PHASE2":6516,"PHASE3":6518,"PHASE4":6532,"NA":6543},{"trials":6513,"activeCount":101},[],{"trials":6515,"activeCount":101},[],{"trials":6517,"activeCount":101},[],{"trials":6519,"activeCount":101},[6520],{"nctId":6521,"briefTitle":6522,"status":107,"phases":6523,"primaryCompletion":3403,"completion":3403,"start":6524,"enrollment":4862,"conditions":6525,"interventions":6527},"NCT01069900","Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection",[92],"2010-07-21",[6526],"Intraabdominal Infections",[1144,6528,6510,6529,6530,6531],"Ertapenem","Moxifloxacin placebo","Ertapenem placebo","Amoxicillin\u002FClavulanate placebo",{"trials":6533,"activeCount":101},[6534],{"nctId":6535,"briefTitle":6536,"status":156,"phases":6537,"primaryCompletion":3818,"completion":3818,"start":3724,"enrollment":6538,"conditions":6539,"interventions":6542},"NCT00493038","Study to Evaluate the Efficacy and Safety of Moxifloxacin Versus Amoxicillin\u002FClavulanate in the Treatment of Acute Bacterial Rhinosinusitis",[93],293,[6540,6541],"Sinusitis","Bacterial Infections",[1144,6510],{"trials":6544,"activeCount":101},[],{"intervention":6546,"totalTrials":175,"cells":6547},"Paracetamol",{"EARLY_PHASE1":6548,"PHASE1":6550,"PHASE2":6552,"PHASE3":6554,"PHASE4":6556,"NA":6577},{"trials":6549,"activeCount":101},[],{"trials":6551,"activeCount":101},[],{"trials":6553,"activeCount":101},[],{"trials":6555,"activeCount":101},[],{"trials":6557,"activeCount":101},[6558,6567],{"nctId":6559,"briefTitle":6560,"status":107,"phases":6561,"completion":4707,"start":3657,"enrollment":6562,"conditions":6563,"interventions":6566},"NCT01464944","Placebo and Active Controlled Study to Compare the Antipyretic Efficacy of Aspirin® in Patients With Acute Febrile Upper Respiratory Tract Infections Suspected to be of Viral Origin",[93],392,[6564,6565],"Respiratory Tract Infections","Fever",[3745,3745,6546,6546],{"nctId":6568,"briefTitle":6569,"status":107,"phases":6570,"completion":4836,"start":3657,"enrollment":6571,"conditions":6572,"interventions":6576},"NCT01465009","Placebo and Active Controlled Study to Compare the Efficacy of Aspirin and Paracetamol in Treatment of Sore Throat Associated With a Common Cold",[93],508,[6573,6574,6575],"Common Cold","Pharyngitis","Tonsillitis",[3745,6546],{"trials":6578,"activeCount":101},[],{"intervention":5477,"totalTrials":175,"cells":6580},{"EARLY_PHASE1":6581,"PHASE1":6583,"PHASE2":6585,"PHASE3":6587,"PHASE4":6589,"NA":6604},{"trials":6582,"activeCount":101},[],{"trials":6584,"activeCount":101},[],{"trials":6586,"activeCount":101},[],{"trials":6588,"activeCount":101},[],{"trials":6590,"activeCount":101},[6591,6595],{"nctId":5469,"briefTitle":5470,"status":107,"phases":6592,"primaryCompletion":2970,"completion":2970,"start":5472,"enrollment":5473,"conditions":6593,"interventions":6594},[93],[5475],[5477,5422,5477],{"nctId":6596,"briefTitle":6597,"status":107,"phases":6598,"completion":4789,"start":6599,"enrollment":6600,"conditions":6601,"interventions":6603},"NCT00206648","An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS",[93],"2003-03",271,[6602],"Multiple Sclerosis, Relapsing-Remitting",[5477,5477],{"trials":6605,"activeCount":101},[],{"intervention":6607,"totalTrials":175,"cells":6608},"Diovan",{"EARLY_PHASE1":6609,"PHASE1":6611,"PHASE2":6613,"PHASE3":6615,"PHASE4":6617,"NA":6637},{"trials":6610,"activeCount":101},[],{"trials":6612,"activeCount":101},[],{"trials":6614,"activeCount":101},[],{"trials":6616,"activeCount":101},[],{"trials":6618,"activeCount":101},[6619,6629],{"nctId":6620,"briefTitle":6621,"status":107,"phases":6622,"primaryCompletion":4648,"completion":4648,"start":6384,"enrollment":6623,"conditions":6624,"interventions":6626},"NCT01518855","Controlled Release Nifedipine and Valsartan Combination Therapy in Patients With Essential Hypertension",[93],514,[6625],"Hypertension",[6627,6628,6607],"Nifedipine","Amlodipine",{"nctId":6630,"briefTitle":6631,"status":107,"phases":6632,"primaryCompletion":3618,"completion":3618,"start":2255,"enrollment":6633,"conditions":6634,"interventions":6635},"NCT00993109","Low-dose Nifedipine-Valsartan Combination Compared to Up-titrated Valsartan Monotherapy in Essential Hypertension",[93],360,[6625],[6636,6607],"Adalat",{"trials":6638,"activeCount":101},[],{"intervention":6636,"totalTrials":175,"cells":6640},{"EARLY_PHASE1":6641,"PHASE1":6643,"PHASE2":6645,"PHASE3":6647,"PHASE4":6649,"NA":6662},{"trials":6642,"activeCount":101},[],{"trials":6644,"activeCount":101},[],{"trials":6646,"activeCount":101},[],{"trials":6648,"activeCount":101},[],{"trials":6650,"activeCount":101},[6651,6655],{"nctId":6630,"briefTitle":6631,"status":107,"phases":6652,"primaryCompletion":3618,"completion":3618,"start":2255,"enrollment":6633,"conditions":6653,"interventions":6654},[93],[6625],[6636,6607],{"nctId":6656,"briefTitle":6657,"status":107,"phases":6658,"completion":6281,"start":6113,"enrollment":1303,"conditions":6659,"interventions":6660},"NCT00672113","Effects of Adalat LA and Coracten on Drug Levels, Blood Pressure, and Heart Rate in Fed Patients With Hypertension",[93],[6625],[6636,6661],"Coracten",{"trials":6663,"activeCount":101},[],{"intervention":6665,"totalTrials":175,"cells":6666},"Polyethylene Glycol",{"EARLY_PHASE1":6667,"PHASE1":6669,"PHASE2":6671,"PHASE3":6683,"PHASE4":6685,"NA":6697},{"trials":6668,"activeCount":101},[],{"trials":6670,"activeCount":101},[],{"trials":6672,"activeCount":101},[6673],{"nctId":6674,"briefTitle":6675,"status":107,"phases":6676,"primaryCompletion":6677,"completion":1629,"start":4250,"enrollment":6678,"conditions":6679,"interventions":6681},"NCT01885104","Safety and Tolerability of Oral Polyethylene Glycol (PEG 3350) Solution in Participants With Constipation (MK-8114-003)",[91],"2013-09",65,[6680],"Constipation",[6665,6682],"Bisacodyl laxative",{"trials":6684,"activeCount":101},[],{"trials":6686,"activeCount":101},[6687],{"nctId":6688,"briefTitle":6689,"status":107,"phases":6690,"primaryCompletion":6691,"completion":6691,"start":6692,"enrollment":229,"conditions":6693,"interventions":6694},"NCT04534465","Study to Gather Information on the Acceptability of a New Flavor System With Increasing Levels of 2, 4, 6 g or Higher of Mannitol for PEG 3350 in Subjects Having Infrequent Bowel Movements.",[93],"2013-03-19","2013-02-13",[6680],[6695,6696],"Polyethylene glycol","Mannitol",{"trials":6698,"activeCount":101},[],{"intervention":6700,"totalTrials":233,"cells":6701},"Levofloxacin",{"EARLY_PHASE1":6702,"PHASE1":6704,"PHASE2":6706,"PHASE3":6708,"PHASE4":6710,"NA":6721},{"trials":6703,"activeCount":101},[],{"trials":6705,"activeCount":101},[],{"trials":6707,"activeCount":101},[],{"trials":6709,"activeCount":101},[],{"trials":6711,"activeCount":101},[6712],{"nctId":6713,"briefTitle":6714,"status":107,"phases":6715,"primaryCompletion":4707,"completion":4707,"start":5395,"enrollment":6716,"conditions":6717,"interventions":6719},"NCT00665327","Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia",[93],401,[6718],"Pneumonia",[6720,6700],"Avelox",{"trials":6722,"activeCount":101},[],{"intervention":6724,"totalTrials":233,"cells":6725},"Vardenafil (Levitra, BAY 38-9456), 10 mg",{"EARLY_PHASE1":6726,"PHASE1":6728,"PHASE2":6730,"PHASE3":6732,"PHASE4":6734,"NA":6744},{"trials":6727,"activeCount":101},[],{"trials":6729,"activeCount":101},[],{"trials":6731,"activeCount":101},[],{"trials":6733,"activeCount":101},[],{"trials":6735,"activeCount":101},[6736],{"nctId":6737,"briefTitle":6738,"status":107,"phases":6739,"completion":1328,"start":3627,"enrollment":510,"conditions":6740,"interventions":6742},"NCT00667966","Assess Efficacy in Subjects With Traumatic Spinal Cord Injury",[93],[27,6741],"Spinal Cord Injury",[6724,6743],"Vardenafil (Levitra, BAY 38-9456), 20 mg",{"trials":6745,"activeCount":101},[],{"intervention":6743,"totalTrials":233,"cells":6747},{"EARLY_PHASE1":6748,"PHASE1":6750,"PHASE2":6752,"PHASE3":6754,"PHASE4":6756,"NA":6762},{"trials":6749,"activeCount":101},[],{"trials":6751,"activeCount":101},[],{"trials":6753,"activeCount":101},[],{"trials":6755,"activeCount":101},[],{"trials":6757,"activeCount":101},[6758],{"nctId":6737,"briefTitle":6738,"status":107,"phases":6759,"completion":1328,"start":3627,"enrollment":510,"conditions":6760,"interventions":6761},[93],[27,6741],[6724,6743],{"trials":6763,"activeCount":101},[],{"intervention":6765,"totalTrials":233,"cells":6766},"rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU\u002Fkg, dosing once per week",{"EARLY_PHASE1":6767,"PHASE1":6769,"PHASE2":6771,"PHASE3":6773,"PHASE4":6775,"NA":6784},{"trials":6768,"activeCount":101},[],{"trials":6770,"activeCount":101},[],{"trials":6772,"activeCount":101},[],{"trials":6774,"activeCount":101},[],{"trials":6776,"activeCount":101},[6777],{"nctId":6778,"briefTitle":6779,"status":107,"phases":6780,"primaryCompletion":3576,"completion":3576,"start":3723,"enrollment":1509,"conditions":6781,"interventions":6782},"NCT00632814","Russian Kogenate Pediatric Study",[93],[24],[6765,6783,6783],"rFVIII-FS",{"trials":6785,"activeCount":101},[],{"intervention":6783,"totalTrials":233,"cells":6787},{"EARLY_PHASE1":6788,"PHASE1":6790,"PHASE2":6792,"PHASE3":6794,"PHASE4":6796,"NA":6802},{"trials":6789,"activeCount":101},[],{"trials":6791,"activeCount":101},[],{"trials":6793,"activeCount":101},[],{"trials":6795,"activeCount":101},[],{"trials":6797,"activeCount":101},[6798],{"nctId":6778,"briefTitle":6779,"status":107,"phases":6799,"primaryCompletion":3576,"completion":3576,"start":3723,"enrollment":1509,"conditions":6800,"interventions":6801},[93],[24],[6765,6783,6783],{"trials":6803,"activeCount":101},[],{"intervention":6805,"totalTrials":233,"cells":6806},"Climodien \u002F Lafamme",{"EARLY_PHASE1":6807,"PHASE1":6809,"PHASE2":6811,"PHASE3":6813,"PHASE4":6815,"NA":6825},{"trials":6808,"activeCount":101},[],{"trials":6810,"activeCount":101},[],{"trials":6812,"activeCount":101},[],{"trials":6814,"activeCount":101},[],{"trials":6816,"activeCount":101},[6817],{"nctId":6818,"briefTitle":6819,"status":107,"phases":6820,"completion":6281,"start":6821,"enrollment":6822,"conditions":6823,"interventions":6824},"NCT00335218","Fat Distribution in Healthy Early Postmenopausal Women",[93],"2002-07",67,[5948,6505],[6805],{"trials":6826,"activeCount":101},[],{"intervention":6828,"totalTrials":233,"cells":6829},"Nifidipine",{"EARLY_PHASE1":6830,"PHASE1":6832,"PHASE2":6834,"PHASE3":6836,"PHASE4":6838,"NA":6849},{"trials":6831,"activeCount":101},[],{"trials":6833,"activeCount":101},[],{"trials":6835,"activeCount":101},[],{"trials":6837,"activeCount":101},[],{"trials":6839,"activeCount":101},[6840],{"nctId":6841,"briefTitle":6842,"status":107,"phases":6843,"primaryCompletion":4587,"completion":1314,"start":6493,"enrollment":6844,"conditions":6845,"interventions":6846},"NCT00750113","Study Evaluating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control.",[93],405,[6625],[6828,6847,6848],"Telmisartan","Nifedipine\u002FTelmisartan",{"trials":6850,"activeCount":101},[],{"intervention":6848,"totalTrials":233,"cells":6852},{"EARLY_PHASE1":6853,"PHASE1":6855,"PHASE2":6857,"PHASE3":6859,"PHASE4":6861,"NA":6867},{"trials":6854,"activeCount":101},[],{"trials":6856,"activeCount":101},[],{"trials":6858,"activeCount":101},[],{"trials":6860,"activeCount":101},[],{"trials":6862,"activeCount":101},[6863],{"nctId":6841,"briefTitle":6842,"status":107,"phases":6864,"primaryCompletion":4587,"completion":1314,"start":6493,"enrollment":6844,"conditions":6865,"interventions":6866},[93],[6625],[6828,6847,6848],{"trials":6868,"activeCount":101},[],{"intervention":6870,"totalTrials":233,"cells":6871},"Voglibose",{"EARLY_PHASE1":6872,"PHASE1":6874,"PHASE2":6876,"PHASE3":6878,"PHASE4":6880,"NA":6891},{"trials":6873,"activeCount":101},[],{"trials":6875,"activeCount":101},[],{"trials":6877,"activeCount":101},[],{"trials":6879,"activeCount":101},[],{"trials":6881,"activeCount":101},[6882],{"nctId":6883,"briefTitle":6884,"status":107,"phases":6885,"primaryCompletion":410,"completion":410,"start":1497,"enrollment":6886,"conditions":6887,"interventions":6889},"NCT00970528","Glucose Reduction by Early Acarbose Treatment in Basal Insulin",[93],124,[6888],"Diabetes Mellitus, Type 2",[6890,6870],"Acarbose",{"trials":6892,"activeCount":101},[],{"intervention":6894,"totalTrials":233,"cells":6895},"Cytotec",{"EARLY_PHASE1":6896,"PHASE1":6898,"PHASE2":6900,"PHASE3":6902,"PHASE4":6904,"NA":6913},{"trials":6897,"activeCount":101},[],{"trials":6899,"activeCount":101},[],{"trials":6901,"activeCount":101},[],{"trials":6903,"activeCount":101},[],{"trials":6905,"activeCount":101},[6906],{"nctId":6907,"briefTitle":6908,"status":107,"phases":6909,"primaryCompletion":408,"completion":408,"start":4666,"enrollment":2408,"conditions":6910,"interventions":6911},"NCT00393198","Bleeding Pattern and User Satisfaction During Second Consecutive MIRENA® in Contraception and Treatment of Menorrhagia",[93],[15,1426],[6912,6894],"Levonorgestrel",{"trials":6914,"activeCount":101},[],{"intervention":6916,"totalTrials":233,"cells":6917},"Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon",{"EARLY_PHASE1":6918,"PHASE1":6920,"PHASE2":6922,"PHASE3":6924,"PHASE4":6926,"NA":6936},{"trials":6919,"activeCount":101},[],{"trials":6921,"activeCount":101},[],{"trials":6923,"activeCount":101},[],{"trials":6925,"activeCount":101},[],{"trials":6927,"activeCount":101},[6928],{"nctId":6929,"briefTitle":6930,"status":156,"phases":6931,"completion":6354,"start":6932,"enrollment":175,"conditions":6933,"interventions":6934},"NCT00352859","Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib",[93],"2006-08",[2328],[6916,6935],"Gemcitabine or Interferon",{"trials":6937,"activeCount":101},[],{"intervention":6935,"totalTrials":233,"cells":6939},{"EARLY_PHASE1":6940,"PHASE1":6942,"PHASE2":6944,"PHASE3":6946,"PHASE4":6948,"NA":6954},{"trials":6941,"activeCount":101},[],{"trials":6943,"activeCount":101},[],{"trials":6945,"activeCount":101},[],{"trials":6947,"activeCount":101},[],{"trials":6949,"activeCount":101},[6950],{"nctId":6929,"briefTitle":6930,"status":156,"phases":6951,"completion":6354,"start":6932,"enrollment":175,"conditions":6952,"interventions":6953},[93],[2328],[6916,6935],{"trials":6955,"activeCount":101},[],{"intervention":6957,"totalTrials":233,"cells":6958},"Gadoterate",{"EARLY_PHASE1":6959,"PHASE1":6961,"PHASE2":6963,"PHASE3":6965,"PHASE4":6967,"NA":6981},{"trials":6960,"activeCount":101},[],{"trials":6962,"activeCount":101},[],{"trials":6964,"activeCount":101},[],{"trials":6966,"activeCount":101},[],{"trials":6968,"activeCount":101},[6969],{"nctId":6970,"briefTitle":6971,"status":107,"phases":6972,"primaryCompletion":6973,"completion":6974,"start":6975,"enrollment":6976,"conditions":6977,"interventions":6979},"NCT03602339","Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose",[93],"2020-03-13","2020-05-26","2018-11-14",157,[6978],"Magnetic Resonance Imaging",[6957,6980],"Gadobutrol",{"trials":6982,"activeCount":101},[],{"intervention":6628,"totalTrials":233,"cells":6984},{"EARLY_PHASE1":6985,"PHASE1":6987,"PHASE2":6989,"PHASE3":6991,"PHASE4":6993,"NA":6999},{"trials":6986,"activeCount":101},[],{"trials":6988,"activeCount":101},[],{"trials":6990,"activeCount":101},[],{"trials":6992,"activeCount":101},[],{"trials":6994,"activeCount":101},[6995],{"nctId":6620,"briefTitle":6621,"status":107,"phases":6996,"primaryCompletion":4648,"completion":4648,"start":6384,"enrollment":6623,"conditions":6997,"interventions":6998},[93],[6625],[6627,6628,6607],{"trials":7000,"activeCount":101},[],{"intervention":7002,"totalTrials":233,"cells":7003},"Tranexamic acid",{"EARLY_PHASE1":7004,"PHASE1":7006,"PHASE2":7008,"PHASE3":7010,"PHASE4":7012,"NA":7024},{"trials":7005,"activeCount":101},[],{"trials":7007,"activeCount":101},[],{"trials":7009,"activeCount":101},[],{"trials":7011,"activeCount":101},[],{"trials":7013,"activeCount":101},[7014],{"nctId":7015,"briefTitle":7016,"status":107,"phases":7017,"primaryCompletion":2919,"completion":2919,"start":5975,"enrollment":7018,"conditions":7019,"interventions":7021},"NCT01295294","Management of Initial Bleeding\u002FSpotting Associated With the Levonorgestrel-releasing Intrauterine System (MIRENA)",[93],187,[7020],"Uterine Hemorrhage",[7002,7022,7023],"Mefenamic acid","Mirena",{"trials":7025,"activeCount":101},[],{"intervention":7022,"totalTrials":233,"cells":7027},{"EARLY_PHASE1":7028,"PHASE1":7030,"PHASE2":7032,"PHASE3":7034,"PHASE4":7036,"NA":7042},{"trials":7029,"activeCount":101},[],{"trials":7031,"activeCount":101},[],{"trials":7033,"activeCount":101},[],{"trials":7035,"activeCount":101},[],{"trials":7037,"activeCount":101},[7038],{"nctId":7015,"briefTitle":7016,"status":107,"phases":7039,"primaryCompletion":2919,"completion":2919,"start":5975,"enrollment":7018,"conditions":7040,"interventions":7041},[93],[7020],[7002,7022,7023],{"trials":7043,"activeCount":101},[],{"intervention":7045,"totalTrials":233,"cells":7046},"Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment",{"EARLY_PHASE1":7047,"PHASE1":7049,"PHASE2":7051,"PHASE3":7053,"PHASE4":7055,"NA":7065},{"trials":7048,"activeCount":101},[],{"trials":7050,"activeCount":101},[],{"trials":7052,"activeCount":101},[],{"trials":7054,"activeCount":101},[],{"trials":7056,"activeCount":101},[7057],{"nctId":7058,"briefTitle":7059,"status":107,"phases":7060,"primaryCompletion":7061,"completion":1629,"start":1587,"enrollment":7062,"conditions":7063,"interventions":7064},"NCT01098760","Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients",[93],"2013-03",151,[1056],[7045],{"trials":7066,"activeCount":101},[],{"intervention":7068,"totalTrials":233,"cells":7069},"NEBIDO",{"EARLY_PHASE1":7070,"PHASE1":7072,"PHASE2":7074,"PHASE3":7076,"PHASE4":7078,"NA":7087},{"trials":7071,"activeCount":101},[],{"trials":7073,"activeCount":101},[],{"trials":7075,"activeCount":101},[],{"trials":7077,"activeCount":101},[],{"trials":7079,"activeCount":101},[7080],{"nctId":7081,"briefTitle":7082,"status":464,"phases":7083,"completion":1498,"start":1498,"enrollment":101,"conditions":7084,"interventions":7086},"NCT00710827","Nebido Versus Placebo in Elderly Men With Typical Symptoms of Late Onset Hypogonadism Over a Period of 54 Weeks",[93],[7085],"Hypogonadism",[7068],{"trials":7088,"activeCount":101},[],{"intervention":6004,"totalTrials":233,"cells":7090},{"EARLY_PHASE1":7091,"PHASE1":7093,"PHASE2":7095,"PHASE3":7097,"PHASE4":7099,"NA":7105},{"trials":7092,"activeCount":101},[],{"trials":7094,"activeCount":101},[],{"trials":7096,"activeCount":101},[],{"trials":7098,"activeCount":101},[],{"trials":7100,"activeCount":101},[7101],{"nctId":5996,"briefTitle":5997,"status":107,"phases":7102,"primaryCompletion":5999,"completion":5999,"start":1352,"enrollment":6000,"conditions":7103,"interventions":7104},[93],[5978],[6003,6004],{"trials":7106,"activeCount":101},[],{"intervention":7108,"totalTrials":233,"cells":7109},"Nifedipine (Adalat, BAYA1040) and Valsartan",{"EARLY_PHASE1":7110,"PHASE1":7112,"PHASE2":7114,"PHASE3":7116,"PHASE4":7118,"NA":7128},{"trials":7111,"activeCount":101},[],{"trials":7113,"activeCount":101},[],{"trials":7115,"activeCount":101},[],{"trials":7117,"activeCount":101},[],{"trials":7119,"activeCount":101},[7120],{"nctId":7121,"briefTitle":7122,"status":107,"phases":7123,"primaryCompletion":2959,"completion":2959,"start":3809,"enrollment":7124,"conditions":7125,"interventions":7126},"NCT01071122","FOCUS (Nifedipine GITS's Effect on Central Pressure Assessed by Applanation Tonometry)",[93],365,[6625],[7108,6627,7127],"Valsartan",{"trials":7129,"activeCount":101},[],{"intervention":7127,"totalTrials":233,"cells":7131},{"EARLY_PHASE1":7132,"PHASE1":7134,"PHASE2":7136,"PHASE3":7138,"PHASE4":7140,"NA":7146},{"trials":7133,"activeCount":101},[],{"trials":7135,"activeCount":101},[],{"trials":7137,"activeCount":101},[],{"trials":7139,"activeCount":101},[],{"trials":7141,"activeCount":101},[7142],{"nctId":7121,"briefTitle":7122,"status":107,"phases":7143,"primaryCompletion":2959,"completion":2959,"start":3809,"enrollment":7124,"conditions":7144,"interventions":7145},[93],[6625],[7108,6627,7127],{"trials":7147,"activeCount":101},[],{"intervention":7149,"totalTrials":233,"cells":7150},"Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).",{"EARLY_PHASE1":7151,"PHASE1":7153,"PHASE2":7155,"PHASE3":7157,"PHASE4":7159,"NA":7169},{"trials":7152,"activeCount":101},[],{"trials":7154,"activeCount":101},[],{"trials":7156,"activeCount":101},[],{"trials":7158,"activeCount":101},[],{"trials":7160,"activeCount":101},[7161],{"nctId":7162,"briefTitle":7163,"status":107,"phases":7164,"primaryCompletion":7165,"completion":7165,"start":7166,"enrollment":1599,"conditions":7167,"interventions":7168},"NCT05036278","Prophylaxis Regimen for Hemophilia A Patients",[93],"2024-09-12","2022-07-28",[24,3338],[7149],{"trials":7170,"activeCount":101},[],{"intervention":7172,"totalTrials":233,"cells":7173},"Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1",{"EARLY_PHASE1":7174,"PHASE1":7176,"PHASE2":7178,"PHASE3":7180,"PHASE4":7182,"NA":7194},{"trials":7175,"activeCount":101},[],{"trials":7177,"activeCount":101},[],{"trials":7179,"activeCount":101},[],{"trials":7181,"activeCount":101},[],{"trials":7183,"activeCount":101},[7184],{"nctId":7185,"briefTitle":7186,"status":107,"phases":7187,"primaryCompletion":7188,"completion":7188,"start":7189,"enrollment":510,"conditions":7190,"interventions":7191},"NCT04565236","A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents \u002FAdults With Severe Hemophilia A",[93],"2024-03-15","2020-09-22",[24],[7172,7192,7193],"Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2","Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 3",{"trials":7195,"activeCount":101},[],{"intervention":7192,"totalTrials":233,"cells":7197},{"EARLY_PHASE1":7198,"PHASE1":7200,"PHASE2":7202,"PHASE3":7204,"PHASE4":7206,"NA":7212},{"trials":7199,"activeCount":101},[],{"trials":7201,"activeCount":101},[],{"trials":7203,"activeCount":101},[],{"trials":7205,"activeCount":101},[],{"trials":7207,"activeCount":101},[7208],{"nctId":7185,"briefTitle":7186,"status":107,"phases":7209,"primaryCompletion":7188,"completion":7188,"start":7189,"enrollment":510,"conditions":7210,"interventions":7211},[93],[24],[7172,7192,7193],{"trials":7213,"activeCount":101},[],{"intervention":7193,"totalTrials":233,"cells":7215},{"EARLY_PHASE1":7216,"PHASE1":7218,"PHASE2":7220,"PHASE3":7222,"PHASE4":7224,"NA":7230},{"trials":7217,"activeCount":101},[],{"trials":7219,"activeCount":101},[],{"trials":7221,"activeCount":101},[],{"trials":7223,"activeCount":101},[],{"trials":7225,"activeCount":101},[7226],{"nctId":7185,"briefTitle":7186,"status":107,"phases":7227,"primaryCompletion":7188,"completion":7188,"start":7189,"enrollment":510,"conditions":7228,"interventions":7229},[93],[24],[7172,7192,7193],{"trials":7231,"activeCount":101},[],{"intervention":7233,"totalTrials":233,"cells":7234},"Elidel",{"EARLY_PHASE1":7235,"PHASE1":7237,"PHASE2":7239,"PHASE3":7241,"PHASE4":7243,"NA":7254},{"trials":7236,"activeCount":101},[],{"trials":7238,"activeCount":101},[],{"trials":7240,"activeCount":101},[],{"trials":7242,"activeCount":101},[],{"trials":7244,"activeCount":101},[7245],{"nctId":7246,"briefTitle":7247,"status":107,"phases":7248,"primaryCompletion":7249,"completion":7249,"start":3768,"enrollment":7250,"conditions":7251,"interventions":7253},"NCT00568412","A Clinical Study in Children and Adolescents With Mild to Moderate Atopic Dermatitis",[93],"2008-09",80,[7252],"Mild to Moderate Atopic Dermatitis",[7233],{"trials":7255,"activeCount":101},[],{"intervention":7257,"totalTrials":233,"cells":7258},"Interferon beta-1b, FRP within 15 days after randomization",{"EARLY_PHASE1":7259,"PHASE1":7261,"PHASE2":7263,"PHASE3":7265,"PHASE4":7267,"NA":7276},{"trials":7260,"activeCount":101},[],{"trials":7262,"activeCount":101},[],{"trials":7264,"activeCount":101},[],{"trials":7266,"activeCount":101},[],{"trials":7268,"activeCount":101},[7269],{"nctId":7270,"briefTitle":7271,"status":156,"phases":7272,"primaryCompletion":3576,"completion":3576,"start":1498,"enrollment":855,"conditions":7273,"interventions":7274},"NCT00780455","Rehabilitation Study in MS Patients",[93],[6602],[7257,7275],"Interferon beta-1b, FRP about 6 weeks after randomization",{"trials":7277,"activeCount":101},[],{"intervention":7275,"totalTrials":233,"cells":7279},{"EARLY_PHASE1":7280,"PHASE1":7282,"PHASE2":7284,"PHASE3":7286,"PHASE4":7288,"NA":7294},{"trials":7281,"activeCount":101},[],{"trials":7283,"activeCount":101},[],{"trials":7285,"activeCount":101},[],{"trials":7287,"activeCount":101},[],{"trials":7289,"activeCount":101},[7290],{"nctId":7270,"briefTitle":7271,"status":156,"phases":7291,"primaryCompletion":3576,"completion":3576,"start":1498,"enrollment":855,"conditions":7292,"interventions":7293},[93],[6602],[7257,7275],{"trials":7295,"activeCount":101},[],{"intervention":7297,"totalTrials":233,"cells":7298},"Polyethylene glycol 3350",{"EARLY_PHASE1":7299,"PHASE1":7301,"PHASE2":7303,"PHASE3":7305,"PHASE4":7307,"NA":7316},{"trials":7300,"activeCount":101},[],{"trials":7302,"activeCount":101},[],{"trials":7304,"activeCount":101},[],{"trials":7306,"activeCount":101},[],{"trials":7308,"activeCount":101},[7309],{"nctId":7310,"briefTitle":7311,"status":107,"phases":7312,"primaryCompletion":3818,"completion":3818,"start":4579,"enrollment":7313,"conditions":7314,"interventions":7315},"NCT00770432","Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(P08216)",[93],203,[6680],[7297],{"trials":7317,"activeCount":101},[],{"intervention":7319,"totalTrials":233,"cells":7320},"Talcid",{"EARLY_PHASE1":7321,"PHASE1":7323,"PHASE2":7325,"PHASE3":7327,"PHASE4":7329,"NA":7341},{"trials":7322,"activeCount":101},[],{"trials":7324,"activeCount":101},[],{"trials":7326,"activeCount":101},[],{"trials":7328,"activeCount":101},[],{"trials":7330,"activeCount":101},[7331],{"nctId":7332,"briefTitle":7333,"status":107,"phases":7334,"primaryCompletion":446,"completion":446,"start":7335,"enrollment":7336,"conditions":7337,"interventions":7339},"NCT01928888","Placebo Controlled Phase IV Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid, a Single Dose of Oral Famotidine and a Single Dose of Placebo in Patients With Acute Heartburn Episodes",[93],"2003-05",559,[7338],"Heartburn",[7319,7340],"Famotidine",{"trials":7342,"activeCount":101},[],{"intervention":7340,"totalTrials":233,"cells":7344},{"EARLY_PHASE1":7345,"PHASE1":7347,"PHASE2":7349,"PHASE3":7351,"PHASE4":7353,"NA":7359},{"trials":7346,"activeCount":101},[],{"trials":7348,"activeCount":101},[],{"trials":7350,"activeCount":101},[],{"trials":7352,"activeCount":101},[],{"trials":7354,"activeCount":101},[7355],{"nctId":7332,"briefTitle":7333,"status":107,"phases":7356,"primaryCompletion":446,"completion":446,"start":7335,"enrollment":7336,"conditions":7357,"interventions":7358},[93],[7338],[7319,7340],{"trials":7360,"activeCount":101},[],{"intervention":6450,"totalTrials":233,"cells":7362},{"EARLY_PHASE1":7363,"PHASE1":7365,"PHASE2":7367,"PHASE3":7369,"PHASE4":7371,"NA":7377},{"trials":7364,"activeCount":101},[],{"trials":7366,"activeCount":101},[],{"trials":7368,"activeCount":101},[],{"trials":7370,"activeCount":101},[],{"trials":7372,"activeCount":101},[7373],{"nctId":6440,"briefTitle":6441,"status":107,"phases":7374,"primaryCompletion":6443,"completion":6443,"start":6444,"enrollment":6445,"conditions":7375,"interventions":7376},[93],[6447],[6449,6450],{"trials":7378,"activeCount":101},[],{"intervention":7380,"totalTrials":233,"cells":7381},"Omeprazole 20 mg + Sodium Bicarbonate 1100 mg",{"EARLY_PHASE1":7382,"PHASE1":7384,"PHASE2":7386,"PHASE3":7388,"PHASE4":7390,"NA":7399},{"trials":7383,"activeCount":101},[],{"trials":7385,"activeCount":101},[],{"trials":7387,"activeCount":101},[],{"trials":7389,"activeCount":101},[],{"trials":7391,"activeCount":101},[7392],{"nctId":7393,"briefTitle":7394,"status":107,"phases":7395,"primaryCompletion":1506,"completion":1507,"start":1508,"enrollment":25,"conditions":7396,"interventions":7397},"NCT01587885","Comparison of Two Omeprazole-Containing Products for Relief of Frequent Heartburn (MK-0764A-036)",[93],[7338],[7380,7398],"Omeprazole 20 mg",{"trials":7400,"activeCount":101},[],{"intervention":7398,"totalTrials":233,"cells":7402},{"EARLY_PHASE1":7403,"PHASE1":7405,"PHASE2":7407,"PHASE3":7409,"PHASE4":7411,"NA":7417},{"trials":7404,"activeCount":101},[],{"trials":7406,"activeCount":101},[],{"trials":7408,"activeCount":101},[],{"trials":7410,"activeCount":101},[],{"trials":7412,"activeCount":101},[7413],{"nctId":7393,"briefTitle":7394,"status":107,"phases":7414,"primaryCompletion":1506,"completion":1507,"start":1508,"enrollment":25,"conditions":7415,"interventions":7416},[93],[7338],[7380,7398],{"trials":7418,"activeCount":101},[],{"intervention":7420,"totalTrials":233,"cells":7421},"Amoxicillin clavulanic acid",{"EARLY_PHASE1":7422,"PHASE1":7424,"PHASE2":7426,"PHASE3":7428,"PHASE4":7430,"NA":7440},{"trials":7423,"activeCount":101},[],{"trials":7425,"activeCount":101},[],{"trials":7427,"activeCount":101},[],{"trials":7429,"activeCount":101},[],{"trials":7431,"activeCount":101},[7432],{"nctId":7433,"briefTitle":7434,"status":107,"phases":7435,"primaryCompletion":5409,"completion":5409,"start":4612,"enrollment":7436,"conditions":7437,"interventions":7439},"NCT00656747","Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis",[93],1372,[7438],"Chronic Bronchitis",[6720,7420],{"trials":7441,"activeCount":101},[],{"intervention":7443,"totalTrials":233,"cells":7444},"Gadovist®",{"EARLY_PHASE1":7445,"PHASE1":7447,"PHASE2":7449,"PHASE3":7451,"PHASE4":7453,"NA":7463},{"trials":7446,"activeCount":101},[],{"trials":7448,"activeCount":101},[],{"trials":7450,"activeCount":101},[],{"trials":7452,"activeCount":101},[],{"trials":7454,"activeCount":101},[7455],{"nctId":7456,"briefTitle":7457,"status":107,"phases":7458,"primaryCompletion":3619,"completion":3619,"start":4612,"enrollment":5084,"conditions":7459,"interventions":7461},"NCT00764387","Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions.",[93],[7460],"Neoplastic CNS Lesions",[7443,7462],"Dotarem",{"trials":7464,"activeCount":101},[],{"intervention":7462,"totalTrials":233,"cells":7466},{"EARLY_PHASE1":7467,"PHASE1":7469,"PHASE2":7471,"PHASE3":7473,"PHASE4":7475,"NA":7481},{"trials":7468,"activeCount":101},[],{"trials":7470,"activeCount":101},[],{"trials":7472,"activeCount":101},[],{"trials":7474,"activeCount":101},[],{"trials":7476,"activeCount":101},[7477],{"nctId":7456,"briefTitle":7457,"status":107,"phases":7478,"primaryCompletion":3619,"completion":3619,"start":4612,"enrollment":5084,"conditions":7479,"interventions":7480},[93],[7460],[7443,7462],{"trials":7482,"activeCount":101},[],{"intervention":7484,"totalTrials":233,"cells":7485},"Diagnostic procedures",{"EARLY_PHASE1":7486,"PHASE1":7488,"PHASE2":7490,"PHASE3":7492,"PHASE4":7494,"NA":7506},{"trials":7487,"activeCount":101},[],{"trials":7489,"activeCount":101},[],{"trials":7491,"activeCount":101},[],{"trials":7493,"activeCount":101},[],{"trials":7495,"activeCount":101},[7496],{"nctId":7497,"briefTitle":7498,"status":156,"phases":7499,"primaryCompletion":7500,"completion":7501,"start":7502,"enrollment":3374,"conditions":7503,"interventions":7505},"NCT00867815","PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)",[93],"2017-12-29","2018-03-28","2009-07-13",[7504],"Anterior Ischemic Optic Neuropathy",[7484],{"trials":7507,"activeCount":101},[],{"intervention":6366,"totalTrials":233,"cells":7509},{"EARLY_PHASE1":7510,"PHASE1":7512,"PHASE2":7514,"PHASE3":7516,"PHASE4":7518,"NA":7524},{"trials":7511,"activeCount":101},[],{"trials":7513,"activeCount":101},[],{"trials":7515,"activeCount":101},[],{"trials":7517,"activeCount":101},[],{"trials":7519,"activeCount":101},[7520],{"nctId":6360,"briefTitle":6361,"status":107,"phases":7521,"completion":3724,"start":6363,"enrollment":3121,"conditions":7522,"interventions":7523},[93],[1103],[6366,6332],{"trials":7525,"activeCount":101},[],{"intervention":6696,"totalTrials":233,"cells":7527},{"EARLY_PHASE1":7528,"PHASE1":7530,"PHASE2":7532,"PHASE3":7534,"PHASE4":7536,"NA":7542},{"trials":7529,"activeCount":101},[],{"trials":7531,"activeCount":101},[],{"trials":7533,"activeCount":101},[],{"trials":7535,"activeCount":101},[],{"trials":7537,"activeCount":101},[7538],{"nctId":6688,"briefTitle":6689,"status":107,"phases":7539,"primaryCompletion":6691,"completion":6691,"start":6692,"enrollment":229,"conditions":7540,"interventions":7541},[93],[6680],[6695,6696],{"trials":7543,"activeCount":101},[],{"intervention":7545,"totalTrials":233,"cells":7546},"Azelastine and placebo",{"EARLY_PHASE1":7547,"PHASE1":7549,"PHASE2":7551,"PHASE3":7553,"PHASE4":7555,"NA":7565},{"trials":7548,"activeCount":101},[],{"trials":7550,"activeCount":101},[],{"trials":7552,"activeCount":101},[],{"trials":7554,"activeCount":101},[],{"trials":7556,"activeCount":101},[7557],{"nctId":7558,"briefTitle":7559,"status":107,"phases":7560,"primaryCompletion":3768,"completion":4691,"start":6493,"enrollment":550,"conditions":7561,"interventions":7562},"NCT00561717","A Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis",[93],[5990],[7545,7563,7564],"Loratadine and Placebo","Cetirizine and Placebo",{"trials":7566,"activeCount":101},[],{"intervention":7563,"totalTrials":233,"cells":7568},{"EARLY_PHASE1":7569,"PHASE1":7571,"PHASE2":7573,"PHASE3":7575,"PHASE4":7577,"NA":7583},{"trials":7570,"activeCount":101},[],{"trials":7572,"activeCount":101},[],{"trials":7574,"activeCount":101},[],{"trials":7576,"activeCount":101},[],{"trials":7578,"activeCount":101},[7579],{"nctId":7558,"briefTitle":7559,"status":107,"phases":7580,"primaryCompletion":3768,"completion":4691,"start":6493,"enrollment":550,"conditions":7581,"interventions":7582},[93],[5990],[7545,7563,7564],{"trials":7584,"activeCount":101},[],{"intervention":7564,"totalTrials":233,"cells":7586},{"EARLY_PHASE1":7587,"PHASE1":7589,"PHASE2":7591,"PHASE3":7593,"PHASE4":7595,"NA":7601},{"trials":7588,"activeCount":101},[],{"trials":7590,"activeCount":101},[],{"trials":7592,"activeCount":101},[],{"trials":7594,"activeCount":101},[],{"trials":7596,"activeCount":101},[7597],{"nctId":7558,"briefTitle":7559,"status":107,"phases":7598,"primaryCompletion":3768,"completion":4691,"start":6493,"enrollment":550,"conditions":7599,"interventions":7600},[93],[5990],[7545,7563,7564],{"trials":7602,"activeCount":101},[],{"intervention":7604,"totalTrials":233,"cells":7605},"Macrogol",{"EARLY_PHASE1":7606,"PHASE1":7608,"PHASE2":7610,"PHASE3":7612,"PHASE4":7614,"NA":7623},{"trials":7607,"activeCount":101},[],{"trials":7609,"activeCount":101},[],{"trials":7611,"activeCount":101},[],{"trials":7613,"activeCount":101},[],{"trials":7615,"activeCount":101},[7616],{"nctId":7617,"briefTitle":7618,"status":107,"phases":7619,"primaryCompletion":498,"completion":498,"start":4861,"enrollment":7620,"conditions":7621,"interventions":7622},"NCT01810653","A Study to Compare the Effect of Transipeg 2.95 g or Forlax Junior 4 g in Children With Constipation",[93],97,[6680],[7604,7604],{"trials":7624,"activeCount":101},[],{"intervention":6248,"totalTrials":233,"cells":7626},{"EARLY_PHASE1":7627,"PHASE1":7629,"PHASE2":7631,"PHASE3":7633,"PHASE4":7635,"NA":7641},{"trials":7628,"activeCount":101},[],{"trials":7630,"activeCount":101},[],{"trials":7632,"activeCount":101},[],{"trials":7634,"activeCount":101},[],{"trials":7636,"activeCount":101},[7637],{"nctId":6242,"briefTitle":6243,"status":107,"phases":7638,"primaryCompletion":4691,"completion":4691,"start":3818,"enrollment":3033,"conditions":7639,"interventions":7640},[93],[6246],[6248,6210,6249,6250,6251,6252],{"trials":7642,"activeCount":101},[],{"intervention":6249,"totalTrials":233,"cells":7644},{"EARLY_PHASE1":7645,"PHASE1":7647,"PHASE2":7649,"PHASE3":7651,"PHASE4":7653,"NA":7659},{"trials":7646,"activeCount":101},[],{"trials":7648,"activeCount":101},[],{"trials":7650,"activeCount":101},[],{"trials":7652,"activeCount":101},[],{"trials":7654,"activeCount":101},[7655],{"nctId":6242,"briefTitle":6243,"status":107,"phases":7656,"primaryCompletion":4691,"completion":4691,"start":3818,"enrollment":3033,"conditions":7657,"interventions":7658},[93],[6246],[6248,6210,6249,6250,6251,6252],{"trials":7660,"activeCount":101},[],{"intervention":6250,"totalTrials":233,"cells":7662},{"EARLY_PHASE1":7663,"PHASE1":7665,"PHASE2":7667,"PHASE3":7669,"PHASE4":7671,"NA":7677},{"trials":7664,"activeCount":101},[],{"trials":7666,"activeCount":101},[],{"trials":7668,"activeCount":101},[],{"trials":7670,"activeCount":101},[],{"trials":7672,"activeCount":101},[7673],{"nctId":6242,"briefTitle":6243,"status":107,"phases":7674,"primaryCompletion":4691,"completion":4691,"start":3818,"enrollment":3033,"conditions":7675,"interventions":7676},[93],[6246],[6248,6210,6249,6250,6251,6252],{"trials":7678,"activeCount":101},[],{"intervention":6251,"totalTrials":233,"cells":7680},{"EARLY_PHASE1":7681,"PHASE1":7683,"PHASE2":7685,"PHASE3":7687,"PHASE4":7689,"NA":7695},{"trials":7682,"activeCount":101},[],{"trials":7684,"activeCount":101},[],{"trials":7686,"activeCount":101},[],{"trials":7688,"activeCount":101},[],{"trials":7690,"activeCount":101},[7691],{"nctId":6242,"briefTitle":6243,"status":107,"phases":7692,"primaryCompletion":4691,"completion":4691,"start":3818,"enrollment":3033,"conditions":7693,"interventions":7694},[93],[6246],[6248,6210,6249,6250,6251,6252],{"trials":7696,"activeCount":101},[],{"intervention":6252,"totalTrials":233,"cells":7698},{"EARLY_PHASE1":7699,"PHASE1":7701,"PHASE2":7703,"PHASE3":7705,"PHASE4":7707,"NA":7713},{"trials":7700,"activeCount":101},[],{"trials":7702,"activeCount":101},[],{"trials":7704,"activeCount":101},[],{"trials":7706,"activeCount":101},[],{"trials":7708,"activeCount":101},[7709],{"nctId":6242,"briefTitle":6243,"status":107,"phases":7710,"primaryCompletion":4691,"completion":4691,"start":3818,"enrollment":3033,"conditions":7711,"interventions":7712},[93],[6246],[6248,6210,6249,6250,6251,6252],{"trials":7714,"activeCount":101},[],{"intervention":5883,"totalTrials":233,"cells":7716},{"EARLY_PHASE1":7717,"PHASE1":7719,"PHASE2":7721,"PHASE3":7723,"PHASE4":7725,"NA":7731},{"trials":7718,"activeCount":101},[],{"trials":7720,"activeCount":101},[],{"trials":7722,"activeCount":101},[],{"trials":7724,"activeCount":101},[],{"trials":7726,"activeCount":101},[7727],{"nctId":5873,"briefTitle":5874,"status":107,"phases":7728,"primaryCompletion":5876,"completion":5877,"start":5878,"enrollment":5879,"conditions":7729,"interventions":7730},[93],[5881],[5803,5883],{"trials":7732,"activeCount":101},[],{"intervention":6661,"totalTrials":233,"cells":7734},{"EARLY_PHASE1":7735,"PHASE1":7737,"PHASE2":7739,"PHASE3":7741,"PHASE4":7743,"NA":7749},{"trials":7736,"activeCount":101},[],{"trials":7738,"activeCount":101},[],{"trials":7740,"activeCount":101},[],{"trials":7742,"activeCount":101},[],{"trials":7744,"activeCount":101},[7745],{"nctId":6656,"briefTitle":6657,"status":107,"phases":7746,"completion":6281,"start":6113,"enrollment":1303,"conditions":7747,"interventions":7748},[93],[6625],[6636,6661],{"trials":7750,"activeCount":101},[],{"intervention":5917,"totalTrials":2316,"cells":7752},{"EARLY_PHASE1":7753,"PHASE1":7755,"PHASE2":7795,"PHASE3":7813,"PHASE4":7869,"NA":7871},{"trials":7754,"activeCount":101},[],{"trials":7756,"activeCount":101},[7757,7764,7772,7780,7784],{"nctId":7758,"briefTitle":7759,"status":107,"phases":7760,"primaryCompletion":4066,"completion":5249,"start":3989,"enrollment":550,"conditions":7761,"interventions":7763},"NCT02262663","Study in Healthy Young Women to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of Vilaprisan",[90],[7762],"Clinical Trial, Phase I",[5917],{"nctId":7765,"briefTitle":7766,"status":107,"phases":7767,"primaryCompletion":5913,"completion":5913,"start":7768,"enrollment":1265,"conditions":7769,"interventions":7771},"NCT03092999","Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan)",[90],"2017-03-28",[7770],"Leiomyoma",[5917],{"nctId":7773,"briefTitle":7774,"status":107,"phases":7775,"primaryCompletion":4066,"completion":7776,"start":1487,"enrollment":1181,"conditions":7777,"interventions":7778},"NCT02456129","Study in Postmenopausal Women to Investigate the Drug-drug Interaction (DDI) Between Itraconazole(ITZ) and Orally Administered Vilaprisan; Absolute Bioavailability Using Intravenous Microtracer Dose of [14C]Vilaprisan",[90],"2016-02",[7762],[5917,7779],"[14C] Vilaprisan",{"nctId":5908,"briefTitle":5909,"status":107,"phases":7781,"primaryCompletion":5911,"completion":5912,"start":5913,"enrollment":4934,"conditions":7782,"interventions":7783},[90],[5915],[5917,5918,1492,5919],{"nctId":7785,"briefTitle":7786,"status":107,"phases":7787,"primaryCompletion":7788,"completion":7789,"start":7790,"enrollment":124,"conditions":7791,"interventions":7794},"NCT03411980","Pharmacokinetics and Safety of Vilaprisan in Renal Impairment",[90],"2018-10-10","2019-02-06","2018-02-02",[7792,7793],"Uterine Fibroids","Endometriosis",[5917],{"trials":7796,"activeCount":101},[7797,7805],{"nctId":7798,"briefTitle":7799,"status":156,"phases":7800,"primaryCompletion":5196,"completion":7801,"start":7802,"enrollment":421,"conditions":7803,"interventions":7804},"NCT03573336","Assess Safety and Efficacy of Vilaprisan in Subjects With Endometriosis",[91],"2020-11-26","2018-07-04",[7793],[5917],{"nctId":7806,"briefTitle":7807,"status":107,"phases":7808,"primaryCompletion":468,"completion":468,"start":548,"enrollment":2126,"conditions":7809,"interventions":7810},"NCT02465814","Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids",[91],[7770],[5917,7811,7811,5917,7812,7812,7812],"Vilaprisan (BAY1002670","Ulipristal",{"trials":7814,"activeCount":101},[7815,7824,7834,7843,7852,7860],{"nctId":7816,"briefTitle":7817,"status":156,"phases":7818,"primaryCompletion":7819,"completion":7820,"start":4488,"enrollment":7821,"conditions":7822,"interventions":7823},"NCT03194646","Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids",[92],"2019-05-10","2024-07-11",1272,[7792],[5917,5917,5917,5917,5917,5917],{"nctId":7825,"briefTitle":7826,"status":156,"phases":7827,"primaryCompletion":7828,"completion":7828,"start":7829,"enrollment":7830,"conditions":7831,"interventions":7833},"NCT03476928","A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding",[92],"2021-07-12","2018-03-30",153,[7832],"Uterine Fibroids and Heavy Menstrual Bleeding",[5917],{"nctId":7835,"briefTitle":7836,"status":156,"phases":7837,"primaryCompletion":7838,"completion":7839,"start":7840,"enrollment":1869,"conditions":7841,"interventions":7842},"NCT03400943","Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)",[92],"2019-06-09","2022-04-06","2018-01-17",[7792],[5917],{"nctId":7844,"briefTitle":7845,"status":156,"phases":7846,"primaryCompletion":7847,"completion":909,"start":7848,"enrollment":7849,"conditions":7850,"interventions":7851},"NCT03400956","Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)",[92],"2019-03-23","2018-01-24",103,[7792],[5917],{"nctId":7853,"briefTitle":7854,"status":464,"phases":7855,"primaryCompletion":7856,"completion":7856,"start":7857,"enrollment":101,"conditions":7858,"interventions":7859},"NCT03699176","Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids",[92],"2019-12-25","2018-10-27",[7792],[5917],{"nctId":7861,"briefTitle":7862,"status":156,"phases":7863,"primaryCompletion":7864,"completion":2064,"start":7865,"enrollment":7866,"conditions":7867,"interventions":7868},"NCT03240523","A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids",[92],"2020-06-28","2017-07-31",766,[7792],[5917],{"trials":7870,"activeCount":101},[],{"trials":7872,"activeCount":101},[],{"intervention":3633,"totalTrials":2041,"cells":7874},{"EARLY_PHASE1":7875,"PHASE1":7877,"PHASE2":7879,"PHASE3":7905,"PHASE4":7935,"NA":7937},{"trials":7876,"activeCount":101},[],{"trials":7878,"activeCount":101},[],{"trials":7880,"activeCount":101},[7881,7893,7897,7901],{"nctId":7882,"briefTitle":7883,"status":107,"phases":7884,"primaryCompletion":7885,"completion":7886,"start":7887,"enrollment":7888,"conditions":7889,"interventions":7891},"NCT03276143","FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty",[91],"2018-08-20","2019-01-02","2017-09-21",813,[7890],"Knee Arthroplasty, Total",[3633,3943,7892],"BAY1213790",{"nctId":3624,"briefTitle":3625,"status":107,"phases":7894,"primaryCompletion":3627,"completion":3627,"start":3628,"enrollment":3629,"conditions":7895,"interventions":7896},[91],[3631],[3542,3542,3542,3542,3542,3633],{"nctId":3654,"briefTitle":3655,"status":107,"phases":7898,"primaryCompletion":3657,"completion":3657,"start":3658,"enrollment":3659,"conditions":7899,"interventions":7900},[91],[3641,3661],[3542,3633],{"nctId":3664,"briefTitle":3665,"status":107,"phases":7902,"completion":3667,"start":3668,"enrollment":3669,"conditions":7903,"interventions":7904},[91],[3631],[3542,3542,3542,3542,3542,3633],{"trials":7906,"activeCount":101},[7907,7911,7915,7919,7923,7927,7931],{"nctId":3720,"briefTitle":3721,"status":107,"phases":7908,"primaryCompletion":445,"completion":3723,"start":3724,"enrollment":3725,"conditions":7909,"interventions":7910},[92],[3661,3631],[3542,3633],{"nctId":3765,"briefTitle":3766,"status":107,"phases":7912,"primaryCompletion":1587,"completion":1570,"start":3768,"enrollment":3769,"conditions":7913,"interventions":7914},[92],[3631],[3542,3633,3772,3773],{"nctId":3790,"briefTitle":3791,"status":107,"phases":7916,"primaryCompletion":3618,"completion":1327,"start":3793,"enrollment":3794,"conditions":7917,"interventions":7918},[92],[3631],[3542,3542,3542,3633],{"nctId":3815,"briefTitle":3816,"status":107,"phases":7920,"primaryCompletion":1648,"completion":3818,"start":3819,"enrollment":3820,"conditions":7921,"interventions":7922},[92],[3631],[3542,3633],{"nctId":3831,"briefTitle":3832,"status":107,"phases":7924,"primaryCompletion":1648,"completion":1648,"start":3724,"enrollment":3834,"conditions":7925,"interventions":7926},[92],[3661,3631],[3542,3633],{"nctId":3853,"briefTitle":3854,"status":107,"phases":7928,"primaryCompletion":1327,"completion":2969,"start":2968,"enrollment":217,"conditions":7929,"interventions":7930},[92],[3631],[3542,3542,3542,3633],{"nctId":3878,"briefTitle":3879,"status":107,"phases":7932,"primaryCompletion":3778,"completion":3778,"start":3724,"enrollment":3881,"conditions":7933,"interventions":7934},[92],[3631],[3542,3633],{"trials":7936,"activeCount":101},[],{"trials":7938,"activeCount":101},[],{"intervention":5521,"totalTrials":5220,"cells":7940},{"EARLY_PHASE1":7941,"PHASE1":7943,"PHASE2":7974,"PHASE3":7985,"PHASE4":7998,"NA":8000},{"trials":7942,"activeCount":101},[],{"trials":7944,"activeCount":101},[7945,7953,7957,7965],{"nctId":7946,"briefTitle":7947,"status":107,"phases":7948,"primaryCompletion":7949,"completion":530,"start":7950,"enrollment":5220,"conditions":7951,"interventions":7952},"NCT03484585","Rogaratinib (BAY1163877) Human Mass Balance Study",[90],"2018-05-25","2018-04-06",[7762,1790],[5521],{"nctId":5513,"briefTitle":5514,"status":107,"phases":7954,"primaryCompletion":1772,"completion":5516,"start":5517,"enrollment":5231,"conditions":7955,"interventions":7956},[90],[5519],[5521,77],{"nctId":7958,"briefTitle":7959,"status":107,"phases":7960,"primaryCompletion":7961,"completion":823,"start":7962,"enrollment":233,"conditions":7963,"interventions":7964},"NCT03788603","Rogaratinib (BAY1163877) in Chinese Patients",[90],"2019-04-30","2019-01-07",[29],[5521],{"nctId":7966,"briefTitle":7967,"status":107,"phases":7968,"primaryCompletion":7969,"completion":7969,"start":5269,"enrollment":1081,"conditions":7970,"interventions":7972},"NCT03517956","Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors",[90],"2021-02-01",[7971],"Advanced or Metastatic Solid Tumor",[5521,7973],"Copanlisib",{"trials":7975,"activeCount":101},[7976],{"nctId":7977,"briefTitle":7978,"status":107,"phases":7979,"primaryCompletion":7980,"completion":7980,"start":7981,"enrollment":233,"conditions":7982,"interventions":7983},"NCT04125693","Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety",[91],"2021-02-16","2019-10-30",[219],[5521,7984],"Combination drug",{"trials":7986,"activeCount":101},[7987],{"nctId":7988,"briefTitle":7989,"status":107,"phases":7990,"primaryCompletion":7991,"completion":7991,"start":7992,"enrollment":7993,"conditions":7994,"interventions":7996},"NCT03410693","Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma",[91,92],"2020-10-27","2018-05-31",175,[7995],"Carcinoma, Transitional Cell",[5521,7997],"Chemotherapy",{"trials":7999,"activeCount":101},[],{"trials":8001,"activeCount":101},[],{"intervention":8003,"totalTrials":5220,"cells":8004},"YAZ",{"EARLY_PHASE1":8005,"PHASE1":8007,"PHASE2":8009,"PHASE3":8020,"PHASE4":8059,"NA":8061},{"trials":8006,"activeCount":101},[],{"trials":8008,"activeCount":101},[],{"trials":8010,"activeCount":101},[8011],{"nctId":8012,"briefTitle":8013,"status":107,"phases":8014,"primaryCompletion":5946,"completion":5946,"start":6068,"enrollment":8015,"conditions":8016,"interventions":8018},"NCT00673686","Study to Investigate the Effect of Missed Pills on Follicular Development in Two Application Regimens of SH T 00186 D",[91],105,[8017],"Contraceptives, Oral",[8003,8019],"Yasminelle",{"trials":8021,"activeCount":101},[8022,8030,8037,8044,8052],{"nctId":8023,"briefTitle":8024,"status":107,"phases":8025,"primaryCompletion":499,"completion":499,"start":3768,"enrollment":136,"conditions":8026,"interventions":8028},"NCT00569244","SH T00186 in the Treatment of Primary Dysmenorrhea",[92],[8027],"Primary Dysmenorrhea",[8029,8003],"Drug: YAZ flex",{"nctId":8031,"briefTitle":8032,"status":107,"phases":8033,"completion":4675,"start":6384,"enrollment":8034,"conditions":8035,"interventions":8036},"NCT00185484","Efficacy and Safety Oral Contraceptive Study",[92],1113,[15],[8003],{"nctId":8038,"briefTitle":8039,"status":107,"phases":8040,"primaryCompletion":1569,"completion":1569,"start":498,"enrollment":8041,"conditions":8042,"interventions":8043},"NCT00819312","YAZ, Oral Contraceptive Registration in China",[92],675,[15],[8003],{"nctId":8045,"briefTitle":8046,"status":107,"phases":8047,"completion":6112,"start":8048,"enrollment":5865,"conditions":8049,"interventions":8051},"NCT00656981","Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne",[92],"2003-01",[8050],"Acne Vulgaris",[8003],{"nctId":8053,"briefTitle":8054,"status":107,"phases":8055,"completion":3706,"start":8048,"enrollment":8056,"conditions":8057,"interventions":8058},"NCT00651469","Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.",[92],534,[8050],[8003],{"trials":8060,"activeCount":101},[],{"trials":8062,"activeCount":101},[],{"intervention":8064,"totalTrials":5220,"cells":8065},"Naproxen Sodium ER",{"EARLY_PHASE1":8066,"PHASE1":8068,"PHASE2":8078,"PHASE3":8080,"PHASE4":8121,"NA":8123},{"trials":8067,"activeCount":101},[],{"trials":8069,"activeCount":101},[8070],{"nctId":8071,"briefTitle":8072,"status":107,"phases":8073,"primaryCompletion":3567,"completion":3567,"start":3567,"enrollment":1509,"conditions":8074,"interventions":8075},"NCT00818415","Naproxen Sodium ER Pharmacokinetic Study",[90],[5881],[8076,8077],"Naproxen sodium ER","Commercial Naproxen",{"trials":8079,"activeCount":101},[],{"trials":8081,"activeCount":101},[8082,8091,8098,8105,8114],{"nctId":8083,"briefTitle":8084,"status":107,"phases":8085,"primaryCompletion":1351,"completion":1351,"start":1327,"enrollment":977,"conditions":8086,"interventions":8087},"NCT01389284","Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium",[92],[5843],[8064,8088,8089,8090],"Naproxen Sodium IR","Naproxen Sodium ER Placebo","Naproxen Sodium IR Placebo",{"nctId":8092,"briefTitle":8093,"status":107,"phases":8094,"primaryCompletion":2919,"completion":2919,"start":1351,"enrollment":8095,"conditions":8096,"interventions":8097},"NCT01427803","Actual Use Trial of Naproxen Sodium",[92],778,[5881],[8064],{"nctId":8099,"briefTitle":8100,"status":107,"phases":8101,"primaryCompletion":2969,"completion":2969,"start":2366,"enrollment":4059,"conditions":8102,"interventions":8103},"NCT01383486","Self Selection Trial of Naproxen Sodium",[92],[5881],[8076,8104],"Advil",{"nctId":8106,"briefTitle":8107,"status":107,"phases":8108,"primaryCompletion":8109,"completion":8109,"start":1423,"enrollment":8110,"conditions":8111,"interventions":8113},"NCT00720057","Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.",[92],"2008-08",312,[8112],"Toothache",[8064],{"nctId":8115,"briefTitle":8116,"status":107,"phases":8117,"primaryCompletion":3567,"completion":3567,"start":4647,"enrollment":8118,"conditions":8119,"interventions":8120},"NCT00751400","Naproxen Sodium Extended-Release Actual Use Study",[92],497,[5881],[8064],{"trials":8122,"activeCount":101},[],{"trials":8124,"activeCount":101},[],{"intervention":8126,"totalTrials":328,"cells":8127},"Gestodene\u002FEE Patch",{"EARLY_PHASE1":8128,"PHASE1":8130,"PHASE2":8139,"PHASE3":8163,"PHASE4":8173,"NA":8175},{"trials":8129,"activeCount":101},[],{"trials":8131,"activeCount":101},[8132],{"nctId":8133,"briefTitle":8134,"status":107,"phases":8135,"primaryCompletion":8136,"completion":8136,"start":2256,"enrollment":1303,"conditions":8137,"interventions":8138},"NCT01083264","Relative Bioavailability, Transdermally Administered EE and GSD, 3 Applications Sites",[90],"2010-05",[15],[8126,8126,8126],{"trials":8140,"activeCount":101},[8141,8148,8154],{"nctId":8142,"briefTitle":8143,"status":107,"phases":8144,"primaryCompletion":2968,"completion":2968,"start":4736,"enrollment":160,"conditions":8145,"interventions":8146},"NCT00933179","FC Patch Low: Metabolism Study",[91],[15],[8126,8147],"EE\u002FLevonorgestrel",{"nctId":8149,"briefTitle":8150,"status":107,"phases":8151,"primaryCompletion":2366,"completion":2969,"start":2968,"enrollment":1277,"conditions":8152,"interventions":8153},"NCT01204190","Investigation of Three Contraceptive Hormone Patches in Regard to Inhibition of Ovulation Following Application Over 3 Treatment Cycles in Healthy, Young Women.",[91],[15],[8126,8126,8126],{"nctId":8155,"briefTitle":8156,"status":107,"phases":8157,"primaryCompletion":487,"completion":8158,"start":8159,"enrollment":8160,"conditions":8161,"interventions":8162},"NCT02550977","Russia\u002FUkraine Suppression of Ovarian Activity Study",[91],"2016-08-15","2015-09-18",91,[15],[8126],{"trials":8164,"activeCount":101},[8165],{"nctId":8166,"briefTitle":8167,"status":107,"phases":8168,"primaryCompletion":5019,"completion":5019,"start":8169,"enrollment":8170,"conditions":8171,"interventions":8172},"NCT00910637","Study Investigating the Efficacy and Safety of a Contraceptive Patch for 13 Cycles",[92],"2009-05-01",1502,[15],[8126],{"trials":8174,"activeCount":101},[],{"trials":8176,"activeCount":101},[],{"intervention":8178,"totalTrials":328,"cells":8179},"Ethinylestradiol\u002FGestodene",{"EARLY_PHASE1":8180,"PHASE1":8182,"PHASE2":8184,"PHASE3":8207,"PHASE4":8224,"NA":8226},{"trials":8181,"activeCount":101},[],{"trials":8183,"activeCount":101},[],{"trials":8185,"activeCount":101},[8186,8193,8199],{"nctId":8187,"briefTitle":8188,"status":156,"phases":8189,"primaryCompletion":4292,"completion":4292,"start":8109,"enrollment":4580,"conditions":8190,"interventions":8192},"NCT00729404","Inhibition of Ovulation, Patch, Ethinylestradiol and Gestodene",[91],[15,8191],"Ovulation Inhibition",[8178,8178],{"nctId":8194,"briefTitle":8195,"status":107,"phases":8196,"primaryCompletion":1326,"completion":1326,"start":4736,"enrollment":3688,"conditions":8197,"interventions":8198},"NCT00915915","Inhibition of Ovulation and Pharmacokinetics of Transdermal Ethinylestradiol (EE) and Gestodene (GSD)",[91],[15,8191],[8178,8178],{"nctId":8200,"briefTitle":8201,"status":107,"phases":8202,"primaryCompletion":8203,"completion":8203,"start":8204,"enrollment":1277,"conditions":8205,"interventions":8206},"NCT00873483","US Ovulation Inhibition Study in Obese Women",[91],"2010-03-03","2009-04-30",[15],[8178],{"trials":8208,"activeCount":101},[8209,8217],{"nctId":8210,"briefTitle":8211,"status":107,"phases":8212,"primaryCompletion":2968,"completion":2968,"start":3619,"enrollment":8213,"conditions":8214,"interventions":8215},"NCT00984789","Birth Control Patch Study",[92],393,[15],[8178,8216],"Norelgestromin\u002FEthinylestradiol",{"nctId":8218,"briefTitle":8219,"status":107,"phases":8220,"primaryCompletion":1351,"completion":1351,"start":4700,"enrollment":8221,"conditions":8222,"interventions":8223},"NCT00914693","EU\u002FLA Pearl Index Study - Transdermal Contraceptive Patch",[92],1694,[15],[8178],{"trials":8225,"activeCount":101},[],{"trials":8227,"activeCount":101},[],{"intervention":8229,"totalTrials":855,"cells":8230},"Trasylol",{"EARLY_PHASE1":8231,"PHASE1":8233,"PHASE2":8235,"PHASE3":8237,"PHASE4":8269,"NA":8271},{"trials":8232,"activeCount":101},[],{"trials":8234,"activeCount":101},[],{"trials":8236,"activeCount":101},[],{"trials":8238,"activeCount":101},[8239,8249,8255,8262],{"nctId":8240,"briefTitle":8241,"status":156,"phases":8242,"primaryCompletion":8243,"completion":8243,"start":8244,"enrollment":2345,"conditions":8245,"interventions":8248},"NCT00327379","Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery",[92],"2007-03-01","2006-02-27",[8246,8247],"Blood Loss, Surgical","Postoperative Hemorrhage",[8229],{"nctId":8250,"briefTitle":8251,"status":156,"phases":8252,"completion":3778,"start":4571,"enrollment":2701,"conditions":8253,"interventions":8254},"NCT00306137","Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer",[92],[8246],[8229],{"nctId":8256,"briefTitle":8257,"status":107,"phases":8258,"primaryCompletion":4675,"completion":4675,"start":5946,"enrollment":8259,"conditions":8260,"interventions":8261},"NCT00668031","Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement",[92],359,[8246],[8229],{"nctId":8263,"briefTitle":8264,"status":156,"phases":8265,"completion":3778,"start":4571,"enrollment":8266,"conditions":8267,"interventions":8268},"NCT00306150","Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy",[92],57,[8246,8247],[8229],{"trials":8270,"activeCount":101},[],{"trials":8272,"activeCount":101},[],{"intervention":1280,"totalTrials":855,"cells":8274},{"EARLY_PHASE1":8275,"PHASE1":8277,"PHASE2":8296,"PHASE3":8298,"PHASE4":8304,"NA":8306},{"trials":8276,"activeCount":101},[],{"trials":8278,"activeCount":101},[8279,8283,8292],{"nctId":1271,"briefTitle":1272,"status":107,"phases":8280,"primaryCompletion":1274,"completion":1275,"start":1276,"enrollment":1277,"conditions":8281,"interventions":8282},[90],[29],[1073,1280,1281],{"nctId":8284,"briefTitle":8285,"status":107,"phases":8286,"primaryCompletion":8287,"completion":8288,"start":8289,"enrollment":1630,"conditions":8290,"interventions":8291},"NCT01764828","BAY86-9766 Plus Gemcitabine Phase I Study in Asian",[90],"2014-12-18","2015-02-10","2013-02-05",[29],[2276,1280],{"nctId":1283,"briefTitle":1284,"status":107,"phases":8293,"primaryCompletion":1286,"completion":1287,"start":1288,"enrollment":229,"conditions":8294,"interventions":8295},[90],[29],[1280,1291,1073,1292,1293],{"trials":8297,"activeCount":101},[],{"trials":8299,"activeCount":101},[8300],{"nctId":1323,"briefTitle":1324,"status":107,"phases":8301,"primaryCompletion":1326,"completion":1327,"start":1328,"enrollment":1329,"conditions":8302,"interventions":8303},[92],[423],[42,1280,1073],{"trials":8305,"activeCount":101},[],{"trials":8307,"activeCount":101},[],{"intervention":8309,"totalTrials":855,"cells":8310},"Gadoquatrane",{"EARLY_PHASE1":8311,"PHASE1":8313,"PHASE2":8315,"PHASE3":8326,"PHASE4":8359,"NA":8361},{"trials":8312,"activeCount":101},[],{"trials":8314,"activeCount":101},[],{"trials":8316,"activeCount":101},[8317],{"nctId":8318,"briefTitle":8319,"status":107,"phases":8320,"primaryCompletion":8321,"completion":1005,"start":8322,"enrollment":8266,"conditions":8323,"interventions":8325},"NCT04307186","Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and\u002For Spinal Cord Conditions",[91],"2022-09-05","2020-11-18",[8324],"Central Nervous System Pathology",[8309,6980],{"trials":8327,"activeCount":101},[8328,8342,8351],{"nctId":8329,"briefTitle":8330,"status":107,"phases":8331,"primaryCompletion":8332,"completion":8333,"start":8334,"enrollment":8335,"conditions":8336,"interventions":8339},"NCT05915728","A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)",[92],"2024-05-31","2024-06-01","2023-07-24",404,[8337,8338],"Contrast Enhancement in Magnetic Resonance Imaging","Non-central Nervous System Pathology",[8309,6980,8340,8341],"Gadoterate meglumine","Gadoteridol",{"nctId":8343,"briefTitle":8344,"status":107,"phases":8345,"primaryCompletion":8346,"completion":8347,"start":8348,"enrollment":1869,"conditions":8349,"interventions":8350},"NCT05915026","A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to \u003C18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)",[92],"2024-09-18","2024-10-16","2023-08-16",[8337,835],[8309],{"nctId":8352,"briefTitle":8353,"status":107,"phases":8354,"primaryCompletion":8355,"completion":8332,"start":8334,"enrollment":8356,"conditions":8357,"interventions":8358},"NCT05915702","A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems",[92],"2024-05-30",303,[8337,8324],[8309,6980,8340,8341],{"trials":8360,"activeCount":101},[],{"trials":8362,"activeCount":101},[],{"intervention":5124,"totalTrials":855,"cells":8364},{"EARLY_PHASE1":8365,"PHASE1":8367,"PHASE2":8369,"PHASE3":8381,"PHASE4":8395,"NA":8397},{"trials":8366,"activeCount":101},[],{"trials":8368,"activeCount":101},[],{"trials":8370,"activeCount":101},[8371],{"nctId":8372,"briefTitle":8373,"status":107,"phases":8374,"primaryCompletion":8375,"completion":8376,"start":8377,"enrollment":3214,"conditions":8378,"interventions":8379},"NCT02021409","Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934",[91],"2015-10-15","2015-11-23","2014-01-28",[5074,5063],[8380,5124],"BAY85-3934",{"trials":8382,"activeCount":101},[8383,8387,8391],{"nctId":5116,"briefTitle":5117,"status":107,"phases":8384,"primaryCompletion":2377,"completion":5119,"start":5120,"enrollment":5121,"conditions":8385,"interventions":8386},[92],[5074,5063],[5042,5124],{"nctId":5126,"briefTitle":5127,"status":107,"phases":8388,"primaryCompletion":5129,"completion":2929,"start":5130,"enrollment":5131,"conditions":8389,"interventions":8390},[92],[5074,5063],[5042,5124],{"nctId":5135,"briefTitle":5136,"status":107,"phases":8392,"primaryCompletion":5138,"completion":5139,"start":5140,"enrollment":3033,"conditions":8393,"interventions":8394},[92],[5074,5063],[5042,5124],{"trials":8396,"activeCount":101},[],{"trials":8398,"activeCount":101},[],{"intervention":8400,"totalTrials":1341,"cells":8401},"VEGF Trap-Eye",{"EARLY_PHASE1":8402,"PHASE1":8404,"PHASE2":8406,"PHASE3":8408,"PHASE4":8434,"NA":8436},{"trials":8403,"activeCount":101},[],{"trials":8405,"activeCount":101},[],{"trials":8407,"activeCount":101},[],{"trials":8409,"activeCount":101},[8410,8416,8427],{"nctId":8411,"briefTitle":8412,"status":107,"phases":8413,"primaryCompletion":6677,"completion":6677,"start":1508,"enrollment":3233,"conditions":8414,"interventions":8415},"NCT01512966","Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema)",[92],[2953],[8400],{"nctId":8417,"briefTitle":8418,"status":107,"phases":8419,"primaryCompletion":8420,"completion":8421,"start":8422,"enrollment":8423,"conditions":8424,"interventions":8426},"NCT01331681","Intravitreal Aflibercept Injection in Vision Impairment Due to DME",[92],"2013-06-03","2015-03-30","2011-05-09",406,[8425,2953],"Diabetes Mellitus",[8400,8400],{"nctId":8428,"briefTitle":8429,"status":107,"phases":8430,"primaryCompletion":2950,"completion":2187,"start":5409,"enrollment":500,"conditions":8431,"interventions":8433},"NCT01249664","VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)",[92],[8432],"Myopia, Pathological",[8400],{"trials":8435,"activeCount":101},[],{"trials":8437,"activeCount":101},[],{"intervention":8439,"totalTrials":1341,"cells":8440},"Rituximab",{"EARLY_PHASE1":8441,"PHASE1":8443,"PHASE2":8445,"PHASE3":8458,"PHASE4":8484,"NA":8486},{"trials":8442,"activeCount":101},[],{"trials":8444,"activeCount":101},[],{"trials":8446,"activeCount":101},[8447],{"nctId":8448,"briefTitle":8449,"status":107,"phases":8450,"primaryCompletion":3705,"completion":2256,"start":8451,"conditions":8452,"interventions":8454},"NCT00086775","Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia",[91],"2003-07",[8453],"Leukemia",[8455,8456,8457],"alemtuzumab","rituximab","fludarabine phosphate",{"trials":8459,"activeCount":101},[8460,8474],{"nctId":8461,"briefTitle":8462,"status":156,"phases":8463,"primaryCompletion":8464,"completion":8465,"start":8466,"enrollment":8467,"conditions":8468,"interventions":8470},"NCT02626455","Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)",[92],"2023-09-15","2023-11-10","2016-01-06",551,[8469],"Lymphoma, Non-Hodgkin",[7973,8439,8471,8472,2177,8473,493],"Cyclophosphamide","Doxorubicin","Bendamustine",{"nctId":8475,"briefTitle":8476,"status":107,"phases":8477,"primaryCompletion":8478,"completion":8479,"start":8480,"enrollment":4862,"conditions":8481,"interventions":8483},"NCT02367040","Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)",[92],"2020-08-31","2024-11-15","2015-08-03",[8482],"Lymphoma,Non-Hodgkin",[7973,8439],{"trials":8485,"activeCount":101},[],{"trials":8487,"activeCount":101},[],{"intervention":8489,"totalTrials":1341,"cells":8490},"Butenafine HCl 1%",{"EARLY_PHASE1":8491,"PHASE1":8493,"PHASE2":8495,"PHASE3":8497,"PHASE4":8526,"NA":8528},{"trials":8492,"activeCount":101},[],{"trials":8494,"activeCount":101},[],{"trials":8496,"activeCount":101},[],{"trials":8498,"activeCount":101},[8499,8508,8518],{"nctId":8500,"briefTitle":8501,"status":107,"phases":8502,"primaryCompletion":8503,"completion":8503,"start":8504,"enrollment":1509,"conditions":8505,"interventions":8507},"NCT04531527","Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects",[92],"2013-06-28","2013-06-24",[8506],"Dermatitis, Phototoxic",[8489],{"nctId":8509,"briefTitle":8510,"status":107,"phases":8511,"primaryCompletion":8512,"completion":8512,"start":8513,"enrollment":1509,"conditions":8514,"interventions":8516},"NCT04531813","Study to Determine Skin Irritation Potential of an Antifungal Cream Containing Trolamine After Repeated Skin Application (Cumulative Irritation Patch Test)",[92],"2013-07-01","2013-06-10",[8515],"Hypersensitivity",[8489,8517],"Positive Control-Sodium lauryl sulfate",{"nctId":8519,"briefTitle":8520,"status":107,"phases":8521,"primaryCompletion":8522,"completion":8522,"start":8523,"enrollment":1713,"conditions":8524,"interventions":8525},"NCT04531540","Study to Determine Skin Irritation and\u002For Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test)",[92],"2013-10-18","2013-09-09",[8515],[8489],{"trials":8527,"activeCount":101},[],{"trials":8529,"activeCount":101},[],{"intervention":8531,"totalTrials":1341,"cells":8532},"Magnevist",{"EARLY_PHASE1":8533,"PHASE1":8535,"PHASE2":8537,"PHASE3":8546,"PHASE4":8563,"NA":8565},{"trials":8534,"activeCount":101},[],{"trials":8536,"activeCount":101},[],{"trials":8538,"activeCount":101},[8539],{"nctId":8540,"briefTitle":8541,"status":107,"phases":8542,"completion":4750,"start":5472,"enrollment":3233,"conditions":8543,"interventions":8545},"NCT00310544","Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction",[91],[8544],"Myocardial Infarction",[8531,8531],{"trials":8547,"activeCount":101},[8548,8555],{"nctId":8549,"briefTitle":8550,"status":107,"phases":8551,"primaryCompletion":6317,"completion":6317,"start":4750,"enrollment":1621,"conditions":8552,"interventions":8554},"NCT00395460","Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients",[92],[8553],"Central Nervous System Diseases",[6980,8531],{"nctId":8556,"briefTitle":8557,"status":107,"phases":8558,"completion":6384,"start":8559,"enrollment":510,"conditions":8560,"interventions":8562},"NCT00681551","Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis",[92],"2003-02",[8561],"Brain Neoplasms",[8531,8531],{"trials":8564,"activeCount":101},[],{"trials":8566,"activeCount":101},[],{"intervention":8568,"totalTrials":1341,"cells":8569},"Omeprazole\u002Fsodium bicarbonate",{"EARLY_PHASE1":8570,"PHASE1":8572,"PHASE2":8582,"PHASE3":8584,"PHASE4":8601,"NA":8603},{"trials":8571,"activeCount":101},[],{"trials":8573,"activeCount":101},[8574],{"nctId":8575,"briefTitle":8576,"status":107,"phases":8577,"primaryCompletion":1569,"completion":1569,"start":1569,"enrollment":229,"conditions":8578,"interventions":8579},"NCT01337804","A Study to Compare Omeprazole Administered as Zegerid® Powder and as Prilosec® Capsule in Healthy Participants (P08050)(CL2010-12)",[90],[7338],[8580,8581],"omeprazole\u002Fsodium bicarbonate","omeprazole magnesium",{"trials":8583,"activeCount":101},[],{"trials":8585,"activeCount":101},[8586,8594],{"nctId":8587,"briefTitle":8588,"status":107,"phases":8589,"primaryCompletion":8109,"completion":8109,"start":4597,"enrollment":2151,"conditions":8590,"interventions":8593},"NCT00765206","A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (Study CL2008-02)(P07814)(COMPLETED)",[92],[8591,8592],"Gastric Acid","Human Experimentation",[8568,8581],{"nctId":8595,"briefTitle":8596,"status":107,"phases":8597,"primaryCompletion":1423,"completion":1423,"start":2970,"enrollment":2151,"conditions":8598,"interventions":8599},"NCT00674115","A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED)",[92],[8591,8592],[8568,8581,8600],"sodium bicarbonate",{"trials":8602,"activeCount":101},[],{"trials":8604,"activeCount":101},[],{"intervention":8581,"totalTrials":1341,"cells":8606},{"EARLY_PHASE1":8607,"PHASE1":8609,"PHASE2":8615,"PHASE3":8617,"PHASE4":8627,"NA":8629},{"trials":8608,"activeCount":101},[],{"trials":8610,"activeCount":101},[8611],{"nctId":8575,"briefTitle":8576,"status":107,"phases":8612,"primaryCompletion":1569,"completion":1569,"start":1569,"enrollment":229,"conditions":8613,"interventions":8614},[90],[7338],[8580,8581],{"trials":8616,"activeCount":101},[],{"trials":8618,"activeCount":101},[8619,8623],{"nctId":8587,"briefTitle":8588,"status":107,"phases":8620,"primaryCompletion":8109,"completion":8109,"start":4597,"enrollment":2151,"conditions":8621,"interventions":8622},[92],[8591,8592],[8568,8581],{"nctId":8595,"briefTitle":8596,"status":107,"phases":8624,"primaryCompletion":1423,"completion":1423,"start":2970,"enrollment":2151,"conditions":8625,"interventions":8626},[92],[8591,8592],[8568,8581,8600],{"trials":8628,"activeCount":101},[],{"trials":8630,"activeCount":101},[],{"intervention":8632,"totalTrials":1341,"cells":8633},"Asundexian",{"EARLY_PHASE1":8634,"PHASE1":8636,"PHASE2":8651,"PHASE3":8653,"PHASE4":8677,"NA":8679},{"trials":8635,"activeCount":101},[],{"trials":8637,"activeCount":101},[8638],{"nctId":8639,"briefTitle":8640,"status":107,"phases":8641,"primaryCompletion":8642,"completion":8643,"start":8644,"enrollment":701,"conditions":8645,"interventions":8650},"NCT05419635","A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body in Participants With Mild or Moderate Reduction of Liver Function Compared to Participants With Normal Liver Function",[90],"2023-05-24","2023-08-21","2022-06-14",[8646,21,8647,8648,8649],"Prevention of Thromboembolic Events","Acute Myocardial Infarction","Non-cardioembolic Ischemic Stroke","Hepatic Impairment",[8632],{"trials":8652,"activeCount":101},[],{"trials":8654,"activeCount":101},[8655,8667],{"nctId":8656,"briefTitle":8657,"status":107,"phases":8658,"primaryCompletion":8659,"completion":8659,"start":8660,"enrollment":8661,"conditions":8662,"interventions":8666},"NCT05686070","A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke",[92],"2025-10-23","2023-01-26",12327,[8663,8664,8665],"Prevention of Ischemic Stroke","Acute Non-cardioembolic Ischemic Stroke","High-risk Transient Ischemic Attack",[8632],{"nctId":8668,"briefTitle":8669,"status":156,"phases":8670,"primaryCompletion":8671,"completion":8671,"start":8672,"enrollment":8673,"conditions":8674,"interventions":8676},"NCT05643573","A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke",[92],"2024-01-31","2022-12-05",14830,[8675,21],"Prevention of Stroke or Systemic Embolism",[8632,3943],{"trials":8678,"activeCount":101},[],{"trials":8680,"activeCount":101},[],{"intervention":3772,"totalTrials":1341,"cells":8682},{"EARLY_PHASE1":8683,"PHASE1":8685,"PHASE2":8687,"PHASE3":8689,"PHASE4":8703,"NA":8705},{"trials":8684,"activeCount":101},[],{"trials":8686,"activeCount":101},[],{"trials":8688,"activeCount":101},[],{"trials":8690,"activeCount":101},[8691,8695,8699],{"nctId":3765,"briefTitle":3766,"status":107,"phases":8692,"primaryCompletion":1587,"completion":1570,"start":3768,"enrollment":3769,"conditions":8693,"interventions":8694},[92],[3631],[3542,3633,3772,3773],{"nctId":3806,"briefTitle":3807,"status":107,"phases":8696,"primaryCompletion":499,"completion":3809,"start":3723,"enrollment":3810,"conditions":8697,"interventions":8698},[92],[21],[3542,2202,3772,3813],{"nctId":3838,"briefTitle":3839,"status":107,"phases":8700,"primaryCompletion":3841,"completion":3842,"start":3843,"enrollment":3844,"conditions":8701,"interventions":8702},[92],[3846],[3542,3542,3848,3849,3772,3850,3851],{"trials":8704,"activeCount":101},[],{"trials":8706,"activeCount":101},[],{"intervention":8341,"totalTrials":1341,"cells":8708},{"EARLY_PHASE1":8709,"PHASE1":8711,"PHASE2":8713,"PHASE3":8715,"PHASE4":8732,"NA":8734},{"trials":8710,"activeCount":101},[],{"trials":8712,"activeCount":101},[],{"trials":8714,"activeCount":101},[],{"trials":8716,"activeCount":101},[8717,8721,8728],{"nctId":8329,"briefTitle":8330,"status":107,"phases":8718,"primaryCompletion":8332,"completion":8333,"start":8334,"enrollment":8335,"conditions":8719,"interventions":8720},[92],[8337,8338],[8309,6980,8340,8341],{"nctId":8722,"briefTitle":8723,"status":107,"phases":8724,"primaryCompletion":4700,"completion":4700,"start":1423,"enrollment":217,"conditions":8725,"interventions":8727},"NCT00709852","Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging",[92],[8726,8553],"Diagnostic Imaging",[6980,8341],{"nctId":8352,"briefTitle":8353,"status":107,"phases":8729,"primaryCompletion":8355,"completion":8332,"start":8334,"enrollment":8356,"conditions":8730,"interventions":8731},[92],[8337,8324],[8309,6980,8340,8341],{"trials":8733,"activeCount":101},[],{"trials":8735,"activeCount":101},[],{"intervention":2177,"totalTrials":175,"cells":8737},{"EARLY_PHASE1":8738,"PHASE1":8740,"PHASE2":8746,"PHASE3":8748,"PHASE4":8754,"NA":8756},{"trials":8739,"activeCount":101},[],{"trials":8741,"activeCount":101},[8742],{"nctId":2168,"briefTitle":2169,"status":107,"phases":8743,"primaryCompletion":2171,"completion":2172,"start":2173,"enrollment":1133,"conditions":8744,"interventions":8745},[90],[2175],[1011,2177,2178],{"trials":8747,"activeCount":101},[],{"trials":8749,"activeCount":101},[8750],{"nctId":8461,"briefTitle":8462,"status":156,"phases":8751,"primaryCompletion":8464,"completion":8465,"start":8466,"enrollment":8467,"conditions":8752,"interventions":8753},[92],[8469],[7973,8439,8471,8472,2177,8473,493],{"trials":8755,"activeCount":101},[],{"trials":8757,"activeCount":101},[],{"intervention":8759,"totalTrials":175,"cells":8760},"Zevalin",{"EARLY_PHASE1":8761,"PHASE1":8763,"PHASE2":8765,"PHASE3":8776,"PHASE4":8786,"NA":8788},{"trials":8762,"activeCount":101},[],{"trials":8764,"activeCount":101},[],{"trials":8766,"activeCount":101},[8767],{"nctId":8768,"briefTitle":8769,"status":107,"phases":8770,"completion":4789,"start":6281,"enrollment":510,"conditions":8771,"interventions":8775},"NCT00220285","Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma",[91],[8772,8773,8774],"Non-Hodgkin's Lymphoma","Lymphoma, B-Cell","Lymphoma, Low-Grade",[8759,8759],{"trials":8777,"activeCount":101},[8778],{"nctId":8779,"briefTitle":8780,"status":107,"phases":8781,"completion":1328,"start":8782,"enrollment":8783,"conditions":8784,"interventions":8785},"NCT00185393","Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy",[92],"2001-08",414,[8469],[8759],{"trials":8787,"activeCount":101},[],{"trials":8789,"activeCount":101},[],{"intervention":3718,"totalTrials":175,"cells":8791},{"EARLY_PHASE1":8792,"PHASE1":8794,"PHASE2":8796,"PHASE3":8798,"PHASE4":8808,"NA":8810},{"trials":8793,"activeCount":101},[],{"trials":8795,"activeCount":101},[],{"trials":8797,"activeCount":101},[],{"trials":8799,"activeCount":101},[8800,8804],{"nctId":3712,"briefTitle":3713,"status":107,"phases":8801,"primaryCompletion":1629,"completion":2406,"start":2959,"enrollment":1519,"conditions":8802,"interventions":8803},[92],[3716],[3542,3718,2202],{"nctId":3784,"briefTitle":3785,"status":107,"phases":8805,"primaryCompletion":2230,"completion":2367,"start":410,"enrollment":2151,"conditions":8806,"interventions":8807},[92],[3621],[3542,3542,3718,2202],{"trials":8809,"activeCount":101},[],{"trials":8811,"activeCount":101},[],{"intervention":6230,"totalTrials":175,"cells":8813},{"EARLY_PHASE1":8814,"PHASE1":8816,"PHASE2":8818,"PHASE3":8820,"PHASE4":8830,"NA":8832},{"trials":8815,"activeCount":101},[],{"trials":8817,"activeCount":101},[],{"trials":8819,"activeCount":101},[],{"trials":8821,"activeCount":101},[8822,8826],{"nctId":6221,"briefTitle":6222,"status":107,"phases":8823,"primaryCompletion":1569,"completion":2344,"start":3793,"enrollment":6224,"conditions":8824,"interventions":8825},[92],[5843],[6227,6228,6229,6230],{"nctId":6232,"briefTitle":6233,"status":107,"phases":8827,"primaryCompletion":2959,"completion":2959,"start":2919,"enrollment":6235,"conditions":8828,"interventions":8829},[92],[5843],[6238,6210,6230],{"trials":8831,"activeCount":101},[],{"trials":8833,"activeCount":101},[],{"intervention":8835,"totalTrials":175,"cells":8836},"Angeliq",{"EARLY_PHASE1":8837,"PHASE1":8839,"PHASE2":8841,"PHASE3":8843,"PHASE4":8859,"NA":8861},{"trials":8838,"activeCount":101},[],{"trials":8840,"activeCount":101},[],{"trials":8842,"activeCount":101},[],{"trials":8844,"activeCount":101},[8845,8852],{"nctId":8846,"briefTitle":8847,"status":107,"phases":8848,"completion":3627,"start":4707,"enrollment":8849,"conditions":8850,"interventions":8851},"NCT00102141","Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women",[92],750,[6625,6505],[8835,8835,8835,8835],{"nctId":8853,"briefTitle":8854,"status":107,"phases":8855,"completion":4770,"start":3706,"enrollment":8856,"conditions":8857,"interventions":8858},"NCT00651599","Treatment of Vasomotor Symptoms in Korean Post Menopausal Women",[92],90,[6495],[8835],{"trials":8860,"activeCount":101},[],{"trials":8862,"activeCount":101},[],{"intervention":8864,"totalTrials":175,"cells":8865},"Estradiol valerate, Dienogest",{"EARLY_PHASE1":8866,"PHASE1":8868,"PHASE2":8870,"PHASE3":8872,"PHASE4":8892,"NA":8894},{"trials":8867,"activeCount":101},[],{"trials":8869,"activeCount":101},[],{"trials":8871,"activeCount":101},[],{"trials":8873,"activeCount":101},[8874,8882],{"nctId":8875,"briefTitle":8876,"status":107,"phases":8877,"primaryCompletion":1570,"completion":1570,"start":4700,"enrollment":8878,"conditions":8879,"interventions":8880},"NCT00909857","Effect on Primary Dysmenorrhea",[92],507,[8027],[8864,8881],"Ethinyl estradiol, Levonorgestrel",{"nctId":8883,"briefTitle":8884,"status":107,"phases":8885,"primaryCompletion":8886,"completion":8886,"start":8887,"enrollment":8888,"conditions":8889,"interventions":8890},"NCT00754065","To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US\u002FCanada)",[92],"2011-05-10","2008-09-08",409,[15],[8864,8891],"Ortho Tri Cyclen Lo",{"trials":8893,"activeCount":101},[],{"trials":8895,"activeCount":101},[],{"intervention":8897,"totalTrials":175,"cells":8898},"Vardenafil ODT",{"EARLY_PHASE1":8899,"PHASE1":8901,"PHASE2":8903,"PHASE3":8905,"PHASE4":8921,"NA":8923},{"trials":8900,"activeCount":101},[],{"trials":8902,"activeCount":101},[],{"trials":8904,"activeCount":101},[],{"trials":8906,"activeCount":101},[8907,8914],{"nctId":8908,"briefTitle":8909,"status":107,"phases":8910,"primaryCompletion":4292,"completion":4292,"start":2970,"enrollment":8911,"conditions":8912,"interventions":8913},"NCT00655629","Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.",[92],339,[27],[8897],{"nctId":8915,"briefTitle":8916,"status":107,"phases":8917,"primaryCompletion":4588,"completion":4588,"start":2970,"enrollment":8918,"conditions":8919,"interventions":8920},"NCT00631969","Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction",[92],362,[27],[8897],{"trials":8922,"activeCount":101},[],{"trials":8924,"activeCount":101},[],{"intervention":493,"totalTrials":175,"cells":8926},{"EARLY_PHASE1":8927,"PHASE1":8929,"PHASE2":8931,"PHASE3":8937,"PHASE4":8943,"NA":8945},{"trials":8928,"activeCount":101},[],{"trials":8930,"activeCount":101},[],{"trials":8932,"activeCount":101},[8933],{"nctId":484,"briefTitle":485,"status":107,"phases":8934,"primaryCompletion":487,"completion":488,"start":489,"enrollment":490,"conditions":8935,"interventions":8936},[91],[187],[72,288,493,128],{"trials":8938,"activeCount":101},[8939],{"nctId":8461,"briefTitle":8462,"status":156,"phases":8940,"primaryCompletion":8464,"completion":8465,"start":8466,"enrollment":8467,"conditions":8941,"interventions":8942},[92],[8469],[7973,8439,8471,8472,2177,8473,493],{"trials":8944,"activeCount":101},[],{"trials":8946,"activeCount":101},[],{"intervention":8948,"totalTrials":175,"cells":8949},"Fosrenol",{"EARLY_PHASE1":8950,"PHASE1":8952,"PHASE2":8954,"PHASE3":8956,"PHASE4":8974,"NA":8976},{"trials":8951,"activeCount":101},[],{"trials":8953,"activeCount":101},[],{"trials":8955,"activeCount":101},[],{"trials":8957,"activeCount":101},[8958,8967],{"nctId":8959,"briefTitle":8960,"status":107,"phases":8961,"primaryCompletion":5999,"completion":5999,"start":8962,"enrollment":8963,"conditions":8964,"interventions":8966},"NCT01110629","Study in Chronic Kidney Disease (CKD) Not on Dialysis",[92],"2010-06",143,[8965],"Hyperphosphatemia",[8948],{"nctId":8968,"briefTitle":8969,"status":107,"phases":8970,"primaryCompletion":4250,"completion":4250,"start":2968,"enrollment":8971,"conditions":8972,"interventions":8973},"NCT01187628","Long-term Study in Chronic Kidney Disease (Extension From Study 14817)",[92],123,[8965],[8948],{"trials":8975,"activeCount":101},[],{"trials":8977,"activeCount":101},[],{"intervention":8979,"totalTrials":175,"cells":8980},"Nifedipine GITS\u002FCandesartan Cilexetil FDC",{"EARLY_PHASE1":8981,"PHASE1":8983,"PHASE2":8985,"PHASE3":8987,"PHASE4":9005,"NA":9007},{"trials":8982,"activeCount":101},[],{"trials":8984,"activeCount":101},[],{"trials":8986,"activeCount":101},[],{"trials":8988,"activeCount":101},[8989,8997],{"nctId":8990,"briefTitle":8991,"status":107,"phases":8992,"primaryCompletion":8993,"completion":8993,"start":8994,"enrollment":6571,"conditions":8995,"interventions":8996},"NCT01788358","Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension",[92],"2014-05-01","2013-02-14",[6625],[8979,8979,8979,8979],{"nctId":8998,"briefTitle":8999,"status":464,"phases":9000,"primaryCompletion":9001,"completion":9001,"start":4107,"enrollment":101,"conditions":9002,"interventions":9003},"NCT02047019","Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil",[92],"2019-12-08",[6625],[8979,8979,9004,8979],"Candesartan Cilexetil",{"trials":9006,"activeCount":101},[],{"trials":9008,"activeCount":101},[],{"intervention":9010,"totalTrials":175,"cells":9011},"Amikacin inhalation solution",{"EARLY_PHASE1":9012,"PHASE1":9014,"PHASE2":9016,"PHASE3":9025,"PHASE4":9039,"NA":9041},{"trials":9013,"activeCount":101},[],{"trials":9015,"activeCount":101},[],{"trials":9017,"activeCount":101},[9018],{"nctId":9019,"briefTitle":9020,"status":107,"phases":9021,"primaryCompletion":9022,"completion":9022,"start":3778,"enrollment":160,"conditions":9023,"interventions":9024},"NCT01021436","Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-ventilated Patients With Nosocomial Pneumonia",[91],"2007-08",[6718],[9010],{"trials":9026,"activeCount":101},[9027],{"nctId":9028,"briefTitle":9029,"status":107,"phases":9030,"primaryCompletion":9031,"completion":9031,"start":9032,"enrollment":9033,"conditions":9034,"interventions":9036},"NCT01799993","Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia",[92],"2017-04-07","2013-04-13",725,[9035],"Pneumonia, Bacterial",[9037,9038],"Amikacin Inhalation Solution","Aerosolized Placebo",{"trials":9040,"activeCount":101},[],{"trials":9042,"activeCount":101},[],{"intervention":5981,"totalTrials":175,"cells":9044},{"EARLY_PHASE1":9045,"PHASE1":9047,"PHASE2":9049,"PHASE3":9055,"PHASE4":9066,"NA":9068},{"trials":9046,"activeCount":101},[],{"trials":9048,"activeCount":101},[],{"trials":9050,"activeCount":101},[9051],{"nctId":5972,"briefTitle":5973,"status":107,"phases":9052,"primaryCompletion":3618,"completion":1327,"start":5975,"enrollment":5976,"conditions":9053,"interventions":9054},[91],[5978,5979],[5981,5954],{"trials":9056,"activeCount":101},[9057],{"nctId":9058,"briefTitle":9059,"status":107,"phases":9060,"primaryCompletion":1638,"completion":1638,"start":9061,"enrollment":9062,"conditions":9063,"interventions":9065},"NCT04534452","Study to Find Out Whether Participants With a History of Stuffy Nose Due to Allergic Reactions in the Nose Would Intend to Buy Drug Phenylephrine Hydrochloride Extended Release Tablets After Receiving it Once in This Study",[92],"2012-05-12",347,[9064],"Nasal Congestion Due to Allergic Rhinitis",[5981],{"trials":9067,"activeCount":101},[],{"trials":9069,"activeCount":101},[],{"intervention":9071,"totalTrials":175,"cells":9072},"Zegerid",{"EARLY_PHASE1":9073,"PHASE1":9075,"PHASE2":9077,"PHASE3":9079,"PHASE4":9096,"NA":9098},{"trials":9074,"activeCount":101},[],{"trials":9076,"activeCount":101},[],{"trials":9078,"activeCount":101},[],{"trials":9080,"activeCount":101},[9081,9088],{"nctId":9082,"briefTitle":9083,"status":107,"phases":9084,"primaryCompletion":3809,"completion":3809,"start":3576,"enrollment":112,"conditions":9085,"interventions":9086},"NCT01005719","Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)(P07815)(COMPLETED)",[92],[8592],[9071,9087],"Prevacid®",{"nctId":9089,"briefTitle":9090,"status":107,"phases":9091,"primaryCompletion":1313,"completion":1313,"start":498,"enrollment":160,"conditions":9092,"interventions":9094},"NCT01077076","Pharmacodynamic Study Comparing the Effects of Two Different Forms of Omeprazole (P07812) (COMPLETED)",[92],[9093],"Intragastric Acidity",[9071,9095],"Prilosec OTC™",{"trials":9097,"activeCount":101},[],{"trials":9099,"activeCount":101},[],{"intervention":9101,"totalTrials":175,"cells":9102},"EE20\u002FDRSP\u002FL-5-MTHF",{"EARLY_PHASE1":9103,"PHASE1":9105,"PHASE2":9107,"PHASE3":9109,"PHASE4":9125,"NA":9127},{"trials":9104,"activeCount":101},[],{"trials":9106,"activeCount":101},[],{"trials":9108,"activeCount":101},[],{"trials":9110,"activeCount":101},[9111,9118],{"nctId":9112,"briefTitle":9113,"status":107,"phases":9114,"primaryCompletion":3594,"completion":3594,"start":2187,"enrollment":9115,"conditions":9116,"interventions":9117},"NCT01902264","Study of Treatment With the Combination of Drospirenone Plus Ethinyl Estradiol Plus Levomefolate Calcium in Mexican Women Seeking Contraception",[92],34,[15],[9101],{"nctId":9119,"briefTitle":9120,"status":464,"phases":9121,"primaryCompletion":3732,"completion":3732,"start":4250,"enrollment":101,"conditions":9122,"interventions":9123},"NCT01331655","Clinical Study of a Conventional and Flexible Extended Oral Contraceptive of EE\u002FDRSP With or Without Metafolin in Latin America",[92],[15],[9124,9101,9101],"EE20\u002FDRSP",{"trials":9126,"activeCount":101},[],{"trials":9128,"activeCount":101},[],{"intervention":9130,"totalTrials":175,"cells":9131},"Pseudoephedrine",{"EARLY_PHASE1":9132,"PHASE1":9134,"PHASE2":9136,"PHASE3":9138,"PHASE4":9157,"NA":9159},{"trials":9133,"activeCount":101},[],{"trials":9135,"activeCount":101},[],{"trials":9137,"activeCount":101},[],{"trials":9139,"activeCount":101},[9140,9150],{"nctId":9141,"briefTitle":9142,"status":107,"phases":9143,"primaryCompletion":9144,"completion":9144,"start":9145,"enrollment":9146,"conditions":9147,"interventions":9148},"NCT01062360","Placebo and Active Controlled Study to Assess Efficacy and Tolerability of Aspirin Plus Pseudoephedrine",[92],"2007-05-14","2005-12-23",1016,[6573,6574],[9149,3761,9130],"Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine",{"nctId":9151,"briefTitle":9152,"status":107,"phases":9153,"primaryCompletion":410,"completion":410,"start":3576,"enrollment":9154,"conditions":9155,"interventions":9156},"NCT00963443","Acetylsalicylic Acid Combined With Pseudoephedrine in Common Cold",[92],833,[6573],[3761,9130],{"trials":9158,"activeCount":101},[],{"trials":9160,"activeCount":101},[],{"intervention":9162,"totalTrials":175,"cells":9163},"0.25mg DRSP \u002F 0.5mg E2",{"EARLY_PHASE1":9164,"PHASE1":9166,"PHASE2":9168,"PHASE3":9170,"PHASE4":9189,"NA":9191},{"trials":9165,"activeCount":101},[],{"trials":9167,"activeCount":101},[],{"trials":9169,"activeCount":101},[],{"trials":9171,"activeCount":101},[9172,9180],{"nctId":9173,"briefTitle":9174,"status":107,"phases":9175,"primaryCompletion":1314,"completion":1314,"start":9022,"enrollment":9176,"conditions":9177,"interventions":9178},"NCT00522873","Endometrial Safety Study",[92],662,[6505],[9162,9179],"0.5mg NETA \u002F 1.0mg E2",{"nctId":9181,"briefTitle":9182,"status":107,"phases":9183,"primaryCompletion":1498,"completion":3567,"start":3778,"enrollment":9184,"conditions":9185,"interventions":9186},"NCT00446199","Low-dose Hormone Therapy for Relief of Vasomotor Symptoms",[92],735,[6495,1103],[9187,9162,9188],"0.5mg DRSP \u002F 0.5mg E2","Estradiol",{"trials":9190,"activeCount":101},[],{"trials":9192,"activeCount":101},[],{"intervention":9194,"totalTrials":175,"cells":9195},"Valette",{"EARLY_PHASE1":9196,"PHASE1":9198,"PHASE2":9200,"PHASE3":9202,"PHASE4":9222,"NA":9224},{"trials":9197,"activeCount":101},[],{"trials":9199,"activeCount":101},[],{"trials":9201,"activeCount":101},[],{"trials":9203,"activeCount":101},[9204,9212],{"nctId":9205,"briefTitle":9206,"status":107,"phases":9207,"completion":5946,"start":5394,"enrollment":9208,"conditions":9209,"interventions":9211},"NCT00302666","Bleeding Pattern Study",[92],1315,[9210],"Oral Contraceptive",[9194,9194],{"nctId":9213,"briefTitle":9214,"status":107,"phases":9215,"primaryCompletion":9216,"completion":9216,"start":9217,"enrollment":9218,"conditions":9219,"interventions":9220},"NCT00280657","Study on Safety and Efficacy of an Oral Contraceptive in Treating Acne Papulopustulosa",[92],"2005-05-21","2004-03-10",1326,[8050],[9194,9221],"Diane",{"trials":9223,"activeCount":101},[],{"trials":9225,"activeCount":101},[],{"intervention":9227,"totalTrials":175,"cells":9228},"Estradiol valerate\u002FDienogest",{"EARLY_PHASE1":9229,"PHASE1":9231,"PHASE2":9233,"PHASE3":9235,"PHASE4":9251,"NA":9253},{"trials":9230,"activeCount":101},[],{"trials":9232,"activeCount":101},[],{"trials":9234,"activeCount":101},[],{"trials":9236,"activeCount":101},[9237,9245],{"nctId":9238,"briefTitle":9239,"status":107,"phases":9240,"primaryCompletion":4597,"completion":4597,"start":4571,"enrollment":9241,"conditions":9242,"interventions":9244},"NCT00293059","Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding",[92],190,[9243],"Metrorrhagia",[9227],{"nctId":9246,"briefTitle":9239,"status":107,"phases":9247,"primaryCompletion":4597,"completion":4597,"start":3724,"enrollment":9248,"conditions":9249,"interventions":9250},"NCT00307801",[92],231,[9243],[9227],{"trials":9252,"activeCount":101},[],{"trials":9254,"activeCount":101},[],{"intervention":8340,"totalTrials":175,"cells":9256},{"EARLY_PHASE1":9257,"PHASE1":9259,"PHASE2":9261,"PHASE3":9263,"PHASE4":9273,"NA":9275},{"trials":9258,"activeCount":101},[],{"trials":9260,"activeCount":101},[],{"trials":9262,"activeCount":101},[],{"trials":9264,"activeCount":101},[9265,9269],{"nctId":8329,"briefTitle":8330,"status":107,"phases":9266,"primaryCompletion":8332,"completion":8333,"start":8334,"enrollment":8335,"conditions":9267,"interventions":9268},[92],[8337,8338],[8309,6980,8340,8341],{"nctId":8352,"briefTitle":8353,"status":107,"phases":9270,"primaryCompletion":8355,"completion":8332,"start":8334,"enrollment":8356,"conditions":9271,"interventions":9272},[92],[8337,8324],[8309,6980,8340,8341],{"trials":9274,"activeCount":101},[],{"trials":9276,"activeCount":101},[],{"intervention":6162,"totalTrials":175,"cells":9278},{"EARLY_PHASE1":9279,"PHASE1":9281,"PHASE2":9283,"PHASE3":9285,"PHASE4":9301,"NA":9303},{"trials":9280,"activeCount":101},[],{"trials":9282,"activeCount":101},[],{"trials":9284,"activeCount":101},[],{"trials":9286,"activeCount":101},[9287,9297],{"nctId":9288,"briefTitle":9289,"status":107,"phases":9290,"primaryCompletion":9291,"completion":9292,"start":9293,"enrollment":874,"conditions":9294,"interventions":9296},"NCT01122602","Evaluate Analgesic Efficacy of Fast Release Aspirin",[92],"2010-07-29","2010-08-06","2010-04-29",[9295],"Drugs, Investigational",[6162,6162],{"nctId":6153,"briefTitle":6154,"status":107,"phases":9298,"primaryCompletion":6156,"completion":6156,"start":6157,"enrollment":6158,"conditions":9299,"interventions":9300},[92],[6160],[6162,6133],{"trials":9302,"activeCount":101},[],{"trials":9304,"activeCount":101},[],{"intervention":9306,"totalTrials":233,"cells":9307},"Aflibercept High Dose VEGF Trap-Eye",{"EARLY_PHASE1":9308,"PHASE1":9310,"PHASE2":9312,"PHASE3":9314,"PHASE4":9328,"NA":9330},{"trials":9309,"activeCount":101},[],{"trials":9311,"activeCount":101},[],{"trials":9313,"activeCount":101},[],{"trials":9315,"activeCount":101},[9316],{"nctId":9317,"briefTitle":9318,"status":107,"phases":9319,"primaryCompletion":9320,"completion":9321,"start":9322,"enrollment":9323,"conditions":9324,"interventions":9326},"NCT04423718","Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye",[92],"2022-07-27","2024-08-07","2020-08-11",1011,[9325],"Neovascular Age-Related Macular Degeneration",[9306,9327],"Aflibercept VEGF Trap-Eye",{"trials":9329,"activeCount":101},[],{"trials":9331,"activeCount":101},[],{"intervention":9327,"totalTrials":233,"cells":9333},{"EARLY_PHASE1":9334,"PHASE1":9336,"PHASE2":9338,"PHASE3":9340,"PHASE4":9346,"NA":9348},{"trials":9335,"activeCount":101},[],{"trials":9337,"activeCount":101},[],{"trials":9339,"activeCount":101},[],{"trials":9341,"activeCount":101},[9342],{"nctId":9317,"briefTitle":9318,"status":107,"phases":9343,"primaryCompletion":9320,"completion":9321,"start":9322,"enrollment":9323,"conditions":9344,"interventions":9345},[92],[9325],[9306,9327],{"trials":9347,"activeCount":101},[],{"trials":9349,"activeCount":101},[],{"intervention":9351,"totalTrials":233,"cells":9352},"Testogel",{"EARLY_PHASE1":9353,"PHASE1":9355,"PHASE2":9357,"PHASE3":9359,"PHASE4":9370,"NA":9372},{"trials":9354,"activeCount":101},[],{"trials":9356,"activeCount":101},[],{"trials":9358,"activeCount":101},[],{"trials":9360,"activeCount":101},[9361],{"nctId":9362,"briefTitle":9363,"status":107,"phases":9364,"primaryCompletion":4750,"completion":6493,"start":3667,"enrollment":9365,"conditions":9366,"interventions":9369},"NCT00185198","Efficacy and Safety of Testogel® in Men With Partial Androgen Deficiency of Aging Males (PADAM)",[92],363,[9367,9368],"Androgens (Deficiency)","Male",[9351],{"trials":9371,"activeCount":101},[],{"trials":9373,"activeCount":101},[],{"intervention":4774,"totalTrials":233,"cells":9375},{"EARLY_PHASE1":9376,"PHASE1":9378,"PHASE2":9380,"PHASE3":9382,"PHASE4":9388,"NA":9390},{"trials":9377,"activeCount":101},[],{"trials":9379,"activeCount":101},[],{"trials":9381,"activeCount":101},[],{"trials":9383,"activeCount":101},[9384],{"nctId":4767,"briefTitle":4768,"status":107,"phases":9385,"primaryCompletion":4750,"completion":4588,"start":4770,"enrollment":4771,"conditions":9386,"interventions":9387},[92],[4651],[42,4774],{"trials":9389,"activeCount":101},[],{"trials":9391,"activeCount":101},[],{"intervention":9393,"totalTrials":233,"cells":9394},"BAY86-5300",{"EARLY_PHASE1":9395,"PHASE1":9397,"PHASE2":9399,"PHASE3":9401,"PHASE4":9410,"NA":9412},{"trials":9396,"activeCount":101},[],{"trials":9398,"activeCount":101},[],{"trials":9400,"activeCount":101},[],{"trials":9402,"activeCount":101},[9403],{"nctId":9404,"briefTitle":9405,"status":107,"phases":9406,"primaryCompletion":9407,"completion":5052,"start":5409,"enrollment":6571,"conditions":9408,"interventions":9409},"NCT01257984","Study to Investigate Compliance With the Oral Contraceptive SH T00186D in a Flexible Extended Regimen Supported by a Dispenser With a Reminder Function",[92],"2012-08",[15],[9393,9393],{"trials":9411,"activeCount":101},[],{"trials":9413,"activeCount":101},[],{"intervention":9415,"totalTrials":233,"cells":9416},"Ceftriaxone + Metronidazole",{"EARLY_PHASE1":9417,"PHASE1":9419,"PHASE2":9421,"PHASE3":9423,"PHASE4":9433,"NA":9435},{"trials":9418,"activeCount":101},[],{"trials":9420,"activeCount":101},[],{"trials":9422,"activeCount":101},[],{"trials":9424,"activeCount":101},[9425],{"nctId":9426,"briefTitle":9427,"status":107,"phases":9428,"primaryCompletion":6269,"completion":1648,"start":4789,"enrollment":9429,"conditions":9430,"interventions":9432},"NCT00769171","Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections)",[92],364,[9431],"Infection, Intra-abdominal",[6720,9415],{"trials":9434,"activeCount":101},[],{"trials":9436,"activeCount":101},[],{"intervention":8029,"totalTrials":233,"cells":9438},{"EARLY_PHASE1":9439,"PHASE1":9441,"PHASE2":9443,"PHASE3":9445,"PHASE4":9451,"NA":9453},{"trials":9440,"activeCount":101},[],{"trials":9442,"activeCount":101},[],{"trials":9444,"activeCount":101},[],{"trials":9446,"activeCount":101},[9447],{"nctId":8023,"briefTitle":8024,"status":107,"phases":9448,"primaryCompletion":499,"completion":499,"start":3768,"enrollment":136,"conditions":9449,"interventions":9450},[92],[8027],[8029,8003],{"trials":9452,"activeCount":101},[],{"trials":9454,"activeCount":101},[],{"intervention":9456,"totalTrials":233,"cells":9457},"Oxybutynin",{"EARLY_PHASE1":9458,"PHASE1":9460,"PHASE2":9462,"PHASE3":9464,"PHASE4":9476,"NA":9478},{"trials":9459,"activeCount":101},[],{"trials":9461,"activeCount":101},[],{"trials":9463,"activeCount":101},[],{"trials":9465,"activeCount":101},[9466],{"nctId":9467,"briefTitle":9468,"status":107,"phases":9469,"primaryCompletion":9470,"completion":9470,"start":9471,"enrollment":9472,"conditions":9473,"interventions":9475},"NCT04534491","Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.",[92],"2011-06-22","2010-05-25",855,[9474],"Overactive Bladder",[9456],{"trials":9477,"activeCount":101},[],{"trials":9479,"activeCount":101},[],{"intervention":6227,"totalTrials":233,"cells":9481},{"EARLY_PHASE1":9482,"PHASE1":9484,"PHASE2":9486,"PHASE3":9488,"PHASE4":9494,"NA":9496},{"trials":9483,"activeCount":101},[],{"trials":9485,"activeCount":101},[],{"trials":9487,"activeCount":101},[],{"trials":9489,"activeCount":101},[9490],{"nctId":6221,"briefTitle":6222,"status":107,"phases":9491,"primaryCompletion":1569,"completion":2344,"start":3793,"enrollment":6224,"conditions":9492,"interventions":9493},[92],[5843],[6227,6228,6229,6230],{"trials":9495,"activeCount":101},[],{"trials":9497,"activeCount":101},[],{"intervention":6228,"totalTrials":233,"cells":9499},{"EARLY_PHASE1":9500,"PHASE1":9502,"PHASE2":9504,"PHASE3":9506,"PHASE4":9512,"NA":9514},{"trials":9501,"activeCount":101},[],{"trials":9503,"activeCount":101},[],{"trials":9505,"activeCount":101},[],{"trials":9507,"activeCount":101},[9508],{"nctId":6221,"briefTitle":6222,"status":107,"phases":9509,"primaryCompletion":1569,"completion":2344,"start":3793,"enrollment":6224,"conditions":9510,"interventions":9511},[92],[5843],[6227,6228,6229,6230],{"trials":9513,"activeCount":101},[],{"trials":9515,"activeCount":101},[],{"intervention":9517,"totalTrials":233,"cells":9518},"LNG-IUS",{"EARLY_PHASE1":9519,"PHASE1":9521,"PHASE2":9523,"PHASE3":9525,"PHASE4":9534,"NA":9536},{"trials":9520,"activeCount":101},[],{"trials":9522,"activeCount":101},[],{"trials":9524,"activeCount":101},[],{"trials":9526,"activeCount":101},[9527],{"nctId":9528,"briefTitle":9529,"status":107,"phases":9530,"primaryCompletion":2282,"completion":2290,"start":1351,"enrollment":7866,"conditions":9531,"interventions":9532},"NCT01397097","LCS12 vs. ENG Subdermal Implant (Nexplanon) Discontinuation Rate Study",[92],[15],[9517,9533],"68 mg etonorgestrel implant for subdermal use",{"trials":9535,"activeCount":101},[],{"trials":9537,"activeCount":101},[],{"intervention":9533,"totalTrials":233,"cells":9539},{"EARLY_PHASE1":9540,"PHASE1":9542,"PHASE2":9544,"PHASE3":9546,"PHASE4":9552,"NA":9554},{"trials":9541,"activeCount":101},[],{"trials":9543,"activeCount":101},[],{"trials":9545,"activeCount":101},[],{"trials":9547,"activeCount":101},[9548],{"nctId":9528,"briefTitle":9529,"status":107,"phases":9549,"primaryCompletion":2282,"completion":2290,"start":1351,"enrollment":7866,"conditions":9550,"interventions":9551},[92],[15],[9517,9533],{"trials":9553,"activeCount":101},[],{"trials":9555,"activeCount":101},[],{"intervention":8881,"totalTrials":233,"cells":9557},{"EARLY_PHASE1":9558,"PHASE1":9560,"PHASE2":9562,"PHASE3":9564,"PHASE4":9570,"NA":9572},{"trials":9559,"activeCount":101},[],{"trials":9561,"activeCount":101},[],{"trials":9563,"activeCount":101},[],{"trials":9565,"activeCount":101},[9566],{"nctId":8875,"briefTitle":8876,"status":107,"phases":9567,"primaryCompletion":1570,"completion":1570,"start":4700,"enrollment":8878,"conditions":9568,"interventions":9569},[92],[8027],[8864,8881],{"trials":9571,"activeCount":101},[],{"trials":9573,"activeCount":101},[],{"intervention":9575,"totalTrials":233,"cells":9576},"Skyla",{"EARLY_PHASE1":9577,"PHASE1":9579,"PHASE2":9581,"PHASE3":9583,"PHASE4":9591,"NA":9593},{"trials":9578,"activeCount":101},[],{"trials":9580,"activeCount":101},[],{"trials":9582,"activeCount":101},[],{"trials":9584,"activeCount":101},[9585],{"nctId":9586,"briefTitle":9587,"status":107,"phases":9588,"primaryCompletion":2282,"completion":4067,"start":1351,"enrollment":2920,"conditions":9589,"interventions":9590},"NCT01434160","LCS12 Adolescent Study",[92],[15],[9575],{"trials":9592,"activeCount":101},[],{"trials":9594,"activeCount":101},[],{"intervention":8471,"totalTrials":233,"cells":9596},{"EARLY_PHASE1":9597,"PHASE1":9599,"PHASE2":9601,"PHASE3":9603,"PHASE4":9609,"NA":9611},{"trials":9598,"activeCount":101},[],{"trials":9600,"activeCount":101},[],{"trials":9602,"activeCount":101},[],{"trials":9604,"activeCount":101},[9605],{"nctId":8461,"briefTitle":8462,"status":156,"phases":9606,"primaryCompletion":8464,"completion":8465,"start":8466,"enrollment":8467,"conditions":9607,"interventions":9608},[92],[8469],[7973,8439,8471,8472,2177,8473,493],{"trials":9610,"activeCount":101},[],{"trials":9612,"activeCount":101},[],{"intervention":8472,"totalTrials":233,"cells":9614},{"EARLY_PHASE1":9615,"PHASE1":9617,"PHASE2":9619,"PHASE3":9621,"PHASE4":9627,"NA":9629},{"trials":9616,"activeCount":101},[],{"trials":9618,"activeCount":101},[],{"trials":9620,"activeCount":101},[],{"trials":9622,"activeCount":101},[9623],{"nctId":8461,"briefTitle":8462,"status":156,"phases":9624,"primaryCompletion":8464,"completion":8465,"start":8466,"enrollment":8467,"conditions":9625,"interventions":9626},[92],[8469],[7973,8439,8471,8472,2177,8473,493],{"trials":9628,"activeCount":101},[],{"trials":9630,"activeCount":101},[],{"intervention":8473,"totalTrials":233,"cells":9632},{"EARLY_PHASE1":9633,"PHASE1":9635,"PHASE2":9637,"PHASE3":9639,"PHASE4":9645,"NA":9647},{"trials":9634,"activeCount":101},[],{"trials":9636,"activeCount":101},[],{"trials":9638,"activeCount":101},[],{"trials":9640,"activeCount":101},[9641],{"nctId":8461,"briefTitle":8462,"status":156,"phases":9642,"primaryCompletion":8464,"completion":8465,"start":8466,"enrollment":8467,"conditions":9643,"interventions":9644},[92],[8469],[7973,8439,8471,8472,2177,8473,493],{"trials":9646,"activeCount":101},[],{"trials":9648,"activeCount":101},[],{"intervention":9650,"totalTrials":233,"cells":9651},"Non-quinolone antibiotic",{"EARLY_PHASE1":9652,"PHASE1":9654,"PHASE2":9656,"PHASE3":9658,"PHASE4":9670,"NA":9672},{"trials":9653,"activeCount":101},[],{"trials":9655,"activeCount":101},[],{"trials":9657,"activeCount":101},[],{"trials":9659,"activeCount":101},[9660],{"nctId":9661,"briefTitle":9662,"status":107,"phases":9663,"primaryCompletion":3818,"completion":3818,"start":9664,"enrollment":9665,"conditions":9666,"interventions":9668},"NCT00761462","BAY 0 9867 Cipro Pediatric Use Study (QUIP)",[92],"1999-10",1029,[9667],"Infectious Diseases",[9669,9650],"Ciprofloxacin",{"trials":9671,"activeCount":101},[],{"trials":9673,"activeCount":101},[],{"intervention":9675,"totalTrials":233,"cells":9676},"Clotrimazole, vaginal ovule",{"EARLY_PHASE1":9677,"PHASE1":9679,"PHASE2":9681,"PHASE3":9683,"PHASE4":9696,"NA":9698},{"trials":9678,"activeCount":101},[],{"trials":9680,"activeCount":101},[],{"trials":9682,"activeCount":101},[],{"trials":9684,"activeCount":101},[9685],{"nctId":9686,"briefTitle":9687,"status":107,"phases":9688,"primaryCompletion":3619,"completion":3619,"start":7249,"enrollment":9689,"conditions":9690,"interventions":9694},"NCT00755053","Comparative Efficacy of Ovule vs Tablet",[92],466,[9691,9692,9693],"Clotrimazole","Ovulen","Vulvovaginal Candidiasis",[9675,9695],"Clotrimazole, vaginal",{"trials":9697,"activeCount":101},[],{"trials":9699,"activeCount":101},[],{"intervention":9695,"totalTrials":233,"cells":9701},{"EARLY_PHASE1":9702,"PHASE1":9704,"PHASE2":9706,"PHASE3":9708,"PHASE4":9714,"NA":9716},{"trials":9703,"activeCount":101},[],{"trials":9705,"activeCount":101},[],{"trials":9707,"activeCount":101},[],{"trials":9709,"activeCount":101},[9710],{"nctId":9686,"briefTitle":9687,"status":107,"phases":9711,"primaryCompletion":3619,"completion":3619,"start":7249,"enrollment":9689,"conditions":9712,"interventions":9713},[92],[9691,9692,9693],[9675,9695],{"trials":9715,"activeCount":101},[],{"trials":9717,"activeCount":101},[],{"intervention":566,"totalTrials":233,"cells":9719},{"EARLY_PHASE1":9720,"PHASE1":9722,"PHASE2":9724,"PHASE3":9726,"PHASE4":9732,"NA":9734},{"trials":9721,"activeCount":101},[],{"trials":9723,"activeCount":101},[],{"trials":9725,"activeCount":101},[],{"trials":9727,"activeCount":101},[9728],{"nctId":557,"briefTitle":558,"status":107,"phases":9729,"primaryCompletion":560,"completion":561,"start":562,"enrollment":563,"conditions":9730,"interventions":9731},[92],[437,438],[72,566],{"trials":9733,"activeCount":101},[],{"trials":9735,"activeCount":101},[],{"intervention":9737,"totalTrials":233,"cells":9738},"Levofloxacin + Ceftriaxone",{"EARLY_PHASE1":9739,"PHASE1":9741,"PHASE2":9743,"PHASE3":9745,"PHASE4":9754,"NA":9756},{"trials":9740,"activeCount":101},[],{"trials":9742,"activeCount":101},[],{"trials":9744,"activeCount":101},[],{"trials":9746,"activeCount":101},[9747],{"nctId":9748,"briefTitle":9749,"status":107,"phases":9750,"primaryCompletion":3627,"completion":3627,"start":3668,"enrollment":9751,"conditions":9752,"interventions":9753},"NCT00431678","Efficacy and Safety of Sequential IV\u002FPO Moxifloxacin in Comparison to IV Levofloxacin Plus IV Ceftriaxone Followed by PO Levofloxacin, in the Treatment of Patients With Community-acquired Pneumonia",[92],738,[6718],[6720,9737],{"trials":9755,"activeCount":101},[],{"trials":9757,"activeCount":101},[],{"intervention":9759,"totalTrials":233,"cells":9760},"Amoxicilline\u002Fclavulanic",{"EARLY_PHASE1":9761,"PHASE1":9763,"PHASE2":9765,"PHASE3":9767,"PHASE4":9775,"NA":9777},{"trials":9762,"activeCount":101},[],{"trials":9764,"activeCount":101},[],{"trials":9766,"activeCount":101},[],{"trials":9768,"activeCount":101},[9769],{"nctId":9770,"briefTitle":9771,"status":107,"phases":9772,"primaryCompletion":3576,"completion":2256,"start":3567,"enrollment":1081,"conditions":9773,"interventions":9774},"NCT00828971","A Study to Assess Efficacy and Safety of IV\u002FPO Moxifloxacin in the Treatment of cSSSIs",[92],[9667],[6720,9759],{"trials":9776,"activeCount":101},[],{"trials":9778,"activeCount":101},[],{"intervention":9780,"totalTrials":233,"cells":9781},"Sorafenib + Paclitaxel + Carboplatin",{"EARLY_PHASE1":9782,"PHASE1":9784,"PHASE2":9786,"PHASE3":9788,"PHASE4":9797,"NA":9799},{"trials":9783,"activeCount":101},[],{"trials":9785,"activeCount":101},[],{"trials":9787,"activeCount":101},[],{"trials":9789,"activeCount":101},[9790],{"nctId":9791,"briefTitle":9792,"status":156,"phases":9793,"primaryCompletion":4597,"completion":4597,"start":9794,"enrollment":8160,"conditions":9795,"interventions":9796},"NCT00558636","A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)",[92],"2007-09",[423],[9780],{"trials":9798,"activeCount":101},[],{"trials":9800,"activeCount":101},[],{"intervention":2924,"totalTrials":233,"cells":9802},{"EARLY_PHASE1":9803,"PHASE1":9805,"PHASE2":9807,"PHASE3":9809,"PHASE4":9815,"NA":9817},{"trials":9804,"activeCount":101},[],{"trials":9806,"activeCount":101},[],{"trials":9808,"activeCount":101},[],{"trials":9810,"activeCount":101},[9811],{"nctId":2914,"briefTitle":2915,"status":107,"phases":9812,"primaryCompletion":2917,"completion":2918,"start":2919,"enrollment":2920,"conditions":9813,"interventions":9814},[92],[2922],[82,2924],{"trials":9816,"activeCount":101},[],{"trials":9818,"activeCount":101},[],{"intervention":9820,"totalTrials":233,"cells":9821},"Ceftriaxone; Azithromycin; Amoxicilline\u002Fclavulanate; Clarithromycin",{"EARLY_PHASE1":9822,"PHASE1":9824,"PHASE2":9826,"PHASE3":9828,"PHASE4":9836,"NA":9838},{"trials":9823,"activeCount":101},[],{"trials":9825,"activeCount":101},[],{"trials":9827,"activeCount":101},[],{"trials":9829,"activeCount":101},[9830],{"nctId":9831,"briefTitle":9832,"status":107,"phases":9833,"primaryCompletion":3619,"completion":4736,"start":4691,"enrollment":2151,"conditions":9834,"interventions":9835},"NCT00717561","A Study to Assess the Efficacy and Safety of IV\u002FPO Moxifloxacin in Subjects With Community-acquired Pneumonia",[92],[6718],[6720,9820],{"trials":9837,"activeCount":101},[],{"trials":9839,"activeCount":101},[],{"intervention":9841,"totalTrials":233,"cells":9842},"LCS12",{"EARLY_PHASE1":9843,"PHASE1":9845,"PHASE2":9847,"PHASE3":9849,"PHASE4":9859,"NA":9861},{"trials":9844,"activeCount":101},[],{"trials":9846,"activeCount":101},[],{"trials":9848,"activeCount":101},[],{"trials":9850,"activeCount":101},[9851],{"nctId":9852,"briefTitle":9853,"status":107,"phases":9854,"primaryCompletion":2366,"completion":2282,"start":9022,"enrollment":9855,"conditions":9856,"interventions":9857},"NCT00528112","Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study",[92],2885,[15],[9841,9858],"LCS16",{"trials":9860,"activeCount":101},[],{"trials":9862,"activeCount":101},[],{"intervention":9858,"totalTrials":233,"cells":9864},{"EARLY_PHASE1":9865,"PHASE1":9867,"PHASE2":9869,"PHASE3":9871,"PHASE4":9877,"NA":9879},{"trials":9866,"activeCount":101},[],{"trials":9868,"activeCount":101},[],{"trials":9870,"activeCount":101},[],{"trials":9872,"activeCount":101},[9873],{"nctId":9852,"briefTitle":9853,"status":107,"phases":9874,"primaryCompletion":2366,"completion":2282,"start":9022,"enrollment":9855,"conditions":9875,"interventions":9876},[92],[15],[9841,9858],{"trials":9878,"activeCount":101},[],{"trials":9880,"activeCount":101},[],{"intervention":9882,"totalTrials":233,"cells":9883},"Adalat XL",{"EARLY_PHASE1":9884,"PHASE1":9886,"PHASE2":9888,"PHASE3":9890,"PHASE4":9899,"NA":9901},{"trials":9885,"activeCount":101},[],{"trials":9887,"activeCount":101},[],{"trials":9889,"activeCount":101},[],{"trials":9891,"activeCount":101},[9892],{"nctId":9893,"briefTitle":9894,"status":464,"phases":9895,"primaryCompletion":1313,"completion":1313,"start":3567,"enrollment":101,"conditions":9896,"interventions":9897},"NCT00713011","Adalat XL vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients",[92],[760,6625],[9882,9898],"Tiazac XC",{"trials":9900,"activeCount":101},[],{"trials":9902,"activeCount":101},[],{"intervention":9898,"totalTrials":233,"cells":9904},{"EARLY_PHASE1":9905,"PHASE1":9907,"PHASE2":9909,"PHASE3":9911,"PHASE4":9917,"NA":9919},{"trials":9906,"activeCount":101},[],{"trials":9908,"activeCount":101},[],{"trials":9910,"activeCount":101},[],{"trials":9912,"activeCount":101},[9913],{"nctId":9893,"briefTitle":9894,"status":464,"phases":9914,"primaryCompletion":1313,"completion":1313,"start":3567,"enrollment":101,"conditions":9915,"interventions":9916},[92],[760,6625],[9882,9898],{"trials":9918,"activeCount":101},[],{"trials":9920,"activeCount":101},[],{"intervention":9922,"totalTrials":233,"cells":9923},"Testosterone undecanoate (TU) - NebidoTM",{"EARLY_PHASE1":9924,"PHASE1":9926,"PHASE2":9928,"PHASE3":9930,"PHASE4":9938,"NA":9940},{"trials":9925,"activeCount":101},[],{"trials":9927,"activeCount":101},[],{"trials":9929,"activeCount":101},[],{"trials":9931,"activeCount":101},[9932],{"nctId":9933,"briefTitle":9934,"status":107,"phases":9935,"primaryCompletion":6493,"completion":6493,"start":8559,"enrollment":3568,"conditions":9936,"interventions":9937},"NCT00220298","Assessment of Long Term Treatment With Testosterone Undecanoate in Males With Hypogonadism",[92],[7085],[9922],{"trials":9939,"activeCount":101},[],{"trials":9941,"activeCount":101},[],{"intervention":9943,"totalTrials":233,"cells":9944},"Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo",{"EARLY_PHASE1":9945,"PHASE1":9947,"PHASE2":9949,"PHASE3":9951,"PHASE4":9963,"NA":9965},{"trials":9946,"activeCount":101},[],{"trials":9948,"activeCount":101},[],{"trials":9950,"activeCount":101},[],{"trials":9952,"activeCount":101},[9953],{"nctId":9954,"briefTitle":9955,"status":107,"phases":9956,"primaryCompletion":9957,"completion":9958,"start":9959,"enrollment":2960,"conditions":9960,"interventions":9961},"NCT01453400","Evaluate the Time of Pain Relief of Fast Acting Aspirin Versus Acetaminophen in Subjects Diagnosed With Sore Throat Pain",[92],"2012-04-05","2012-04-06","2011-09-27",[6574],[9943,9962],"Acetaminophen + placebo",{"trials":9964,"activeCount":101},[],{"trials":9966,"activeCount":101},[],{"intervention":9962,"totalTrials":233,"cells":9968},{"EARLY_PHASE1":9969,"PHASE1":9971,"PHASE2":9973,"PHASE3":9975,"PHASE4":9981,"NA":9983},{"trials":9970,"activeCount":101},[],{"trials":9972,"activeCount":101},[],{"trials":9974,"activeCount":101},[],{"trials":9976,"activeCount":101},[9977],{"nctId":9954,"briefTitle":9955,"status":107,"phases":9978,"primaryCompletion":9957,"completion":9958,"start":9959,"enrollment":2960,"conditions":9979,"interventions":9980},[92],[6574],[9943,9962],{"trials":9982,"activeCount":101},[],{"trials":9984,"activeCount":101},[],{"intervention":9986,"totalTrials":233,"cells":9987},"Ciprofloxacin DPI",{"EARLY_PHASE1":9988,"PHASE1":9990,"PHASE2":9992,"PHASE3":9994,"PHASE4":10006,"NA":10008},{"trials":9989,"activeCount":101},[],{"trials":9991,"activeCount":101},[],{"trials":9993,"activeCount":101},[],{"trials":9995,"activeCount":101},[9996],{"nctId":9997,"briefTitle":9998,"status":107,"phases":9999,"primaryCompletion":10000,"completion":10000,"start":10001,"enrollment":10002,"conditions":10003,"interventions":10005},"NCT01764841","Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)",[92],"2016-03-09","2013-05-02",416,[10004],"Bronchiectasis",[9986],{"trials":10007,"activeCount":101},[],{"trials":10009,"activeCount":101},[],{"intervention":10011,"totalTrials":233,"cells":10012},"EE20\u002FDrospirenone",{"EARLY_PHASE1":10013,"PHASE1":10015,"PHASE2":10017,"PHASE3":10019,"PHASE4":10028,"NA":10030},{"trials":10014,"activeCount":101},[],{"trials":10016,"activeCount":101},[],{"trials":10018,"activeCount":101},[],{"trials":10020,"activeCount":101},[10021],{"nctId":10022,"briefTitle":10023,"status":107,"phases":10024,"primaryCompletion":8136,"completion":8136,"start":498,"enrollment":10025,"conditions":10026,"interventions":10027},"NCT00818519","GA YAZ ACNE in China Phase III",[92],179,[8050],[10011],{"trials":10029,"activeCount":101},[],{"trials":10031,"activeCount":101},[],{"intervention":9087,"totalTrials":233,"cells":10033},{"EARLY_PHASE1":10034,"PHASE1":10036,"PHASE2":10038,"PHASE3":10040,"PHASE4":10046,"NA":10048},{"trials":10035,"activeCount":101},[],{"trials":10037,"activeCount":101},[],{"trials":10039,"activeCount":101},[],{"trials":10041,"activeCount":101},[10042],{"nctId":9082,"briefTitle":9083,"status":107,"phases":10043,"primaryCompletion":3809,"completion":3809,"start":3576,"enrollment":112,"conditions":10044,"interventions":10045},[92],[8592],[9071,9087],{"trials":10047,"activeCount":101},[],{"trials":10049,"activeCount":101},[],{"intervention":10051,"totalTrials":233,"cells":10052},"Phenylephrine Hydrochloride (HCl) Extended-Release tablets 30 mg",{"EARLY_PHASE1":10053,"PHASE1":10055,"PHASE2":10057,"PHASE3":10059,"PHASE4":10069,"NA":10071},{"trials":10054,"activeCount":101},[],{"trials":10056,"activeCount":101},[],{"trials":10058,"activeCount":101},[],{"trials":10060,"activeCount":101},[10061],{"nctId":10062,"briefTitle":10063,"status":107,"phases":10064,"primaryCompletion":4292,"completion":4292,"start":498,"enrollment":10065,"conditions":10066,"interventions":10068},"NCT00874120","Safety Study Comparing Phenylephrine HCL Extended Release Tablets 30 mg and Placebo (Study CL2007-07)(P07529)(COMPLETED)",[92],116,[10067,8592],"Blood Pressure",[10051],{"trials":10070,"activeCount":101},[],{"trials":10072,"activeCount":101},[],{"intervention":10074,"totalTrials":233,"cells":10075},"Flexible",{"EARLY_PHASE1":10076,"PHASE1":10078,"PHASE2":10080,"PHASE3":10082,"PHASE4":10093,"NA":10095},{"trials":10077,"activeCount":101},[],{"trials":10079,"activeCount":101},[],{"trials":10081,"activeCount":101},[],{"trials":10083,"activeCount":101},[10084],{"nctId":10085,"briefTitle":10086,"status":107,"phases":10087,"primaryCompletion":1498,"completion":1498,"start":4571,"enrollment":10088,"conditions":10089,"interventions":10090},"NCT00266032","Study on Safety and Efficacy of an Oral Contraceptive in Long Cycles",[92],1166,[15],[10074,10091,10092],"Fixed extended treatment of EE20\u002FDRSP","Standard 24+4 treatment of EE20\u002FDRSP",{"trials":10094,"activeCount":101},[],{"trials":10096,"activeCount":101},[],{"intervention":10091,"totalTrials":233,"cells":10098},{"EARLY_PHASE1":10099,"PHASE1":10101,"PHASE2":10103,"PHASE3":10105,"PHASE4":10111,"NA":10113},{"trials":10100,"activeCount":101},[],{"trials":10102,"activeCount":101},[],{"trials":10104,"activeCount":101},[],{"trials":10106,"activeCount":101},[10107],{"nctId":10085,"briefTitle":10086,"status":107,"phases":10108,"primaryCompletion":1498,"completion":1498,"start":4571,"enrollment":10088,"conditions":10109,"interventions":10110},[92],[15],[10074,10091,10092],{"trials":10112,"activeCount":101},[],{"trials":10114,"activeCount":101},[],{"intervention":10092,"totalTrials":233,"cells":10116},{"EARLY_PHASE1":10117,"PHASE1":10119,"PHASE2":10121,"PHASE3":10123,"PHASE4":10129,"NA":10131},{"trials":10118,"activeCount":101},[],{"trials":10120,"activeCount":101},[],{"trials":10122,"activeCount":101},[],{"trials":10124,"activeCount":101},[10125],{"nctId":10085,"briefTitle":10086,"status":107,"phases":10126,"primaryCompletion":1498,"completion":1498,"start":4571,"enrollment":10088,"conditions":10127,"interventions":10128},[92],[15],[10074,10091,10092],{"trials":10130,"activeCount":101},[],{"trials":10132,"activeCount":101},[],{"intervention":6349,"totalTrials":233,"cells":10134},{"EARLY_PHASE1":10135,"PHASE1":10137,"PHASE2":10139,"PHASE3":10141,"PHASE4":10147,"NA":10149},{"trials":10136,"activeCount":101},[],{"trials":10138,"activeCount":101},[],{"trials":10140,"activeCount":101},[],{"trials":10142,"activeCount":101},[10143],{"nctId":6343,"briefTitle":6344,"status":107,"phases":10144,"completion":3723,"start":446,"enrollment":874,"conditions":10145,"interventions":10146},[92],[6347],[6332,6349],{"trials":10148,"activeCount":101},[],{"trials":10150,"activeCount":101},[],{"intervention":10152,"totalTrials":233,"cells":10153},"Tedizolid Phosphate",{"EARLY_PHASE1":10154,"PHASE1":10156,"PHASE2":10158,"PHASE3":10160,"PHASE4":10172,"NA":10174},{"trials":10155,"activeCount":101},[],{"trials":10157,"activeCount":101},[],{"trials":10159,"activeCount":101},[],{"trials":10161,"activeCount":101},[10162],{"nctId":10163,"briefTitle":10164,"status":107,"phases":10165,"primaryCompletion":10166,"completion":10166,"start":10167,"enrollment":1744,"conditions":10168,"interventions":10170},"NCT01967225","Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections",[92],"2016-10-28","2013-11-23",[10169],"Skin Diseases, Infectious",[10152,10171],"Linezolid",{"trials":10173,"activeCount":101},[],{"trials":10175,"activeCount":101},[],{"intervention":6389,"totalTrials":233,"cells":10177},{"EARLY_PHASE1":10178,"PHASE1":10180,"PHASE2":10182,"PHASE3":10184,"PHASE4":10190,"NA":10192},{"trials":10179,"activeCount":101},[],{"trials":10181,"activeCount":101},[],{"trials":10183,"activeCount":101},[],{"trials":10185,"activeCount":101},[10186],{"nctId":6381,"briefTitle":6382,"status":107,"phases":10187,"completion":4675,"start":6384,"enrollment":6385,"conditions":10188,"interventions":10189},[92],[6387],[6370,6389],{"trials":10191,"activeCount":101},[],{"trials":10193,"activeCount":101},[],{"intervention":10195,"totalTrials":233,"cells":10196},"Butenafine HCl 1% (BAY1896425) - Induction Phase",{"EARLY_PHASE1":10197,"PHASE1":10199,"PHASE2":10201,"PHASE3":10203,"PHASE4":10213,"NA":10215},{"trials":10198,"activeCount":101},[],{"trials":10200,"activeCount":101},[],{"trials":10202,"activeCount":101},[],{"trials":10204,"activeCount":101},[10205],{"nctId":10206,"briefTitle":10207,"status":107,"phases":10208,"primaryCompletion":2221,"completion":2221,"start":8513,"enrollment":4693,"conditions":10209,"interventions":10211},"NCT04532164","Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy Participants",[92],[10210],"Dermatitis, Photoallergic",[10195,10212],"Butenafine HCl 1% (BAY1896425) - Challenge Phase",{"trials":10214,"activeCount":101},[],{"trials":10216,"activeCount":101},[],{"intervention":10212,"totalTrials":233,"cells":10218},{"EARLY_PHASE1":10219,"PHASE1":10221,"PHASE2":10223,"PHASE3":10225,"PHASE4":10231,"NA":10233},{"trials":10220,"activeCount":101},[],{"trials":10222,"activeCount":101},[],{"trials":10224,"activeCount":101},[],{"trials":10226,"activeCount":101},[10227],{"nctId":10206,"briefTitle":10207,"status":107,"phases":10228,"primaryCompletion":2221,"completion":2221,"start":8513,"enrollment":4693,"conditions":10229,"interventions":10230},[92],[10210],[10195,10212],{"trials":10232,"activeCount":101},[],{"trials":10234,"activeCount":101},[],{"intervention":10236,"totalTrials":233,"cells":10237},"Ofloxacin",{"EARLY_PHASE1":10238,"PHASE1":10240,"PHASE2":10242,"PHASE3":10244,"PHASE4":10256,"NA":10258},{"trials":10239,"activeCount":101},[],{"trials":10241,"activeCount":101},[],{"trials":10243,"activeCount":101},[],{"trials":10245,"activeCount":101},[10246],{"nctId":10247,"briefTitle":10248,"status":107,"phases":10249,"primaryCompletion":10250,"completion":10250,"start":10251,"enrollment":10252,"conditions":10253,"interventions":10255},"NCT00683865","Uncomplicated Pelvic Inflammatory Disease. Treatment With Moxifloxacin.",[92],"2004-10","2003-04",749,[10254],"Pelvic Inflammatory Disease",[10236,6720],{"trials":10257,"activeCount":101},[],{"trials":10259,"activeCount":101},[],{"intervention":10261,"totalTrials":233,"cells":10262},"Gadoxetate disodium",{"EARLY_PHASE1":10263,"PHASE1":10265,"PHASE2":10267,"PHASE3":10269,"PHASE4":10277,"NA":10279},{"trials":10264,"activeCount":101},[],{"trials":10266,"activeCount":101},[],{"trials":10268,"activeCount":101},[],{"trials":10270,"activeCount":101},[10271],{"nctId":10272,"briefTitle":10273,"status":156,"phases":10274,"primaryCompletion":4880,"completion":4880,"start":3594,"enrollment":233,"conditions":10275,"interventions":10276},"NCT02084628","Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist\u002FPrimovist Which is a Contrast Agent",[92],[6978],[10261],{"trials":10278,"activeCount":101},[],{"trials":10280,"activeCount":101},[],{"intervention":10282,"totalTrials":233,"cells":10283},"Vasovist",{"EARLY_PHASE1":10284,"PHASE1":10286,"PHASE2":10288,"PHASE3":10290,"PHASE4":10300,"NA":10302},{"trials":10285,"activeCount":101},[],{"trials":10287,"activeCount":101},[],{"trials":10289,"activeCount":101},[],{"trials":10291,"activeCount":101},[10292],{"nctId":10293,"briefTitle":10294,"status":107,"phases":10295,"completion":1328,"start":3724,"enrollment":10296,"conditions":10297,"interventions":10299},"NCT00296855","Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery Disease",[92],261,[10298],"Peripheral Vascular Diseases",[10282],{"trials":10301,"activeCount":101},[],{"trials":10303,"activeCount":101},[],{"intervention":8088,"totalTrials":233,"cells":10305},{"EARLY_PHASE1":10306,"PHASE1":10308,"PHASE2":10310,"PHASE3":10312,"PHASE4":10318,"NA":10320},{"trials":10307,"activeCount":101},[],{"trials":10309,"activeCount":101},[],{"trials":10311,"activeCount":101},[],{"trials":10313,"activeCount":101},[10314],{"nctId":8083,"briefTitle":8084,"status":107,"phases":10315,"primaryCompletion":1351,"completion":1351,"start":1327,"enrollment":977,"conditions":10316,"interventions":10317},[92],[5843],[8064,8088,8089,8090],{"trials":10319,"activeCount":101},[],{"trials":10321,"activeCount":101},[],{"intervention":8089,"totalTrials":233,"cells":10323},{"EARLY_PHASE1":10324,"PHASE1":10326,"PHASE2":10328,"PHASE3":10330,"PHASE4":10336,"NA":10338},{"trials":10325,"activeCount":101},[],{"trials":10327,"activeCount":101},[],{"trials":10329,"activeCount":101},[],{"trials":10331,"activeCount":101},[10332],{"nctId":8083,"briefTitle":8084,"status":107,"phases":10333,"primaryCompletion":1351,"completion":1351,"start":1327,"enrollment":977,"conditions":10334,"interventions":10335},[92],[5843],[8064,8088,8089,8090],{"trials":10337,"activeCount":101},[],{"trials":10339,"activeCount":101},[],{"intervention":8090,"totalTrials":233,"cells":10341},{"EARLY_PHASE1":10342,"PHASE1":10344,"PHASE2":10346,"PHASE3":10348,"PHASE4":10354,"NA":10356},{"trials":10343,"activeCount":101},[],{"trials":10345,"activeCount":101},[],{"trials":10347,"activeCount":101},[],{"trials":10349,"activeCount":101},[10350],{"nctId":8083,"briefTitle":8084,"status":107,"phases":10351,"primaryCompletion":1351,"completion":1351,"start":1327,"enrollment":977,"conditions":10352,"interventions":10353},[92],[5843],[8064,8088,8089,8090],{"trials":10355,"activeCount":101},[],{"trials":10357,"activeCount":101},[],{"intervention":9095,"totalTrials":233,"cells":10359},{"EARLY_PHASE1":10360,"PHASE1":10362,"PHASE2":10364,"PHASE3":10366,"PHASE4":10372,"NA":10374},{"trials":10361,"activeCount":101},[],{"trials":10363,"activeCount":101},[],{"trials":10365,"activeCount":101},[],{"trials":10367,"activeCount":101},[10368],{"nctId":9089,"briefTitle":9090,"status":107,"phases":10369,"primaryCompletion":1313,"completion":1313,"start":498,"enrollment":160,"conditions":10370,"interventions":10371},[92],[9093],[9071,9095],{"trials":10373,"activeCount":101},[],{"trials":10375,"activeCount":101},[],{"intervention":9149,"totalTrials":233,"cells":10377},{"EARLY_PHASE1":10378,"PHASE1":10380,"PHASE2":10382,"PHASE3":10384,"PHASE4":10390,"NA":10392},{"trials":10379,"activeCount":101},[],{"trials":10381,"activeCount":101},[],{"trials":10383,"activeCount":101},[],{"trials":10385,"activeCount":101},[10386],{"nctId":9141,"briefTitle":9142,"status":107,"phases":10387,"primaryCompletion":9144,"completion":9144,"start":9145,"enrollment":9146,"conditions":10388,"interventions":10389},[92],[6573,6574],[9149,3761,9130],{"trials":10391,"activeCount":101},[],{"trials":10393,"activeCount":101},[],{"intervention":10395,"totalTrials":233,"cells":10396},"Gestodene\u002FEE",{"EARLY_PHASE1":10397,"PHASE1":10399,"PHASE2":10401,"PHASE3":10403,"PHASE4":10412,"NA":10414},{"trials":10398,"activeCount":101},[],{"trials":10400,"activeCount":101},[],{"trials":10402,"activeCount":101},[],{"trials":10404,"activeCount":101},[10405],{"nctId":10406,"briefTitle":10407,"status":107,"phases":10408,"primaryCompletion":1587,"completion":2968,"start":4736,"enrollment":5197,"conditions":10409,"interventions":10410},"NCT00920985","US Cycle Control and Blood Pressure Study",[92],[15],[10395,10411],"Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A",{"trials":10413,"activeCount":101},[],{"trials":10415,"activeCount":101},[],{"intervention":10411,"totalTrials":233,"cells":10417},{"EARLY_PHASE1":10418,"PHASE1":10420,"PHASE2":10422,"PHASE3":10424,"PHASE4":10430,"NA":10432},{"trials":10419,"activeCount":101},[],{"trials":10421,"activeCount":101},[],{"trials":10423,"activeCount":101},[],{"trials":10425,"activeCount":101},[10426],{"nctId":10406,"briefTitle":10407,"status":107,"phases":10427,"primaryCompletion":1587,"completion":2968,"start":4736,"enrollment":5197,"conditions":10428,"interventions":10429},[92],[15],[10395,10411],{"trials":10431,"activeCount":101},[],{"trials":10433,"activeCount":101},[],{"intervention":4811,"totalTrials":233,"cells":10435},{"EARLY_PHASE1":10436,"PHASE1":10438,"PHASE2":10440,"PHASE3":10442,"PHASE4":10448,"NA":10450},{"trials":10437,"activeCount":101},[],{"trials":10439,"activeCount":101},[],{"trials":10441,"activeCount":101},[],{"trials":10443,"activeCount":101},[10444],{"nctId":4802,"briefTitle":4803,"status":107,"phases":10445,"primaryCompletion":4805,"completion":4806,"start":4807,"enrollment":4808,"conditions":10446,"interventions":10447},[92],[4677],[42,4811],{"trials":10449,"activeCount":101},[],{"trials":10451,"activeCount":101},[],{"intervention":9179,"totalTrials":233,"cells":10453},{"EARLY_PHASE1":10454,"PHASE1":10456,"PHASE2":10458,"PHASE3":10460,"PHASE4":10466,"NA":10468},{"trials":10455,"activeCount":101},[],{"trials":10457,"activeCount":101},[],{"trials":10459,"activeCount":101},[],{"trials":10461,"activeCount":101},[10462],{"nctId":9173,"briefTitle":9174,"status":107,"phases":10463,"primaryCompletion":1314,"completion":1314,"start":9022,"enrollment":9176,"conditions":10464,"interventions":10465},[92],[6505],[9162,9179],{"trials":10467,"activeCount":101},[],{"trials":10469,"activeCount":101},[],{"intervention":2945,"totalTrials":233,"cells":10471},{"EARLY_PHASE1":10472,"PHASE1":10474,"PHASE2":10476,"PHASE3":10478,"PHASE4":10484,"NA":10486},{"trials":10473,"activeCount":101},[],{"trials":10475,"activeCount":101},[],{"trials":10477,"activeCount":101},[],{"trials":10479,"activeCount":101},[10480],{"nctId":2936,"briefTitle":2937,"status":107,"phases":10481,"primaryCompletion":2939,"completion":2940,"start":2941,"enrollment":1081,"conditions":10482,"interventions":10483},[92],[2943],[82,2945],{"trials":10485,"activeCount":101},[],{"trials":10487,"activeCount":101},[],{"intervention":10489,"totalTrials":233,"cells":10490},"rFVIII (BAY81-8973) on demand",{"EARLY_PHASE1":10491,"PHASE1":10493,"PHASE2":10495,"PHASE3":10497,"PHASE4":10507,"NA":10509},{"trials":10492,"activeCount":101},[],{"trials":10494,"activeCount":101},[],{"trials":10496,"activeCount":101},[],{"trials":10498,"activeCount":101},[10499],{"nctId":10500,"briefTitle":10501,"status":107,"phases":10502,"primaryCompletion":4657,"completion":4657,"start":1569,"enrollment":7250,"conditions":10503,"interventions":10504},"NCT01233258","A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A",[92],[24],[10489,10505,10506],"rFVIII (BAY81-8973) prophylaxis low-dose","rFVIII (BAY81-8973) prophylaxis high-dose",{"trials":10508,"activeCount":101},[],{"trials":10510,"activeCount":101},[],{"intervention":10505,"totalTrials":233,"cells":10512},{"EARLY_PHASE1":10513,"PHASE1":10515,"PHASE2":10517,"PHASE3":10519,"PHASE4":10525,"NA":10527},{"trials":10514,"activeCount":101},[],{"trials":10516,"activeCount":101},[],{"trials":10518,"activeCount":101},[],{"trials":10520,"activeCount":101},[10521],{"nctId":10500,"briefTitle":10501,"status":107,"phases":10522,"primaryCompletion":4657,"completion":4657,"start":1569,"enrollment":7250,"conditions":10523,"interventions":10524},[92],[24],[10489,10505,10506],{"trials":10526,"activeCount":101},[],{"trials":10528,"activeCount":101},[],{"intervention":10506,"totalTrials":233,"cells":10530},{"EARLY_PHASE1":10531,"PHASE1":10533,"PHASE2":10535,"PHASE3":10537,"PHASE4":10543,"NA":10545},{"trials":10532,"activeCount":101},[],{"trials":10534,"activeCount":101},[],{"trials":10536,"activeCount":101},[],{"trials":10538,"activeCount":101},[10539],{"nctId":10500,"briefTitle":10501,"status":107,"phases":10540,"primaryCompletion":4657,"completion":4657,"start":1569,"enrollment":7250,"conditions":10541,"interventions":10542},[92],[24],[10489,10505,10506],{"trials":10544,"activeCount":101},[],{"trials":10546,"activeCount":101},[],{"intervention":10548,"totalTrials":233,"cells":10549},"Iopromide 370 mg I\u002FmL",{"EARLY_PHASE1":10550,"PHASE1":10552,"PHASE2":10554,"PHASE3":10556,"PHASE4":10567,"NA":10569},{"trials":10551,"activeCount":101},[],{"trials":10553,"activeCount":101},[],{"trials":10555,"activeCount":101},[],{"trials":10557,"activeCount":101},[10558],{"nctId":10559,"briefTitle":10560,"status":107,"phases":10561,"primaryCompletion":2970,"completion":2970,"start":4789,"enrollment":10562,"conditions":10563,"interventions":10565},"NCT00244140","Ultravist: Safety and Efficacy in Computed Tomography of Head and Body",[92],435,[10564,8726],"Computed Tomography",[10548,10566],"Iopromide 300 mg I\u002FmL",{"trials":10568,"activeCount":101},[],{"trials":10570,"activeCount":101},[],{"intervention":10566,"totalTrials":233,"cells":10572},{"EARLY_PHASE1":10573,"PHASE1":10575,"PHASE2":10577,"PHASE3":10579,"PHASE4":10585,"NA":10587},{"trials":10574,"activeCount":101},[],{"trials":10576,"activeCount":101},[],{"trials":10578,"activeCount":101},[],{"trials":10580,"activeCount":101},[10581],{"nctId":10559,"briefTitle":10560,"status":107,"phases":10582,"primaryCompletion":2970,"completion":2970,"start":4789,"enrollment":10562,"conditions":10583,"interventions":10584},[92],[10564,8726],[10548,10566],{"trials":10586,"activeCount":101},[],{"trials":10588,"activeCount":101},[],{"intervention":10590,"totalTrials":233,"cells":10591},"Polyethylene Glycol 3350 Powder for Solution",{"EARLY_PHASE1":10592,"PHASE1":10594,"PHASE2":10596,"PHASE3":10598,"PHASE4":10607,"NA":10609},{"trials":10593,"activeCount":101},[],{"trials":10595,"activeCount":101},[],{"trials":10597,"activeCount":101},[],{"trials":10599,"activeCount":101},[10600],{"nctId":10601,"briefTitle":10602,"status":464,"phases":10603,"primaryCompletion":5249,"completion":5249,"start":5249,"enrollment":101,"conditions":10604,"interventions":10605},"NCT02292459","Efficacy and Safety of Polyethylene Glycol 3350 (PEG 3350) for Relief of Constipation (MK-8114-005)",[92],[6680],[10590,10606],"Polyethylene Glycol 4000 Powder for Solution",{"trials":10608,"activeCount":101},[],{"trials":10610,"activeCount":101},[],{"intervention":10606,"totalTrials":233,"cells":10612},{"EARLY_PHASE1":10613,"PHASE1":10615,"PHASE2":10617,"PHASE3":10619,"PHASE4":10625,"NA":10627},{"trials":10614,"activeCount":101},[],{"trials":10616,"activeCount":101},[],{"trials":10618,"activeCount":101},[],{"trials":10620,"activeCount":101},[10621],{"nctId":10601,"briefTitle":10602,"status":464,"phases":10622,"primaryCompletion":5249,"completion":5249,"start":5249,"enrollment":101,"conditions":10623,"interventions":10624},[92],[6680],[10590,10606],{"trials":10626,"activeCount":101},[],{"trials":10628,"activeCount":101},[],{"intervention":10630,"totalTrials":233,"cells":10631},"BAY86-6150",{"EARLY_PHASE1":10632,"PHASE1":10634,"PHASE2":10636,"PHASE3":10638,"PHASE4":10648,"NA":10650},{"trials":10633,"activeCount":101},[],{"trials":10635,"activeCount":101},[],{"trials":10637,"activeCount":101},[],{"trials":10639,"activeCount":101},[10640],{"nctId":10641,"briefTitle":10642,"status":107,"phases":10643,"primaryCompletion":2917,"completion":2917,"start":1585,"enrollment":3374,"conditions":10644,"interventions":10646},"NCT01625390","A Phase 2\u002F 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150",[91,92],[10645],"Hemophilia A, Hemophilia B",[10630,10647,10630],"eptacog alfa [activated]",{"trials":10649,"activeCount":101},[],{"trials":10651,"activeCount":101},[],{"intervention":10647,"totalTrials":233,"cells":10653},{"EARLY_PHASE1":10654,"PHASE1":10656,"PHASE2":10658,"PHASE3":10660,"PHASE4":10666,"NA":10668},{"trials":10655,"activeCount":101},[],{"trials":10657,"activeCount":101},[],{"trials":10659,"activeCount":101},[],{"trials":10661,"activeCount":101},[10662],{"nctId":10641,"briefTitle":10642,"status":107,"phases":10663,"primaryCompletion":2917,"completion":2917,"start":1585,"enrollment":3374,"conditions":10664,"interventions":10665},[91,92],[10645],[10630,10647,10630],{"trials":10667,"activeCount":101},[],{"trials":10669,"activeCount":101},[],{"intervention":3762,"totalTrials":233,"cells":10671},{"EARLY_PHASE1":10672,"PHASE1":10674,"PHASE2":10676,"PHASE3":10678,"PHASE4":10684,"NA":10686},{"trials":10673,"activeCount":101},[],{"trials":10675,"activeCount":101},[],{"trials":10677,"activeCount":101},[],{"trials":10679,"activeCount":101},[10680],{"nctId":3754,"briefTitle":3755,"status":156,"phases":10681,"primaryCompletion":3221,"completion":3221,"start":1832,"enrollment":3757,"conditions":10682,"interventions":10683},[92],[3759],[3542,3761,3762,3542,3763],{"trials":10685,"activeCount":101},[],{"trials":10687,"activeCount":101},[],{"intervention":6089,"totalTrials":233,"cells":10689},{"EARLY_PHASE1":10690,"PHASE1":10692,"PHASE2":10694,"PHASE3":10696,"PHASE4":10702,"NA":10704},{"trials":10691,"activeCount":101},[],{"trials":10693,"activeCount":101},[],{"trials":10695,"activeCount":101},[],{"trials":10697,"activeCount":101},[10698],{"nctId":6083,"briefTitle":6084,"status":107,"phases":10699,"primaryCompletion":5472,"completion":5472,"start":3657,"enrollment":6086,"conditions":10700,"interventions":10701},[92],[15],[5950,6089],{"trials":10703,"activeCount":101},[],{"trials":10705,"activeCount":101},[],{"intervention":8104,"totalTrials":233,"cells":10707},{"EARLY_PHASE1":10708,"PHASE1":10710,"PHASE2":10712,"PHASE3":10714,"PHASE4":10720,"NA":10722},{"trials":10709,"activeCount":101},[],{"trials":10711,"activeCount":101},[],{"trials":10713,"activeCount":101},[],{"trials":10715,"activeCount":101},[10716],{"nctId":8099,"briefTitle":8100,"status":107,"phases":10717,"primaryCompletion":2969,"completion":2969,"start":2366,"enrollment":4059,"conditions":10718,"interventions":10719},[92],[5881],[8076,8104],{"trials":10721,"activeCount":101},[],{"trials":10723,"activeCount":101},[],{"intervention":7997,"totalTrials":233,"cells":10725},{"EARLY_PHASE1":10726,"PHASE1":10728,"PHASE2":10730,"PHASE3":10732,"PHASE4":10738,"NA":10740},{"trials":10727,"activeCount":101},[],{"trials":10729,"activeCount":101},[],{"trials":10731,"activeCount":101},[],{"trials":10733,"activeCount":101},[10734],{"nctId":7988,"briefTitle":7989,"status":107,"phases":10735,"primaryCompletion":7991,"completion":7991,"start":7992,"enrollment":7993,"conditions":10736,"interventions":10737},[91,92],[7995],[5521,7997],{"trials":10739,"activeCount":101},[],{"trials":10741,"activeCount":101},[],{"intervention":10743,"totalTrials":233,"cells":10744},"Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose",{"EARLY_PHASE1":10745,"PHASE1":10747,"PHASE2":10749,"PHASE3":10751,"PHASE4":10764,"NA":10766},{"trials":10746,"activeCount":101},[],{"trials":10748,"activeCount":101},[],{"trials":10750,"activeCount":101},[],{"trials":10752,"activeCount":101},[10753],{"nctId":10754,"briefTitle":10755,"status":107,"phases":10756,"primaryCompletion":1203,"completion":10757,"start":10758,"enrollment":10759,"conditions":10760,"interventions":10762},"NCT05850520","A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)",[92],"2025-05-27","2023-05-15",892,[10761],"Macular Edema Secondary to Retinal Vein Occlusion",[10743,10763],"Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg",{"trials":10765,"activeCount":101},[],{"trials":10767,"activeCount":101},[],{"intervention":10763,"totalTrials":233,"cells":10769},{"EARLY_PHASE1":10770,"PHASE1":10772,"PHASE2":10774,"PHASE3":10776,"PHASE4":10782,"NA":10784},{"trials":10771,"activeCount":101},[],{"trials":10773,"activeCount":101},[],{"trials":10775,"activeCount":101},[],{"trials":10777,"activeCount":101},[10778],{"nctId":10754,"briefTitle":10755,"status":107,"phases":10779,"primaryCompletion":1203,"completion":10757,"start":10758,"enrollment":10759,"conditions":10780,"interventions":10781},[92],[10761],[10743,10763],{"trials":10783,"activeCount":101},[],{"trials":10785,"activeCount":101},[],{"intervention":587,"totalTrials":233,"cells":10787},{"EARLY_PHASE1":10788,"PHASE1":10790,"PHASE2":10792,"PHASE3":10794,"PHASE4":10800,"NA":10802},{"trials":10789,"activeCount":101},[],{"trials":10791,"activeCount":101},[],{"trials":10793,"activeCount":101},[],{"trials":10795,"activeCount":101},[10796],{"nctId":577,"briefTitle":578,"status":107,"phases":10797,"primaryCompletion":580,"completion":581,"start":582,"enrollment":583,"conditions":10798,"interventions":10799},[92],[187],[72,586,587],{"trials":10801,"activeCount":101},[],{"trials":10803,"activeCount":101},[],{"intervention":10805,"totalTrials":233,"cells":10806},"Sunscreen Test Code: V53-028",{"EARLY_PHASE1":10807,"PHASE1":10809,"PHASE2":10811,"PHASE3":10813,"PHASE4":10824,"NA":10826},{"trials":10808,"activeCount":101},[],{"trials":10810,"activeCount":101},[],{"trials":10812,"activeCount":101},[],{"trials":10814,"activeCount":101},[10815],{"nctId":10816,"briefTitle":10817,"status":107,"phases":10818,"primaryCompletion":1314,"completion":1314,"start":4587,"enrollment":3374,"conditions":10819,"interventions":10821},"NCT01001975","Determination of Sun Protection in Sunscreen Formulas (Study SR09-15)(P08236)(COMPLETED)",[92],[10820],"Sun Protection",[10805,10822,10823],"Sunscreen Test Code: V53-030","Standard SPF 4 Sunscreen",{"trials":10825,"activeCount":101},[],{"trials":10827,"activeCount":101},[],{"intervention":10822,"totalTrials":233,"cells":10829},{"EARLY_PHASE1":10830,"PHASE1":10832,"PHASE2":10834,"PHASE3":10836,"PHASE4":10842,"NA":10844},{"trials":10831,"activeCount":101},[],{"trials":10833,"activeCount":101},[],{"trials":10835,"activeCount":101},[],{"trials":10837,"activeCount":101},[10838],{"nctId":10816,"briefTitle":10817,"status":107,"phases":10839,"primaryCompletion":1314,"completion":1314,"start":4587,"enrollment":3374,"conditions":10840,"interventions":10841},[92],[10820],[10805,10822,10823],{"trials":10843,"activeCount":101},[],{"trials":10845,"activeCount":101},[],{"intervention":10823,"totalTrials":233,"cells":10847},{"EARLY_PHASE1":10848,"PHASE1":10850,"PHASE2":10852,"PHASE3":10854,"PHASE4":10860,"NA":10862},{"trials":10849,"activeCount":101},[],{"trials":10851,"activeCount":101},[],{"trials":10853,"activeCount":101},[],{"trials":10855,"activeCount":101},[10856],{"nctId":10816,"briefTitle":10817,"status":107,"phases":10857,"primaryCompletion":1314,"completion":1314,"start":4587,"enrollment":3374,"conditions":10858,"interventions":10859},[92],[10820],[10805,10822,10823],{"trials":10861,"activeCount":101},[],{"trials":10863,"activeCount":101},[],{"intervention":8517,"totalTrials":233,"cells":10865},{"EARLY_PHASE1":10866,"PHASE1":10868,"PHASE2":10870,"PHASE3":10872,"PHASE4":10878,"NA":10880},{"trials":10867,"activeCount":101},[],{"trials":10869,"activeCount":101},[],{"trials":10871,"activeCount":101},[],{"trials":10873,"activeCount":101},[10874],{"nctId":8509,"briefTitle":8510,"status":107,"phases":10875,"primaryCompletion":8512,"completion":8512,"start":8513,"enrollment":1509,"conditions":10876,"interventions":10877},[92],[8515],[8489,8517],{"trials":10879,"activeCount":101},[],{"trials":10881,"activeCount":101},[],{"intervention":3773,"totalTrials":233,"cells":10883},{"EARLY_PHASE1":10884,"PHASE1":10886,"PHASE2":10888,"PHASE3":10890,"PHASE4":10896,"NA":10898},{"trials":10885,"activeCount":101},[],{"trials":10887,"activeCount":101},[],{"trials":10889,"activeCount":101},[],{"trials":10891,"activeCount":101},[10892],{"nctId":3765,"briefTitle":3766,"status":107,"phases":10893,"primaryCompletion":1587,"completion":1570,"start":3768,"enrollment":3769,"conditions":10894,"interventions":10895},[92],[3631],[3542,3633,3772,3773],{"trials":10897,"activeCount":101},[],{"trials":10899,"activeCount":101},[],{"intervention":10901,"totalTrials":233,"cells":10902},"Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain",{"EARLY_PHASE1":10903,"PHASE1":10905,"PHASE2":10907,"PHASE3":10909,"PHASE4":10921,"NA":10923},{"trials":10904,"activeCount":101},[],{"trials":10906,"activeCount":101},[],{"trials":10908,"activeCount":101},[],{"trials":10910,"activeCount":101},[10911],{"nctId":10912,"briefTitle":10913,"status":107,"phases":10914,"primaryCompletion":10915,"completion":10915,"start":10916,"enrollment":10917,"conditions":10918,"interventions":10919},"NCT01361399","Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold",[92],"2005-05-28","2004-11-30",1088,[6573,6574,6575],[10901,3761,10920],"Lidocain",{"trials":10922,"activeCount":101},[],{"trials":10924,"activeCount":101},[],{"intervention":10920,"totalTrials":233,"cells":10926},{"EARLY_PHASE1":10927,"PHASE1":10929,"PHASE2":10931,"PHASE3":10933,"PHASE4":10939,"NA":10941},{"trials":10928,"activeCount":101},[],{"trials":10930,"activeCount":101},[],{"trials":10932,"activeCount":101},[],{"trials":10934,"activeCount":101},[10935],{"nctId":10912,"briefTitle":10913,"status":107,"phases":10936,"primaryCompletion":10915,"completion":10915,"start":10916,"enrollment":10917,"conditions":10937,"interventions":10938},[92],[6573,6574,6575],[10901,3761,10920],{"trials":10940,"activeCount":101},[],{"trials":10942,"activeCount":101},[],{"intervention":10944,"totalTrials":233,"cells":10945},"SH D 593 B",{"EARLY_PHASE1":10946,"PHASE1":10948,"PHASE2":10950,"PHASE3":10952,"PHASE4":10961,"NA":10963},{"trials":10947,"activeCount":101},[],{"trials":10949,"activeCount":101},[],{"trials":10951,"activeCount":101},[],{"trials":10953,"activeCount":101},[10954],{"nctId":10955,"briefTitle":10956,"status":107,"phases":10957,"completion":4750,"start":4836,"enrollment":10958,"conditions":10959,"interventions":10960},"NCT00185367","Comparative Cycle Control Europe",[92],798,[15],[5939,10944],{"trials":10962,"activeCount":101},[],{"trials":10964,"activeCount":101},[],{"intervention":10966,"totalTrials":233,"cells":10967},"Yasmin 20",{"EARLY_PHASE1":10968,"PHASE1":10970,"PHASE2":10972,"PHASE3":10974,"PHASE4":10983,"NA":10985},{"trials":10969,"activeCount":101},[],{"trials":10971,"activeCount":101},[],{"trials":10973,"activeCount":101},[],{"trials":10975,"activeCount":101},[10976],{"nctId":10977,"briefTitle":10978,"status":107,"phases":10979,"completion":3705,"start":6384,"enrollment":4901,"conditions":10980,"interventions":10981},"NCT00624130","Yasmin 20 Cycle Control - Yasmin 20 Versus Mercilon in Healthy Female Volunteers",[92],[15],[10966,10982],"Mercilon",{"trials":10984,"activeCount":101},[],{"trials":10986,"activeCount":101},[],{"intervention":10982,"totalTrials":233,"cells":10988},{"EARLY_PHASE1":10989,"PHASE1":10991,"PHASE2":10993,"PHASE3":10995,"PHASE4":11001,"NA":11003},{"trials":10990,"activeCount":101},[],{"trials":10992,"activeCount":101},[],{"trials":10994,"activeCount":101},[],{"trials":10996,"activeCount":101},[10997],{"nctId":10977,"briefTitle":10978,"status":107,"phases":10998,"completion":3705,"start":6384,"enrollment":4901,"conditions":10999,"interventions":11000},[92],[15],[10966,10982],{"trials":11002,"activeCount":101},[],{"trials":11004,"activeCount":101},[],{"intervention":11006,"totalTrials":233,"cells":11007},"Ethinyl estradiol and drospirenone",{"EARLY_PHASE1":11008,"PHASE1":11010,"PHASE2":11012,"PHASE3":11014,"PHASE4":11024,"NA":11026},{"trials":11009,"activeCount":101},[],{"trials":11011,"activeCount":101},[],{"trials":11013,"activeCount":101},[],{"trials":11015,"activeCount":101},[11016],{"nctId":11017,"briefTitle":11018,"status":107,"phases":11019,"primaryCompletion":193,"completion":1122,"start":11020,"enrollment":11021,"conditions":11022,"interventions":11023},"NCT03074045","LCS16 vs. COC User Satisfaction and Tolerability Study",[92],"2017-03-13",145,[15],[6912,11006],{"trials":11025,"activeCount":101},[],{"trials":11027,"activeCount":101},[],{"intervention":11029,"totalTrials":233,"cells":11030},"ProHance",{"EARLY_PHASE1":11031,"PHASE1":11033,"PHASE2":11035,"PHASE3":11037,"PHASE4":11046,"NA":11048},{"trials":11032,"activeCount":101},[],{"trials":11034,"activeCount":101},[],{"trials":11036,"activeCount":101},[],{"trials":11038,"activeCount":101},[11039],{"nctId":11040,"briefTitle":11041,"status":107,"phases":11042,"primaryCompletion":8109,"completion":8109,"start":9022,"enrollment":1424,"conditions":11043,"interventions":11045},"NCT00522951","SH L 562BB Phase II\u002FIII Dose Justification and Gadoteridol-controlled Comparative Study",[92],[11044],"Brain Metastases",[6980,6980,11029],{"trials":11047,"activeCount":101},[],{"trials":11049,"activeCount":101},[],{"intervention":2401,"totalTrials":233,"cells":11051},{"EARLY_PHASE1":11052,"PHASE1":11054,"PHASE2":11056,"PHASE3":11058,"PHASE4":11064,"NA":11066},{"trials":11053,"activeCount":101},[],{"trials":11055,"activeCount":101},[],{"trials":11057,"activeCount":101},[],{"trials":11059,"activeCount":101},[11060],{"nctId":2392,"briefTitle":2393,"status":107,"phases":11061,"primaryCompletion":2395,"completion":2396,"start":2397,"enrollment":1193,"conditions":11062,"interventions":11063},[92],[2399],[1011,2401],{"trials":11065,"activeCount":101},[],{"trials":11067,"activeCount":101},[],{"intervention":3782,"totalTrials":233,"cells":11069},{"EARLY_PHASE1":11070,"PHASE1":11072,"PHASE2":11074,"PHASE3":11076,"PHASE4":11082,"NA":11084},{"trials":11071,"activeCount":101},[],{"trials":11073,"activeCount":101},[],{"trials":11075,"activeCount":101},[],{"trials":11077,"activeCount":101},[11078],{"nctId":3775,"briefTitle":3776,"status":107,"phases":11079,"primaryCompletion":1326,"completion":1326,"start":3778,"enrollment":3779,"conditions":11080,"interventions":11081},[92],[3560],[3542,3782],{"trials":11083,"activeCount":101},[],{"trials":11085,"activeCount":101},[],{"intervention":11087,"totalTrials":233,"cells":11088},"Piperacillin\u002FTazobactam & Amoxicillin\u002FClavulanic acid",{"EARLY_PHASE1":11089,"PHASE1":11091,"PHASE2":11093,"PHASE3":11095,"PHASE4":11107,"NA":11109},{"trials":11090,"activeCount":101},[],{"trials":11092,"activeCount":101},[],{"trials":11094,"activeCount":101},[],{"trials":11096,"activeCount":101},[11097],{"nctId":11098,"briefTitle":11099,"status":107,"phases":11100,"primaryCompletion":1423,"completion":1423,"start":4750,"enrollment":7888,"conditions":11101,"interventions":11106},"NCT00402727","Comparison of Sequential IV\u002FPO Moxifloxacin With IV Piperacillin\u002FTazobactam Followed by PO Amoxicillin\u002FClavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection",[92],[11102,11103,11104,11105],"Abscess","Wound Infection","Diabetic Foot","Ulcer",[1144,11087],{"trials":11108,"activeCount":101},[],{"trials":11110,"activeCount":101},[],{"intervention":9221,"totalTrials":233,"cells":11112},{"EARLY_PHASE1":11113,"PHASE1":11115,"PHASE2":11117,"PHASE3":11119,"PHASE4":11125,"NA":11127},{"trials":11114,"activeCount":101},[],{"trials":11116,"activeCount":101},[],{"trials":11118,"activeCount":101},[],{"trials":11120,"activeCount":101},[11121],{"nctId":9213,"briefTitle":9214,"status":107,"phases":11122,"primaryCompletion":9216,"completion":9216,"start":9217,"enrollment":9218,"conditions":11123,"interventions":11124},[92],[8050],[9194,9221],{"trials":11126,"activeCount":101},[],{"trials":11128,"activeCount":101},[],{"intervention":11130,"totalTrials":233,"cells":11131},"Copaxone",{"EARLY_PHASE1":11132,"PHASE1":11134,"PHASE2":11136,"PHASE3":11138,"PHASE4":11148,"NA":11150},{"trials":11133,"activeCount":101},[],{"trials":11135,"activeCount":101},[],{"trials":11137,"activeCount":101},[],{"trials":11139,"activeCount":101},[11140],{"nctId":11141,"briefTitle":11142,"status":107,"phases":11143,"completion":9022,"start":3657,"enrollment":11144,"conditions":11145,"interventions":11146},"NCT00099502","BEYOND: Betaferon\u002FBetaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients",[92],2244,[6602],[11147,11147,11130],"Interferon beta-1b",{"trials":11149,"activeCount":101},[],{"trials":11151,"activeCount":101},[],{"intervention":5371,"totalTrials":233,"cells":11153},{"EARLY_PHASE1":11154,"PHASE1":11156,"PHASE2":11158,"PHASE3":11160,"PHASE4":11166,"NA":11168},{"trials":11155,"activeCount":101},[],{"trials":11157,"activeCount":101},[],{"trials":11159,"activeCount":101},[],{"trials":11161,"activeCount":101},[11162],{"nctId":5364,"briefTitle":5365,"status":107,"phases":11163,"primaryCompletion":2064,"completion":993,"start":5367,"enrollment":5368,"conditions":11164,"interventions":11165},[92],[138],[5371,5372,247],{"trials":11167,"activeCount":101},[],{"trials":11169,"activeCount":101},[],{"intervention":5372,"totalTrials":233,"cells":11171},{"EARLY_PHASE1":11172,"PHASE1":11174,"PHASE2":11176,"PHASE3":11178,"PHASE4":11184,"NA":11186},{"trials":11173,"activeCount":101},[],{"trials":11175,"activeCount":101},[],{"trials":11177,"activeCount":101},[],{"trials":11179,"activeCount":101},[11180],{"nctId":5364,"briefTitle":5365,"status":107,"phases":11181,"primaryCompletion":2064,"completion":993,"start":5367,"enrollment":5368,"conditions":11182,"interventions":11183},[92],[138],[5371,5372,247],{"trials":11185,"activeCount":101},[],{"trials":11187,"activeCount":101},[],{"intervention":3804,"totalTrials":233,"cells":11189},{"EARLY_PHASE1":11190,"PHASE1":11192,"PHASE2":11194,"PHASE3":11196,"PHASE4":11202,"NA":11204},{"trials":11191,"activeCount":101},[],{"trials":11193,"activeCount":101},[],{"trials":11195,"activeCount":101},[],{"trials":11197,"activeCount":101},[11198],{"nctId":3798,"briefTitle":3799,"status":107,"phases":11199,"primaryCompletion":1351,"completion":2919,"start":3778,"enrollment":3801,"conditions":11200,"interventions":11201},[92],[3716],[3542,3804],{"trials":11203,"activeCount":101},[],{"trials":11205,"activeCount":101},[],{"intervention":8216,"totalTrials":233,"cells":11207},{"EARLY_PHASE1":11208,"PHASE1":11210,"PHASE2":11212,"PHASE3":11214,"PHASE4":11220,"NA":11222},{"trials":11209,"activeCount":101},[],{"trials":11211,"activeCount":101},[],{"trials":11213,"activeCount":101},[],{"trials":11215,"activeCount":101},[11216],{"nctId":8210,"briefTitle":8211,"status":107,"phases":11217,"primaryCompletion":2968,"completion":2968,"start":3619,"enrollment":8213,"conditions":11218,"interventions":11219},[92],[15],[8178,8216],{"trials":11221,"activeCount":101},[],{"trials":11223,"activeCount":101},[],{"intervention":11225,"totalTrials":233,"cells":11226},"Bifonazole cream 1%",{"EARLY_PHASE1":11227,"PHASE1":11229,"PHASE2":11231,"PHASE3":11233,"PHASE4":11243,"NA":11245},{"trials":11228,"activeCount":101},[],{"trials":11230,"activeCount":101},[],{"trials":11232,"activeCount":101},[],{"trials":11234,"activeCount":101},[11235],{"nctId":11236,"briefTitle":11237,"status":107,"phases":11238,"primaryCompletion":3809,"completion":3809,"start":1498,"enrollment":11239,"conditions":11240,"interventions":11242},"NCT00781820","Comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste",[92],693,[11241],"Onychomycosis",[11225],{"trials":11244,"activeCount":101},[],{"trials":11246,"activeCount":101},[],{"intervention":5992,"totalTrials":233,"cells":11248},{"EARLY_PHASE1":11249,"PHASE1":11251,"PHASE2":11253,"PHASE3":11255,"PHASE4":11261,"NA":11263},{"trials":11250,"activeCount":101},[],{"trials":11252,"activeCount":101},[],{"trials":11254,"activeCount":101},[],{"trials":11256,"activeCount":101},[11257],{"nctId":5985,"briefTitle":5986,"status":107,"phases":11258,"primaryCompletion":1352,"completion":1352,"start":2969,"enrollment":5988,"conditions":11259,"interventions":11260},[92],[5990],[5992,5954],{"trials":11262,"activeCount":101},[],{"trials":11264,"activeCount":101},[],{"intervention":8891,"totalTrials":233,"cells":11266},{"EARLY_PHASE1":11267,"PHASE1":11269,"PHASE2":11271,"PHASE3":11273,"PHASE4":11279,"NA":11281},{"trials":11268,"activeCount":101},[],{"trials":11270,"activeCount":101},[],{"trials":11272,"activeCount":101},[],{"trials":11274,"activeCount":101},[11275],{"nctId":8883,"briefTitle":8884,"status":107,"phases":11276,"primaryCompletion":8886,"completion":8886,"start":8887,"enrollment":8888,"conditions":11277,"interventions":11278},[92],[15],[8864,8891],{"trials":11280,"activeCount":101},[],{"trials":11282,"activeCount":101},[],{"intervention":11284,"totalTrials":233,"cells":11285},"DRSP 3 mg\u002FEE 20 µg",{"EARLY_PHASE1":11286,"PHASE1":11288,"PHASE2":11290,"PHASE3":11292,"PHASE4":11302,"NA":11304},{"trials":11287,"activeCount":101},[],{"trials":11289,"activeCount":101},[],{"trials":11291,"activeCount":101},[],{"trials":11293,"activeCount":101},[11294],{"nctId":11295,"briefTitle":11296,"status":107,"phases":11297,"primaryCompletion":4588,"completion":1314,"start":1328,"enrollment":11298,"conditions":11299,"interventions":11300},"NCT00461305","Safety Study of Ethinylestradiol\u002FDrospirenone in Dysmenorrhea",[91,92],420,[6172],[11284,11301],"DRSP 3 mg\u002FEE 30 µg",{"trials":11303,"activeCount":101},[],{"trials":11305,"activeCount":101},[],{"intervention":11301,"totalTrials":233,"cells":11307},{"EARLY_PHASE1":11308,"PHASE1":11310,"PHASE2":11312,"PHASE3":11314,"PHASE4":11320,"NA":11322},{"trials":11309,"activeCount":101},[],{"trials":11311,"activeCount":101},[],{"trials":11313,"activeCount":101},[],{"trials":11315,"activeCount":101},[11316],{"nctId":11295,"briefTitle":11296,"status":107,"phases":11317,"primaryCompletion":4588,"completion":1314,"start":1328,"enrollment":11298,"conditions":11318,"interventions":11319},[91,92],[6172],[11284,11301],{"trials":11321,"activeCount":101},[],{"trials":11323,"activeCount":101},[],{"intervention":11325,"totalTrials":233,"cells":11326},"BAY86-5016, SH P00331F",{"EARLY_PHASE1":11327,"PHASE1":11329,"PHASE2":11331,"PHASE3":11333,"PHASE4":11343,"NA":11345},{"trials":11328,"activeCount":101},[],{"trials":11330,"activeCount":101},[],{"trials":11332,"activeCount":101},[],{"trials":11334,"activeCount":101},[11335],{"nctId":11336,"briefTitle":11337,"status":107,"phases":11338,"primaryCompletion":4861,"completion":4861,"start":3628,"enrollment":11339,"conditions":11340,"interventions":11341},"NCT00185354","FC Patch Comparator Study",[92],422,[15],[11325,11342],"SH P00331N",{"trials":11344,"activeCount":101},[],{"trials":11346,"activeCount":101},[],{"intervention":11342,"totalTrials":233,"cells":11348},{"EARLY_PHASE1":11349,"PHASE1":11351,"PHASE2":11353,"PHASE3":11355,"PHASE4":11361,"NA":11363},{"trials":11350,"activeCount":101},[],{"trials":11352,"activeCount":101},[],{"trials":11354,"activeCount":101},[],{"trials":11356,"activeCount":101},[11357],{"nctId":11336,"briefTitle":11337,"status":107,"phases":11358,"primaryCompletion":4861,"completion":4861,"start":3628,"enrollment":11339,"conditions":11359,"interventions":11360},[92],[15],[11325,11342],{"trials":11362,"activeCount":101},[],{"trials":11364,"activeCount":101},[],{"intervention":11366,"totalTrials":233,"cells":11367},"Laif® 900, BAY98-7108",{"EARLY_PHASE1":11368,"PHASE1":11370,"PHASE2":11372,"PHASE3":11374,"PHASE4":11386,"NA":11388},{"trials":11369,"activeCount":101},[],{"trials":11371,"activeCount":101},[],{"trials":11373,"activeCount":101},[],{"trials":11375,"activeCount":101},[11376],{"nctId":11377,"briefTitle":11378,"status":107,"phases":11379,"primaryCompletion":11380,"completion":11380,"start":11381,"enrollment":11382,"conditions":11383,"interventions":11385},"NCT04315597","Study to Learn About Relapse Prevention of Hypericumextract (a Drug Based on the Plant St. John Wort) in Outpatients Suffering From Moderate Depressive Episodes",[92],"2011-11-22","2009-03-03",398,[11384],"Moderate Depressive Episodes (Major Depression)",[11366],{"trials":11387,"activeCount":101},[],{"trials":11389,"activeCount":101},[],{"intervention":11391,"totalTrials":233,"cells":11392},"Ciprofloxacin (BAYQ3939) dry powder for inhalation",{"EARLY_PHASE1":11393,"PHASE1":11395,"PHASE2":11397,"PHASE3":11399,"PHASE4":11410,"NA":11412},{"trials":11394,"activeCount":101},[],{"trials":11396,"activeCount":101},[],{"trials":11398,"activeCount":101},[],{"trials":11400,"activeCount":101},[11401],{"nctId":11402,"briefTitle":11403,"status":107,"phases":11404,"primaryCompletion":11405,"completion":5092,"start":11406,"enrollment":11407,"conditions":11408,"interventions":11409},"NCT02106832","Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)",[92],"2016-09-13","2014-04-30",521,[10004],[11391,11391],{"trials":11411,"activeCount":101},[],{"trials":11413,"activeCount":101},[],{"intervention":11415,"totalTrials":233,"cells":11416},"Gynodian® Depot",{"EARLY_PHASE1":11417,"PHASE1":11419,"PHASE2":11421,"PHASE3":11423,"PHASE4":11435,"NA":11437},{"trials":11418,"activeCount":101},[],{"trials":11420,"activeCount":101},[],{"trials":11422,"activeCount":101},[],{"trials":11424,"activeCount":101},[11425],{"nctId":11426,"briefTitle":11427,"status":107,"phases":11428,"completion":4707,"start":11429,"enrollment":11430,"conditions":11431,"interventions":11433},"NCT00463450","Efficacy of Gynodian® Depot in Women With Impaired Well-being",[92],"2002-05",140,[11432],"Hormone Replacement Therapy",[11415,11434],"BAY86-4980",{"trials":11436,"activeCount":101},[],{"trials":11438,"activeCount":101},[],{"intervention":11434,"totalTrials":233,"cells":11440},{"EARLY_PHASE1":11441,"PHASE1":11443,"PHASE2":11445,"PHASE3":11447,"PHASE4":11453,"NA":11455},{"trials":11442,"activeCount":101},[],{"trials":11444,"activeCount":101},[],{"trials":11446,"activeCount":101},[],{"trials":11448,"activeCount":101},[11449],{"nctId":11426,"briefTitle":11427,"status":107,"phases":11450,"completion":4707,"start":11429,"enrollment":11430,"conditions":11451,"interventions":11452},[92],[11432],[11415,11434],{"trials":11454,"activeCount":101},[],{"trials":11456,"activeCount":101},[],{"intervention":6528,"totalTrials":233,"cells":11458},{"EARLY_PHASE1":11459,"PHASE1":11461,"PHASE2":11463,"PHASE3":11465,"PHASE4":11471,"NA":11473},{"trials":11460,"activeCount":101},[],{"trials":11462,"activeCount":101},[],{"trials":11464,"activeCount":101},[],{"trials":11466,"activeCount":101},[11467],{"nctId":6521,"briefTitle":6522,"status":107,"phases":11468,"primaryCompletion":3403,"completion":3403,"start":6524,"enrollment":4862,"conditions":11469,"interventions":11470},[92],[6526],[1144,6528,6510,6529,6530,6531],{"trials":11472,"activeCount":101},[],{"trials":11474,"activeCount":101},[],{"intervention":6529,"totalTrials":233,"cells":11476},{"EARLY_PHASE1":11477,"PHASE1":11479,"PHASE2":11481,"PHASE3":11483,"PHASE4":11489,"NA":11491},{"trials":11478,"activeCount":101},[],{"trials":11480,"activeCount":101},[],{"trials":11482,"activeCount":101},[],{"trials":11484,"activeCount":101},[11485],{"nctId":6521,"briefTitle":6522,"status":107,"phases":11486,"primaryCompletion":3403,"completion":3403,"start":6524,"enrollment":4862,"conditions":11487,"interventions":11488},[92],[6526],[1144,6528,6510,6529,6530,6531],{"trials":11490,"activeCount":101},[],{"trials":11492,"activeCount":101},[],{"intervention":6530,"totalTrials":233,"cells":11494},{"EARLY_PHASE1":11495,"PHASE1":11497,"PHASE2":11499,"PHASE3":11501,"PHASE4":11507,"NA":11509},{"trials":11496,"activeCount":101},[],{"trials":11498,"activeCount":101},[],{"trials":11500,"activeCount":101},[],{"trials":11502,"activeCount":101},[11503],{"nctId":6521,"briefTitle":6522,"status":107,"phases":11504,"primaryCompletion":3403,"completion":3403,"start":6524,"enrollment":4862,"conditions":11505,"interventions":11506},[92],[6526],[1144,6528,6510,6529,6530,6531],{"trials":11508,"activeCount":101},[],{"trials":11510,"activeCount":101},[],{"intervention":6531,"totalTrials":233,"cells":11512},{"EARLY_PHASE1":11513,"PHASE1":11515,"PHASE2":11517,"PHASE3":11519,"PHASE4":11525,"NA":11527},{"trials":11514,"activeCount":101},[],{"trials":11516,"activeCount":101},[],{"trials":11518,"activeCount":101},[],{"trials":11520,"activeCount":101},[11521],{"nctId":6521,"briefTitle":6522,"status":107,"phases":11522,"primaryCompletion":3403,"completion":3403,"start":6524,"enrollment":4862,"conditions":11523,"interventions":11524},[92],[6526],[1144,6528,6510,6529,6530,6531],{"trials":11526,"activeCount":101},[],{"trials":11528,"activeCount":101},[],{"intervention":11530,"totalTrials":233,"cells":11531},"Azelastine hydrochloride",{"EARLY_PHASE1":11532,"PHASE1":11534,"PHASE2":11536,"PHASE3":11538,"PHASE4":11548,"NA":11550},{"trials":11533,"activeCount":101},[],{"trials":11535,"activeCount":101},[],{"trials":11537,"activeCount":101},[],{"trials":11539,"activeCount":101},[11540],{"nctId":11541,"briefTitle":11542,"status":107,"phases":11543,"primaryCompletion":11544,"completion":11544,"start":11545,"enrollment":1205,"conditions":11546,"interventions":11547},"NCT04264637","Study to Find Out How Long it Takes Azelastine Hydrochloride 0.15% Nasal Spray to Relieve Symptoms in Patients Suffering From Allergic Rhinitis",[92],"2021-03-17","2020-02-03",[6012],[11530],{"trials":11549,"activeCount":101},[],{"trials":11551,"activeCount":101},[],{"intervention":11553,"totalTrials":233,"cells":11554},"D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV",{"EARLY_PHASE1":11555,"PHASE1":11557,"PHASE2":11559,"PHASE3":11561,"PHASE4":11571,"NA":11573},{"trials":11556,"activeCount":101},[],{"trials":11558,"activeCount":101},[],{"trials":11560,"activeCount":101},[],{"trials":11562,"activeCount":101},[11563],{"nctId":11564,"briefTitle":11565,"status":107,"phases":11566,"primaryCompletion":2229,"completion":1647,"start":5975,"enrollment":4771,"conditions":11567,"interventions":11568},"NCT00910065","BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)",[92],[4099],[11553,11569,11570],"D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 250 mg IV","Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg",{"trials":11572,"activeCount":101},[],{"trials":11574,"activeCount":101},[],{"intervention":11569,"totalTrials":233,"cells":11576},{"EARLY_PHASE1":11577,"PHASE1":11579,"PHASE2":11581,"PHASE3":11583,"PHASE4":11589,"NA":11591},{"trials":11578,"activeCount":101},[],{"trials":11580,"activeCount":101},[],{"trials":11582,"activeCount":101},[],{"trials":11584,"activeCount":101},[11585],{"nctId":11564,"briefTitle":11565,"status":107,"phases":11586,"primaryCompletion":2229,"completion":1647,"start":5975,"enrollment":4771,"conditions":11587,"interventions":11588},[92],[4099],[11553,11569,11570],{"trials":11590,"activeCount":101},[],{"trials":11592,"activeCount":101},[],{"intervention":11570,"totalTrials":233,"cells":11594},{"EARLY_PHASE1":11595,"PHASE1":11597,"PHASE2":11599,"PHASE3":11601,"PHASE4":11607,"NA":11609},{"trials":11596,"activeCount":101},[],{"trials":11598,"activeCount":101},[],{"trials":11600,"activeCount":101},[],{"trials":11602,"activeCount":101},[11603],{"nctId":11564,"briefTitle":11565,"status":107,"phases":11604,"primaryCompletion":2229,"completion":1647,"start":5975,"enrollment":4771,"conditions":11605,"interventions":11606},[92],[4099],[11553,11569,11570],{"trials":11608,"activeCount":101},[],{"trials":11610,"activeCount":101},[],{"intervention":11612,"totalTrials":233,"cells":11613},"Gadopentate dimeglumine",{"EARLY_PHASE1":11614,"PHASE1":11616,"PHASE2":11618,"PHASE3":11620,"PHASE4":11629,"NA":11631},{"trials":11615,"activeCount":101},[],{"trials":11617,"activeCount":101},[],{"trials":11619,"activeCount":101},[],{"trials":11621,"activeCount":101},[11622],{"nctId":11623,"briefTitle":11624,"status":107,"phases":11625,"primaryCompletion":6493,"completion":6493,"start":4666,"enrollment":4649,"conditions":11626,"interventions":11628},"NCT00395733","Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients",[92],[11627],"Vascular Diseases",[6980,11612],{"trials":11630,"activeCount":101},[],{"trials":11632,"activeCount":101},[],{"intervention":11634,"totalTrials":233,"cells":11635},"Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg",{"EARLY_PHASE1":11636,"PHASE1":11638,"PHASE2":11640,"PHASE3":11642,"PHASE4":11653,"NA":11655},{"trials":11637,"activeCount":101},[],{"trials":11639,"activeCount":101},[],{"trials":11641,"activeCount":101},[],{"trials":11643,"activeCount":101},[11644],{"nctId":11645,"briefTitle":11646,"status":107,"phases":11647,"primaryCompletion":1497,"completion":1497,"start":1314,"enrollment":11648,"conditions":11649,"interventions":11651},"NCT00976209","Consumer Preference Study of Two Formulations of Phenylephrine Hydrochloride (Study CL2008-15)(P07530)(COMPLETED)",[92],331,[11650,5990],"Vasomotor Rhinitis",[11634,11652],"Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mg",{"trials":11654,"activeCount":101},[],{"trials":11656,"activeCount":101},[],{"intervention":11652,"totalTrials":233,"cells":11658},{"EARLY_PHASE1":11659,"PHASE1":11661,"PHASE2":11663,"PHASE3":11665,"PHASE4":11671,"NA":11673},{"trials":11660,"activeCount":101},[],{"trials":11662,"activeCount":101},[],{"trials":11664,"activeCount":101},[],{"trials":11666,"activeCount":101},[11667],{"nctId":11645,"briefTitle":11646,"status":107,"phases":11668,"primaryCompletion":1497,"completion":1497,"start":1314,"enrollment":11648,"conditions":11669,"interventions":11670},[92],[11650,5990],[11634,11652],{"trials":11672,"activeCount":101},[],{"trials":11674,"activeCount":101},[],{"intervention":11676,"totalTrials":233,"cells":11677},"Ciprofloxacin single dose",{"EARLY_PHASE1":11678,"PHASE1":11680,"PHASE2":11682,"PHASE3":11684,"PHASE4":11693,"NA":11695},{"trials":11679,"activeCount":101},[],{"trials":11681,"activeCount":101},[],{"trials":11683,"activeCount":101},[],{"trials":11685,"activeCount":101},[11686],{"nctId":11687,"briefTitle":11688,"status":107,"phases":11689,"completion":10250,"start":4707,"enrollment":8118,"conditions":11690,"interventions":11691},"NCT00670215","BAYQ3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis",[92],[6541],[11676,11692],"Ciprofloxacin triple dose",{"trials":11694,"activeCount":101},[],{"trials":11696,"activeCount":101},[],{"intervention":11692,"totalTrials":233,"cells":11698},{"EARLY_PHASE1":11699,"PHASE1":11701,"PHASE2":11703,"PHASE3":11705,"PHASE4":11711,"NA":11713},{"trials":11700,"activeCount":101},[],{"trials":11702,"activeCount":101},[],{"trials":11704,"activeCount":101},[],{"trials":11706,"activeCount":101},[11707],{"nctId":11687,"briefTitle":11688,"status":107,"phases":11708,"completion":10250,"start":4707,"enrollment":8118,"conditions":11709,"interventions":11710},[92],[6541],[11676,11692],{"trials":11712,"activeCount":101},[],{"trials":11714,"activeCount":101},[],{"intervention":11716,"totalTrials":233,"cells":11717},"Zidovudine",{"EARLY_PHASE1":11718,"PHASE1":11720,"PHASE2":11722,"PHASE3":11724,"PHASE4":11733,"NA":11735},{"trials":11719,"activeCount":101},[],{"trials":11721,"activeCount":101},[],{"trials":11723,"activeCount":101},[],{"trials":11725,"activeCount":101},[11726],{"nctId":11727,"briefTitle":11728,"status":107,"phases":11729,"conditions":11730,"interventions":11732},"NCT00002238","Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen",[92],[11731],"HIV Infections",[11147,11716],{"trials":11734,"activeCount":101},[],{"trials":11736,"activeCount":101},[],{"intervention":11738,"totalTrials":233,"cells":11739},"Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel",{"EARLY_PHASE1":11740,"PHASE1":11742,"PHASE2":11744,"PHASE3":11746,"PHASE4":11756,"NA":11758},{"trials":11741,"activeCount":101},[],{"trials":11743,"activeCount":101},[],{"trials":11745,"activeCount":101},[],{"trials":11747,"activeCount":101},[11748],{"nctId":11749,"briefTitle":11750,"status":156,"phases":11751,"primaryCompletion":6493,"completion":4292,"start":3724,"enrollment":11752,"conditions":11753,"interventions":11754},"NCT00300885","A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)",[92],926,[4709],[11738,11755],"Carboplatin plus Paclitaxel",{"trials":11757,"activeCount":101},[],{"trials":11759,"activeCount":101},[],{"intervention":11755,"totalTrials":233,"cells":11761},{"EARLY_PHASE1":11762,"PHASE1":11764,"PHASE2":11766,"PHASE3":11768,"PHASE4":11774,"NA":11776},{"trials":11763,"activeCount":101},[],{"trials":11765,"activeCount":101},[],{"trials":11767,"activeCount":101},[],{"trials":11769,"activeCount":101},[11770],{"nctId":11749,"briefTitle":11750,"status":156,"phases":11771,"primaryCompletion":6493,"completion":4292,"start":3724,"enrollment":11752,"conditions":11772,"interventions":11773},[92],[4709],[11738,11755],{"trials":11775,"activeCount":101},[],{"trials":11777,"activeCount":101},[],{"intervention":11779,"totalTrials":233,"cells":11780},"Naproxen sodium 440 mg\u002FDPH 50 mg",{"EARLY_PHASE1":11781,"PHASE1":11783,"PHASE2":11785,"PHASE3":11787,"PHASE4":11796,"NA":11798},{"trials":11782,"activeCount":101},[],{"trials":11784,"activeCount":101},[],{"trials":11786,"activeCount":101},[],{"trials":11788,"activeCount":101},[11789],{"nctId":11790,"briefTitle":11791,"status":107,"phases":11792,"primaryCompletion":2366,"completion":2366,"start":3618,"enrollment":11793,"conditions":11794,"interventions":11795},"NCT01365052","Safety Trial of Naproxen Sodium\u002F Diphenhydramine",[92],326,[5881],[11779],{"trials":11797,"activeCount":101},[],{"trials":11799,"activeCount":101},[],{"intervention":11801,"totalTrials":233,"cells":11802},"Calcium carbonate",{"EARLY_PHASE1":11803,"PHASE1":11805,"PHASE2":11807,"PHASE3":11809,"PHASE4":11819,"NA":11821},{"trials":11804,"activeCount":101},[],{"trials":11806,"activeCount":101},[],{"trials":11808,"activeCount":101},[],{"trials":11810,"activeCount":101},[11811],{"nctId":11812,"briefTitle":11813,"status":107,"phases":11814,"primaryCompletion":444,"completion":444,"start":4675,"enrollment":11815,"conditions":11816,"interventions":11817},"NCT01514851","Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate",[92],259,[8965],[11818,11801],"Lanthanum carbonate",{"trials":11820,"activeCount":101},[],{"trials":11822,"activeCount":101},[],{"intervention":11824,"totalTrials":233,"cells":11825},"LNG IUS",{"EARLY_PHASE1":11826,"PHASE1":11828,"PHASE2":11830,"PHASE3":11832,"PHASE4":11842,"NA":11844},{"trials":11827,"activeCount":101},[],{"trials":11829,"activeCount":101},[],{"trials":11831,"activeCount":101},[],{"trials":11833,"activeCount":101},[11834],{"nctId":11835,"briefTitle":11836,"status":107,"phases":11837,"primaryCompletion":4597,"completion":4597,"start":11838,"enrollment":11839,"conditions":11840,"interventions":11841},"NCT00185458","Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT).",[92],"2000-05",394,[1195],[11824],{"trials":11843,"activeCount":101},[],{"trials":11845,"activeCount":101},[],{"intervention":11847,"totalTrials":233,"cells":11848},"SH T04740B",{"EARLY_PHASE1":11849,"PHASE1":11851,"PHASE2":11853,"PHASE3":11855,"PHASE4":11866,"NA":11868},{"trials":11850,"activeCount":101},[],{"trials":11852,"activeCount":101},[],{"trials":11854,"activeCount":101},[],{"trials":11856,"activeCount":101},[11857],{"nctId":11858,"briefTitle":11859,"status":107,"phases":11860,"primaryCompletion":4588,"completion":4588,"start":11861,"enrollment":4278,"conditions":11862,"interventions":11863},"NCT00511797","SH T00186 Phase II\u002F III Optimal Drospirenone (DRSP) Dose Finding and Placebo-controlled Comparative Study",[91,92],"2007-07",[6172],[11847,11864,11865],"SH T00186DF","SH T04740F",{"trials":11867,"activeCount":101},[],{"trials":11869,"activeCount":101},[],{"intervention":11864,"totalTrials":233,"cells":11871},{"EARLY_PHASE1":11872,"PHASE1":11874,"PHASE2":11876,"PHASE3":11878,"PHASE4":11884,"NA":11886},{"trials":11873,"activeCount":101},[],{"trials":11875,"activeCount":101},[],{"trials":11877,"activeCount":101},[],{"trials":11879,"activeCount":101},[11880],{"nctId":11858,"briefTitle":11859,"status":107,"phases":11881,"primaryCompletion":4588,"completion":4588,"start":11861,"enrollment":4278,"conditions":11882,"interventions":11883},[91,92],[6172],[11847,11864,11865],{"trials":11885,"activeCount":101},[],{"trials":11887,"activeCount":101},[],{"intervention":11865,"totalTrials":233,"cells":11889},{"EARLY_PHASE1":11890,"PHASE1":11892,"PHASE2":11894,"PHASE3":11896,"PHASE4":11902,"NA":11904},{"trials":11891,"activeCount":101},[],{"trials":11893,"activeCount":101},[],{"trials":11895,"activeCount":101},[],{"trials":11897,"activeCount":101},[11898],{"nctId":11858,"briefTitle":11859,"status":107,"phases":11899,"primaryCompletion":4588,"completion":4588,"start":11861,"enrollment":4278,"conditions":11900,"interventions":11901},[91,92],[6172],[11847,11864,11865],{"trials":11903,"activeCount":101},[],{"trials":11905,"activeCount":101},[],{"intervention":3813,"totalTrials":233,"cells":11907},{"EARLY_PHASE1":11908,"PHASE1":11910,"PHASE2":11912,"PHASE3":11914,"PHASE4":11920,"NA":11922},{"trials":11909,"activeCount":101},[],{"trials":11911,"activeCount":101},[],{"trials":11913,"activeCount":101},[],{"trials":11915,"activeCount":101},[11916],{"nctId":3806,"briefTitle":3807,"status":107,"phases":11917,"primaryCompletion":499,"completion":3809,"start":3723,"enrollment":3810,"conditions":11918,"interventions":11919},[92],[21],[3542,2202,3772,3813],{"trials":11921,"activeCount":101},[],{"trials":11923,"activeCount":101},[],{"intervention":9004,"totalTrials":233,"cells":11925},{"EARLY_PHASE1":11926,"PHASE1":11928,"PHASE2":11930,"PHASE3":11932,"PHASE4":11938,"NA":11940},{"trials":11927,"activeCount":101},[],{"trials":11929,"activeCount":101},[],{"trials":11931,"activeCount":101},[],{"trials":11933,"activeCount":101},[11934],{"nctId":8998,"briefTitle":8999,"status":464,"phases":11935,"primaryCompletion":9001,"completion":9001,"start":4107,"enrollment":101,"conditions":11936,"interventions":11937},[92],[6625],[8979,8979,9004,8979],{"trials":11939,"activeCount":101},[],{"trials":11941,"activeCount":101},[],{"intervention":4856,"totalTrials":233,"cells":11943},{"EARLY_PHASE1":11944,"PHASE1":11946,"PHASE2":11948,"PHASE3":11950,"PHASE4":11956,"NA":11958},{"trials":11945,"activeCount":101},[],{"trials":11947,"activeCount":101},[],{"trials":11949,"activeCount":101},[],{"trials":11951,"activeCount":101},[11952],{"nctId":4848,"briefTitle":4849,"status":107,"phases":11953,"primaryCompletion":4851,"completion":1262,"start":4852,"enrollment":4853,"conditions":11954,"interventions":11955},[92],[1009],[42,4856],{"trials":11957,"activeCount":101},[],{"trials":11959,"activeCount":101},[],{"intervention":11961,"totalTrials":233,"cells":11962},"SARS-CoV-2 mRNA Vaccine",{"EARLY_PHASE1":11963,"PHASE1":11965,"PHASE2":11967,"PHASE3":11969,"PHASE4":11980,"NA":11982},{"trials":11964,"activeCount":101},[],{"trials":11966,"activeCount":101},[],{"trials":11968,"activeCount":101},[],{"trials":11970,"activeCount":101},[11971],{"nctId":11972,"briefTitle":11973,"status":464,"phases":11974,"primaryCompletion":11975,"completion":4213,"start":11976,"enrollment":101,"conditions":11977,"interventions":11978},"NCT04848467","COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older",[92],"2021-11-30","2021-10-01",[2570,2569],[11961,11979],"Quadrivalent influenza vaccine",{"trials":11981,"activeCount":101},[],{"trials":11983,"activeCount":101},[],{"intervention":11979,"totalTrials":233,"cells":11985},{"EARLY_PHASE1":11986,"PHASE1":11988,"PHASE2":11990,"PHASE3":11992,"PHASE4":11998,"NA":12000},{"trials":11987,"activeCount":101},[],{"trials":11989,"activeCount":101},[],{"trials":11991,"activeCount":101},[],{"trials":11993,"activeCount":101},[11994],{"nctId":11972,"briefTitle":11973,"status":464,"phases":11995,"primaryCompletion":11975,"completion":4213,"start":11976,"enrollment":101,"conditions":11996,"interventions":11997},[92],[2570,2569],[11961,11979],{"trials":11999,"activeCount":101},[],{"trials":12001,"activeCount":101},[],{"intervention":12003,"totalTrials":233,"cells":12004},"8 mg aflibercept",{"EARLY_PHASE1":12005,"PHASE1":12007,"PHASE2":12009,"PHASE3":12011,"PHASE4":12023,"NA":12025},{"trials":12006,"activeCount":101},[],{"trials":12008,"activeCount":101},[],{"trials":12010,"activeCount":101},[],{"trials":12012,"activeCount":101},[12013],{"nctId":12014,"briefTitle":12015,"status":107,"phases":12016,"primaryCompletion":12017,"completion":12018,"start":12019,"enrollment":3012,"conditions":12020,"interventions":12021},"NCT06422507","A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema",[92],"2025-12-29","2026-03-25","2024-05-29",[3044],[12003,12022],"2 mg aflibercept",{"trials":12024,"activeCount":101},[],{"trials":12026,"activeCount":101},[],{"intervention":12022,"totalTrials":233,"cells":12028},{"EARLY_PHASE1":12029,"PHASE1":12031,"PHASE2":12033,"PHASE3":12035,"PHASE4":12041,"NA":12043},{"trials":12030,"activeCount":101},[],{"trials":12032,"activeCount":101},[],{"trials":12034,"activeCount":101},[],{"trials":12036,"activeCount":101},[12037],{"nctId":12014,"briefTitle":12015,"status":107,"phases":12038,"primaryCompletion":12017,"completion":12018,"start":12019,"enrollment":3012,"conditions":12039,"interventions":12040},[92],[3044],[12003,12022],{"trials":12042,"activeCount":101},[],{"trials":12044,"activeCount":101},[],{"intervention":6238,"totalTrials":233,"cells":12046},{"EARLY_PHASE1":12047,"PHASE1":12049,"PHASE2":12051,"PHASE3":12053,"PHASE4":12059,"NA":12061},{"trials":12048,"activeCount":101},[],{"trials":12050,"activeCount":101},[],{"trials":12052,"activeCount":101},[],{"trials":12054,"activeCount":101},[12055],{"nctId":6232,"briefTitle":6233,"status":107,"phases":12056,"primaryCompletion":2959,"completion":2959,"start":2919,"enrollment":6235,"conditions":12057,"interventions":12058},[92],[5843],[6238,6210,6230],{"trials":12060,"activeCount":101},[],{"trials":12062,"activeCount":101},[],{"intervention":12064,"totalTrials":233,"cells":12065},"Ethinylestradiol",{"EARLY_PHASE1":12066,"PHASE1":12068,"PHASE2":12070,"PHASE3":12072,"PHASE4":12081,"NA":12083},{"trials":12067,"activeCount":101},[],{"trials":12069,"activeCount":101},[],{"trials":12071,"activeCount":101},[],{"trials":12073,"activeCount":101},[12074],{"nctId":12075,"briefTitle":12076,"status":107,"phases":12077,"primaryCompletion":1352,"completion":1352,"start":1326,"enrollment":12078,"conditions":12079,"interventions":12080},"NCT01076582","Comparative Trial in Hormone Withdrawal Associated Symptoms",[92],592,[9210],[9124,12064],{"trials":12082,"activeCount":101},[],{"trials":12084,"activeCount":101},[],{"intervention":3849,"totalTrials":233,"cells":12086},{"EARLY_PHASE1":12087,"PHASE1":12089,"PHASE2":12091,"PHASE3":12093,"PHASE4":12099,"NA":12101},{"trials":12088,"activeCount":101},[],{"trials":12090,"activeCount":101},[],{"trials":12092,"activeCount":101},[],{"trials":12094,"activeCount":101},[12095],{"nctId":3838,"briefTitle":3839,"status":107,"phases":12096,"primaryCompletion":3841,"completion":3842,"start":3843,"enrollment":3844,"conditions":12097,"interventions":12098},[92],[3846],[3542,3542,3848,3849,3772,3850,3851],{"trials":12100,"activeCount":101},[],{"trials":12102,"activeCount":101},[],{"intervention":3850,"totalTrials":233,"cells":12104},{"EARLY_PHASE1":12105,"PHASE1":12107,"PHASE2":12109,"PHASE3":12111,"PHASE4":12117,"NA":12119},{"trials":12106,"activeCount":101},[],{"trials":12108,"activeCount":101},[],{"trials":12110,"activeCount":101},[],{"trials":12112,"activeCount":101},[12113],{"nctId":3838,"briefTitle":3839,"status":107,"phases":12114,"primaryCompletion":3841,"completion":3842,"start":3843,"enrollment":3844,"conditions":12115,"interventions":12116},[92],[3846],[3542,3542,3848,3849,3772,3850,3851],{"trials":12118,"activeCount":101},[],{"trials":12120,"activeCount":101},[],{"intervention":3851,"totalTrials":233,"cells":12122},{"EARLY_PHASE1":12123,"PHASE1":12125,"PHASE2":12127,"PHASE3":12129,"PHASE4":12135,"NA":12137},{"trials":12124,"activeCount":101},[],{"trials":12126,"activeCount":101},[],{"trials":12128,"activeCount":101},[],{"trials":12130,"activeCount":101},[12131],{"nctId":3838,"briefTitle":3839,"status":107,"phases":12132,"primaryCompletion":3841,"completion":3842,"start":3843,"enrollment":3844,"conditions":12133,"interventions":12134},[92],[3846],[3542,3542,3848,3849,3772,3850,3851],{"trials":12136,"activeCount":101},[],{"trials":12138,"activeCount":101},[],{"intervention":12140,"totalTrials":233,"cells":12141},"Acyclovir 50mg buccal\u002Ftopical tablet, BAYM008894\u002FUI1614773",{"EARLY_PHASE1":12142,"PHASE1":12144,"PHASE2":12146,"PHASE3":12148,"PHASE4":12161,"NA":12163},{"trials":12143,"activeCount":101},[],{"trials":12145,"activeCount":101},[],{"trials":12147,"activeCount":101},[],{"trials":12149,"activeCount":101},[12150],{"nctId":12151,"briefTitle":12152,"status":107,"phases":12153,"primaryCompletion":12154,"completion":12155,"start":12156,"enrollment":12157,"conditions":12158,"interventions":12160},"NCT05098938","A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally",[92],"2023-07-19","2024-07-02","2021-11-23",2020,[12159],"Recurrent Herpes Labialis",[12140],{"trials":12162,"activeCount":101},[],{"trials":12164,"activeCount":101},[],{"intervention":12166,"totalTrials":233,"cells":12167},"Sulbactam\u002FAmpicillin",{"EARLY_PHASE1":12168,"PHASE1":12170,"PHASE2":12172,"PHASE3":12174,"PHASE4":12186,"NA":12188},{"trials":12169,"activeCount":101},[],{"trials":12171,"activeCount":101},[],{"trials":12173,"activeCount":101},[],{"trials":12175,"activeCount":101},[12176],{"nctId":12177,"briefTitle":12178,"status":107,"phases":12179,"completion":6048,"start":12180,"enrollment":12181,"conditions":12182,"interventions":12185},"NCT01045902","BAY12-8039, iv\u002FOral Pulmonary Abscess\u002FAspiration Pneumonia",[92],"2001-02",139,[12183,12184],"Pneumonia, Aspiration","Lung Abscess",[6720,12166],{"trials":12187,"activeCount":101},[],{"trials":12189,"activeCount":101},[],{"intervention":9038,"totalTrials":233,"cells":12191},{"EARLY_PHASE1":12192,"PHASE1":12194,"PHASE2":12196,"PHASE3":12198,"PHASE4":12204,"NA":12206},{"trials":12193,"activeCount":101},[],{"trials":12195,"activeCount":101},[],{"trials":12197,"activeCount":101},[],{"trials":12199,"activeCount":101},[12200],{"nctId":9028,"briefTitle":9029,"status":107,"phases":12201,"primaryCompletion":9031,"completion":9031,"start":9032,"enrollment":9033,"conditions":12202,"interventions":12203},[92],[9035],[9037,9038],{"trials":12205,"activeCount":101},[],{"trials":12207,"activeCount":101},[],{"intervention":12209,"totalTrials":233,"cells":12210},"Minisiston",{"EARLY_PHASE1":12211,"PHASE1":12213,"PHASE2":12215,"PHASE3":12217,"PHASE4":12226,"NA":12228},{"trials":12212,"activeCount":101},[],{"trials":12214,"activeCount":101},[],{"trials":12216,"activeCount":101},[],{"trials":12218,"activeCount":101},[12219],{"nctId":12220,"briefTitle":12221,"status":107,"phases":12222,"completion":6270,"start":446,"enrollment":12223,"conditions":12224,"interventions":12225},"NCT00220324","Pearl Index Study With Low Dose Combined Oral Contraceptive",[92],840,[15],[12209],{"trials":12227,"activeCount":101},[],{"trials":12229,"activeCount":101},[],{"intervention":8600,"totalTrials":233,"cells":12231},{"EARLY_PHASE1":12232,"PHASE1":12234,"PHASE2":12236,"PHASE3":12238,"PHASE4":12244,"NA":12246},{"trials":12233,"activeCount":101},[],{"trials":12235,"activeCount":101},[],{"trials":12237,"activeCount":101},[],{"trials":12239,"activeCount":101},[12240],{"nctId":8595,"briefTitle":8596,"status":107,"phases":12241,"primaryCompletion":1423,"completion":1423,"start":2970,"enrollment":2151,"conditions":12242,"interventions":12243},[92],[8591,8592],[8568,8581,8600],{"trials":12245,"activeCount":101},[],{"trials":12247,"activeCount":101},[],{"intervention":3868,"totalTrials":233,"cells":12249},{"EARLY_PHASE1":12250,"PHASE1":12252,"PHASE2":12254,"PHASE3":12256,"PHASE4":12262,"NA":12264},{"trials":12251,"activeCount":101},[],{"trials":12253,"activeCount":101},[],{"trials":12255,"activeCount":101},[],{"trials":12257,"activeCount":101},[12258],{"nctId":3859,"briefTitle":3860,"status":107,"phases":12259,"primaryCompletion":3862,"completion":3863,"start":3277,"enrollment":3864,"conditions":12260,"interventions":12261},[92],[3866],[3542,3868],{"trials":12263,"activeCount":101},[],{"trials":12265,"activeCount":101},[],{"intervention":12267,"totalTrials":233,"cells":12268},"Levofloxacin & Metronidazole",{"EARLY_PHASE1":12269,"PHASE1":12271,"PHASE2":12273,"PHASE3":12275,"PHASE4":12284,"NA":12286},{"trials":12270,"activeCount":101},[],{"trials":12272,"activeCount":101},[],{"trials":12274,"activeCount":101},[],{"trials":12276,"activeCount":101},[12277],{"nctId":12278,"briefTitle":12279,"status":107,"phases":12280,"primaryCompletion":4597,"completion":4597,"start":1648,"enrollment":12281,"conditions":12282,"interventions":12283},"NCT00453349","A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease",[92],460,[10254],[1144,12267],{"trials":12285,"activeCount":101},[],{"trials":12287,"activeCount":101},[],{"intervention":12289,"totalTrials":233,"cells":12290},"Drospirenone\u002FEthinylestradiol\u002FMethyltetrahydrofolate",{"EARLY_PHASE1":12291,"PHASE1":12293,"PHASE2":12295,"PHASE3":12297,"PHASE4":12308,"NA":12310},{"trials":12292,"activeCount":101},[],{"trials":12294,"activeCount":101},[],{"trials":12296,"activeCount":101},[],{"trials":12298,"activeCount":101},[12299],{"nctId":12300,"briefTitle":12301,"status":107,"phases":12302,"primaryCompletion":8109,"completion":7249,"start":6317,"enrollment":3103,"conditions":12303,"interventions":12306},"NCT00468481","Efficacy and Safety Study for an Oral Contraceptive Containing Folate",[92],[12304,15,12305],"Neural Tube Defects","Oral Contraceptives (OC)",[12289,12307],"Drospirenone\u002FEthinylestradiol",{"trials":12309,"activeCount":101},[],{"trials":12311,"activeCount":101},[],{"intervention":12307,"totalTrials":233,"cells":12313},{"EARLY_PHASE1":12314,"PHASE1":12316,"PHASE2":12318,"PHASE3":12320,"PHASE4":12326,"NA":12328},{"trials":12315,"activeCount":101},[],{"trials":12317,"activeCount":101},[],{"trials":12319,"activeCount":101},[],{"trials":12321,"activeCount":101},[12322],{"nctId":12300,"briefTitle":12301,"status":107,"phases":12323,"primaryCompletion":8109,"completion":7249,"start":6317,"enrollment":3103,"conditions":12324,"interventions":12325},[92],[12304,15,12305],[12289,12307],{"trials":12327,"activeCount":101},[],{"trials":12329,"activeCount":101},[],{"intervention":12331,"totalTrials":233,"cells":12332},"Encapsulated Microgynon + Placebo",{"EARLY_PHASE1":12333,"PHASE1":12335,"PHASE2":12337,"PHASE3":12339,"PHASE4":12349,"NA":12351},{"trials":12334,"activeCount":101},[],{"trials":12336,"activeCount":101},[],{"trials":12338,"activeCount":101},[],{"trials":12340,"activeCount":101},[12341],{"nctId":12342,"briefTitle":12343,"status":107,"phases":12344,"primaryCompletion":5409,"completion":5409,"start":498,"enrollment":12345,"conditions":12346,"interventions":12348},"NCT00778609","Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache",[92],449,[9210,6150,12347],"Pelvic Pain",[5939,12331],{"trials":12350,"activeCount":101},[],{"trials":12352,"activeCount":101},[],{"intervention":12354,"totalTrials":233,"cells":12355},"Ertapenem intravenous",{"EARLY_PHASE1":12356,"PHASE1":12358,"PHASE2":12360,"PHASE3":12362,"PHASE4":12372,"NA":12374},{"trials":12357,"activeCount":101},[],{"trials":12359,"activeCount":101},[],{"trials":12361,"activeCount":101},[],{"trials":12363,"activeCount":101},[12364],{"nctId":12365,"briefTitle":12366,"status":107,"phases":12367,"primaryCompletion":4292,"completion":4292,"start":1315,"enrollment":12368,"conditions":12369,"interventions":12371},"NCT00492726","Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem",[92],804,[12370],"Infection",[1144,12354],{"trials":12373,"activeCount":101},[],{"trials":12375,"activeCount":101},[],{"intervention":2994,"totalTrials":233,"cells":12377},{"EARLY_PHASE1":12378,"PHASE1":12380,"PHASE2":12382,"PHASE3":12384,"PHASE4":12390,"NA":12392},{"trials":12379,"activeCount":101},[],{"trials":12381,"activeCount":101},[],{"trials":12383,"activeCount":101},[],{"trials":12385,"activeCount":101},[12386],{"nctId":2986,"briefTitle":2987,"status":107,"phases":12387,"primaryCompletion":2989,"completion":2990,"start":2991,"enrollment":2345,"conditions":12388,"interventions":12389},[92],[2943],[82,2994],{"trials":12391,"activeCount":101},[],{"trials":12393,"activeCount":101},[],{"intervention":9187,"totalTrials":233,"cells":12395},{"EARLY_PHASE1":12396,"PHASE1":12398,"PHASE2":12400,"PHASE3":12402,"PHASE4":12408,"NA":12410},{"trials":12397,"activeCount":101},[],{"trials":12399,"activeCount":101},[],{"trials":12401,"activeCount":101},[],{"trials":12403,"activeCount":101},[12404],{"nctId":9181,"briefTitle":9182,"status":107,"phases":12405,"primaryCompletion":1498,"completion":3567,"start":3778,"enrollment":9184,"conditions":12406,"interventions":12407},[92],[6495,1103],[9187,9162,9188],{"trials":12409,"activeCount":101},[],{"trials":12411,"activeCount":101},[],{"intervention":9188,"totalTrials":233,"cells":12413},{"EARLY_PHASE1":12414,"PHASE1":12416,"PHASE2":12418,"PHASE3":12420,"PHASE4":12426,"NA":12428},{"trials":12415,"activeCount":101},[],{"trials":12417,"activeCount":101},[],{"trials":12419,"activeCount":101},[],{"trials":12421,"activeCount":101},[12422],{"nctId":9181,"briefTitle":9182,"status":107,"phases":12423,"primaryCompletion":1498,"completion":3567,"start":3778,"enrollment":9184,"conditions":12424,"interventions":12425},[92],[6495,1103],[9187,9162,9188],{"trials":12427,"activeCount":101},[],{"trials":12429,"activeCount":101},[],{"intervention":5869,"totalTrials":233,"cells":12431},{"EARLY_PHASE1":12432,"PHASE1":12434,"PHASE2":12436,"PHASE3":12438,"PHASE4":12444,"NA":12446},{"trials":12433,"activeCount":101},[],{"trials":12435,"activeCount":101},[],{"trials":12437,"activeCount":101},[],{"trials":12439,"activeCount":101},[12440],{"nctId":5860,"briefTitle":5861,"status":107,"phases":12441,"primaryCompletion":5863,"completion":51,"start":5864,"enrollment":5865,"conditions":12442,"interventions":12443},[92],[5867],[5869,5816,5846],{"trials":12445,"activeCount":101},[],{"trials":12447,"activeCount":101},[],{"intervention":12449,"totalTrials":233,"cells":12450},"BAY 59-7939",{"EARLY_PHASE1":12451,"PHASE1":12453,"PHASE2":12455,"PHASE3":12457,"PHASE4":12471,"NA":12473},{"trials":12452,"activeCount":101},[],{"trials":12454,"activeCount":101},[],{"trials":12456,"activeCount":101},[],{"trials":12458,"activeCount":101},[12459],{"nctId":12460,"briefTitle":12461,"status":107,"phases":12462,"primaryCompletion":12463,"completion":12464,"start":12465,"enrollment":12466,"conditions":12467,"interventions":12469},"NCT02064439","Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)",[92],"2016-09-22","2016-11-04","2014-03-05",3365,[3716,3641,12468,3560,3631],"Thrombosis",[12449,12449,12470],"ASA",{"trials":12472,"activeCount":101},[],{"trials":12474,"activeCount":101},[],{"intervention":12470,"totalTrials":233,"cells":12476},{"EARLY_PHASE1":12477,"PHASE1":12479,"PHASE2":12481,"PHASE3":12483,"PHASE4":12489,"NA":12491},{"trials":12478,"activeCount":101},[],{"trials":12480,"activeCount":101},[],{"trials":12482,"activeCount":101},[],{"trials":12484,"activeCount":101},[12485],{"nctId":12460,"briefTitle":12461,"status":107,"phases":12486,"primaryCompletion":12463,"completion":12464,"start":12465,"enrollment":12466,"conditions":12487,"interventions":12488},[92],[3716,3641,12468,3560,3631],[12449,12449,12470],{"trials":12490,"activeCount":101},[],{"trials":12492,"activeCount":101},[],{"intervention":12494,"totalTrials":4620,"cells":12495},"BAY1817080",{"EARLY_PHASE1":12496,"PHASE1":12498,"PHASE2":12562,"PHASE3":12611,"PHASE4":12613,"NA":12615},{"trials":12497,"activeCount":101},[],{"trials":12499,"activeCount":101},[12500,12512,12521,12528,12536,12545,12555],{"nctId":12501,"briefTitle":12502,"status":107,"phases":12503,"primaryCompletion":12504,"completion":12505,"start":12506,"enrollment":1509,"conditions":12507,"interventions":12511},"NCT04471337","Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function",[90],"2021-02-15","2021-05-06","2020-08-12",[12508,9474,12509,12510],"Endometriosis Related Pain","Diabetic Neuropathic Pain","Refractory or Unexplained Chronic Cough",[12494],{"nctId":12513,"briefTitle":12514,"status":107,"phases":12515,"primaryCompletion":380,"completion":12516,"start":12517,"enrollment":2212,"conditions":12518,"interventions":12520},"NCT04423744","Study to Gather Information on the Influence of BAY1817080 on the Electrical Activity of the Heart Recorded by an Electrocardiogram in Healthy Male and Female Participants",[90],"2021-01-21","2020-06-18",[12519,7793,9474],"Cough",[12494,1144],{"nctId":12522,"briefTitle":12523,"status":107,"phases":12524,"primaryCompletion":12525,"completion":12525,"start":611,"enrollment":1265,"conditions":12526,"interventions":12527},"NCT04265781","Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants",[90],"2020-09-20",[12508,9474,12509,12510],[12494],{"nctId":12529,"briefTitle":12530,"status":107,"phases":12531,"primaryCompletion":12532,"completion":1224,"start":12533,"enrollment":1561,"conditions":12534,"interventions":12535},"NCT04802343","A Trial to Learn How BAY1817080 Moves Into, Through and Out of the Body and How Safe it is in Healthy Chinese Men",[90],"2021-07-19","2021-04-02",[1124],[12494],{"nctId":12537,"briefTitle":12538,"status":107,"phases":12539,"primaryCompletion":4095,"completion":12540,"start":12541,"enrollment":1181,"conditions":12542,"interventions":12543},"NCT04487431","A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B)",[90],"2021-02-11","2020-08-05",[12508,9474,12509,12510],[12494,12544],"[14C]BAY1817080",{"nctId":12546,"briefTitle":12547,"status":107,"phases":12548,"primaryCompletion":12549,"completion":12550,"start":12551,"enrollment":5094,"conditions":12552,"interventions":12554},"NCT02817100","First in Human Study to Investigate the Safety and Tolerability, Pharmacokinetics, Itraconazole Drug-drug-interaction and Food Effect of BAY1817080",[90],"2017-05-11","2017-08-23","2016-07-22",[12553],"Clinical Trials, Phase I as Topic",[12494,1934],{"nctId":12556,"briefTitle":12557,"status":107,"phases":12558,"primaryCompletion":12559,"completion":4048,"start":966,"enrollment":5231,"conditions":12560,"interventions":12561},"NCT04454424","Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function",[90],"2021-06-24",[12508,9474,12509,12510],[12494,1154],{"trials":12563,"activeCount":101},[12564,12575,12586,12594,12602],{"nctId":12565,"briefTitle":12566,"status":156,"phases":12567,"primaryCompletion":12568,"completion":12569,"start":12570,"enrollment":1833,"conditions":12571,"interventions":12573},"NCT04641273","A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain",[91],"2021-09-23","2021-10-18","2021-01-22",[12572],"Neuropathic Pain Associated With Diabetic Peripheral Neuropathy",[12494,12574],"Pregabalin",{"nctId":12576,"briefTitle":12577,"status":156,"phases":12578,"primaryCompletion":12579,"completion":12580,"start":12581,"enrollment":12582,"conditions":12583,"interventions":12584},"NCT04614246","Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb",[91],"2022-01-17","2022-05-03","2021-01-29",215,[7793],[12494,12585],"Elagolix",{"nctId":12587,"briefTitle":12588,"status":107,"phases":12589,"primaryCompletion":640,"completion":1110,"start":5876,"enrollment":12590,"conditions":12591,"interventions":12593},"NCT04562155","Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough",[91],310,[12592],"Refractory and\u002For Unexplained Chronic Cough",[12494],{"nctId":12595,"briefTitle":12596,"status":107,"phases":12597,"primaryCompletion":12598,"completion":12599,"start":1274,"enrollment":541,"conditions":12600,"interventions":12601},"NCT04545580","Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB)",[91],"2021-12-22","2022-01-21",[9474],[12494],{"nctId":12603,"briefTitle":12604,"status":107,"phases":12605,"primaryCompletion":12606,"completion":12607,"start":4926,"enrollment":12608,"conditions":12609,"interventions":12610},"NCT03310645","Repeat Doses of BAY 1817080 in Healthy Males & Proof of Concept in Chronic Cough Patients",[90,91],"2019-05-28","2019-06-19",87,[12519],[12494],{"trials":12612,"activeCount":101},[],{"trials":12614,"activeCount":101},[],{"trials":12616,"activeCount":101},[],{"intervention":1154,"totalTrials":3374,"cells":12618},{"EARLY_PHASE1":12619,"PHASE1":12621,"PHASE2":12688,"PHASE3":12699,"PHASE4":12701,"NA":12703},{"trials":12620,"activeCount":101},[],{"trials":12622,"activeCount":101},[12623,12627,12638,12648,12652,12661,12665,12675,12679],{"nctId":2193,"briefTitle":2194,"status":107,"phases":12624,"primaryCompletion":2196,"completion":2197,"start":2198,"enrollment":2199,"conditions":12625,"interventions":12626},[90],[29],[1011,2202,2203,1154,2204],{"nctId":12628,"briefTitle":12629,"status":107,"phases":12630,"primaryCompletion":12631,"completion":12632,"start":12633,"enrollment":4620,"conditions":12634,"interventions":12635},"NCT02975440","Drug-drug Interaction Study Between Orally Administered Rifampicin and Vilaprisan",[90],"2017-01-27","2017-04-11","2016-11-10",[7793],[12636,1154,12637],"Rifampicin","BAY1002670_Vilaprisan",{"nctId":12639,"briefTitle":12640,"status":107,"phases":12641,"primaryCompletion":12599,"completion":12642,"start":12643,"enrollment":6822,"conditions":12644,"interventions":12645},"NCT03965728","Study to Investigate Safety, Tolerability, Pharmacokinetics, and Drug-drug Interaction of Multiple Oral Doses of BAY1830839 in Healthy Male Participants",[90],"2022-05-11","2019-06-05",[1124],[12646,1154,12647],"BAY1830839","Methotrexate",{"nctId":1146,"briefTitle":1147,"status":107,"phases":12649,"primaryCompletion":1149,"completion":1150,"start":1151,"enrollment":1081,"conditions":12650,"interventions":12651},[90],[1094],[52,1154,1155],{"nctId":12653,"briefTitle":12654,"status":107,"phases":12655,"primaryCompletion":12656,"completion":399,"start":3031,"enrollment":229,"conditions":12657,"interventions":12658},"NCT04027192","Study to Test the Safety of Increasing Multiple Doses of BAY2328065 Given by Mouth, How the Drug is Tolerated and Acts in the Human Body of Healthy Male Participants. Alteration of the Study Drug Effects by Another Drug and the Availability of the Drug Given in Different Formulations is Also Tested.",[90],"2020-09-11",[7793],[12659,12660,1154],"BAY2328065 LSF","BAY2328065",{"nctId":1953,"briefTitle":1954,"status":107,"phases":12662,"primaryCompletion":313,"completion":313,"start":1956,"enrollment":1949,"conditions":12663,"interventions":12664},[90],[1069,1932,1070,1124],[1919,1154],{"nctId":12666,"briefTitle":12667,"status":107,"phases":12668,"primaryCompletion":1274,"completion":12669,"start":12670,"enrollment":11,"conditions":12671,"interventions":12673},"NCT03493269","A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Psoriasis",[90],"2021-02-05","2018-04-16",[1124,12672],"Psoriasis",[12674,1154],"BAY1834845",{"nctId":12556,"briefTitle":12557,"status":107,"phases":12676,"primaryCompletion":12559,"completion":4048,"start":966,"enrollment":5231,"conditions":12677,"interventions":12678},[90],[12508,9474,12509,12510],[12494,1154],{"nctId":12680,"briefTitle":12681,"status":107,"phases":12682,"primaryCompletion":12683,"completion":3638,"start":12684,"enrollment":1949,"conditions":12685,"interventions":12686},"NCT03237416","Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers",[90],"2017-10-05","2017-08-02",[187],[1126,1154,12687],"BAY1841788",{"trials":12689,"activeCount":101},[12690],{"nctId":12691,"briefTitle":12692,"status":107,"phases":12693,"primaryCompletion":12694,"completion":5139,"start":12695,"enrollment":2307,"conditions":12696,"interventions":12697},"NCT03535168","Repeat Doses of BAY1902607 in Healthy Males and Proof of Concept in Chronic Cough Patients",[90,91],"2019-09-25","2018-05-29",[12519],[12698,1154],"BAY1902607",{"trials":12700,"activeCount":101},[],{"trials":12702,"activeCount":101},[],{"trials":12704,"activeCount":101},[],{"intervention":1319,"totalTrials":480,"cells":12706},{"EARLY_PHASE1":12707,"PHASE1":12709,"PHASE2":12717,"PHASE3":12757,"PHASE4":12759,"NA":12761},{"trials":12708,"activeCount":101},[],{"trials":12710,"activeCount":101},[12711],{"nctId":12712,"briefTitle":12713,"status":107,"phases":12714,"primaryCompletion":4579,"completion":4579,"start":1648,"enrollment":480,"conditions":12715,"interventions":12716},"NCT00432302","Investigation of Mass Balance of the Test Drug and Major Metabolites",[90],[29],[1319],{"trials":12718,"activeCount":101},[12719,12723,12729,12735,12743,12750],{"nctId":1310,"briefTitle":1311,"status":107,"phases":12720,"primaryCompletion":1313,"completion":1314,"start":1315,"enrollment":124,"conditions":12721,"interventions":12722},[90,91],[1317],[1319,1073],{"nctId":12724,"briefTitle":12725,"status":156,"phases":12726,"primaryCompletion":6317,"completion":6317,"start":4861,"enrollment":3374,"conditions":12727,"interventions":12728},"NCT00299390","Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer",[91],[1305],[1319],{"nctId":12730,"briefTitle":12731,"status":107,"phases":12732,"primaryCompletion":3723,"completion":3723,"start":6270,"enrollment":112,"conditions":12733,"interventions":12734},"NCT00246688","Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer",[91],[4660],[1319],{"nctId":12736,"briefTitle":12737,"status":107,"phases":12738,"primaryCompletion":2970,"completion":4700,"start":4613,"enrollment":12739,"conditions":12740,"interventions":12742},"NCT00160069","Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer",[91],128,[12741],"Carcinoma, Non Small Cell Lung",[1319,1319,1319],{"nctId":12744,"briefTitle":12745,"status":107,"phases":12746,"primaryCompletion":4612,"completion":4588,"start":4571,"enrollment":6445,"conditions":12747,"interventions":12749},"NCT00288249","Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer",[91],[521,12748],"Breast Cancer, Metastatic",[1319,1319,1319,1319],{"nctId":12751,"briefTitle":12752,"status":107,"phases":12753,"primaryCompletion":1498,"completion":3567,"start":4861,"enrollment":6678,"conditions":12754,"interventions":12756},"NCT00313248","Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer",[91],[12755],"Breast Neoplasm",[1319,1319],{"trials":12758,"activeCount":101},[],{"trials":12760,"activeCount":101},[],{"trials":12762,"activeCount":101},[],{"intervention":12764,"totalTrials":5220,"cells":12765},"BAY3283142",{"EARLY_PHASE1":12766,"PHASE1":12768,"PHASE2":12807,"PHASE3":12818,"PHASE4":12820,"NA":12822},{"trials":12767,"activeCount":101},[],{"trials":12769,"activeCount":101},[12770,12778,12785,12793,12801],{"nctId":12771,"briefTitle":12772,"status":107,"phases":12773,"primaryCompletion":12774,"completion":632,"start":12775,"enrollment":995,"conditions":12776,"interventions":12777},"NCT05491642","A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses",[90],"2023-01-03","2022-09-08",[32,6625],[12764],{"nctId":12779,"briefTitle":12780,"status":107,"phases":12781,"primaryCompletion":71,"completion":71,"start":9321,"enrollment":1649,"conditions":12782,"interventions":12784},"NCT06428825","A Study to Learn About the Safety of BAY3283142 in People With Mild to Moderate High Blood Pressure",[90],[32,12783],"Arterial Hypertension",[12764],{"nctId":12786,"briefTitle":12787,"status":107,"phases":12788,"primaryCompletion":3474,"completion":3474,"start":12789,"enrollment":1701,"conditions":12790,"interventions":12792},"NCT06487845","A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants",[90],"2024-07-04",[32,12791,1124],"Non-proliferative Diabetic Retinopathy",[12764],{"nctId":12794,"briefTitle":12795,"status":107,"phases":12796,"primaryCompletion":12797,"completion":12797,"start":12798,"enrollment":1701,"conditions":12799,"interventions":12800},"NCT06402721","A Study to Learn About How BAY 3283142 Moves Into, Through, and Out of the Body After a Single Dose in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function",[90],"2025-02-24","2024-05-17",[32,8649],[12764],{"nctId":12802,"briefTitle":12803,"status":107,"phases":12804,"primaryCompletion":12154,"completion":12154,"start":207,"enrollment":1701,"conditions":12805,"interventions":12806},"NCT05800444","A Study to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body, How it Moves Into, Through and Out of the Body When Single and Multiple Amounts Are Taken as Tablets in Japanese Healthy Male Participants",[90],[32,1124],[12764],{"trials":12808,"activeCount":101},[12809],{"nctId":12810,"briefTitle":12811,"status":107,"phases":12812,"primaryCompletion":12813,"completion":4548,"start":12814,"enrollment":12815,"conditions":12816,"interventions":12817},"NCT06522997","A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease",[91],"2025-10-24","2024-08-08",1222,[32],[12764],{"trials":12819,"activeCount":101},[],{"trials":12821,"activeCount":101},[],{"trials":12823,"activeCount":101},[],{"intervention":8380,"totalTrials":328,"cells":12825},{"EARLY_PHASE1":12826,"PHASE1":12828,"PHASE2":12851,"PHASE3":12865,"PHASE4":12867,"NA":12869},{"trials":12827,"activeCount":101},[],{"trials":12829,"activeCount":101},[12830,12836,12842],{"nctId":12831,"briefTitle":12832,"status":107,"phases":12833,"primaryCompletion":2919,"completion":2919,"start":1351,"enrollment":25,"conditions":12834,"interventions":12835},"NCT01458028","Age and Gender Effects on the Pharmacokinetics of BAY85-3934",[90],[5074],[8380],{"nctId":12837,"briefTitle":12838,"status":107,"phases":12839,"primaryCompletion":1586,"completion":2230,"start":2188,"enrollment":30,"conditions":12840,"interventions":12841},"NCT01332942","Combined Single \u002F Multiple Dose Escalation Study in Patients With Renal Anemia Due to CKD (Chronic Kidney Disease)",[90],[5074],[8380,8380,8380,8380,8380,8380],{"nctId":12843,"briefTitle":12844,"status":107,"phases":12845,"primaryCompletion":12846,"completion":12847,"start":12848,"enrollment":995,"conditions":12849,"interventions":12850},"NCT01318551","Single Dose Group Stratified Study in Renal Impaired and Healthy Aged and Gender Matched Subjects",[90],"2013-09-05","2014-08-14","2011-03-16",[5074],[8380,8380,8380],{"trials":12852,"activeCount":101},[12853,12861],{"nctId":12854,"briefTitle":12855,"status":107,"phases":12856,"primaryCompletion":1743,"completion":12857,"start":12858,"enrollment":1610,"conditions":12859,"interventions":12860},"NCT02021370","15141 Fixed Dose Correction \u002F naïve and Pre Dialysis (Europe and Asia Pacific)",[91],"2015-09-23","2014-02-10",[5074,5063],[8380],{"nctId":8372,"briefTitle":8373,"status":107,"phases":12862,"primaryCompletion":8375,"completion":8376,"start":8377,"enrollment":3214,"conditions":12863,"interventions":12864},[91],[5074,5063],[8380,5124],{"trials":12866,"activeCount":101},[],{"trials":12868,"activeCount":101},[],{"trials":12870,"activeCount":101},[],{"intervention":1307,"totalTrials":328,"cells":12872},{"EARLY_PHASE1":12873,"PHASE1":12875,"PHASE2":12898,"PHASE3":12914,"PHASE4":12916,"NA":12918},{"trials":12874,"activeCount":101},[],{"trials":12876,"activeCount":101},[12877,12885,12892],{"nctId":12878,"briefTitle":12879,"status":107,"phases":12880,"primaryCompletion":2289,"completion":12881,"start":1587,"enrollment":12882,"conditions":12883,"interventions":12884},"NCT01188252","Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on \u002F 4 Days Off Schedule in Subjects With Advanced Malignancies",[90],"2016-12",112,[29],[1307],{"nctId":12886,"briefTitle":12887,"status":107,"phases":12888,"primaryCompletion":5964,"completion":2289,"start":2290,"enrollment":480,"conditions":12889,"interventions":12890},"NCT02390154","Roniciclib Mass Balance Study",[90],[29],[12891,12891],"roniciclib",{"nctId":12893,"briefTitle":12894,"status":107,"phases":12895,"primaryCompletion":7776,"completion":409,"start":1487,"enrollment":1181,"conditions":12896,"interventions":12897},"NCT02457351","Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study",[90],[1267],[1307,1934],{"trials":12899,"activeCount":101},[12900,12904],{"nctId":1297,"briefTitle":1298,"status":156,"phases":12901,"primaryCompletion":1300,"completion":1301,"start":1302,"enrollment":1303,"conditions":12902,"interventions":12903},[90,91],[1305],[1307,1308,1073,1074],{"nctId":12905,"briefTitle":12906,"status":156,"phases":12907,"primaryCompletion":12908,"completion":12909,"start":12910,"enrollment":12911,"conditions":12912,"interventions":12913},"NCT02161419","RONICICLIB \u002F Placebo in Combination With Chemotherapy in Small Cell Lung Cancer",[91],"2015-12-31","2016-05-25","2014-07-30",142,[1305],[1307],{"trials":12915,"activeCount":101},[],{"trials":12917,"activeCount":101},[],{"trials":12919,"activeCount":101},[],{"intervention":1281,"totalTrials":328,"cells":12921},{"EARLY_PHASE1":12922,"PHASE1":12924,"PHASE2":12957,"PHASE3":12971,"PHASE4":12973,"NA":12975},{"trials":12923,"activeCount":101},[],{"trials":12925,"activeCount":101},[12926,12935,12943,12953],{"nctId":12927,"briefTitle":12928,"status":107,"phases":12929,"primaryCompletion":12930,"completion":12931,"start":12932,"enrollment":112,"conditions":12933,"interventions":12934},"NCT02824042","Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole",[90],"2018-06-27","2019-08-05","2016-09-07",[1267],[1281,1934],{"nctId":12936,"briefTitle":12937,"status":107,"phases":12938,"primaryCompletion":12939,"completion":1658,"start":12940,"enrollment":2345,"conditions":12941,"interventions":12942},"NCT02696642","Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment",[90],"2018-07-31","2016-04-14",[29],[1281],{"nctId":12944,"briefTitle":12945,"status":107,"phases":12946,"primaryCompletion":12947,"completion":12948,"start":12949,"enrollment":6678,"conditions":12950,"interventions":12951},"NCT02751918","Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer",[90],"2019-08-23","2019-10-31","2016-06-08",[4660],[1281,12952],"Pegylated Liposomal Doxorubicin",{"nctId":1271,"briefTitle":1272,"status":107,"phases":12954,"primaryCompletion":1274,"completion":1275,"start":1276,"enrollment":1277,"conditions":12955,"interventions":12956},[90],[29],[1073,1280,1281],{"trials":12958,"activeCount":101},[12959],{"nctId":12960,"briefTitle":12961,"status":107,"phases":12962,"primaryCompletion":12963,"completion":12964,"start":12965,"enrollment":12966,"conditions":12967,"interventions":12969},"NCT02610140","Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)",[91],"2017-05-31","2019-09-06","2015-12-03",248,[12968],"Mesothelioma",[1281,12970],"Vinorelbine",{"trials":12972,"activeCount":101},[],{"trials":12974,"activeCount":101},[],{"trials":12976,"activeCount":101},[],{"intervention":12978,"totalTrials":855,"cells":12979},"BAY94-8862",{"EARLY_PHASE1":12980,"PHASE1":12982,"PHASE2":12993,"PHASE3":13022,"PHASE4":13024,"NA":13026},{"trials":12981,"activeCount":101},[],{"trials":12983,"activeCount":101},[12984],{"nctId":12985,"briefTitle":12986,"status":107,"phases":12987,"primaryCompletion":12988,"completion":12989,"start":12990,"enrollment":2388,"conditions":12991,"interventions":12992},"NCT01687920","Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets",[90],"2012-11-28","2013-03-21","2012-09-17",[738],[12978,12978,12978,12978,12978],{"trials":12994,"activeCount":101},[12995,13004,13013],{"nctId":12996,"briefTitle":12997,"status":107,"phases":12998,"primaryCompletion":12999,"completion":13000,"start":4984,"enrollment":3568,"conditions":13001,"interventions":13002},"NCT01968668","Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)",[91],"2014-10-09","2014-11-07",[760],[12978,12978,12978,12978,12978,13003,13003],"BAY 94-8862",{"nctId":13005,"briefTitle":13006,"status":107,"phases":13007,"primaryCompletion":13008,"completion":13009,"start":2221,"enrollment":11,"conditions":13010,"interventions":13011},"NCT01955694","Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone",[91],"2015-01-23","2015-02-20",[738],[12978,13012],"Eplerenone",{"nctId":13014,"briefTitle":13015,"status":107,"phases":13016,"primaryCompletion":4339,"completion":13017,"start":8422,"enrollment":13018,"conditions":13019,"interventions":13020},"NCT01345656","BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease",[91],"2012-07-16",457,[738],[12978,12978,12978,12978,13021],"Spironolactone",{"trials":13023,"activeCount":101},[],{"trials":13025,"activeCount":101},[],{"trials":13027,"activeCount":101},[],{"intervention":13029,"totalTrials":855,"cells":13030},"Neladenoson bialanate",{"EARLY_PHASE1":13031,"PHASE1":13033,"PHASE2":13051,"PHASE3":13071,"PHASE4":13073,"NA":13075},{"trials":13032,"activeCount":101},[],{"trials":13034,"activeCount":101},[13035,13043],{"nctId":13036,"briefTitle":13037,"status":156,"phases":13038,"primaryCompletion":3294,"completion":13039,"start":13040,"enrollment":6203,"conditions":13041,"interventions":13042},"NCT04322253","Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose in Participants With Liver Impairment and Healthy Participants Matched for Age-, Gender-, and Weight",[90],"2018-12-17","2017-08-24",[1511],[13029],{"nctId":13044,"briefTitle":13045,"status":156,"phases":13046,"primaryCompletion":13047,"completion":13039,"start":13048,"enrollment":1163,"conditions":13049,"interventions":13050},"NCT04320771","Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose of 10 mg Immediate Release Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight",[90],"2018-08-08","2017-11-02",[1511],[13029],{"trials":13052,"activeCount":101},[13053,13062],{"nctId":13054,"briefTitle":13055,"status":107,"phases":13056,"primaryCompletion":7501,"completion":13057,"start":13058,"enrollment":13059,"conditions":13060,"interventions":13061},"NCT02992288","A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction",[91],"2018-05-16","2017-02-22",427,[738],[13029,13029,13029,13029,13029],{"nctId":13063,"briefTitle":13064,"status":107,"phases":13065,"primaryCompletion":1262,"completion":13066,"start":13067,"enrollment":13068,"conditions":13069,"interventions":13070},"NCT03098979","A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction",[91],"2018-06-20","2017-05-10",305,[738],[13029,13029,13029,13029,13029],{"trials":13072,"activeCount":101},[],{"trials":13074,"activeCount":101},[],{"trials":13076,"activeCount":101},[],{"intervention":13078,"totalTrials":855,"cells":13079},"Xarelto",{"EARLY_PHASE1":13080,"PHASE1":13082,"PHASE2":13084,"PHASE3":13114,"PHASE4":13116,"NA":13118},{"trials":13081,"activeCount":101},[],{"trials":13083,"activeCount":101},[],{"trials":13085,"activeCount":101},[13086,13093,13101,13107],{"nctId":13087,"briefTitle":13088,"status":107,"phases":13089,"primaryCompletion":4789,"completion":4789,"start":6384,"enrollment":3676,"conditions":13090,"interventions":13091},"NCT00839163","Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)",[91],[3560,3621],[13078,13078,13078,13078,13092],"Enoxaparin\u002FVitamin K-Antagonist",{"nctId":13094,"briefTitle":13095,"status":107,"phases":13096,"completion":4571,"start":6363,"enrollment":13097,"conditions":13098,"interventions":13099},"NCT00395772","Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis",[91],543,[3631],[13078,13078,13078,13100],"(LMW) Heparin + Vitamin K Antagonist",{"nctId":13102,"briefTitle":13103,"status":107,"phases":13104,"completion":5472,"start":6396,"enrollment":435,"conditions":13105,"interventions":13106},"NCT00973323","BAY59-7939 Japanese in Atrial Fibrillation (2nd)",[91],[21],[13078,13078,13078,2202],{"nctId":13108,"briefTitle":13109,"status":107,"phases":13110,"completion":1648,"start":1315,"enrollment":13111,"conditions":13112,"interventions":13113},"NCT00973245","BAY59-7939 in Atrial Fibrillation Once Daily (OD)",[91],102,[21],[13078,13078,13078,2202],{"trials":13115,"activeCount":101},[],{"trials":13117,"activeCount":101},[],{"trials":13119,"activeCount":101},[],{"intervention":13121,"totalTrials":855,"cells":13122},"Mapracorat",{"EARLY_PHASE1":13123,"PHASE1":13125,"PHASE2":13139,"PHASE3":13168,"PHASE4":13170,"NA":13172},{"trials":13124,"activeCount":101},[],{"trials":13126,"activeCount":101},[13127],{"nctId":13128,"briefTitle":13129,"status":107,"phases":13130,"primaryCompletion":13131,"completion":13131,"start":13132,"enrollment":1701,"conditions":13133,"interventions":13134},"NCT03399526","1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat",[90],"2013-05-31","2013-02-11",[12672],[13121,13135,13136,13137,13138],"Prednicarbate 0.25% ointment","Clobetasol 0.05% ointment","Calcipotriene 0.005% ointment","Calcipotriene 0.005%\u002FBetamethasone dipropionate 0.05% ointment",{"trials":13140,"activeCount":101},[13141,13151,13160],{"nctId":13142,"briefTitle":13143,"status":107,"phases":13144,"primaryCompletion":13145,"completion":13146,"start":8422,"enrollment":4620,"conditions":13147,"interventions":13150},"NCT01407510","HPA Axis Study in Japanese Adults",[91],"2011-09-16","2012-04-15",[13148,13149],"Atopic Dermatitis","Eczema",[13121],{"nctId":13152,"briefTitle":13153,"status":107,"phases":13154,"primaryCompletion":13155,"completion":13156,"start":13157,"enrollment":1630,"conditions":13158,"interventions":13159},"NCT01408511","HPA Axis Study in Adults",[91],"2011-12-15","2011-12-21","2011-07-19",[13148,13149],[13121],{"nctId":13161,"briefTitle":13162,"status":107,"phases":13163,"primaryCompletion":1351,"completion":1351,"start":3618,"enrollment":13164,"conditions":13165,"interventions":13166},"NCT01359787","Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD)",[91],197,[13148,13149],[13121,13167],"Vehicle without active",{"trials":13169,"activeCount":101},[],{"trials":13171,"activeCount":101},[],{"trials":13173,"activeCount":101},[],{"intervention":13175,"totalTrials":855,"cells":13176},"Cinaciguat",{"EARLY_PHASE1":13177,"PHASE1":13179,"PHASE2":13181,"PHASE3":13210,"PHASE4":13212,"NA":13214},{"trials":13178,"activeCount":101},[],{"trials":13180,"activeCount":101},[],{"trials":13182,"activeCount":101},[13183,13190,13197,13204],{"nctId":13184,"briefTitle":13185,"status":156,"phases":13186,"primaryCompletion":1569,"completion":2344,"start":4596,"enrollment":4620,"conditions":13187,"interventions":13189},"NCT01065077","BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)",[91],[13188],"Acute Heart Failure",[13175,13175,13175],{"nctId":13191,"briefTitle":13192,"status":156,"phases":13193,"primaryCompletion":2344,"completion":5975,"start":1326,"enrollment":1133,"conditions":13194,"interventions":13196},"NCT01064037","A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg\u002Fh, 100 µg\u002Fh, 50 µg\u002Fh) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)",[91],[738,13195],"Heart Decompensation",[13175,13175,13175],{"nctId":13198,"briefTitle":13199,"status":156,"phases":13200,"primaryCompletion":4292,"completion":1313,"start":3768,"enrollment":1858,"conditions":13201,"interventions":13203},"NCT00559650","Placebo Controlled, Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Tolerability of BAY58-2667",[91],[13202],"Congestive Heart Failure",[13175],{"nctId":13205,"briefTitle":13206,"status":156,"phases":13207,"primaryCompletion":2968,"completion":1570,"start":4596,"enrollment":328,"conditions":13208,"interventions":13209},"NCT01067859","A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg\u002Fh, 10 µg\u002Fh) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)",[91],[13188],[13175,13175],{"trials":13211,"activeCount":101},[],{"trials":13213,"activeCount":101},[],{"trials":13215,"activeCount":101},[],{"intervention":13217,"totalTrials":855,"cells":13218},"BAY2395840",{"EARLY_PHASE1":13219,"PHASE1":13221,"PHASE2":13247,"PHASE3":13259,"PHASE4":13261,"NA":13263},{"trials":13220,"activeCount":101},[],{"trials":13222,"activeCount":101},[13223,13232,13241],{"nctId":13224,"briefTitle":13225,"status":107,"phases":13226,"primaryCompletion":1004,"completion":13227,"start":13228,"enrollment":112,"conditions":13229,"interventions":13230},"NCT05517746","Study on the Safety of the Drug BAY2395840 at Different Doses, the Way the Body Absorbs, Distributes and Excretes the Drug Including the Effect of Its Formulation (Tablet or Liquid) and the Effect of Food on the Absorption, Distribution or Excretion of the Drug in Healthy Male Participants",[90],"2021-03-11","2019-12-18",[7793],[13217,13231],"BAY2395840 oral solution",{"nctId":13233,"briefTitle":13234,"status":464,"phases":13235,"primaryCompletion":13236,"completion":13237,"start":10758,"enrollment":101,"conditions":13238,"interventions":13240},"NCT05406219","A Study to Learn How the Study Treatment BAY2395840 Moves Into, Through and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Moderate Reduced Kidney Function and in Healthy Male and Female Participants With Normal Kidney Function",[90],"2023-08-17","2023-10-12",[12509,13239,1124],"Renal Impairment",[13217],{"nctId":13242,"briefTitle":13243,"status":107,"phases":13244,"primaryCompletion":3905,"completion":3905,"start":1030,"enrollment":1701,"conditions":13245,"interventions":13246},"NCT05563454","A Study to Learn How Safe the Study Treatment BAY2395840 is, How it Affects the Body and How it Moves Into, Through, and Out of the Body if Given in Single and in Repetitive Doses to Japanese Healthy Male Participants",[90],[12509,1124],[13217],{"trials":13248,"activeCount":101},[13249],{"nctId":13250,"briefTitle":13251,"status":107,"phases":13252,"primaryCompletion":13253,"completion":13254,"start":13255,"enrollment":7250,"conditions":13256,"interventions":13258},"NCT05219812","A Study to Learn How Safe BAY2395840 is and How Well it Works in Participants Who Have Diabetic Nerve Pain",[91],"2022-11-07","2022-11-21","2022-02-16",[12572,13257,8425],"Peripheral Neuropathic Pain",[13217],{"trials":13260,"activeCount":101},[],{"trials":13262,"activeCount":101},[],{"trials":13264,"activeCount":101},[],{"intervention":2276,"totalTrials":855,"cells":13266},{"EARLY_PHASE1":13267,"PHASE1":13269,"PHASE2":13279,"PHASE3":13293,"PHASE4":13295,"NA":13297},{"trials":13268,"activeCount":101},[],{"trials":13270,"activeCount":101},[13271,13275],{"nctId":8284,"briefTitle":8285,"status":107,"phases":13272,"primaryCompletion":8287,"completion":8288,"start":8289,"enrollment":1630,"conditions":13273,"interventions":13274},[90],[29],[2276,1280],{"nctId":2268,"briefTitle":2269,"status":156,"phases":13276,"primaryCompletion":2271,"completion":2272,"start":2273,"enrollment":97,"conditions":13277,"interventions":13278},[90],[29],[2276,1011],{"trials":13280,"activeCount":101},[13281,13289],{"nctId":13282,"briefTitle":13283,"status":107,"phases":13284,"primaryCompletion":13285,"completion":13285,"start":13286,"enrollment":1081,"conditions":13287,"interventions":13288},"NCT01915589","Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)",[91],"2014-10-08","2013-09-16",[1009],[2276],{"nctId":4756,"briefTitle":4757,"status":107,"phases":13290,"primaryCompletion":4759,"completion":4760,"start":4761,"enrollment":1181,"conditions":13291,"interventions":13292},[91],[1009],[2276,42],{"trials":13294,"activeCount":101},[],{"trials":13296,"activeCount":101},[],{"trials":13298,"activeCount":101},[],{"intervention":13300,"totalTrials":1341,"cells":13301},"Radium-223 chloride",{"EARLY_PHASE1":13302,"PHASE1":13304,"PHASE2":13320,"PHASE3":13328,"PHASE4":13330,"NA":13332},{"trials":13303,"activeCount":101},[],{"trials":13305,"activeCount":101},[13306,13313],{"nctId":13307,"briefTitle":13308,"status":107,"phases":13309,"primaryCompletion":498,"completion":498,"start":11861,"enrollment":5220,"conditions":13310,"interventions":13311},"NCT00667537","PK in Pts With HRPC & Skeletal Metastes",[90],[187],[13312],"Radium-223 chloride (Xofigo®, BAY88-8223)",{"nctId":13314,"briefTitle":13315,"status":107,"phases":13316,"primaryCompletion":2256,"completion":2256,"start":8109,"enrollment":3374,"conditions":13317,"interventions":13319},"NCT00748046","Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton",[90],[307,13318,1790],"Metastases",[13300],{"trials":13321,"activeCount":101},[13322],{"nctId":13323,"briefTitle":13324,"status":107,"phases":13325,"primaryCompletion":5975,"completion":1508,"start":3809,"enrollment":1630,"conditions":13326,"interventions":13327},"NCT01070485","BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease",[91],[4677,438],[13300],{"trials":13329,"activeCount":101},[],{"trials":13331,"activeCount":101},[],{"trials":13333,"activeCount":101},[],{"intervention":12698,"totalTrials":1341,"cells":13335},{"EARLY_PHASE1":13336,"PHASE1":13338,"PHASE2":13358,"PHASE3":13364,"PHASE4":13366,"NA":13368},{"trials":13337,"activeCount":101},[],{"trials":13339,"activeCount":101},[13340,13349],{"nctId":13341,"briefTitle":13342,"status":107,"phases":13343,"primaryCompletion":13344,"completion":13345,"start":13346,"enrollment":11,"conditions":13347,"interventions":13348},"NCT03212586","BAY 1902607: Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Bioavailability, Food Effect",[90],"2018-05-03","2018-07-27","2017-07-18",[12553],[12698],{"nctId":13350,"briefTitle":13351,"status":107,"phases":13352,"primaryCompletion":13353,"completion":13354,"start":13355,"enrollment":1181,"conditions":13356,"interventions":13357},"NCT03789890","Study to Learn More About the Effect of Itraconazole (ITZ) Given Repeatedly by Mouth on the Way How the Study Drug BAY1902607 Given One Time by Mouth Acts in the Human Body of Healthy Male Participants",[90],"2019-03-04","2019-05-23","2019-01-08",[1490],[12698,1934],{"trials":13359,"activeCount":101},[13360],{"nctId":12691,"briefTitle":12692,"status":107,"phases":13361,"primaryCompletion":12694,"completion":5139,"start":12695,"enrollment":2307,"conditions":13362,"interventions":13363},[90,91],[12519],[12698,1154],{"trials":13365,"activeCount":101},[],{"trials":13367,"activeCount":101},[],{"trials":13369,"activeCount":101},[],{"intervention":13371,"totalTrials":1341,"cells":13372},"BAY2433334",{"EARLY_PHASE1":13373,"PHASE1":13375,"PHASE2":13377,"PHASE3":13406,"PHASE4":13408,"NA":13410},{"trials":13374,"activeCount":101},[],{"trials":13376,"activeCount":101},[],{"trials":13378,"activeCount":101},[13379,13388,13397],{"nctId":13380,"briefTitle":13381,"status":107,"phases":13382,"primaryCompletion":13383,"completion":13383,"start":13384,"enrollment":13385,"conditions":13386,"interventions":13387},"NCT04304534","Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack",[91],"2022-02-21","2020-06-17",1601,[8647],[13371],{"nctId":13389,"briefTitle":13390,"status":107,"phases":13391,"primaryCompletion":13392,"completion":13392,"start":324,"enrollment":13393,"conditions":13394,"interventions":13396},"NCT04218266","Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.",[91],"2021-10-08",755,[13395],"Atrial Fibrillation (AF)",[13371,3943],{"nctId":13398,"briefTitle":13399,"status":107,"phases":13400,"primaryCompletion":13401,"completion":13401,"start":13402,"enrollment":13403,"conditions":13404,"interventions":13405},"NCT04304508","Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.",[91],"2022-02-18","2020-06-15",1808,[8664],[13371],{"trials":13407,"activeCount":101},[],{"trials":13409,"activeCount":101},[],{"trials":13411,"activeCount":101},[],{"intervention":13413,"totalTrials":1341,"cells":13414},"BAY94-9343",{"EARLY_PHASE1":13415,"PHASE1":13417,"PHASE2":13436,"PHASE3":13447,"PHASE4":13449,"NA":13451},{"trials":13416,"activeCount":101},[],{"trials":13418,"activeCount":101},[13419,13427],{"nctId":13420,"briefTitle":13421,"status":107,"phases":13422,"primaryCompletion":4348,"completion":13423,"start":13424,"enrollment":2873,"conditions":13425,"interventions":13426},"NCT01439152","Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.",[90],"2019-07-30","2011-09-07",[2292],[13413,13413,13413,13413],{"nctId":13428,"briefTitle":13429,"status":107,"phases":13430,"primaryCompletion":13431,"completion":13432,"start":13433,"enrollment":4620,"conditions":13434,"interventions":13435},"NCT02485119","Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies",[90],"2017-04-28","2017-07-04","2015-08-14",[29],[13413],{"trials":13437,"activeCount":101},[13438],{"nctId":13439,"briefTitle":13440,"status":156,"phases":13441,"primaryCompletion":13442,"completion":13442,"start":13443,"enrollment":4466,"conditions":13444,"interventions":13446},"NCT03926143","A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies",[91],"2022-05-18","2019-06-03",[13445],"Solid Tumors",[13413],{"trials":13448,"activeCount":101},[],{"trials":13450,"activeCount":101},[],{"trials":13452,"activeCount":101},[],{"intervention":13454,"totalTrials":1341,"cells":13455},"Fulacimstat",{"EARLY_PHASE1":13456,"PHASE1":13458,"PHASE2":13468,"PHASE3":13488,"PHASE4":13490,"NA":13492},{"trials":13457,"activeCount":101},[],{"trials":13459,"activeCount":101},[13460],{"nctId":13461,"briefTitle":13462,"status":107,"phases":13463,"primaryCompletion":13464,"completion":13465,"start":5890,"enrollment":1265,"conditions":13466,"interventions":13467},"NCT03402438","Renal Impairment Study",[90],"2018-12-04","2019-03-19",[7762],[13454],{"trials":13469,"activeCount":101},[13470,13479],{"nctId":13471,"briefTitle":13472,"status":107,"phases":13473,"primaryCompletion":12939,"completion":13474,"start":13475,"enrollment":13476,"conditions":13477,"interventions":13478},"NCT02976467","A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction",[91],"2018-09-04","2016-12-30",107,[8544],[13454],{"nctId":13480,"briefTitle":13481,"status":107,"phases":13482,"primaryCompletion":13483,"completion":13484,"start":7790,"enrollment":13485,"conditions":13486,"interventions":13487},"NCT03412006","A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease",[91],"2019-10-02","2019-10-10",152,[817],[13454],{"trials":13489,"activeCount":101},[],{"trials":13491,"activeCount":101},[],{"trials":13493,"activeCount":101},[],{"intervention":7892,"totalTrials":1341,"cells":13495},{"EARLY_PHASE1":13496,"PHASE1":13498,"PHASE2":13510,"PHASE3":13529,"PHASE4":13531,"NA":13533},{"trials":13497,"activeCount":101},[],{"trials":13499,"activeCount":101},[13500],{"nctId":13501,"briefTitle":13502,"status":107,"phases":13503,"primaryCompletion":13504,"completion":13504,"start":13505,"enrollment":6503,"conditions":13506,"interventions":13508},"NCT03787368","End-stage Renal Disease (ESRD) Pilot Study",[90],"2021-09-15","2019-01-31",[13507],"Renal Dialysis",[7892,13509],"0.9% sodium chloride solution",{"trials":13511,"activeCount":101},[13512,13516],{"nctId":7882,"briefTitle":7883,"status":107,"phases":13513,"primaryCompletion":7885,"completion":7886,"start":7887,"enrollment":7888,"conditions":13514,"interventions":13515},[91],[7890],[3633,3943,7892],{"nctId":13517,"briefTitle":13518,"status":107,"phases":13519,"primaryCompletion":13520,"completion":13521,"start":13522,"enrollment":13523,"conditions":13524,"interventions":13528},"NCT04523220","Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis",[91],"2021-12-28","2022-05-30","2020-08-28",704,[13525,8646,13526,13527],"End-stage Renal Disease","Hemodialysis","Hemodiafiltration",[7892],{"trials":13530,"activeCount":101},[],{"trials":13532,"activeCount":101},[],{"trials":13534,"activeCount":101},[],{"intervention":2339,"totalTrials":1341,"cells":13536},{"EARLY_PHASE1":13537,"PHASE1":13539,"PHASE2":13552,"PHASE3":13566,"PHASE4":13568,"NA":13570},{"trials":13538,"activeCount":101},[],{"trials":13540,"activeCount":101},[13541],{"nctId":13542,"briefTitle":13543,"status":107,"phases":13544,"primaryCompletion":13545,"completion":13545,"start":13546,"enrollment":1081,"conditions":13547,"interventions":13551},"NCT03735628","An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors",[90],"2022-10-13","2018-10-17",[13548,13549,13550],"Non-small Cell Lung Cancer (NSCLC)","Head and Neck Squamous Cell Carcinoma (HNSCC)","Hepatocellular Carcinoma (HCC)",[7973,2339],{"trials":13553,"activeCount":101},[13554,13562],{"nctId":13555,"briefTitle":13556,"status":107,"phases":13557,"primaryCompletion":13558,"completion":1940,"start":1053,"enrollment":7993,"conditions":13559,"interventions":13560},"NCT04704154","A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors",[91],"2023-03-09",[13445],[13561,2339],"Regorafenib,",{"nctId":2331,"briefTitle":2332,"status":107,"phases":13563,"primaryCompletion":2334,"completion":770,"start":2335,"enrollment":550,"conditions":13564,"interventions":13565},[91],[2337],[1011,2339],{"trials":13567,"activeCount":101},[],{"trials":13569,"activeCount":101},[],{"trials":13571,"activeCount":101},[],{"intervention":13573,"totalTrials":1341,"cells":13574},"Runcaciguat",{"EARLY_PHASE1":13575,"PHASE1":13577,"PHASE2":13587,"PHASE3":13608,"PHASE4":13610,"NA":13612},{"trials":13576,"activeCount":101},[],{"trials":13578,"activeCount":101},[13579],{"nctId":13580,"briefTitle":13581,"status":156,"phases":13582,"primaryCompletion":13583,"completion":13583,"start":13584,"enrollment":328,"conditions":13585,"interventions":13586},"NCT04820621","Study of the Influence of Liver Function on Blood Concentrations of Runcaciguat in Participants With Different Degrees of Liver Impairment",[90],"2021-07-01","2021-04-07",[32],[13573],{"trials":13588,"activeCount":101},[13589,13598],{"nctId":13590,"briefTitle":13591,"status":107,"phases":13592,"primaryCompletion":13593,"completion":13594,"start":11544,"enrollment":13595,"conditions":13596,"interventions":13597},"NCT04722991","Non-proliferative Diabetic Retinopathy Treated With Runcaciguat",[91],"2024-03-18","2024-04-22",109,[912],[13573],{"nctId":13599,"briefTitle":13600,"status":107,"phases":13601,"primaryCompletion":13602,"completion":13603,"start":13604,"enrollment":573,"conditions":13605,"interventions":13606},"NCT04507061","Study on the Safety of the Drug Runcaciguat and How Well it Works When Given at the Highest Dose as Tolerated by Individual Patient Whose Kidneys Are Not Working Properly and Suffering at the Same Time From High Blood Sugar and\u002For High Blood Pressure and a Disease of the Heart and the Blood Vessels.",[91],"2022-03-08","2022-04-05","2020-09-01",[32],[13607],"runcaciguat",{"trials":13609,"activeCount":101},[],{"trials":13611,"activeCount":101},[],{"trials":13613,"activeCount":101},[],{"intervention":13615,"totalTrials":1341,"cells":13616},"BAY2586116",{"EARLY_PHASE1":13617,"PHASE1":13619,"PHASE2":13631,"PHASE3":13650,"PHASE4":13652,"NA":13654},{"trials":13618,"activeCount":101},[],{"trials":13620,"activeCount":101},[13621],{"nctId":13622,"briefTitle":13623,"status":107,"phases":13624,"primaryCompletion":13625,"completion":13626,"start":13627,"enrollment":1265,"conditions":13628,"interventions":13630},"NCT04872387","A Study to Learn More About How Safe BAY2586116 is, How it Affects the Body, How it Moves Into, Through and Out of the Body at Different Doses in Healthy Japanese Male Participants After Taking Single and Multiple Doses Through the Nose",[90],"2021-08-04","2021-08-26","2021-05-11",[13629],"Obstructive Sleep Apnea",[13615],{"trials":13632,"activeCount":101},[13633,13641],{"nctId":13634,"briefTitle":13635,"status":107,"phases":13636,"primaryCompletion":12505,"completion":12559,"start":13637,"enrollment":1181,"conditions":13638,"interventions":13640},"NCT04236440","Study on the Safety of Drug BAY2586116 and How it Works in Patients With Obstructive Sleep Apnea (a Sleep Disorder Caused by the Narrowing and Collapse of the Airway During Sleep) Including the Blood Level of the Drug and Effect of Its Doses and Routes of Administration",[91],"2020-02-04",[13639],"Sleep Apnea, Obstructive",[13615,13615,13615,13615,13615],{"nctId":13642,"briefTitle":13643,"status":107,"phases":13644,"primaryCompletion":13645,"completion":13646,"start":13647,"enrollment":1869,"conditions":13648,"interventions":13649},"NCT04713826","A Trial to Learn More About How Well BAY2586116 Works and How Safe it is in Participants With Moderate to Severe Obstructive Sleep Apnea",[91],"2021-08-17","2021-11-11","2021-03-03",[13639],[13615],{"trials":13651,"activeCount":101},[],{"trials":13653,"activeCount":101},[],{"trials":13655,"activeCount":101},[],{"intervention":13657,"totalTrials":1341,"cells":13658},"BAY2327949",{"EARLY_PHASE1":13659,"PHASE1":13661,"PHASE2":13679,"PHASE3":13689,"PHASE4":13691,"NA":13693},{"trials":13660,"activeCount":101},[],{"trials":13662,"activeCount":101},[13663,13670],{"nctId":13664,"briefTitle":13665,"status":107,"phases":13666,"primaryCompletion":13667,"completion":2930,"start":3258,"enrollment":1509,"conditions":13668,"interventions":13669},"NCT04004195","Study to Investigate Safety, Absorption, Elimination, and Drug Effect of BAY2327949 in Participants With Different Renal Function Status",[90],"2020-02-07",[1790],[13657],{"nctId":13671,"briefTitle":13672,"status":156,"phases":13673,"primaryCompletion":13674,"completion":13675,"start":4095,"enrollment":480,"conditions":13676,"interventions":13678},"NCT04552262","Study to Learn More About the Effect of a New Drug Called BAY2327949 on the Blood Flow Through Kidneys in Adult Participants With Moderate Chronic Kidney Disease",[90],"2020-12-21","2021-05-05",[13677],"Moderate Chronic Kidney Disease",[13657],{"trials":13680,"activeCount":101},[13681],{"nctId":13682,"briefTitle":13683,"status":464,"phases":13684,"primaryCompletion":13685,"completion":13686,"start":4019,"enrollment":101,"conditions":13687,"interventions":13688},"NCT04661917","A Trial to Learn More About How BAY2327949 Works and How Safe it is in Patients Whose Kidneys Are Damaged Due to High Blood Sugar Levels or High Blood Pressures, and With a Further Disease of the Heart or the Blood Vessels.",[91],"2022-04-25","2022-05-19",[32,817],[13657],{"trials":13690,"activeCount":101},[],{"trials":13692,"activeCount":101},[],{"trials":13694,"activeCount":101},[],{"intervention":13696,"totalTrials":175,"cells":13697},"Capadenoson",{"EARLY_PHASE1":13698,"PHASE1":13700,"PHASE2":13702,"PHASE3":13717,"PHASE4":13719,"NA":13721},{"trials":13699,"activeCount":101},[],{"trials":13701,"activeCount":101},[],{"trials":13703,"activeCount":101},[13704,13711],{"nctId":13705,"briefTitle":13706,"status":464,"phases":13707,"completion":3567,"start":4612,"enrollment":101,"conditions":13708,"interventions":13710},"NCT00518921","Capadenoson in Angina Pectoris",[91],[13709],"Chronic Stable Angina",[13696,13696,13696],{"nctId":13712,"briefTitle":13713,"status":107,"phases":13714,"primaryCompletion":3567,"completion":498,"start":3818,"enrollment":171,"conditions":13715,"interventions":13716},"NCT00568945","Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.",[91],[21],[13696],{"trials":13718,"activeCount":101},[],{"trials":13720,"activeCount":101},[],{"trials":13722,"activeCount":101},[],{"intervention":472,"totalTrials":175,"cells":13724},{"EARLY_PHASE1":13725,"PHASE1":13727,"PHASE2":13729,"PHASE3":13739,"PHASE4":13741,"NA":13743},{"trials":13726,"activeCount":101},[],{"trials":13728,"activeCount":101},[],{"trials":13730,"activeCount":101},[13731,13735],{"nctId":462,"briefTitle":463,"status":464,"phases":13732,"primaryCompletion":466,"completion":467,"start":468,"enrollment":101,"conditions":13733,"interventions":13734},[90,91],[470],[72,472,473],{"nctId":475,"briefTitle":476,"status":156,"phases":13736,"primaryCompletion":478,"completion":478,"start":479,"enrollment":480,"conditions":13737,"interventions":13738},[90,91],[470],[72,472,473],{"trials":13740,"activeCount":101},[],{"trials":13742,"activeCount":101},[],{"trials":13744,"activeCount":101},[],{"intervention":473,"totalTrials":175,"cells":13746},{"EARLY_PHASE1":13747,"PHASE1":13749,"PHASE2":13751,"PHASE3":13761,"PHASE4":13763,"NA":13765},{"trials":13748,"activeCount":101},[],{"trials":13750,"activeCount":101},[],{"trials":13752,"activeCount":101},[13753,13757],{"nctId":462,"briefTitle":463,"status":464,"phases":13754,"primaryCompletion":466,"completion":467,"start":468,"enrollment":101,"conditions":13755,"interventions":13756},[90,91],[470],[72,472,473],{"nctId":475,"briefTitle":476,"status":156,"phases":13758,"primaryCompletion":478,"completion":478,"start":479,"enrollment":480,"conditions":13759,"interventions":13760},[90,91],[470],[72,472,473],{"trials":13762,"activeCount":101},[],{"trials":13764,"activeCount":101},[],{"trials":13766,"activeCount":101},[],{"intervention":13768,"totalTrials":175,"cells":13769},"BAY73-4506",{"EARLY_PHASE1":13770,"PHASE1":13772,"PHASE2":13774,"PHASE3":13789,"PHASE4":13791,"NA":13793},{"trials":13771,"activeCount":101},[],{"trials":13773,"activeCount":101},[],{"trials":13775,"activeCount":101},[13776,13783],{"nctId":13777,"briefTitle":13778,"status":107,"phases":13779,"primaryCompletion":3905,"completion":3905,"start":2325,"enrollment":5220,"conditions":13780,"interventions":13782},"NCT03890731","A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed",[91],[13781],"Solid Cancer",[13768],{"nctId":13784,"briefTitle":13785,"status":107,"phases":13786,"primaryCompletion":1570,"completion":7061,"start":3576,"enrollment":1265,"conditions":13787,"interventions":13788},"NCT01003015","Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma",[91],[1009],[13768],{"trials":13790,"activeCount":101},[],{"trials":13792,"activeCount":101},[],{"trials":13794,"activeCount":101},[],{"intervention":13796,"totalTrials":175,"cells":13797},"BAY1128688",{"EARLY_PHASE1":13798,"PHASE1":13800,"PHASE2":13808,"PHASE3":13819,"PHASE4":13821,"NA":13823},{"trials":13799,"activeCount":101},[],{"trials":13801,"activeCount":101},[13802],{"nctId":13803,"briefTitle":13804,"status":107,"phases":13805,"primaryCompletion":5249,"completion":409,"start":2290,"enrollment":22,"conditions":13806,"interventions":13807},"NCT02434640","Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1128688 After Multiple Oral Administrations in Healthy Women",[90],[7793],[13796,13796],{"trials":13809,"activeCount":101},[13810],{"nctId":13811,"briefTitle":13812,"status":156,"phases":13813,"primaryCompletion":13814,"completion":13815,"start":13816,"enrollment":1610,"conditions":13817,"interventions":13818},"NCT03373422","A Study to Test Whether Study Drug BAY1128688 Brings Pain Relief to Women With Endometriosis and if so to Get a First Idea Which Dose(s) Work Best",[91],"2018-07-23","2018-10-22","2017-11-30",[7793],[13796],{"trials":13820,"activeCount":101},[],{"trials":13822,"activeCount":101},[],{"trials":13824,"activeCount":101},[],{"intervention":4686,"totalTrials":175,"cells":13826},{"EARLY_PHASE1":13827,"PHASE1":13829,"PHASE2":13841,"PHASE3":13847,"PHASE4":13849,"NA":13851},{"trials":13828,"activeCount":101},[],{"trials":13830,"activeCount":101},[13831],{"nctId":13832,"briefTitle":13833,"status":107,"phases":13834,"primaryCompletion":13835,"completion":13836,"start":13837,"enrollment":13838,"conditions":13839,"interventions":13840},"NCT00610194","Phase 1 Dose-escalation PK\u002FPD Trial in Advanced Cancer Patients",[90],"2010-11-24","2012-08-01","2007-11-28",69,[4684],[4686],{"trials":13842,"activeCount":101},[13843],{"nctId":4680,"briefTitle":4681,"status":107,"phases":13844,"primaryCompletion":1506,"completion":1506,"start":3567,"enrollment":1133,"conditions":13845,"interventions":13846},[90,91],[4684],[4686,42],{"trials":13848,"activeCount":101},[],{"trials":13850,"activeCount":101},[],{"trials":13852,"activeCount":101},[],{"intervention":5076,"totalTrials":175,"cells":13854},{"EARLY_PHASE1":13855,"PHASE1":13857,"PHASE2":13859,"PHASE3":13869,"PHASE4":13871,"NA":13873},{"trials":13856,"activeCount":101},[],{"trials":13858,"activeCount":101},[],{"trials":13860,"activeCount":101},[13861,13865],{"nctId":5068,"briefTitle":5069,"status":107,"phases":13862,"primaryCompletion":2271,"completion":5071,"start":4984,"enrollment":5072,"conditions":13863,"interventions":13864},[91],[5074,5063],[5042,5076],{"nctId":5089,"briefTitle":5090,"status":107,"phases":13866,"primaryCompletion":5092,"completion":2981,"start":5093,"enrollment":5094,"conditions":13867,"interventions":13868},[91],[5074,5063],[5042,5076],{"trials":13870,"activeCount":101},[],{"trials":13872,"activeCount":101},[],{"trials":13874,"activeCount":101},[],{"intervention":13876,"totalTrials":175,"cells":13877},"BAY1067197",{"EARLY_PHASE1":13878,"PHASE1":13880,"PHASE2":13882,"PHASE3":13899,"PHASE4":13901,"NA":13903},{"trials":13879,"activeCount":101},[],{"trials":13881,"activeCount":101},[],{"trials":13883,"activeCount":101},[13884,13892],{"nctId":13885,"briefTitle":13886,"status":107,"phases":13887,"primaryCompletion":13888,"completion":13889,"start":3453,"enrollment":2041,"conditions":13890,"interventions":13891},"NCT01945606","Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker",[91],"2014-09-09","2015-03-17",[738],[13876],{"nctId":13893,"briefTitle":13894,"status":107,"phases":13895,"primaryCompletion":13896,"completion":2991,"start":8377,"enrollment":36,"conditions":13897,"interventions":13898},"NCT02040233","Multiple Dose Study in Heart Failure of BAY 1067197",[91],"2015-01-29",[738],[13876,13876],{"trials":13900,"activeCount":101},[],{"trials":13902,"activeCount":101},[],{"trials":13904,"activeCount":101},[],{"intervention":13906,"totalTrials":175,"cells":13907},"BAY1002670",{"EARLY_PHASE1":13908,"PHASE1":13910,"PHASE2":13918,"PHASE3":13929,"PHASE4":13931,"NA":13933},{"trials":13909,"activeCount":101},[],{"trials":13911,"activeCount":101},[13912],{"nctId":13913,"briefTitle":13914,"status":107,"phases":13915,"primaryCompletion":408,"completion":1577,"start":5999,"enrollment":3233,"conditions":13916,"interventions":13917},"NCT01816815","Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670",[90],[7770],[13906],{"trials":13919,"activeCount":101},[13920],{"nctId":13921,"briefTitle":13922,"status":107,"phases":13923,"primaryCompletion":13924,"completion":13924,"start":13925,"enrollment":13926,"conditions":13927,"interventions":13928},"NCT02131662","Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap",[91],"2016-05-04","2014-05-15",309,[7770],[13906,13906,13906,13906],{"trials":13930,"activeCount":101},[],{"trials":13932,"activeCount":101},[],{"trials":13934,"activeCount":101},[],{"intervention":13012,"totalTrials":175,"cells":13936},{"EARLY_PHASE1":13937,"PHASE1":13939,"PHASE2":13952,"PHASE3":13958,"PHASE4":13960,"NA":13962},{"trials":13938,"activeCount":101},[],{"trials":13940,"activeCount":101},[13941],{"nctId":13942,"briefTitle":13943,"status":107,"phases":13944,"primaryCompletion":13945,"completion":13946,"start":13947,"enrollment":6822,"conditions":13948,"interventions":13949},"NCT01473108","Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862",[90],"2010-11-30","2011-05-17","2010-03-29",[1536],[13950,13951,13012],"Finerenone (BAY 94-8862) PEG solution","Finerenone (BAY 94-8862) immediate release",{"trials":13953,"activeCount":101},[13954],{"nctId":13005,"briefTitle":13006,"status":107,"phases":13955,"primaryCompletion":13008,"completion":13009,"start":2221,"enrollment":11,"conditions":13956,"interventions":13957},[91],[738],[12978,13012],{"trials":13959,"activeCount":101},[],{"trials":13961,"activeCount":101},[],{"trials":13963,"activeCount":101},[],{"intervention":7812,"totalTrials":175,"cells":13965},{"EARLY_PHASE1":13966,"PHASE1":13968,"PHASE2":13979,"PHASE3":13985,"PHASE4":13987,"NA":13989},{"trials":13967,"activeCount":101},[],{"trials":13969,"activeCount":101},[13970],{"nctId":13971,"briefTitle":13972,"status":156,"phases":13973,"primaryCompletion":13039,"completion":13974,"start":13975,"enrollment":3374,"conditions":13976,"interventions":13977},"NCT03342859","Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned",[90],"2020-01-13","2017-11-16",[7770],[13978,7812],"Vilaprisan, BAY1002670",{"trials":13980,"activeCount":101},[13981],{"nctId":7806,"briefTitle":7807,"status":107,"phases":13982,"primaryCompletion":468,"completion":468,"start":548,"enrollment":2126,"conditions":13983,"interventions":13984},[91],[7770],[5917,7811,7811,5917,7812,7812,7812],{"trials":13986,"activeCount":101},[],{"trials":13988,"activeCount":101},[],{"trials":13990,"activeCount":101},[],{"intervention":13992,"totalTrials":175,"cells":13993},"Spheramine",{"EARLY_PHASE1":13994,"PHASE1":13996,"PHASE2":13998,"PHASE3":14015,"PHASE4":14017,"NA":14019},{"trials":13995,"activeCount":101},[],{"trials":13997,"activeCount":101},[],{"trials":13999,"activeCount":101},[14000,14008],{"nctId":14001,"briefTitle":14002,"status":156,"phases":14003,"primaryCompletion":1692,"completion":1692,"start":14004,"enrollment":5220,"conditions":14005,"interventions":14007},"NCT00761436","Pilot Study of Safety and Efficacy of Spheramine",[91],"2000-02-29",[14006],"Parkinson''s Disease",[13992],{"nctId":14009,"briefTitle":14010,"status":156,"phases":14011,"primaryCompletion":1692,"completion":1692,"start":14012,"enrollment":4934,"conditions":14013,"interventions":14014},"NCT00206687","STEPS Trial - Spheramine Safety and Efficacy Study",[91],"2003-01-08",[2018],[13992],{"trials":14016,"activeCount":101},[],{"trials":14018,"activeCount":101},[],{"trials":14020,"activeCount":101},[],{"intervention":14022,"totalTrials":175,"cells":14023},"BAY59-8862",{"EARLY_PHASE1":14024,"PHASE1":14026,"PHASE2":14028,"PHASE3":14044,"PHASE4":14046,"NA":14048},{"trials":14025,"activeCount":101},[],{"trials":14027,"activeCount":101},[],{"trials":14029,"activeCount":101},[14030,14037],{"nctId":14031,"briefTitle":14032,"status":107,"phases":14033,"completion":6112,"start":14034,"enrollment":13111,"conditions":14035,"interventions":14036},"NCT00044538","Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients",[91],"2001-12",[423],[14022],{"nctId":14038,"briefTitle":14039,"status":107,"phases":14040,"primaryCompletion":446,"completion":446,"start":14041,"enrollment":6445,"conditions":14042,"interventions":14043},"NCT00044525","Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients",[91],"2002-04",[521,12748],[14022],{"trials":14045,"activeCount":101},[],{"trials":14047,"activeCount":101},[],{"trials":14049,"activeCount":101},[],{"intervention":14051,"totalTrials":175,"cells":14052},"Dexpanthenol foam spray, new formulation",{"EARLY_PHASE1":14053,"PHASE1":14055,"PHASE2":14057,"PHASE3":14074,"PHASE4":14076,"NA":14078},{"trials":14054,"activeCount":101},[],{"trials":14056,"activeCount":101},[],{"trials":14058,"activeCount":101},[14059,14067],{"nctId":14060,"briefTitle":14061,"status":107,"phases":14062,"primaryCompletion":9794,"completion":9794,"start":9022,"enrollment":411,"conditions":14063,"interventions":14065},"NCT00839280","Moisturizing Effect of Two Dexpanthenol Formulations",[91],[14064],"Skin Abnormalities",[14051,14066],"Dexpanthenol foam spray, old formulation",{"nctId":14068,"briefTitle":14069,"status":107,"phases":14070,"primaryCompletion":9794,"completion":9794,"start":9794,"enrollment":6503,"conditions":14071,"interventions":14073},"NCT00839462","Efficacy of Dexpanthenol in Thermic Erythema",[91],[14072],"Erythema",[14051,14066],{"trials":14075,"activeCount":101},[],{"trials":14077,"activeCount":101},[],{"trials":14079,"activeCount":101},[],{"intervention":14066,"totalTrials":175,"cells":14081},{"EARLY_PHASE1":14082,"PHASE1":14084,"PHASE2":14086,"PHASE3":14096,"PHASE4":14098,"NA":14100},{"trials":14083,"activeCount":101},[],{"trials":14085,"activeCount":101},[],{"trials":14087,"activeCount":101},[14088,14092],{"nctId":14060,"briefTitle":14061,"status":107,"phases":14089,"primaryCompletion":9794,"completion":9794,"start":9022,"enrollment":411,"conditions":14090,"interventions":14091},[91],[14064],[14051,14066],{"nctId":14068,"briefTitle":14069,"status":107,"phases":14093,"primaryCompletion":9794,"completion":9794,"start":9794,"enrollment":6503,"conditions":14094,"interventions":14095},[91],[14072],[14051,14066],{"trials":14097,"activeCount":101},[],{"trials":14099,"activeCount":101},[],{"trials":14101,"activeCount":101},[],{"intervention":14103,"totalTrials":175,"cells":14104},"BAY3427080",{"EARLY_PHASE1":14105,"PHASE1":14107,"PHASE2":14116,"PHASE3":14126,"PHASE4":14128,"NA":14130},{"trials":14106,"activeCount":101},[],{"trials":14108,"activeCount":101},[14109],{"nctId":14110,"briefTitle":14111,"status":107,"phases":14112,"primaryCompletion":14113,"completion":14113,"start":610,"enrollment":33,"conditions":14114,"interventions":14115},"NCT04903821","A Study to Learn How Different Levels of Decreased Liver Function Influence Blood Levels of Elinzanetant Compared to Normal Liver Function in Male and Female Participants",[90],"2022-03-15",[1094],[14103],{"trials":14117,"activeCount":101},[14118],{"nctId":14119,"briefTitle":14120,"status":107,"phases":14121,"primaryCompletion":7768,"completion":7768,"start":14122,"enrollment":2507,"conditions":14123,"interventions":14125},"NCT02865538","Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms",[90,91],"2016-08-01",[14124],"Post-menopausal Vasomotor Symptoms",[14103],{"trials":14127,"activeCount":101},[],{"trials":14129,"activeCount":101},[],{"trials":14131,"activeCount":101},[],{"intervention":14133,"totalTrials":233,"cells":14134},"STW5-II",{"EARLY_PHASE1":14135,"PHASE1":14137,"PHASE2":14139,"PHASE3":14148,"PHASE4":14150,"NA":14152},{"trials":14136,"activeCount":101},[],{"trials":14138,"activeCount":101},[],{"trials":14140,"activeCount":101},[14141],{"nctId":14142,"briefTitle":14143,"status":156,"phases":14144,"primaryCompletion":3594,"completion":409,"start":3732,"enrollment":1341,"conditions":14145,"interventions":14147},"NCT02246686","Efficacy\u002FSafety Pilot Study to Investigate Iberogast N's Efficacy in Mild to Moderate Colitis Ulcerosa Patients",[91],[14146],"Colitis, Ulcerative",[14133],{"trials":14149,"activeCount":101},[],{"trials":14151,"activeCount":101},[],{"trials":14153,"activeCount":101},[],{"intervention":14155,"totalTrials":233,"cells":14156},"Vericiguat (BAY1021189) 5 mg",{"EARLY_PHASE1":14157,"PHASE1":14159,"PHASE2":14161,"PHASE3":14171,"PHASE4":14173,"NA":14175},{"trials":14158,"activeCount":101},[],{"trials":14160,"activeCount":101},[],{"trials":14162,"activeCount":101},[14163],{"nctId":14164,"briefTitle":14165,"status":107,"phases":14166,"primaryCompletion":14167,"completion":14167,"start":14168,"enrollment":3990,"conditions":14169,"interventions":14170},"NCT06195930","A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction",[91],"2024-07-29","2024-04-18",[3478],[14155],{"trials":14172,"activeCount":101},[],{"trials":14174,"activeCount":101},[],{"trials":14176,"activeCount":101},[],{"intervention":13003,"totalTrials":233,"cells":14178},{"EARLY_PHASE1":14179,"PHASE1":14181,"PHASE2":14183,"PHASE3":14189,"PHASE4":14191,"NA":14193},{"trials":14180,"activeCount":101},[],{"trials":14182,"activeCount":101},[],{"trials":14184,"activeCount":101},[14185],{"nctId":12996,"briefTitle":12997,"status":107,"phases":14186,"primaryCompletion":12999,"completion":13000,"start":4984,"enrollment":3568,"conditions":14187,"interventions":14188},[91],[760],[12978,12978,12978,12978,12978,13003,13003],{"trials":14190,"activeCount":101},[],{"trials":14192,"activeCount":101},[],{"trials":14194,"activeCount":101},[],{"intervention":7984,"totalTrials":233,"cells":14196},{"EARLY_PHASE1":14197,"PHASE1":14199,"PHASE2":14201,"PHASE3":14207,"PHASE4":14209,"NA":14211},{"trials":14198,"activeCount":101},[],{"trials":14200,"activeCount":101},[],{"trials":14202,"activeCount":101},[14203],{"nctId":7977,"briefTitle":7978,"status":107,"phases":14204,"primaryCompletion":7980,"completion":7980,"start":7981,"enrollment":233,"conditions":14205,"interventions":14206},[91],[219],[5521,7984],{"trials":14208,"activeCount":101},[],{"trials":14210,"activeCount":101},[],{"trials":14212,"activeCount":101},[],{"intervention":451,"totalTrials":233,"cells":14214},{"EARLY_PHASE1":14215,"PHASE1":14217,"PHASE2":14219,"PHASE3":14225,"PHASE4":14227,"NA":14229},{"trials":14216,"activeCount":101},[],{"trials":14218,"activeCount":101},[],{"trials":14220,"activeCount":101},[14221],{"nctId":441,"briefTitle":442,"status":107,"phases":14222,"primaryCompletion":444,"completion":445,"start":446,"enrollment":447,"conditions":14223,"interventions":14224},[91],[307,449],[72,451],{"trials":14226,"activeCount":101},[],{"trials":14228,"activeCount":101},[],{"trials":14230,"activeCount":101},[],{"intervention":5845,"totalTrials":233,"cells":14232},{"EARLY_PHASE1":14233,"PHASE1":14235,"PHASE2":14237,"PHASE3":14243,"PHASE4":14245,"NA":14247},{"trials":14234,"activeCount":101},[],{"trials":14236,"activeCount":101},[],{"trials":14238,"activeCount":101},[14239],{"nctId":5836,"briefTitle":5837,"status":107,"phases":14240,"primaryCompletion":5839,"completion":1711,"start":5840,"enrollment":5841,"conditions":14241,"interventions":14242},[91],[5843],[5845,5816,5846],{"trials":14244,"activeCount":101},[],{"trials":14246,"activeCount":101},[],{"trials":14248,"activeCount":101},[],{"intervention":14250,"totalTrials":233,"cells":14251},"Asoprisnil",{"EARLY_PHASE1":14252,"PHASE1":14254,"PHASE2":14256,"PHASE3":14265,"PHASE4":14267,"NA":14269},{"trials":14253,"activeCount":101},[],{"trials":14255,"activeCount":101},[],{"trials":14257,"activeCount":101},[14258],{"nctId":14259,"briefTitle":14260,"status":107,"phases":14261,"completion":3668,"start":14262,"enrollment":124,"conditions":14263,"interventions":14264},"NCT00288691","Menorrhagia Study in Women With Treatment-resistant Menorrhagia",[91],"2001-11",[1426],[14250,14250,14250],{"trials":14266,"activeCount":101},[],{"trials":14268,"activeCount":101},[],{"trials":14270,"activeCount":101},[],{"intervention":1308,"totalTrials":233,"cells":14272},{"EARLY_PHASE1":14273,"PHASE1":14275,"PHASE2":14277,"PHASE3":14283,"PHASE4":14285,"NA":14287},{"trials":14274,"activeCount":101},[],{"trials":14276,"activeCount":101},[],{"trials":14278,"activeCount":101},[14279],{"nctId":1297,"briefTitle":1298,"status":156,"phases":14280,"primaryCompletion":1300,"completion":1301,"start":1302,"enrollment":1303,"conditions":14281,"interventions":14282},[90,91],[1305],[1307,1308,1073,1074],{"trials":14284,"activeCount":101},[],{"trials":14286,"activeCount":101},[],{"trials":14288,"activeCount":101},[],{"intervention":8147,"totalTrials":233,"cells":14290},{"EARLY_PHASE1":14291,"PHASE1":14293,"PHASE2":14295,"PHASE3":14301,"PHASE4":14303,"NA":14305},{"trials":14292,"activeCount":101},[],{"trials":14294,"activeCount":101},[],{"trials":14296,"activeCount":101},[14297],{"nctId":8142,"briefTitle":8143,"status":107,"phases":14298,"primaryCompletion":2968,"completion":2968,"start":4736,"enrollment":160,"conditions":14299,"interventions":14300},[91],[15],[8126,8147],{"trials":14302,"activeCount":101},[],{"trials":14304,"activeCount":101},[],{"trials":14306,"activeCount":101},[],{"intervention":14308,"totalTrials":233,"cells":14309},"Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR",{"EARLY_PHASE1":14310,"PHASE1":14312,"PHASE2":14314,"PHASE3":14326,"PHASE4":14328,"NA":14330},{"trials":14311,"activeCount":101},[],{"trials":14313,"activeCount":101},[],{"trials":14315,"activeCount":101},[14316],{"nctId":14317,"briefTitle":14318,"status":107,"phases":14319,"primaryCompletion":14320,"completion":14321,"start":3959,"enrollment":14322,"conditions":14323,"interventions":14325},"NCT03547583","Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF",[91],"2019-10-15","2019-11-04",789,[14324],"Chronic Heart Failure With Preserved Ejection Fraction",[14308],{"trials":14327,"activeCount":101},[],{"trials":14329,"activeCount":101},[],{"trials":14331,"activeCount":101},[],{"intervention":14333,"totalTrials":233,"cells":14334},"BAY1142524",{"EARLY_PHASE1":14335,"PHASE1":14337,"PHASE2":14339,"PHASE3":14347,"PHASE4":14349,"NA":14351},{"trials":14336,"activeCount":101},[],{"trials":14338,"activeCount":101},[],{"trials":14340,"activeCount":101},[14341],{"nctId":14342,"briefTitle":14343,"status":107,"phases":14344,"primaryCompletion":2407,"completion":5964,"start":1487,"enrollment":458,"conditions":14345,"interventions":14346},"NCT02452515","A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction",[91],[738],[14333,14333,14333,14333],{"trials":14348,"activeCount":101},[],{"trials":14350,"activeCount":101},[],{"trials":14352,"activeCount":101},[],{"intervention":14354,"totalTrials":233,"cells":14355},"Candesartan cilexetil (Atacand), 4 mg",{"EARLY_PHASE1":14356,"PHASE1":14358,"PHASE2":14360,"PHASE3":14376,"PHASE4":14378,"NA":14380},{"trials":14357,"activeCount":101},[],{"trials":14359,"activeCount":101},[],{"trials":14361,"activeCount":101},[14362],{"nctId":14363,"briefTitle":14364,"status":107,"phases":14365,"primaryCompletion":1507,"completion":1507,"start":2188,"enrollment":14366,"conditions":14367,"interventions":14369},"NCT01303783","Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension",[91],1381,[14368],"Hypertension, Essential",[14354,14370,14371,14372,14373,14374,14375],"Candesartan cilexetil (Atacand), 8 mg","Nifedipine GITS (Adalat, BAYA1040), 20 mg","Nifedipine GITS (Adalat, BAYA1040), 30 mg","Nifedipine GITS (Adalat, BAYA1040), 60 mg","Candesartan cilexetil (Atacand), 16 mg","Candesartan cilexetil (Atacand), 32 mg",{"trials":14377,"activeCount":101},[],{"trials":14379,"activeCount":101},[],{"trials":14381,"activeCount":101},[],{"intervention":14370,"totalTrials":233,"cells":14383},{"EARLY_PHASE1":14384,"PHASE1":14386,"PHASE2":14388,"PHASE3":14394,"PHASE4":14396,"NA":14398},{"trials":14385,"activeCount":101},[],{"trials":14387,"activeCount":101},[],{"trials":14389,"activeCount":101},[14390],{"nctId":14363,"briefTitle":14364,"status":107,"phases":14391,"primaryCompletion":1507,"completion":1507,"start":2188,"enrollment":14366,"conditions":14392,"interventions":14393},[91],[14368],[14354,14370,14371,14372,14373,14374,14375],{"trials":14395,"activeCount":101},[],{"trials":14397,"activeCount":101},[],{"trials":14399,"activeCount":101},[],{"intervention":14371,"totalTrials":233,"cells":14401},{"EARLY_PHASE1":14402,"PHASE1":14404,"PHASE2":14406,"PHASE3":14412,"PHASE4":14414,"NA":14416},{"trials":14403,"activeCount":101},[],{"trials":14405,"activeCount":101},[],{"trials":14407,"activeCount":101},[14408],{"nctId":14363,"briefTitle":14364,"status":107,"phases":14409,"primaryCompletion":1507,"completion":1507,"start":2188,"enrollment":14366,"conditions":14410,"interventions":14411},[91],[14368],[14354,14370,14371,14372,14373,14374,14375],{"trials":14413,"activeCount":101},[],{"trials":14415,"activeCount":101},[],{"trials":14417,"activeCount":101},[],{"intervention":14372,"totalTrials":233,"cells":14419},{"EARLY_PHASE1":14420,"PHASE1":14422,"PHASE2":14424,"PHASE3":14430,"PHASE4":14432,"NA":14434},{"trials":14421,"activeCount":101},[],{"trials":14423,"activeCount":101},[],{"trials":14425,"activeCount":101},[14426],{"nctId":14363,"briefTitle":14364,"status":107,"phases":14427,"primaryCompletion":1507,"completion":1507,"start":2188,"enrollment":14366,"conditions":14428,"interventions":14429},[91],[14368],[14354,14370,14371,14372,14373,14374,14375],{"trials":14431,"activeCount":101},[],{"trials":14433,"activeCount":101},[],{"trials":14435,"activeCount":101},[],{"intervention":14373,"totalTrials":233,"cells":14437},{"EARLY_PHASE1":14438,"PHASE1":14440,"PHASE2":14442,"PHASE3":14448,"PHASE4":14450,"NA":14452},{"trials":14439,"activeCount":101},[],{"trials":14441,"activeCount":101},[],{"trials":14443,"activeCount":101},[14444],{"nctId":14363,"briefTitle":14364,"status":107,"phases":14445,"primaryCompletion":1507,"completion":1507,"start":2188,"enrollment":14366,"conditions":14446,"interventions":14447},[91],[14368],[14354,14370,14371,14372,14373,14374,14375],{"trials":14449,"activeCount":101},[],{"trials":14451,"activeCount":101},[],{"trials":14453,"activeCount":101},[],{"intervention":14374,"totalTrials":233,"cells":14455},{"EARLY_PHASE1":14456,"PHASE1":14458,"PHASE2":14460,"PHASE3":14466,"PHASE4":14468,"NA":14470},{"trials":14457,"activeCount":101},[],{"trials":14459,"activeCount":101},[],{"trials":14461,"activeCount":101},[14462],{"nctId":14363,"briefTitle":14364,"status":107,"phases":14463,"primaryCompletion":1507,"completion":1507,"start":2188,"enrollment":14366,"conditions":14464,"interventions":14465},[91],[14368],[14354,14370,14371,14372,14373,14374,14375],{"trials":14467,"activeCount":101},[],{"trials":14469,"activeCount":101},[],{"trials":14471,"activeCount":101},[],{"intervention":14375,"totalTrials":233,"cells":14473},{"EARLY_PHASE1":14474,"PHASE1":14476,"PHASE2":14478,"PHASE3":14484,"PHASE4":14486,"NA":14488},{"trials":14475,"activeCount":101},[],{"trials":14477,"activeCount":101},[],{"trials":14479,"activeCount":101},[14480],{"nctId":14363,"briefTitle":14364,"status":107,"phases":14481,"primaryCompletion":1507,"completion":1507,"start":2188,"enrollment":14366,"conditions":14482,"interventions":14483},[91],[14368],[14354,14370,14371,14372,14373,14374,14375],{"trials":14485,"activeCount":101},[],{"trials":14487,"activeCount":101},[],{"trials":14489,"activeCount":101},[],{"intervention":8455,"totalTrials":233,"cells":14491},{"EARLY_PHASE1":14492,"PHASE1":14494,"PHASE2":14496,"PHASE3":14502,"PHASE4":14504,"NA":14506},{"trials":14493,"activeCount":101},[],{"trials":14495,"activeCount":101},[],{"trials":14497,"activeCount":101},[14498],{"nctId":8448,"briefTitle":8449,"status":107,"phases":14499,"primaryCompletion":3705,"completion":2256,"start":8451,"conditions":14500,"interventions":14501},[91],[8453],[8455,8456,8457],{"trials":14503,"activeCount":101},[],{"trials":14505,"activeCount":101},[],{"trials":14507,"activeCount":101},[],{"intervention":8457,"totalTrials":233,"cells":14509},{"EARLY_PHASE1":14510,"PHASE1":14512,"PHASE2":14514,"PHASE3":14520,"PHASE4":14522,"NA":14524},{"trials":14511,"activeCount":101},[],{"trials":14513,"activeCount":101},[],{"trials":14515,"activeCount":101},[14516],{"nctId":8448,"briefTitle":8449,"status":107,"phases":14517,"primaryCompletion":3705,"completion":2256,"start":8451,"conditions":14518,"interventions":14519},[91],[8453],[8455,8456,8457],{"trials":14521,"activeCount":101},[],{"trials":14523,"activeCount":101},[],{"trials":14525,"activeCount":101},[],{"intervention":8019,"totalTrials":233,"cells":14527},{"EARLY_PHASE1":14528,"PHASE1":14530,"PHASE2":14532,"PHASE3":14538,"PHASE4":14540,"NA":14542},{"trials":14529,"activeCount":101},[],{"trials":14531,"activeCount":101},[],{"trials":14533,"activeCount":101},[14534],{"nctId":8012,"briefTitle":8013,"status":107,"phases":14535,"primaryCompletion":5946,"completion":5946,"start":6068,"enrollment":8015,"conditions":14536,"interventions":14537},[91],[8017],[8003,8019],{"trials":14539,"activeCount":101},[],{"trials":14541,"activeCount":101},[],{"trials":14543,"activeCount":101},[],{"intervention":14545,"totalTrials":233,"cells":14546},"Befovacimab",{"EARLY_PHASE1":14547,"PHASE1":14549,"PHASE2":14551,"PHASE3":14561,"PHASE4":14563,"NA":14565},{"trials":14548,"activeCount":101},[],{"trials":14550,"activeCount":101},[],{"trials":14552,"activeCount":101},[14553],{"nctId":14554,"briefTitle":14555,"status":156,"phases":14556,"primaryCompletion":14320,"completion":14320,"start":14557,"enrollment":1701,"conditions":14558,"interventions":14560},"NCT03597022","Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors",[91],"2018-07-24",[14559],"Hemophilia A and B",[14545],{"trials":14562,"activeCount":101},[],{"trials":14564,"activeCount":101},[],{"trials":14566,"activeCount":101},[],{"intervention":14568,"totalTrials":233,"cells":14569},"BAY86-9766 MEK Inhibitor + Sorafenib",{"EARLY_PHASE1":14570,"PHASE1":14572,"PHASE2":14574,"PHASE3":14582,"PHASE4":14584,"NA":14586},{"trials":14571,"activeCount":101},[],{"trials":14573,"activeCount":101},[],{"trials":14575,"activeCount":101},[14576],{"nctId":14577,"briefTitle":14578,"status":107,"phases":14579,"primaryCompletion":2969,"completion":2187,"start":5409,"enrollment":550,"conditions":14580,"interventions":14581},"NCT01204177","Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.",[91],[1009],[14568],{"trials":14583,"activeCount":101},[],{"trials":14585,"activeCount":101},[],{"trials":14587,"activeCount":101},[],{"intervention":14589,"totalTrials":233,"cells":14590},"Histone Deacetylase Inhibitor, MS-275",{"EARLY_PHASE1":14591,"PHASE1":14593,"PHASE2":14595,"PHASE3":14603,"PHASE4":14605,"NA":14607},{"trials":14592,"activeCount":101},[],{"trials":14594,"activeCount":101},[],{"trials":14596,"activeCount":101},[14597],{"nctId":14598,"briefTitle":14599,"status":107,"phases":14600,"primaryCompletion":1315,"completion":1315,"start":6363,"enrollment":171,"conditions":14601,"interventions":14602},"NCT00185302","Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma",[91],[4651],[14589,14589],{"trials":14604,"activeCount":101},[],{"trials":14606,"activeCount":101},[],{"trials":14608,"activeCount":101},[],{"intervention":14610,"totalTrials":233,"cells":14611},"Gadobutrol~0.03 mmol\u002Fkg BW",{"EARLY_PHASE1":14612,"PHASE1":14614,"PHASE2":14616,"PHASE3":14629,"PHASE4":14631,"NA":14633},{"trials":14613,"activeCount":101},[],{"trials":14615,"activeCount":101},[],{"trials":14617,"activeCount":101},[14618],{"nctId":14619,"briefTitle":14620,"status":107,"phases":14621,"primaryCompletion":3778,"completion":3778,"start":4613,"enrollment":1660,"conditions":14622,"interventions":14625},"NCT00862459","Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)",[91],[14623,14624],"Brain Diseases","Spinal Cord Diseases",[14610,14626,14627,14628],"Gadobutrol~0.1 mmol\u002Fkg BW","Gadobutrol~0.3 mmol\u002Fkg BW","OptiMARK~0.1 mmol\u002Fkg BW",{"trials":14630,"activeCount":101},[],{"trials":14632,"activeCount":101},[],{"trials":14634,"activeCount":101},[],{"intervention":14626,"totalTrials":233,"cells":14636},{"EARLY_PHASE1":14637,"PHASE1":14639,"PHASE2":14641,"PHASE3":14647,"PHASE4":14649,"NA":14651},{"trials":14638,"activeCount":101},[],{"trials":14640,"activeCount":101},[],{"trials":14642,"activeCount":101},[14643],{"nctId":14619,"briefTitle":14620,"status":107,"phases":14644,"primaryCompletion":3778,"completion":3778,"start":4613,"enrollment":1660,"conditions":14645,"interventions":14646},[91],[14623,14624],[14610,14626,14627,14628],{"trials":14648,"activeCount":101},[],{"trials":14650,"activeCount":101},[],{"trials":14652,"activeCount":101},[],{"intervention":14627,"totalTrials":233,"cells":14654},{"EARLY_PHASE1":14655,"PHASE1":14657,"PHASE2":14659,"PHASE3":14665,"PHASE4":14667,"NA":14669},{"trials":14656,"activeCount":101},[],{"trials":14658,"activeCount":101},[],{"trials":14660,"activeCount":101},[14661],{"nctId":14619,"briefTitle":14620,"status":107,"phases":14662,"primaryCompletion":3778,"completion":3778,"start":4613,"enrollment":1660,"conditions":14663,"interventions":14664},[91],[14623,14624],[14610,14626,14627,14628],{"trials":14666,"activeCount":101},[],{"trials":14668,"activeCount":101},[],{"trials":14670,"activeCount":101},[],{"intervention":14628,"totalTrials":233,"cells":14672},{"EARLY_PHASE1":14673,"PHASE1":14675,"PHASE2":14677,"PHASE3":14683,"PHASE4":14685,"NA":14687},{"trials":14674,"activeCount":101},[],{"trials":14676,"activeCount":101},[],{"trials":14678,"activeCount":101},[14679],{"nctId":14619,"briefTitle":14620,"status":107,"phases":14680,"primaryCompletion":3778,"completion":3778,"start":4613,"enrollment":1660,"conditions":14681,"interventions":14682},[91],[14623,14624],[14610,14626,14627,14628],{"trials":14684,"activeCount":101},[],{"trials":14686,"activeCount":101},[],{"trials":14688,"activeCount":101},[],{"intervention":14690,"totalTrials":233,"cells":14691},"Interleukin-2 SA",{"EARLY_PHASE1":14692,"PHASE1":14694,"PHASE2":14696,"PHASE3":14705,"PHASE4":14707,"NA":14709},{"trials":14693,"activeCount":101},[],{"trials":14695,"activeCount":101},[],{"trials":14697,"activeCount":101},[14698],{"nctId":14699,"briefTitle":14700,"status":107,"phases":14701,"primaryCompletion":4836,"completion":4836,"start":3658,"enrollment":995,"conditions":14702,"interventions":14703},"NCT00059462","Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection",[90,91],[11731],[14690,14704],"HAART",{"trials":14706,"activeCount":101},[],{"trials":14708,"activeCount":101},[],{"trials":14710,"activeCount":101},[],{"intervention":14704,"totalTrials":233,"cells":14712},{"EARLY_PHASE1":14713,"PHASE1":14715,"PHASE2":14717,"PHASE3":14723,"PHASE4":14725,"NA":14727},{"trials":14714,"activeCount":101},[],{"trials":14716,"activeCount":101},[],{"trials":14718,"activeCount":101},[14719],{"nctId":14699,"briefTitle":14700,"status":107,"phases":14720,"primaryCompletion":4836,"completion":4836,"start":3658,"enrollment":995,"conditions":14721,"interventions":14722},[90,91],[11731],[14690,14704],{"trials":14724,"activeCount":101},[],{"trials":14726,"activeCount":101},[],{"trials":14728,"activeCount":101},[],{"intervention":14730,"totalTrials":233,"cells":14731},"Taxane",{"EARLY_PHASE1":14732,"PHASE1":14734,"PHASE2":14736,"PHASE3":14745,"PHASE4":14747,"NA":14749},{"trials":14733,"activeCount":101},[],{"trials":14735,"activeCount":101},[],{"trials":14737,"activeCount":101},[14738],{"nctId":14739,"briefTitle":14740,"status":107,"phases":14741,"completion":8451,"start":14742,"enrollment":6430,"conditions":14743,"interventions":14744},"NCT00044551","Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma",[91],"2002-02",[8469],[14730],{"trials":14746,"activeCount":101},[],{"trials":14748,"activeCount":101},[],{"trials":14750,"activeCount":101},[],{"intervention":14752,"totalTrials":233,"cells":14753},"Naproxen gel",{"EARLY_PHASE1":14754,"PHASE1":14756,"PHASE2":14758,"PHASE3":14770,"PHASE4":14772,"NA":14774},{"trials":14755,"activeCount":101},[],{"trials":14757,"activeCount":101},[],{"trials":14759,"activeCount":101},[14760],{"nctId":14761,"briefTitle":14762,"status":107,"phases":14763,"primaryCompletion":14764,"completion":14764,"start":14765,"enrollment":2507,"conditions":14766,"interventions":14768},"NCT05026320","A Clinical Trial to Compare Safety and Effectiveness for Relieving Tenderness of 10% Naproxen Gel vs. a 2.32% Diclofenac Diethylamine Gel in the Treatment of Strains and Bruises of the Legs.",[91],"2021-12-20","2021-08-08",[14767],"Soft Tissue Injury",[14752,14769],"Diclofenac gel",{"trials":14771,"activeCount":101},[],{"trials":14773,"activeCount":101},[],{"trials":14775,"activeCount":101},[],{"intervention":14769,"totalTrials":233,"cells":14777},{"EARLY_PHASE1":14778,"PHASE1":14780,"PHASE2":14782,"PHASE3":14788,"PHASE4":14790,"NA":14792},{"trials":14779,"activeCount":101},[],{"trials":14781,"activeCount":101},[],{"trials":14783,"activeCount":101},[14784],{"nctId":14761,"briefTitle":14762,"status":107,"phases":14785,"primaryCompletion":14764,"completion":14764,"start":14765,"enrollment":2507,"conditions":14786,"interventions":14787},[91],[14767],[14752,14769],{"trials":14789,"activeCount":101},[],{"trials":14791,"activeCount":101},[],{"trials":14793,"activeCount":101},[],{"intervention":14795,"totalTrials":233,"cells":14796},"ZK 245186",{"EARLY_PHASE1":14797,"PHASE1":14799,"PHASE2":14801,"PHASE3":14811,"PHASE4":14813,"NA":14815},{"trials":14798,"activeCount":101},[],{"trials":14800,"activeCount":101},[],{"trials":14802,"activeCount":101},[14803],{"nctId":14804,"briefTitle":14805,"status":107,"phases":14806,"primaryCompletion":14807,"completion":14807,"start":14808,"enrollment":447,"conditions":14809,"interventions":14810},"NCT00944632","Dose Escalation of Different Concentrations of ZK 245186 in Atopic Dermatitis",[91],"2010-09-15","2009-07-15",[13148],[14795],{"trials":14812,"activeCount":101},[],{"trials":14814,"activeCount":101},[],{"trials":14816,"activeCount":101},[],{"intervention":14818,"totalTrials":233,"cells":14819},"Lonaprisan",{"EARLY_PHASE1":14820,"PHASE1":14822,"PHASE2":14824,"PHASE3":14833,"PHASE4":14835,"NA":14837},{"trials":14821,"activeCount":101},[],{"trials":14823,"activeCount":101},[],{"trials":14825,"activeCount":101},[14826],{"nctId":14827,"briefTitle":14828,"status":107,"phases":14829,"primaryCompletion":1326,"completion":5975,"start":4612,"enrollment":490,"conditions":14830,"interventions":14832},"NCT00555919","ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer",[91],[14831],"Metastatic Breast Cancer",[14818,14818],{"trials":14834,"activeCount":101},[],{"trials":14836,"activeCount":101},[],{"trials":14838,"activeCount":101},[],{"intervention":14840,"totalTrials":233,"cells":14841},"Bay 59-8862",{"EARLY_PHASE1":14842,"PHASE1":14844,"PHASE2":14846,"PHASE3":14854,"PHASE4":14856,"NA":14858},{"trials":14843,"activeCount":101},[],{"trials":14845,"activeCount":101},[],{"trials":14847,"activeCount":101},[14848],{"nctId":14849,"briefTitle":14850,"status":107,"phases":14851,"completion":8048,"start":14034,"enrollment":2345,"conditions":14852,"interventions":14853},"NCT00044564","Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma",[91],[2328],[14840],{"trials":14855,"activeCount":101},[],{"trials":14857,"activeCount":101},[],{"trials":14859,"activeCount":101},[],{"intervention":14861,"totalTrials":233,"cells":14862},"lloprost",{"EARLY_PHASE1":14863,"PHASE1":14865,"PHASE2":14867,"PHASE3":14877,"PHASE4":14879,"NA":14881},{"trials":14864,"activeCount":101},[],{"trials":14866,"activeCount":101},[],{"trials":14868,"activeCount":101},[14869],{"nctId":14870,"briefTitle":14871,"status":107,"phases":14872,"primaryCompletion":14873,"completion":14874,"start":531,"enrollment":701,"conditions":14875,"interventions":14876},"NCT02032836","Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)",[90,91],"2015-01-07","2017-09-29",[1715],[14861,14861],{"trials":14878,"activeCount":101},[],{"trials":14880,"activeCount":101},[],{"trials":14882,"activeCount":101},[],{"intervention":13021,"totalTrials":233,"cells":14884},{"EARLY_PHASE1":14885,"PHASE1":14887,"PHASE2":14889,"PHASE3":14895,"PHASE4":14897,"NA":14899},{"trials":14886,"activeCount":101},[],{"trials":14888,"activeCount":101},[],{"trials":14890,"activeCount":101},[14891],{"nctId":13014,"briefTitle":13015,"status":107,"phases":14892,"primaryCompletion":4339,"completion":13017,"start":8422,"enrollment":13018,"conditions":14893,"interventions":14894},[91],[738],[12978,12978,12978,12978,13021],{"trials":14896,"activeCount":101},[],{"trials":14898,"activeCount":101},[],{"trials":14900,"activeCount":101},[],{"intervention":12574,"totalTrials":233,"cells":14902},{"EARLY_PHASE1":14903,"PHASE1":14905,"PHASE2":14907,"PHASE3":14913,"PHASE4":14915,"NA":14917},{"trials":14904,"activeCount":101},[],{"trials":14906,"activeCount":101},[],{"trials":14908,"activeCount":101},[14909],{"nctId":12565,"briefTitle":12566,"status":156,"phases":14910,"primaryCompletion":12568,"completion":12569,"start":12570,"enrollment":1833,"conditions":14911,"interventions":14912},[91],[12572],[12494,12574],{"trials":14914,"activeCount":101},[],{"trials":14916,"activeCount":101},[],{"trials":14918,"activeCount":101},[],{"intervention":7811,"totalTrials":233,"cells":14920},{"EARLY_PHASE1":14921,"PHASE1":14923,"PHASE2":14925,"PHASE3":14931,"PHASE4":14933,"NA":14935},{"trials":14922,"activeCount":101},[],{"trials":14924,"activeCount":101},[],{"trials":14926,"activeCount":101},[14927],{"nctId":7806,"briefTitle":7807,"status":107,"phases":14928,"primaryCompletion":468,"completion":468,"start":548,"enrollment":2126,"conditions":14929,"interventions":14930},[91],[7770],[5917,7811,7811,5917,7812,7812,7812],{"trials":14932,"activeCount":101},[],{"trials":14934,"activeCount":101},[],{"trials":14936,"activeCount":101},[],{"intervention":13092,"totalTrials":233,"cells":14938},{"EARLY_PHASE1":14939,"PHASE1":14941,"PHASE2":14943,"PHASE3":14949,"PHASE4":14951,"NA":14953},{"trials":14940,"activeCount":101},[],{"trials":14942,"activeCount":101},[],{"trials":14944,"activeCount":101},[14945],{"nctId":13087,"briefTitle":13088,"status":107,"phases":14946,"primaryCompletion":4789,"completion":4789,"start":6384,"enrollment":3676,"conditions":14947,"interventions":14948},[91],[3560,3621],[13078,13078,13078,13078,13092],{"trials":14950,"activeCount":101},[],{"trials":14952,"activeCount":101},[],{"trials":14954,"activeCount":101},[],{"intervention":14956,"totalTrials":233,"cells":14957},"SH D00264A",{"EARLY_PHASE1":14958,"PHASE1":14960,"PHASE2":14962,"PHASE3":14970,"PHASE4":14972,"NA":14974},{"trials":14959,"activeCount":101},[],{"trials":14961,"activeCount":101},[],{"trials":14963,"activeCount":101},[14964],{"nctId":14965,"briefTitle":14966,"status":107,"phases":14967,"completion":5472,"start":4836,"enrollment":1007,"conditions":14968,"interventions":14969},"NCT00185224","Metabolism Study to Investigate the Impact of a Sequential Oral Contraceptive",[91],[15],[5939,14956],{"trials":14971,"activeCount":101},[],{"trials":14973,"activeCount":101},[],{"trials":14975,"activeCount":101},[],{"intervention":740,"totalTrials":233,"cells":14977},{"EARLY_PHASE1":14978,"PHASE1":14980,"PHASE2":14982,"PHASE3":14988,"PHASE4":14990,"NA":14992},{"trials":14979,"activeCount":101},[],{"trials":14981,"activeCount":101},[],{"trials":14983,"activeCount":101},[14984],{"nctId":730,"briefTitle":731,"status":107,"phases":14985,"primaryCompletion":733,"completion":734,"start":735,"enrollment":736,"conditions":14986,"interventions":14987},[91],[738],[62,740],{"trials":14989,"activeCount":101},[],{"trials":14991,"activeCount":101},[],{"trials":14993,"activeCount":101},[],{"intervention":14995,"totalTrials":233,"cells":14996},"rFVIII-FS\u002Fpegylated liposomes",{"EARLY_PHASE1":14997,"PHASE1":14999,"PHASE2":15001,"PHASE3":15010,"PHASE4":15012,"NA":15014},{"trials":14998,"activeCount":101},[],{"trials":15000,"activeCount":101},[],{"trials":15002,"activeCount":101},[15003],{"nctId":15004,"briefTitle":15005,"status":156,"phases":15006,"primaryCompletion":1326,"completion":3793,"start":1423,"enrollment":8963,"conditions":15007,"interventions":15008},"NCT00623727","BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A",[91],[24],[14995,15009],"rFVIII-FS\u002FWFI",{"trials":15011,"activeCount":101},[],{"trials":15013,"activeCount":101},[],{"trials":15015,"activeCount":101},[],{"intervention":15009,"totalTrials":233,"cells":15017},{"EARLY_PHASE1":15018,"PHASE1":15020,"PHASE2":15022,"PHASE3":15028,"PHASE4":15030,"NA":15032},{"trials":15019,"activeCount":101},[],{"trials":15021,"activeCount":101},[],{"trials":15023,"activeCount":101},[15024],{"nctId":15004,"briefTitle":15005,"status":156,"phases":15025,"primaryCompletion":1326,"completion":3793,"start":1423,"enrollment":8963,"conditions":15026,"interventions":15027},[91],[24],[14995,15009],{"trials":15029,"activeCount":101},[],{"trials":15031,"activeCount":101},[],{"trials":15033,"activeCount":101},[],{"intervention":12585,"totalTrials":233,"cells":15035},{"EARLY_PHASE1":15036,"PHASE1":15038,"PHASE2":15040,"PHASE3":15046,"PHASE4":15048,"NA":15050},{"trials":15037,"activeCount":101},[],{"trials":15039,"activeCount":101},[],{"trials":15041,"activeCount":101},[15042],{"nctId":12576,"briefTitle":12577,"status":156,"phases":15043,"primaryCompletion":12579,"completion":12580,"start":12581,"enrollment":12582,"conditions":15044,"interventions":15045},[91],[7793],[12494,12585],{"trials":15047,"activeCount":101},[],{"trials":15049,"activeCount":101},[],{"trials":15051,"activeCount":101},[],{"intervention":15053,"totalTrials":233,"cells":15054},"BAY3018250",{"EARLY_PHASE1":15055,"PHASE1":15057,"PHASE2":15059,"PHASE3":15073,"PHASE4":15075,"NA":15077},{"trials":15056,"activeCount":101},[],{"trials":15058,"activeCount":101},[],{"trials":15060,"activeCount":101},[15061],{"nctId":15062,"briefTitle":15063,"status":107,"phases":15064,"primaryCompletion":15065,"completion":15066,"start":15067,"enrollment":15068,"conditions":15069,"interventions":15072},"NCT06149520","A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis",[91],"2025-10-07","2025-12-02","2024-01-15",258,[15070,15071],"Thrombolysis","Symptomatic Proximal Deep Vein Thrombosis",[15053],{"trials":15074,"activeCount":101},[],{"trials":15076,"activeCount":101},[],{"trials":15078,"activeCount":101},[],{"intervention":15080,"totalTrials":233,"cells":15081},"Hydrocortison cream",{"EARLY_PHASE1":15082,"PHASE1":15084,"PHASE2":15086,"PHASE3":15094,"PHASE4":15096,"NA":15098},{"trials":15083,"activeCount":101},[],{"trials":15085,"activeCount":101},[],{"trials":15087,"activeCount":101},[15088],{"nctId":15089,"briefTitle":15090,"status":107,"phases":15091,"primaryCompletion":8136,"completion":8136,"start":1497,"enrollment":1519,"conditions":15092,"interventions":15093},"NCT00980135","Sinecort Pilot Efficacy Study",[91],[13148],[15080],{"trials":15095,"activeCount":101},[],{"trials":15097,"activeCount":101},[],{"trials":15099,"activeCount":101},[],{"intervention":15101,"totalTrials":233,"cells":15102},"BAY60-4552 plus Vardenafil",{"EARLY_PHASE1":15103,"PHASE1":15105,"PHASE2":15107,"PHASE3":15115,"PHASE4":15117,"NA":15119},{"trials":15104,"activeCount":101},[],{"trials":15106,"activeCount":101},[],{"trials":15108,"activeCount":101},[15109],{"nctId":15110,"briefTitle":15111,"status":107,"phases":15112,"primaryCompletion":3618,"completion":3618,"start":1587,"enrollment":11430,"conditions":15113,"interventions":15114},"NCT01168817","Clinical Proof-of-concept Study for the Combination BAY60-4552 \u002F Vardenafil for the Treatment of Erectile Dysfunction Not Sufficiently Responsive to Standard Therapy With PDE5 Inhibitors",[91],[27],[15101,6043],{"trials":15116,"activeCount":101},[],{"trials":15118,"activeCount":101},[],{"trials":15120,"activeCount":101},[],{"intervention":5087,"totalTrials":233,"cells":15122},{"EARLY_PHASE1":15123,"PHASE1":15125,"PHASE2":15127,"PHASE3":15133,"PHASE4":15135,"NA":15137},{"trials":15124,"activeCount":101},[],{"trials":15126,"activeCount":101},[],{"trials":15128,"activeCount":101},[15129],{"nctId":5078,"briefTitle":5079,"status":107,"phases":15130,"primaryCompletion":5081,"completion":5082,"start":5083,"enrollment":5084,"conditions":15131,"interventions":15132},[91],[5074,5063],[5042,5087],{"trials":15134,"activeCount":101},[],{"trials":15136,"activeCount":101},[],{"trials":15138,"activeCount":101},[],{"intervention":15140,"totalTrials":233,"cells":15141},"Sagopilone (ZK 219477) + carboplatin",{"EARLY_PHASE1":15142,"PHASE1":15144,"PHASE2":15146,"PHASE3":15157,"PHASE4":15159,"NA":15161},{"trials":15143,"activeCount":101},[],{"trials":15145,"activeCount":101},[],{"trials":15147,"activeCount":101},[15148],{"nctId":15149,"briefTitle":15150,"status":107,"phases":15151,"primaryCompletion":15152,"completion":15153,"start":15154,"enrollment":510,"conditions":15155,"interventions":15156},"NCT00325351","ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer",[91],"2008-07-08","2009-03-25","2006-08-24",[4660],[15140],{"trials":15158,"activeCount":101},[],{"trials":15160,"activeCount":101},[],{"trials":15162,"activeCount":101},[],{"intervention":15164,"totalTrials":233,"cells":15165},"DRSP",{"EARLY_PHASE1":15166,"PHASE1":15168,"PHASE2":15170,"PHASE3":15181,"PHASE4":15183,"NA":15185},{"trials":15167,"activeCount":101},[],{"trials":15169,"activeCount":101},[],{"trials":15171,"activeCount":101},[15172],{"nctId":15173,"briefTitle":15174,"status":107,"phases":15175,"primaryCompletion":4736,"completion":4736,"start":4612,"enrollment":15176,"conditions":15177,"interventions":15179},"NCT00653614","Cycle Control and Safety of E2-DRSP",[91],635,[15178],"Contraceptive, Oral, Hormonal",[15180,15180,15180,15180,15180,15164,15164],"E2\u002FDRSP",{"trials":15182,"activeCount":101},[],{"trials":15184,"activeCount":101},[],{"trials":15186,"activeCount":101},[],{"intervention":15188,"totalTrials":233,"cells":15189},"Darolutamide 600 mg twice daily",{"EARLY_PHASE1":15190,"PHASE1":15192,"PHASE2":15194,"PHASE3":15204,"PHASE4":15206,"NA":15208},{"trials":15191,"activeCount":101},[],{"trials":15193,"activeCount":101},[],{"trials":15195,"activeCount":101},[15196],{"nctId":15197,"briefTitle":15198,"status":107,"phases":15199,"primaryCompletion":169,"completion":12797,"start":11975,"enrollment":15200,"conditions":15201,"interventions":15202},"NCT05171387","Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer",[91],78,[307],[15188,15203],"Androgen deprivation therapy",{"trials":15205,"activeCount":101},[],{"trials":15207,"activeCount":101},[],{"trials":15209,"activeCount":101},[],{"intervention":15203,"totalTrials":233,"cells":15211},{"EARLY_PHASE1":15212,"PHASE1":15214,"PHASE2":15216,"PHASE3":15222,"PHASE4":15224,"NA":15226},{"trials":15213,"activeCount":101},[],{"trials":15215,"activeCount":101},[],{"trials":15217,"activeCount":101},[15218],{"nctId":15197,"briefTitle":15198,"status":107,"phases":15219,"primaryCompletion":169,"completion":12797,"start":11975,"enrollment":15200,"conditions":15220,"interventions":15221},[91],[307],[15188,15203],{"trials":15223,"activeCount":101},[],{"trials":15225,"activeCount":101},[],{"trials":15227,"activeCount":101},[],{"intervention":5855,"totalTrials":233,"cells":15229},{"EARLY_PHASE1":15230,"PHASE1":15232,"PHASE2":15234,"PHASE3":15240,"PHASE4":15242,"NA":15244},{"trials":15231,"activeCount":101},[],{"trials":15233,"activeCount":101},[],{"trials":15235,"activeCount":101},[15236],{"nctId":5848,"briefTitle":5849,"status":107,"phases":15237,"primaryCompletion":5851,"completion":5851,"start":1752,"enrollment":2199,"conditions":15238,"interventions":15239},[91],[5853],[5803,5855,5856],{"trials":15241,"activeCount":101},[],{"trials":15243,"activeCount":101},[],{"trials":15245,"activeCount":101},[],{"intervention":5856,"totalTrials":233,"cells":15247},{"EARLY_PHASE1":15248,"PHASE1":15250,"PHASE2":15252,"PHASE3":15258,"PHASE4":15260,"NA":15262},{"trials":15249,"activeCount":101},[],{"trials":15251,"activeCount":101},[],{"trials":15253,"activeCount":101},[15254],{"nctId":5848,"briefTitle":5849,"status":107,"phases":15255,"primaryCompletion":5851,"completion":5851,"start":1752,"enrollment":2199,"conditions":15256,"interventions":15257},[91],[5853],[5803,5855,5856],{"trials":15259,"activeCount":101},[],{"trials":15261,"activeCount":101},[],{"trials":15263,"activeCount":101},[],{"intervention":15265,"totalTrials":233,"cells":15266},"BAY2757556",{"EARLY_PHASE1":15267,"PHASE1":15269,"PHASE2":15271,"PHASE3":15281,"PHASE4":15283,"NA":15285},{"trials":15268,"activeCount":101},[],{"trials":15270,"activeCount":101},[],{"trials":15272,"activeCount":101},[15273],{"nctId":15274,"briefTitle":15275,"status":107,"phases":15276,"primaryCompletion":15277,"completion":15277,"start":15278,"enrollment":12582,"conditions":15279,"interventions":15280},"NCT02576431","A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors",[91],"2025-09-29","2015-09-30",[1826],[15265],{"trials":15282,"activeCount":101},[],{"trials":15284,"activeCount":101},[],{"trials":15286,"activeCount":101},[],{"intervention":15288,"totalTrials":233,"cells":15289},"Regorafenib, ophthalmic oily suspension",{"EARLY_PHASE1":15290,"PHASE1":15292,"PHASE2":15294,"PHASE3":15302,"PHASE4":15304,"NA":15306},{"trials":15291,"activeCount":101},[],{"trials":15293,"activeCount":101},[],{"trials":15295,"activeCount":101},[15296],{"nctId":15297,"briefTitle":15298,"status":156,"phases":15299,"primaryCompletion":4067,"completion":548,"start":3989,"enrollment":19,"conditions":15300,"interventions":15301},"NCT02222207","Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration",[91],[2922],[15288,2974],{"trials":15303,"activeCount":101},[],{"trials":15305,"activeCount":101},[],{"trials":15307,"activeCount":101},[],{"intervention":4670,"totalTrials":233,"cells":15309},{"EARLY_PHASE1":15310,"PHASE1":15312,"PHASE2":15314,"PHASE3":15320,"PHASE4":15322,"NA":15324},{"trials":15311,"activeCount":101},[],{"trials":15313,"activeCount":101},[],{"trials":15315,"activeCount":101},[15316],{"nctId":4663,"briefTitle":4664,"status":107,"phases":15317,"primaryCompletion":4666,"completion":4612,"start":4648,"enrollment":4667,"conditions":15318,"interventions":15319},[91],[219,4651],[42,4670],{"trials":15321,"activeCount":101},[],{"trials":15323,"activeCount":101},[],{"trials":15325,"activeCount":101},[],{"intervention":15327,"totalTrials":233,"cells":15328},"BAY1007626",{"EARLY_PHASE1":15329,"PHASE1":15331,"PHASE2":15333,"PHASE3":15345,"PHASE4":15347,"NA":15349},{"trials":15330,"activeCount":101},[],{"trials":15332,"activeCount":101},[],{"trials":15334,"activeCount":101},[15335],{"nctId":15336,"briefTitle":15337,"status":156,"phases":15338,"primaryCompletion":15339,"completion":12551,"start":15340,"enrollment":15341,"conditions":15342,"interventions":15343},"NCT02490774","To Investigate the Pharmacological Effects, Drug Blood Levels and Safety of an Intrauterine System Releasing the Study Drug BAY1007626 in Comparison to Mirena and Jaydess in Healthy Young Women Treated for 90 Days to Determine the Drug Dose for Further Development",[91],"2016-05-26","2015-06-22",174,[15],[15327,15344,7023],"Jaydess",{"trials":15346,"activeCount":101},[],{"trials":15348,"activeCount":101},[],{"trials":15350,"activeCount":101},[],{"intervention":15344,"totalTrials":233,"cells":15352},{"EARLY_PHASE1":15353,"PHASE1":15355,"PHASE2":15357,"PHASE3":15363,"PHASE4":15365,"NA":15367},{"trials":15354,"activeCount":101},[],{"trials":15356,"activeCount":101},[],{"trials":15358,"activeCount":101},[15359],{"nctId":15336,"briefTitle":15337,"status":156,"phases":15360,"primaryCompletion":15339,"completion":12551,"start":15340,"enrollment":15341,"conditions":15361,"interventions":15362},[91],[15],[15327,15344,7023],{"trials":15364,"activeCount":101},[],{"trials":15366,"activeCount":101},[],{"trials":15368,"activeCount":101},[],{"intervention":15370,"totalTrials":233,"cells":15371},"Interferon beta 1b",{"EARLY_PHASE1":15372,"PHASE1":15374,"PHASE2":15376,"PHASE3":15384,"PHASE4":15386,"NA":15388},{"trials":15373,"activeCount":101},[],{"trials":15375,"activeCount":101},[],{"trials":15377,"activeCount":101},[15378],{"nctId":15379,"briefTitle":15380,"status":107,"phases":15381,"primaryCompletion":3818,"completion":3818,"start":5394,"enrollment":112,"conditions":15382,"interventions":15383},"NCT00235989","Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis",[91],[6602],[15370,15370,15370,15370],{"trials":15385,"activeCount":101},[],{"trials":15387,"activeCount":101},[],{"trials":15389,"activeCount":101},[],{"intervention":15391,"totalTrials":233,"cells":15392},"BAY98-7443",{"EARLY_PHASE1":15393,"PHASE1":15395,"PHASE2":15397,"PHASE3":15409,"PHASE4":15411,"NA":15413},{"trials":15394,"activeCount":101},[],{"trials":15396,"activeCount":101},[],{"trials":15398,"activeCount":101},[15399],{"nctId":15400,"briefTitle":15401,"status":107,"phases":15402,"primaryCompletion":15403,"completion":15404,"start":15405,"enrollment":2960,"conditions":15406,"interventions":15407},"NCT03562624","A Study to Compare 3 Doses of a Hormonal Intra-uterine Device Containing Levonorgestrel and Indomethacin With a Hormonal Intra-uterine Device Containing Only Levonorgestrel to Assess the Effect and Safety of the Combined Components",[91],"2019-05-16","2019-08-01","2018-06-22",[15],[15391,15408],"Levonogestrel",{"trials":15410,"activeCount":101},[],{"trials":15412,"activeCount":101},[],{"trials":15414,"activeCount":101},[],{"intervention":15408,"totalTrials":233,"cells":15416},{"EARLY_PHASE1":15417,"PHASE1":15419,"PHASE2":15421,"PHASE3":15427,"PHASE4":15429,"NA":15431},{"trials":15418,"activeCount":101},[],{"trials":15420,"activeCount":101},[],{"trials":15422,"activeCount":101},[15423],{"nctId":15400,"briefTitle":15401,"status":107,"phases":15424,"primaryCompletion":15403,"completion":15404,"start":15405,"enrollment":2960,"conditions":15425,"interventions":15426},[91],[15],[15391,15408],{"trials":15428,"activeCount":101},[],{"trials":15430,"activeCount":101},[],{"trials":15432,"activeCount":101},[],{"intervention":15434,"totalTrials":233,"cells":15435},"Anastrozole",{"EARLY_PHASE1":15436,"PHASE1":15438,"PHASE2":15440,"PHASE3":15452,"PHASE4":15454,"NA":15456},{"trials":15437,"activeCount":101},[],{"trials":15439,"activeCount":101},[],{"trials":15441,"activeCount":101},[15442],{"nctId":15443,"briefTitle":15444,"status":107,"phases":15445,"primaryCompletion":15446,"completion":15446,"start":15447,"enrollment":15448,"conditions":15449,"interventions":15450},"NCT02203331","Bay98-7196, Dose Finding \u002F POC Study",[91],"2016-10-24","2014-10-16",319,[7793],[6912,15434,15451],"Lupron \u002F Leuprolide acetate",{"trials":15453,"activeCount":101},[],{"trials":15455,"activeCount":101},[],{"trials":15457,"activeCount":101},[],{"intervention":15451,"totalTrials":233,"cells":15459},{"EARLY_PHASE1":15460,"PHASE1":15462,"PHASE2":15464,"PHASE3":15470,"PHASE4":15472,"NA":15474},{"trials":15461,"activeCount":101},[],{"trials":15463,"activeCount":101},[],{"trials":15465,"activeCount":101},[15466],{"nctId":15443,"briefTitle":15444,"status":107,"phases":15467,"primaryCompletion":15446,"completion":15446,"start":15447,"enrollment":15448,"conditions":15468,"interventions":15469},[91],[7793],[6912,15434,15451],{"trials":15471,"activeCount":101},[],{"trials":15473,"activeCount":101},[],{"trials":15475,"activeCount":101},[],{"intervention":15477,"totalTrials":233,"cells":15478},"Zabedosertib",{"EARLY_PHASE1":15479,"PHASE1":15481,"PHASE2":15483,"PHASE3":15494,"PHASE4":15496,"NA":15498},{"trials":15480,"activeCount":101},[],{"trials":15482,"activeCount":101},[],{"trials":15484,"activeCount":101},[15485],{"nctId":15486,"briefTitle":15487,"status":107,"phases":15488,"primaryCompletion":15489,"completion":8671,"start":15490,"enrollment":15491,"conditions":15492,"interventions":15493},"NCT05656911","A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis",[91],"2024-01-03","2022-12-21",77,[13148],[15477],{"trials":15495,"activeCount":101},[],{"trials":15497,"activeCount":101},[],{"trials":15499,"activeCount":101},[],{"intervention":13561,"totalTrials":233,"cells":15501},{"EARLY_PHASE1":15502,"PHASE1":15504,"PHASE2":15506,"PHASE3":15512,"PHASE4":15514,"NA":15516},{"trials":15503,"activeCount":101},[],{"trials":15505,"activeCount":101},[],{"trials":15507,"activeCount":101},[15508],{"nctId":13555,"briefTitle":13556,"status":107,"phases":15509,"primaryCompletion":13558,"completion":1940,"start":1053,"enrollment":7993,"conditions":15510,"interventions":15511},[91],[13445],[13561,2339],{"trials":15513,"activeCount":101},[],{"trials":15515,"activeCount":101},[],{"trials":15517,"activeCount":101},[],{"intervention":13100,"totalTrials":233,"cells":15519},{"EARLY_PHASE1":15520,"PHASE1":15522,"PHASE2":15524,"PHASE3":15530,"PHASE4":15532,"NA":15534},{"trials":15521,"activeCount":101},[],{"trials":15523,"activeCount":101},[],{"trials":15525,"activeCount":101},[15526],{"nctId":13094,"briefTitle":13095,"status":107,"phases":15527,"completion":4571,"start":6363,"enrollment":13097,"conditions":15528,"interventions":15529},[91],[3631],[13078,13078,13078,13100],{"trials":15531,"activeCount":101},[],{"trials":15533,"activeCount":101},[],{"trials":15535,"activeCount":101},[],{"intervention":15537,"totalTrials":233,"cells":15538},"Riociguat (Adempas, BAY63-2521).",{"EARLY_PHASE1":15539,"PHASE1":15541,"PHASE2":15543,"PHASE3":15552,"PHASE4":15554,"NA":15556},{"trials":15540,"activeCount":101},[],{"trials":15542,"activeCount":101},[],{"trials":15544,"activeCount":101},[15545],{"nctId":15546,"briefTitle":15547,"status":107,"phases":15548,"primaryCompletion":862,"completion":862,"start":15549,"enrollment":6203,"conditions":15550,"interventions":15551},"NCT00694850","Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)",[91],"2008-08-02",[1500],[15537],{"trials":15553,"activeCount":101},[],{"trials":15555,"activeCount":101},[],{"trials":15557,"activeCount":101},[],{"intervention":15559,"totalTrials":233,"cells":15560},"Repinotan HCl",{"EARLY_PHASE1":15561,"PHASE1":15563,"PHASE2":15565,"PHASE3":15576,"PHASE4":15578,"NA":15580},{"trials":15562,"activeCount":101},[],{"trials":15564,"activeCount":101},[],{"trials":15566,"activeCount":101},[15567],{"nctId":15568,"briefTitle":15569,"status":107,"phases":15570,"completion":3667,"start":15571,"enrollment":15572,"conditions":15573,"interventions":15575},"NCT00044915","Repinotan in Patients With Acute Ischemic Stroke",[91],"2000-12",782,[3743,15574],"Acute Ischemic Stroke",[15559],{"trials":15577,"activeCount":101},[],{"trials":15579,"activeCount":101},[],{"trials":15581,"activeCount":101},[],{"intervention":15583,"totalTrials":233,"cells":15584},"BAY86-9766+Gemcitabine",{"EARLY_PHASE1":15585,"PHASE1":15587,"PHASE2":15589,"PHASE3":15600,"PHASE4":15602,"NA":15604},{"trials":15586,"activeCount":101},[],{"trials":15588,"activeCount":101},[],{"trials":15590,"activeCount":101},[15591],{"nctId":15592,"briefTitle":15593,"status":107,"phases":15594,"primaryCompletion":13132,"completion":15595,"start":15596,"enrollment":8856,"conditions":15597,"interventions":15599},"NCT01251640","Combination With Gemcitabine in Advanced Pancreatic Cancer",[90,91],"2013-08-01","2011-01-01",[15598],"Pancreatic Neoplasms",[15583],{"trials":15601,"activeCount":101},[],{"trials":15603,"activeCount":101},[],{"trials":15605,"activeCount":101},[],{"intervention":15607,"totalTrials":233,"cells":15608},"SH T04769G",{"EARLY_PHASE1":15609,"PHASE1":15611,"PHASE2":15613,"PHASE3":15622,"PHASE4":15624,"NA":15626},{"trials":15610,"activeCount":101},[],{"trials":15612,"activeCount":101},[],{"trials":15614,"activeCount":101},[15615],{"nctId":15616,"briefTitle":15617,"status":107,"phases":15618,"primaryCompletion":3768,"completion":3768,"start":6317,"enrollment":2151,"conditions":15619,"interventions":15620},"NCT00471991","Valette (Combined Oral Contraceptive SH T04769G and SH D00659AF) Low Ovulation Inhibition",[91],[9210],[15607,15621],"Ethinyl estradiol \u002F dienogest",{"trials":15623,"activeCount":101},[],{"trials":15625,"activeCount":101},[],{"trials":15627,"activeCount":101},[],{"intervention":15621,"totalTrials":233,"cells":15629},{"EARLY_PHASE1":15630,"PHASE1":15632,"PHASE2":15634,"PHASE3":15640,"PHASE4":15642,"NA":15644},{"trials":15631,"activeCount":101},[],{"trials":15633,"activeCount":101},[],{"trials":15635,"activeCount":101},[15636],{"nctId":15616,"briefTitle":15617,"status":107,"phases":15637,"primaryCompletion":3768,"completion":3768,"start":6317,"enrollment":2151,"conditions":15638,"interventions":15639},[91],[9210],[15607,15621],{"trials":15641,"activeCount":101},[],{"trials":15643,"activeCount":101},[],{"trials":15645,"activeCount":101},[],{"intervention":15647,"totalTrials":233,"cells":15648},"SH T00268C",{"EARLY_PHASE1":15649,"PHASE1":15651,"PHASE2":15653,"PHASE3":15663,"PHASE4":15665,"NA":15667},{"trials":15650,"activeCount":101},[],{"trials":15652,"activeCount":101},[],{"trials":15654,"activeCount":101},[15655],{"nctId":15656,"briefTitle":15657,"status":107,"phases":15658,"primaryCompletion":9022,"completion":3567,"start":4836,"enrollment":12882,"conditions":15659,"interventions":15661},"NCT00160043","Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.",[91],[15660],"Non Small Cell Lung Cancer",[15647,15662],"PTK787\u002F ZK 222584",{"trials":15664,"activeCount":101},[],{"trials":15666,"activeCount":101},[],{"trials":15668,"activeCount":101},[],{"intervention":15662,"totalTrials":233,"cells":15670},{"EARLY_PHASE1":15671,"PHASE1":15673,"PHASE2":15675,"PHASE3":15681,"PHASE4":15683,"NA":15685},{"trials":15672,"activeCount":101},[],{"trials":15674,"activeCount":101},[],{"trials":15676,"activeCount":101},[15677],{"nctId":15656,"briefTitle":15657,"status":107,"phases":15678,"primaryCompletion":9022,"completion":3567,"start":4836,"enrollment":12882,"conditions":15679,"interventions":15680},[91],[15660],[15647,15662],{"trials":15682,"activeCount":101},[],{"trials":15684,"activeCount":101},[],{"trials":15686,"activeCount":101},[],{"intervention":3651,"totalTrials":233,"cells":15688},{"EARLY_PHASE1":15689,"PHASE1":15691,"PHASE2":15693,"PHASE3":15699,"PHASE4":15701,"NA":15703},{"trials":15690,"activeCount":101},[],{"trials":15692,"activeCount":101},[],{"trials":15694,"activeCount":101},[15695],{"nctId":3644,"briefTitle":3645,"status":107,"phases":15696,"primaryCompletion":3647,"completion":3647,"start":3648,"enrollment":447,"conditions":15697,"interventions":15698},[91],[3560],[3542,3651,3652],{"trials":15700,"activeCount":101},[],{"trials":15702,"activeCount":101},[],{"trials":15704,"activeCount":101},[],{"intervention":3652,"totalTrials":233,"cells":15706},{"EARLY_PHASE1":15707,"PHASE1":15709,"PHASE2":15711,"PHASE3":15717,"PHASE4":15719,"NA":15721},{"trials":15708,"activeCount":101},[],{"trials":15710,"activeCount":101},[],{"trials":15712,"activeCount":101},[15713],{"nctId":3644,"briefTitle":3645,"status":107,"phases":15714,"primaryCompletion":3647,"completion":3647,"start":3648,"enrollment":447,"conditions":15715,"interventions":15716},[91],[3560],[3542,3651,3652],{"trials":15718,"activeCount":101},[],{"trials":15720,"activeCount":101},[],{"trials":15722,"activeCount":101},[],{"intervention":523,"totalTrials":233,"cells":15724},{"EARLY_PHASE1":15725,"PHASE1":15727,"PHASE2":15729,"PHASE3":15735,"PHASE4":15737,"NA":15739},{"trials":15726,"activeCount":101},[],{"trials":15728,"activeCount":101},[],{"trials":15730,"activeCount":101},[15731],{"nctId":514,"briefTitle":515,"status":107,"phases":15732,"primaryCompletion":517,"completion":518,"start":507,"enrollment":519,"conditions":15733,"interventions":15734},[91],[521],[72,523,524],{"trials":15736,"activeCount":101},[],{"trials":15738,"activeCount":101},[],{"trials":15740,"activeCount":101},[],{"intervention":524,"totalTrials":233,"cells":15742},{"EARLY_PHASE1":15743,"PHASE1":15745,"PHASE2":15747,"PHASE3":15753,"PHASE4":15755,"NA":15757},{"trials":15744,"activeCount":101},[],{"trials":15746,"activeCount":101},[],{"trials":15748,"activeCount":101},[15749],{"nctId":514,"briefTitle":515,"status":107,"phases":15750,"primaryCompletion":517,"completion":518,"start":507,"enrollment":519,"conditions":15751,"interventions":15752},[91],[521],[72,523,524],{"trials":15754,"activeCount":101},[],{"trials":15756,"activeCount":101},[],{"trials":15758,"activeCount":101},[],{"intervention":15760,"totalTrials":233,"cells":15761},"Fesomersen sodium",{"EARLY_PHASE1":15762,"PHASE1":15764,"PHASE2":15766,"PHASE3":15777,"PHASE4":15779,"NA":15781},{"trials":15763,"activeCount":101},[],{"trials":15765,"activeCount":101},[],{"trials":15767,"activeCount":101},[15768],{"nctId":15769,"briefTitle":15770,"status":107,"phases":15771,"primaryCompletion":3970,"completion":15772,"start":15773,"enrollment":4721,"conditions":15774,"interventions":15776},"NCT04534114","Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug",[91],"2022-05-12","2020-09-04",[15775],"End Stage Renal Disease Requiring Hemodialysis",[15760],{"trials":15778,"activeCount":101},[],{"trials":15780,"activeCount":101},[],{"trials":15782,"activeCount":101},[],{"intervention":15784,"totalTrials":233,"cells":15785},"Drospirenone\u002F17ß-estradiol",{"EARLY_PHASE1":15786,"PHASE1":15788,"PHASE2":15790,"PHASE3":15801,"PHASE4":15803,"NA":15805},{"trials":15787,"activeCount":101},[],{"trials":15789,"activeCount":101},[],{"trials":15791,"activeCount":101},[15792],{"nctId":15793,"briefTitle":15794,"status":107,"phases":15795,"primaryCompletion":7249,"completion":7249,"start":1648,"enrollment":15796,"conditions":15797,"interventions":15799},"NCT00420342","Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension",[91],92,[6505,6625,15798],"Pre-Hypertension",[15784,15784,15800],"SH K 00641 C - Medroxyprogesterone acetate \u002F conjugated equine",{"trials":15802,"activeCount":101},[],{"trials":15804,"activeCount":101},[],{"trials":15806,"activeCount":101},[],{"intervention":15800,"totalTrials":233,"cells":15808},{"EARLY_PHASE1":15809,"PHASE1":15811,"PHASE2":15813,"PHASE3":15819,"PHASE4":15821,"NA":15823},{"trials":15810,"activeCount":101},[],{"trials":15812,"activeCount":101},[],{"trials":15814,"activeCount":101},[15815],{"nctId":15793,"briefTitle":15794,"status":107,"phases":15816,"primaryCompletion":7249,"completion":7249,"start":1648,"enrollment":15796,"conditions":15817,"interventions":15818},[91],[6505,6625,15798],[15784,15784,15800],{"trials":15820,"activeCount":101},[],{"trials":15822,"activeCount":101},[],{"trials":15824,"activeCount":101},[],{"intervention":15826,"totalTrials":233,"cells":15827},"Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin",{"EARLY_PHASE1":15828,"PHASE1":15830,"PHASE2":15832,"PHASE3":15841,"PHASE4":15843,"NA":15845},{"trials":15829,"activeCount":101},[],{"trials":15831,"activeCount":101},[],{"trials":15833,"activeCount":101},[15834],{"nctId":15835,"briefTitle":15836,"status":107,"phases":15837,"primaryCompletion":2970,"completion":2970,"start":4648,"enrollment":3568,"conditions":15838,"interventions":15839},"NCT00108953","A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma",[91],[1009],[15826,15840],"Doxorubicin\u002FPlacebo",{"trials":15842,"activeCount":101},[],{"trials":15844,"activeCount":101},[],{"trials":15846,"activeCount":101},[],{"intervention":15840,"totalTrials":233,"cells":15848},{"EARLY_PHASE1":15849,"PHASE1":15851,"PHASE2":15853,"PHASE3":15859,"PHASE4":15861,"NA":15863},{"trials":15850,"activeCount":101},[],{"trials":15852,"activeCount":101},[],{"trials":15854,"activeCount":101},[15855],{"nctId":15835,"briefTitle":15836,"status":107,"phases":15856,"primaryCompletion":2970,"completion":2970,"start":4648,"enrollment":3568,"conditions":15857,"interventions":15858},[91],[1009],[15826,15840],{"trials":15860,"activeCount":101},[],{"trials":15862,"activeCount":101},[],{"trials":15864,"activeCount":101},[],{"intervention":15866,"totalTrials":233,"cells":15867},"Sagopilone 16 mg\u002Fm^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid",{"EARLY_PHASE1":15868,"PHASE1":15870,"PHASE2":15872,"PHASE3":15882,"PHASE4":15884,"NA":15886},{"trials":15869,"activeCount":101},[],{"trials":15871,"activeCount":101},[],{"trials":15873,"activeCount":101},[15874],{"nctId":15875,"briefTitle":15876,"status":107,"phases":15877,"primaryCompletion":2255,"completion":1587,"start":8109,"enrollment":1858,"conditions":15878,"interventions":15880},"NCT00751205","Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)",[91],[307,15879],"Ovarian Cancer",[15866,15881],"Sagopilone 16 mg\u002Fm^2 i.v. and placebo 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid",{"trials":15883,"activeCount":101},[],{"trials":15885,"activeCount":101},[],{"trials":15887,"activeCount":101},[],{"intervention":15881,"totalTrials":233,"cells":15889},{"EARLY_PHASE1":15890,"PHASE1":15892,"PHASE2":15894,"PHASE3":15900,"PHASE4":15902,"NA":15904},{"trials":15891,"activeCount":101},[],{"trials":15893,"activeCount":101},[],{"trials":15895,"activeCount":101},[15896],{"nctId":15875,"briefTitle":15876,"status":107,"phases":15897,"primaryCompletion":2255,"completion":1587,"start":8109,"enrollment":1858,"conditions":15898,"interventions":15899},[91],[307,15879],[15866,15881],{"trials":15901,"activeCount":101},[],{"trials":15903,"activeCount":101},[],{"trials":15905,"activeCount":101},[],{"intervention":15907,"totalTrials":233,"cells":15908},"BAY 77-1931",{"EARLY_PHASE1":15909,"PHASE1":15911,"PHASE2":15913,"PHASE3":15921,"PHASE4":15923,"NA":15925},{"trials":15910,"activeCount":101},[],{"trials":15912,"activeCount":101},[],{"trials":15914,"activeCount":101},[15915],{"nctId":15916,"briefTitle":15917,"status":107,"phases":15918,"primaryCompletion":4597,"completion":4597,"start":6048,"enrollment":11021,"conditions":15919,"interventions":15920},"NCT00769496","BAY 77-1931 Long-term Extension From Phase II Study",[91],[8965],[15907],{"trials":15922,"activeCount":101},[],{"trials":15924,"activeCount":101},[],{"trials":15926,"activeCount":101},[],{"intervention":15928,"totalTrials":233,"cells":15929},"Amikacin",{"EARLY_PHASE1":15930,"PHASE1":15932,"PHASE2":15934,"PHASE3":15942,"PHASE4":15944,"NA":15946},{"trials":15931,"activeCount":101},[],{"trials":15933,"activeCount":101},[],{"trials":15935,"activeCount":101},[15936],{"nctId":15937,"briefTitle":15938,"status":107,"phases":15939,"primaryCompletion":3819,"completion":3819,"start":4770,"enrollment":13838,"conditions":15940,"interventions":15941},"NCT01004445","A Study to Determine the Correct Dose of Amikacin Which is Delivered Directly to the Lungs of Ventilated Patients as an Aerosol Via an Investigational Device Called the Pulmonary Delivery Device System (PDDS)",[91],[6718],[15928,15928],{"trials":15943,"activeCount":101},[],{"trials":15945,"activeCount":101},[],{"trials":15947,"activeCount":101},[],{"intervention":15949,"totalTrials":233,"cells":15950},"BAY 86-5310",{"EARLY_PHASE1":15951,"PHASE1":15953,"PHASE2":15955,"PHASE3":15965,"PHASE4":15967,"NA":15969},{"trials":15952,"activeCount":101},[],{"trials":15954,"activeCount":101},[],{"trials":15956,"activeCount":101},[15957],{"nctId":15958,"briefTitle":15959,"status":107,"phases":15960,"primaryCompletion":498,"completion":498,"start":6493,"enrollment":10065,"conditions":15961,"interventions":15963},"NCT00537836","ZK283197 for Treatment of Vasomotor Symptoms",[91],[15962],"Vasomotor System",[15949,15964],"17ß-estradiol",{"trials":15966,"activeCount":101},[],{"trials":15968,"activeCount":101},[],{"trials":15970,"activeCount":101},[],{"intervention":15964,"totalTrials":233,"cells":15972},{"EARLY_PHASE1":15973,"PHASE1":15975,"PHASE2":15977,"PHASE3":15983,"PHASE4":15985,"NA":15987},{"trials":15974,"activeCount":101},[],{"trials":15976,"activeCount":101},[],{"trials":15978,"activeCount":101},[15979],{"nctId":15958,"briefTitle":15959,"status":107,"phases":15980,"primaryCompletion":498,"completion":498,"start":6493,"enrollment":10065,"conditions":15981,"interventions":15982},[91],[15962],[15949,15964],{"trials":15984,"activeCount":101},[],{"trials":15986,"activeCount":101},[],{"trials":15988,"activeCount":101},[],{"intervention":15990,"totalTrials":233,"cells":15991},"Vardenafil HCl",{"EARLY_PHASE1":15992,"PHASE1":15994,"PHASE2":15996,"PHASE3":16006,"PHASE4":16008,"NA":16010},{"trials":15993,"activeCount":101},[],{"trials":15995,"activeCount":101},[],{"trials":15997,"activeCount":101},[15998],{"nctId":15999,"briefTitle":16000,"status":107,"phases":16001,"primaryCompletion":3567,"completion":3567,"start":9022,"enrollment":16002,"conditions":16003,"interventions":16005},"NCT00478881","A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function",[91],397,[9474,16004],"Detrusor Overactivity",[15990],{"trials":16007,"activeCount":101},[],{"trials":16009,"activeCount":101},[],{"trials":16011,"activeCount":101},[],{"intervention":6682,"totalTrials":233,"cells":16013},{"EARLY_PHASE1":16014,"PHASE1":16016,"PHASE2":16018,"PHASE3":16024,"PHASE4":16026,"NA":16028},{"trials":16015,"activeCount":101},[],{"trials":16017,"activeCount":101},[],{"trials":16019,"activeCount":101},[16020],{"nctId":6674,"briefTitle":6675,"status":107,"phases":16021,"primaryCompletion":6677,"completion":1629,"start":4250,"enrollment":6678,"conditions":16022,"interventions":16023},[91],[6680],[6665,6682],{"trials":16025,"activeCount":101},[],{"trials":16027,"activeCount":101},[],{"trials":16029,"activeCount":101},[],{"intervention":3679,"totalTrials":233,"cells":16031},{"EARLY_PHASE1":16032,"PHASE1":16034,"PHASE2":16036,"PHASE3":16042,"PHASE4":16044,"NA":16046},{"trials":16033,"activeCount":101},[],{"trials":16035,"activeCount":101},[],{"trials":16037,"activeCount":101},[16038],{"nctId":3673,"briefTitle":3674,"status":107,"phases":16039,"primaryCompletion":3628,"completion":3628,"start":446,"enrollment":3676,"conditions":16040,"interventions":16041},[91],[3631],[3542,3679,3679,3679,3680,3680],{"trials":16043,"activeCount":101},[],{"trials":16045,"activeCount":101},[],{"trials":16047,"activeCount":101},[],{"intervention":3680,"totalTrials":233,"cells":16049},{"EARLY_PHASE1":16050,"PHASE1":16052,"PHASE2":16054,"PHASE3":16060,"PHASE4":16062,"NA":16064},{"trials":16051,"activeCount":101},[],{"trials":16053,"activeCount":101},[],{"trials":16055,"activeCount":101},[16056],{"nctId":3673,"briefTitle":3674,"status":107,"phases":16057,"primaryCompletion":3628,"completion":3628,"start":446,"enrollment":3676,"conditions":16058,"interventions":16059},[91],[3631],[3542,3679,3679,3679,3680,3680],{"trials":16061,"activeCount":101},[],{"trials":16063,"activeCount":101},[],{"trials":16065,"activeCount":101},[],{"intervention":16067,"totalTrials":233,"cells":16068},"Piroxicam",{"EARLY_PHASE1":16069,"PHASE1":16071,"PHASE2":16073,"PHASE3":16082,"PHASE4":16084,"NA":16086},{"trials":16070,"activeCount":101},[],{"trials":16072,"activeCount":101},[],{"trials":16074,"activeCount":101},[16075],{"nctId":16076,"briefTitle":16077,"status":107,"phases":16078,"primaryCompletion":410,"completion":1507,"start":5975,"enrollment":11,"conditions":16079,"interventions":16081},"NCT01320709","Effect of Piroxicam on Ovulation",[91],[16080],"Contraception, Postcoital",[16067,16067,16067],{"trials":16083,"activeCount":101},[],{"trials":16085,"activeCount":101},[],{"trials":16087,"activeCount":101},[],{"intervention":16089,"totalTrials":233,"cells":16090},"BAY2253651",{"EARLY_PHASE1":16091,"PHASE1":16093,"PHASE2":16095,"PHASE3":16105,"PHASE4":16107,"NA":16109},{"trials":16092,"activeCount":101},[],{"trials":16094,"activeCount":101},[],{"trials":16096,"activeCount":101},[16097],{"nctId":16098,"briefTitle":16099,"status":107,"phases":16100,"primaryCompletion":13354,"completion":16101,"start":16102,"enrollment":9115,"conditions":16103,"interventions":16104},"NCT03603678","Obstructive Sleep Apnea (OSA) Treated With a Potassium Channel Inhibitor",[91],"2019-09-02","2018-08-13",[13639],[16089],{"trials":16106,"activeCount":101},[],{"trials":16108,"activeCount":101},[],{"trials":16110,"activeCount":101},[],{"intervention":16112,"totalTrials":233,"cells":16113},"Nifedipine (Adalat CR, BAYA1040) 80mg OD",{"EARLY_PHASE1":16114,"PHASE1":16116,"PHASE2":16118,"PHASE3":16129,"PHASE4":16131,"NA":16133},{"trials":16115,"activeCount":101},[],{"trials":16117,"activeCount":101},[],{"trials":16119,"activeCount":101},[16120],{"nctId":16121,"briefTitle":16122,"status":107,"phases":16123,"primaryCompletion":4597,"completion":4597,"start":3818,"enrollment":16124,"conditions":16125,"interventions":16126},"NCT00768560","Nifedipine (Adalat CR, BAY A1040) High Dose PK\u002FPD Study",[91],35,[6625],[16112,16127,16128],"Nifedipine (Adalat CR, BAYA1040) 40mg BID","Nifedipine (Adalat CR, BAYA1040) 40mg OD",{"trials":16130,"activeCount":101},[],{"trials":16132,"activeCount":101},[],{"trials":16134,"activeCount":101},[],{"intervention":16127,"totalTrials":233,"cells":16136},{"EARLY_PHASE1":16137,"PHASE1":16139,"PHASE2":16141,"PHASE3":16147,"PHASE4":16149,"NA":16151},{"trials":16138,"activeCount":101},[],{"trials":16140,"activeCount":101},[],{"trials":16142,"activeCount":101},[16143],{"nctId":16121,"briefTitle":16122,"status":107,"phases":16144,"primaryCompletion":4597,"completion":4597,"start":3818,"enrollment":16124,"conditions":16145,"interventions":16146},[91],[6625],[16112,16127,16128],{"trials":16148,"activeCount":101},[],{"trials":16150,"activeCount":101},[],{"trials":16152,"activeCount":101},[],{"intervention":16128,"totalTrials":233,"cells":16154},{"EARLY_PHASE1":16155,"PHASE1":16157,"PHASE2":16159,"PHASE3":16165,"PHASE4":16167,"NA":16169},{"trials":16156,"activeCount":101},[],{"trials":16158,"activeCount":101},[],{"trials":16160,"activeCount":101},[16161],{"nctId":16121,"briefTitle":16122,"status":107,"phases":16162,"primaryCompletion":4597,"completion":4597,"start":3818,"enrollment":16124,"conditions":16163,"interventions":16164},[91],[6625],[16112,16127,16128],{"trials":16166,"activeCount":101},[],{"trials":16168,"activeCount":101},[],{"trials":16170,"activeCount":101},[],{"intervention":13167,"totalTrials":233,"cells":16172},{"EARLY_PHASE1":16173,"PHASE1":16175,"PHASE2":16177,"PHASE3":16183,"PHASE4":16185,"NA":16187},{"trials":16174,"activeCount":101},[],{"trials":16176,"activeCount":101},[],{"trials":16178,"activeCount":101},[16179],{"nctId":13161,"briefTitle":13162,"status":107,"phases":16180,"primaryCompletion":1351,"completion":1351,"start":3618,"enrollment":13164,"conditions":16181,"interventions":16182},[91],[13148,13149],[13121,13167],{"trials":16184,"activeCount":101},[],{"trials":16186,"activeCount":101},[],{"trials":16188,"activeCount":101},[],{"intervention":3692,"totalTrials":233,"cells":16190},{"EARLY_PHASE1":16191,"PHASE1":16193,"PHASE2":16195,"PHASE3":16201,"PHASE4":16203,"NA":16205},{"trials":16192,"activeCount":101},[],{"trials":16194,"activeCount":101},[],{"trials":16196,"activeCount":101},[16197],{"nctId":3682,"briefTitle":3683,"status":107,"phases":16198,"primaryCompletion":3685,"completion":3686,"start":3687,"enrollment":3688,"conditions":16199,"interventions":16200},[91],[3690,1579],[3692,3542,3542,3693],{"trials":16202,"activeCount":101},[],{"trials":16204,"activeCount":101},[],{"trials":16206,"activeCount":101},[],{"intervention":3693,"totalTrials":233,"cells":16208},{"EARLY_PHASE1":16209,"PHASE1":16211,"PHASE2":16213,"PHASE3":16219,"PHASE4":16221,"NA":16223},{"trials":16210,"activeCount":101},[],{"trials":16212,"activeCount":101},[],{"trials":16214,"activeCount":101},[16215],{"nctId":3682,"briefTitle":3683,"status":107,"phases":16216,"primaryCompletion":3685,"completion":3686,"start":3687,"enrollment":3688,"conditions":16217,"interventions":16218},[91],[3690,1579],[3692,3542,3542,3693],{"trials":16220,"activeCount":101},[],{"trials":16222,"activeCount":101},[],{"trials":16224,"activeCount":101},[],{"intervention":16226,"totalTrials":233,"cells":16227},"PEG 3350 laxative plus electrolytes",{"EARLY_PHASE1":16228,"PHASE1":16230,"PHASE2":16232,"PHASE3":16240,"PHASE4":16242,"NA":16244},{"trials":16229,"activeCount":101},[],{"trials":16231,"activeCount":101},[],{"trials":16233,"activeCount":101},[16234],{"nctId":16235,"briefTitle":16236,"status":107,"phases":16237,"primaryCompletion":5999,"completion":5999,"start":3793,"enrollment":1833,"conditions":16238,"interventions":16239},"NCT01212445","Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation (Protocol P07515)",[91],[6680],[16226],{"trials":16241,"activeCount":101},[],{"trials":16243,"activeCount":101},[],{"trials":16245,"activeCount":101},[],{"intervention":16247,"totalTrials":233,"cells":16248},"BAY 1753011",{"EARLY_PHASE1":16249,"PHASE1":16251,"PHASE2":16253,"PHASE3":16267,"PHASE4":16269,"NA":16271},{"trials":16250,"activeCount":101},[],{"trials":16252,"activeCount":101},[],{"trials":16254,"activeCount":101},[16255],{"nctId":16256,"briefTitle":16257,"status":107,"phases":16258,"primaryCompletion":16259,"completion":16260,"start":16261,"enrollment":16262,"conditions":16263,"interventions":16265},"NCT03901729","A Trial to Study BAY1753011 in Patients With Congestive Heart Failure",[91],"2021-04-16","2021-05-21","2019-05-29",482,[16264],"Heart Failure (HF)",[16247,16266],"Furosemide",{"trials":16268,"activeCount":101},[],{"trials":16270,"activeCount":101},[],{"trials":16272,"activeCount":101},[],{"intervention":16266,"totalTrials":233,"cells":16274},{"EARLY_PHASE1":16275,"PHASE1":16277,"PHASE2":16279,"PHASE3":16285,"PHASE4":16287,"NA":16289},{"trials":16276,"activeCount":101},[],{"trials":16278,"activeCount":101},[],{"trials":16280,"activeCount":101},[16281],{"nctId":16256,"briefTitle":16257,"status":107,"phases":16282,"primaryCompletion":16259,"completion":16260,"start":16261,"enrollment":16262,"conditions":16283,"interventions":16284},[91],[16264],[16247,16266],{"trials":16286,"activeCount":101},[],{"trials":16288,"activeCount":101},[],{"trials":16290,"activeCount":101},[],{"intervention":16292,"totalTrials":233,"cells":16293},"Ethinylestradiol\u002FGestogene",{"EARLY_PHASE1":16294,"PHASE1":16296,"PHASE2":16298,"PHASE3":16306,"PHASE4":16308,"NA":16310},{"trials":16295,"activeCount":101},[],{"trials":16297,"activeCount":101},[],{"trials":16299,"activeCount":101},[16300],{"nctId":16301,"briefTitle":16302,"status":107,"phases":16303,"primaryCompletion":3618,"completion":2969,"start":4587,"enrollment":15796,"conditions":16304,"interventions":16305},"NCT00896571","Transdermal Contraceptive Patch - Endometrial Effects Study",[91],[15],[16292],{"trials":16307,"activeCount":101},[],{"trials":16309,"activeCount":101},[],{"trials":16311,"activeCount":101},[],{"intervention":16313,"totalTrials":233,"cells":16314},"Sagopilone (ZK 219477) + prednisone",{"EARLY_PHASE1":16315,"PHASE1":16317,"PHASE2":16319,"PHASE3":16330,"PHASE4":16332,"NA":16334},{"trials":16316,"activeCount":101},[],{"trials":16318,"activeCount":101},[],{"trials":16320,"activeCount":101},[16321],{"nctId":16322,"briefTitle":16323,"status":107,"phases":16324,"primaryCompletion":16325,"completion":16326,"start":16327,"enrollment":2189,"conditions":16328,"interventions":16329},"NCT00350051","ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer",[91],"2008-09-24","2009-12-21","2006-08-01",[307],[16313],{"trials":16331,"activeCount":101},[],{"trials":16333,"activeCount":101},[],{"trials":16335,"activeCount":101},[],{"intervention":16337,"totalTrials":233,"cells":16338},"BAY1193397",{"EARLY_PHASE1":16339,"PHASE1":16341,"PHASE2":16343,"PHASE3":16353,"PHASE4":16355,"NA":16357},{"trials":16340,"activeCount":101},[],{"trials":16342,"activeCount":101},[],{"trials":16344,"activeCount":101},[16345],{"nctId":16346,"briefTitle":16347,"status":107,"phases":16348,"primaryCompletion":12964,"completion":16349,"start":16350,"enrollment":1630,"conditions":16351,"interventions":16352},"NCT03128320","The Effects of BAY1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure",[91],"2019-10-28","2017-05-25",[11104],[16337,16337],{"trials":16354,"activeCount":101},[],{"trials":16356,"activeCount":101},[],{"trials":16358,"activeCount":101},[],{"intervention":4739,"totalTrials":233,"cells":16360},{"EARLY_PHASE1":16361,"PHASE1":16363,"PHASE2":16365,"PHASE3":16371,"PHASE4":16373,"NA":16375},{"trials":16362,"activeCount":101},[],{"trials":16364,"activeCount":101},[],{"trials":16366,"activeCount":101},[16367],{"nctId":4733,"briefTitle":4734,"status":156,"phases":16368,"primaryCompletion":4736,"completion":4736,"start":2970,"enrollment":1081,"conditions":16369,"interventions":16370},[91],[2328],[42,4739],{"trials":16372,"activeCount":101},[],{"trials":16374,"activeCount":101},[],{"trials":16376,"activeCount":101},[],{"intervention":16378,"totalTrials":233,"cells":16379},"Dehydroepiandrosterone, BAY86-5314",{"EARLY_PHASE1":16380,"PHASE1":16382,"PHASE2":16384,"PHASE3":16392,"PHASE4":16394,"NA":16396},{"trials":16381,"activeCount":101},[],{"trials":16383,"activeCount":101},[],{"trials":16385,"activeCount":101},[16386],{"nctId":16387,"briefTitle":16388,"status":107,"phases":16389,"primaryCompletion":4700,"completion":4700,"start":4579,"enrollment":435,"conditions":16390,"interventions":16391},"NCT00566384","Efficacy and Safety of Oral Dehydroepiandrosterone as a Concomitant Therapy to Oral Contraceptives in Women Complaining of Reduced Libido",[91],[5937],[16378],{"trials":16393,"activeCount":101},[],{"trials":16395,"activeCount":101},[],{"trials":16397,"activeCount":101},[],{"intervention":16399,"totalTrials":233,"cells":16400},"Chlorpheniramine maleate",{"EARLY_PHASE1":16401,"PHASE1":16403,"PHASE2":16405,"PHASE3":16416,"PHASE4":16418,"NA":16420},{"trials":16402,"activeCount":101},[],{"trials":16404,"activeCount":101},[],{"trials":16406,"activeCount":101},[16407],{"nctId":16408,"briefTitle":16409,"status":156,"phases":16410,"primaryCompletion":16411,"completion":16412,"start":16413,"enrollment":233,"conditions":16414,"interventions":16415},"NCT02722083","Exploratory Study for Allergy Relief Onset",[91],"2016-05-27","2016-07-13","2016-05-07",[6447],[16399],{"trials":16417,"activeCount":101},[],{"trials":16419,"activeCount":101},[],{"trials":16421,"activeCount":101},[],{"intervention":12970,"totalTrials":233,"cells":16423},{"EARLY_PHASE1":16424,"PHASE1":16426,"PHASE2":16428,"PHASE3":16434,"PHASE4":16436,"NA":16438},{"trials":16425,"activeCount":101},[],{"trials":16427,"activeCount":101},[],{"trials":16429,"activeCount":101},[16430],{"nctId":12960,"briefTitle":12961,"status":107,"phases":16431,"primaryCompletion":12963,"completion":12964,"start":12965,"enrollment":12966,"conditions":16432,"interventions":16433},[91],[12968],[1281,12970],{"trials":16435,"activeCount":101},[],{"trials":16437,"activeCount":101},[],{"trials":16439,"activeCount":101},[],{"intervention":16441,"totalTrials":233,"cells":16442},"SH D01155E",{"EARLY_PHASE1":16443,"PHASE1":16445,"PHASE2":16447,"PHASE3":16456,"PHASE4":16458,"NA":16460},{"trials":16444,"activeCount":101},[],{"trials":16446,"activeCount":101},[],{"trials":16448,"activeCount":101},[16449],{"nctId":16450,"briefTitle":16451,"status":107,"phases":16452,"primaryCompletion":445,"completion":445,"start":4861,"enrollment":6430,"conditions":16453,"interventions":16455},"NCT00318799","Impact of SH T00658ID as Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D01155E) on Hemostatic Parameters",[91],[16454],"Pregnancy, Unplanned",[5939,16441],{"trials":16457,"activeCount":101},[],{"trials":16459,"activeCount":101},[],{"trials":16461,"activeCount":101},[],{"intervention":16463,"totalTrials":233,"cells":16464},"Bifonazole spray once daily",{"EARLY_PHASE1":16465,"PHASE1":16467,"PHASE2":16469,"PHASE3":16480,"PHASE4":16482,"NA":16484},{"trials":16466,"activeCount":101},[],{"trials":16468,"activeCount":101},[],{"trials":16470,"activeCount":101},[16471],{"nctId":16472,"briefTitle":16473,"status":107,"phases":16474,"primaryCompletion":8136,"completion":8136,"start":499,"enrollment":5473,"conditions":16475,"interventions":16477},"NCT01013909","Comparative Safety and Efficacy Study of New Bifonazol Spray vs Terbinafine Solution vs Placebo",[91],[16476],"Tinea Pedis",[16463,16478,16479],"Bifonazole spray twice daily","Lamisil Once",{"trials":16481,"activeCount":101},[],{"trials":16483,"activeCount":101},[],{"trials":16485,"activeCount":101},[],{"intervention":16478,"totalTrials":233,"cells":16487},{"EARLY_PHASE1":16488,"PHASE1":16490,"PHASE2":16492,"PHASE3":16498,"PHASE4":16500,"NA":16502},{"trials":16489,"activeCount":101},[],{"trials":16491,"activeCount":101},[],{"trials":16493,"activeCount":101},[16494],{"nctId":16472,"briefTitle":16473,"status":107,"phases":16495,"primaryCompletion":8136,"completion":8136,"start":499,"enrollment":5473,"conditions":16496,"interventions":16497},[91],[16476],[16463,16478,16479],{"trials":16499,"activeCount":101},[],{"trials":16501,"activeCount":101},[],{"trials":16503,"activeCount":101},[],{"intervention":16479,"totalTrials":233,"cells":16505},{"EARLY_PHASE1":16506,"PHASE1":16508,"PHASE2":16510,"PHASE3":16516,"PHASE4":16518,"NA":16520},{"trials":16507,"activeCount":101},[],{"trials":16509,"activeCount":101},[],{"trials":16511,"activeCount":101},[16512],{"nctId":16472,"briefTitle":16473,"status":107,"phases":16513,"primaryCompletion":8136,"completion":8136,"start":499,"enrollment":5473,"conditions":16514,"interventions":16515},[91],[16476],[16463,16478,16479],{"trials":16517,"activeCount":101},[],{"trials":16519,"activeCount":101},[],{"trials":16521,"activeCount":101},[],{"intervention":16523,"totalTrials":233,"cells":16524},"CCR1-Antagonist",{"EARLY_PHASE1":16525,"PHASE1":16527,"PHASE2":16529,"PHASE3":16537,"PHASE4":16539,"NA":16541},{"trials":16526,"activeCount":101},[],{"trials":16528,"activeCount":101},[],{"trials":16530,"activeCount":101},[16531],{"nctId":16532,"briefTitle":16533,"status":107,"phases":16534,"primaryCompletion":1328,"completion":1328,"start":5946,"enrollment":1205,"conditions":16535,"interventions":16536},"NCT00185341","Study to Investigate the Efficacy of a Non-hormonal Drug Against Endometriosis Associated Pelvic Pain",[91],[7793],[16523],{"trials":16538,"activeCount":101},[],{"trials":16540,"activeCount":101},[],{"trials":16542,"activeCount":101},[],{"intervention":16544,"totalTrials":233,"cells":16545},"Finerenone (BAY94-8862 ) 10 mg",{"EARLY_PHASE1":16546,"PHASE1":16548,"PHASE2":16550,"PHASE3":16564,"PHASE4":16566,"NA":16568},{"trials":16547,"activeCount":101},[],{"trials":16549,"activeCount":101},[],{"trials":16551,"activeCount":101},[16552],{"nctId":16553,"briefTitle":16554,"status":107,"phases":16555,"primaryCompletion":16556,"completion":16556,"start":16557,"enrollment":6,"conditions":16558,"interventions":16559},"NCT05254002","A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes",[91],"2025-03-14","2022-06-23",[749,32],[16544,16560,16561,16562,16563],"Empagliflozin","Empagliflozin Placebo","Finerenone (BAY94-8862 ) 20 mg","Finerenone Placebo",{"trials":16565,"activeCount":101},[],{"trials":16567,"activeCount":101},[],{"trials":16569,"activeCount":101},[],{"intervention":16560,"totalTrials":233,"cells":16571},{"EARLY_PHASE1":16572,"PHASE1":16574,"PHASE2":16576,"PHASE3":16582,"PHASE4":16584,"NA":16586},{"trials":16573,"activeCount":101},[],{"trials":16575,"activeCount":101},[],{"trials":16577,"activeCount":101},[16578],{"nctId":16553,"briefTitle":16554,"status":107,"phases":16579,"primaryCompletion":16556,"completion":16556,"start":16557,"enrollment":6,"conditions":16580,"interventions":16581},[91],[749,32],[16544,16560,16561,16562,16563],{"trials":16583,"activeCount":101},[],{"trials":16585,"activeCount":101},[],{"trials":16587,"activeCount":101},[],{"intervention":16561,"totalTrials":233,"cells":16589},{"EARLY_PHASE1":16590,"PHASE1":16592,"PHASE2":16594,"PHASE3":16600,"PHASE4":16602,"NA":16604},{"trials":16591,"activeCount":101},[],{"trials":16593,"activeCount":101},[],{"trials":16595,"activeCount":101},[16596],{"nctId":16553,"briefTitle":16554,"status":107,"phases":16597,"primaryCompletion":16556,"completion":16556,"start":16557,"enrollment":6,"conditions":16598,"interventions":16599},[91],[749,32],[16544,16560,16561,16562,16563],{"trials":16601,"activeCount":101},[],{"trials":16603,"activeCount":101},[],{"trials":16605,"activeCount":101},[],{"intervention":16562,"totalTrials":233,"cells":16607},{"EARLY_PHASE1":16608,"PHASE1":16610,"PHASE2":16612,"PHASE3":16618,"PHASE4":16620,"NA":16622},{"trials":16609,"activeCount":101},[],{"trials":16611,"activeCount":101},[],{"trials":16613,"activeCount":101},[16614],{"nctId":16553,"briefTitle":16554,"status":107,"phases":16615,"primaryCompletion":16556,"completion":16556,"start":16557,"enrollment":6,"conditions":16616,"interventions":16617},[91],[749,32],[16544,16560,16561,16562,16563],{"trials":16619,"activeCount":101},[],{"trials":16621,"activeCount":101},[],{"trials":16623,"activeCount":101},[],{"intervention":16563,"totalTrials":233,"cells":16625},{"EARLY_PHASE1":16626,"PHASE1":16628,"PHASE2":16630,"PHASE3":16636,"PHASE4":16638,"NA":16640},{"trials":16627,"activeCount":101},[],{"trials":16629,"activeCount":101},[],{"trials":16631,"activeCount":101},[16632],{"nctId":16553,"briefTitle":16554,"status":107,"phases":16633,"primaryCompletion":16556,"completion":16556,"start":16557,"enrollment":6,"conditions":16634,"interventions":16635},[91],[749,32],[16544,16560,16561,16562,16563],{"trials":16637,"activeCount":101},[],{"trials":16639,"activeCount":101},[],{"trials":16641,"activeCount":101},[],{"intervention":16643,"totalTrials":233,"cells":16644},"BAY1097761 Active Dose 1",{"EARLY_PHASE1":16645,"PHASE1":16647,"PHASE2":16649,"PHASE3":16660,"PHASE4":16662,"NA":16664},{"trials":16646,"activeCount":101},[],{"trials":16648,"activeCount":101},[],{"trials":16650,"activeCount":101},[16651],{"nctId":16652,"briefTitle":16653,"status":156,"phases":16654,"primaryCompletion":16655,"completion":16655,"start":679,"enrollment":8856,"conditions":16656,"interventions":16658},"NCT04417036","This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Affects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the Lungs Making Breathing Difficult (ARDS)",[91],"2022-12-28",[16657],"Acute Respiratory Distress Syndrome",[16643,16659],"BAY1097761 Active Dose 2",{"trials":16661,"activeCount":101},[],{"trials":16663,"activeCount":101},[],{"trials":16665,"activeCount":101},[],{"intervention":16659,"totalTrials":233,"cells":16667},{"EARLY_PHASE1":16668,"PHASE1":16670,"PHASE2":16672,"PHASE3":16678,"PHASE4":16680,"NA":16682},{"trials":16669,"activeCount":101},[],{"trials":16671,"activeCount":101},[],{"trials":16673,"activeCount":101},[16674],{"nctId":16652,"briefTitle":16653,"status":156,"phases":16675,"primaryCompletion":16655,"completion":16655,"start":679,"enrollment":8856,"conditions":16676,"interventions":16677},[91],[16657],[16643,16659],{"trials":16679,"activeCount":101},[],{"trials":16681,"activeCount":101},[],{"trials":16683,"activeCount":101},[],{"intervention":2348,"totalTrials":233,"cells":16685},{"EARLY_PHASE1":16686,"PHASE1":16688,"PHASE2":16690,"PHASE3":16696,"PHASE4":16698,"NA":16700},{"trials":16687,"activeCount":101},[],{"trials":16689,"activeCount":101},[],{"trials":16691,"activeCount":101},[16692],{"nctId":2341,"briefTitle":2342,"status":107,"phases":16693,"primaryCompletion":410,"completion":1488,"start":2344,"enrollment":2345,"conditions":16694,"interventions":16695},[91],[2249],[1011,2348,2349,2350],{"trials":16697,"activeCount":101},[],{"trials":16699,"activeCount":101},[],{"trials":16701,"activeCount":101},[],{"intervention":2349,"totalTrials":233,"cells":16703},{"EARLY_PHASE1":16704,"PHASE1":16706,"PHASE2":16708,"PHASE3":16714,"PHASE4":16716,"NA":16718},{"trials":16705,"activeCount":101},[],{"trials":16707,"activeCount":101},[],{"trials":16709,"activeCount":101},[16710],{"nctId":2341,"briefTitle":2342,"status":107,"phases":16711,"primaryCompletion":410,"completion":1488,"start":2344,"enrollment":2345,"conditions":16712,"interventions":16713},[91],[2249],[1011,2348,2349,2350],{"trials":16715,"activeCount":101},[],{"trials":16717,"activeCount":101},[],{"trials":16719,"activeCount":101},[],{"intervention":2350,"totalTrials":233,"cells":16721},{"EARLY_PHASE1":16722,"PHASE1":16724,"PHASE2":16726,"PHASE3":16732,"PHASE4":16734,"NA":16736},{"trials":16723,"activeCount":101},[],{"trials":16725,"activeCount":101},[],{"trials":16727,"activeCount":101},[16728],{"nctId":2341,"briefTitle":2342,"status":107,"phases":16729,"primaryCompletion":410,"completion":1488,"start":2344,"enrollment":2345,"conditions":16730,"interventions":16731},[91],[2249],[1011,2348,2349,2350],{"trials":16733,"activeCount":101},[],{"trials":16735,"activeCount":101},[],{"trials":16737,"activeCount":101},[],{"intervention":4754,"totalTrials":233,"cells":16739},{"EARLY_PHASE1":16740,"PHASE1":16742,"PHASE2":16744,"PHASE3":16750,"PHASE4":16752,"NA":16754},{"trials":16741,"activeCount":101},[],{"trials":16743,"activeCount":101},[],{"trials":16745,"activeCount":101},[16746],{"nctId":4747,"briefTitle":4748,"status":107,"phases":16747,"primaryCompletion":4750,"completion":1313,"start":3705,"enrollment":4751,"conditions":16748,"interventions":16749},[91],[2328],[42,4754],{"trials":16751,"activeCount":101},[],{"trials":16753,"activeCount":101},[],{"trials":16755,"activeCount":101},[],{"intervention":16757,"totalTrials":233,"cells":16758},"ZK245186",{"EARLY_PHASE1":16759,"PHASE1":16761,"PHASE2":16763,"PHASE3":16772,"PHASE4":16774,"NA":16776},{"trials":16760,"activeCount":101},[],{"trials":16762,"activeCount":101},[],{"trials":16764,"activeCount":101},[16765],{"nctId":16766,"briefTitle":16767,"status":107,"phases":16768,"primaryCompletion":2366,"completion":1506,"start":1570,"enrollment":16769,"conditions":16770,"interventions":16771},"NCT01228513","Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)",[91],263,[13148],[16757],{"trials":16773,"activeCount":101},[],{"trials":16775,"activeCount":101},[],{"trials":16777,"activeCount":101},[],{"intervention":16779,"totalTrials":233,"cells":16780},"BAY85-8501",{"EARLY_PHASE1":16781,"PHASE1":16783,"PHASE2":16785,"PHASE3":16794,"PHASE4":16796,"NA":16798},{"trials":16782,"activeCount":101},[],{"trials":16784,"activeCount":101},[],{"trials":16786,"activeCount":101},[16787],{"nctId":16788,"briefTitle":16789,"status":107,"phases":16790,"primaryCompletion":1488,"completion":1488,"start":4250,"enrollment":16791,"conditions":16792,"interventions":16793},"NCT01818544","Safety and Efficacy of Oral BAY85-8501 in Patients With Non-CF (Cystic Fibrosis) Bronchiectasis",[91],94,[10004],[16779],{"trials":16795,"activeCount":101},[],{"trials":16797,"activeCount":101},[],{"trials":16799,"activeCount":101},[],{"intervention":1934,"totalTrials":421,"cells":16801},{"EARLY_PHASE1":16802,"PHASE1":16804,"PHASE2":16851,"PHASE3":16853,"PHASE4":16855,"NA":16857},{"trials":16803,"activeCount":101},[],{"trials":16805,"activeCount":101},[16806,16814,16818,16822,16830,16834,16838,16847],{"nctId":16807,"briefTitle":16808,"status":107,"phases":16809,"primaryCompletion":16810,"completion":539,"start":13285,"enrollment":22,"conditions":16811,"interventions":16812},"NCT02253420","COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients",[90],"2018-03-12",[1267],[7973,1934,16813,7973],"Rifampin",{"nctId":12927,"briefTitle":12928,"status":107,"phases":16815,"primaryCompletion":12930,"completion":12931,"start":12932,"enrollment":112,"conditions":16816,"interventions":16817},[90],[1267],[1281,1934],{"nctId":1926,"briefTitle":1927,"status":107,"phases":16819,"primaryCompletion":1929,"completion":1929,"start":1930,"enrollment":160,"conditions":16820,"interventions":16821},[90],[1069,1932,1070,1124],[1919,1934,1155],{"nctId":16823,"briefTitle":16824,"status":107,"phases":16825,"primaryCompletion":16826,"completion":16827,"start":2481,"enrollment":1949,"conditions":16828,"interventions":16829},"NCT03048110","Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction",[90],"2017-05-04","2017-07-19",[3603],[12687,1934,12636],{"nctId":13350,"briefTitle":13351,"status":107,"phases":16831,"primaryCompletion":13353,"completion":13354,"start":13355,"enrollment":1181,"conditions":16832,"interventions":16833},[90],[1490],[12698,1934],{"nctId":12546,"briefTitle":12547,"status":107,"phases":16835,"primaryCompletion":12549,"completion":12550,"start":12551,"enrollment":5094,"conditions":16836,"interventions":16837},[90],[12553],[12494,1934],{"nctId":16839,"briefTitle":16840,"status":156,"phases":16841,"primaryCompletion":4974,"completion":2506,"start":16842,"enrollment":1509,"conditions":16843,"interventions":16845},"NCT03119077","Single Ascending Dose, First-in-Human Study on Safety, Tolerability and Pharmacokinetics of BAY1161116",[90],"2017-04-27",[16844],"Polycystic Ovary Syndrome",[16846,1934],"BAY1161116",{"nctId":12893,"briefTitle":12894,"status":107,"phases":16848,"primaryCompletion":7776,"completion":409,"start":1487,"enrollment":1181,"conditions":16849,"interventions":16850},[90],[1267],[1307,1934],{"trials":16852,"activeCount":101},[],{"trials":16854,"activeCount":101},[],{"trials":16856,"activeCount":101},[],{"trials":16858,"activeCount":101},[],{"intervention":1115,"totalTrials":5220,"cells":16860},{"EARLY_PHASE1":16861,"PHASE1":16863,"PHASE2":16898,"PHASE3":16900,"PHASE4":16902,"NA":16904},{"trials":16862,"activeCount":101},[],{"trials":16864,"activeCount":101},[16865,16874,16878,16882,16886,16894],{"nctId":16866,"briefTitle":16867,"status":107,"phases":16868,"primaryCompletion":16869,"completion":16870,"start":5839,"enrollment":1181,"conditions":16871,"interventions":16872},"NCT04252300","Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants",[90],"2020-08-29","2020-12-07",[1490],[1115,16873],"Rosuvastatin + BAY1817080",{"nctId":2598,"briefTitle":2599,"status":464,"phases":16875,"primaryCompletion":2601,"completion":2601,"start":2602,"enrollment":101,"conditions":16876,"interventions":16877},[90],[32],[2581,1115,1126],{"nctId":1107,"briefTitle":1108,"status":107,"phases":16879,"primaryCompletion":1110,"completion":1111,"start":1112,"enrollment":1081,"conditions":16880,"interventions":16881},[90],[1094],[52,1115],{"nctId":1944,"briefTitle":1945,"status":107,"phases":16883,"primaryCompletion":1947,"completion":1947,"start":1948,"enrollment":1949,"conditions":16884,"interventions":16885},[90],[1069,1932,1070,1124],[1919,1126,1115],{"nctId":16887,"briefTitle":16888,"status":107,"phases":16889,"primaryCompletion":16890,"completion":5248,"start":7776,"enrollment":160,"conditions":16891,"interventions":16893},"NCT02671097","Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate",[90],"2016-05",[1124,1790,16892],"Drug Interaction",[1115,12687],{"nctId":2235,"briefTitle":2236,"status":107,"phases":16895,"primaryCompletion":2238,"completion":2239,"start":2240,"enrollment":2212,"conditions":16896,"interventions":16897},[90],[29],[2243,1115,1011],{"trials":16899,"activeCount":101},[],{"trials":16901,"activeCount":101},[],{"trials":16903,"activeCount":101},[],{"trials":16905,"activeCount":101},[],{"intervention":1358,"totalTrials":328,"cells":16907},{"EARLY_PHASE1":16908,"PHASE1":16910,"PHASE2":16951,"PHASE3":16953,"PHASE4":16955,"NA":16957},{"trials":16909,"activeCount":101},[],{"trials":16911,"activeCount":101},[16912,16916,16924,16933,16942],{"nctId":1348,"briefTitle":1349,"status":107,"phases":16913,"primaryCompletion":1351,"completion":1352,"start":1315,"enrollment":33,"conditions":16914,"interventions":16915},[90],[423,1354],[1356,1356,1357,1357,1357,1357,1358,1074],{"nctId":16917,"briefTitle":16918,"status":107,"phases":16919,"primaryCompletion":16920,"completion":1762,"start":16921,"enrollment":6503,"conditions":16922,"interventions":16923},"NCT01411410","Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer",[90],"2014-10-22","2011-08-24",[29],[1358,7973],{"nctId":16925,"briefTitle":16926,"status":156,"phases":16927,"primaryCompletion":13431,"completion":16928,"start":16929,"enrollment":13838,"conditions":16930,"interventions":16931},"NCT02138812","Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel",[90],"2017-10-02","2014-05-09",[1267],[16932,1358],"BAY1161909",{"nctId":16934,"briefTitle":16935,"status":107,"phases":16936,"primaryCompletion":468,"completion":468,"start":4880,"enrollment":1949,"conditions":16937,"interventions":16939},"NCT02442063","Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions",[90],[29,16938],"Bone Diseases",[16940,16941],"Radium Ra 223 dichloride","paclitaxel",{"nctId":16943,"briefTitle":16944,"status":107,"phases":16945,"primaryCompletion":7829,"completion":16946,"start":16947,"enrollment":1649,"conditions":16948,"interventions":16949},"NCT02366949","Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel",[90],"2019-04-18","2015-02-27",[1267],[16950,1358],"BAY1217389",{"trials":16952,"activeCount":101},[],{"trials":16954,"activeCount":101},[],{"trials":16956,"activeCount":101},[],{"trials":16958,"activeCount":101},[],{"intervention":12687,"totalTrials":855,"cells":16960},{"EARLY_PHASE1":16961,"PHASE1":16963,"PHASE2":16985,"PHASE3":16987,"PHASE4":16989,"NA":16991},{"trials":16962,"activeCount":101},[],{"trials":16964,"activeCount":101},[16965,16969,16977,16981],{"nctId":16823,"briefTitle":16824,"status":107,"phases":16966,"primaryCompletion":16826,"completion":16827,"start":2481,"enrollment":1949,"conditions":16967,"interventions":16968},[90],[3603],[12687,1934,12636],{"nctId":16970,"briefTitle":16971,"status":107,"phases":16972,"primaryCompletion":16973,"completion":1607,"start":11405,"enrollment":6430,"conditions":16974,"interventions":16976},"NCT02894385","Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)",[90],"2017-04-10",[1790,1788,16975],"Renal Insufficiency",[12687],{"nctId":16887,"briefTitle":16888,"status":107,"phases":16978,"primaryCompletion":16890,"completion":5248,"start":7776,"enrollment":160,"conditions":16979,"interventions":16980},[90],[1124,1790,16892],[1115,12687],{"nctId":12680,"briefTitle":12681,"status":107,"phases":16982,"primaryCompletion":12683,"completion":3638,"start":12684,"enrollment":1949,"conditions":16983,"interventions":16984},[90],[187],[1126,1154,12687],{"trials":16986,"activeCount":101},[],{"trials":16988,"activeCount":101},[],{"trials":16990,"activeCount":101},[],{"trials":16992,"activeCount":101},[],{"intervention":12674,"totalTrials":855,"cells":16994},{"EARLY_PHASE1":16995,"PHASE1":16997,"PHASE2":17028,"PHASE3":17030,"PHASE4":17032,"NA":17034},{"trials":16996,"activeCount":101},[],{"trials":16998,"activeCount":101},[16999,17006,17016,17020],{"nctId":17000,"briefTitle":17001,"status":107,"phases":17002,"primaryCompletion":5103,"completion":6420,"start":3175,"enrollment":3374,"conditions":17003,"interventions":17005},"NCT03244462","Food Effect, Oral & Intravenous Pharmacokinetics and Absolute Bioavailability of BAY1834845 Including Drug-drug Interaction With Methotrexate",[90],[17004],"Inflammation",[12674,12674,12647],{"nctId":17007,"briefTitle":17008,"status":107,"phases":17009,"primaryCompletion":17010,"completion":1150,"start":17011,"enrollment":22,"conditions":17012,"interventions":17014},"NCT05003089","A Trial to Learn How BAY1834845 and BAY1830839 Affect Inflammation When Taken by Mouth Twice a Day for 7 Days in a Row in Healthy Male Participants",[90],"2021-12-16","2021-06-28",[17013],"Immune Mediated Inflammatory Diseases",[12674,12646,17015],"Prednisolone",{"nctId":12666,"briefTitle":12667,"status":107,"phases":17017,"primaryCompletion":1274,"completion":12669,"start":12670,"enrollment":11,"conditions":17018,"interventions":17019},[90],[1124,12672],[12674,1154],{"nctId":17021,"briefTitle":17022,"status":107,"phases":17023,"primaryCompletion":13816,"completion":17024,"start":17025,"enrollment":550,"conditions":17026,"interventions":17027},"NCT03054402","First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845",[90],"2018-03-29","2017-02-13",[10254],[12674],{"trials":17029,"activeCount":101},[],{"trials":17031,"activeCount":101},[],{"trials":17033,"activeCount":101},[],{"trials":17035,"activeCount":101},[],{"intervention":17037,"totalTrials":1341,"cells":17038},"BAY1093884",{"EARLY_PHASE1":17039,"PHASE1":17041,"PHASE2":17070,"PHASE3":17072,"PHASE4":17074,"NA":17076},{"trials":17040,"activeCount":101},[],{"trials":17042,"activeCount":101},[17043,17053,17061],{"nctId":17044,"briefTitle":17045,"status":107,"phases":17046,"primaryCompletion":17047,"completion":17048,"start":17049,"enrollment":1509,"conditions":17050,"interventions":17052},"NCT02571569","A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors",[90],"2018-07-09","2018-10-11","2015-10-28",[24,17051],"Hemophilia B",[17037,17037],{"nctId":17054,"briefTitle":17055,"status":464,"phases":17056,"primaryCompletion":17057,"completion":3917,"start":16349,"enrollment":101,"conditions":17058,"interventions":17060},"NCT03996486","Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia",[90],"2020-05-29",[17059],"Hemophilia",[17037],{"nctId":17062,"briefTitle":17063,"status":107,"phases":17064,"primaryCompletion":13546,"completion":17065,"start":17066,"enrollment":5220,"conditions":17067,"interventions":17069},"NCT03481946","A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia",[90],"2019-02-20","2018-05-10",[17068],"Hemophilia A; Hemophilia B",[17037,17037],{"trials":17071,"activeCount":101},[],{"trials":17073,"activeCount":101},[],{"trials":17075,"activeCount":101},[],{"trials":17077,"activeCount":101},[],{"intervention":999,"totalTrials":1341,"cells":17079},{"EARLY_PHASE1":17080,"PHASE1":17082,"PHASE2":17108,"PHASE3":17110,"PHASE4":17112,"NA":17114},{"trials":17081,"activeCount":101},[],{"trials":17083,"activeCount":101},[17084,17088,17097],{"nctId":989,"briefTitle":990,"status":107,"phases":17085,"primaryCompletion":992,"completion":993,"start":994,"enrollment":995,"conditions":17086,"interventions":17087},[90],[997],[999,425],{"nctId":17089,"briefTitle":17090,"status":156,"phases":17091,"primaryCompletion":2417,"completion":2417,"start":17092,"enrollment":1181,"conditions":17093,"interventions":17095},"NCT04267939","ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer",[90],"2020-02-26",[17094,15879],"Advanced Solid Tumors (Excluding Prostate Cancer)",[999,17096],"Niraparib",{"nctId":17098,"briefTitle":17099,"status":107,"phases":17100,"primaryCompletion":17101,"completion":17102,"start":17103,"enrollment":5131,"conditions":17104,"interventions":17107},"NCT03188965","First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas",[90],"2022-12-02","2023-09-13","2017-07-06",[17105,8772,17106],"Advanced Solid Tumor","Mantle Cell Lymphoma",[999],{"trials":17109,"activeCount":101},[],{"trials":17111,"activeCount":101},[],{"trials":17113,"activeCount":101},[],{"trials":17115,"activeCount":101},[],{"intervention":12646,"totalTrials":1341,"cells":17117},{"EARLY_PHASE1":17118,"PHASE1":17120,"PHASE2":17139,"PHASE3":17141,"PHASE4":17143,"NA":17145},{"trials":17119,"activeCount":101},[],{"trials":17121,"activeCount":101},[17122,17131,17135],{"nctId":17123,"briefTitle":17124,"status":107,"phases":17125,"primaryCompletion":17126,"completion":15404,"start":17127,"enrollment":447,"conditions":17128,"interventions":17130},"NCT03540615","BAY1830839: First in Man, Single Dose Escalation, Safety & Tolerability and Pharmacokinetics",[90],"2019-02-05","2018-06-28",[17129],"Arthritis, Rheumatoid",[12646],{"nctId":12639,"briefTitle":12640,"status":107,"phases":17132,"primaryCompletion":12599,"completion":12642,"start":12643,"enrollment":6822,"conditions":17133,"interventions":17134},[90],[1124],[12646,1154,12647],{"nctId":17007,"briefTitle":17008,"status":107,"phases":17136,"primaryCompletion":17010,"completion":1150,"start":17011,"enrollment":22,"conditions":17137,"interventions":17138},[90],[17013],[12674,12646,17015],{"trials":17140,"activeCount":101},[],{"trials":17142,"activeCount":101},[],{"trials":17144,"activeCount":101},[],{"trials":17146,"activeCount":101},[],{"intervention":12636,"totalTrials":1341,"cells":17148},{"EARLY_PHASE1":17149,"PHASE1":17151,"PHASE2":17175,"PHASE3":17177,"PHASE4":17179,"NA":17181},{"trials":17150,"activeCount":101},[],{"trials":17152,"activeCount":101},[17153,17157,17161],{"nctId":16823,"briefTitle":16824,"status":107,"phases":17154,"primaryCompletion":16826,"completion":16827,"start":2481,"enrollment":1949,"conditions":17155,"interventions":17156},[90],[3603],[12687,1934,12636],{"nctId":12628,"briefTitle":12629,"status":107,"phases":17158,"primaryCompletion":12631,"completion":12632,"start":12633,"enrollment":4620,"conditions":17159,"interventions":17160},[90],[7793],[12636,1154,12637],{"nctId":17162,"briefTitle":17163,"status":107,"phases":17164,"primaryCompletion":7802,"completion":17165,"start":17166,"enrollment":490,"conditions":17167,"interventions":17168},"NCT03353857","Drug-drug Interaction Between Rifampicin and Progestins\u002FEthinylestradiol and Midazolam",[90],"2019-02-19","2017-11-29",[3603],[17169,17170,17171,17172,17173,17174,12636],"levonorgestrel\u002F Microlut","Norethindrone\u002F Noriday","Desogestrel\u002F Cerazette","Dienogest\u002F Visanne","Drospirenone, Ethinylestradiol\u002F Yasmin","Midazolam\u002F Midazolam-ratiopharm",{"trials":17176,"activeCount":101},[],{"trials":17178,"activeCount":101},[],{"trials":17180,"activeCount":101},[],{"trials":17182,"activeCount":101},[],{"intervention":17184,"totalTrials":1341,"cells":17185},"Levonorgestrel Emergency Pill",{"EARLY_PHASE1":17186,"PHASE1":17188,"PHASE2":17210,"PHASE3":17212,"PHASE4":17214,"NA":17216},{"trials":17187,"activeCount":101},[],{"trials":17189,"activeCount":101},[17190,17196,17204],{"nctId":17191,"briefTitle":17192,"status":107,"phases":17193,"primaryCompletion":1313,"completion":1313,"start":4292,"enrollment":1701,"conditions":17194,"interventions":17195},"NCT01096498","Cross -Over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel",[90],[15,16080],[17184,6912],{"nctId":17197,"briefTitle":17198,"status":107,"phases":17199,"primaryCompletion":3576,"completion":3576,"start":3576,"enrollment":1509,"conditions":17200,"interventions":17202},"NCT01073904","Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel 1.5 mg",[90],[17201],"Contraceptives, Postcoital",[17184,17203],"Postinor 2",{"nctId":17205,"briefTitle":17206,"status":107,"phases":17207,"primaryCompletion":1313,"completion":1313,"start":4292,"enrollment":1701,"conditions":17208,"interventions":17209},"NCT01096485","Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel",[90],[15,16080],[17184,6912],{"trials":17211,"activeCount":101},[],{"trials":17213,"activeCount":101},[],{"trials":17215,"activeCount":101},[],{"trials":17217,"activeCount":101},[],{"intervention":12660,"totalTrials":1341,"cells":17219},{"EARLY_PHASE1":17220,"PHASE1":17222,"PHASE2":17246,"PHASE3":17248,"PHASE4":17250,"NA":17252},{"trials":17221,"activeCount":101},[],{"trials":17223,"activeCount":101},[17224,17233,17237],{"nctId":17225,"briefTitle":17226,"status":107,"phases":17227,"primaryCompletion":17228,"completion":17229,"start":17230,"enrollment":36,"conditions":17231,"interventions":17232},"NCT04851483","A Trial to Learn What Happens to Different Medicinal Forms of BAY2328065 When They Enter the Body and How Safe They Are in Healthy Male and Female Participants",[90],"2021-12-14","2022-02-14","2021-04-28",[7793],[12660],{"nctId":12653,"briefTitle":12654,"status":107,"phases":17234,"primaryCompletion":12656,"completion":399,"start":3031,"enrollment":229,"conditions":17235,"interventions":17236},[90],[7793],[12659,12660,1154],{"nctId":17238,"briefTitle":17239,"status":107,"phases":17240,"primaryCompletion":17241,"completion":17242,"start":17243,"enrollment":11,"conditions":17244,"interventions":17245},"NCT03427788","BAY2328065 Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Relative Bioavailability, Food Effect",[90],"2018-10-29","2019-02-11","2018-03-21",[7793],[12660],{"trials":17247,"activeCount":101},[],{"trials":17249,"activeCount":101},[],{"trials":17251,"activeCount":101},[],{"trials":17253,"activeCount":101},[],{"intervention":17255,"totalTrials":175,"cells":17256},"BAY1436032",{"EARLY_PHASE1":17257,"PHASE1":17259,"PHASE2":17279,"PHASE3":17281,"PHASE4":17283,"NA":17285},{"trials":17258,"activeCount":101},[],{"trials":17260,"activeCount":101},[17261,17269],{"nctId":17262,"briefTitle":17263,"status":107,"phases":17264,"primaryCompletion":17265,"completion":17266,"start":15339,"enrollment":16,"conditions":17267,"interventions":17268},"NCT02746081","Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors",[90],"2018-11-08","2024-12-03",[13445],[17255],{"nctId":17270,"briefTitle":17271,"status":107,"phases":17272,"primaryCompletion":17273,"completion":17274,"start":17275,"enrollment":701,"conditions":17276,"interventions":17278},"NCT03127735","BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)",[90],"2018-12-06","2019-03-15","2017-06-14",[17277],"Leukemia, Myeloid, Acute",[17255],{"trials":17280,"activeCount":101},[],{"trials":17282,"activeCount":101},[],{"trials":17284,"activeCount":101},[],{"trials":17286,"activeCount":101},[],{"intervention":17288,"totalTrials":175,"cells":17289},"BAY1000394",{"EARLY_PHASE1":17290,"PHASE1":17292,"PHASE2":17309,"PHASE3":17311,"PHASE4":17313,"NA":17315},{"trials":17291,"activeCount":101},[],{"trials":17293,"activeCount":101},[17294,17303],{"nctId":17295,"briefTitle":17296,"status":107,"phases":17297,"primaryCompletion":17298,"completion":17299,"start":17300,"enrollment":4620,"conditions":17301,"interventions":17302},"NCT02047890","Japanese BAY1000394 Monotherapy Phase I Study",[90],"2015-01-06","2018-07-19","2014-05-19",[29],[17288,17288],{"nctId":17304,"briefTitle":17305,"status":107,"phases":17306,"primaryCompletion":1351,"completion":1351,"start":5409,"enrollment":3374,"conditions":17307,"interventions":17308},"NCT01335256","Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on \u002F 2 Week Off Schedule in Subjects With Advanced Malignancies",[90],[29],[17288],{"trials":17310,"activeCount":101},[],{"trials":17312,"activeCount":101},[],{"trials":17314,"activeCount":101},[],{"trials":17316,"activeCount":101},[],{"intervention":17318,"totalTrials":175,"cells":17319},"BAY3018250 Dose 1",{"EARLY_PHASE1":17320,"PHASE1":17322,"PHASE2":17341,"PHASE3":17343,"PHASE4":17345,"NA":17347},{"trials":17321,"activeCount":101},[],{"trials":17323,"activeCount":101},[17324,17333],{"nctId":17325,"briefTitle":17326,"status":107,"phases":17327,"primaryCompletion":17328,"completion":17328,"start":8346,"enrollment":1561,"conditions":17329,"interventions":17331},"NCT06562985","A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years",[90],"2025-01-06",[17330,1124],"Acute Venous and Arterial Thrombotic and Thromboembolic Events",[17318,17332,17332],"BAY3018250 Dose 2",{"nctId":17334,"briefTitle":17335,"status":107,"phases":17336,"primaryCompletion":17337,"completion":17337,"start":17338,"enrollment":1701,"conditions":17339,"interventions":17340},"NCT06619483","A Study to Learn How Safe BAY3018250 is, How it Moves Into, Through and Out of the Body, and How it Affects the Body in Healthy Chinese Participants",[90],"2025-01-24","2024-10-10",[17330,1124],[17318,17332],{"trials":17342,"activeCount":101},[],{"trials":17344,"activeCount":101},[],{"trials":17346,"activeCount":101},[],{"trials":17348,"activeCount":101},[],{"intervention":17332,"totalTrials":175,"cells":17350},{"EARLY_PHASE1":17351,"PHASE1":17353,"PHASE2":17363,"PHASE3":17365,"PHASE4":17367,"NA":17369},{"trials":17352,"activeCount":101},[],{"trials":17354,"activeCount":101},[17355,17359],{"nctId":17325,"briefTitle":17326,"status":107,"phases":17356,"primaryCompletion":17328,"completion":17328,"start":8346,"enrollment":1561,"conditions":17357,"interventions":17358},[90],[17330,1124],[17318,17332,17332],{"nctId":17334,"briefTitle":17335,"status":107,"phases":17360,"primaryCompletion":17337,"completion":17337,"start":17338,"enrollment":1701,"conditions":17361,"interventions":17362},[90],[17330,1124],[17318,17332],{"trials":17364,"activeCount":101},[],{"trials":17366,"activeCount":101},[],{"trials":17368,"activeCount":101},[],{"trials":17370,"activeCount":101},[],{"intervention":1291,"totalTrials":175,"cells":17372},{"EARLY_PHASE1":17373,"PHASE1":17375,"PHASE2":17390,"PHASE3":17392,"PHASE4":17394,"NA":17396},{"trials":17374,"activeCount":101},[],{"trials":17376,"activeCount":101},[17377,17386],{"nctId":17378,"briefTitle":17379,"status":107,"phases":17380,"primaryCompletion":17381,"completion":17382,"start":17383,"enrollment":3374,"conditions":17384,"interventions":17385},"NCT01404390","Japanese BAY80-6946 Monotherapy Phase I Study",[90],"2012-03-22","2012-07-12","2011-08-18",[29],[1291,1291],{"nctId":1283,"briefTitle":1284,"status":107,"phases":17387,"primaryCompletion":1286,"completion":1287,"start":1288,"enrollment":229,"conditions":17388,"interventions":17389},[90],[29],[1280,1291,1073,1292,1293],{"trials":17391,"activeCount":101},[],{"trials":17393,"activeCount":101},[],{"trials":17395,"activeCount":101},[],{"trials":17397,"activeCount":101},[],{"intervention":17399,"totalTrials":175,"cells":17400},"F-18 FEDAA1106",{"EARLY_PHASE1":17401,"PHASE1":17403,"PHASE2":17419,"PHASE3":17421,"PHASE4":17423,"NA":17425},{"trials":17402,"activeCount":101},[],{"trials":17404,"activeCount":101},[17405,17412],{"nctId":17406,"briefTitle":17407,"status":107,"phases":17408,"primaryCompletion":499,"completion":499,"start":4588,"enrollment":1081,"conditions":17409,"interventions":17411},"NCT01031199","Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers",[90],[17410,35],"Positron-Emission Tomography",[17399,17399],{"nctId":17413,"briefTitle":17414,"status":107,"phases":17415,"primaryCompletion":3809,"completion":3809,"start":3723,"enrollment":2388,"conditions":17416,"interventions":17418},"NCT01035164","Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers",[90],[17410,17417],"Alzheimer's Disease",[17399,17399,17399],{"trials":17420,"activeCount":101},[],{"trials":17422,"activeCount":101},[],{"trials":17424,"activeCount":101},[],{"trials":17426,"activeCount":101},[],{"intervention":17428,"totalTrials":175,"cells":17429},"BAY1101042",{"EARLY_PHASE1":17430,"PHASE1":17432,"PHASE2":17451,"PHASE3":17453,"PHASE4":17455,"NA":17457},{"trials":17431,"activeCount":101},[],{"trials":17433,"activeCount":101},[17434,17443],{"nctId":17435,"briefTitle":17436,"status":107,"phases":17437,"primaryCompletion":7961,"completion":17438,"start":17439,"enrollment":3568,"conditions":17440,"interventions":17442},"NCT03252002","Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single and Multiple Oral BAY1101042 Tablet Doses in Healthy Male Subjects",[90],"2019-07-24","2017-08-16",[17441],"Healthy Volunteer",[17428],{"nctId":17444,"briefTitle":17445,"status":107,"phases":17446,"primaryCompletion":2040,"completion":17447,"start":17448,"enrollment":1265,"conditions":17449,"interventions":17450},"NCT03235076","Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single Oral 10 mg BAY1101042 Tablet Dose in Men and Woman With Renal Impairment and in Healthy Subjects",[90],"2019-03-13","2017-08-15",[13239],[17428],{"trials":17452,"activeCount":101},[],{"trials":17454,"activeCount":101},[],{"trials":17456,"activeCount":101},[],{"trials":17458,"activeCount":101},[],{"intervention":17460,"totalTrials":175,"cells":17461},"Acarbose\u002FMetformin FDC",{"EARLY_PHASE1":17462,"PHASE1":17464,"PHASE2":17483,"PHASE3":17485,"PHASE4":17487,"NA":17489},{"trials":17463,"activeCount":101},[],{"trials":17465,"activeCount":101},[17466,17475],{"nctId":17467,"briefTitle":17468,"status":107,"phases":17469,"primaryCompletion":17470,"completion":420,"start":2335,"enrollment":1701,"conditions":17471,"interventions":17472},"NCT04065581","Bioequivalence Study for Acarbose\u002FMetformin FDC",[90],"2019-11-25",[6888],[17460,17473,17474],"Glucobay","Glucophage",{"nctId":17476,"briefTitle":17477,"status":107,"phases":17478,"primaryCompletion":4657,"completion":4657,"start":5052,"enrollment":1519,"conditions":17479,"interventions":17481},"NCT01728740","Bioequivalence Study for Acarbose \u002F Metformin FDC",[90],[17480],"Diabetes Mellitus, Type II",[17460,6890,17482],"Metformin",{"trials":17484,"activeCount":101},[],{"trials":17486,"activeCount":101},[],{"trials":17488,"activeCount":101},[],{"trials":17490,"activeCount":101},[],{"intervention":17492,"totalTrials":175,"cells":17493},"Rivaroxaban (BAY 59-7939, Xarelto) in ODT form",{"EARLY_PHASE1":17494,"PHASE1":17496,"PHASE2":17516,"PHASE3":17518,"PHASE4":17520,"NA":17522},{"trials":17495,"activeCount":101},[],{"trials":17497,"activeCount":101},[17498,17508],{"nctId":17499,"briefTitle":17500,"status":107,"phases":17501,"primaryCompletion":17502,"completion":17503,"start":17504,"enrollment":7250,"conditions":17505,"interventions":17506},"NCT04511637","Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects",[90],"2019-03-07","2019-04-12","2019-01-21",[1536],[17492,17507],"Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form",{"nctId":17509,"briefTitle":17510,"status":107,"phases":17511,"primaryCompletion":17512,"completion":17513,"start":2498,"enrollment":7250,"conditions":17514,"interventions":17515},"NCT04511611","Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects",[90],"2019-03-27","2019-05-13",[1536],[17492,17507],{"trials":17517,"activeCount":101},[],{"trials":17519,"activeCount":101},[],{"trials":17521,"activeCount":101},[],{"trials":17523,"activeCount":101},[],{"intervention":17507,"totalTrials":175,"cells":17525},{"EARLY_PHASE1":17526,"PHASE1":17528,"PHASE2":17538,"PHASE3":17540,"PHASE4":17542,"NA":17544},{"trials":17527,"activeCount":101},[],{"trials":17529,"activeCount":101},[17530,17534],{"nctId":17499,"briefTitle":17500,"status":107,"phases":17531,"primaryCompletion":17502,"completion":17503,"start":17504,"enrollment":7250,"conditions":17532,"interventions":17533},[90],[1536],[17492,17507],{"nctId":17509,"briefTitle":17510,"status":107,"phases":17535,"primaryCompletion":17512,"completion":17513,"start":2498,"enrollment":7250,"conditions":17536,"interventions":17537},[90],[1536],[17492,17507],{"trials":17539,"activeCount":101},[],{"trials":17541,"activeCount":101},[],{"trials":17543,"activeCount":101},[],{"trials":17545,"activeCount":101},[],{"intervention":1155,"totalTrials":175,"cells":17547},{"EARLY_PHASE1":17548,"PHASE1":17550,"PHASE2":17560,"PHASE3":17562,"PHASE4":17564,"NA":17566},{"trials":17549,"activeCount":101},[],{"trials":17551,"activeCount":101},[17552,17556],{"nctId":1926,"briefTitle":1927,"status":107,"phases":17553,"primaryCompletion":1929,"completion":1929,"start":1930,"enrollment":160,"conditions":17554,"interventions":17555},[90],[1069,1932,1070,1124],[1919,1934,1155],{"nctId":1146,"briefTitle":1147,"status":107,"phases":17557,"primaryCompletion":1149,"completion":1150,"start":1151,"enrollment":1081,"conditions":17558,"interventions":17559},[90],[1094],[52,1154,1155],{"trials":17561,"activeCount":101},[],{"trials":17563,"activeCount":101},[],{"trials":17565,"activeCount":101},[],{"trials":17567,"activeCount":101},[],{"intervention":17569,"totalTrials":175,"cells":17570},"Naproxen",{"EARLY_PHASE1":17571,"PHASE1":17573,"PHASE2":17592,"PHASE3":17594,"PHASE4":17596,"NA":17598},{"trials":17572,"activeCount":101},[],{"trials":17574,"activeCount":101},[17575,17584],{"nctId":17576,"briefTitle":17577,"status":107,"phases":17578,"primaryCompletion":17579,"completion":17579,"start":17580,"enrollment":3177,"conditions":17581,"interventions":17582},"NCT06415019","A Study to Learn About Whether BAY H006689 Causes an Allergic Reaction When Applied as a Topical Gel in Healthy Participants",[90],"2024-08-01","2024-06-05",[5881,1124],[17569,17583],"A solution of 0.9% Saline",{"nctId":17585,"briefTitle":17586,"status":107,"phases":17587,"primaryCompletion":168,"completion":168,"start":17588,"enrollment":2212,"conditions":17589,"interventions":17590},"NCT06511973","A Study to Learn About Whether BAYH006689 Causes Skin Irritation When Applied as a Topical Gel in Healthy Participants",[90],"2024-07-23",[5881,1124],[17569,17583,17591],"A solution of 0.2% SLS",{"trials":17593,"activeCount":101},[],{"trials":17595,"activeCount":101},[],{"trials":17597,"activeCount":101},[],{"trials":17599,"activeCount":101},[],{"intervention":17583,"totalTrials":175,"cells":17601},{"EARLY_PHASE1":17602,"PHASE1":17604,"PHASE2":17614,"PHASE3":17616,"PHASE4":17618,"NA":17620},{"trials":17603,"activeCount":101},[],{"trials":17605,"activeCount":101},[17606,17610],{"nctId":17576,"briefTitle":17577,"status":107,"phases":17607,"primaryCompletion":17579,"completion":17579,"start":17580,"enrollment":3177,"conditions":17608,"interventions":17609},[90],[5881,1124],[17569,17583],{"nctId":17585,"briefTitle":17586,"status":107,"phases":17611,"primaryCompletion":168,"completion":168,"start":17588,"enrollment":2212,"conditions":17612,"interventions":17613},[90],[5881,1124],[17569,17583,17591],{"trials":17615,"activeCount":101},[],{"trials":17617,"activeCount":101},[],{"trials":17619,"activeCount":101},[],{"trials":17621,"activeCount":101},[],{"intervention":1184,"totalTrials":175,"cells":17623},{"EARLY_PHASE1":17624,"PHASE1":17626,"PHASE2":17636,"PHASE3":17638,"PHASE4":17640,"NA":17642},{"trials":17625,"activeCount":101},[],{"trials":17627,"activeCount":101},[17628,17632],{"nctId":1936,"briefTitle":1937,"status":107,"phases":17629,"primaryCompletion":1939,"completion":1939,"start":1940,"enrollment":1599,"conditions":17630,"interventions":17631},[90],[1069,1932,1070,1124],[1919,1184],{"nctId":1175,"briefTitle":1176,"status":107,"phases":17633,"primaryCompletion":1178,"completion":1179,"start":1180,"enrollment":1181,"conditions":17634,"interventions":17635},[90],[1094,1103],[52,1184],{"trials":17637,"activeCount":101},[],{"trials":17639,"activeCount":101},[],{"trials":17641,"activeCount":101},[],{"trials":17643,"activeCount":101},[],{"intervention":1044,"totalTrials":175,"cells":17645},{"EARLY_PHASE1":17646,"PHASE1":17648,"PHASE2":17662,"PHASE3":17664,"PHASE4":17666,"NA":17668},{"trials":17647,"activeCount":101},[],{"trials":17649,"activeCount":101},[17650,17658],{"nctId":17651,"briefTitle":17652,"status":107,"phases":17653,"primaryCompletion":17654,"completion":17654,"start":17655,"enrollment":15200,"conditions":17656,"interventions":17657},"NCT04069026","A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer",[90],"2024-01-17","2019-08-15",[997],[1044,1044],{"nctId":1036,"briefTitle":1037,"status":156,"phases":17659,"primaryCompletion":313,"completion":1039,"start":1040,"enrollment":1041,"conditions":17660,"interventions":17661},[90],[997],[1044,1044,425],{"trials":17663,"activeCount":101},[],{"trials":17665,"activeCount":101},[],{"trials":17667,"activeCount":101},[],{"trials":17669,"activeCount":101},[],{"intervention":12647,"totalTrials":175,"cells":17671},{"EARLY_PHASE1":17672,"PHASE1":17674,"PHASE2":17684,"PHASE3":17686,"PHASE4":17688,"NA":17690},{"trials":17673,"activeCount":101},[],{"trials":17675,"activeCount":101},[17676,17680],{"nctId":17000,"briefTitle":17001,"status":107,"phases":17677,"primaryCompletion":5103,"completion":6420,"start":3175,"enrollment":3374,"conditions":17678,"interventions":17679},[90],[17004],[12674,12674,12647],{"nctId":12639,"briefTitle":12640,"status":107,"phases":17681,"primaryCompletion":12599,"completion":12642,"start":12643,"enrollment":6822,"conditions":17682,"interventions":17683},[90],[1124],[12646,1154,12647],{"trials":17685,"activeCount":101},[],{"trials":17687,"activeCount":101},[],{"trials":17689,"activeCount":101},[],{"trials":17691,"activeCount":101},[],{"intervention":17693,"totalTrials":175,"cells":17694},"BAY1747846",{"EARLY_PHASE1":17695,"PHASE1":17697,"PHASE2":17714,"PHASE3":17716,"PHASE4":17718,"NA":17720},{"trials":17696,"activeCount":101},[],{"trials":17698,"activeCount":101},[17699,17707],{"nctId":17700,"briefTitle":17701,"status":107,"phases":17702,"primaryCompletion":17703,"completion":3939,"start":17704,"enrollment":1701,"conditions":17705,"interventions":17706},"NCT05061979","A Study to Evaluate the Pharmacokinetics (How it Moves Into, Through and Out From the Body) of a New Gadolinium-based Contrast Agent (GBCA) After Injection and How Safe it is in Participants With Normal and Impaired Renal Function",[90],"2022-03-16","2021-10-12",[8337],[17693],{"nctId":17708,"briefTitle":17709,"status":107,"phases":17710,"primaryCompletion":12607,"completion":17711,"start":3194,"enrollment":2388,"conditions":17712,"interventions":17713},"NCT06125366","A Study to Learn More About the Safety and the Level of BAY 1747846 in Body Given as Injection Into the Vein at Increasing Single Doses in Japanese Healthy Male Participants",[90],"2019-07-11",[8337,1124],[17693],{"trials":17715,"activeCount":101},[],{"trials":17717,"activeCount":101},[],{"trials":17719,"activeCount":101},[],{"trials":17721,"activeCount":101},[],{"intervention":17723,"totalTrials":175,"cells":17724},"BAY79-4620",{"EARLY_PHASE1":17725,"PHASE1":17727,"PHASE2":17741,"PHASE3":17743,"PHASE4":17745,"NA":17747},{"trials":17726,"activeCount":101},[],{"trials":17728,"activeCount":101},[17729,17735],{"nctId":17730,"briefTitle":17731,"status":107,"phases":17732,"primaryCompletion":4250,"completion":4250,"start":1497,"enrollment":4620,"conditions":17733,"interventions":17734},"NCT01028755","To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors",[90],[29],[17723],{"nctId":17736,"briefTitle":17737,"status":156,"phases":17738,"primaryCompletion":1587,"completion":1587,"start":1326,"enrollment":175,"conditions":17739,"interventions":17740},"NCT01065623","Clinical Study to Evaluate the Maximum Tolerated Dose of BAY79-4620 Given Every 2 Weeks to Patients With Advanced Solid Tumors",[90],[29],[17723],{"trials":17742,"activeCount":101},[],{"trials":17744,"activeCount":101},[],{"trials":17746,"activeCount":101},[],{"trials":17748,"activeCount":101},[],{"intervention":17750,"totalTrials":175,"cells":17751},"Clobetasol propionate",{"EARLY_PHASE1":17752,"PHASE1":17754,"PHASE2":17779,"PHASE3":17781,"PHASE4":17783,"NA":17785},{"trials":17753,"activeCount":101},[],{"trials":17755,"activeCount":101},[17756,17766],{"nctId":17757,"briefTitle":17758,"status":107,"phases":17759,"primaryCompletion":12631,"completion":17760,"start":17761,"enrollment":1630,"conditions":17762,"interventions":17763},"NCT02940002","BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test",[90],"2017-03-17","2016-10-12",[12672],[17764,17750,17765],"BAY1003803","Betamethasone\u002Fcalcipotriene",{"nctId":17767,"briefTitle":17768,"status":156,"phases":17769,"primaryCompletion":17770,"completion":4441,"start":15446,"enrollment":1509,"conditions":17771,"interventions":17772},"NCT02936492","BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study",[90],"2017-04-18",[12672],[17773,17774,17775,17776,17777,17778,17750],"BAY1003803 0.01% lipophilic cream","BAY1003803 0.1% lipophilic cream","BAY1003803 0.01% ointment","BAY1003803 0.1% ointment","Lipophilic cream vehicle","Ointment vehicle",{"trials":17780,"activeCount":101},[],{"trials":17782,"activeCount":101},[],{"trials":17784,"activeCount":101},[],{"trials":17786,"activeCount":101},[],{"intervention":17788,"totalTrials":175,"cells":17789},"Cephalexin suspension",{"EARLY_PHASE1":17790,"PHASE1":17792,"PHASE2":17807,"PHASE3":17809,"PHASE4":17811,"NA":17813},{"trials":17791,"activeCount":101},[],{"trials":17793,"activeCount":101},[17794,17801],{"nctId":17795,"briefTitle":17796,"status":107,"phases":17797,"primaryCompletion":3576,"completion":3576,"start":3576,"enrollment":124,"conditions":17798,"interventions":17800},"NCT01073540","Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension",[90],[17799],"Anti-Infective Agents",[17788,17788],{"nctId":17802,"briefTitle":17803,"status":107,"phases":17804,"primaryCompletion":4596,"completion":4596,"start":4596,"enrollment":124,"conditions":17805,"interventions":17806},"NCT01105208","Cross Over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension",[90],[17799],[17788,17788],{"trials":17808,"activeCount":101},[],{"trials":17810,"activeCount":101},[],{"trials":17812,"activeCount":101},[],{"trials":17814,"activeCount":101},[],{"intervention":17816,"totalTrials":175,"cells":17817},"Naproxen sodium and diphenhydramine hydrochloride soft",{"EARLY_PHASE1":17818,"PHASE1":17820,"PHASE2":17838,"PHASE3":17840,"PHASE4":17842,"NA":17844},{"trials":17819,"activeCount":101},[],{"trials":17821,"activeCount":101},[17822,17830],{"nctId":17823,"briefTitle":17824,"status":107,"phases":17825,"primaryCompletion":17826,"completion":17024,"start":5890,"enrollment":1265,"conditions":17827,"interventions":17828},"NCT03396250","A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects",[90],"2018-03-26",[5881],[17816,17829],"Naproxen sodium and diphenhydramine hydrochloride coated",{"nctId":17831,"briefTitle":17832,"status":107,"phases":17833,"primaryCompletion":17834,"completion":17834,"start":17835,"enrollment":2151,"conditions":17836,"interventions":17837},"NCT03424135","A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fed Conditions",[90],"2018-04-04","2018-03-02",[1536],[17816,17829],{"trials":17839,"activeCount":101},[],{"trials":17841,"activeCount":101},[],{"trials":17843,"activeCount":101},[],{"trials":17845,"activeCount":101},[],{"intervention":17829,"totalTrials":175,"cells":17847},{"EARLY_PHASE1":17848,"PHASE1":17850,"PHASE2":17860,"PHASE3":17862,"PHASE4":17864,"NA":17866},{"trials":17849,"activeCount":101},[],{"trials":17851,"activeCount":101},[17852,17856],{"nctId":17823,"briefTitle":17824,"status":107,"phases":17853,"primaryCompletion":17826,"completion":17024,"start":5890,"enrollment":1265,"conditions":17854,"interventions":17855},[90],[5881],[17816,17829],{"nctId":17831,"briefTitle":17832,"status":107,"phases":17857,"primaryCompletion":17834,"completion":17834,"start":17835,"enrollment":2151,"conditions":17858,"interventions":17859},[90],[1536],[17816,17829],{"trials":17861,"activeCount":101},[],{"trials":17863,"activeCount":101},[],{"trials":17865,"activeCount":101},[],{"trials":17867,"activeCount":101},[],{"intervention":17869,"totalTrials":175,"cells":17870},"BAY86-9766",{"EARLY_PHASE1":17871,"PHASE1":17873,"PHASE2":17890,"PHASE3":17892,"PHASE4":17894,"NA":17896},{"trials":17872,"activeCount":101},[],{"trials":17874,"activeCount":101},[17875,17883],{"nctId":17876,"briefTitle":17877,"status":107,"phases":17878,"primaryCompletion":17879,"completion":17879,"start":17880,"enrollment":4620,"conditions":17881,"interventions":17882},"NCT01179295","Japanese BAY86-9766 Monotherapy Phase I Study",[90],"2012-04-27","2010-11-19",[29],[17869,17869,17869,17869],{"nctId":17884,"briefTitle":17885,"status":107,"phases":17886,"primaryCompletion":2230,"completion":2230,"start":6677,"enrollment":1163,"conditions":17887,"interventions":17888},"NCT01925638","Effect of Ketoconazole on the Pharmacokinetics of Refametinib",[90],[1490],[17869,17889],"Ketoconazole",{"trials":17891,"activeCount":101},[],{"trials":17893,"activeCount":101},[],{"trials":17895,"activeCount":101},[],{"trials":17897,"activeCount":101},[],{"intervention":17899,"totalTrials":233,"cells":17900},"Nifedipine-candesartan FDC",{"EARLY_PHASE1":17901,"PHASE1":17903,"PHASE2":17913,"PHASE3":17915,"PHASE4":17917,"NA":17919},{"trials":17902,"activeCount":101},[],{"trials":17904,"activeCount":101},[17905],{"nctId":17906,"briefTitle":17907,"status":107,"phases":17908,"primaryCompletion":5975,"completion":2366,"start":1570,"enrollment":458,"conditions":17909,"interventions":17910},"NCT01227603","Single Dose Bioequivalence Study Comparing Nifedipine\u002FCandesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions",[90],[14368],[17899,17911,17912],"Nifedipine GITS","Candesartan",{"trials":17914,"activeCount":101},[],{"trials":17916,"activeCount":101},[],{"trials":17918,"activeCount":101},[],{"trials":17920,"activeCount":101},[],{"intervention":17911,"totalTrials":233,"cells":17922},{"EARLY_PHASE1":17923,"PHASE1":17925,"PHASE2":17931,"PHASE3":17933,"PHASE4":17935,"NA":17937},{"trials":17924,"activeCount":101},[],{"trials":17926,"activeCount":101},[17927],{"nctId":17906,"briefTitle":17907,"status":107,"phases":17928,"primaryCompletion":5975,"completion":2366,"start":1570,"enrollment":458,"conditions":17929,"interventions":17930},[90],[14368],[17899,17911,17912],{"trials":17932,"activeCount":101},[],{"trials":17934,"activeCount":101},[],{"trials":17936,"activeCount":101},[],{"trials":17938,"activeCount":101},[],{"intervention":17912,"totalTrials":233,"cells":17940},{"EARLY_PHASE1":17941,"PHASE1":17943,"PHASE2":17949,"PHASE3":17951,"PHASE4":17953,"NA":17955},{"trials":17942,"activeCount":101},[],{"trials":17944,"activeCount":101},[17945],{"nctId":17906,"briefTitle":17907,"status":107,"phases":17946,"primaryCompletion":5975,"completion":2366,"start":1570,"enrollment":458,"conditions":17947,"interventions":17948},[90],[14368],[17899,17911,17912],{"trials":17950,"activeCount":101},[],{"trials":17952,"activeCount":101},[],{"trials":17954,"activeCount":101},[],{"trials":17956,"activeCount":101},[],{"intervention":2178,"totalTrials":233,"cells":17958},{"EARLY_PHASE1":17959,"PHASE1":17961,"PHASE2":17967,"PHASE3":17969,"PHASE4":17971,"NA":17973},{"trials":17960,"activeCount":101},[],{"trials":17962,"activeCount":101},[17963],{"nctId":2168,"briefTitle":2169,"status":107,"phases":17964,"primaryCompletion":2171,"completion":2172,"start":2173,"enrollment":1133,"conditions":17965,"interventions":17966},[90],[2175],[1011,2177,2178],{"trials":17968,"activeCount":101},[],{"trials":17970,"activeCount":101},[],{"trials":17972,"activeCount":101},[],{"trials":17974,"activeCount":101},[],{"intervention":17976,"totalTrials":233,"cells":17977},"BAY2413555 Dose 1",{"EARLY_PHASE1":17978,"PHASE1":17980,"PHASE2":17990,"PHASE3":17992,"PHASE4":17994,"NA":17996},{"trials":17979,"activeCount":101},[],{"trials":17981,"activeCount":101},[17982],{"nctId":17983,"briefTitle":17984,"status":156,"phases":17985,"primaryCompletion":17986,"completion":17986,"start":1120,"enrollment":6203,"conditions":17987,"interventions":17988},"NCT05532046","A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD\u002FCRT)",[90],"2023-03-31",[979],[17976,17989],"BAY2413555 Dose 2",{"trials":17991,"activeCount":101},[],{"trials":17993,"activeCount":101},[],{"trials":17995,"activeCount":101},[],{"trials":17997,"activeCount":101},[],{"intervention":17989,"totalTrials":233,"cells":17999},{"EARLY_PHASE1":18000,"PHASE1":18002,"PHASE2":18008,"PHASE3":18010,"PHASE4":18012,"NA":18014},{"trials":18001,"activeCount":101},[],{"trials":18003,"activeCount":101},[18004],{"nctId":17983,"briefTitle":17984,"status":156,"phases":18005,"primaryCompletion":17986,"completion":17986,"start":1120,"enrollment":6203,"conditions":18006,"interventions":18007},[90],[979],[17976,17989],{"trials":18009,"activeCount":101},[],{"trials":18011,"activeCount":101},[],{"trials":18013,"activeCount":101},[],{"trials":18015,"activeCount":101},[],{"intervention":18017,"totalTrials":233,"cells":18018},"BAY1163877",{"EARLY_PHASE1":18019,"PHASE1":18021,"PHASE2":18031,"PHASE3":18033,"PHASE4":18035,"NA":18037},{"trials":18020,"activeCount":101},[],{"trials":18022,"activeCount":101},[18023],{"nctId":18024,"briefTitle":18025,"status":107,"phases":18026,"primaryCompletion":18027,"completion":18028,"start":5071,"enrollment":4466,"conditions":18029,"interventions":18030},"NCT02592785","Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors",[90],"2017-02-05","2017-12-06",[29],[18017],{"trials":18032,"activeCount":101},[],{"trials":18034,"activeCount":101},[],{"trials":18036,"activeCount":101},[],{"trials":18038,"activeCount":101},[],{"intervention":18040,"totalTrials":233,"cells":18041},"20 mg tablet rivaroxaban",{"EARLY_PHASE1":18042,"PHASE1":18044,"PHASE2":18054,"PHASE3":18056,"PHASE4":18058,"NA":18060},{"trials":18043,"activeCount":101},[],{"trials":18045,"activeCount":101},[18046],{"nctId":18047,"briefTitle":18048,"status":107,"phases":18049,"primaryCompletion":18050,"completion":3585,"start":13432,"enrollment":160,"conditions":18051,"interventions":18052},"NCT04727021","A Trial to Learn How Much Rivaroxaban Gets Into the Blood When Taken in Different Forms and How Safe They Are in Healthy Men",[90],"2017-09-04",[1124],[18040,18053],"20 mg rivaroxaban, granules for oral suspension",{"trials":18055,"activeCount":101},[],{"trials":18057,"activeCount":101},[],{"trials":18059,"activeCount":101},[],{"trials":18061,"activeCount":101},[],{"intervention":18053,"totalTrials":233,"cells":18063},{"EARLY_PHASE1":18064,"PHASE1":18066,"PHASE2":18072,"PHASE3":18074,"PHASE4":18076,"NA":18078},{"trials":18065,"activeCount":101},[],{"trials":18067,"activeCount":101},[18068],{"nctId":18047,"briefTitle":18048,"status":107,"phases":18069,"primaryCompletion":18050,"completion":3585,"start":13432,"enrollment":160,"conditions":18070,"interventions":18071},[90],[1124],[18040,18053],{"trials":18073,"activeCount":101},[],{"trials":18075,"activeCount":101},[],{"trials":18077,"activeCount":101},[],{"trials":18079,"activeCount":101},[],{"intervention":16873,"totalTrials":233,"cells":18081},{"EARLY_PHASE1":18082,"PHASE1":18084,"PHASE2":18090,"PHASE3":18092,"PHASE4":18094,"NA":18096},{"trials":18083,"activeCount":101},[],{"trials":18085,"activeCount":101},[18086],{"nctId":16866,"briefTitle":16867,"status":107,"phases":18087,"primaryCompletion":16869,"completion":16870,"start":5839,"enrollment":1181,"conditions":18088,"interventions":18089},[90],[1490],[1115,16873],{"trials":18091,"activeCount":101},[],{"trials":18093,"activeCount":101},[],{"trials":18095,"activeCount":101},[],{"trials":18097,"activeCount":101},[],{"intervention":18099,"totalTrials":233,"cells":18100},"Sorafenib 100 mg",{"EARLY_PHASE1":18101,"PHASE1":18103,"PHASE2":18114,"PHASE3":18116,"PHASE4":18118,"NA":18120},{"trials":18102,"activeCount":101},[],{"trials":18104,"activeCount":101},[18105],{"nctId":18106,"briefTitle":18107,"status":107,"phases":18108,"primaryCompletion":4770,"completion":2970,"start":6821,"enrollment":18109,"conditions":18110,"interventions":18111},"NCT00941863","Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)",[90],158,[4829],[18099,18112,18113,18113,18113],"Sorafenib 200 mg","Sorafenib 400 mg",{"trials":18115,"activeCount":101},[],{"trials":18117,"activeCount":101},[],{"trials":18119,"activeCount":101},[],{"trials":18121,"activeCount":101},[],{"intervention":18112,"totalTrials":233,"cells":18123},{"EARLY_PHASE1":18124,"PHASE1":18126,"PHASE2":18132,"PHASE3":18134,"PHASE4":18136,"NA":18138},{"trials":18125,"activeCount":101},[],{"trials":18127,"activeCount":101},[18128],{"nctId":18106,"briefTitle":18107,"status":107,"phases":18129,"primaryCompletion":4770,"completion":2970,"start":6821,"enrollment":18109,"conditions":18130,"interventions":18131},[90],[4829],[18099,18112,18113,18113,18113],{"trials":18133,"activeCount":101},[],{"trials":18135,"activeCount":101},[],{"trials":18137,"activeCount":101},[],{"trials":18139,"activeCount":101},[],{"intervention":18113,"totalTrials":233,"cells":18141},{"EARLY_PHASE1":18142,"PHASE1":18144,"PHASE2":18150,"PHASE3":18152,"PHASE4":18154,"NA":18156},{"trials":18143,"activeCount":101},[],{"trials":18145,"activeCount":101},[18146],{"nctId":18106,"briefTitle":18107,"status":107,"phases":18147,"primaryCompletion":4770,"completion":2970,"start":6821,"enrollment":18109,"conditions":18148,"interventions":18149},[90],[4829],[18099,18112,18113,18113,18113],{"trials":18151,"activeCount":101},[],{"trials":18153,"activeCount":101},[],{"trials":18155,"activeCount":101},[],{"trials":18157,"activeCount":101},[],{"intervention":16813,"totalTrials":233,"cells":18159},{"EARLY_PHASE1":18160,"PHASE1":18162,"PHASE2":18168,"PHASE3":18170,"PHASE4":18172,"NA":18174},{"trials":18161,"activeCount":101},[],{"trials":18163,"activeCount":101},[18164],{"nctId":16807,"briefTitle":16808,"status":107,"phases":18165,"primaryCompletion":16810,"completion":539,"start":13285,"enrollment":22,"conditions":18166,"interventions":18167},[90],[1267],[7973,1934,16813,7973],{"trials":18169,"activeCount":101},[],{"trials":18171,"activeCount":101},[],{"trials":18173,"activeCount":101},[],{"trials":18175,"activeCount":101},[],{"intervention":18177,"totalTrials":233,"cells":18178},"Naproxen Sodium 660mg",{"EARLY_PHASE1":18179,"PHASE1":18181,"PHASE2":18190,"PHASE3":18192,"PHASE4":18194,"NA":18196},{"trials":18180,"activeCount":101},[],{"trials":18182,"activeCount":101},[18183],{"nctId":18184,"briefTitle":18185,"status":107,"phases":18186,"primaryCompletion":4612,"completion":4612,"start":4691,"enrollment":1509,"conditions":18187,"interventions":18188},"NCT00751556","Single\u002FMultiple Dose Bioavailability Trial",[90],[5948],[18177,18189],"Commercial Aleve 220 mg",{"trials":18191,"activeCount":101},[],{"trials":18193,"activeCount":101},[],{"trials":18195,"activeCount":101},[],{"trials":18197,"activeCount":101},[],{"intervention":18189,"totalTrials":233,"cells":18199},{"EARLY_PHASE1":18200,"PHASE1":18202,"PHASE2":18208,"PHASE3":18210,"PHASE4":18212,"NA":18214},{"trials":18201,"activeCount":101},[],{"trials":18203,"activeCount":101},[18204],{"nctId":18184,"briefTitle":18185,"status":107,"phases":18205,"primaryCompletion":4612,"completion":4612,"start":4691,"enrollment":1509,"conditions":18206,"interventions":18207},[90],[5948],[18177,18189],{"trials":18209,"activeCount":101},[],{"trials":18211,"activeCount":101},[],{"trials":18213,"activeCount":101},[],{"trials":18215,"activeCount":101},[],{"intervention":18217,"totalTrials":233,"cells":18218},"Cephalexin",{"EARLY_PHASE1":18219,"PHASE1":18221,"PHASE2":18229,"PHASE3":18231,"PHASE4":18233,"NA":18235},{"trials":18220,"activeCount":101},[],{"trials":18222,"activeCount":101},[18223],{"nctId":18224,"briefTitle":18225,"status":107,"phases":18226,"primaryCompletion":2256,"completion":2256,"start":2256,"enrollment":124,"conditions":18227,"interventions":18228},"NCT01073553","Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Capsules",[90],[17799],[18217,18217],{"trials":18230,"activeCount":101},[],{"trials":18232,"activeCount":101},[],{"trials":18234,"activeCount":101},[],{"trials":18236,"activeCount":101},[],{"intervention":18238,"totalTrials":233,"cells":18239},"Copanlisib + Refametinib",{"EARLY_PHASE1":18240,"PHASE1":18242,"PHASE2":18250,"PHASE3":18252,"PHASE4":18254,"NA":18256},{"trials":18241,"activeCount":101},[],{"trials":18243,"activeCount":101},[18244],{"nctId":18245,"briefTitle":18246,"status":107,"phases":18247,"primaryCompletion":3609,"completion":2229,"start":2366,"enrollment":447,"conditions":18248,"interventions":18249},"NCT01392521","Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer",[90],[29],[18238,18238],{"trials":18251,"activeCount":101},[],{"trials":18253,"activeCount":101},[],{"trials":18255,"activeCount":101},[],{"trials":18257,"activeCount":101},[],{"intervention":18259,"totalTrials":233,"cells":18260},"Rivaroxaban (Xarelto, BAY59-7939",{"EARLY_PHASE1":18261,"PHASE1":18263,"PHASE2":18273,"PHASE3":18275,"PHASE4":18277,"NA":18279},{"trials":18262,"activeCount":101},[],{"trials":18264,"activeCount":101},[18265],{"nctId":18266,"briefTitle":18267,"status":107,"phases":18268,"primaryCompletion":18269,"completion":18269,"start":18270,"enrollment":1041,"conditions":18271,"interventions":18272},"NCT02497716","Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children",[90],"2018-05-22","2015-11-04",[12468],[18259],{"trials":18274,"activeCount":101},[],{"trials":18276,"activeCount":101},[],{"trials":18278,"activeCount":101},[],{"trials":18280,"activeCount":101},[],{"intervention":6306,"totalTrials":233,"cells":18282},{"EARLY_PHASE1":18283,"PHASE1":18285,"PHASE2":18291,"PHASE3":18293,"PHASE4":18295,"NA":18297},{"trials":18284,"activeCount":101},[],{"trials":18286,"activeCount":101},[18287],{"nctId":6301,"briefTitle":6302,"status":107,"phases":18288,"primaryCompletion":3619,"completion":3619,"start":4700,"enrollment":33,"conditions":18289,"interventions":18290},[90],[5948],[6294,6306],{"trials":18292,"activeCount":101},[],{"trials":18294,"activeCount":101},[],{"trials":18296,"activeCount":101},[],{"trials":18298,"activeCount":101},[],{"intervention":18300,"totalTrials":233,"cells":18301},"BAY2010112",{"EARLY_PHASE1":18302,"PHASE1":18304,"PHASE2":18315,"PHASE3":18317,"PHASE4":18319,"NA":18321},{"trials":18303,"activeCount":101},[],{"trials":18305,"activeCount":101},[18306],{"nctId":18307,"briefTitle":18308,"status":107,"phases":18309,"primaryCompletion":18310,"completion":18311,"start":18312,"enrollment":1041,"conditions":18313,"interventions":18314},"NCT01723475","First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer",[90],"2018-07-18","2018-09-26","2012-11-02",[187],[18300,18300],{"trials":18316,"activeCount":101},[],{"trials":18318,"activeCount":101},[],{"trials":18320,"activeCount":101},[],{"trials":18322,"activeCount":101},[],{"intervention":18324,"totalTrials":233,"cells":18325},"Gadoquatrane (BAY1747846) 0.03 mmol Gd\u002Fkg",{"EARLY_PHASE1":18326,"PHASE1":18328,"PHASE2":18337,"PHASE3":18339,"PHASE4":18341,"NA":18343},{"trials":18327,"activeCount":101},[],{"trials":18329,"activeCount":101},[18330],{"nctId":18331,"briefTitle":18332,"status":107,"phases":18333,"primaryCompletion":813,"completion":3916,"start":4321,"enrollment":1701,"conditions":18334,"interventions":18335},"NCT06135181","A Study to Learn More About the Safety and the Blood Level of BAY1747846 Given as Injection Into the Vein at Increasing Single Doses in Chinese Healthy Male Participants",[90],[8337,1124],[18324,18336],"Gadoquatrane (BAY1747846) 0.1 mmol Gd\u002Fkg",{"trials":18338,"activeCount":101},[],{"trials":18340,"activeCount":101},[],{"trials":18342,"activeCount":101},[],{"trials":18344,"activeCount":101},[],{"intervention":18336,"totalTrials":233,"cells":18346},{"EARLY_PHASE1":18347,"PHASE1":18349,"PHASE2":18355,"PHASE3":18357,"PHASE4":18359,"NA":18361},{"trials":18348,"activeCount":101},[],{"trials":18350,"activeCount":101},[18351],{"nctId":18331,"briefTitle":18332,"status":107,"phases":18352,"primaryCompletion":813,"completion":3916,"start":4321,"enrollment":1701,"conditions":18353,"interventions":18354},[90],[8337,1124],[18324,18336],{"trials":18356,"activeCount":101},[],{"trials":18358,"activeCount":101},[],{"trials":18360,"activeCount":101},[],{"trials":18362,"activeCount":101},[],{"intervention":5968,"totalTrials":233,"cells":18364},{"EARLY_PHASE1":18365,"PHASE1":18367,"PHASE2":18373,"PHASE3":18375,"PHASE4":18377,"NA":18379},{"trials":18366,"activeCount":101},[],{"trials":18368,"activeCount":101},[18369],{"nctId":5961,"briefTitle":5962,"status":107,"phases":18370,"primaryCompletion":2407,"completion":5964,"start":5249,"enrollment":2345,"conditions":18371,"interventions":18372},[90],[5966],[5968,5954],{"trials":18374,"activeCount":101},[],{"trials":18376,"activeCount":101},[],{"trials":18378,"activeCount":101},[],{"trials":18380,"activeCount":101},[],{"intervention":5441,"totalTrials":233,"cells":18382},{"EARLY_PHASE1":18383,"PHASE1":18385,"PHASE2":18391,"PHASE3":18393,"PHASE4":18395,"NA":18397},{"trials":18384,"activeCount":101},[],{"trials":18386,"activeCount":101},[18387],{"nctId":5434,"briefTitle":5435,"status":107,"phases":18388,"primaryCompletion":5437,"completion":1710,"start":5438,"enrollment":1163,"conditions":18389,"interventions":18390},[90],[24],[5427,5441],{"trials":18392,"activeCount":101},[],{"trials":18394,"activeCount":101},[],{"trials":18396,"activeCount":101},[],{"trials":18398,"activeCount":101},[],{"intervention":18400,"totalTrials":233,"cells":18401},"BAY2666605",{"EARLY_PHASE1":18402,"PHASE1":18404,"PHASE2":18416,"PHASE3":18418,"PHASE4":18420,"NA":18422},{"trials":18403,"activeCount":101},[],{"trials":18405,"activeCount":101},[18406],{"nctId":18407,"briefTitle":18408,"status":156,"phases":18409,"primaryCompletion":18410,"completion":18411,"start":18412,"enrollment":328,"conditions":18413,"interventions":18415},"NCT04809805","A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer",[90],"2022-11-09","2023-04-27","2021-04-15",[18414],"Metastatic Melanoma and Other Solid Tumors",[18400],{"trials":18417,"activeCount":101},[],{"trials":18419,"activeCount":101},[],{"trials":18421,"activeCount":101},[],{"trials":18423,"activeCount":101},[],{"intervention":18425,"totalTrials":233,"cells":18426},"EE 0.03 mg\u002FDRSP 3 mg\u002FMetafolin + folic acid placebo",{"EARLY_PHASE1":18427,"PHASE1":18429,"PHASE2":18439,"PHASE3":18441,"PHASE4":18443,"NA":18445},{"trials":18428,"activeCount":101},[],{"trials":18430,"activeCount":101},[18431],{"nctId":18432,"briefTitle":18433,"status":107,"phases":18434,"primaryCompletion":3818,"completion":3818,"start":6269,"enrollment":18435,"conditions":18436,"interventions":18437},"NCT01258660","Assessment of the Pharmacodynamic Effect on Plasma Folate and Red Blood Cell Folate and Comparison of the Folate Metabolites During the 24 Weeks of Treatment (Yasmin + Metafolin Versus Yasmin + Folic Acid) Followed by a 20 Week Elimination Phase of Folate",[90],172,[15],[18425,18438],"EE 0.03 mg\u002FDRSP 3 mg (Yasmin) + folic acid",{"trials":18440,"activeCount":101},[],{"trials":18442,"activeCount":101},[],{"trials":18444,"activeCount":101},[],{"trials":18446,"activeCount":101},[],{"intervention":18438,"totalTrials":233,"cells":18448},{"EARLY_PHASE1":18449,"PHASE1":18451,"PHASE2":18457,"PHASE3":18459,"PHASE4":18461,"NA":18463},{"trials":18450,"activeCount":101},[],{"trials":18452,"activeCount":101},[18453],{"nctId":18432,"briefTitle":18433,"status":107,"phases":18454,"primaryCompletion":3818,"completion":3818,"start":6269,"enrollment":18435,"conditions":18455,"interventions":18456},[90],[15],[18425,18438],{"trials":18458,"activeCount":101},[],{"trials":18460,"activeCount":101},[],{"trials":18462,"activeCount":101},[],{"trials":18464,"activeCount":101},[],{"intervention":17474,"totalTrials":233,"cells":18466},{"EARLY_PHASE1":18467,"PHASE1":18469,"PHASE2":18475,"PHASE3":18477,"PHASE4":18479,"NA":18481},{"trials":18468,"activeCount":101},[],{"trials":18470,"activeCount":101},[18471],{"nctId":17467,"briefTitle":17468,"status":107,"phases":18472,"primaryCompletion":17470,"completion":420,"start":2335,"enrollment":1701,"conditions":18473,"interventions":18474},[90],[6888],[17460,17473,17474],{"trials":18476,"activeCount":101},[],{"trials":18478,"activeCount":101},[],{"trials":18480,"activeCount":101},[],{"trials":18482,"activeCount":101},[],{"intervention":18484,"totalTrials":233,"cells":18485},"Bapotulimab",{"EARLY_PHASE1":18486,"PHASE1":18488,"PHASE2":18499,"PHASE3":18501,"PHASE4":18503,"NA":18505},{"trials":18487,"activeCount":101},[],{"trials":18489,"activeCount":101},[18490],{"nctId":18491,"briefTitle":18492,"status":107,"phases":18493,"primaryCompletion":18494,"completion":849,"start":18495,"enrollment":2151,"conditions":18496,"interventions":18498},"NCT03666273","Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.",[90],"2023-06-16","2018-09-12",[17105,18497],"Head and Neck Squamous Cell Carcinoma",[18484,18484],{"trials":18500,"activeCount":101},[],{"trials":18502,"activeCount":101},[],{"trials":18504,"activeCount":101},[],{"trials":18506,"activeCount":101},[],{"intervention":18508,"totalTrials":233,"cells":18509},"Fosrenol ODT",{"EARLY_PHASE1":18510,"PHASE1":18512,"PHASE2":18524,"PHASE3":18526,"PHASE4":18528,"NA":18530},{"trials":18511,"activeCount":101},[],{"trials":18513,"activeCount":101},[18514],{"nctId":18515,"briefTitle":18516,"status":107,"phases":18517,"primaryCompletion":18518,"completion":18519,"start":18520,"enrollment":97,"conditions":18521,"interventions":18522},"NCT03074058","Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet",[90],"2015-08-04","2015-08-21","2015-06-10",[1536],[18508,18523],"Fosrenol chewable",{"trials":18525,"activeCount":101},[],{"trials":18527,"activeCount":101},[],{"trials":18529,"activeCount":101},[],{"trials":18531,"activeCount":101},[],{"intervention":18523,"totalTrials":233,"cells":18533},{"EARLY_PHASE1":18534,"PHASE1":18536,"PHASE2":18542,"PHASE3":18544,"PHASE4":18546,"NA":18548},{"trials":18535,"activeCount":101},[],{"trials":18537,"activeCount":101},[18538],{"nctId":18515,"briefTitle":18516,"status":107,"phases":18539,"primaryCompletion":18518,"completion":18519,"start":18520,"enrollment":97,"conditions":18540,"interventions":18541},[90],[1536],[18508,18523],{"trials":18543,"activeCount":101},[],{"trials":18545,"activeCount":101},[],{"trials":18547,"activeCount":101},[],{"trials":18549,"activeCount":101},[],{"intervention":18551,"totalTrials":233,"cells":18552},"Estradiol Valerate",{"EARLY_PHASE1":18553,"PHASE1":18555,"PHASE2":18564,"PHASE3":18566,"PHASE4":18568,"NA":18570},{"trials":18554,"activeCount":101},[],{"trials":18556,"activeCount":101},[18557],{"nctId":18558,"briefTitle":18559,"status":107,"phases":18560,"primaryCompletion":2255,"completion":4596,"start":499,"enrollment":2212,"conditions":18561,"interventions":18562},"NCT01031355","Bioequivalence Study: 3 mg Estradiol Valerate (EV) With and Without Levomefolate Calcium",[90],[15,8191],[18551,18551,18563],"Levomefolate Calcium",{"trials":18565,"activeCount":101},[],{"trials":18567,"activeCount":101},[],{"trials":18569,"activeCount":101},[],{"trials":18571,"activeCount":101},[],{"intervention":18563,"totalTrials":233,"cells":18573},{"EARLY_PHASE1":18574,"PHASE1":18576,"PHASE2":18582,"PHASE3":18584,"PHASE4":18586,"NA":18588},{"trials":18575,"activeCount":101},[],{"trials":18577,"activeCount":101},[18578],{"nctId":18558,"briefTitle":18559,"status":107,"phases":18579,"primaryCompletion":2255,"completion":4596,"start":499,"enrollment":2212,"conditions":18580,"interventions":18581},[90],[15,8191],[18551,18551,18563],{"trials":18583,"activeCount":101},[],{"trials":18585,"activeCount":101},[],{"trials":18587,"activeCount":101},[],{"trials":18589,"activeCount":101},[],{"intervention":2203,"totalTrials":233,"cells":18591},{"EARLY_PHASE1":18592,"PHASE1":18594,"PHASE2":18600,"PHASE3":18602,"PHASE4":18604,"NA":18606},{"trials":18593,"activeCount":101},[],{"trials":18595,"activeCount":101},[18596],{"nctId":2193,"briefTitle":2194,"status":107,"phases":18597,"primaryCompletion":2196,"completion":2197,"start":2198,"enrollment":2199,"conditions":18598,"interventions":18599},[90],[29],[1011,2202,2203,1154,2204],{"trials":18601,"activeCount":101},[],{"trials":18603,"activeCount":101},[],{"trials":18605,"activeCount":101},[],{"trials":18607,"activeCount":101},[],{"intervention":2204,"totalTrials":233,"cells":18609},{"EARLY_PHASE1":18610,"PHASE1":18612,"PHASE2":18618,"PHASE3":18620,"PHASE4":18622,"NA":18624},{"trials":18611,"activeCount":101},[],{"trials":18613,"activeCount":101},[18614],{"nctId":2193,"briefTitle":2194,"status":107,"phases":18615,"primaryCompletion":2196,"completion":2197,"start":2198,"enrollment":2199,"conditions":18616,"interventions":18617},[90],[29],[1011,2202,2203,1154,2204],{"trials":18619,"activeCount":101},[],{"trials":18621,"activeCount":101},[],{"trials":18623,"activeCount":101},[],{"trials":18625,"activeCount":101},[],{"intervention":18627,"totalTrials":233,"cells":18628},"[14C]-NT-814",{"EARLY_PHASE1":18629,"PHASE1":18631,"PHASE2":18640,"PHASE3":18642,"PHASE4":18644,"NA":18646},{"trials":18630,"activeCount":101},[],{"trials":18632,"activeCount":101},[18633],{"nctId":18634,"briefTitle":18635,"status":107,"phases":18636,"primaryCompletion":18637,"completion":18637,"start":4095,"enrollment":5220,"conditions":18638,"interventions":18639},"NCT04654897","Mass Balance Study of [14C]-NT-814 Oral Suspension in Healthy Male Subjects",[90],"2020-10-29",[5948],[18627],{"trials":18641,"activeCount":101},[],{"trials":18643,"activeCount":101},[],{"trials":18645,"activeCount":101},[],{"trials":18647,"activeCount":101},[],{"intervention":18649,"totalTrials":233,"cells":18650},"Selitrectinib (BAY2731954) Adult",{"EARLY_PHASE1":18651,"PHASE1":18653,"PHASE2":18666,"PHASE3":18668,"PHASE4":18670,"NA":18672},{"trials":18652,"activeCount":101},[],{"trials":18654,"activeCount":101},[18655],{"nctId":18656,"briefTitle":18657,"status":107,"phases":18658,"primaryCompletion":18659,"completion":18660,"start":7980,"enrollment":19,"conditions":18661,"interventions":18662},"NCT04771390","Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants",[90],"2021-05-20","2021-07-06",[1826],[18649,18663,18664,18665],"Selitrectinib (BAY2731954) Pediatric","Selitrectinib (BAY2731954) Oral solution","Selitrectinib (BAY2731954) Oral suspension",{"trials":18667,"activeCount":101},[],{"trials":18669,"activeCount":101},[],{"trials":18671,"activeCount":101},[],{"trials":18673,"activeCount":101},[],{"intervention":18663,"totalTrials":233,"cells":18675},{"EARLY_PHASE1":18676,"PHASE1":18678,"PHASE2":18684,"PHASE3":18686,"PHASE4":18688,"NA":18690},{"trials":18677,"activeCount":101},[],{"trials":18679,"activeCount":101},[18680],{"nctId":18656,"briefTitle":18657,"status":107,"phases":18681,"primaryCompletion":18659,"completion":18660,"start":7980,"enrollment":19,"conditions":18682,"interventions":18683},[90],[1826],[18649,18663,18664,18665],{"trials":18685,"activeCount":101},[],{"trials":18687,"activeCount":101},[],{"trials":18689,"activeCount":101},[],{"trials":18691,"activeCount":101},[],{"intervention":18664,"totalTrials":233,"cells":18693},{"EARLY_PHASE1":18694,"PHASE1":18696,"PHASE2":18702,"PHASE3":18704,"PHASE4":18706,"NA":18708},{"trials":18695,"activeCount":101},[],{"trials":18697,"activeCount":101},[18698],{"nctId":18656,"briefTitle":18657,"status":107,"phases":18699,"primaryCompletion":18659,"completion":18660,"start":7980,"enrollment":19,"conditions":18700,"interventions":18701},[90],[1826],[18649,18663,18664,18665],{"trials":18703,"activeCount":101},[],{"trials":18705,"activeCount":101},[],{"trials":18707,"activeCount":101},[],{"trials":18709,"activeCount":101},[],{"intervention":18665,"totalTrials":233,"cells":18711},{"EARLY_PHASE1":18712,"PHASE1":18714,"PHASE2":18720,"PHASE3":18722,"PHASE4":18724,"NA":18726},{"trials":18713,"activeCount":101},[],{"trials":18715,"activeCount":101},[18716],{"nctId":18656,"briefTitle":18657,"status":107,"phases":18717,"primaryCompletion":18659,"completion":18660,"start":7980,"enrollment":19,"conditions":18718,"interventions":18719},[90],[1826],[18649,18663,18664,18665],{"trials":18721,"activeCount":101},[],{"trials":18723,"activeCount":101},[],{"trials":18725,"activeCount":101},[],{"trials":18727,"activeCount":101},[],{"intervention":18729,"totalTrials":233,"cells":18730},"BAY1817080 - Formulation A",{"EARLY_PHASE1":18731,"PHASE1":18733,"PHASE2":18745,"PHASE3":18747,"PHASE4":18749,"NA":18751},{"trials":18732,"activeCount":101},[],{"trials":18734,"activeCount":101},[18735],{"nctId":18736,"briefTitle":18737,"status":107,"phases":18738,"primaryCompletion":18739,"completion":3091,"start":18740,"enrollment":160,"conditions":18741,"interventions":18742},"NCT03773068","A Study in Healthy Volunteers Investigating How Quickly and to What Extent BAY1817080 is Taken up, Distributed, Broken Down and Eliminated From the Body, as Well as the Difference Between 2 Different Types of Tablets of BAY1817080 and the Difference Between Oral Dose and Dose in the Vein",[90],"2019-06-21","2018-12-13",[3603],[18729,18743,18744],"BAY1817080 - Formulation B","[13C715N]-BAY 181708 stable isotope label",{"trials":18746,"activeCount":101},[],{"trials":18748,"activeCount":101},[],{"trials":18750,"activeCount":101},[],{"trials":18752,"activeCount":101},[],{"intervention":18743,"totalTrials":233,"cells":18754},{"EARLY_PHASE1":18755,"PHASE1":18757,"PHASE2":18763,"PHASE3":18765,"PHASE4":18767,"NA":18769},{"trials":18756,"activeCount":101},[],{"trials":18758,"activeCount":101},[18759],{"nctId":18736,"briefTitle":18737,"status":107,"phases":18760,"primaryCompletion":18739,"completion":3091,"start":18740,"enrollment":160,"conditions":18761,"interventions":18762},[90],[3603],[18729,18743,18744],{"trials":18764,"activeCount":101},[],{"trials":18766,"activeCount":101},[],{"trials":18768,"activeCount":101},[],{"trials":18770,"activeCount":101},[],{"intervention":18744,"totalTrials":233,"cells":18772},{"EARLY_PHASE1":18773,"PHASE1":18775,"PHASE2":18781,"PHASE3":18783,"PHASE4":18785,"NA":18787},{"trials":18774,"activeCount":101},[],{"trials":18776,"activeCount":101},[18777],{"nctId":18736,"briefTitle":18737,"status":107,"phases":18778,"primaryCompletion":18739,"completion":3091,"start":18740,"enrollment":160,"conditions":18779,"interventions":18780},[90],[3603],[18729,18743,18744],{"trials":18782,"activeCount":101},[],{"trials":18784,"activeCount":101},[],{"trials":18786,"activeCount":101},[],{"trials":18788,"activeCount":101},[],{"intervention":18790,"totalTrials":233,"cells":18791},"EE 0.02 mg\u002FDRSP 3 mg",{"EARLY_PHASE1":18792,"PHASE1":18794,"PHASE2":18804,"PHASE3":18806,"PHASE4":18808,"NA":18810},{"trials":18793,"activeCount":101},[],{"trials":18795,"activeCount":101},[18796],{"nctId":18797,"briefTitle":18798,"status":107,"phases":18799,"primaryCompletion":9794,"completion":9794,"start":4666,"enrollment":30,"conditions":18800,"interventions":18801},"NCT01253187","Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: YAZ and YAZ + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and YAZ + Levomefolate Calcium (Metafolin)",[90],[15],[18790,18802,18803],"EE 0.02 mg\u002FDRSP 3 mg\u002FL-5-MTHF Ca 0.451 mg","L-5-MTHF 0.451mg",{"trials":18805,"activeCount":101},[],{"trials":18807,"activeCount":101},[],{"trials":18809,"activeCount":101},[],{"trials":18811,"activeCount":101},[],{"intervention":18802,"totalTrials":233,"cells":18813},{"EARLY_PHASE1":18814,"PHASE1":18816,"PHASE2":18822,"PHASE3":18824,"PHASE4":18826,"NA":18828},{"trials":18815,"activeCount":101},[],{"trials":18817,"activeCount":101},[18818],{"nctId":18797,"briefTitle":18798,"status":107,"phases":18819,"primaryCompletion":9794,"completion":9794,"start":4666,"enrollment":30,"conditions":18820,"interventions":18821},[90],[15],[18790,18802,18803],{"trials":18823,"activeCount":101},[],{"trials":18825,"activeCount":101},[],{"trials":18827,"activeCount":101},[],{"trials":18829,"activeCount":101},[],{"intervention":18803,"totalTrials":233,"cells":18831},{"EARLY_PHASE1":18832,"PHASE1":18834,"PHASE2":18840,"PHASE3":18842,"PHASE4":18844,"NA":18846},{"trials":18833,"activeCount":101},[],{"trials":18835,"activeCount":101},[18836],{"nctId":18797,"briefTitle":18798,"status":107,"phases":18837,"primaryCompletion":9794,"completion":9794,"start":4666,"enrollment":30,"conditions":18838,"interventions":18839},[90],[15],[18790,18802,18803],{"trials":18841,"activeCount":101},[],{"trials":18843,"activeCount":101},[],{"trials":18845,"activeCount":101},[],{"trials":18847,"activeCount":101},[],{"intervention":1105,"totalTrials":233,"cells":18849},{"EARLY_PHASE1":18850,"PHASE1":18852,"PHASE2":18858,"PHASE3":18860,"PHASE4":18862,"NA":18864},{"trials":18851,"activeCount":101},[],{"trials":18853,"activeCount":101},[18854],{"nctId":1097,"briefTitle":1098,"status":107,"phases":18855,"primaryCompletion":1100,"completion":1100,"start":1101,"enrollment":447,"conditions":18856,"interventions":18857},[90],[1094,1103],[52,1105],{"trials":18859,"activeCount":101},[],{"trials":18861,"activeCount":101},[],{"trials":18863,"activeCount":101},[],{"trials":18865,"activeCount":101},[],{"intervention":18867,"totalTrials":233,"cells":18868},"BAY1082439",{"EARLY_PHASE1":18869,"PHASE1":18871,"PHASE2":18882,"PHASE3":18884,"PHASE4":18886,"NA":18888},{"trials":18870,"activeCount":101},[],{"trials":18872,"activeCount":101},[18873],{"nctId":18874,"briefTitle":18875,"status":107,"phases":18876,"primaryCompletion":18877,"completion":18878,"start":18879,"enrollment":2151,"conditions":18880,"interventions":18881},"NCT01728311","Open Label Study of BAY1082439 in Patients With Advanced Cancer",[90],"2016-06-03","2017-02-06","2012-11-21",[29],[18867],{"trials":18883,"activeCount":101},[],{"trials":18885,"activeCount":101},[],{"trials":18887,"activeCount":101},[],{"trials":18889,"activeCount":101},[],{"intervention":18891,"totalTrials":233,"cells":18892},"BAY87-2243",{"EARLY_PHASE1":18893,"PHASE1":18895,"PHASE2":18903,"PHASE3":18905,"PHASE4":18907,"NA":18909},{"trials":18894,"activeCount":101},[],{"trials":18896,"activeCount":101},[18897],{"nctId":18898,"briefTitle":18899,"status":156,"phases":18900,"primaryCompletion":4627,"completion":4627,"start":2188,"enrollment":328,"conditions":18901,"interventions":18902},"NCT01297530","Clinical Study to Evaluate the Maximum Tolerated Dose of BAY87-2243 in Patients With Advanced Malignancies",[90],[29],[18891],{"trials":18904,"activeCount":101},[],{"trials":18906,"activeCount":101},[],{"trials":18908,"activeCount":101},[],{"trials":18910,"activeCount":101},[],{"intervention":18912,"totalTrials":233,"cells":18913},"BAY 98-7079, Estradiolvalerate (EV) \u002F Dienogest (DNG) \u002F Levomefolate calcium",{"EARLY_PHASE1":18914,"PHASE1":18916,"PHASE2":18926,"PHASE3":18928,"PHASE4":18930,"NA":18932},{"trials":18915,"activeCount":101},[],{"trials":18917,"activeCount":101},[18918],{"nctId":18919,"briefTitle":18920,"status":107,"phases":18921,"primaryCompletion":499,"completion":3809,"start":3576,"enrollment":1303,"conditions":18922,"interventions":18923},"NCT00941057","Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium",[90],[1511],[18912,18924,18925],"BAY 86-5027,Estradiolvalerate","BAY 86-7660,levomefolate calcium",{"trials":18927,"activeCount":101},[],{"trials":18929,"activeCount":101},[],{"trials":18931,"activeCount":101},[],{"trials":18933,"activeCount":101},[],{"intervention":18924,"totalTrials":233,"cells":18935},{"EARLY_PHASE1":18936,"PHASE1":18938,"PHASE2":18944,"PHASE3":18946,"PHASE4":18948,"NA":18950},{"trials":18937,"activeCount":101},[],{"trials":18939,"activeCount":101},[18940],{"nctId":18919,"briefTitle":18920,"status":107,"phases":18941,"primaryCompletion":499,"completion":3809,"start":3576,"enrollment":1303,"conditions":18942,"interventions":18943},[90],[1511],[18912,18924,18925],{"trials":18945,"activeCount":101},[],{"trials":18947,"activeCount":101},[],{"trials":18949,"activeCount":101},[],{"trials":18951,"activeCount":101},[],{"intervention":18925,"totalTrials":233,"cells":18953},{"EARLY_PHASE1":18954,"PHASE1":18956,"PHASE2":18962,"PHASE3":18964,"PHASE4":18966,"NA":18968},{"trials":18955,"activeCount":101},[],{"trials":18957,"activeCount":101},[18958],{"nctId":18919,"briefTitle":18920,"status":107,"phases":18959,"primaryCompletion":499,"completion":3809,"start":3576,"enrollment":1303,"conditions":18960,"interventions":18961},[90],[1511],[18912,18924,18925],{"trials":18963,"activeCount":101},[],{"trials":18965,"activeCount":101},[],{"trials":18967,"activeCount":101},[],{"trials":18969,"activeCount":101},[],{"intervention":18971,"totalTrials":233,"cells":18972},"BAY60-4552 + Vardenafil",{"EARLY_PHASE1":18973,"PHASE1":18975,"PHASE2":18983,"PHASE3":18985,"PHASE4":18987,"NA":18989},{"trials":18974,"activeCount":101},[],{"trials":18976,"activeCount":101},[18977],{"nctId":18978,"briefTitle":18979,"status":107,"phases":18980,"primaryCompletion":1326,"completion":8136,"start":3809,"enrollment":5231,"conditions":18981,"interventions":18982},"NCT01110590","Multiple Dose Escalation Study (14 Days) to Investigate Safety, Tolerability, PK and PD of Vardenafil and BAY60-4552",[90],[27],[18971,18971,18971],{"trials":18984,"activeCount":101},[],{"trials":18986,"activeCount":101},[],{"trials":18988,"activeCount":101},[],{"trials":18990,"activeCount":101},[],{"intervention":1269,"totalTrials":233,"cells":18992},{"EARLY_PHASE1":18993,"PHASE1":18995,"PHASE2":19001,"PHASE3":19003,"PHASE4":19005,"NA":19007},{"trials":18994,"activeCount":101},[],{"trials":18996,"activeCount":101},[18997],{"nctId":1259,"briefTitle":1260,"status":107,"phases":18998,"primaryCompletion":1262,"completion":1263,"start":1264,"enrollment":1265,"conditions":18999,"interventions":19000},[90],[1267],[1269,1075,1073],{"trials":19002,"activeCount":101},[],{"trials":19004,"activeCount":101},[],{"trials":19006,"activeCount":101},[],{"trials":19008,"activeCount":101},[],{"intervention":19010,"totalTrials":233,"cells":19011},"BAY1187982",{"EARLY_PHASE1":19012,"PHASE1":19014,"PHASE2":19024,"PHASE3":19026,"PHASE4":19028,"NA":19030},{"trials":19013,"activeCount":101},[],{"trials":19015,"activeCount":101},[19016],{"nctId":19017,"briefTitle":19018,"status":156,"phases":19019,"primaryCompletion":19020,"completion":19020,"start":19021,"enrollment":97,"conditions":19022,"interventions":19023},"NCT02368951","Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)",[90],"2016-07-27","2015-03-24",[1267],[19010],{"trials":19025,"activeCount":101},[],{"trials":19027,"activeCount":101},[],{"trials":19029,"activeCount":101},[],{"trials":19031,"activeCount":101},[],{"intervention":17096,"totalTrials":233,"cells":19033},{"EARLY_PHASE1":19034,"PHASE1":19036,"PHASE2":19042,"PHASE3":19044,"PHASE4":19046,"NA":19048},{"trials":19035,"activeCount":101},[],{"trials":19037,"activeCount":101},[19038],{"nctId":17089,"briefTitle":17090,"status":156,"phases":19039,"primaryCompletion":2417,"completion":2417,"start":17092,"enrollment":1181,"conditions":19040,"interventions":19041},[90],[17094,15879],[999,17096],{"trials":19043,"activeCount":101},[],{"trials":19045,"activeCount":101},[],{"trials":19047,"activeCount":101},[],{"trials":19049,"activeCount":101},[],{"intervention":2233,"totalTrials":233,"cells":19051},{"EARLY_PHASE1":19052,"PHASE1":19054,"PHASE2":19060,"PHASE3":19062,"PHASE4":19064,"NA":19066},{"trials":19053,"activeCount":101},[],{"trials":19055,"activeCount":101},[19056],{"nctId":2226,"briefTitle":2227,"status":107,"phases":19057,"primaryCompletion":2229,"completion":2229,"start":2230,"enrollment":701,"conditions":19058,"interventions":19059},[90],[29],[1011,2233],{"trials":19061,"activeCount":101},[],{"trials":19063,"activeCount":101},[],{"trials":19065,"activeCount":101},[],{"trials":19067,"activeCount":101},[],{"intervention":19069,"totalTrials":233,"cells":19070},"BAY86-4367",{"EARLY_PHASE1":19071,"PHASE1":19073,"PHASE2":19081,"PHASE3":19083,"PHASE4":19085,"NA":19087},{"trials":19072,"activeCount":101},[],{"trials":19074,"activeCount":101},[19075],{"nctId":19076,"briefTitle":19077,"status":156,"phases":19078,"primaryCompletion":3793,"completion":3793,"start":3576,"enrollment":1081,"conditions":19079,"interventions":19080},"NCT00975299","Positron Emission Tomography\u002FComputed Tomography (PET\u002FCT) Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-4367 in Patients With Prostate Cancer and Healthy Volunteers",[90],[8726],[19069,19069],{"trials":19082,"activeCount":101},[],{"trials":19084,"activeCount":101},[],{"trials":19086,"activeCount":101},[],{"trials":19088,"activeCount":101},[],{"intervention":17591,"totalTrials":233,"cells":19090},{"EARLY_PHASE1":19091,"PHASE1":19093,"PHASE2":19099,"PHASE3":19101,"PHASE4":19103,"NA":19105},{"trials":19092,"activeCount":101},[],{"trials":19094,"activeCount":101},[19095],{"nctId":17585,"briefTitle":17586,"status":107,"phases":19096,"primaryCompletion":168,"completion":168,"start":17588,"enrollment":2212,"conditions":19097,"interventions":19098},[90],[5881,1124],[17569,17583,17591],{"trials":19100,"activeCount":101},[],{"trials":19102,"activeCount":101},[],{"trials":19104,"activeCount":101},[],{"trials":19106,"activeCount":101},[],{"intervention":19108,"totalTrials":233,"cells":19109},"Vardenafil ODT,",{"EARLY_PHASE1":19110,"PHASE1":19112,"PHASE2":19120,"PHASE3":19122,"PHASE4":19124,"NA":19126},{"trials":19111,"activeCount":101},[],{"trials":19113,"activeCount":101},[19114],{"nctId":19115,"briefTitle":19116,"status":107,"phases":19117,"primaryCompletion":2919,"completion":2919,"start":3618,"enrollment":2212,"conditions":19118,"interventions":19119},"NCT01348880","Vardenafil ODT (Orally Disintegrating Tablet) - Nifedipine Interaction Study",[90],[27],[19108],{"trials":19121,"activeCount":101},[],{"trials":19123,"activeCount":101},[],{"trials":19125,"activeCount":101},[],{"trials":19127,"activeCount":101},[],{"intervention":3571,"totalTrials":233,"cells":19129},{"EARLY_PHASE1":19130,"PHASE1":19132,"PHASE2":19138,"PHASE3":19140,"PHASE4":19142,"NA":19144},{"trials":19131,"activeCount":101},[],{"trials":19133,"activeCount":101},[19134],{"nctId":3564,"briefTitle":3565,"status":107,"phases":19135,"primaryCompletion":1497,"completion":1497,"start":3567,"enrollment":3568,"conditions":19136,"interventions":19137},[90],[3560],[2202,3542,3571],{"trials":19139,"activeCount":101},[],{"trials":19141,"activeCount":101},[],{"trials":19143,"activeCount":101},[],{"trials":19145,"activeCount":101},[],{"intervention":19147,"totalTrials":233,"cells":19148},"500 mg acetylsalicylic acid",{"EARLY_PHASE1":19149,"PHASE1":19151,"PHASE2":19164,"PHASE3":19166,"PHASE4":19168,"NA":19170},{"trials":19150,"activeCount":101},[],{"trials":19152,"activeCount":101},[19153],{"nctId":19154,"briefTitle":19155,"status":107,"phases":19156,"primaryCompletion":19157,"completion":4441,"start":19158,"enrollment":4620,"conditions":19159,"interventions":19161},"NCT03225352","A Study to Assess Disintegration of the New Aspirin Disintegrating Tablets",[90],"2017-10-07","2017-08-07",[19160],"Moderate Pain",[19147,19162,19163,19163],"1000 mg acetylsalicylic acid","400 mg ibuprofen",{"trials":19165,"activeCount":101},[],{"trials":19167,"activeCount":101},[],{"trials":19169,"activeCount":101},[],{"trials":19171,"activeCount":101},[],{"intervention":19162,"totalTrials":233,"cells":19173},{"EARLY_PHASE1":19174,"PHASE1":19176,"PHASE2":19182,"PHASE3":19184,"PHASE4":19186,"NA":19188},{"trials":19175,"activeCount":101},[],{"trials":19177,"activeCount":101},[19178],{"nctId":19154,"briefTitle":19155,"status":107,"phases":19179,"primaryCompletion":19157,"completion":4441,"start":19158,"enrollment":4620,"conditions":19180,"interventions":19181},[90],[19160],[19147,19162,19163,19163],{"trials":19183,"activeCount":101},[],{"trials":19185,"activeCount":101},[],{"trials":19187,"activeCount":101},[],{"trials":19189,"activeCount":101},[],{"intervention":19163,"totalTrials":233,"cells":19191},{"EARLY_PHASE1":19192,"PHASE1":19194,"PHASE2":19200,"PHASE3":19202,"PHASE4":19204,"NA":19206},{"trials":19193,"activeCount":101},[],{"trials":19195,"activeCount":101},[19196],{"nctId":19154,"briefTitle":19155,"status":107,"phases":19197,"primaryCompletion":19157,"completion":4441,"start":19158,"enrollment":4620,"conditions":19198,"interventions":19199},[90],[19160],[19147,19162,19163,19163],{"trials":19201,"activeCount":101},[],{"trials":19203,"activeCount":101},[],{"trials":19205,"activeCount":101},[],{"trials":19207,"activeCount":101},[],{"intervention":19209,"totalTrials":233,"cells":19210},"BAY94-9027 + Recombinant Factor VIII",{"EARLY_PHASE1":19211,"PHASE1":19213,"PHASE2":19223,"PHASE3":19225,"PHASE4":19227,"NA":19229},{"trials":19212,"activeCount":101},[],{"trials":19214,"activeCount":101},[19215],{"nctId":19216,"briefTitle":19217,"status":107,"phases":19218,"primaryCompletion":19219,"completion":19219,"start":19220,"enrollment":1181,"conditions":19221,"interventions":19222},"NCT01184820","Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration",[90],"2011-10-10","2010-10-13",[24],[19209,19209],{"trials":19224,"activeCount":101},[],{"trials":19226,"activeCount":101},[],{"trials":19228,"activeCount":101},[],{"trials":19230,"activeCount":101},[],{"intervention":13231,"totalTrials":233,"cells":19232},{"EARLY_PHASE1":19233,"PHASE1":19235,"PHASE2":19241,"PHASE3":19243,"PHASE4":19245,"NA":19247},{"trials":19234,"activeCount":101},[],{"trials":19236,"activeCount":101},[19237],{"nctId":13224,"briefTitle":13225,"status":107,"phases":19238,"primaryCompletion":1004,"completion":13227,"start":13228,"enrollment":112,"conditions":19239,"interventions":19240},[90],[7793],[13217,13231],{"trials":19242,"activeCount":101},[],{"trials":19244,"activeCount":101},[],{"trials":19246,"activeCount":101},[],{"trials":19248,"activeCount":101},[],{"intervention":19250,"totalTrials":233,"cells":19251},"BAY1143572",{"EARLY_PHASE1":19252,"PHASE1":19254,"PHASE2":19265,"PHASE3":19267,"PHASE4":19269,"NA":19271},{"trials":19253,"activeCount":101},[],{"trials":19255,"activeCount":101},[19256],{"nctId":19257,"briefTitle":19258,"status":107,"phases":19259,"primaryCompletion":19260,"completion":19261,"start":19262,"enrollment":7250,"conditions":19263,"interventions":19264},"NCT01938638","Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer",[90],"2016-08-17","2016-09-19","2013-09-26",[29],[19250],{"trials":19266,"activeCount":101},[],{"trials":19268,"activeCount":101},[],{"trials":19270,"activeCount":101},[],{"trials":19272,"activeCount":101},[],{"intervention":19274,"totalTrials":233,"cells":19275},"BAY2287411",{"EARLY_PHASE1":19276,"PHASE1":19278,"PHASE2":19292,"PHASE3":19294,"PHASE4":19296,"NA":19298},{"trials":19277,"activeCount":101},[],{"trials":19279,"activeCount":101},[19280],{"nctId":19281,"briefTitle":19282,"status":107,"phases":19283,"primaryCompletion":1111,"completion":19284,"start":19285,"enrollment":1265,"conditions":19286,"interventions":19291},"NCT03507452","First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin",[90],"2022-03-29","2018-06-13",[19287,19288,19289,19290],"Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma","Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma","Advanced Recurrent Serous Ovarian Cancer","Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)",[19274,19274],{"trials":19293,"activeCount":101},[],{"trials":19295,"activeCount":101},[],{"trials":19297,"activeCount":101},[],{"trials":19299,"activeCount":101},[],{"intervention":16932,"totalTrials":233,"cells":19301},{"EARLY_PHASE1":19302,"PHASE1":19304,"PHASE2":19310,"PHASE3":19312,"PHASE4":19314,"NA":19316},{"trials":19303,"activeCount":101},[],{"trials":19305,"activeCount":101},[19306],{"nctId":16925,"briefTitle":16926,"status":156,"phases":19307,"primaryCompletion":13431,"completion":16928,"start":16929,"enrollment":13838,"conditions":19308,"interventions":19309},[90],[1267],[16932,1358],{"trials":19311,"activeCount":101},[],{"trials":19313,"activeCount":101},[],{"trials":19315,"activeCount":101},[],{"trials":19317,"activeCount":101},[],{"intervention":19319,"totalTrials":233,"cells":19320},"EE 0.03 mg\u002FDRSP 3 mg",{"EARLY_PHASE1":19321,"PHASE1":19323,"PHASE2":19333,"PHASE3":19335,"PHASE4":19337,"NA":19339},{"trials":19322,"activeCount":101},[],{"trials":19324,"activeCount":101},[19325],{"nctId":19326,"briefTitle":19327,"status":107,"phases":19328,"primaryCompletion":11861,"completion":11861,"start":6932,"enrollment":25,"conditions":19329,"interventions":19330},"NCT01253174","Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: Yasmin and Yasmin + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and Yasmin + Levomefolate Calcium (Metafolin)",[90],[15],[19319,19331,19332],"EE 0.03mg\u002FDRSP 3mg\u002FL-5-MTHF Ca 0.451mg","L-5-MTHF Ca 0.451 mg",{"trials":19334,"activeCount":101},[],{"trials":19336,"activeCount":101},[],{"trials":19338,"activeCount":101},[],{"trials":19340,"activeCount":101},[],{"intervention":19331,"totalTrials":233,"cells":19342},{"EARLY_PHASE1":19343,"PHASE1":19345,"PHASE2":19351,"PHASE3":19353,"PHASE4":19355,"NA":19357},{"trials":19344,"activeCount":101},[],{"trials":19346,"activeCount":101},[19347],{"nctId":19326,"briefTitle":19327,"status":107,"phases":19348,"primaryCompletion":11861,"completion":11861,"start":6932,"enrollment":25,"conditions":19349,"interventions":19350},[90],[15],[19319,19331,19332],{"trials":19352,"activeCount":101},[],{"trials":19354,"activeCount":101},[],{"trials":19356,"activeCount":101},[],{"trials":19358,"activeCount":101},[],{"intervention":19332,"totalTrials":233,"cells":19360},{"EARLY_PHASE1":19361,"PHASE1":19363,"PHASE2":19369,"PHASE3":19371,"PHASE4":19373,"NA":19375},{"trials":19362,"activeCount":101},[],{"trials":19364,"activeCount":101},[19365],{"nctId":19326,"briefTitle":19327,"status":107,"phases":19366,"primaryCompletion":11861,"completion":11861,"start":6932,"enrollment":25,"conditions":19367,"interventions":19368},[90],[15],[19319,19331,19332],{"trials":19370,"activeCount":101},[],{"trials":19372,"activeCount":101},[],{"trials":19374,"activeCount":101},[],{"trials":19376,"activeCount":101},[],{"intervention":19378,"totalTrials":233,"cells":19379},"Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg",{"EARLY_PHASE1":19380,"PHASE1":19382,"PHASE2":19399,"PHASE3":19401,"PHASE4":19403,"NA":19405},{"trials":19381,"activeCount":101},[],{"trials":19383,"activeCount":101},[19384],{"nctId":19385,"briefTitle":19386,"status":107,"phases":19387,"primaryCompletion":2406,"completion":2406,"start":1328,"enrollment":19388,"conditions":19389,"interventions":19391},"NCT01117623","Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies",[90],86,[19390],"Neoplasm",[19378,19392,19393,19394,19395,19396,19397,19398],"Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg","Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg","Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg","Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg","HCC Child-Pugh A expansion cohort: Regorafenib 100 mg","HCC Child-Pugh B expansion cohort: Regorafenib 100 mg","NSCLC expansion cohort: Regorafenib 100 mg",{"trials":19400,"activeCount":101},[],{"trials":19402,"activeCount":101},[],{"trials":19404,"activeCount":101},[],{"trials":19406,"activeCount":101},[],{"intervention":19392,"totalTrials":233,"cells":19408},{"EARLY_PHASE1":19409,"PHASE1":19411,"PHASE2":19417,"PHASE3":19419,"PHASE4":19421,"NA":19423},{"trials":19410,"activeCount":101},[],{"trials":19412,"activeCount":101},[19413],{"nctId":19385,"briefTitle":19386,"status":107,"phases":19414,"primaryCompletion":2406,"completion":2406,"start":1328,"enrollment":19388,"conditions":19415,"interventions":19416},[90],[19390],[19378,19392,19393,19394,19395,19396,19397,19398],{"trials":19418,"activeCount":101},[],{"trials":19420,"activeCount":101},[],{"trials":19422,"activeCount":101},[],{"trials":19424,"activeCount":101},[],{"intervention":19393,"totalTrials":233,"cells":19426},{"EARLY_PHASE1":19427,"PHASE1":19429,"PHASE2":19435,"PHASE3":19437,"PHASE4":19439,"NA":19441},{"trials":19428,"activeCount":101},[],{"trials":19430,"activeCount":101},[19431],{"nctId":19385,"briefTitle":19386,"status":107,"phases":19432,"primaryCompletion":2406,"completion":2406,"start":1328,"enrollment":19388,"conditions":19433,"interventions":19434},[90],[19390],[19378,19392,19393,19394,19395,19396,19397,19398],{"trials":19436,"activeCount":101},[],{"trials":19438,"activeCount":101},[],{"trials":19440,"activeCount":101},[],{"trials":19442,"activeCount":101},[],{"intervention":19394,"totalTrials":233,"cells":19444},{"EARLY_PHASE1":19445,"PHASE1":19447,"PHASE2":19453,"PHASE3":19455,"PHASE4":19457,"NA":19459},{"trials":19446,"activeCount":101},[],{"trials":19448,"activeCount":101},[19449],{"nctId":19385,"briefTitle":19386,"status":107,"phases":19450,"primaryCompletion":2406,"completion":2406,"start":1328,"enrollment":19388,"conditions":19451,"interventions":19452},[90],[19390],[19378,19392,19393,19394,19395,19396,19397,19398],{"trials":19454,"activeCount":101},[],{"trials":19456,"activeCount":101},[],{"trials":19458,"activeCount":101},[],{"trials":19460,"activeCount":101},[],{"intervention":19395,"totalTrials":233,"cells":19462},{"EARLY_PHASE1":19463,"PHASE1":19465,"PHASE2":19471,"PHASE3":19473,"PHASE4":19475,"NA":19477},{"trials":19464,"activeCount":101},[],{"trials":19466,"activeCount":101},[19467],{"nctId":19385,"briefTitle":19386,"status":107,"phases":19468,"primaryCompletion":2406,"completion":2406,"start":1328,"enrollment":19388,"conditions":19469,"interventions":19470},[90],[19390],[19378,19392,19393,19394,19395,19396,19397,19398],{"trials":19472,"activeCount":101},[],{"trials":19474,"activeCount":101},[],{"trials":19476,"activeCount":101},[],{"trials":19478,"activeCount":101},[],{"intervention":19396,"totalTrials":233,"cells":19480},{"EARLY_PHASE1":19481,"PHASE1":19483,"PHASE2":19489,"PHASE3":19491,"PHASE4":19493,"NA":19495},{"trials":19482,"activeCount":101},[],{"trials":19484,"activeCount":101},[19485],{"nctId":19385,"briefTitle":19386,"status":107,"phases":19486,"primaryCompletion":2406,"completion":2406,"start":1328,"enrollment":19388,"conditions":19487,"interventions":19488},[90],[19390],[19378,19392,19393,19394,19395,19396,19397,19398],{"trials":19490,"activeCount":101},[],{"trials":19492,"activeCount":101},[],{"trials":19494,"activeCount":101},[],{"trials":19496,"activeCount":101},[],{"intervention":19397,"totalTrials":233,"cells":19498},{"EARLY_PHASE1":19499,"PHASE1":19501,"PHASE2":19507,"PHASE3":19509,"PHASE4":19511,"NA":19513},{"trials":19500,"activeCount":101},[],{"trials":19502,"activeCount":101},[19503],{"nctId":19385,"briefTitle":19386,"status":107,"phases":19504,"primaryCompletion":2406,"completion":2406,"start":1328,"enrollment":19388,"conditions":19505,"interventions":19506},[90],[19390],[19378,19392,19393,19394,19395,19396,19397,19398],{"trials":19508,"activeCount":101},[],{"trials":19510,"activeCount":101},[],{"trials":19512,"activeCount":101},[],{"trials":19514,"activeCount":101},[],{"intervention":19398,"totalTrials":233,"cells":19516},{"EARLY_PHASE1":19517,"PHASE1":19519,"PHASE2":19525,"PHASE3":19527,"PHASE4":19529,"NA":19531},{"trials":19518,"activeCount":101},[],{"trials":19520,"activeCount":101},[19521],{"nctId":19385,"briefTitle":19386,"status":107,"phases":19522,"primaryCompletion":2406,"completion":2406,"start":1328,"enrollment":19388,"conditions":19523,"interventions":19524},[90],[19390],[19378,19392,19393,19394,19395,19396,19397,19398],{"trials":19526,"activeCount":101},[],{"trials":19528,"activeCount":101},[],{"trials":19530,"activeCount":101},[],{"trials":19532,"activeCount":101},[],{"intervention":7779,"totalTrials":233,"cells":19534},{"EARLY_PHASE1":19535,"PHASE1":19537,"PHASE2":19543,"PHASE3":19545,"PHASE4":19547,"NA":19549},{"trials":19536,"activeCount":101},[],{"trials":19538,"activeCount":101},[19539],{"nctId":7773,"briefTitle":7774,"status":107,"phases":19540,"primaryCompletion":4066,"completion":7776,"start":1487,"enrollment":1181,"conditions":19541,"interventions":19542},[90],[7762],[5917,7779],{"trials":19544,"activeCount":101},[],{"trials":19546,"activeCount":101},[],{"trials":19548,"activeCount":101},[],{"trials":19550,"activeCount":101},[],{"intervention":19552,"totalTrials":233,"cells":19553},"BAY2927088 coated tablet 10 mg",{"EARLY_PHASE1":19554,"PHASE1":19556,"PHASE2":19568,"PHASE3":19570,"PHASE4":19572,"NA":19574},{"trials":19555,"activeCount":101},[],{"trials":19557,"activeCount":101},[19558],{"nctId":19559,"briefTitle":19560,"status":107,"phases":19561,"primaryCompletion":19562,"completion":19563,"start":5863,"enrollment":421,"conditions":19564,"interventions":19565},"NCT06221475","A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants",[90],"2024-04-05","2024-05-08",[1069,1932,1070,1124],[19552,19566,19567],"[14C]-BAY2927088 solution for","[14C]-BAY2927088 oral solution",{"trials":19569,"activeCount":101},[],{"trials":19571,"activeCount":101},[],{"trials":19573,"activeCount":101},[],{"trials":19575,"activeCount":101},[],{"intervention":19566,"totalTrials":233,"cells":19577},{"EARLY_PHASE1":19578,"PHASE1":19580,"PHASE2":19586,"PHASE3":19588,"PHASE4":19590,"NA":19592},{"trials":19579,"activeCount":101},[],{"trials":19581,"activeCount":101},[19582],{"nctId":19559,"briefTitle":19560,"status":107,"phases":19583,"primaryCompletion":19562,"completion":19563,"start":5863,"enrollment":421,"conditions":19584,"interventions":19585},[90],[1069,1932,1070,1124],[19552,19566,19567],{"trials":19587,"activeCount":101},[],{"trials":19589,"activeCount":101},[],{"trials":19591,"activeCount":101},[],{"trials":19593,"activeCount":101},[],{"intervention":19567,"totalTrials":233,"cells":19595},{"EARLY_PHASE1":19596,"PHASE1":19598,"PHASE2":19604,"PHASE3":19606,"PHASE4":19608,"NA":19610},{"trials":19597,"activeCount":101},[],{"trials":19599,"activeCount":101},[19600],{"nctId":19559,"briefTitle":19560,"status":107,"phases":19601,"primaryCompletion":19562,"completion":19563,"start":5863,"enrollment":421,"conditions":19602,"interventions":19603},[90],[1069,1932,1070,1124],[19552,19566,19567],{"trials":19605,"activeCount":101},[],{"trials":19607,"activeCount":101},[],{"trials":19609,"activeCount":101},[],{"trials":19611,"activeCount":101},[],{"intervention":5831,"totalTrials":233,"cells":19613},{"EARLY_PHASE1":19614,"PHASE1":19616,"PHASE2":19622,"PHASE3":19624,"PHASE4":19626,"NA":19628},{"trials":19615,"activeCount":101},[],{"trials":19617,"activeCount":101},[19618],{"nctId":5825,"briefTitle":5826,"status":107,"phases":19619,"primaryCompletion":2959,"completion":410,"start":1508,"enrollment":1509,"conditions":19620,"interventions":19621},[90],[5829],[5831,5803,5832,5831],{"trials":19623,"activeCount":101},[],{"trials":19625,"activeCount":101},[],{"trials":19627,"activeCount":101},[],{"trials":19629,"activeCount":101},[],{"intervention":5832,"totalTrials":233,"cells":19631},{"EARLY_PHASE1":19632,"PHASE1":19634,"PHASE2":19640,"PHASE3":19642,"PHASE4":19644,"NA":19646},{"trials":19633,"activeCount":101},[],{"trials":19635,"activeCount":101},[19636],{"nctId":5825,"briefTitle":5826,"status":107,"phases":19637,"primaryCompletion":2959,"completion":410,"start":1508,"enrollment":1509,"conditions":19638,"interventions":19639},[90],[5829],[5831,5803,5832,5831],{"trials":19641,"activeCount":101},[],{"trials":19643,"activeCount":101},[],{"trials":19645,"activeCount":101},[],{"trials":19647,"activeCount":101},[],{"intervention":17203,"totalTrials":233,"cells":19649},{"EARLY_PHASE1":19650,"PHASE1":19652,"PHASE2":19658,"PHASE3":19660,"PHASE4":19662,"NA":19664},{"trials":19651,"activeCount":101},[],{"trials":19653,"activeCount":101},[19654],{"nctId":17197,"briefTitle":17198,"status":107,"phases":19655,"primaryCompletion":3576,"completion":3576,"start":3576,"enrollment":1509,"conditions":19656,"interventions":19657},[90],[17201],[17184,17203],{"trials":19659,"activeCount":101},[],{"trials":19661,"activeCount":101},[],{"trials":19663,"activeCount":101},[],{"trials":19665,"activeCount":101},[],{"intervention":19667,"totalTrials":233,"cells":19668},"F-18 DPA-714",{"EARLY_PHASE1":19669,"PHASE1":19671,"PHASE2":19679,"PHASE3":19681,"PHASE4":19683,"NA":19685},{"trials":19670,"activeCount":101},[],{"trials":19672,"activeCount":101},[19673],{"nctId":19674,"briefTitle":19675,"status":107,"phases":19676,"primaryCompletion":549,"completion":3793,"start":2256,"enrollment":6203,"conditions":19677,"interventions":19678},"NCT01009359","Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers",[90],[8726],[19667,19667,19667],{"trials":19680,"activeCount":101},[],{"trials":19682,"activeCount":101},[],{"trials":19684,"activeCount":101},[],{"trials":19686,"activeCount":101},[],{"intervention":19688,"totalTrials":233,"cells":19689},"BAY2701250 IV",{"EARLY_PHASE1":19690,"PHASE1":19692,"PHASE2":19703,"PHASE3":19705,"PHASE4":19707,"NA":19709},{"trials":19691,"activeCount":101},[],{"trials":19693,"activeCount":101},[19694],{"nctId":19695,"briefTitle":19696,"status":107,"phases":19697,"primaryCompletion":19698,"completion":19698,"start":8464,"enrollment":6445,"conditions":19699,"interventions":19701},"NCT06048120","A Study to Learn How Safe the Study Treatment BAY2701250 is, How it Affects the Body and How it Moves Into, Through and Out of the Body in Healthy Male Participants When a Single Amount is Given as an Injection Into the Vein (Intravenous Infusion) or Under the Skin (Subcutaneous Injection)",[90],"2025-05-20",[19700],"Pulmonary Hypertension Due to Left Heart Disease",[19688,19702],"BAY2701250 SC",{"trials":19704,"activeCount":101},[],{"trials":19706,"activeCount":101},[],{"trials":19708,"activeCount":101},[],{"trials":19710,"activeCount":101},[],{"intervention":19702,"totalTrials":233,"cells":19712},{"EARLY_PHASE1":19713,"PHASE1":19715,"PHASE2":19721,"PHASE3":19723,"PHASE4":19725,"NA":19727},{"trials":19714,"activeCount":101},[],{"trials":19716,"activeCount":101},[19717],{"nctId":19695,"briefTitle":19696,"status":107,"phases":19718,"primaryCompletion":19698,"completion":19698,"start":8464,"enrollment":6445,"conditions":19719,"interventions":19720},[90],[19700],[19688,19702],{"trials":19722,"activeCount":101},[],{"trials":19724,"activeCount":101},[],{"trials":19726,"activeCount":101},[],{"trials":19728,"activeCount":101},[],{"intervention":19730,"totalTrials":233,"cells":19731},"Treatment A",{"EARLY_PHASE1":19732,"PHASE1":19734,"PHASE2":19746,"PHASE3":19748,"PHASE4":19750,"NA":19752},{"trials":19733,"activeCount":101},[],{"trials":19735,"activeCount":101},[19736],{"nctId":19737,"briefTitle":19738,"status":107,"phases":19739,"primaryCompletion":19740,"completion":19740,"start":19741,"enrollment":1163,"conditions":19742,"interventions":19743},"NCT07229404","A Study to Investigate Relative Bioavailability, Safety and Tolerability of Single- and Multiple-doses of Elinzanetant in Healthy Female Participants",[90],"2026-01-14","2025-11-05",[6495],[19730,19744,19745],"Treatment B","Treatment C",{"trials":19747,"activeCount":101},[],{"trials":19749,"activeCount":101},[],{"trials":19751,"activeCount":101},[],{"trials":19753,"activeCount":101},[],{"intervention":19744,"totalTrials":233,"cells":19755},{"EARLY_PHASE1":19756,"PHASE1":19758,"PHASE2":19764,"PHASE3":19766,"PHASE4":19768,"NA":19770},{"trials":19757,"activeCount":101},[],{"trials":19759,"activeCount":101},[19760],{"nctId":19737,"briefTitle":19738,"status":107,"phases":19761,"primaryCompletion":19740,"completion":19740,"start":19741,"enrollment":1163,"conditions":19762,"interventions":19763},[90],[6495],[19730,19744,19745],{"trials":19765,"activeCount":101},[],{"trials":19767,"activeCount":101},[],{"trials":19769,"activeCount":101},[],{"trials":19771,"activeCount":101},[],{"intervention":19745,"totalTrials":233,"cells":19773},{"EARLY_PHASE1":19774,"PHASE1":19776,"PHASE2":19782,"PHASE3":19784,"PHASE4":19786,"NA":19788},{"trials":19775,"activeCount":101},[],{"trials":19777,"activeCount":101},[19778],{"nctId":19737,"briefTitle":19738,"status":107,"phases":19779,"primaryCompletion":19740,"completion":19740,"start":19741,"enrollment":1163,"conditions":19780,"interventions":19781},[90],[6495],[19730,19744,19745],{"trials":19783,"activeCount":101},[],{"trials":19785,"activeCount":101},[],{"trials":19787,"activeCount":101},[],{"trials":19789,"activeCount":101},[],{"intervention":19791,"totalTrials":233,"cells":19792},"Cipro Inhale",{"EARLY_PHASE1":19793,"PHASE1":19795,"PHASE2":19804,"PHASE3":19806,"PHASE4":19808,"NA":19810},{"trials":19794,"activeCount":101},[],{"trials":19796,"activeCount":101},[19797],{"nctId":19798,"briefTitle":19799,"status":107,"phases":19800,"primaryCompletion":2968,"completion":2968,"start":549,"enrollment":4620,"conditions":19801,"interventions":19803},"NCT01168895","Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder",[90],[12370,19802],"Pulmonary Disease, Chronic Obstructive",[19791,19791],{"trials":19805,"activeCount":101},[],{"trials":19807,"activeCount":101},[],{"trials":19809,"activeCount":101},[],{"trials":19811,"activeCount":101},[],{"intervention":19813,"totalTrials":233,"cells":19814},"Recomb. Factor VIII",{"EARLY_PHASE1":19815,"PHASE1":19817,"PHASE2":19826,"PHASE3":19828,"PHASE4":19830,"NA":19832},{"trials":19816,"activeCount":101},[],{"trials":19818,"activeCount":101},[19819],{"nctId":19820,"briefTitle":19821,"status":107,"phases":19822,"completion":5472,"start":6396,"enrollment":701,"conditions":19823,"interventions":19824},"NCT00629837","Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980",[90],[24],[19813,19813,19825,19825],"Recombinant Factor VIII",{"trials":19827,"activeCount":101},[],{"trials":19829,"activeCount":101},[],{"trials":19831,"activeCount":101},[],{"trials":19833,"activeCount":101},[],{"intervention":19835,"totalTrials":233,"cells":19836},"Vericiguat(BAY1021189, high-dose pediatric-formulation)_fed",{"EARLY_PHASE1":19837,"PHASE1":19839,"PHASE2":19854,"PHASE3":19856,"PHASE4":19858,"NA":19860},{"trials":19838,"activeCount":101},[],{"trials":19840,"activeCount":101},[19841],{"nctId":19842,"briefTitle":19843,"status":107,"phases":19844,"primaryCompletion":19845,"completion":19846,"start":456,"enrollment":160,"conditions":19847,"interventions":19848},"NCT03145038","Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects",[90],"2017-08-29","2017-10-09",[1790],[19835,19849,19850,19851,19852,19853],"Vericiguat(BAY1021189, high-dose pediatric-formulation)_fasted","Vericiguat(BAY1021189, low-dose pediatric-formulation)_fed","Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;American breakfast","Vericiguat(BAY1021189,10 mg IR film-coated tablets,crushed)_fed;American breakfast","Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;Continental breakfast",{"trials":19855,"activeCount":101},[],{"trials":19857,"activeCount":101},[],{"trials":19859,"activeCount":101},[],{"trials":19861,"activeCount":101},[],{"intervention":19849,"totalTrials":233,"cells":19863},{"EARLY_PHASE1":19864,"PHASE1":19866,"PHASE2":19872,"PHASE3":19874,"PHASE4":19876,"NA":19878},{"trials":19865,"activeCount":101},[],{"trials":19867,"activeCount":101},[19868],{"nctId":19842,"briefTitle":19843,"status":107,"phases":19869,"primaryCompletion":19845,"completion":19846,"start":456,"enrollment":160,"conditions":19870,"interventions":19871},[90],[1790],[19835,19849,19850,19851,19852,19853],{"trials":19873,"activeCount":101},[],{"trials":19875,"activeCount":101},[],{"trials":19877,"activeCount":101},[],{"trials":19879,"activeCount":101},[],{"intervention":19850,"totalTrials":233,"cells":19881},{"EARLY_PHASE1":19882,"PHASE1":19884,"PHASE2":19890,"PHASE3":19892,"PHASE4":19894,"NA":19896},{"trials":19883,"activeCount":101},[],{"trials":19885,"activeCount":101},[19886],{"nctId":19842,"briefTitle":19843,"status":107,"phases":19887,"primaryCompletion":19845,"completion":19846,"start":456,"enrollment":160,"conditions":19888,"interventions":19889},[90],[1790],[19835,19849,19850,19851,19852,19853],{"trials":19891,"activeCount":101},[],{"trials":19893,"activeCount":101},[],{"trials":19895,"activeCount":101},[],{"trials":19897,"activeCount":101},[],{"intervention":19851,"totalTrials":233,"cells":19899},{"EARLY_PHASE1":19900,"PHASE1":19902,"PHASE2":19908,"PHASE3":19910,"PHASE4":19912,"NA":19914},{"trials":19901,"activeCount":101},[],{"trials":19903,"activeCount":101},[19904],{"nctId":19842,"briefTitle":19843,"status":107,"phases":19905,"primaryCompletion":19845,"completion":19846,"start":456,"enrollment":160,"conditions":19906,"interventions":19907},[90],[1790],[19835,19849,19850,19851,19852,19853],{"trials":19909,"activeCount":101},[],{"trials":19911,"activeCount":101},[],{"trials":19913,"activeCount":101},[],{"trials":19915,"activeCount":101},[],{"intervention":19852,"totalTrials":233,"cells":19917},{"EARLY_PHASE1":19918,"PHASE1":19920,"PHASE2":19926,"PHASE3":19928,"PHASE4":19930,"NA":19932},{"trials":19919,"activeCount":101},[],{"trials":19921,"activeCount":101},[19922],{"nctId":19842,"briefTitle":19843,"status":107,"phases":19923,"primaryCompletion":19845,"completion":19846,"start":456,"enrollment":160,"conditions":19924,"interventions":19925},[90],[1790],[19835,19849,19850,19851,19852,19853],{"trials":19927,"activeCount":101},[],{"trials":19929,"activeCount":101},[],{"trials":19931,"activeCount":101},[],{"trials":19933,"activeCount":101},[],{"intervention":19853,"totalTrials":233,"cells":19935},{"EARLY_PHASE1":19936,"PHASE1":19938,"PHASE2":19944,"PHASE3":19946,"PHASE4":19948,"NA":19950},{"trials":19937,"activeCount":101},[],{"trials":19939,"activeCount":101},[19940],{"nctId":19842,"briefTitle":19843,"status":107,"phases":19941,"primaryCompletion":19845,"completion":19846,"start":456,"enrollment":160,"conditions":19942,"interventions":19943},[90],[1790],[19835,19849,19850,19851,19852,19853],{"trials":19945,"activeCount":101},[],{"trials":19947,"activeCount":101},[],{"trials":19949,"activeCount":101},[],{"trials":19951,"activeCount":101},[],{"intervention":19953,"totalTrials":233,"cells":19954},"Naproxen Sodium ER (BAY117031), 20% HPMC",{"EARLY_PHASE1":19955,"PHASE1":19957,"PHASE2":19968,"PHASE3":19970,"PHASE4":19972,"NA":19974},{"trials":19956,"activeCount":101},[],{"trials":19958,"activeCount":101},[19959],{"nctId":19960,"briefTitle":19961,"status":107,"phases":19962,"primaryCompletion":445,"completion":445,"start":3778,"enrollment":1509,"conditions":19963,"interventions":19964},"NCT02549469","Bioequivalence of Single Dose Extended Release Naproxen Sodium (660 mg) Tablet Versus Naproxen Sodium (220 mg) Tablet Three Times Daily",[90],[5881],[19953,19965,19966,19967],"Naproxen Sodium ER (BAY117031), 30% HPMC","Naproxen Sodium ER (BAY117031), 40% HPMC","Aleve",{"trials":19969,"activeCount":101},[],{"trials":19971,"activeCount":101},[],{"trials":19973,"activeCount":101},[],{"trials":19975,"activeCount":101},[],{"intervention":19965,"totalTrials":233,"cells":19977},{"EARLY_PHASE1":19978,"PHASE1":19980,"PHASE2":19986,"PHASE3":19988,"PHASE4":19990,"NA":19992},{"trials":19979,"activeCount":101},[],{"trials":19981,"activeCount":101},[19982],{"nctId":19960,"briefTitle":19961,"status":107,"phases":19983,"primaryCompletion":445,"completion":445,"start":3778,"enrollment":1509,"conditions":19984,"interventions":19985},[90],[5881],[19953,19965,19966,19967],{"trials":19987,"activeCount":101},[],{"trials":19989,"activeCount":101},[],{"trials":19991,"activeCount":101},[],{"trials":19993,"activeCount":101},[],{"intervention":19966,"totalTrials":233,"cells":19995},{"EARLY_PHASE1":19996,"PHASE1":19998,"PHASE2":20004,"PHASE3":20006,"PHASE4":20008,"NA":20010},{"trials":19997,"activeCount":101},[],{"trials":19999,"activeCount":101},[20000],{"nctId":19960,"briefTitle":19961,"status":107,"phases":20001,"primaryCompletion":445,"completion":445,"start":3778,"enrollment":1509,"conditions":20002,"interventions":20003},[90],[5881],[19953,19965,19966,19967],{"trials":20005,"activeCount":101},[],{"trials":20007,"activeCount":101},[],{"trials":20009,"activeCount":101},[],{"trials":20011,"activeCount":101},[],{"intervention":19967,"totalTrials":233,"cells":20013},{"EARLY_PHASE1":20014,"PHASE1":20016,"PHASE2":20022,"PHASE3":20024,"PHASE4":20026,"NA":20028},{"trials":20015,"activeCount":101},[],{"trials":20017,"activeCount":101},[20018],{"nctId":19960,"briefTitle":19961,"status":107,"phases":20019,"primaryCompletion":445,"completion":445,"start":3778,"enrollment":1509,"conditions":20020,"interventions":20021},[90],[5881],[19953,19965,19966,19967],{"trials":20023,"activeCount":101},[],{"trials":20025,"activeCount":101},[],{"trials":20027,"activeCount":101},[],{"trials":20029,"activeCount":101},[],{"intervention":13950,"totalTrials":233,"cells":20031},{"EARLY_PHASE1":20032,"PHASE1":20034,"PHASE2":20040,"PHASE3":20042,"PHASE4":20044,"NA":20046},{"trials":20033,"activeCount":101},[],{"trials":20035,"activeCount":101},[20036],{"nctId":13942,"briefTitle":13943,"status":107,"phases":20037,"primaryCompletion":13945,"completion":13946,"start":13947,"enrollment":6822,"conditions":20038,"interventions":20039},[90],[1536],[13950,13951,13012],{"trials":20041,"activeCount":101},[],{"trials":20043,"activeCount":101},[],{"trials":20045,"activeCount":101},[],{"trials":20047,"activeCount":101},[],{"intervention":13951,"totalTrials":233,"cells":20049},{"EARLY_PHASE1":20050,"PHASE1":20052,"PHASE2":20058,"PHASE3":20060,"PHASE4":20062,"NA":20064},{"trials":20051,"activeCount":101},[],{"trials":20053,"activeCount":101},[20054],{"nctId":13942,"briefTitle":13943,"status":107,"phases":20055,"primaryCompletion":13945,"completion":13946,"start":13947,"enrollment":6822,"conditions":20056,"interventions":20057},[90],[1536],[13950,13951,13012],{"trials":20059,"activeCount":101},[],{"trials":20061,"activeCount":101},[],{"trials":20063,"activeCount":101},[],{"trials":20065,"activeCount":101},[],{"intervention":3426,"totalTrials":233,"cells":20067},{"EARLY_PHASE1":20068,"PHASE1":20070,"PHASE2":20076,"PHASE3":20078,"PHASE4":20080,"NA":20082},{"trials":20069,"activeCount":101},[],{"trials":20071,"activeCount":101},[20072],{"nctId":3418,"briefTitle":3419,"status":107,"phases":20073,"primaryCompletion":3421,"completion":3422,"start":3423,"enrollment":1265,"conditions":20074,"interventions":20075},[90],[1579],[3393,3426],{"trials":20077,"activeCount":101},[],{"trials":20079,"activeCount":101},[],{"trials":20081,"activeCount":101},[],{"trials":20083,"activeCount":101},[],{"intervention":20085,"totalTrials":233,"cells":20086},"Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule",{"EARLY_PHASE1":20087,"PHASE1":20089,"PHASE2":20098,"PHASE3":20100,"PHASE4":20102,"NA":20104},{"trials":20088,"activeCount":101},[],{"trials":20090,"activeCount":101},[20091],{"nctId":20092,"briefTitle":20093,"status":107,"phases":20094,"primaryCompletion":1326,"completion":1326,"start":3809,"enrollment":2307,"conditions":20095,"interventions":20096},"NCT01053676","Bioequivalence Study of BAY77-1931 Granule",[90],[8965],[20085,20097],"Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable",{"trials":20099,"activeCount":101},[],{"trials":20101,"activeCount":101},[],{"trials":20103,"activeCount":101},[],{"trials":20105,"activeCount":101},[],{"intervention":20097,"totalTrials":233,"cells":20107},{"EARLY_PHASE1":20108,"PHASE1":20110,"PHASE2":20116,"PHASE3":20118,"PHASE4":20120,"NA":20122},{"trials":20109,"activeCount":101},[],{"trials":20111,"activeCount":101},[20112],{"nctId":20092,"briefTitle":20093,"status":107,"phases":20113,"primaryCompletion":1326,"completion":1326,"start":3809,"enrollment":2307,"conditions":20114,"interventions":20115},[90],[8965],[20085,20097],{"trials":20117,"activeCount":101},[],{"trials":20119,"activeCount":101},[],{"trials":20121,"activeCount":101},[],{"trials":20123,"activeCount":101},[],{"intervention":12637,"totalTrials":233,"cells":20125},{"EARLY_PHASE1":20126,"PHASE1":20128,"PHASE2":20134,"PHASE3":20136,"PHASE4":20138,"NA":20140},{"trials":20127,"activeCount":101},[],{"trials":20129,"activeCount":101},[20130],{"nctId":12628,"briefTitle":12629,"status":107,"phases":20131,"primaryCompletion":12631,"completion":12632,"start":12633,"enrollment":4620,"conditions":20132,"interventions":20133},[90],[7793],[12636,1154,12637],{"trials":20135,"activeCount":101},[],{"trials":20137,"activeCount":101},[],{"trials":20139,"activeCount":101},[],{"trials":20141,"activeCount":101},[],{"intervention":20143,"totalTrials":233,"cells":20144},"bi-layer calcium carbonate",{"EARLY_PHASE1":20145,"PHASE1":20147,"PHASE2":20160,"PHASE3":20162,"PHASE4":20164,"NA":20166},{"trials":20146,"activeCount":101},[],{"trials":20148,"activeCount":101},[20149],{"nctId":20150,"briefTitle":20151,"status":107,"phases":20152,"primaryCompletion":849,"completion":849,"start":20153,"enrollment":1599,"conditions":20154,"interventions":20158},"NCT06293326","A First-in-Human Study to Learn How Well a Bi-Layer Calcium Carbonate Antacid Tablet Works Compared to a Standard, Non-Layered Calcium Carbonate Tablet in Healthy Male Participants",[90],"2024-03-06",[7338,20155,20156,20157,1124],"Indigestion","Stomach Acid Related Symptoms","Nocturnal Stomach Acid Related Symptoms",[20143,20159],"Immediate release calcium carbonate",{"trials":20161,"activeCount":101},[],{"trials":20163,"activeCount":101},[],{"trials":20165,"activeCount":101},[],{"trials":20167,"activeCount":101},[],{"intervention":20159,"totalTrials":233,"cells":20169},{"EARLY_PHASE1":20170,"PHASE1":20172,"PHASE2":20178,"PHASE3":20180,"PHASE4":20182,"NA":20184},{"trials":20171,"activeCount":101},[],{"trials":20173,"activeCount":101},[20174],{"nctId":20150,"briefTitle":20151,"status":107,"phases":20175,"primaryCompletion":849,"completion":849,"start":20153,"enrollment":1599,"conditions":20176,"interventions":20177},[90],[7338,20155,20156,20157,1124],[20143,20159],{"trials":20179,"activeCount":101},[],{"trials":20181,"activeCount":101},[],{"trials":20183,"activeCount":101},[],{"trials":20185,"activeCount":101},[],{"intervention":20187,"totalTrials":233,"cells":20188},"Pecavaptan",{"EARLY_PHASE1":20189,"PHASE1":20191,"PHASE2":20200,"PHASE3":20202,"PHASE4":20204,"NA":20206},{"trials":20190,"activeCount":101},[],{"trials":20192,"activeCount":101},[20193],{"nctId":20194,"briefTitle":20195,"status":107,"phases":20196,"primaryCompletion":12570,"completion":20197,"start":17470,"enrollment":1509,"conditions":20198,"interventions":20199},"NCT05599997","A Study to Learn How the Study Treatment BAY1753011 Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body When Given Once as Tablet in Male and Female Participants With Reduced Kidney Function Compared to Matched Participants With Normal Kidney Function",[90],"2021-05-18",[13202,13239],[20187,20187],{"trials":20201,"activeCount":101},[],{"trials":20203,"activeCount":101},[],{"trials":20205,"activeCount":101},[],{"trials":20207,"activeCount":101},[],{"intervention":116,"totalTrials":233,"cells":20209},{"EARLY_PHASE1":20210,"PHASE1":20212,"PHASE2":20218,"PHASE3":20220,"PHASE4":20222,"NA":20224},{"trials":20211,"activeCount":101},[],{"trials":20213,"activeCount":101},[20214],{"nctId":105,"briefTitle":106,"status":107,"phases":20215,"primaryCompletion":109,"completion":110,"start":111,"enrollment":112,"conditions":20216,"interventions":20217},[90],[114],[116,67],{"trials":20219,"activeCount":101},[],{"trials":20221,"activeCount":101},[],{"trials":20223,"activeCount":101},[],{"trials":20225,"activeCount":101},[],{"intervention":20227,"totalTrials":233,"cells":20228},"BAY 1841788",{"EARLY_PHASE1":20229,"PHASE1":20231,"PHASE2":20240,"PHASE3":20242,"PHASE4":20244,"NA":20246},{"trials":20230,"activeCount":101},[],{"trials":20232,"activeCount":101},[20233],{"nctId":20234,"briefTitle":20235,"status":107,"phases":20236,"primaryCompletion":3639,"completion":20237,"start":4637,"enrollment":4466,"conditions":20238,"interventions":20239},"NCT02363855","Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects",[90],"2018-01-18",[187],[20227],{"trials":20241,"activeCount":101},[],{"trials":20243,"activeCount":101},[],{"trials":20245,"activeCount":101},[],{"trials":20247,"activeCount":101},[],{"intervention":17764,"totalTrials":233,"cells":20249},{"EARLY_PHASE1":20250,"PHASE1":20252,"PHASE2":20258,"PHASE3":20260,"PHASE4":20262,"NA":20264},{"trials":20251,"activeCount":101},[],{"trials":20253,"activeCount":101},[20254],{"nctId":17757,"briefTitle":17758,"status":107,"phases":20255,"primaryCompletion":12631,"completion":17760,"start":17761,"enrollment":1630,"conditions":20256,"interventions":20257},[90],[12672],[17764,17750,17765],{"trials":20259,"activeCount":101},[],{"trials":20261,"activeCount":101},[],{"trials":20263,"activeCount":101},[],{"trials":20265,"activeCount":101},[],{"intervention":17765,"totalTrials":233,"cells":20267},{"EARLY_PHASE1":20268,"PHASE1":20270,"PHASE2":20276,"PHASE3":20278,"PHASE4":20280,"NA":20282},{"trials":20269,"activeCount":101},[],{"trials":20271,"activeCount":101},[20272],{"nctId":17757,"briefTitle":17758,"status":107,"phases":20273,"primaryCompletion":12631,"completion":17760,"start":17761,"enrollment":1630,"conditions":20274,"interventions":20275},[90],[12672],[17764,17750,17765],{"trials":20277,"activeCount":101},[],{"trials":20279,"activeCount":101},[],{"trials":20281,"activeCount":101},[],{"trials":20283,"activeCount":101},[],{"intervention":20285,"totalTrials":233,"cells":20286},"BAY1211163",{"EARLY_PHASE1":20287,"PHASE1":20289,"PHASE2":20299,"PHASE3":20301,"PHASE4":20303,"NA":20305},{"trials":20288,"activeCount":101},[],{"trials":20290,"activeCount":101},[20291],{"nctId":20292,"briefTitle":20293,"status":156,"phases":20294,"primaryCompletion":13236,"completion":20295,"start":20296,"enrollment":1081,"conditions":20297,"interventions":20298},"NCT04609943","Study to Find the Highest Safe Dose of Soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 Administered as Multiple Doses by Inhalation to Patients Who Cannot Breathe by Their Own and Suffer From a Type of Lung Failure That Causes Fluid to Build up in the Lungs Making Breathing Difficult (ARDS)",[90],"2023-09-14","2020-11-24",[16657],[20285],{"trials":20300,"activeCount":101},[],{"trials":20302,"activeCount":101},[],{"trials":20304,"activeCount":101},[],{"trials":20306,"activeCount":101},[],{"intervention":13509,"totalTrials":233,"cells":20308},{"EARLY_PHASE1":20309,"PHASE1":20311,"PHASE2":20317,"PHASE3":20319,"PHASE4":20321,"NA":20323},{"trials":20310,"activeCount":101},[],{"trials":20312,"activeCount":101},[20313],{"nctId":13501,"briefTitle":13502,"status":107,"phases":20314,"primaryCompletion":13504,"completion":13504,"start":13505,"enrollment":6503,"conditions":20315,"interventions":20316},[90],[13507],[7892,13509],{"trials":20318,"activeCount":101},[],{"trials":20320,"activeCount":101},[],{"trials":20322,"activeCount":101},[],{"trials":20324,"activeCount":101},[],{"intervention":20326,"totalTrials":233,"cells":20327},"BAY1251152",{"EARLY_PHASE1":20328,"PHASE1":20330,"PHASE2":20341,"PHASE3":20343,"PHASE4":20345,"NA":20347},{"trials":20329,"activeCount":101},[],{"trials":20331,"activeCount":101},[20332],{"nctId":20333,"briefTitle":20334,"status":107,"phases":20335,"primaryCompletion":20336,"completion":20336,"start":20337,"enrollment":1599,"conditions":20338,"interventions":20340},"NCT02745743","Phase I Trial of BAY1251152 for Advanced Blood Cancers",[90],"2018-08-03","2016-06-17",[20339],"Hematologic Neoplasms",[20326],{"trials":20342,"activeCount":101},[],{"trials":20344,"activeCount":101},[],{"trials":20346,"activeCount":101},[],{"trials":20348,"activeCount":101},[],{"intervention":17015,"totalTrials":233,"cells":20350},{"EARLY_PHASE1":20351,"PHASE1":20353,"PHASE2":20359,"PHASE3":20361,"PHASE4":20363,"NA":20365},{"trials":20352,"activeCount":101},[],{"trials":20354,"activeCount":101},[20355],{"nctId":17007,"briefTitle":17008,"status":107,"phases":20356,"primaryCompletion":17010,"completion":1150,"start":17011,"enrollment":22,"conditions":20357,"interventions":20358},[90],[17013],[12674,12646,17015],{"trials":20360,"activeCount":101},[],{"trials":20362,"activeCount":101},[],{"trials":20364,"activeCount":101},[],{"trials":20366,"activeCount":101},[],{"intervention":20368,"totalTrials":233,"cells":20369},"Alka Seltzer Extra Strength",{"EARLY_PHASE1":20370,"PHASE1":20372,"PHASE2":20382,"PHASE3":20384,"PHASE4":20386,"NA":20388},{"trials":20371,"activeCount":101},[],{"trials":20373,"activeCount":101},[20374],{"nctId":20375,"briefTitle":20376,"status":107,"phases":20377,"primaryCompletion":4596,"completion":4596,"start":2255,"enrollment":124,"conditions":20378,"interventions":20379},"NCT01081353","Pharmacokinetic Study Comparing Aspirin and Effervescent Aspirin",[90],[1790],[3761,20368,20380,20381],"Aspirin Migraine","Aspirin Aspro",{"trials":20383,"activeCount":101},[],{"trials":20385,"activeCount":101},[],{"trials":20387,"activeCount":101},[],{"trials":20389,"activeCount":101},[],{"intervention":20380,"totalTrials":233,"cells":20391},{"EARLY_PHASE1":20392,"PHASE1":20394,"PHASE2":20400,"PHASE3":20402,"PHASE4":20404,"NA":20406},{"trials":20393,"activeCount":101},[],{"trials":20395,"activeCount":101},[20396],{"nctId":20375,"briefTitle":20376,"status":107,"phases":20397,"primaryCompletion":4596,"completion":4596,"start":2255,"enrollment":124,"conditions":20398,"interventions":20399},[90],[1790],[3761,20368,20380,20381],{"trials":20401,"activeCount":101},[],{"trials":20403,"activeCount":101},[],{"trials":20405,"activeCount":101},[],{"trials":20407,"activeCount":101},[],{"intervention":20381,"totalTrials":233,"cells":20409},{"EARLY_PHASE1":20410,"PHASE1":20412,"PHASE2":20418,"PHASE3":20420,"PHASE4":20422,"NA":20424},{"trials":20411,"activeCount":101},[],{"trials":20413,"activeCount":101},[20414],{"nctId":20375,"briefTitle":20376,"status":107,"phases":20415,"primaryCompletion":4596,"completion":4596,"start":2255,"enrollment":124,"conditions":20416,"interventions":20417},[90],[1790],[3761,20368,20380,20381],{"trials":20419,"activeCount":101},[],{"trials":20421,"activeCount":101},[],{"trials":20423,"activeCount":101},[],{"trials":20425,"activeCount":101},[],{"intervention":4607,"totalTrials":233,"cells":20427},{"EARLY_PHASE1":20428,"PHASE1":20430,"PHASE2":20436,"PHASE3":20438,"PHASE4":20440,"NA":20442},{"trials":20429,"activeCount":101},[],{"trials":20431,"activeCount":101},[20432],{"nctId":4602,"briefTitle":4603,"status":107,"phases":20433,"primaryCompletion":548,"completion":4066,"start":3594,"enrollment":2388,"conditions":20434,"interventions":20435},[90],[1490],[42,4607],{"trials":20437,"activeCount":101},[],{"trials":20439,"activeCount":101},[],{"trials":20441,"activeCount":101},[],{"trials":20443,"activeCount":101},[],{"intervention":1523,"totalTrials":233,"cells":20445},{"EARLY_PHASE1":20446,"PHASE1":20448,"PHASE2":20454,"PHASE3":20456,"PHASE4":20458,"NA":20460},{"trials":20447,"activeCount":101},[],{"trials":20449,"activeCount":101},[20450],{"nctId":1514,"briefTitle":1515,"status":107,"phases":20451,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":1519,"conditions":20452,"interventions":20453},[90],[1521],[47,1523,1524,1525,1526,1527],{"trials":20455,"activeCount":101},[],{"trials":20457,"activeCount":101},[],{"trials":20459,"activeCount":101},[],{"trials":20461,"activeCount":101},[],{"intervention":1524,"totalTrials":233,"cells":20463},{"EARLY_PHASE1":20464,"PHASE1":20466,"PHASE2":20472,"PHASE3":20474,"PHASE4":20476,"NA":20478},{"trials":20465,"activeCount":101},[],{"trials":20467,"activeCount":101},[20468],{"nctId":1514,"briefTitle":1515,"status":107,"phases":20469,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":1519,"conditions":20470,"interventions":20471},[90],[1521],[47,1523,1524,1525,1526,1527],{"trials":20473,"activeCount":101},[],{"trials":20475,"activeCount":101},[],{"trials":20477,"activeCount":101},[],{"trials":20479,"activeCount":101},[],{"intervention":1525,"totalTrials":233,"cells":20481},{"EARLY_PHASE1":20482,"PHASE1":20484,"PHASE2":20490,"PHASE3":20492,"PHASE4":20494,"NA":20496},{"trials":20483,"activeCount":101},[],{"trials":20485,"activeCount":101},[20486],{"nctId":1514,"briefTitle":1515,"status":107,"phases":20487,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":1519,"conditions":20488,"interventions":20489},[90],[1521],[47,1523,1524,1525,1526,1527],{"trials":20491,"activeCount":101},[],{"trials":20493,"activeCount":101},[],{"trials":20495,"activeCount":101},[],{"trials":20497,"activeCount":101},[],{"intervention":1526,"totalTrials":233,"cells":20499},{"EARLY_PHASE1":20500,"PHASE1":20502,"PHASE2":20508,"PHASE3":20510,"PHASE4":20512,"NA":20514},{"trials":20501,"activeCount":101},[],{"trials":20503,"activeCount":101},[20504],{"nctId":1514,"briefTitle":1515,"status":107,"phases":20505,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":1519,"conditions":20506,"interventions":20507},[90],[1521],[47,1523,1524,1525,1526,1527],{"trials":20509,"activeCount":101},[],{"trials":20511,"activeCount":101},[],{"trials":20513,"activeCount":101},[],{"trials":20515,"activeCount":101},[],{"intervention":1527,"totalTrials":233,"cells":20517},{"EARLY_PHASE1":20518,"PHASE1":20520,"PHASE2":20526,"PHASE3":20528,"PHASE4":20530,"NA":20532},{"trials":20519,"activeCount":101},[],{"trials":20521,"activeCount":101},[20522],{"nctId":1514,"briefTitle":1515,"status":107,"phases":20523,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":1519,"conditions":20524,"interventions":20525},[90],[1521],[47,1523,1524,1525,1526,1527],{"trials":20527,"activeCount":101},[],{"trials":20529,"activeCount":101},[],{"trials":20531,"activeCount":101},[],{"trials":20533,"activeCount":101},[],{"intervention":20535,"totalTrials":233,"cells":20536},"BAY1179470",{"EARLY_PHASE1":20537,"PHASE1":20539,"PHASE2":20549,"PHASE3":20551,"PHASE4":20553,"NA":20555},{"trials":20538,"activeCount":101},[],{"trials":20540,"activeCount":101},[20541],{"nctId":20542,"briefTitle":20543,"status":107,"phases":20544,"primaryCompletion":20545,"completion":20546,"start":8503,"enrollment":16124,"conditions":20547,"interventions":20548},"NCT01881217","First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors",[90],"2016-03-18","2016-08-16",[29],[20535],{"trials":20550,"activeCount":101},[],{"trials":20552,"activeCount":101},[],{"trials":20554,"activeCount":101},[],{"trials":20556,"activeCount":101},[],{"intervention":12544,"totalTrials":233,"cells":20558},{"EARLY_PHASE1":20559,"PHASE1":20561,"PHASE2":20567,"PHASE3":20569,"PHASE4":20571,"NA":20573},{"trials":20560,"activeCount":101},[],{"trials":20562,"activeCount":101},[20563],{"nctId":12537,"briefTitle":12538,"status":107,"phases":20564,"primaryCompletion":4095,"completion":12540,"start":12541,"enrollment":1181,"conditions":20565,"interventions":20566},[90],[12508,9474,12509,12510],[12494,12544],{"trials":20568,"activeCount":101},[],{"trials":20570,"activeCount":101},[],{"trials":20572,"activeCount":101},[],{"trials":20574,"activeCount":101},[],{"intervention":20576,"totalTrials":233,"cells":20577},"Anastrozole \u002F Levonorgestrel",{"EARLY_PHASE1":20578,"PHASE1":20580,"PHASE2":20593,"PHASE3":20595,"PHASE4":20597,"NA":20599},{"trials":20579,"activeCount":101},[],{"trials":20581,"activeCount":101},[20582],{"nctId":20583,"briefTitle":20584,"status":107,"phases":20585,"primaryCompletion":20586,"completion":20587,"start":1743,"enrollment":19,"conditions":20588,"interventions":20589},"NCT02545452","Effect of Concomitant Use of an Antimycotic, an Antibiotic, a Spermicide or Tampons on Pharmacokinetics of Anastrozole and Levonorgestrel Released From Intra-vaginal Ring",[90],"2016-03-14","2016-07-29",[7793],[20576,20590,20591,20592],"Gyno-Daktarin","Sobelin vaginal creme","Patentex oval",{"trials":20594,"activeCount":101},[],{"trials":20596,"activeCount":101},[],{"trials":20598,"activeCount":101},[],{"trials":20600,"activeCount":101},[],{"intervention":20590,"totalTrials":233,"cells":20602},{"EARLY_PHASE1":20603,"PHASE1":20605,"PHASE2":20611,"PHASE3":20613,"PHASE4":20615,"NA":20617},{"trials":20604,"activeCount":101},[],{"trials":20606,"activeCount":101},[20607],{"nctId":20583,"briefTitle":20584,"status":107,"phases":20608,"primaryCompletion":20586,"completion":20587,"start":1743,"enrollment":19,"conditions":20609,"interventions":20610},[90],[7793],[20576,20590,20591,20592],{"trials":20612,"activeCount":101},[],{"trials":20614,"activeCount":101},[],{"trials":20616,"activeCount":101},[],{"trials":20618,"activeCount":101},[],{"intervention":20591,"totalTrials":233,"cells":20620},{"EARLY_PHASE1":20621,"PHASE1":20623,"PHASE2":20629,"PHASE3":20631,"PHASE4":20633,"NA":20635},{"trials":20622,"activeCount":101},[],{"trials":20624,"activeCount":101},[20625],{"nctId":20583,"briefTitle":20584,"status":107,"phases":20626,"primaryCompletion":20586,"completion":20587,"start":1743,"enrollment":19,"conditions":20627,"interventions":20628},[90],[7793],[20576,20590,20591,20592],{"trials":20630,"activeCount":101},[],{"trials":20632,"activeCount":101},[],{"trials":20634,"activeCount":101},[],{"trials":20636,"activeCount":101},[],{"intervention":20592,"totalTrials":233,"cells":20638},{"EARLY_PHASE1":20639,"PHASE1":20641,"PHASE2":20647,"PHASE3":20649,"PHASE4":20651,"NA":20653},{"trials":20640,"activeCount":101},[],{"trials":20642,"activeCount":101},[20643],{"nctId":20583,"briefTitle":20584,"status":107,"phases":20644,"primaryCompletion":20586,"completion":20587,"start":1743,"enrollment":19,"conditions":20645,"interventions":20646},[90],[7793],[20576,20590,20591,20592],{"trials":20648,"activeCount":101},[],{"trials":20650,"activeCount":101},[],{"trials":20652,"activeCount":101},[],{"trials":20654,"activeCount":101},[],{"intervention":20656,"totalTrials":233,"cells":20657},"Phenylephrine HCl Extended Release",{"EARLY_PHASE1":20658,"PHASE1":20660,"PHASE2":20669,"PHASE3":20671,"PHASE4":20673,"NA":20675},{"trials":20659,"activeCount":101},[],{"trials":20661,"activeCount":101},[20662],{"nctId":20663,"briefTitle":20664,"status":107,"phases":20665,"primaryCompletion":1327,"completion":2366,"start":3618,"enrollment":1701,"conditions":20666,"interventions":20667},"NCT01354418","Bioequivalence of Single Dose Phenylephrine Extended Release Tablets and Phenylephrine HCl Immediate Release Tablets Dosed Every Four Hours (P08340)(COMPLETED)",[90],[2128],[20656,20668],"Phenylephrine HCl Immediate Release",{"trials":20670,"activeCount":101},[],{"trials":20672,"activeCount":101},[],{"trials":20674,"activeCount":101},[],{"trials":20676,"activeCount":101},[],{"intervention":20668,"totalTrials":233,"cells":20678},{"EARLY_PHASE1":20679,"PHASE1":20681,"PHASE2":20687,"PHASE3":20689,"PHASE4":20691,"NA":20693},{"trials":20680,"activeCount":101},[],{"trials":20682,"activeCount":101},[20683],{"nctId":20663,"briefTitle":20664,"status":107,"phases":20684,"primaryCompletion":1327,"completion":2366,"start":3618,"enrollment":1701,"conditions":20685,"interventions":20686},[90],[2128],[20656,20668],{"trials":20688,"activeCount":101},[],{"trials":20690,"activeCount":101},[],{"trials":20692,"activeCount":101},[],{"trials":20694,"activeCount":101},[],{"intervention":20696,"totalTrials":233,"cells":20697},"Lupartumab Amadotin",{"EARLY_PHASE1":20698,"PHASE1":20700,"PHASE2":20709,"PHASE3":20711,"PHASE4":20713,"NA":20715},{"trials":20699,"activeCount":101},[],{"trials":20701,"activeCount":101},[20702],{"nctId":20703,"briefTitle":20704,"status":156,"phases":20705,"primaryCompletion":6428,"completion":6428,"start":20706,"enrollment":13838,"conditions":20707,"interventions":20708},"NCT02134197","Dose-escalation Study of Lupartumab Amadotin (BAY1129980)",[90],"2014-05-22",[29],[20696],{"trials":20710,"activeCount":101},[],{"trials":20712,"activeCount":101},[],{"trials":20714,"activeCount":101},[],{"trials":20716,"activeCount":101},[],{"intervention":20718,"totalTrials":233,"cells":20719},"Finerenone (BAY94-8862): 20 mg intact",{"EARLY_PHASE1":20720,"PHASE1":20722,"PHASE2":20734,"PHASE3":20736,"PHASE4":20738,"NA":20740},{"trials":20721,"activeCount":101},[],{"trials":20723,"activeCount":101},[20724],{"nctId":20725,"briefTitle":20726,"status":107,"phases":20727,"primaryCompletion":20728,"completion":529,"start":20729,"enrollment":1081,"conditions":20730,"interventions":20731},"NCT02957396","Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects",[90],"2017-01-13","2016-11-17",[1790],[20718,20732,20733],"Finerenone (BAY94-8862): 20 mg crushed and resuspended","Finerenone (BAY94-8862): 20 mg suspension",{"trials":20735,"activeCount":101},[],{"trials":20737,"activeCount":101},[],{"trials":20739,"activeCount":101},[],{"trials":20741,"activeCount":101},[],{"intervention":20732,"totalTrials":233,"cells":20743},{"EARLY_PHASE1":20744,"PHASE1":20746,"PHASE2":20752,"PHASE3":20754,"PHASE4":20756,"NA":20758},{"trials":20745,"activeCount":101},[],{"trials":20747,"activeCount":101},[20748],{"nctId":20725,"briefTitle":20726,"status":107,"phases":20749,"primaryCompletion":20728,"completion":529,"start":20729,"enrollment":1081,"conditions":20750,"interventions":20751},[90],[1790],[20718,20732,20733],{"trials":20753,"activeCount":101},[],{"trials":20755,"activeCount":101},[],{"trials":20757,"activeCount":101},[],{"trials":20759,"activeCount":101},[],{"intervention":20733,"totalTrials":233,"cells":20761},{"EARLY_PHASE1":20762,"PHASE1":20764,"PHASE2":20770,"PHASE3":20772,"PHASE4":20774,"NA":20776},{"trials":20763,"activeCount":101},[],{"trials":20765,"activeCount":101},[20766],{"nctId":20725,"briefTitle":20726,"status":107,"phases":20767,"primaryCompletion":20728,"completion":529,"start":20729,"enrollment":1081,"conditions":20768,"interventions":20769},[90],[1790],[20718,20732,20733],{"trials":20771,"activeCount":101},[],{"trials":20773,"activeCount":101},[],{"trials":20775,"activeCount":101},[],{"trials":20777,"activeCount":101},[],{"intervention":20779,"totalTrials":233,"cells":20780},"Rogaratinib (BAY1163877) oral solution",{"EARLY_PHASE1":20781,"PHASE1":20783,"PHASE2":20796,"PHASE3":20798,"PHASE4":20800,"NA":20802},{"trials":20782,"activeCount":101},[],{"trials":20784,"activeCount":101},[20785],{"nctId":20786,"briefTitle":20787,"status":107,"phases":20788,"primaryCompletion":20789,"completion":3863,"start":20790,"enrollment":20791,"conditions":20792,"interventions":20793},"NCT01976741","Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)",[90],"2019-03-11","2013-12-30",168,[29],[20779,20794,20795],"Rogaratinib (BAY1163877) oral","Rogaratinib (BAY1163877) 800 mg BID",{"trials":20797,"activeCount":101},[],{"trials":20799,"activeCount":101},[],{"trials":20801,"activeCount":101},[],{"trials":20803,"activeCount":101},[],{"intervention":20794,"totalTrials":233,"cells":20805},{"EARLY_PHASE1":20806,"PHASE1":20808,"PHASE2":20814,"PHASE3":20816,"PHASE4":20818,"NA":20820},{"trials":20807,"activeCount":101},[],{"trials":20809,"activeCount":101},[20810],{"nctId":20786,"briefTitle":20787,"status":107,"phases":20811,"primaryCompletion":20789,"completion":3863,"start":20790,"enrollment":20791,"conditions":20812,"interventions":20813},[90],[29],[20779,20794,20795],{"trials":20815,"activeCount":101},[],{"trials":20817,"activeCount":101},[],{"trials":20819,"activeCount":101},[],{"trials":20821,"activeCount":101},[],{"intervention":20795,"totalTrials":233,"cells":20823},{"EARLY_PHASE1":20824,"PHASE1":20826,"PHASE2":20832,"PHASE3":20834,"PHASE4":20836,"NA":20838},{"trials":20825,"activeCount":101},[],{"trials":20827,"activeCount":101},[20828],{"nctId":20786,"briefTitle":20787,"status":107,"phases":20829,"primaryCompletion":20789,"completion":3863,"start":20790,"enrollment":20791,"conditions":20830,"interventions":20831},[90],[29],[20779,20794,20795],{"trials":20833,"activeCount":101},[],{"trials":20835,"activeCount":101},[],{"trials":20837,"activeCount":101},[],{"trials":20839,"activeCount":101},[],{"intervention":20841,"totalTrials":233,"cells":20842},"Single oral dose of BAY3283142 IR (immediate release)",{"EARLY_PHASE1":20843,"PHASE1":20845,"PHASE2":20856,"PHASE3":20858,"PHASE4":20860,"NA":20862},{"trials":20844,"activeCount":101},[],{"trials":20846,"activeCount":101},[20847],{"nctId":20848,"briefTitle":20849,"status":107,"phases":20850,"primaryCompletion":20851,"completion":20852,"start":20853,"enrollment":510,"conditions":20854,"interventions":20855},"NCT05515432","A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight",[90],"2023-03-07","2023-06-06","2022-08-11",[32,13239,1124],[20841],{"trials":20857,"activeCount":101},[],{"trials":20859,"activeCount":101},[],{"trials":20861,"activeCount":101},[],{"trials":20863,"activeCount":101},[],{"intervention":2243,"totalTrials":233,"cells":20865},{"EARLY_PHASE1":20866,"PHASE1":20868,"PHASE2":20874,"PHASE3":20876,"PHASE4":20878,"NA":20880},{"trials":20867,"activeCount":101},[],{"trials":20869,"activeCount":101},[20870],{"nctId":2235,"briefTitle":2236,"status":107,"phases":20871,"primaryCompletion":2238,"completion":2239,"start":2240,"enrollment":2212,"conditions":20872,"interventions":20873},[90],[29],[2243,1115,1011],{"trials":20875,"activeCount":101},[],{"trials":20877,"activeCount":101},[],{"trials":20879,"activeCount":101},[],{"trials":20881,"activeCount":101},[],{"intervention":12659,"totalTrials":233,"cells":20883},{"EARLY_PHASE1":20884,"PHASE1":20886,"PHASE2":20892,"PHASE3":20894,"PHASE4":20896,"NA":20898},{"trials":20885,"activeCount":101},[],{"trials":20887,"activeCount":101},[20888],{"nctId":12653,"briefTitle":12654,"status":107,"phases":20889,"primaryCompletion":12656,"completion":399,"start":3031,"enrollment":229,"conditions":20890,"interventions":20891},[90],[7793],[12659,12660,1154],{"trials":20893,"activeCount":101},[],{"trials":20895,"activeCount":101},[],{"trials":20897,"activeCount":101},[],{"trials":20899,"activeCount":101},[],{"intervention":20901,"totalTrials":233,"cells":20902},"Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole",{"EARLY_PHASE1":20903,"PHASE1":20905,"PHASE2":20913,"PHASE3":20915,"PHASE4":20917,"NA":20919},{"trials":20904,"activeCount":101},[],{"trials":20906,"activeCount":101},[20907],{"nctId":20908,"briefTitle":20909,"status":107,"phases":20910,"primaryCompletion":2366,"completion":2366,"start":5975,"enrollment":1701,"conditions":20911,"interventions":20912},"NCT01318265","Effect of Ketoconazole on Regorafenib (BAY73-4506) Pharmacokinetics",[90],[1790],[20901],{"trials":20914,"activeCount":101},[],{"trials":20916,"activeCount":101},[],{"trials":20918,"activeCount":101},[],{"trials":20920,"activeCount":101},[],{"intervention":20922,"totalTrials":233,"cells":20923},"Nifedipine gastrointestinal therapeutic system (GITS) (Adalat LA, BAY a1040) + Candesartan cilexetil",{"EARLY_PHASE1":20924,"PHASE1":20926,"PHASE2":20936,"PHASE3":20938,"PHASE4":20940,"NA":20942},{"trials":20925,"activeCount":101},[],{"trials":20927,"activeCount":101},[20928],{"nctId":20929,"briefTitle":20930,"status":107,"phases":20931,"primaryCompletion":20932,"completion":20932,"start":20933,"enrollment":4620,"conditions":20934,"interventions":20935},"NCT03136666","Single Dose Escalation Study to Investigate the Pharmacokinetics as Well as Safety and Tolerability of a Concomitant Administration of Nifedipne GITS and Candesartan Tablets Under Fasting Conditions in Healthy Male Subjects in an Open Label, Non-randomized, Sequential Design.",[90],"2010-06-07","2010-04-19",[1536],[20922],{"trials":20937,"activeCount":101},[],{"trials":20939,"activeCount":101},[],{"trials":20941,"activeCount":101},[],{"trials":20943,"activeCount":101},[],{"intervention":20945,"totalTrials":233,"cells":20946},"BAY3630942",{"EARLY_PHASE1":20947,"PHASE1":20949,"PHASE2":20960,"PHASE3":20962,"PHASE4":20964,"NA":20966},{"trials":20948,"activeCount":101},[],{"trials":20950,"activeCount":101},[20951],{"nctId":20952,"briefTitle":20953,"status":107,"phases":20954,"primaryCompletion":20955,"completion":61,"start":20956,"enrollment":1181,"conditions":20957,"interventions":20958},"NCT06345001","A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers",[90],"2025-03-10","2024-08-26",[13550,13445],[20945,20959],"BAY3547922",{"trials":20961,"activeCount":101},[],{"trials":20963,"activeCount":101},[],{"trials":20965,"activeCount":101},[],{"trials":20967,"activeCount":101},[],{"intervention":20959,"totalTrials":233,"cells":20969},{"EARLY_PHASE1":20970,"PHASE1":20972,"PHASE2":20978,"PHASE3":20980,"PHASE4":20982,"NA":20984},{"trials":20971,"activeCount":101},[],{"trials":20973,"activeCount":101},[20974],{"nctId":20952,"briefTitle":20953,"status":107,"phases":20975,"primaryCompletion":20955,"completion":61,"start":20956,"enrollment":1181,"conditions":20976,"interventions":20977},[90],[13550,13445],[20945,20959],{"trials":20979,"activeCount":101},[],{"trials":20981,"activeCount":101},[],{"trials":20983,"activeCount":101},[],{"trials":20985,"activeCount":101},[],{"intervention":17773,"totalTrials":233,"cells":20987},{"EARLY_PHASE1":20988,"PHASE1":20990,"PHASE2":20996,"PHASE3":20998,"PHASE4":21000,"NA":21002},{"trials":20989,"activeCount":101},[],{"trials":20991,"activeCount":101},[20992],{"nctId":17767,"briefTitle":17768,"status":156,"phases":20993,"primaryCompletion":17770,"completion":4441,"start":15446,"enrollment":1509,"conditions":20994,"interventions":20995},[90],[12672],[17773,17774,17775,17776,17777,17778,17750],{"trials":20997,"activeCount":101},[],{"trials":20999,"activeCount":101},[],{"trials":21001,"activeCount":101},[],{"trials":21003,"activeCount":101},[],{"intervention":17774,"totalTrials":233,"cells":21005},{"EARLY_PHASE1":21006,"PHASE1":21008,"PHASE2":21014,"PHASE3":21016,"PHASE4":21018,"NA":21020},{"trials":21007,"activeCount":101},[],{"trials":21009,"activeCount":101},[21010],{"nctId":17767,"briefTitle":17768,"status":156,"phases":21011,"primaryCompletion":17770,"completion":4441,"start":15446,"enrollment":1509,"conditions":21012,"interventions":21013},[90],[12672],[17773,17774,17775,17776,17777,17778,17750],{"trials":21015,"activeCount":101},[],{"trials":21017,"activeCount":101},[],{"trials":21019,"activeCount":101},[],{"trials":21021,"activeCount":101},[],{"intervention":17775,"totalTrials":233,"cells":21023},{"EARLY_PHASE1":21024,"PHASE1":21026,"PHASE2":21032,"PHASE3":21034,"PHASE4":21036,"NA":21038},{"trials":21025,"activeCount":101},[],{"trials":21027,"activeCount":101},[21028],{"nctId":17767,"briefTitle":17768,"status":156,"phases":21029,"primaryCompletion":17770,"completion":4441,"start":15446,"enrollment":1509,"conditions":21030,"interventions":21031},[90],[12672],[17773,17774,17775,17776,17777,17778,17750],{"trials":21033,"activeCount":101},[],{"trials":21035,"activeCount":101},[],{"trials":21037,"activeCount":101},[],{"trials":21039,"activeCount":101},[],{"intervention":17776,"totalTrials":233,"cells":21041},{"EARLY_PHASE1":21042,"PHASE1":21044,"PHASE2":21050,"PHASE3":21052,"PHASE4":21054,"NA":21056},{"trials":21043,"activeCount":101},[],{"trials":21045,"activeCount":101},[21046],{"nctId":17767,"briefTitle":17768,"status":156,"phases":21047,"primaryCompletion":17770,"completion":4441,"start":15446,"enrollment":1509,"conditions":21048,"interventions":21049},[90],[12672],[17773,17774,17775,17776,17777,17778,17750],{"trials":21051,"activeCount":101},[],{"trials":21053,"activeCount":101},[],{"trials":21055,"activeCount":101},[],{"trials":21057,"activeCount":101},[],{"intervention":17777,"totalTrials":233,"cells":21059},{"EARLY_PHASE1":21060,"PHASE1":21062,"PHASE2":21068,"PHASE3":21070,"PHASE4":21072,"NA":21074},{"trials":21061,"activeCount":101},[],{"trials":21063,"activeCount":101},[21064],{"nctId":17767,"briefTitle":17768,"status":156,"phases":21065,"primaryCompletion":17770,"completion":4441,"start":15446,"enrollment":1509,"conditions":21066,"interventions":21067},[90],[12672],[17773,17774,17775,17776,17777,17778,17750],{"trials":21069,"activeCount":101},[],{"trials":21071,"activeCount":101},[],{"trials":21073,"activeCount":101},[],{"trials":21075,"activeCount":101},[],{"intervention":17778,"totalTrials":233,"cells":21077},{"EARLY_PHASE1":21078,"PHASE1":21080,"PHASE2":21086,"PHASE3":21088,"PHASE4":21090,"NA":21092},{"trials":21079,"activeCount":101},[],{"trials":21081,"activeCount":101},[21082],{"nctId":17767,"briefTitle":17768,"status":156,"phases":21083,"primaryCompletion":17770,"completion":4441,"start":15446,"enrollment":1509,"conditions":21084,"interventions":21085},[90],[12672],[17773,17774,17775,17776,17777,17778,17750],{"trials":21087,"activeCount":101},[],{"trials":21089,"activeCount":101},[],{"trials":21091,"activeCount":101},[],{"trials":21093,"activeCount":101},[],{"intervention":21095,"totalTrials":233,"cells":21096},"BAY2402234",{"EARLY_PHASE1":21097,"PHASE1":21099,"PHASE2":21108,"PHASE3":21110,"PHASE4":21112,"NA":21114},{"trials":21098,"activeCount":101},[],{"trials":21100,"activeCount":101},[21101],{"nctId":21102,"briefTitle":21103,"status":156,"phases":21104,"primaryCompletion":21105,"completion":21105,"start":17024,"enrollment":1519,"conditions":21106,"interventions":21107},"NCT03404726","A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies",[90],"2021-01-26",[8453],[21095],{"trials":21109,"activeCount":101},[],{"trials":21111,"activeCount":101},[],{"trials":21113,"activeCount":101},[],{"trials":21115,"activeCount":101},[],{"intervention":12952,"totalTrials":233,"cells":21117},{"EARLY_PHASE1":21118,"PHASE1":21120,"PHASE2":21126,"PHASE3":21128,"PHASE4":21130,"NA":21132},{"trials":21119,"activeCount":101},[],{"trials":21121,"activeCount":101},[21122],{"nctId":12944,"briefTitle":12945,"status":107,"phases":21123,"primaryCompletion":12947,"completion":12948,"start":12949,"enrollment":6678,"conditions":21124,"interventions":21125},[90],[4660],[1281,12952],{"trials":21127,"activeCount":101},[],{"trials":21129,"activeCount":101},[],{"trials":21131,"activeCount":101},[],{"trials":21133,"activeCount":101},[],{"intervention":21135,"totalTrials":233,"cells":21136},"Fluconazole (BAYT006267) 150 mg",{"EARLY_PHASE1":21137,"PHASE1":21139,"PHASE2":21150,"PHASE3":21152,"PHASE4":21154,"NA":21156},{"trials":21138,"activeCount":101},[],{"trials":21140,"activeCount":101},[21141],{"nctId":21142,"briefTitle":21143,"status":107,"phases":21144,"primaryCompletion":21145,"completion":21145,"start":21146,"enrollment":124,"conditions":21147,"interventions":21148},"NCT03929861","Bioequivalence Trial to Prove Equal Blood Concentrations of Two Different Fluconazole Formulations",[90],"2012-09-10","2012-07-31",[1511],[21135,21149],"Fluconazole 150 mg",{"trials":21151,"activeCount":101},[],{"trials":21153,"activeCount":101},[],{"trials":21155,"activeCount":101},[],{"trials":21157,"activeCount":101},[],{"intervention":21149,"totalTrials":233,"cells":21159},{"EARLY_PHASE1":21160,"PHASE1":21162,"PHASE2":21168,"PHASE3":21170,"PHASE4":21172,"NA":21174},{"trials":21161,"activeCount":101},[],{"trials":21163,"activeCount":101},[21164],{"nctId":21142,"briefTitle":21143,"status":107,"phases":21165,"primaryCompletion":21145,"completion":21145,"start":21146,"enrollment":124,"conditions":21166,"interventions":21167},[90],[1511],[21135,21149],{"trials":21169,"activeCount":101},[],{"trials":21171,"activeCount":101},[],{"trials":21173,"activeCount":101},[],{"trials":21175,"activeCount":101},[],{"intervention":21177,"totalTrials":233,"cells":21178},"Damoctocog",{"EARLY_PHASE1":21179,"PHASE1":21181,"PHASE2":21192,"PHASE3":21194,"PHASE4":21196,"NA":21198},{"trials":21180,"activeCount":101},[],{"trials":21182,"activeCount":101},[21183],{"nctId":21184,"briefTitle":21185,"status":107,"phases":21186,"primaryCompletion":21187,"completion":21188,"start":13816,"enrollment":1163,"conditions":21189,"interventions":21190},"NCT03364998","BAY94-9027 PK Study Comparing to Another Long Acting Product",[90],"2018-01-25","2018-09-28",[24],[21177,21191],"Elocta",{"trials":21193,"activeCount":101},[],{"trials":21195,"activeCount":101},[],{"trials":21197,"activeCount":101},[],{"trials":21199,"activeCount":101},[],{"intervention":21191,"totalTrials":233,"cells":21201},{"EARLY_PHASE1":21202,"PHASE1":21204,"PHASE2":21210,"PHASE3":21212,"PHASE4":21214,"NA":21216},{"trials":21203,"activeCount":101},[],{"trials":21205,"activeCount":101},[21206],{"nctId":21184,"briefTitle":21185,"status":107,"phases":21207,"primaryCompletion":21187,"completion":21188,"start":13816,"enrollment":1163,"conditions":21208,"interventions":21209},[90],[24],[21177,21191],{"trials":21211,"activeCount":101},[],{"trials":21213,"activeCount":101},[],{"trials":21215,"activeCount":101},[],{"trials":21217,"activeCount":101},[],{"intervention":21219,"totalTrials":233,"cells":21220},"BAY2433334 single dose in treatment groups 1-4 and 6 as well as on the dialysis free day of treatment 5",{"EARLY_PHASE1":21221,"PHASE1":21223,"PHASE2":21232,"PHASE3":21234,"PHASE4":21236,"NA":21238},{"trials":21222,"activeCount":101},[],{"trials":21224,"activeCount":101},[21225],{"nctId":21226,"briefTitle":21227,"status":107,"phases":21228,"primaryCompletion":21229,"completion":4048,"start":12506,"enrollment":25,"conditions":21230,"interventions":21231},"NCT04510987","Study to Assess the Safety, Tolerability, Effects on the Body, Absorption, Distribution and Elimination of 25 mg BAY2433334 in Renal Impairment Including Renal Replacement Therapy (\"Dialysis\")",[90],"2021-09-13",[8646],[21219],{"trials":21233,"activeCount":101},[],{"trials":21235,"activeCount":101},[],{"trials":21237,"activeCount":101},[],{"trials":21239,"activeCount":101},[],{"intervention":21241,"totalTrials":233,"cells":21242},"Riociguat (Adempas, BAY63-2521) immediate release tablet of 2.5 mg",{"EARLY_PHASE1":21243,"PHASE1":21245,"PHASE2":21253,"PHASE3":21255,"PHASE4":21257,"NA":21259},{"trials":21244,"activeCount":101},[],{"trials":21246,"activeCount":101},[21247],{"nctId":21248,"briefTitle":21249,"status":107,"phases":21250,"primaryCompletion":499,"completion":549,"start":1313,"enrollment":4580,"conditions":21251,"interventions":21252},"NCT00855660","Effect of Riociguat on Bone Metabolism",[90],[1511],[21241],{"trials":21254,"activeCount":101},[],{"trials":21256,"activeCount":101},[],{"trials":21258,"activeCount":101},[],{"trials":21260,"activeCount":101},[],{"intervention":21262,"totalTrials":233,"cells":21263},"BAY1143269",{"EARLY_PHASE1":21264,"PHASE1":21266,"PHASE2":21276,"PHASE3":21278,"PHASE4":21280,"NA":21282},{"trials":21265,"activeCount":101},[],{"trials":21267,"activeCount":101},[21268],{"nctId":21269,"briefTitle":21270,"status":156,"phases":21271,"primaryCompletion":21272,"completion":21273,"start":4096,"enrollment":1949,"conditions":21274,"interventions":21275},"NCT02439346","Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel",[90],"2017-03-27","2017-04-24",[1267],[21262],{"trials":21277,"activeCount":101},[],{"trials":21279,"activeCount":101},[],{"trials":21281,"activeCount":101},[],{"trials":21283,"activeCount":101},[],{"intervention":21285,"totalTrials":233,"cells":21286},"BAY1237592",{"EARLY_PHASE1":21287,"PHASE1":21289,"PHASE2":21300,"PHASE3":21302,"PHASE4":21304,"NA":21306},{"trials":21288,"activeCount":101},[],{"trials":21290,"activeCount":101},[21291],{"nctId":21292,"briefTitle":21293,"status":107,"phases":21294,"primaryCompletion":21295,"completion":21296,"start":17504,"enrollment":21297,"conditions":21298,"interventions":21299},"NCT03754660","This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)",[90],"2022-04-24","2022-11-03",38,[1500],[21285],{"trials":21301,"activeCount":101},[],{"trials":21303,"activeCount":101},[],{"trials":21305,"activeCount":101},[],{"trials":21307,"activeCount":101},[],{"intervention":21309,"totalTrials":233,"cells":21310},"BAY 44-4400",{"EARLY_PHASE1":21311,"PHASE1":21313,"PHASE2":21324,"PHASE3":21326,"PHASE4":21328,"NA":21330},{"trials":21312,"activeCount":101},[],{"trials":21314,"activeCount":101},[21315],{"nctId":21316,"briefTitle":21317,"status":107,"phases":21318,"primaryCompletion":21319,"completion":21319,"start":3371,"enrollment":1181,"conditions":21320,"interventions":21323},"NCT06412926","A Study to Learn About How Much Emodepside Gets Absorbed in the Blood and How Food Affects Its Absorption When Given as a New Type of Tablet to Healthy Participants",[90],"2024-08-27",[21321,21322],"Soil-transmitted Helminth Infection","Onchocerciasis (River Blindness)",[21309,21309],{"trials":21325,"activeCount":101},[],{"trials":21327,"activeCount":101},[],{"trials":21329,"activeCount":101},[],{"trials":21331,"activeCount":101},[],{"intervention":21333,"totalTrials":233,"cells":21334},"Regorafenib (BAY73-4506) - sequential \u002F Cisplatin \u002F Pemetrexed",{"EARLY_PHASE1":21335,"PHASE1":21337,"PHASE2":21346,"PHASE3":21348,"PHASE4":21350,"NA":21352},{"trials":21336,"activeCount":101},[],{"trials":21338,"activeCount":101},[21339],{"nctId":21340,"briefTitle":21341,"status":156,"phases":21342,"primaryCompletion":1585,"completion":1585,"start":1587,"enrollment":4466,"conditions":21343,"interventions":21344},"NCT01187615","Determination of Safety, Efficacy, and Pharmacokinetics of \"Regorafenib\" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer",[90],[1305],[21333,21345],"Regorafenib (BAY73-4506) - continuous \u002F Cisplatin \u002F Pemetrexed",{"trials":21347,"activeCount":101},[],{"trials":21349,"activeCount":101},[],{"trials":21351,"activeCount":101},[],{"trials":21353,"activeCount":101},[],{"intervention":21345,"totalTrials":233,"cells":21355},{"EARLY_PHASE1":21356,"PHASE1":21358,"PHASE2":21364,"PHASE3":21366,"PHASE4":21368,"NA":21370},{"trials":21357,"activeCount":101},[],{"trials":21359,"activeCount":101},[21360],{"nctId":21340,"briefTitle":21341,"status":156,"phases":21361,"primaryCompletion":1585,"completion":1585,"start":1587,"enrollment":4466,"conditions":21362,"interventions":21363},[90],[1305],[21333,21345],{"trials":21365,"activeCount":101},[],{"trials":21367,"activeCount":101},[],{"trials":21369,"activeCount":101},[],{"trials":21371,"activeCount":101},[],{"intervention":5918,"totalTrials":233,"cells":21373},{"EARLY_PHASE1":21374,"PHASE1":21376,"PHASE2":21382,"PHASE3":21384,"PHASE4":21386,"NA":21388},{"trials":21375,"activeCount":101},[],{"trials":21377,"activeCount":101},[21378],{"nctId":5908,"briefTitle":5909,"status":107,"phases":21379,"primaryCompletion":5911,"completion":5912,"start":5913,"enrollment":4934,"conditions":21380,"interventions":21381},[90],[5915],[5917,5918,1492,5919],{"trials":21383,"activeCount":101},[],{"trials":21385,"activeCount":101},[],{"trials":21387,"activeCount":101},[],{"trials":21389,"activeCount":101},[],{"intervention":5919,"totalTrials":233,"cells":21391},{"EARLY_PHASE1":21392,"PHASE1":21394,"PHASE2":21400,"PHASE3":21402,"PHASE4":21404,"NA":21406},{"trials":21393,"activeCount":101},[],{"trials":21395,"activeCount":101},[21396],{"nctId":5908,"briefTitle":5909,"status":107,"phases":21397,"primaryCompletion":5911,"completion":5912,"start":5913,"enrollment":4934,"conditions":21398,"interventions":21399},[90],[5915],[5917,5918,1492,5919],{"trials":21401,"activeCount":101},[],{"trials":21403,"activeCount":101},[],{"trials":21405,"activeCount":101},[],{"trials":21407,"activeCount":101},[],{"intervention":21409,"totalTrials":233,"cells":21410},"BAY2862789",{"EARLY_PHASE1":21411,"PHASE1":21413,"PHASE2":21424,"PHASE3":21426,"PHASE4":21428,"NA":21430},{"trials":21412,"activeCount":101},[],{"trials":21414,"activeCount":101},[21415],{"nctId":21416,"briefTitle":21417,"status":107,"phases":21418,"primaryCompletion":21419,"completion":21419,"start":21420,"enrollment":510,"conditions":21421,"interventions":21423},"NCT05858164","A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors",[90],"2025-09-26","2023-08-07",[997,21422],"Non-small Cell Lung Cancer",[21409],{"trials":21425,"activeCount":101},[],{"trials":21427,"activeCount":101},[],{"trials":21429,"activeCount":101},[],{"trials":21431,"activeCount":101},[],{"intervention":6465,"totalTrials":233,"cells":21433},{"EARLY_PHASE1":21434,"PHASE1":21436,"PHASE2":21442,"PHASE3":21444,"PHASE4":21446,"NA":21448},{"trials":21435,"activeCount":101},[],{"trials":21437,"activeCount":101},[21438],{"nctId":6460,"briefTitle":6461,"status":107,"phases":21439,"primaryCompletion":3619,"completion":3619,"start":4700,"enrollment":171,"conditions":21440,"interventions":21441},[90],[1790],[6174,6465],{"trials":21443,"activeCount":101},[],{"trials":21445,"activeCount":101},[],{"trials":21447,"activeCount":101},[],{"trials":21449,"activeCount":101},[],{"intervention":21451,"totalTrials":233,"cells":21452},"Sorafenib (BAY43-9006) Film-coated",{"EARLY_PHASE1":21453,"PHASE1":21455,"PHASE2":21466,"PHASE3":21468,"PHASE4":21470,"NA":21472},{"trials":21454,"activeCount":101},[],{"trials":21456,"activeCount":101},[21457],{"nctId":21458,"briefTitle":21459,"status":107,"phases":21460,"primaryCompletion":21461,"completion":4489,"start":21462,"enrollment":160,"conditions":21463,"interventions":21464},"NCT02538393","Relative Bioavailability of Sorafenib Tablet for Oral Suspension",[90],"2016-03-15","2015-11-20",[3603],[21451,21465],"Sorafenib (BAY43-9006) Oral suspension",{"trials":21467,"activeCount":101},[],{"trials":21469,"activeCount":101},[],{"trials":21471,"activeCount":101},[],{"trials":21473,"activeCount":101},[],{"intervention":21465,"totalTrials":233,"cells":21475},{"EARLY_PHASE1":21476,"PHASE1":21478,"PHASE2":21484,"PHASE3":21486,"PHASE4":21488,"NA":21490},{"trials":21477,"activeCount":101},[],{"trials":21479,"activeCount":101},[21480],{"nctId":21458,"briefTitle":21459,"status":107,"phases":21481,"primaryCompletion":21461,"completion":4489,"start":21462,"enrollment":160,"conditions":21482,"interventions":21483},[90],[3603],[21451,21465],{"trials":21485,"activeCount":101},[],{"trials":21487,"activeCount":101},[],{"trials":21489,"activeCount":101},[],{"trials":21491,"activeCount":101},[],{"intervention":21493,"totalTrials":233,"cells":21494},"BAY1214784",{"EARLY_PHASE1":21495,"PHASE1":21497,"PHASE2":21505,"PHASE3":21507,"PHASE4":21509,"NA":21511},{"trials":21496,"activeCount":101},[],{"trials":21498,"activeCount":101},[21499],{"nctId":21500,"briefTitle":21501,"status":107,"phases":21502,"primaryCompletion":1486,"completion":1486,"start":1542,"enrollment":25,"conditions":21503,"interventions":21504},"NCT02212080","First in Human Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1214784",[90],[12553],[21493],{"trials":21506,"activeCount":101},[],{"trials":21508,"activeCount":101},[],{"trials":21510,"activeCount":101},[],{"trials":21512,"activeCount":101},[],{"intervention":21514,"totalTrials":233,"cells":21515},"BAY81-8973",{"EARLY_PHASE1":21516,"PHASE1":21518,"PHASE2":21527,"PHASE3":21529,"PHASE4":21531,"NA":21533},{"trials":21517,"activeCount":101},[],{"trials":21519,"activeCount":101},[21520],{"nctId":21521,"briefTitle":21522,"status":107,"phases":21523,"primaryCompletion":1487,"completion":5249,"start":548,"enrollment":1163,"conditions":21524,"interventions":21525},"NCT02483208","Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate",[90],[24],[21514,21526],"Advate",{"trials":21528,"activeCount":101},[],{"trials":21530,"activeCount":101},[],{"trials":21532,"activeCount":101},[],{"trials":21534,"activeCount":101},[],{"intervention":21526,"totalTrials":233,"cells":21536},{"EARLY_PHASE1":21537,"PHASE1":21539,"PHASE2":21545,"PHASE3":21547,"PHASE4":21549,"NA":21551},{"trials":21538,"activeCount":101},[],{"trials":21540,"activeCount":101},[21541],{"nctId":21521,"briefTitle":21522,"status":107,"phases":21542,"primaryCompletion":1487,"completion":5249,"start":548,"enrollment":1163,"conditions":21543,"interventions":21544},[90],[24],[21514,21526],{"trials":21546,"activeCount":101},[],{"trials":21548,"activeCount":101},[],{"trials":21550,"activeCount":101},[],{"trials":21552,"activeCount":101},[],{"intervention":3444,"totalTrials":233,"cells":21554},{"EARLY_PHASE1":21555,"PHASE1":21557,"PHASE2":21563,"PHASE3":21565,"PHASE4":21567,"NA":21569},{"trials":21556,"activeCount":101},[],{"trials":21558,"activeCount":101},[21559],{"nctId":3436,"briefTitle":3437,"status":107,"phases":21560,"primaryCompletion":3439,"completion":3440,"start":3441,"enrollment":2199,"conditions":21561,"interventions":21562},[90],[1579],[3393,3444],{"trials":21564,"activeCount":101},[],{"trials":21566,"activeCount":101},[],{"trials":21568,"activeCount":101},[],{"trials":21570,"activeCount":101},[],{"intervention":21572,"totalTrials":233,"cells":21573},"F-18",{"EARLY_PHASE1":21574,"PHASE1":21576,"PHASE2":21586,"PHASE3":21588,"PHASE4":21590,"NA":21592},{"trials":21575,"activeCount":101},[],{"trials":21577,"activeCount":101},[21578],{"nctId":21579,"briefTitle":21580,"status":107,"phases":21581,"primaryCompletion":21582,"completion":21582,"start":21583,"enrollment":97,"conditions":21584,"interventions":21585},"NCT00961831","Radiation Dosimetry, Metabolism, Safety, Tolerability and Positron Emission Tomography\u002FComputed Tomography (PET\u002FCT) Imaging With BAY 85-8050 in Healthy Volunteers and Patients",[90],"2009-12-16","2009-04-15",[19390],[21572,21572],{"trials":21587,"activeCount":101},[],{"trials":21589,"activeCount":101},[],{"trials":21591,"activeCount":101},[],{"trials":21593,"activeCount":101},[],{"intervention":21595,"totalTrials":233,"cells":21596},"Nifedipine\u002FCandesartan",{"EARLY_PHASE1":21597,"PHASE1":21599,"PHASE2":21607,"PHASE3":21609,"PHASE4":21611,"NA":21613},{"trials":21598,"activeCount":101},[],{"trials":21600,"activeCount":101},[21601],{"nctId":21602,"briefTitle":21603,"status":107,"phases":21604,"primaryCompletion":2969,"completion":1351,"start":2188,"enrollment":458,"conditions":21605,"interventions":21606},"NCT01350609","Pivotal Bioequivalence FDC Nifedipine \u002F Candesartan vs. Loose Combination of Single Components, Fed",[90],[14368],[21595,6627],{"trials":21608,"activeCount":101},[],{"trials":21610,"activeCount":101},[],{"trials":21612,"activeCount":101},[],{"trials":21614,"activeCount":101},[],{"intervention":21616,"totalTrials":233,"cells":21617},"BAY1125976",{"EARLY_PHASE1":21618,"PHASE1":21620,"PHASE2":21630,"PHASE3":21632,"PHASE4":21634,"NA":21636},{"trials":21619,"activeCount":101},[],{"trials":21621,"activeCount":101},[21622],{"nctId":21623,"briefTitle":21624,"status":107,"phases":21625,"primaryCompletion":21626,"completion":12881,"start":6677,"enrollment":21627,"conditions":21628,"interventions":21629},"NCT01915576","Phase I Dose Escalation Study With an Allosteric AKT 1\u002F2 Inhibitor in Patients",[90],"2016-07",79,[29],[21616,21616,21616],{"trials":21631,"activeCount":101},[],{"trials":21633,"activeCount":101},[],{"trials":21635,"activeCount":101},[],{"trials":21637,"activeCount":101},[],{"intervention":21639,"totalTrials":233,"cells":21640},"Regorafenib (BAY73-4506) + rifampin",{"EARLY_PHASE1":21641,"PHASE1":21643,"PHASE2":21651,"PHASE3":21653,"PHASE4":21655,"NA":21657},{"trials":21642,"activeCount":101},[],{"trials":21644,"activeCount":101},[21645],{"nctId":21646,"briefTitle":21647,"status":107,"phases":21648,"primaryCompletion":1327,"completion":1327,"start":5975,"enrollment":1701,"conditions":21649,"interventions":21650},"NCT01322438","Effect of Rifampin on the Pharmacokinetics of BAY73-4506",[90],[29],[21639],{"trials":21652,"activeCount":101},[],{"trials":21654,"activeCount":101},[],{"trials":21656,"activeCount":101},[],{"trials":21658,"activeCount":101},[],{"intervention":13978,"totalTrials":233,"cells":21660},{"EARLY_PHASE1":21661,"PHASE1":21663,"PHASE2":21669,"PHASE3":21671,"PHASE4":21673,"NA":21675},{"trials":21662,"activeCount":101},[],{"trials":21664,"activeCount":101},[21665],{"nctId":13971,"briefTitle":13972,"status":156,"phases":21666,"primaryCompletion":13039,"completion":13974,"start":13975,"enrollment":3374,"conditions":21667,"interventions":21668},[90],[7770],[13978,7812],{"trials":21670,"activeCount":101},[],{"trials":21672,"activeCount":101},[],{"trials":21674,"activeCount":101},[],{"trials":21676,"activeCount":101},[],{"intervention":21678,"totalTrials":233,"cells":21679},"Atuveciclib, BAY1143572",{"EARLY_PHASE1":21680,"PHASE1":21682,"PHASE2":21692,"PHASE3":21694,"PHASE4":21696,"NA":21698},{"trials":21681,"activeCount":101},[],{"trials":21683,"activeCount":101},[21684],{"nctId":21685,"briefTitle":21686,"status":107,"phases":21687,"primaryCompletion":1619,"completion":21688,"start":21689,"enrollment":2212,"conditions":21690,"interventions":21691},"NCT02345382","Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia",[90],"2017-07-30","2015-02-19",[8453],[21678],{"trials":21693,"activeCount":101},[],{"trials":21695,"activeCount":101},[],{"trials":21697,"activeCount":101},[],{"trials":21699,"activeCount":101},[],{"intervention":17169,"totalTrials":233,"cells":21701},{"EARLY_PHASE1":21702,"PHASE1":21704,"PHASE2":21710,"PHASE3":21712,"PHASE4":21714,"NA":21716},{"trials":21703,"activeCount":101},[],{"trials":21705,"activeCount":101},[21706],{"nctId":17162,"briefTitle":17163,"status":107,"phases":21707,"primaryCompletion":7802,"completion":17165,"start":17166,"enrollment":490,"conditions":21708,"interventions":21709},[90],[3603],[17169,17170,17171,17172,17173,17174,12636],{"trials":21711,"activeCount":101},[],{"trials":21713,"activeCount":101},[],{"trials":21715,"activeCount":101},[],{"trials":21717,"activeCount":101},[],{"intervention":17170,"totalTrials":233,"cells":21719},{"EARLY_PHASE1":21720,"PHASE1":21722,"PHASE2":21728,"PHASE3":21730,"PHASE4":21732,"NA":21734},{"trials":21721,"activeCount":101},[],{"trials":21723,"activeCount":101},[21724],{"nctId":17162,"briefTitle":17163,"status":107,"phases":21725,"primaryCompletion":7802,"completion":17165,"start":17166,"enrollment":490,"conditions":21726,"interventions":21727},[90],[3603],[17169,17170,17171,17172,17173,17174,12636],{"trials":21729,"activeCount":101},[],{"trials":21731,"activeCount":101},[],{"trials":21733,"activeCount":101},[],{"trials":21735,"activeCount":101},[],{"intervention":17171,"totalTrials":233,"cells":21737},{"EARLY_PHASE1":21738,"PHASE1":21740,"PHASE2":21746,"PHASE3":21748,"PHASE4":21750,"NA":21752},{"trials":21739,"activeCount":101},[],{"trials":21741,"activeCount":101},[21742],{"nctId":17162,"briefTitle":17163,"status":107,"phases":21743,"primaryCompletion":7802,"completion":17165,"start":17166,"enrollment":490,"conditions":21744,"interventions":21745},[90],[3603],[17169,17170,17171,17172,17173,17174,12636],{"trials":21747,"activeCount":101},[],{"trials":21749,"activeCount":101},[],{"trials":21751,"activeCount":101},[],{"trials":21753,"activeCount":101},[],{"intervention":17172,"totalTrials":233,"cells":21755},{"EARLY_PHASE1":21756,"PHASE1":21758,"PHASE2":21764,"PHASE3":21766,"PHASE4":21768,"NA":21770},{"trials":21757,"activeCount":101},[],{"trials":21759,"activeCount":101},[21760],{"nctId":17162,"briefTitle":17163,"status":107,"phases":21761,"primaryCompletion":7802,"completion":17165,"start":17166,"enrollment":490,"conditions":21762,"interventions":21763},[90],[3603],[17169,17170,17171,17172,17173,17174,12636],{"trials":21765,"activeCount":101},[],{"trials":21767,"activeCount":101},[],{"trials":21769,"activeCount":101},[],{"trials":21771,"activeCount":101},[],{"intervention":17173,"totalTrials":233,"cells":21773},{"EARLY_PHASE1":21774,"PHASE1":21776,"PHASE2":21782,"PHASE3":21784,"PHASE4":21786,"NA":21788},{"trials":21775,"activeCount":101},[],{"trials":21777,"activeCount":101},[21778],{"nctId":17162,"briefTitle":17163,"status":107,"phases":21779,"primaryCompletion":7802,"completion":17165,"start":17166,"enrollment":490,"conditions":21780,"interventions":21781},[90],[3603],[17169,17170,17171,17172,17173,17174,12636],{"trials":21783,"activeCount":101},[],{"trials":21785,"activeCount":101},[],{"trials":21787,"activeCount":101},[],{"trials":21789,"activeCount":101},[],{"intervention":17174,"totalTrials":233,"cells":21791},{"EARLY_PHASE1":21792,"PHASE1":21794,"PHASE2":21800,"PHASE3":21802,"PHASE4":21804,"NA":21806},{"trials":21793,"activeCount":101},[],{"trials":21795,"activeCount":101},[21796],{"nctId":17162,"briefTitle":17163,"status":107,"phases":21797,"primaryCompletion":7802,"completion":17165,"start":17166,"enrollment":490,"conditions":21798,"interventions":21799},[90],[3603],[17169,17170,17171,17172,17173,17174,12636],{"trials":21801,"activeCount":101},[],{"trials":21803,"activeCount":101},[],{"trials":21805,"activeCount":101},[],{"trials":21807,"activeCount":101},[],{"intervention":16950,"totalTrials":233,"cells":21809},{"EARLY_PHASE1":21810,"PHASE1":21812,"PHASE2":21818,"PHASE3":21820,"PHASE4":21822,"NA":21824},{"trials":21811,"activeCount":101},[],{"trials":21813,"activeCount":101},[21814],{"nctId":16943,"briefTitle":16944,"status":107,"phases":21815,"primaryCompletion":7829,"completion":16946,"start":16947,"enrollment":1649,"conditions":21816,"interventions":21817},[90],[1267],[16950,1358],{"trials":21819,"activeCount":101},[],{"trials":21821,"activeCount":101},[],{"trials":21823,"activeCount":101},[],{"trials":21825,"activeCount":101},[],{"intervention":21827,"totalTrials":233,"cells":21828},"BAY Factor VII",{"EARLY_PHASE1":21829,"PHASE1":21831,"PHASE2":21839,"PHASE3":21841,"PHASE4":21843,"NA":21845},{"trials":21830,"activeCount":101},[],{"trials":21832,"activeCount":101},[21833],{"nctId":21834,"briefTitle":21835,"status":107,"phases":21836,"primaryCompletion":499,"completion":499,"start":4588,"enrollment":1081,"conditions":21837,"interventions":21838},"NCT01921855","Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors",[90],[24,17051],[21827,21827,21827,21827],{"trials":21840,"activeCount":101},[],{"trials":21842,"activeCount":101},[],{"trials":21844,"activeCount":101},[],{"trials":21846,"activeCount":101},[],{"intervention":21848,"totalTrials":233,"cells":21849},"BAY1862864",{"EARLY_PHASE1":21850,"PHASE1":21852,"PHASE2":21862,"PHASE3":21864,"PHASE4":21866,"NA":21868},{"trials":21851,"activeCount":101},[],{"trials":21853,"activeCount":101},[21854],{"nctId":21855,"briefTitle":21856,"status":107,"phases":21857,"primaryCompletion":21858,"completion":21859,"start":21462,"enrollment":1599,"conditions":21860,"interventions":21861},"NCT02581878","Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma",[90],"2019-11-11","2019-11-26",[8469],[21848],{"trials":21863,"activeCount":101},[],{"trials":21865,"activeCount":101},[],{"trials":21867,"activeCount":101},[],{"trials":21869,"activeCount":101},[],{"intervention":5926,"totalTrials":233,"cells":21871},{"EARLY_PHASE1":21872,"PHASE1":21874,"PHASE2":21880,"PHASE3":21882,"PHASE4":21884,"NA":21886},{"trials":21873,"activeCount":101},[],{"trials":21875,"activeCount":101},[21876],{"nctId":5921,"briefTitle":5922,"status":107,"phases":21877,"primaryCompletion":3733,"completion":1486,"start":1488,"enrollment":1081,"conditions":21878,"interventions":21879},[90],[1790],[1492,5926],{"trials":21881,"activeCount":101},[],{"trials":21883,"activeCount":101},[],{"trials":21885,"activeCount":101},[],{"trials":21887,"activeCount":101},[],{"intervention":21889,"totalTrials":233,"cells":21890},"Vericiguat (BAY1021189) - Intervention A",{"EARLY_PHASE1":21891,"PHASE1":21893,"PHASE2":21905,"PHASE3":21907,"PHASE4":21909,"NA":21911},{"trials":21892,"activeCount":101},[],{"trials":21894,"activeCount":101},[21895],{"nctId":21896,"briefTitle":21897,"status":107,"phases":21898,"primaryCompletion":12598,"completion":21899,"start":17704,"enrollment":1265,"conditions":21900,"interventions":21901},"NCT05086952","A Study in Healthy Adult Male Participants to Learn the Way Vericiguat is Absorbed With and Without Food When Taken as a Single Dose in Liquid Form Suitable for Children Compared to a 10 Milligram (mg) Tablet That Releases the Active Substance Immediately",[90],"2022-02-15",[738,835],[21889,21902,21903,21904],"Vericiguat (BAY1021189) - Intervention B","Vericiguat (BAY1021189) - Intervention C","Vericiguat (Verquvo, BAY1021189) - Intervention D",{"trials":21906,"activeCount":101},[],{"trials":21908,"activeCount":101},[],{"trials":21910,"activeCount":101},[],{"trials":21912,"activeCount":101},[],{"intervention":21902,"totalTrials":233,"cells":21914},{"EARLY_PHASE1":21915,"PHASE1":21917,"PHASE2":21923,"PHASE3":21925,"PHASE4":21927,"NA":21929},{"trials":21916,"activeCount":101},[],{"trials":21918,"activeCount":101},[21919],{"nctId":21896,"briefTitle":21897,"status":107,"phases":21920,"primaryCompletion":12598,"completion":21899,"start":17704,"enrollment":1265,"conditions":21921,"interventions":21922},[90],[738,835],[21889,21902,21903,21904],{"trials":21924,"activeCount":101},[],{"trials":21926,"activeCount":101},[],{"trials":21928,"activeCount":101},[],{"trials":21930,"activeCount":101},[],{"intervention":21903,"totalTrials":233,"cells":21932},{"EARLY_PHASE1":21933,"PHASE1":21935,"PHASE2":21941,"PHASE3":21943,"PHASE4":21945,"NA":21947},{"trials":21934,"activeCount":101},[],{"trials":21936,"activeCount":101},[21937],{"nctId":21896,"briefTitle":21897,"status":107,"phases":21938,"primaryCompletion":12598,"completion":21899,"start":17704,"enrollment":1265,"conditions":21939,"interventions":21940},[90],[738,835],[21889,21902,21903,21904],{"trials":21942,"activeCount":101},[],{"trials":21944,"activeCount":101},[],{"trials":21946,"activeCount":101},[],{"trials":21948,"activeCount":101},[],{"intervention":21904,"totalTrials":233,"cells":21950},{"EARLY_PHASE1":21951,"PHASE1":21953,"PHASE2":21959,"PHASE3":21961,"PHASE4":21963,"NA":21965},{"trials":21952,"activeCount":101},[],{"trials":21954,"activeCount":101},[21955],{"nctId":21896,"briefTitle":21897,"status":107,"phases":21956,"primaryCompletion":12598,"completion":21899,"start":17704,"enrollment":1265,"conditions":21957,"interventions":21958},[90],[738,835],[21889,21902,21903,21904],{"trials":21960,"activeCount":101},[],{"trials":21962,"activeCount":101},[],{"trials":21964,"activeCount":101},[],{"trials":21966,"activeCount":101},[],{"intervention":21968,"totalTrials":233,"cells":21969},"BAY2701439",{"EARLY_PHASE1":21970,"PHASE1":21972,"PHASE2":21983,"PHASE3":21985,"PHASE4":21987,"NA":21989},{"trials":21971,"activeCount":101},[],{"trials":21973,"activeCount":101},[21974],{"nctId":21975,"briefTitle":21976,"status":107,"phases":21977,"primaryCompletion":8643,"completion":21978,"start":21979,"enrollment":1181,"conditions":21980,"interventions":21982},"NCT04147819","A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein",[90],"2023-09-26","2020-07-02",[21981],"Cancers With HER2 Expression",[21968,21968],{"trials":21984,"activeCount":101},[],{"trials":21986,"activeCount":101},[],{"trials":21988,"activeCount":101},[],{"trials":21990,"activeCount":101},[],{"intervention":13135,"totalTrials":233,"cells":21992},{"EARLY_PHASE1":21993,"PHASE1":21995,"PHASE2":22001,"PHASE3":22003,"PHASE4":22005,"NA":22007},{"trials":21994,"activeCount":101},[],{"trials":21996,"activeCount":101},[21997],{"nctId":13128,"briefTitle":13129,"status":107,"phases":21998,"primaryCompletion":13131,"completion":13131,"start":13132,"enrollment":1701,"conditions":21999,"interventions":22000},[90],[12672],[13121,13135,13136,13137,13138],{"trials":22002,"activeCount":101},[],{"trials":22004,"activeCount":101},[],{"trials":22006,"activeCount":101},[],{"trials":22008,"activeCount":101},[],{"intervention":13136,"totalTrials":233,"cells":22010},{"EARLY_PHASE1":22011,"PHASE1":22013,"PHASE2":22019,"PHASE3":22021,"PHASE4":22023,"NA":22025},{"trials":22012,"activeCount":101},[],{"trials":22014,"activeCount":101},[22015],{"nctId":13128,"briefTitle":13129,"status":107,"phases":22016,"primaryCompletion":13131,"completion":13131,"start":13132,"enrollment":1701,"conditions":22017,"interventions":22018},[90],[12672],[13121,13135,13136,13137,13138],{"trials":22020,"activeCount":101},[],{"trials":22022,"activeCount":101},[],{"trials":22024,"activeCount":101},[],{"trials":22026,"activeCount":101},[],{"intervention":13137,"totalTrials":233,"cells":22028},{"EARLY_PHASE1":22029,"PHASE1":22031,"PHASE2":22037,"PHASE3":22039,"PHASE4":22041,"NA":22043},{"trials":22030,"activeCount":101},[],{"trials":22032,"activeCount":101},[22033],{"nctId":13128,"briefTitle":13129,"status":107,"phases":22034,"primaryCompletion":13131,"completion":13131,"start":13132,"enrollment":1701,"conditions":22035,"interventions":22036},[90],[12672],[13121,13135,13136,13137,13138],{"trials":22038,"activeCount":101},[],{"trials":22040,"activeCount":101},[],{"trials":22042,"activeCount":101},[],{"trials":22044,"activeCount":101},[],{"intervention":13138,"totalTrials":233,"cells":22046},{"EARLY_PHASE1":22047,"PHASE1":22049,"PHASE2":22055,"PHASE3":22057,"PHASE4":22059,"NA":22061},{"trials":22048,"activeCount":101},[],{"trials":22050,"activeCount":101},[22051],{"nctId":13128,"briefTitle":13129,"status":107,"phases":22052,"primaryCompletion":13131,"completion":13131,"start":13132,"enrollment":1701,"conditions":22053,"interventions":22054},[90],[12672],[13121,13135,13136,13137,13138],{"trials":22056,"activeCount":101},[],{"trials":22058,"activeCount":101},[],{"trials":22060,"activeCount":101},[],{"trials":22062,"activeCount":101},[],{"intervention":8077,"totalTrials":233,"cells":22064},{"EARLY_PHASE1":22065,"PHASE1":22067,"PHASE2":22073,"PHASE3":22075,"PHASE4":22077,"NA":22079},{"trials":22066,"activeCount":101},[],{"trials":22068,"activeCount":101},[22069],{"nctId":8071,"briefTitle":8072,"status":107,"phases":22070,"primaryCompletion":3567,"completion":3567,"start":3567,"enrollment":1509,"conditions":22071,"interventions":22072},[90],[5881],[8076,8077],{"trials":22074,"activeCount":101},[],{"trials":22076,"activeCount":101},[],{"trials":22078,"activeCount":101},[],{"trials":22080,"activeCount":101},[],{"intervention":16846,"totalTrials":233,"cells":22082},{"EARLY_PHASE1":22083,"PHASE1":22085,"PHASE2":22091,"PHASE3":22093,"PHASE4":22095,"NA":22097},{"trials":22084,"activeCount":101},[],{"trials":22086,"activeCount":101},[22087],{"nctId":16839,"briefTitle":16840,"status":156,"phases":22088,"primaryCompletion":4974,"completion":2506,"start":16842,"enrollment":1509,"conditions":22089,"interventions":22090},[90],[16844],[16846,1934],{"trials":22092,"activeCount":101},[],{"trials":22094,"activeCount":101},[],{"trials":22096,"activeCount":101},[],{"trials":22098,"activeCount":101},[],{"intervention":22100,"totalTrials":233,"cells":22101},"Elinzanetant (BAY3427080) treatment A",{"EARLY_PHASE1":22102,"PHASE1":22104,"PHASE2":22113,"PHASE3":22115,"PHASE4":22117,"NA":22119},{"trials":22103,"activeCount":101},[],{"trials":22105,"activeCount":101},[22106],{"nctId":22107,"briefTitle":22108,"status":107,"phases":22109,"primaryCompletion":610,"completion":610,"start":1823,"enrollment":1081,"conditions":22110,"interventions":22111},"NCT04845841","Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the Body",[90],[1094],[22100,22112],"Elinzanetant (BAY3427080) treatment B",{"trials":22114,"activeCount":101},[],{"trials":22116,"activeCount":101},[],{"trials":22118,"activeCount":101},[],{"trials":22120,"activeCount":101},[],{"intervention":22112,"totalTrials":233,"cells":22122},{"EARLY_PHASE1":22123,"PHASE1":22125,"PHASE2":22131,"PHASE3":22133,"PHASE4":22135,"NA":22137},{"trials":22124,"activeCount":101},[],{"trials":22126,"activeCount":101},[22127],{"nctId":22107,"briefTitle":22108,"status":107,"phases":22128,"primaryCompletion":610,"completion":610,"start":1823,"enrollment":1081,"conditions":22129,"interventions":22130},[90],[1094],[22100,22112],{"trials":22132,"activeCount":101},[],{"trials":22134,"activeCount":101},[],{"trials":22136,"activeCount":101},[],{"trials":22138,"activeCount":101},[],{"intervention":22140,"totalTrials":233,"cells":22141},"BAY 1238097",{"EARLY_PHASE1":22142,"PHASE1":22144,"PHASE2":22152,"PHASE3":22154,"PHASE4":22156,"NA":22158},{"trials":22143,"activeCount":101},[],{"trials":22145,"activeCount":101},[22146],{"nctId":22147,"briefTitle":22148,"status":156,"phases":22149,"primaryCompletion":2407,"completion":2407,"start":1486,"enrollment":421,"conditions":22150,"interventions":22151},"NCT02369029","BAY1238097, First in Man",[90],[29],[22140],{"trials":22153,"activeCount":101},[],{"trials":22155,"activeCount":101},[],{"trials":22157,"activeCount":101},[],{"trials":22159,"activeCount":101},[],{"intervention":4630,"totalTrials":233,"cells":22161},{"EARLY_PHASE1":22162,"PHASE1":22164,"PHASE2":22170,"PHASE3":22172,"PHASE4":22174,"NA":22176},{"trials":22163,"activeCount":101},[],{"trials":22165,"activeCount":101},[22166],{"nctId":4624,"briefTitle":4625,"status":107,"phases":22167,"primaryCompletion":4066,"completion":4066,"start":4627,"enrollment":1519,"conditions":22168,"interventions":22169},[90],[29],[42,4630],{"trials":22171,"activeCount":101},[],{"trials":22173,"activeCount":101},[],{"trials":22175,"activeCount":101},[],{"trials":22177,"activeCount":101},[],{"intervention":17889,"totalTrials":233,"cells":22179},{"EARLY_PHASE1":22180,"PHASE1":22182,"PHASE2":22188,"PHASE3":22190,"PHASE4":22192,"NA":22194},{"trials":22181,"activeCount":101},[],{"trials":22183,"activeCount":101},[22184],{"nctId":17884,"briefTitle":17885,"status":107,"phases":22185,"primaryCompletion":2230,"completion":2230,"start":6677,"enrollment":1163,"conditions":22186,"interventions":22187},[90],[1490],[17869,17889],{"trials":22189,"activeCount":101},[],{"trials":22191,"activeCount":101},[],{"trials":22193,"activeCount":101},[],{"trials":22195,"activeCount":101},[],{"intervention":22197,"totalTrials":233,"cells":22198},"Finerenone (BAY94-8862): 1 0mg",{"EARLY_PHASE1":22199,"PHASE1":22201,"PHASE2":22211,"PHASE3":22213,"PHASE4":22215,"NA":22217},{"trials":22200,"activeCount":101},[],{"trials":22202,"activeCount":101},[22203],{"nctId":22204,"briefTitle":22205,"status":107,"phases":22206,"primaryCompletion":3020,"completion":17760,"start":2981,"enrollment":1081,"conditions":22207,"interventions":22208},"NCT02956109","Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers",[90],[1790],[22197,22209,22210],"Finerenone (BAY94-8862): 5 X 0.25 mg oro-dispersible","Finerenone (BAY94-8862): 1.25 mg oro-dispersible",{"trials":22212,"activeCount":101},[],{"trials":22214,"activeCount":101},[],{"trials":22216,"activeCount":101},[],{"trials":22218,"activeCount":101},[],{"intervention":22209,"totalTrials":233,"cells":22220},{"EARLY_PHASE1":22221,"PHASE1":22223,"PHASE2":22229,"PHASE3":22231,"PHASE4":22233,"NA":22235},{"trials":22222,"activeCount":101},[],{"trials":22224,"activeCount":101},[22225],{"nctId":22204,"briefTitle":22205,"status":107,"phases":22226,"primaryCompletion":3020,"completion":17760,"start":2981,"enrollment":1081,"conditions":22227,"interventions":22228},[90],[1790],[22197,22209,22210],{"trials":22230,"activeCount":101},[],{"trials":22232,"activeCount":101},[],{"trials":22234,"activeCount":101},[],{"trials":22236,"activeCount":101},[],{"intervention":22210,"totalTrials":233,"cells":22238},{"EARLY_PHASE1":22239,"PHASE1":22241,"PHASE2":22247,"PHASE3":22249,"PHASE4":22251,"NA":22253},{"trials":22240,"activeCount":101},[],{"trials":22242,"activeCount":101},[22243],{"nctId":22204,"briefTitle":22205,"status":107,"phases":22244,"primaryCompletion":3020,"completion":17760,"start":2981,"enrollment":1081,"conditions":22245,"interventions":22246},[90],[1790],[22197,22209,22210],{"trials":22248,"activeCount":101},[],{"trials":22250,"activeCount":101},[],{"trials":22252,"activeCount":101},[],{"trials":22254,"activeCount":101},[],{"intervention":22256,"totalTrials":233,"cells":22257},"Finerenone (BAY94-8862): intervention A",{"EARLY_PHASE1":22258,"PHASE1":22260,"PHASE2":22272,"PHASE3":22274,"PHASE4":22276,"NA":22278},{"trials":22259,"activeCount":101},[],{"trials":22261,"activeCount":101},[22262],{"nctId":22263,"briefTitle":22264,"status":107,"phases":22265,"primaryCompletion":22266,"completion":22266,"start":22267,"enrollment":2151,"conditions":22268,"interventions":22270},"NCT07116512","A Study to Compare How Much of the Study Treatment Finerenone Gets Into the Blood When the Same Amount is Taken in One and in Two Tablets of Different Strengths in Healthy Male Participants",[90],"2023-07-28","2023-05-02",[22269,1124],"Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent",[22256,22271],"Finerenone (BAY94-8862): intervention B",{"trials":22273,"activeCount":101},[],{"trials":22275,"activeCount":101},[],{"trials":22277,"activeCount":101},[],{"trials":22279,"activeCount":101},[],{"intervention":22271,"totalTrials":233,"cells":22281},{"EARLY_PHASE1":22282,"PHASE1":22284,"PHASE2":22290,"PHASE3":22292,"PHASE4":22294,"NA":22296},{"trials":22283,"activeCount":101},[],{"trials":22285,"activeCount":101},[22286],{"nctId":22263,"briefTitle":22264,"status":107,"phases":22287,"primaryCompletion":22266,"completion":22266,"start":22267,"enrollment":2151,"conditions":22288,"interventions":22289},[90],[22269,1124],[22256,22271],{"trials":22291,"activeCount":101},[],{"trials":22293,"activeCount":101},[],{"trials":22295,"activeCount":101},[],{"trials":22297,"activeCount":101},[],{"intervention":1292,"totalTrials":233,"cells":22299},{"EARLY_PHASE1":22300,"PHASE1":22302,"PHASE2":22308,"PHASE3":22310,"PHASE4":22312,"NA":22314},{"trials":22301,"activeCount":101},[],{"trials":22303,"activeCount":101},[22304],{"nctId":1283,"briefTitle":1284,"status":107,"phases":22305,"primaryCompletion":1286,"completion":1287,"start":1288,"enrollment":229,"conditions":22306,"interventions":22307},[90],[29],[1280,1291,1073,1292,1293],{"trials":22309,"activeCount":101},[],{"trials":22311,"activeCount":101},[],{"trials":22313,"activeCount":101},[],{"trials":22315,"activeCount":101},[],{"intervention":1293,"totalTrials":233,"cells":22317},{"EARLY_PHASE1":22318,"PHASE1":22320,"PHASE2":22326,"PHASE3":22328,"PHASE4":22330,"NA":22332},{"trials":22319,"activeCount":101},[],{"trials":22321,"activeCount":101},[22322],{"nctId":1283,"briefTitle":1284,"status":107,"phases":22323,"primaryCompletion":1286,"completion":1287,"start":1288,"enrollment":229,"conditions":22324,"interventions":22325},[90],[29],[1280,1291,1073,1292,1293],{"trials":22327,"activeCount":101},[],{"trials":22329,"activeCount":101},[],{"trials":22331,"activeCount":101},[],{"trials":22333,"activeCount":101},[],{"intervention":22335,"totalTrials":233,"cells":22336},"BAY60-4552",{"EARLY_PHASE1":22337,"PHASE1":22339,"PHASE2":22347,"PHASE3":22349,"PHASE4":22351,"NA":22353},{"trials":22338,"activeCount":101},[],{"trials":22340,"activeCount":101},[22341],{"nctId":22342,"briefTitle":22343,"status":107,"phases":22344,"primaryCompletion":498,"completion":4700,"start":6493,"enrollment":6503,"conditions":22345,"interventions":22346},"NCT00565565","Single Dose Escalation Study in Patients With Chronic Heart Failure",[90],[738],[22335],{"trials":22348,"activeCount":101},[],{"trials":22350,"activeCount":101},[],{"trials":22352,"activeCount":101},[],{"trials":22354,"activeCount":101},[],{"intervention":22356,"totalTrials":233,"cells":22357},"Formulation 1",{"EARLY_PHASE1":22358,"PHASE1":22360,"PHASE2":22374,"PHASE3":22376,"PHASE4":22378,"NA":22380},{"trials":22359,"activeCount":101},[],{"trials":22361,"activeCount":101},[22362],{"nctId":22363,"briefTitle":22364,"status":107,"phases":22365,"primaryCompletion":22366,"completion":22366,"start":22367,"enrollment":411,"conditions":22368,"interventions":22369},"NCT06474208","A Study to Learn About the Taste of Vericiguat Given in Liquid Form in Healthy Male Participants Aged 18 to 45 Years",[90],"2024-09-30","2024-07-01",[738],[22356,22370,22371,22372,22373],"Formulation 2","Formulation 3","Formulation 4","Formulation 5",{"trials":22375,"activeCount":101},[],{"trials":22377,"activeCount":101},[],{"trials":22379,"activeCount":101},[],{"trials":22381,"activeCount":101},[],{"intervention":22370,"totalTrials":233,"cells":22383},{"EARLY_PHASE1":22384,"PHASE1":22386,"PHASE2":22392,"PHASE3":22394,"PHASE4":22396,"NA":22398},{"trials":22385,"activeCount":101},[],{"trials":22387,"activeCount":101},[22388],{"nctId":22363,"briefTitle":22364,"status":107,"phases":22389,"primaryCompletion":22366,"completion":22366,"start":22367,"enrollment":411,"conditions":22390,"interventions":22391},[90],[738],[22356,22370,22371,22372,22373],{"trials":22393,"activeCount":101},[],{"trials":22395,"activeCount":101},[],{"trials":22397,"activeCount":101},[],{"trials":22399,"activeCount":101},[],{"intervention":22371,"totalTrials":233,"cells":22401},{"EARLY_PHASE1":22402,"PHASE1":22404,"PHASE2":22410,"PHASE3":22412,"PHASE4":22414,"NA":22416},{"trials":22403,"activeCount":101},[],{"trials":22405,"activeCount":101},[22406],{"nctId":22363,"briefTitle":22364,"status":107,"phases":22407,"primaryCompletion":22366,"completion":22366,"start":22367,"enrollment":411,"conditions":22408,"interventions":22409},[90],[738],[22356,22370,22371,22372,22373],{"trials":22411,"activeCount":101},[],{"trials":22413,"activeCount":101},[],{"trials":22415,"activeCount":101},[],{"trials":22417,"activeCount":101},[],{"intervention":22372,"totalTrials":233,"cells":22419},{"EARLY_PHASE1":22420,"PHASE1":22422,"PHASE2":22428,"PHASE3":22430,"PHASE4":22432,"NA":22434},{"trials":22421,"activeCount":101},[],{"trials":22423,"activeCount":101},[22424],{"nctId":22363,"briefTitle":22364,"status":107,"phases":22425,"primaryCompletion":22366,"completion":22366,"start":22367,"enrollment":411,"conditions":22426,"interventions":22427},[90],[738],[22356,22370,22371,22372,22373],{"trials":22429,"activeCount":101},[],{"trials":22431,"activeCount":101},[],{"trials":22433,"activeCount":101},[],{"trials":22435,"activeCount":101},[],{"intervention":22373,"totalTrials":233,"cells":22437},{"EARLY_PHASE1":22438,"PHASE1":22440,"PHASE2":22446,"PHASE3":22448,"PHASE4":22450,"NA":22452},{"trials":22439,"activeCount":101},[],{"trials":22441,"activeCount":101},[22442],{"nctId":22363,"briefTitle":22364,"status":107,"phases":22443,"primaryCompletion":22366,"completion":22366,"start":22367,"enrollment":411,"conditions":22444,"interventions":22445},[90],[738],[22356,22370,22371,22372,22373],{"trials":22447,"activeCount":101},[],{"trials":22449,"activeCount":101},[],{"trials":22451,"activeCount":101},[],{"trials":22453,"activeCount":101},[],{"intervention":22455,"totalTrials":233,"cells":22456},"Nifurtimox (Lampit, BAYA2502)_Test",{"EARLY_PHASE1":22457,"PHASE1":22459,"PHASE2":22471,"PHASE3":22473,"PHASE4":22475,"NA":22477},{"trials":22458,"activeCount":101},[],{"trials":22460,"activeCount":101},[22461],{"nctId":22462,"briefTitle":22463,"status":107,"phases":22464,"primaryCompletion":3194,"completion":22465,"start":22466,"enrollment":1701,"conditions":22467,"interventions":22469},"NCT03708133","Study to Assess Bioequivalence of a New Nifurtimox Oral Tablet Formulation",[90],"2019-06-18","2018-12-05",[22468],"Bioequivalence",[22455,22470],"Nifurtimox (Lampit, BAYA2502)_Reference",{"trials":22472,"activeCount":101},[],{"trials":22474,"activeCount":101},[],{"trials":22476,"activeCount":101},[],{"trials":22478,"activeCount":101},[],{"intervention":22470,"totalTrials":233,"cells":22480},{"EARLY_PHASE1":22481,"PHASE1":22483,"PHASE2":22489,"PHASE3":22491,"PHASE4":22493,"NA":22495},{"trials":22482,"activeCount":101},[],{"trials":22484,"activeCount":101},[22485],{"nctId":22462,"briefTitle":22463,"status":107,"phases":22486,"primaryCompletion":3194,"completion":22465,"start":22466,"enrollment":1701,"conditions":22487,"interventions":22488},[90],[22468],[22455,22470],{"trials":22490,"activeCount":101},[],{"trials":22492,"activeCount":101},[],{"trials":22494,"activeCount":101},[],{"trials":22496,"activeCount":101},[],{"intervention":22498,"totalTrials":233,"cells":22499},"Riociguat (Adempas, BAY63-2521) 1.0 mg",{"EARLY_PHASE1":22500,"PHASE1":22502,"PHASE2":22511,"PHASE3":22513,"PHASE4":22515,"NA":22517},{"trials":22501,"activeCount":101},[],{"trials":22503,"activeCount":101},[22504],{"nctId":22505,"briefTitle":22506,"status":107,"phases":22507,"primaryCompletion":3576,"completion":3576,"start":8109,"enrollment":1630,"conditions":22508,"interventions":22509},"NCT00640315","Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.",[90],[1500,19802],[22498,22510],"Riociguat (Adempas, BAY63-2521) 2.5 mg",{"trials":22512,"activeCount":101},[],{"trials":22514,"activeCount":101},[],{"trials":22516,"activeCount":101},[],{"trials":22518,"activeCount":101},[],{"intervention":22510,"totalTrials":233,"cells":22520},{"EARLY_PHASE1":22521,"PHASE1":22523,"PHASE2":22529,"PHASE3":22531,"PHASE4":22533,"NA":22535},{"trials":22522,"activeCount":101},[],{"trials":22524,"activeCount":101},[22525],{"nctId":22505,"briefTitle":22506,"status":107,"phases":22526,"primaryCompletion":3576,"completion":3576,"start":8109,"enrollment":1630,"conditions":22527,"interventions":22528},[90],[1500,19802],[22498,22510],{"trials":22530,"activeCount":101},[],{"trials":22532,"activeCount":101},[],{"trials":22534,"activeCount":101},[],{"trials":22536,"activeCount":101},[],{"intervention":22538,"totalTrials":233,"cells":22539},"BAY1834942",{"EARLY_PHASE1":22540,"PHASE1":22542,"PHASE2":22553,"PHASE3":22555,"PHASE4":22557,"NA":22559},{"trials":22541,"activeCount":101},[],{"trials":22543,"activeCount":101},[22544],{"nctId":22545,"briefTitle":22546,"status":107,"phases":22547,"primaryCompletion":399,"completion":22548,"start":22549,"enrollment":160,"conditions":22550,"interventions":22552},"NCT03596372","Study of BAY1834942 in Patients With Solid Tumors",[90],"2021-02-22","2018-06-19",[22551],"Advanced CEACAM6-expressing Solid Tumors",[22538],{"trials":22554,"activeCount":101},[],{"trials":22556,"activeCount":101},[],{"trials":22558,"activeCount":101},[],{"trials":22560,"activeCount":101},[],{"intervention":22562,"totalTrials":233,"cells":22563},"SH U04722",{"EARLY_PHASE1":22564,"PHASE1":22566,"PHASE2":22574,"PHASE3":22576,"PHASE4":22578,"NA":22580},{"trials":22565,"activeCount":101},[],{"trials":22567,"activeCount":101},[22568],{"nctId":22569,"briefTitle":22570,"status":156,"phases":22571,"primaryCompletion":6493,"completion":6493,"start":1648,"enrollment":3374,"conditions":22572,"interventions":22573},"NCT00375453","Dose Escalation Study of SH U04722 in Solid Tumors",[90],[2223],[22562],{"trials":22575,"activeCount":101},[],{"trials":22577,"activeCount":101},[],{"trials":22579,"activeCount":101},[],{"trials":22581,"activeCount":101},[],{"intervention":6051,"totalTrials":5231,"cells":22583},{"EARLY_PHASE1":22584,"PHASE1":22586,"PHASE2":22588,"PHASE3":22611,"PHASE4":22741,"NA":22825},{"trials":22585,"activeCount":101},[],{"trials":22587,"activeCount":101},[],{"trials":22589,"activeCount":101},[22590,22598,22605],{"nctId":22591,"briefTitle":22592,"status":107,"phases":22593,"completion":3819,"start":4789,"enrollment":22594,"conditions":22595,"interventions":22597},"NCT00657839","Assessment of Efficacy of Vardenafil in the Treatment of Subjects With Symptomatic Benign Prostatic Hyperplasia",[91],222,[22596],"Benign Prostatic Hyperplasia",[6051],{"nctId":22599,"briefTitle":22600,"status":107,"phases":22601,"completion":445,"start":4666,"enrollment":1303,"conditions":22602,"interventions":22604},"NCT00666809","Vardenafil in Tinnitus",[91],[22603],"Tinnitus",[6051],{"nctId":22606,"briefTitle":22607,"status":107,"phases":22608,"completion":1648,"start":4789,"enrollment":3177,"conditions":22609,"interventions":22610},"NCT00786253","Sustainable Efficacy of Vardenafil OD Versus Vardenafil PRN in Erectile Dysfunction",[91],[27],[6051,6051],{"trials":22612,"activeCount":101},[22613,22621,22628,22635,22641,22649,22657,22664,22671,22678,22684,22691,22695,22701,22707,22714,22721,22727,22734],{"nctId":22614,"briefTitle":22615,"status":107,"phases":22616,"primaryCompletion":22617,"completion":22617,"start":8048,"enrollment":22618,"conditions":22619,"interventions":22620},"NCT00668018","Assess Efficacy of Vardenafil 10mg in Erectile Dysfunction Within Intake of 6 Hours",[92],"2003-10",887,[27],[6051],{"nctId":22622,"briefTitle":22623,"status":107,"phases":22624,"primaryCompletion":7335,"completion":7335,"start":22625,"enrollment":2982,"conditions":22626,"interventions":22627},"NCT00656188","Placebo-controlled Study Evaluating the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction",[91,92],"2002-10",[27],[6051],{"nctId":22629,"briefTitle":22630,"status":107,"phases":22631,"completion":3668,"start":5394,"enrollment":22632,"conditions":22633,"interventions":22634},"NCT00661297","Study Evaluating the Efficacy, Safety, and Reliability of Vardenafil",[92],523,[27],[6051],{"nctId":22636,"briefTitle":22637,"status":107,"phases":22638,"primaryCompletion":3668,"completion":3668,"start":7335,"enrollment":1031,"conditions":22639,"interventions":22640},"NCT00661596","Assessment of Efficacy of Vardenafil, Influence on Self-esteem and Self-confidence in Subjects With Erectile Dysfunction",[92],[27],[6051],{"nctId":22642,"briefTitle":22643,"status":107,"phases":22644,"primaryCompletion":22645,"completion":22645,"start":3658,"enrollment":22646,"conditions":22647,"interventions":22648},"NCT00668057","BAY38-9456 (Vardenafil HCL Tablet) in ED Treatment for China Registration.",[92],"2003-09",624,[27],[6051,6051,6051],{"nctId":22650,"briefTitle":22651,"status":107,"phases":22652,"primaryCompletion":3657,"completion":3657,"start":3658,"enrollment":22653,"conditions":22654,"interventions":22656},"NCT00661219","Depression Related Improvement With Vardenafil for Erectile Response",[92],280,[27,22655],"Depression",[6051],{"nctId":22658,"briefTitle":22659,"status":107,"phases":22660,"primaryCompletion":6384,"completion":6384,"start":22661,"enrollment":2630,"conditions":22662,"interventions":22663},"NCT00657644","Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction",[92],"2003-08",[27],[6051],{"nctId":22665,"briefTitle":22666,"status":107,"phases":22667,"primaryCompletion":9794,"completion":9794,"start":6363,"enrollment":1236,"conditions":22668,"interventions":22670},"NCT00492635","Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil vs Vardenafil PRN vs Placebo in Men Immediately After Nerve-sparing Prostatectomy for Improving ED",[92],[27,22669],"Sexual Dysfunction, Physiological",[6051,6051],{"nctId":22672,"briefTitle":22673,"status":107,"phases":22674,"completion":3628,"start":6384,"enrollment":1509,"conditions":22675,"interventions":22677},"NCT00652262","BAY38-9456 - Supportive Trial for Spinal Injury",[92],[27,22676,6741],"Sexual Dysfunction",[6051],{"nctId":22679,"briefTitle":22680,"status":107,"phases":22681,"completion":3657,"start":5394,"enrollment":4853,"conditions":22682,"interventions":22683},"NCT00665496","A Study to Investigate the Time to Onset of Action of 10 mg and 20 mg of Vardenafil Compared to Placebo in Males With Erectile Dysfunction",[92],[27],[6051],{"nctId":22685,"briefTitle":22686,"status":107,"phases":22687,"completion":3628,"start":3668,"enrollment":22688,"conditions":22689,"interventions":22690},"NCT00678704","BAY38-9456 - Pivotal Trial for Diabetes Patient",[92],790,[27,8425],[6051,6051],{"nctId":6109,"briefTitle":6110,"status":107,"phases":22692,"primaryCompletion":6112,"completion":6112,"start":6113,"enrollment":6114,"conditions":22693,"interventions":22694},[92],[27],[6051,1717],{"nctId":22696,"briefTitle":22697,"status":107,"phases":22698,"completion":446,"start":5394,"enrollment":2982,"conditions":22699,"interventions":22700},"NCT00658177","Study Evaluating the Efficacy and Safety of Flexible-dose Vardenafil in Subjects With Erectile Dysfunction",[92],[27],[6051],{"nctId":22702,"briefTitle":22703,"status":107,"phases":22704,"primaryCompletion":446,"completion":446,"start":7335,"enrollment":1277,"conditions":22705,"interventions":22706},"NCT00661115","To Investigate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction.",[92],[27],[6051],{"nctId":22708,"briefTitle":22709,"status":107,"phases":22710,"primaryCompletion":6068,"completion":6068,"start":10251,"enrollment":22711,"conditions":22712,"interventions":22713},"NCT00661700","A Double-blind \"Preferred\" Vardenafil Dose Study of QoL and Functional Outcomes in Males With Erectile Dysfunction",[92],611,[27],[6051],{"nctId":22715,"briefTitle":22716,"status":107,"phases":22717,"completion":6281,"start":6113,"enrollment":22718,"conditions":22719,"interventions":22720},"NCT00682019","Study Evaluation the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction for 10 Weeks",[92],383,[27],[6051],{"nctId":22722,"briefTitle":22723,"status":107,"phases":22724,"completion":6281,"start":22617,"enrollment":5131,"conditions":22725,"interventions":22726},"NCT00657033","Study to Investigate the Efficacy and Safety of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction",[92],[27],[6051],{"nctId":22728,"briefTitle":22729,"status":107,"phases":22730,"primaryCompletion":446,"completion":446,"start":7335,"enrollment":22731,"conditions":22732,"interventions":22733},"NCT00654914","A Study to Assess the Efficacy and Safety of Vardenafil in the Treatment of Male Patients With Erectile Dysfunction",[92],527,[27],[6051],{"nctId":22735,"briefTitle":22736,"status":107,"phases":22737,"completion":22645,"start":8559,"enrollment":22738,"conditions":22739,"interventions":22740},"NCT00668005","Evaluating the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction and Hypertension",[92],388,[27],[6051],{"trials":22742,"activeCount":101},[22743,22751,22758,22765,22772,22779,22785,22791,22797,22804,22811,22815,22819],{"nctId":22744,"briefTitle":22745,"status":107,"phases":22746,"completion":9022,"start":1315,"enrollment":22747,"conditions":22748,"interventions":22750},"NCT00377793","Levitra (Vardenafil, BAY38-9456) Partner Satisfaction Study II",[93],352,[22676,22749],"Male Erectile Dysfunction",[6051],{"nctId":22752,"briefTitle":22753,"status":107,"phases":22754,"primaryCompletion":4613,"completion":4613,"start":6281,"enrollment":22755,"conditions":22756,"interventions":22757},"NCT00665054","BAY38-9456, 5\u002F10\u002F20mg, vs.Placebo in Erectile Dysfunction",[93],160,[27],[6051],{"nctId":22759,"briefTitle":22760,"status":107,"phases":22761,"completion":6317,"start":444,"enrollment":22762,"conditions":22763,"interventions":22764},"NCT00663845","Assessing Efficacy and Safety of Flexible Dosing With Vardenafil in Subjects With Erectile Dysfunction and Hyperlipidemia",[93],395,[27],[6051],{"nctId":22766,"briefTitle":22767,"status":107,"phases":22768,"completion":3668,"start":8559,"enrollment":22769,"conditions":22770,"interventions":22771},"NCT00660998","Evaluation of Efficacy and Safety of Vardenafil in Patients With Erectile Dysfunction and Type 1 Diabetes",[93],318,[27],[6051],{"nctId":22773,"briefTitle":22774,"status":107,"phases":22775,"primaryCompletion":6048,"completion":6048,"start":6068,"enrollment":22776,"conditions":22777,"interventions":22778},"NCT00668096","A Randomised Study of Levitra to Treat Men With Erections Problems and Previously Untreated With Similar Therapy.",[93],260,[27],[6051],{"nctId":22780,"briefTitle":22781,"status":107,"phases":22782,"primaryCompletion":4648,"completion":4648,"start":3667,"enrollment":5072,"conditions":22783,"interventions":22784},"NCT00663728","Assessment of Duration of Erection With Vardenafil 10 mg",[93],[27],[6051],{"nctId":22786,"briefTitle":22787,"status":107,"phases":22788,"completion":6112,"start":22645,"enrollment":13111,"conditions":22789,"interventions":22790},"NCT00662441","Evaluating of the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction",[93],[27],[6051],{"nctId":22792,"briefTitle":22793,"status":107,"phases":22794,"primaryCompletion":6048,"completion":6048,"start":3706,"enrollment":771,"conditions":22795,"interventions":22796},"NCT00665340","Investigate the Responsiveness of the Erectile Quality Scale to Vardenafil Flexible Dose vs Placebo in Males With Erectile Dysfunction (ED)",[93],[27],[6051],{"nctId":22798,"briefTitle":22799,"status":107,"phases":22800,"completion":3667,"start":22617,"enrollment":22801,"conditions":22802,"interventions":22803},"NCT00663598","Levitra® - Real Life Safety and Efficacy of Levitra",[93],30825,[27],[6051],{"nctId":22805,"briefTitle":22806,"status":107,"phases":22807,"completion":6363,"start":3667,"enrollment":22808,"conditions":22809,"interventions":22810},"NCT00667979","Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse",[93],264,[27],[6051],{"nctId":6124,"briefTitle":6125,"status":107,"phases":22812,"primaryCompletion":3706,"completion":3706,"start":4707,"enrollment":6127,"conditions":22813,"interventions":22814},[93],[27],[6051,1717],{"nctId":6045,"briefTitle":6046,"status":107,"phases":22816,"primaryCompletion":3819,"completion":3819,"start":6048,"enrollment":864,"conditions":22817,"interventions":22818},[93],[27],[6051,1591],{"nctId":22820,"briefTitle":22821,"status":107,"phases":22822,"completion":3657,"start":6599,"enrollment":3012,"conditions":22823,"interventions":22824},"NCT00681772","Evaluation of the Safety and Efficacy of Vardenafil in Subjects With Erectile Dysfunction",[93],[27],[6051],{"trials":22826,"activeCount":101},[22827,22834],{"nctId":22828,"briefTitle":22829,"status":107,"phases":22830,"completion":4691,"start":1648,"enrollment":22831,"conditions":22832,"interventions":22833},"NCT00470873","Vardenafil Treatment Of Erectile Dysfunction In Depressive And Non-Depressive Men",[],2471,[27],[6051],{"nctId":22835,"briefTitle":22836,"status":107,"phases":22837,"primaryCompletion":1326,"completion":1326,"start":3778,"enrollment":22838,"conditions":22839,"interventions":22840},"NCT00874679","REPEAT - Real-Life Perception of Efficacy, Attitude, Satisfaction and Safety of Levitra Therapy",[],7293,[27],[6051],{"intervention":11147,"totalTrials":160,"cells":22842},{"EARLY_PHASE1":22843,"PHASE1":22845,"PHASE2":22847,"PHASE3":22858,"PHASE4":22893,"NA":22895},{"trials":22844,"activeCount":101},[],{"trials":22846,"activeCount":101},[],{"trials":22848,"activeCount":101},[22849],{"nctId":22850,"briefTitle":22851,"status":107,"phases":22852,"completion":6270,"start":3658,"enrollment":22853,"conditions":22854,"interventions":22857},"NCT00185250","Betaferon\u002F Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy",[91],138,[22855,22856],"Cardiomyopathies","Heart Diseases",[11147,11147],{"trials":22859,"activeCount":101},[22860,22867,22873,22879,22883,22887],{"nctId":22861,"briefTitle":22862,"status":107,"phases":22863,"primaryCompletion":4612,"completion":4612,"start":445,"enrollment":22864,"conditions":22865,"interventions":22866},"NCT00459667","BEYOND Follow-up: Betaferon®\u002FBetaseron® Efficacy Yielding Outcomes of a New Dose",[92],1420,[6602],[11147,11147,11147],{"nctId":22868,"briefTitle":22869,"status":464,"phases":22870,"enrollment":101,"conditions":22871,"interventions":22872},"NCT00313976","Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)",[92],[35],[11147,11147],{"nctId":22874,"briefTitle":22875,"status":107,"phases":22876,"primaryCompletion":4597,"completion":4597,"start":4692,"enrollment":6010,"conditions":22877,"interventions":22878},"NCT00185211","BENEFIT Study (Betaferon® \u002F Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study",[92],[35],[11147,11147],{"nctId":11141,"briefTitle":11142,"status":107,"phases":22880,"completion":9022,"start":3657,"enrollment":11144,"conditions":22881,"interventions":22882},[92],[6602],[11147,11147,11130],{"nctId":11727,"briefTitle":11728,"status":107,"phases":22884,"conditions":22885,"interventions":22886},[92],[11731],[11147,11716],{"nctId":22888,"briefTitle":22889,"status":107,"phases":22890,"primaryCompletion":7249,"completion":7249,"start":6354,"enrollment":1561,"conditions":22891,"interventions":22892},"NCT00370071","Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis",[92],[35],[11147],{"trials":22894,"activeCount":101},[],{"trials":22896,"activeCount":101},[22897,22905,22912,22920,22927,22935,22944,22952,22958,22967,22973,22980,22987,22996,23004,23012,23018,23024,23035,23042,23050,23057,23064],{"nctId":22898,"briefTitle":22899,"status":107,"phases":22900,"primaryCompletion":4627,"completion":4627,"start":2970,"enrollment":22901,"conditions":22902,"interventions":22904},"NCT01414816","Betaferon® Regulatory Post-Marketing Surveillance",[],355,[35,22903],"Clinically Isolated System",[11147],{"nctId":22906,"briefTitle":22907,"status":107,"phases":22908,"completion":2969,"start":7249,"enrollment":22909,"conditions":22910,"interventions":22911},"NCT01184833","Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis",[],852,[35],[11147],{"nctId":22913,"briefTitle":22914,"status":107,"phases":22915,"primaryCompletion":3020,"completion":3698,"start":22916,"enrollment":22917,"conditions":22918,"interventions":22919},"NCT01491100","Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis",[],"2012-04-30",1085,[35],[11147],{"nctId":22921,"briefTitle":22922,"status":107,"phases":22923,"primaryCompletion":4066,"completion":5964,"start":5052,"enrollment":22924,"conditions":22925,"interventions":22926},"NCT01706055","Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE)",[],629,[35],[11147],{"nctId":22928,"briefTitle":22929,"status":107,"phases":22930,"primaryCompletion":12948,"completion":22931,"start":22932,"enrollment":3033,"conditions":22933,"interventions":22934},"NCT02486640","Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon",[],"2020-01-16","2015-09-08",[35],[11147],{"nctId":22936,"briefTitle":22937,"status":107,"phases":22938,"primaryCompletion":22939,"completion":22940,"start":22941,"enrollment":22853,"conditions":22942,"interventions":22943},"NCT01766063","Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon",[],"2017-01-09","2017-03-14","2012-12-06",[35],[11147],{"nctId":22945,"briefTitle":22946,"status":107,"phases":22947,"primaryCompletion":2230,"completion":2918,"start":3619,"enrollment":22948,"conditions":22949,"interventions":22951},"NCT00902135","Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)",[],702,[22950],"Relapsing-Remitting Multiple Sclerosis",[11147,11147,11147],{"nctId":22953,"briefTitle":22954,"status":107,"phases":22955,"primaryCompletion":1569,"completion":1569,"start":9794,"enrollment":519,"conditions":22956,"interventions":22957},"NCT00544037","BENEFIT Extension Study",[],[35],[11147],{"nctId":22959,"briefTitle":22960,"status":107,"phases":22961,"primaryCompletion":4736,"completion":4736,"start":4707,"enrollment":22962,"conditions":22963,"interventions":22966},"NCT01233245","BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program",[],1077,[22964,22965],"Relapsing Remitting MS (RRMS)","Secondary Progressive MS (SPMS)",[11147],{"nctId":22968,"briefTitle":22969,"status":107,"phases":22970,"primaryCompletion":2406,"completion":1647,"start":8136,"enrollment":3233,"conditions":22971,"interventions":22972},"NCT01076595","Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period",[],[35],[11147],{"nctId":22974,"briefTitle":22975,"status":107,"phases":22976,"primaryCompletion":21583,"completion":21583,"start":22977,"enrollment":550,"conditions":22978,"interventions":22979},"NCT03577977","Betaferon Use in Children and Adolescents With Multiple Sclerosis",[],"2008-06-01",[35],[11147],{"nctId":22981,"briefTitle":22982,"status":107,"phases":22983,"completion":4571,"start":6048,"enrollment":22984,"conditions":22985,"interventions":22986},"NCT00206635","Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis",[],432,[35],[11147],{"nctId":22988,"briefTitle":22989,"status":107,"phases":22990,"primaryCompletion":22991,"completion":2538,"start":22992,"enrollment":22993,"conditions":22994,"interventions":22995},"NCT02652091","Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction",[],"2017-08-11","2016-02-05",146,[6602],[11147],{"nctId":22997,"briefTitle":22998,"status":107,"phases":22999,"primaryCompletion":23000,"completion":23000,"start":23001,"enrollment":2126,"conditions":23002,"interventions":23003},"NCT03408093","Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b",[],"2010-03-30","2009-02-03",[35],[11147],{"nctId":23005,"briefTitle":23006,"status":107,"phases":23007,"primaryCompletion":6677,"completion":3989,"start":1423,"enrollment":23008,"conditions":23009,"interventions":23011},"NCT00787657","Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment",[],1723,[23010],"Relapsing Remitting Multiple Sclerosis (RRMS)",[11147],{"nctId":23013,"briefTitle":23014,"status":107,"phases":23015,"primaryCompletion":10000,"completion":5060,"start":2273,"enrollment":7062,"conditions":23016,"interventions":23017},"NCT02121444","BAY86-5046 (Betaseron), Non Interventional Studies",[],[35],[11147],{"nctId":23019,"briefTitle":23020,"status":107,"phases":23021,"primaryCompletion":2282,"completion":2282,"start":8136,"enrollment":6078,"conditions":23022,"interventions":23023},"NCT01354665","Depression and Fatigue in MS Patients Treated With Betaferon.",[],[35],[11147],{"nctId":23025,"briefTitle":23026,"status":107,"phases":23027,"primaryCompletion":23028,"completion":23029,"start":23030,"enrollment":23031,"conditions":23032,"interventions":23034},"NCT02247310","BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon",[],"2016-07-19","2016-11-08","2014-10-20",498,[23033],"Multiple Sclerosis, Relapsing Remitting",[11147],{"nctId":23036,"briefTitle":23037,"status":107,"phases":23038,"primaryCompletion":4066,"completion":5249,"start":410,"enrollment":1205,"conditions":23039,"interventions":23041},"NCT01436838","China Betaferon Adherence, Coping and Nurse Support Study",[],[23040],"Multiple Sclerosis, Chronic Progressive",[11147],{"nctId":23043,"briefTitle":23044,"status":107,"phases":23045,"primaryCompletion":23046,"completion":3647,"start":23047,"enrollment":490,"conditions":23048,"interventions":23049},"NCT00963833","Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis",[],"2016-04-12","2009-12-17",[35],[11147],{"nctId":23051,"briefTitle":23052,"status":107,"phases":23053,"primaryCompletion":23054,"completion":23054,"start":4460,"enrollment":3568,"conditions":23055,"interventions":23056},"NCT03134573","Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study",[],"2018-05-09",[35],[11147],{"nctId":23058,"briefTitle":23059,"status":107,"phases":23060,"completion":3618,"start":9022,"enrollment":3374,"conditions":23061,"interventions":23063},"NCT01235455","Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors",[],[23010,23062],"Secondary Progressive Multiple Sclerosis (SPMS)",[11147],{"nctId":23065,"briefTitle":23066,"status":107,"phases":23067,"primaryCompletion":5975,"completion":5975,"start":6932,"enrollment":23068,"conditions":23069,"interventions":23070},"NCT00882453","Physical Activity and Fatigue in Early Multiple Sclerosis (MS)",[],1739,[35],[11147],{"intervention":23072,"totalTrials":171,"cells":23073},"Coppertone",{"EARLY_PHASE1":23074,"PHASE1":23076,"PHASE2":23078,"PHASE3":23080,"PHASE4":23082,"NA":23084},{"trials":23075,"activeCount":101},[],{"trials":23077,"activeCount":101},[],{"trials":23079,"activeCount":101},[],{"trials":23081,"activeCount":101},[],{"trials":23083,"activeCount":101},[],{"trials":23085,"activeCount":101},[23086,23094,23099,23107,23114,23120,23127,23132,23138,23146,23151,23158,23166,23172,23178,23184,23191,23197,23204,23210,23215,23221,23226,23233,23240,23245,23250,23257],{"nctId":23087,"briefTitle":23088,"status":107,"phases":23089,"primaryCompletion":3423,"completion":3423,"start":23090,"enrollment":2041,"conditions":23091,"interventions":23093},"NCT02803047","Sun Protection Factor Assay",[94],"2015-11-09",[23092],"Sunscreening Agent",[23072],{"nctId":23095,"briefTitle":23088,"status":107,"phases":23096,"primaryCompletion":3423,"completion":3423,"start":23090,"enrollment":1949,"conditions":23097,"interventions":23098},"NCT02803034",[94],[23092],[23072],{"nctId":23100,"briefTitle":23101,"status":107,"phases":23102,"primaryCompletion":23103,"completion":23103,"start":23104,"enrollment":3374,"conditions":23105,"interventions":23106},"NCT02788162","18616 - Sun Protection Factor Assay",[94],"2015-10-21","2015-10-19",[23092],[23072],{"nctId":23108,"briefTitle":23109,"status":107,"phases":23110,"primaryCompletion":4952,"completion":4952,"start":23111,"enrollment":3374,"conditions":23112,"interventions":23113},"NCT02717325","18842 - Sun Protection Factor Assay",[94],"2016-03-16",[23092],[23072],{"nctId":23115,"briefTitle":23116,"status":107,"phases":23117,"primaryCompletion":3275,"completion":3275,"start":21461,"enrollment":3374,"conditions":23118,"interventions":23119},"NCT02741466","18750-Sun Protection Factor Assay",[94],[18],[23072],{"nctId":23121,"briefTitle":23122,"status":107,"phases":23123,"primaryCompletion":23124,"completion":23124,"start":21462,"enrollment":3374,"conditions":23125,"interventions":23126},"NCT02801929","18670 - Sun Protection Factor Assay",[94],"2015-11-30",[23092],[23072],{"nctId":23128,"briefTitle":23088,"status":107,"phases":23129,"primaryCompletion":12965,"completion":12965,"start":8376,"enrollment":3374,"conditions":23130,"interventions":23131},"NCT02822313",[94],[23092],[23072],{"nctId":23133,"briefTitle":23134,"status":107,"phases":23135,"primaryCompletion":4952,"completion":4952,"start":23111,"enrollment":3374,"conditions":23136,"interventions":23137},"NCT02717351","18841- Sun Protection Factor Assay",[94],[23092],[23072],{"nctId":23139,"briefTitle":23140,"status":107,"phases":23141,"primaryCompletion":23142,"completion":23142,"start":23143,"enrollment":3374,"conditions":23144,"interventions":23145},"NCT02776852","18519 - Sun Protection Factor Assay",[94],"2015-08-28","2015-08-19",[23092],[23072],{"nctId":23147,"briefTitle":23088,"status":107,"phases":23148,"primaryCompletion":5059,"completion":5059,"start":3639,"enrollment":3374,"conditions":23149,"interventions":23150},"NCT02822274",[94],[23092],[23072],{"nctId":23152,"briefTitle":23153,"status":107,"phases":23154,"primaryCompletion":23155,"completion":23155,"start":4759,"enrollment":2316,"conditions":23156,"interventions":23157},"NCT02779829","18432-Sun Protection Factor Assay",[94],"2015-09-01",[23092],[23072],{"nctId":23159,"briefTitle":23160,"status":107,"phases":23161,"primaryCompletion":23162,"completion":23162,"start":23163,"enrollment":3374,"conditions":23164,"interventions":23165},"NCT02682628","18791 - Sun Protection Factor Assay",[94],"2016-02-22","2016-02-18",[23092],[23072],{"nctId":23167,"briefTitle":23168,"status":107,"phases":23169,"primaryCompletion":23103,"completion":23103,"start":23104,"enrollment":3374,"conditions":23170,"interventions":23171},"NCT02756988","18615 - Sun Protection Factor Assay",[94],[23092],[23072],{"nctId":23173,"briefTitle":23088,"status":107,"phases":23174,"primaryCompletion":23175,"completion":23175,"start":1700,"enrollment":3374,"conditions":23176,"interventions":23177},"NCT02803021",[94],"2015-11-05",[23092],[23072],{"nctId":23179,"briefTitle":23088,"status":107,"phases":23180,"primaryCompletion":3139,"completion":3139,"start":23181,"enrollment":3374,"conditions":23182,"interventions":23183},"NCT02823509",[94],"2015-12-10",[23092],[23072],{"nctId":23185,"briefTitle":23186,"status":107,"phases":23187,"primaryCompletion":23188,"completion":23188,"start":23181,"enrollment":3374,"conditions":23189,"interventions":23190},"NCT02825017","Sun Protection Factor Assay (SPF Assay 18677)",[94],"2015-12-17",[23092],[23072],{"nctId":23192,"briefTitle":23193,"status":107,"phases":23194,"primaryCompletion":23188,"completion":23188,"start":23181,"enrollment":3374,"conditions":23195,"interventions":23196},"NCT02825030","Sun Protection Factor Assay (SPF Assay 18676)",[94],[23092],[23072],{"nctId":23198,"briefTitle":23199,"status":107,"phases":23200,"primaryCompletion":23201,"completion":23201,"start":1518,"enrollment":3374,"conditions":23202,"interventions":23203},"NCT02695303","18790 - Sun Protection Factor Assay",[94],"2016-02-25",[23092],[23072],{"nctId":23205,"briefTitle":23088,"status":107,"phases":23206,"primaryCompletion":23207,"completion":23207,"start":3423,"enrollment":2041,"conditions":23208,"interventions":23209},"NCT02822261",[94],"2015-12-01",[23092],[23072],{"nctId":23211,"briefTitle":23088,"status":107,"phases":23212,"primaryCompletion":23175,"completion":23175,"start":1700,"enrollment":3374,"conditions":23213,"interventions":23214},"NCT02803008",[94],[23092],[23072],{"nctId":23216,"briefTitle":23217,"status":107,"phases":23218,"primaryCompletion":3275,"completion":3275,"start":21461,"enrollment":3374,"conditions":23219,"interventions":23220},"NCT02739802","18751-Sun Protection Factor Assay.",[94],[18],[23072],{"nctId":23222,"briefTitle":23088,"status":107,"phases":23223,"primaryCompletion":21462,"completion":21462,"start":3423,"enrollment":3374,"conditions":23224,"interventions":23225},"NCT02803099",[94],[23092],[23072],{"nctId":23227,"briefTitle":23228,"status":107,"phases":23229,"primaryCompletion":2931,"completion":2931,"start":23230,"enrollment":3374,"conditions":23231,"interventions":23232},"NCT02776501","18572 - Sun Protection Factor Assay",[94],"2015-09-24",[23092],[23072],{"nctId":23234,"briefTitle":23235,"status":107,"phases":23236,"primaryCompletion":23237,"completion":23237,"start":23104,"enrollment":3374,"conditions":23238,"interventions":23239},"NCT02757014","18613 - Sun Protection Factor Assay",[94],"2015-10-22",[23092],[23072],{"nctId":23241,"briefTitle":23088,"status":107,"phases":23242,"primaryCompletion":23124,"completion":23124,"start":21462,"enrollment":3374,"conditions":23243,"interventions":23244},"NCT02822300",[94],[23092],[23072],{"nctId":23246,"briefTitle":23088,"status":107,"phases":23247,"primaryCompletion":5059,"completion":5059,"start":3639,"enrollment":3374,"conditions":23248,"interventions":23249},"NCT02822248",[94],[23092],[23072],{"nctId":23251,"briefTitle":23252,"status":107,"phases":23253,"primaryCompletion":23254,"completion":23254,"start":4759,"enrollment":5220,"conditions":23255,"interventions":23256},"NCT02779842","Sun Protection Factor - Assay",[94],"2015-08-11",[23092],[23072],{"nctId":23258,"briefTitle":23088,"status":107,"phases":23259,"primaryCompletion":23260,"completion":23260,"start":23090,"enrollment":1949,"conditions":23261,"interventions":23262},"NCT02803060",[94],"2015-11-17",[23092],[23072],{"intervention":3761,"totalTrials":124,"cells":23264},{"EARLY_PHASE1":23265,"PHASE1":23267,"PHASE2":23298,"PHASE3":23300,"PHASE4":23337,"NA":23351},{"trials":23266,"activeCount":101},[],{"trials":23268,"activeCount":101},[23269,23273,23277,23286,23292],{"nctId":5818,"briefTitle":5819,"status":107,"phases":23270,"primaryCompletion":4067,"completion":4067,"start":3594,"enrollment":842,"conditions":23271,"interventions":23272},[90],[5822],[5803,3761],{"nctId":20375,"briefTitle":20376,"status":107,"phases":23274,"primaryCompletion":4596,"completion":4596,"start":2255,"enrollment":124,"conditions":23275,"interventions":23276},[90],[1790],[3761,20368,20380,20381],{"nctId":23278,"briefTitle":23279,"status":107,"phases":23280,"primaryCompletion":23281,"completion":23281,"start":23282,"enrollment":21297,"conditions":23283,"interventions":23285},"NCT06655194","A Study to Learn if There is a Difference in the Blood Levels of Acetylsalicylic Acid When Taken as Different Chewable Tablets on an Empty Stomach by Healthy Participants",[90],"2025-04-06","2025-02-26",[22468,1124,23284],"Platelet Aggregation Inhibition",[3761,3761],{"nctId":23287,"briefTitle":23288,"status":107,"phases":23289,"primaryCompletion":1314,"completion":1314,"start":4587,"enrollment":160,"conditions":23290,"interventions":23291},"NCT01072604","Pharmacokinetic Study Comparing Aspirin and Aspirin Granules",[90],[1790],[3745,3745,3745,3745],{"nctId":23293,"briefTitle":23294,"status":107,"phases":23295,"primaryCompletion":2917,"completion":2917,"start":3609,"enrollment":21297,"conditions":23296,"interventions":23297},"NCT03056703","Bioequivalence of Single Dose Fast Release Aspirin (1000 mg) Tablet Versus Single Dose of Two 500 mg Fast Release Aspirin Tablets",[90],[5881],[3745,3745],{"trials":23299,"activeCount":101},[],{"trials":23301,"activeCount":101},[23302,23306,23310,23314,23318,23322,23326,23330],{"nctId":3737,"briefTitle":3738,"status":156,"phases":23303,"primaryCompletion":580,"completion":580,"start":3740,"enrollment":3741,"conditions":23304,"interventions":23305},[92],[3743],[3542,3745],{"nctId":6266,"briefTitle":6267,"status":107,"phases":23307,"completion":6269,"start":6270,"enrollment":6271,"conditions":23308,"interventions":23309},[92],[6273],[3761,5894],{"nctId":9141,"briefTitle":9142,"status":107,"phases":23311,"primaryCompletion":9144,"completion":9144,"start":9145,"enrollment":9146,"conditions":23312,"interventions":23313},[92],[6573,6574],[9149,3761,9130],{"nctId":6144,"briefTitle":6145,"status":156,"phases":23315,"primaryCompletion":6147,"completion":6147,"start":6148,"enrollment":4466,"conditions":23316,"interventions":23317},[92],[6150],[3745,6133],{"nctId":3754,"briefTitle":3755,"status":156,"phases":23319,"primaryCompletion":3221,"completion":3221,"start":1832,"enrollment":3757,"conditions":23320,"interventions":23321},[92],[3759],[3542,3761,3762,3542,3763],{"nctId":10912,"briefTitle":10913,"status":107,"phases":23323,"primaryCompletion":10915,"completion":10915,"start":10916,"enrollment":10917,"conditions":23324,"interventions":23325},[92],[6573,6574,6575],[10901,3761,10920],{"nctId":9151,"briefTitle":9152,"status":107,"phases":23327,"primaryCompletion":410,"completion":410,"start":3576,"enrollment":9154,"conditions":23328,"interventions":23329},[92],[6573],[3761,9130],{"nctId":23331,"briefTitle":9289,"status":107,"phases":23332,"primaryCompletion":23333,"completion":23333,"start":23334,"enrollment":6623,"conditions":23335,"interventions":23336},"NCT01117636",[92],"2010-07-07","2010-04-28",[9295],[3745,3761],{"trials":23338,"activeCount":101},[23339,23343,23347],{"nctId":6278,"briefTitle":6279,"status":107,"phases":23340,"completion":6281,"start":3668,"enrollment":6282,"conditions":23341,"interventions":23342},[93],[6150,6284,6285],[3745,3745,5894,5894],{"nctId":6559,"briefTitle":6560,"status":107,"phases":23344,"completion":4707,"start":3657,"enrollment":6562,"conditions":23345,"interventions":23346},[93],[6564,6565],[3745,3745,6546,6546],{"nctId":6568,"briefTitle":6569,"status":107,"phases":23348,"completion":4836,"start":3657,"enrollment":6571,"conditions":23349,"interventions":23350},[93],[6573,6574,6575],[3745,6546],{"trials":23352,"activeCount":101},[23353,23361,23365,23374,23378,23389,23400,23409,23413,23422],{"nctId":23354,"briefTitle":23355,"status":107,"phases":23356,"primaryCompletion":23357,"completion":23357,"start":3031,"enrollment":4097,"conditions":23358,"interventions":23360},"NCT04081831","Effectiveness of Low Dose Aspirin in Decreasing the Chance Getting Stomach and Intestine Cancer",[],"2020-08-25",[23359],"Gastrointestinal Cancer",[3761],{"nctId":3923,"briefTitle":3924,"status":107,"phases":23362,"primaryCompletion":3926,"completion":3927,"start":3928,"enrollment":977,"conditions":23363,"interventions":23364},[],[3930,3931,3932],[3542,3745],{"nctId":23366,"briefTitle":23367,"status":107,"phases":23368,"primaryCompletion":2396,"completion":23369,"start":23370,"enrollment":4097,"conditions":23371,"interventions":23373},"NCT03743883","EffectiveNess of Low-dose Aspirin in Prevention of Cancer in the Stomach and Oesophagus (GastrointEstinal Cancer Prevention) - United Kingdom (\"ENgAGE - UK\"): Study to Evaluate the Risk of Cancer in the Stomach and Oesophagus Among New Users of Low-dose Aspirin Using the THIN Database in the UK",[],"2019-05-31","2018-10-30",[23372],"Prevention of Oesophagus Cancer and Stomach Cancer",[3761],{"nctId":4025,"briefTitle":4026,"status":107,"phases":23375,"primaryCompletion":4028,"completion":4029,"start":2979,"enrollment":4030,"conditions":23376,"interventions":23377},[],[4032],[3542,3745],{"nctId":23379,"briefTitle":23380,"status":107,"phases":23381,"primaryCompletion":23382,"completion":23382,"start":994,"enrollment":4097,"conditions":23383,"interventions":23388},"NCT04097912","Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels",[],"2020-11-15",[8544,23384,23385,23386,23387],"Stroke (Including Ischaemic Stroke and Transient Ischaemic Attack)","Unstable Angina","Angina","Ischaemic Heart Disease",[3761],{"nctId":23390,"briefTitle":23391,"status":107,"phases":23392,"primaryCompletion":2470,"completion":2470,"start":23155,"enrollment":23393,"conditions":23394,"interventions":23398},"NCT02550717","Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN)",[],398158,[23395,3743,23396,23397],"Secondary Prevention","Ischemic Heart Disease","Coronary Heart Disease",[3761,23399],"Clopidogrel, Oral Anticoagulants, NSAIDs and SSRIs",{"nctId":23401,"briefTitle":23402,"status":107,"phases":23403,"completion":3619,"start":9022,"enrollment":23404,"conditions":23405,"interventions":23408},"NCT01669824","Pharmacy Based Pharmacoepidemiological Observational Study With Aspirin Protect 100 mg",[],4235,[3848,23406,23407],"Drug Safety","Effects, Longterm",[3745],{"nctId":4184,"briefTitle":4185,"status":107,"phases":23410,"primaryCompletion":263,"completion":4187,"start":4188,"enrollment":4189,"conditions":23411,"interventions":23412},[],[1579,3866],[3542,3745],{"nctId":23414,"briefTitle":23415,"status":107,"phases":23416,"primaryCompletion":23417,"completion":23417,"start":2396,"enrollment":23418,"conditions":23419,"interventions":23421},"NCT03904732","Study to Develop a Prediction Model to Understand the Effect of Low-dose Aspirin on Cancer That Develops in the Colon and\u002For the Rectum, Diseases That Affects the Heart or Blood Vessels and Safety Outcomes in European Countries. The Study is Also Called PEACOS Model EU",[],"2020-01-31",2000000,[2337,3690,23420],"Bleeding",[3761],{"nctId":23423,"briefTitle":23424,"status":107,"phases":23425,"primaryCompletion":2335,"completion":2335,"start":23426,"enrollment":23427,"conditions":23428,"interventions":23429},"NCT03603366","Study to Evaluate How Patients Regard the Benefits and Risks of Low-dose Aspirin for the Prevention of Heart and Blood Vessels Disease and for the Prevention of Cancer of the Colon and Rectum",[],"2019-08-14",1028,[3690,2337],[3745],{"intervention":6980,"totalTrials":124,"cells":23431},{"EARLY_PHASE1":23432,"PHASE1":23434,"PHASE2":23450,"PHASE3":23463,"PHASE4":23557,"NA":23571},{"trials":23433,"activeCount":101},[],{"trials":23435,"activeCount":101},[23436,23442],{"nctId":23437,"briefTitle":23438,"status":107,"phases":23439,"primaryCompletion":2970,"completion":2970,"start":445,"enrollment":11430,"conditions":23440,"interventions":23441},"NCT00468819","A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children",[90],[6978],[6980],{"nctId":23443,"briefTitle":23444,"status":107,"phases":23445,"primaryCompletion":23446,"completion":23446,"start":23447,"enrollment":30,"conditions":23448,"interventions":23449},"NCT01544166","Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged \u003C2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)",[90],"2013-11-28","2012-05-16",[6978],[6980],{"trials":23451,"activeCount":101},[23452,23459],{"nctId":23453,"briefTitle":23454,"status":107,"phases":23455,"primaryCompletion":444,"completion":444,"start":6384,"enrollment":2821,"conditions":23456,"interventions":23458},"NCT01490294","Myocardial Perfusion MRI",[91],[23457,6978],"Myocardial Perfusion Imaging",[6980,6980,6980,6980],{"nctId":8318,"briefTitle":8319,"status":107,"phases":23460,"primaryCompletion":8321,"completion":1005,"start":8322,"enrollment":8266,"conditions":23461,"interventions":23462},[91],[8324],[8309,6980],{"trials":23464,"activeCount":101},[23465,23473,23479,23488,23492,23499,23503,23507,23511,23519,23529,23533,23540,23544,23550],{"nctId":23466,"briefTitle":23467,"status":107,"phases":23468,"primaryCompletion":4895,"completion":12633,"start":23469,"enrollment":23470,"conditions":23471,"interventions":23472},"NCT01890434","Gadobutrol \u002F Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)",[92],"2013-08-26",478,[1579],[6980],{"nctId":23474,"briefTitle":23475,"status":107,"phases":23476,"primaryCompletion":1351,"completion":1508,"start":8136,"enrollment":12281,"conditions":23477,"interventions":23478},"NCT01104584","Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)",[92],[4677],[6980],{"nctId":23480,"briefTitle":23481,"status":107,"phases":23482,"primaryCompletion":6076,"completion":6076,"start":23483,"enrollment":23484,"conditions":23485,"interventions":23487},"NCT01344447","Gadobutrol Enhanced MRA of the Supra-aortic Vessels",[92],"2011-05-12",479,[23486],"Carotid Stenosis",[6980],{"nctId":11040,"briefTitle":11041,"status":107,"phases":23489,"primaryCompletion":8109,"completion":8109,"start":9022,"enrollment":1424,"conditions":23490,"interventions":23491},[92],[11044],[6980,6980,11029],{"nctId":23493,"briefTitle":23494,"status":107,"phases":23495,"primaryCompletion":498,"completion":498,"start":3768,"enrollment":23496,"conditions":23497,"interventions":23498},"NCT00623467","Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging",[92],343,[8553],[6980],{"nctId":8549,"briefTitle":8550,"status":107,"phases":23500,"primaryCompletion":6317,"completion":6317,"start":4750,"enrollment":1621,"conditions":23501,"interventions":23502},[92],[8553],[6980,8531],{"nctId":8329,"briefTitle":8330,"status":107,"phases":23504,"primaryCompletion":8332,"completion":8333,"start":8334,"enrollment":8335,"conditions":23505,"interventions":23506},[92],[8337,8338],[8309,6980,8340,8341],{"nctId":11623,"briefTitle":11624,"status":107,"phases":23508,"primaryCompletion":6493,"completion":6493,"start":4666,"enrollment":4649,"conditions":23509,"interventions":23510},[92],[11627],[6980,11612],{"nctId":23512,"briefTitle":23513,"status":107,"phases":23514,"primaryCompletion":4627,"completion":4627,"start":3618,"enrollment":23515,"conditions":23516,"interventions":23518},"NCT01344460","Gadobutrol Enhanced MRA of the Renal Arteries",[92],317,[23517],"Renal Artery Obstruction",[6980],{"nctId":23520,"briefTitle":23521,"status":107,"phases":23522,"primaryCompletion":23523,"completion":23524,"start":23525,"enrollment":23526,"conditions":23527,"interventions":23528},"NCT01890421","Gadobutrol\u002FGadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)",[92],"2015-04-10","2017-08-31","2013-07-19",426,[1579],[6980],{"nctId":8722,"briefTitle":8723,"status":107,"phases":23530,"primaryCompletion":4700,"completion":4700,"start":1423,"enrollment":217,"conditions":23531,"interventions":23532},[92],[8726,8553],[6980,8341],{"nctId":23534,"briefTitle":23535,"status":107,"phases":23536,"primaryCompletion":2366,"completion":1508,"start":2255,"enrollment":23537,"conditions":23538,"interventions":23539},"NCT01067976","Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI",[92],446,[4677,8726],[6980],{"nctId":8352,"briefTitle":8353,"status":107,"phases":23541,"primaryCompletion":8355,"completion":8332,"start":8334,"enrollment":8356,"conditions":23542,"interventions":23543},[92],[8337,8324],[8309,6980,8340,8341],{"nctId":23545,"briefTitle":23546,"status":107,"phases":23547,"primaryCompletion":2187,"completion":2187,"start":5052,"enrollment":136,"conditions":23548,"interventions":23549},"NCT01660841","Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging",[92],[6978],[6980],{"nctId":23551,"briefTitle":23552,"status":107,"phases":23553,"primaryCompletion":2188,"completion":2188,"start":3809,"enrollment":1991,"conditions":23554,"interventions":23555},"NCT01050829","Gadobutrol Magnevist-controlled Body Study",[92],[6978],[6980,23556],"Gadopentetate Dimeglumine",{"trials":23558,"activeCount":101},[23559,23563],{"nctId":6970,"briefTitle":6971,"status":107,"phases":23560,"primaryCompletion":6973,"completion":6974,"start":6975,"enrollment":6976,"conditions":23561,"interventions":23562},[93],[6978],[6957,6980],{"nctId":23564,"briefTitle":23565,"status":107,"phases":23566,"primaryCompletion":1543,"completion":1543,"start":498,"enrollment":23567,"conditions":23568,"interventions":23570},"NCT00828737","Safety of Gadovist in Renally Impaired Patients",[93],927,[23569,13239],"Fibrosis",[6980],{"trials":23572,"activeCount":101},[23573,23579,23587,23595,23603],{"nctId":23574,"briefTitle":23575,"status":107,"phases":23576,"completion":1569,"start":4736,"enrollment":160,"conditions":23577,"interventions":23578},"NCT00905879","Observational Study on the Safety and Tolerability of Gadobutrol (Gadovist) Among Filipino Patients in Magnetic Resonance Imaging",[],[6978],[6980],{"nctId":23580,"briefTitle":23581,"status":107,"phases":23582,"primaryCompletion":23583,"completion":18411,"start":21296,"enrollment":23584,"conditions":23585,"interventions":23586},"NCT05350189","A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting",[],"2023-03-28",1602,[8337],[6980],{"nctId":23588,"briefTitle":23589,"status":107,"phases":23590,"primaryCompletion":1351,"completion":5999,"start":1313,"enrollment":23591,"conditions":23592,"interventions":23594},"NCT00874640","Patient Characteristics in Daily Radiological Practice of Gadovist® Application (PATRON)",[],3711,[23593],"Epidemiologic Factors",[6980],{"nctId":23596,"briefTitle":23597,"status":107,"phases":23598,"primaryCompletion":4250,"completion":4250,"start":549,"enrollment":23599,"conditions":23600,"interventions":23602},"NCT01095081","GARDIAN, Gadovist in Routine Diagnostic Magnetic Resonance Imaging Administration in Non-selected Patients",[],23775,[6978,23601],"Magnetic Resonance Angiography",[6980],{"nctId":23604,"briefTitle":23605,"status":107,"phases":23606,"primaryCompletion":13048,"completion":13048,"start":23607,"enrollment":23608,"conditions":23609,"interventions":23611},"NCT02540967","Drug Use Investigation of Gadovist.",[],"2015-10-27",3357,[6978,23610],"Image Enhancement",[6980],{"intervention":7973,"totalTrials":97,"cells":23613},{"EARLY_PHASE1":23614,"PHASE1":23616,"PHASE2":23683,"PHASE3":23735,"PHASE4":23753,"NA":23755},{"trials":23615,"activeCount":101},[],{"trials":23617,"activeCount":101},[23618,23622,23631,23635,23643,23649,23658,23668,23675,23679],{"nctId":16807,"briefTitle":16808,"status":107,"phases":23619,"primaryCompletion":16810,"completion":539,"start":13285,"enrollment":22,"conditions":23620,"interventions":23621},[90],[1267],[7973,1934,16813,7973],{"nctId":23623,"briefTitle":23624,"status":107,"phases":23625,"primaryCompletion":23626,"completion":23627,"start":23628,"enrollment":2316,"conditions":23629,"interventions":23630},"NCT03655301","Effect of Copanlisib on Metformin Pharmacokinetics and Pharmacodynamics",[90],"2018-11-12","2019-02-12","2018-09-11",[1124],[7973,17482],{"nctId":16917,"briefTitle":16918,"status":107,"phases":23632,"primaryCompletion":16920,"completion":1762,"start":16921,"enrollment":6503,"conditions":23633,"interventions":23634},[90],[29],[1358,7973],{"nctId":23636,"briefTitle":23637,"status":107,"phases":23638,"primaryCompletion":6973,"completion":23639,"start":17275,"enrollment":160,"conditions":23640,"interventions":23642},"NCT03172884","Study of Copanlisib in Hepatic or Renal Impairment",[90],"2020-05-15",[23641],"Hepatic Insufficiency, Renal Insufficiency",[7973],{"nctId":23644,"briefTitle":23645,"status":107,"phases":23646,"primaryCompletion":2229,"completion":3989,"start":3609,"enrollment":5220,"conditions":23647,"interventions":23648},"NCT02119221","Copanlisib Mass Balance Study",[90],[1124],[7973],{"nctId":23650,"briefTitle":23651,"status":107,"phases":23652,"primaryCompletion":23653,"completion":23654,"start":23655,"enrollment":2316,"conditions":23656,"interventions":23657},"NCT03498430","Copanlisib Chinese PK Study",[90],"2019-08-06","2020-06-02","2018-04-27",[8469],[7973],{"nctId":23659,"briefTitle":23660,"status":107,"phases":23661,"primaryCompletion":23662,"completion":23663,"start":23664,"enrollment":112,"conditions":23665,"interventions":23667},"NCT02155582","Copanlisib Pharmacodynamic Study",[90],"2016-10-04","2017-03-16","2014-08-12",[23666],"Non Hodgkin Lymphoma",[7973],{"nctId":23669,"briefTitle":23670,"status":107,"phases":23671,"primaryCompletion":1518,"completion":1518,"start":23672,"enrollment":8266,"conditions":23673,"interventions":23674},"NCT00962611","BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer",[90],"2009-11-19",[29],[7973],{"nctId":13542,"briefTitle":13543,"status":107,"phases":23676,"primaryCompletion":13545,"completion":13545,"start":13546,"enrollment":1081,"conditions":23677,"interventions":23678},[90],[13548,13549,13550],[7973,2339],{"nctId":7966,"briefTitle":7967,"status":107,"phases":23680,"primaryCompletion":7969,"completion":7969,"start":5269,"enrollment":1081,"conditions":23681,"interventions":23682},[90],[7971],[5521,7973],{"trials":23684,"activeCount":101},[23685,23695,23705,23715,23727],{"nctId":23686,"briefTitle":23687,"status":107,"phases":23688,"primaryCompletion":23689,"completion":23690,"start":23691,"enrollment":2388,"conditions":23692,"interventions":23694},"NCT02342665","Japanese Phase Ib\u002FII Copanlisib in Relapsed, Indolent B-cell NHL",[90,91],"2018-09-14","2022-02-10","2015-04-21",[23693],"Lymphoma Non-Hodgkin",[7973],{"nctId":23696,"briefTitle":23697,"status":107,"phases":23698,"primaryCompletion":23699,"completion":23700,"start":23701,"enrollment":6822,"conditions":23702,"interventions":23704},"NCT02391116","Phase II Copanlisib in Relapsed\u002FRefractory Diffuse Large B-cell Lymphoma (DLBCL)",[91],"2016-07-05","2018-01-19","2015-05-08",[23703],"Diffuse, Large B-Cell, Lymphoma",[7973],{"nctId":23706,"briefTitle":23707,"status":107,"phases":23708,"primaryCompletion":23709,"completion":23710,"start":23711,"enrollment":23712,"conditions":23713,"interventions":23714},"NCT01660451","Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas",[91],"2016-06-22","2023-05-18","2012-11-19",227,[8469],[7973],{"nctId":23716,"briefTitle":23717,"status":156,"phases":23718,"primaryCompletion":3231,"completion":3231,"start":23719,"enrollment":36,"conditions":23720,"interventions":23726},"NCT03458728","Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients",[90,91],"2018-04-30",[23721,23722,23723,23724,23725],"Relapsed or Refractory Solid Tumors or Lymphoma in Children","Neuroblastoma","Osteosarcoma","Rhabdomyosarcoma","Ewing Sarcoma",[7973],{"nctId":23728,"briefTitle":23729,"status":156,"phases":23730,"primaryCompletion":2425,"completion":1742,"start":23731,"enrollment":855,"conditions":23732,"interventions":23734},"NCT02455297","Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)",[91],"2015-08-24",[23733],"Lymphoma, Mantle-Cell",[7973],{"trials":23736,"activeCount":101},[23737,23741,23745],{"nctId":8461,"briefTitle":8462,"status":156,"phases":23738,"primaryCompletion":8464,"completion":8465,"start":8466,"enrollment":8467,"conditions":23739,"interventions":23740},[92],[8469],[7973,8439,8471,8472,2177,8473,493],{"nctId":8475,"briefTitle":8476,"status":107,"phases":23742,"primaryCompletion":8478,"completion":8479,"start":8480,"enrollment":4862,"conditions":23743,"interventions":23744},[92],[8482],[7973,8439],{"nctId":23746,"briefTitle":23747,"status":107,"phases":23748,"primaryCompletion":23749,"completion":23749,"start":23750,"enrollment":2388,"conditions":23751,"interventions":23752},"NCT02369016","Phase III Copanlisib in Rituximab-refractory iNHL",[92],"2022-10-26","2015-09-22",[8469],[7973],{"trials":23754,"activeCount":101},[],{"trials":23756,"activeCount":101},[23757,23763],{"nctId":23758,"briefTitle":23759,"status":687,"phases":23760,"conditions":23761,"interventions":23762},"NCT06238583","Expanded Access to Provide Copanlisib for Patients With Cancer Who Are Experiencing a Positive Response, as Determined by Their Doctors",[],[219],[7973],{"nctId":23764,"briefTitle":23765,"status":107,"phases":23766,"primaryCompletion":23767,"completion":23767,"start":23768,"enrollment":5220,"conditions":23769,"interventions":23771},"NCT05217914","A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions",[],"2024-08-31","2022-07-01",[23770],"Relapsed or Refractory Indolent Non-Hodgkin Lymphoma",[7973],{"intervention":1144,"totalTrials":97,"cells":23773},{"EARLY_PHASE1":23774,"PHASE1":23776,"PHASE2":23810,"PHASE3":23812,"PHASE4":23837,"NA":23843},{"trials":23775,"activeCount":101},[],{"trials":23777,"activeCount":101},[23778,23785,23789,23795,23802,23806],{"nctId":23779,"briefTitle":23780,"status":107,"phases":23781,"primaryCompletion":4657,"completion":2187,"start":8136,"enrollment":36,"conditions":23782,"interventions":23784},"NCT01049022","Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients",[90],[23783],"Infections",[1144,1144,1144],{"nctId":12513,"briefTitle":12514,"status":107,"phases":23786,"primaryCompletion":380,"completion":12516,"start":12517,"enrollment":2212,"conditions":23787,"interventions":23788},[90],[12519,7793,9474],[12494,1144],{"nctId":23790,"briefTitle":23791,"status":107,"phases":23792,"primaryCompletion":1570,"completion":1569,"start":8136,"enrollment":1701,"conditions":23793,"interventions":23794},"NCT01073891","Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults",[90],[5948],[1144,1144,1144],{"nctId":23796,"briefTitle":23797,"status":107,"phases":23798,"completion":6384,"start":3668,"enrollment":4934,"conditions":23799,"interventions":23800},"NCT00310596","Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects",[90],[5948],[23801,23801,23801,23801,1144],"Gadopentetate dimeglumine",{"nctId":3408,"briefTitle":3409,"status":107,"phases":23803,"primaryCompletion":3411,"completion":3412,"start":3413,"enrollment":3414,"conditions":23804,"interventions":23805},[90],[1579],[3393,1144],{"nctId":1137,"briefTitle":1138,"status":107,"phases":23807,"primaryCompletion":1140,"completion":632,"start":1141,"enrollment":22,"conditions":23808,"interventions":23809},[90],[1094,1103,1124],[1144,52],{"trials":23811,"activeCount":101},[],{"trials":23813,"activeCount":101},[23814,23821,23825,23829,23833],{"nctId":23815,"briefTitle":23816,"status":107,"phases":23817,"primaryCompletion":4612,"completion":4612,"start":6048,"enrollment":23818,"conditions":23819,"interventions":23820},"NCT00492024","BAY12-8039: 5 Days for Sinusitis vs Placebo",[92],374,[6540],[1144],{"nctId":11098,"briefTitle":11099,"status":107,"phases":23822,"primaryCompletion":1423,"completion":1423,"start":4750,"enrollment":7888,"conditions":23823,"interventions":23824},[92],[11102,11103,11104,11105],[1144,11087],{"nctId":6521,"briefTitle":6522,"status":107,"phases":23826,"primaryCompletion":3403,"completion":3403,"start":6524,"enrollment":4862,"conditions":23827,"interventions":23828},[92],[6526],[1144,6528,6510,6529,6530,6531],{"nctId":12278,"briefTitle":12279,"status":107,"phases":23830,"primaryCompletion":4597,"completion":4597,"start":1648,"enrollment":12281,"conditions":23831,"interventions":23832},[92],[10254],[1144,12267],{"nctId":12365,"briefTitle":12366,"status":107,"phases":23834,"primaryCompletion":4292,"completion":4292,"start":1315,"enrollment":12368,"conditions":23835,"interventions":23836},[92],[12370],[1144,12354],{"trials":23838,"activeCount":101},[23839],{"nctId":6535,"briefTitle":6536,"status":156,"phases":23840,"primaryCompletion":3818,"completion":3818,"start":3724,"enrollment":6538,"conditions":23841,"interventions":23842},[93],[6540,6541],[1144,6510],{"trials":23844,"activeCount":101},[23845,23855,23863,23870,23879,23887,23895,23902],{"nctId":23846,"briefTitle":23847,"status":107,"phases":23848,"primaryCompletion":1313,"completion":1313,"start":23849,"enrollment":23850,"conditions":23851,"interventions":23853},"NCT01434173","Risk of Acute Liver Injury in Users of Antimicrobials",[],"2001-07",1299056,[23852],"Drug-Induced Liver Injury",[1144,23854],"Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin",{"nctId":23856,"briefTitle":23857,"status":107,"phases":23858,"primaryCompletion":1326,"completion":1326,"start":2970,"enrollment":23859,"conditions":23860,"interventions":23862},"NCT00846911","AVANTI - Avelox® in Acute Exacerbations of chroNic bronchiTIs",[],2672,[23861],"Bronchitis, Chronic",[1144],{"nctId":23864,"briefTitle":23865,"status":107,"phases":23866,"primaryCompletion":4579,"completion":4579,"start":446,"enrollment":920,"conditions":23867,"interventions":23869},"NCT00932802","Greatest International Antiinfective Trial With Avelox",[],[23861,23868],"Bronchial Diseases",[1144],{"nctId":23871,"briefTitle":23872,"status":107,"phases":23873,"primaryCompletion":1569,"completion":1569,"start":499,"enrollment":23874,"conditions":23875,"interventions":23878},"NCT01096511","Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)",[],1001,[23876,23877],"Secondary Peritonitis","Abscess, Intra-Abdominal",[1144],{"nctId":23880,"briefTitle":23881,"status":107,"phases":23882,"primaryCompletion":498,"completion":498,"start":4789,"enrollment":23883,"conditions":23884,"interventions":23886},"NCT00997997","Avelox in Complicated Skin and Skin Structure Infections",[],6127,[23885],"Skin Diseases, Bacterial",[1144],{"nctId":23888,"briefTitle":23889,"status":107,"phases":23890,"primaryCompletion":5975,"completion":5975,"start":3619,"enrollment":23891,"conditions":23892,"interventions":23894},"NCT00876577","VICTOR - Avelox® Intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis",[],1206,[7438,23893],"Disease Exacerbation",[1144],{"nctId":23896,"briefTitle":23897,"status":107,"phases":23898,"primaryCompletion":1587,"completion":1587,"start":499,"enrollment":23899,"conditions":23900,"interventions":23901},"NCT00879008","SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)",[],345,[7438],[1144],{"nctId":23903,"briefTitle":23904,"status":107,"phases":23905,"primaryCompletion":1327,"completion":408,"start":3576,"enrollment":23906,"conditions":23907,"interventions":23908},"NCT00987792","CAPRIVI: Community Acquired Pneumonia: Treatment With Avelox® in Hospitalized Patients",[],2595,[6718],[1144],{"intervention":23910,"totalTrials":1081,"cells":23911},"BAY987517",{"EARLY_PHASE1":23912,"PHASE1":23914,"PHASE2":23916,"PHASE3":23918,"PHASE4":23920,"NA":23922},{"trials":23913,"activeCount":101},[],{"trials":23915,"activeCount":101},[],{"trials":23917,"activeCount":101},[],{"trials":23919,"activeCount":101},[],{"trials":23921,"activeCount":101},[],{"trials":23923,"activeCount":101},[23924,23933,23940,23947,23953,23960,23968,23976,23985,23991,23997,24003,24008,24014,24023,24030],{"nctId":23925,"briefTitle":23926,"status":107,"phases":23927,"primaryCompletion":23928,"completion":23928,"start":23929,"enrollment":13111,"conditions":23930,"interventions":23931},"NCT02877511","Supervised Outdoor-Use Test For Sunscreen Products in Adults",[94],"2016-08-21","2016-08-20",[18],[23910,23932],"Sunscreen Lotion",{"nctId":23934,"briefTitle":23935,"status":107,"phases":23936,"primaryCompletion":23937,"completion":23937,"start":17761,"enrollment":328,"conditions":23938,"interventions":23939},"NCT02930785","Sun Protection Factor Assay (SPF Assay 202\u002F2016)",[94],"2016-10-27",[18],[23910],{"nctId":23941,"briefTitle":23942,"status":107,"phases":23943,"primaryCompletion":2482,"completion":2482,"start":23944,"enrollment":2345,"conditions":23945,"interventions":23946},"NCT02750488","18793 - Human Photoallergy Test",[94],"2016-05-09",[18],[23910],{"nctId":23948,"briefTitle":23088,"status":107,"phases":23949,"primaryCompletion":2482,"completion":2482,"start":23950,"enrollment":328,"conditions":23951,"interventions":23952},"NCT02815241",[94],"2016-06-29",[18],[23910],{"nctId":23954,"briefTitle":23955,"status":107,"phases":23956,"primaryCompletion":23957,"completion":23957,"start":3174,"enrollment":4580,"conditions":23958,"interventions":23959},"NCT03002922","Evaluation of Sunscreen During Exercise Under Conditions of Profuse Sweating (821\u002F2016)",[94],"2017-01-28",[18],[23910],{"nctId":23961,"briefTitle":23962,"status":107,"phases":23963,"primaryCompletion":23964,"completion":23964,"start":23965,"enrollment":21297,"conditions":23966,"interventions":23967},"NCT02962856","Human Phototoxicity Test (823\u002F2016)",[94],"2016-11-05","2016-11-02",[18],[23910],{"nctId":23969,"briefTitle":23970,"status":107,"phases":23971,"primaryCompletion":23972,"completion":23972,"start":23973,"enrollment":328,"conditions":23974,"interventions":23975},"NCT02815228","Sun Protection Factor Assay (SPF Assay 19009)",[94],"2016-06-30","2016-06-28",[18],[23910],{"nctId":23977,"briefTitle":23978,"status":107,"phases":23979,"primaryCompletion":23980,"completion":23980,"start":23981,"enrollment":3374,"conditions":23982,"interventions":23983},"NCT02995135","Sun Protection Factor Assay (341\u002F2016)",[94],"2017-01-06","2017-01-03",[18],[23910,23984],"SFP Control",{"nctId":23986,"briefTitle":23987,"status":107,"phases":23988,"primaryCompletion":4348,"completion":4348,"start":4375,"enrollment":2189,"conditions":23989,"interventions":23990},"NCT02962869","Human Photoallergy Test (824\u002F2016)",[94],[18],[23910],{"nctId":23992,"briefTitle":23993,"status":107,"phases":23994,"primaryCompletion":23709,"completion":23709,"start":20337,"enrollment":1949,"conditions":23995,"interventions":23996},"NCT02842268","Evaluation of Sunscreen During Exercise Under Conditions of Profuse Sweating",[94],[23092],[23910],{"nctId":23998,"briefTitle":23999,"status":107,"phases":24000,"primaryCompletion":2489,"completion":2489,"start":8158,"enrollment":4620,"conditions":24001,"interventions":24002},"NCT02891044","Sun Protection Factor Assay (SPF Assay 105\u002F2016)",[94],[18],[23910],{"nctId":24004,"briefTitle":23088,"status":107,"phases":24005,"primaryCompletion":23950,"completion":23950,"start":1301,"enrollment":328,"conditions":24006,"interventions":24007},"NCT02822339",[94],[18],[23910],{"nctId":24009,"briefTitle":24010,"status":107,"phases":24011,"primaryCompletion":23972,"completion":23972,"start":23973,"enrollment":328,"conditions":24012,"interventions":24013},"NCT02815202","Sun Protection Factor Assay (SPF Assay 19008)",[94],[18],[23910],{"nctId":24015,"briefTitle":24016,"status":107,"phases":24017,"primaryCompletion":24018,"completion":24018,"start":24019,"enrollment":11,"conditions":24020,"interventions":24021},"NCT03012347","Evaluation of a Gel Sunscreen in Controlled Use Conditions (208\u002F2016)",[94],"2017-01-19","2017-01-05",[18],[23910,24022],"BullFrog Gel Sunscreen Land Sport SPF-50",{"nctId":24024,"briefTitle":24025,"status":107,"phases":24026,"primaryCompletion":24027,"completion":24027,"start":8158,"enrollment":3374,"conditions":24028,"interventions":24029},"NCT02891057","Sun Protection Factor Assay (SPF Assay 104\u002F2016)",[94],"2016-08-24",[18],[23910],{"nctId":24031,"briefTitle":24032,"status":107,"phases":24033,"primaryCompletion":24034,"completion":24034,"start":24035,"enrollment":24036,"conditions":24037,"interventions":24038},"NCT02831478","Outdoor-Use Test for Sunscreen Products in Children Ages 3 to 9 Years Old",[94],"2016-07-10","2016-07-09",98,[23092],[23910,23932],{"intervention":6912,"totalTrials":1181,"cells":24040},{"EARLY_PHASE1":24041,"PHASE1":24043,"PHASE2":24053,"PHASE3":24059,"PHASE4":24074,"NA":24080},{"trials":24042,"activeCount":101},[],{"trials":24044,"activeCount":101},[24045,24049],{"nctId":17191,"briefTitle":17192,"status":107,"phases":24046,"primaryCompletion":1313,"completion":1313,"start":4292,"enrollment":1701,"conditions":24047,"interventions":24048},[90],[15,16080],[17184,6912],{"nctId":17205,"briefTitle":17206,"status":107,"phases":24050,"primaryCompletion":1313,"completion":1313,"start":4292,"enrollment":1701,"conditions":24051,"interventions":24052},[90],[15,16080],[17184,6912],{"trials":24054,"activeCount":101},[24055],{"nctId":15443,"briefTitle":15444,"status":107,"phases":24056,"primaryCompletion":15446,"completion":15446,"start":15447,"enrollment":15448,"conditions":24057,"interventions":24058},[91],[7793],[6912,15434,15451],{"trials":24060,"activeCount":101},[24061,24070],{"nctId":24062,"briefTitle":24063,"status":107,"phases":24064,"primaryCompletion":24065,"completion":24065,"start":24066,"enrollment":24067,"conditions":24068,"interventions":24069},"NCT02403401","Safety and Contraceptive Efficacy of an Intravaginal Ring With LNG (Levonorgestrel) Over One Year in Healthy Women",[92],"2016-07-07","2015-05-15",1471,[15],[6912],{"nctId":11017,"briefTitle":11018,"status":107,"phases":24071,"primaryCompletion":193,"completion":1122,"start":11020,"enrollment":11021,"conditions":24072,"interventions":24073},[92],[15],[6912,11006],{"trials":24075,"activeCount":101},[24076],{"nctId":6907,"briefTitle":6908,"status":107,"phases":24077,"primaryCompletion":408,"completion":408,"start":4666,"enrollment":2408,"conditions":24078,"interventions":24079},[93],[15,1426],[6912,6894],{"trials":24081,"activeCount":101},[24082,24090,24097,24103,24112,24122,24131,24140],{"nctId":24083,"briefTitle":24084,"status":107,"phases":24085,"primaryCompletion":2229,"completion":2281,"start":3619,"enrollment":24086,"conditions":24087,"interventions":24089},"NCT00883662","Mirena Observational Program",[],2725,[15,1426,1416,24088],"Estrogen Replacement Therapy",[6912],{"nctId":24091,"briefTitle":24092,"status":107,"phases":24093,"primaryCompletion":2917,"completion":3989,"start":1351,"enrollment":24094,"conditions":24095,"interventions":24096},"NCT01590537","Non-interventional Study of Long-term Intrauterine Contraceptives Acceptability and User Satisfaction",[],2348,[15],[6912],{"nctId":24098,"briefTitle":24099,"status":107,"phases":24100,"completion":498,"start":2970,"enrollment":15200,"conditions":24101,"interventions":24102},"NCT00874653","Survey on Patient Satisfaction Rate for Mirena Use in Heavy Menstrual Bleeding",[],[1426],[6912],{"nctId":24104,"briefTitle":24105,"status":107,"phases":24106,"primaryCompletion":2482,"completion":24107,"start":8159,"enrollment":24108,"conditions":24109,"interventions":24111},"NCT02574715","An Observational Study to Assess Quality of Life and Satisfaction of Young Women (Aged 18-29) Following 6 (±1) Months Using Jaydess as Their Contraceptive Method",[],"2016-09-28",1039,[24110],"Quality of Life",[6912],{"nctId":24113,"briefTitle":24114,"status":107,"phases":24115,"completion":1327,"start":4700,"enrollment":24116,"conditions":24117,"interventions":24119},"NCT01085487","MiCo - Mirena or Conventional Medical Treatment for Menorrhagia",[],1211,[24118],"Idiopathic Menorrhagia",[6912,24120,24121],"Hormonal treatment","Antifibrinolytic treatment",{"nctId":24123,"briefTitle":24124,"status":107,"phases":24125,"primaryCompletion":24126,"completion":24126,"start":24127,"enrollment":24128,"conditions":24129,"interventions":24130},"NCT02349815","JAYDESS Drug Utilization Study in Sweden",[],"2022-04-01","2017-01-01",10000,[15],[6912],{"nctId":24132,"briefTitle":24133,"status":107,"phases":24134,"primaryCompletion":24135,"completion":3212,"start":2489,"enrollment":24136,"conditions":24137,"interventions":24139},"NCT02903888","A Cross-sectional, Observational Multicenter Study to Assess the Reasons for Choosing the 3-year Hormonal IUD and Level of IUDs Knowledge Among Women Aged 18 to 29 Years",[],"2017-10-30",886,[24138],"Intrauterine Devices, Medicated",[6912],{"nctId":24141,"briefTitle":24142,"status":107,"phases":24143,"primaryCompletion":1570,"completion":1570,"start":3567,"enrollment":4144,"conditions":24144,"interventions":24145},"NCT00864136","Mirena or Conventional Medical Treatment for Menorrhagia",[],[1426],[6912,24146,24146],"Conventional medical treatment",{"intervention":2202,"totalTrials":1181,"cells":24148},{"EARLY_PHASE1":24149,"PHASE1":24151,"PHASE2":24161,"PHASE3":24171,"PHASE4":24185,"NA":24187},{"trials":24150,"activeCount":101},[],{"trials":24152,"activeCount":101},[24153,24157],{"nctId":2193,"briefTitle":2194,"status":107,"phases":24154,"primaryCompletion":2196,"completion":2197,"start":2198,"enrollment":2199,"conditions":24155,"interventions":24156},[90],[29],[1011,2202,2203,1154,2204],{"nctId":3564,"briefTitle":3565,"status":107,"phases":24158,"primaryCompletion":1497,"completion":1497,"start":3567,"enrollment":3568,"conditions":24159,"interventions":24160},[90],[3560],[2202,3542,3571],{"trials":24162,"activeCount":101},[24163,24167],{"nctId":13102,"briefTitle":13103,"status":107,"phases":24164,"completion":5472,"start":6396,"enrollment":435,"conditions":24165,"interventions":24166},[91],[21],[13078,13078,13078,2202],{"nctId":13108,"briefTitle":13109,"status":107,"phases":24168,"completion":1648,"start":1315,"enrollment":13111,"conditions":24169,"interventions":24170},[91],[21],[13078,13078,13078,2202],{"trials":24172,"activeCount":101},[24173,24177,24181],{"nctId":3712,"briefTitle":3713,"status":107,"phases":24174,"primaryCompletion":1629,"completion":2406,"start":2959,"enrollment":1519,"conditions":24175,"interventions":24176},[92],[3716],[3542,3718,2202],{"nctId":3784,"briefTitle":3785,"status":107,"phases":24178,"primaryCompletion":2230,"completion":2367,"start":410,"enrollment":2151,"conditions":24179,"interventions":24180},[92],[3621],[3542,3542,3718,2202],{"nctId":3806,"briefTitle":3807,"status":107,"phases":24182,"primaryCompletion":499,"completion":3809,"start":3723,"enrollment":3810,"conditions":24183,"interventions":24184},[92],[21],[3542,2202,3772,3813],{"trials":24186,"activeCount":101},[],{"trials":24188,"activeCount":101},[24189,24193,24197,24207,24211,24215,24219],{"nctId":3976,"briefTitle":3977,"status":156,"phases":24190,"primaryCompletion":3979,"completion":3979,"start":3980,"enrollment":3981,"conditions":24191,"interventions":24192},[],[3983],[3542,3943,1126,2202],{"nctId":3994,"briefTitle":3995,"status":107,"phases":24194,"primaryCompletion":3997,"completion":3997,"start":3998,"enrollment":3999,"conditions":24195,"interventions":24196},[],[21],[3542,3943,4002,2202],{"nctId":24198,"briefTitle":24199,"status":107,"phases":24200,"primaryCompletion":24201,"completion":24201,"start":24202,"enrollment":24203,"conditions":24204,"interventions":24205},"NCT06278051","An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism",[],"2024-11-11","2024-02-19",320,[3631],[24206,2202],"Rivaroxaban granules for oral suspension",{"nctId":4308,"briefTitle":4309,"status":107,"phases":24208,"primaryCompletion":4311,"completion":4311,"start":4312,"enrollment":4313,"conditions":24209,"interventions":24210},[],[21],[3542,2202],{"nctId":4363,"briefTitle":4364,"status":107,"phases":24212,"primaryCompletion":4366,"completion":4366,"start":4367,"enrollment":4368,"conditions":24213,"interventions":24214},[],[4052],[3542,2202],{"nctId":4394,"briefTitle":4395,"status":107,"phases":24216,"primaryCompletion":4397,"completion":4397,"start":4398,"enrollment":4399,"conditions":24217,"interventions":24218},[],[21],[3542,3943,2202],{"nctId":4413,"briefTitle":4414,"status":107,"phases":24220,"primaryCompletion":4095,"completion":4095,"start":4258,"enrollment":4416,"conditions":24221,"interventions":24222},[],[3560,3716,21,4099],[3542,2202,4419],{"intervention":19825,"totalTrials":1181,"cells":24224},{"EARLY_PHASE1":24225,"PHASE1":24227,"PHASE2":24239,"PHASE3":24241,"PHASE4":24266,"NA":24274},{"trials":24226,"activeCount":101},[],{"trials":24228,"activeCount":101},[24229,24235],{"nctId":24230,"briefTitle":24231,"status":107,"phases":24232,"primaryCompletion":4657,"completion":4657,"start":4627,"enrollment":1163,"conditions":24233,"interventions":24234},"NCT01653639","Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222",[90],[24],[19825,19825],{"nctId":19820,"briefTitle":19821,"status":107,"phases":24236,"completion":5472,"start":6396,"enrollment":701,"conditions":24237,"interventions":24238},[90],[24],[19813,19813,19825,19825],{"trials":24240,"activeCount":101},[],{"trials":24242,"activeCount":101},[24243,24250,24257],{"nctId":24244,"briefTitle":24245,"status":107,"phases":24246,"primaryCompletion":1351,"completion":2406,"start":4612,"enrollment":24247,"conditions":24248,"interventions":24249},"NCT00623480","Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and\u002For Adolescent Subjects Compared to That of Episodic Treatment",[92],84,[24],[19825,19825],{"nctId":24251,"briefTitle":24252,"status":107,"phases":24253,"primaryCompletion":1585,"completion":7061,"start":499,"enrollment":3414,"conditions":24254,"interventions":24256},"NCT01029340","Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A",[92],[24255,24],"Blood Coagulation Disorders",[19825,19825,19825,19825],{"nctId":24258,"briefTitle":24259,"status":107,"phases":24260,"primaryCompletion":24261,"completion":7991,"start":24262,"enrollment":16791,"conditions":24263,"interventions":24265},"NCT01311648","BAY81-8973 Pediatric Safety and Efficacy Trial",[92],"2019-09-09","2011-06-09",[24264],"Haemophilia A",[19825,19825],{"trials":24267,"activeCount":101},[24268],{"nctId":24269,"briefTitle":24270,"status":107,"phases":24271,"primaryCompletion":2367,"completion":2367,"start":7061,"enrollment":160,"conditions":24272,"interventions":24273},"NCT01810666","Prophylaxis Versus on Demand Treatment for Children With Hemophilia A",[93],[24],[19825],{"trials":24275,"activeCount":101},[24276,24282,24288,24294,24300,24306,24312,24318],{"nctId":24277,"briefTitle":24278,"status":107,"phases":24279,"primaryCompletion":23663,"completion":5911,"start":12940,"enrollment":1303,"conditions":24280,"interventions":24281},"NCT02581969","Extension at 10 Years of the: \"Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A.\"",[],[24],[19825,19825],{"nctId":24283,"briefTitle":24284,"status":107,"phases":24285,"completion":1351,"start":8109,"enrollment":124,"conditions":24286,"interventions":24287},"NCT00922597","Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery",[],[24],[19825],{"nctId":24289,"briefTitle":24290,"status":107,"phases":24291,"primaryCompletion":1577,"completion":2187,"start":1327,"enrollment":447,"conditions":24292,"interventions":24293},"NCT01386268","Kogenate FS Regulatory Post-Marketing Surveillance",[],[24],[19825],{"nctId":24295,"briefTitle":24296,"status":107,"phases":24297,"completion":2919,"start":4700,"enrollment":6445,"conditions":24298,"interventions":24299},"NCT00932555","EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Taiwan",[],[24],[19825],{"nctId":24301,"briefTitle":24302,"status":107,"phases":24303,"primaryCompletion":1488,"completion":1487,"start":1352,"enrollment":13838,"conditions":24304,"interventions":24305},"NCT01436825","Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients",[],[24264],[19825],{"nctId":24307,"briefTitle":24308,"status":107,"phases":24309,"primaryCompletion":5409,"completion":5409,"start":3706,"enrollment":1007,"conditions":24310,"interventions":24311},"NCT01159587","Prophylaxis Versus On-demand Therapy Through Economic Report",[],[24],[19825,19825],{"nctId":24313,"briefTitle":24314,"status":107,"phases":24315,"primaryCompletion":2264,"completion":4250,"start":1423,"enrollment":6844,"conditions":24316,"interventions":24317},"NCT00874926","EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer\u002FFS",[],[24],[19825],{"nctId":24319,"briefTitle":24320,"status":107,"phases":24321,"primaryCompletion":2950,"completion":3609,"start":3576,"enrollment":8015,"conditions":24322,"interventions":24323},"NCT00969319","Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America",[],[24255,24],[19825],{"intervention":6720,"totalTrials":2316,"cells":24325},{"EARLY_PHASE1":24326,"PHASE1":24328,"PHASE2":24338,"PHASE3":24340,"PHASE4":24374,"NA":24392},{"trials":24327,"activeCount":101},[],{"trials":24329,"activeCount":101},[24330],{"nctId":24331,"briefTitle":24332,"status":107,"phases":24333,"primaryCompletion":8962,"completion":8962,"start":1497,"enrollment":995,"conditions":24334,"interventions":24337},"NCT01014247","Influence of Moxifloxacin on QTc Interval in Healthy Subjects for Positive Control Validation",[90],[24335,24336],"QTc Evaluation","Electrocardiography",[6720],{"trials":24339,"activeCount":101},[],{"trials":24341,"activeCount":101},[24342,24346,24350,24354,24358,24362,24370],{"nctId":9426,"briefTitle":9427,"status":107,"phases":24343,"primaryCompletion":6269,"completion":1648,"start":4789,"enrollment":9429,"conditions":24344,"interventions":24345},[92],[9431],[6720,9415],{"nctId":9748,"briefTitle":9749,"status":107,"phases":24347,"primaryCompletion":3627,"completion":3627,"start":3668,"enrollment":9751,"conditions":24348,"interventions":24349},[92],[6718],[6720,9737],{"nctId":9770,"briefTitle":9771,"status":107,"phases":24351,"primaryCompletion":3576,"completion":2256,"start":3567,"enrollment":1081,"conditions":24352,"interventions":24353},[92],[9667],[6720,9759],{"nctId":9831,"briefTitle":9832,"status":107,"phases":24355,"primaryCompletion":3619,"completion":4736,"start":4691,"enrollment":2151,"conditions":24356,"interventions":24357},[92],[6718],[6720,9820],{"nctId":10247,"briefTitle":10248,"status":107,"phases":24359,"primaryCompletion":10250,"completion":10250,"start":10251,"enrollment":10252,"conditions":24360,"interventions":24361},[92],[10254],[10236,6720],{"nctId":24363,"briefTitle":24364,"status":107,"phases":24365,"primaryCompletion":1648,"completion":1648,"start":10250,"enrollment":24366,"conditions":24367,"interventions":24369},"NCT00473460","Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis",[92],1404,[24368,23861],"Lung Diseases",[6720],{"nctId":12177,"briefTitle":12178,"status":107,"phases":24371,"completion":6048,"start":12180,"enrollment":12181,"conditions":24372,"interventions":24373},[92],[12183,12184],[6720,12166],{"trials":24375,"activeCount":101},[24376,24380,24388],{"nctId":6713,"briefTitle":6714,"status":107,"phases":24377,"primaryCompletion":4707,"completion":4707,"start":5395,"enrollment":6716,"conditions":24378,"interventions":24379},[93],[6718],[6720,6700],{"nctId":24381,"briefTitle":24382,"status":107,"phases":24383,"completion":6048,"start":6112,"enrollment":24384,"conditions":24385,"interventions":24387},"NCT00668304","Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox",[93],192,[24386],"Maxillary Sinusitis",[6720],{"nctId":7433,"briefTitle":7434,"status":107,"phases":24389,"primaryCompletion":5409,"completion":5409,"start":4612,"enrollment":7436,"conditions":24390,"interventions":24391},[93],[7438],[6720,7420],{"trials":24393,"activeCount":101},[24394,24402],{"nctId":24395,"briefTitle":24396,"status":107,"phases":24397,"primaryCompletion":498,"completion":498,"start":3778,"enrollment":24398,"conditions":24399,"interventions":24401},"NCT00930488","Treatment of Patients With Acute Sinusitis",[],6777,[24400],"Acute Bacterial Sinusitis",[6720],{"nctId":24403,"briefTitle":24404,"status":107,"phases":24405,"primaryCompletion":24406,"completion":23525,"start":24407,"enrollment":8118,"conditions":24408,"interventions":24409},"NCT01690533","Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease",[],"2010-12-14","2008-05-13",[17799],[6720],{"intervention":5939,"totalTrials":2316,"cells":24411},{"EARLY_PHASE1":24412,"PHASE1":24414,"PHASE2":24416,"PHASE3":24433,"PHASE4":24474,"NA":24476},{"trials":24413,"activeCount":101},[],{"trials":24415,"activeCount":101},[],{"trials":24417,"activeCount":101},[24418,24425,24429],{"nctId":24419,"briefTitle":24420,"status":107,"phases":24421,"primaryCompletion":446,"completion":446,"start":6599,"enrollment":24422,"conditions":24423,"interventions":24424},"NCT00805415","Ovulation Inhibition of Two 4-phasic Oral Contraceptive Regimens",[91],209,[8191],[5939,5939],{"nctId":14965,"briefTitle":14966,"status":107,"phases":24426,"completion":5472,"start":4836,"enrollment":1007,"conditions":24427,"interventions":24428},[91],[15],[5939,14956],{"nctId":16450,"briefTitle":16451,"status":107,"phases":24430,"primaryCompletion":445,"completion":445,"start":4861,"enrollment":6430,"conditions":24431,"interventions":24432},[91],[16454],[5939,16441],{"trials":24434,"activeCount":101},[24435,24442,24446,24453,24459,24463,24470],{"nctId":24436,"briefTitle":24437,"status":107,"phases":24438,"completion":1315,"start":4707,"enrollment":24439,"conditions":24440,"interventions":24441},"NCT00185289","Study to Investigate Efficacy and Safety of a New Oral Contraceptive",[92],1392,[15],[5939],{"nctId":10955,"briefTitle":10956,"status":107,"phases":24443,"completion":4750,"start":4836,"enrollment":10958,"conditions":24444,"interventions":24445},[92],[15],[5939,10944],{"nctId":24447,"briefTitle":24448,"status":107,"phases":24449,"primaryCompletion":3723,"completion":11861,"start":4836,"enrollment":24450,"conditions":24451,"interventions":24452},"NCT00206583","Efficacy and Safety Study of an Oral Contraceptive in Healthy Females",[92],499,[15],[5939],{"nctId":24454,"briefTitle":24455,"status":107,"phases":24456,"primaryCompletion":548,"completion":548,"start":1585,"enrollment":8911,"conditions":24457,"interventions":24458},"NCT01638923","Study of a 4-phasic Oral Contraceptive for the Treatment of Heavy Menstrual Bleeding",[92],[9243],[5939],{"nctId":5932,"briefTitle":5933,"status":107,"phases":24460,"primaryCompletion":549,"completion":549,"start":4588,"enrollment":5935,"conditions":24461,"interventions":24462},[92],[15,5937],[5939,1492],{"nctId":24464,"briefTitle":24465,"status":107,"phases":24466,"primaryCompletion":3732,"completion":3732,"start":1585,"enrollment":24467,"conditions":24468,"interventions":24469},"NCT01638910","Efficacy and Safety of a Combined Oral Contraceptive of Estradiol Valerate and Dienogest in Healthy Female Subjects",[92],955,[15],[5939],{"nctId":12342,"briefTitle":12343,"status":107,"phases":24471,"primaryCompletion":5409,"completion":5409,"start":498,"enrollment":12345,"conditions":24472,"interventions":24473},[92],[9210,6150,12347],[5939,12331],{"trials":24475,"activeCount":101},[],{"trials":24477,"activeCount":101},[24478,24487,24495],{"nctId":24479,"briefTitle":24480,"status":107,"phases":24481,"primaryCompletion":24482,"completion":24483,"start":24484,"enrollment":233,"conditions":24485,"interventions":24486},"NCT01602770","Qlaira Post-authorization Safety Study Related to Most Common Adverse Events in Mexican Women Who Wish to Avoid Pregnancy",[],"2017-05-17","2017-10-31","2015-02-06",[15],[5939],{"nctId":24488,"briefTitle":24489,"status":107,"phases":24490,"primaryCompletion":3609,"completion":3989,"start":3793,"enrollment":24491,"conditions":24492,"interventions":24493},"NCT01200186","Non-interventional Study on Oral Contraception Not Containing Ethinylestradiol (EE) to Assess Continuation Rates and Satisfaction",[],3258,[8017],[5939,24494],"Progestin Only Pills",{"nctId":24496,"briefTitle":24497,"status":107,"phases":24498,"primaryCompletion":24499,"completion":24500,"start":24501,"enrollment":3205,"conditions":24502,"interventions":24503},"NCT01797809","Qlaira rPMS (Regulatory Post Marketing Surveillance) Study in Korea",[],"2018-01-16","2018-05-08","2013-05-11",[15],[5939],{"intervention":3943,"totalTrials":4620,"cells":24505},{"EARLY_PHASE1":24506,"PHASE1":24508,"PHASE2":24510,"PHASE3":24520,"PHASE4":24526,"NA":24528},{"trials":24507,"activeCount":101},[],{"trials":24509,"activeCount":101},[],{"trials":24511,"activeCount":101},[24512,24516],{"nctId":7882,"briefTitle":7883,"status":107,"phases":24513,"primaryCompletion":7885,"completion":7886,"start":7887,"enrollment":7888,"conditions":24514,"interventions":24515},[91],[7890],[3633,3943,7892],{"nctId":13389,"briefTitle":13390,"status":107,"phases":24517,"primaryCompletion":13392,"completion":13392,"start":324,"enrollment":13393,"conditions":24518,"interventions":24519},[91],[13395],[13371,3943],{"trials":24521,"activeCount":101},[24522],{"nctId":8668,"briefTitle":8669,"status":156,"phases":24523,"primaryCompletion":8671,"completion":8671,"start":8672,"enrollment":8673,"conditions":24524,"interventions":24525},[92],[8675,21],[8632,3943],{"trials":24527,"activeCount":101},[],{"trials":24529,"activeCount":101},[24530,24534,24538,24542,24546,24550,24557,24564,24568],{"nctId":3935,"briefTitle":3936,"status":107,"phases":24531,"primaryCompletion":3938,"completion":3938,"start":3939,"enrollment":3940,"conditions":24532,"interventions":24533},[],[3896,3631,219],[3542,3943],{"nctId":3955,"briefTitle":3956,"status":107,"phases":24535,"primaryCompletion":3958,"completion":3958,"start":3959,"enrollment":3960,"conditions":24536,"interventions":24537},[],[21],[3963,3943,3542,3964],{"nctId":3976,"briefTitle":3977,"status":156,"phases":24539,"primaryCompletion":3979,"completion":3979,"start":3980,"enrollment":3981,"conditions":24540,"interventions":24541},[],[3983],[3542,3943,1126,2202],{"nctId":3994,"briefTitle":3995,"status":107,"phases":24543,"primaryCompletion":3997,"completion":3997,"start":3998,"enrollment":3999,"conditions":24544,"interventions":24545},[],[21],[3542,3943,4002,2202],{"nctId":4113,"briefTitle":4114,"status":107,"phases":24547,"primaryCompletion":4116,"completion":4116,"start":4117,"enrollment":4118,"conditions":24548,"interventions":24549},[],[4120],[3542,3943,4122],{"nctId":24551,"briefTitle":24552,"status":107,"phases":24553,"primaryCompletion":2417,"completion":2417,"start":24554,"enrollment":296,"conditions":24555,"interventions":24556},"NCT05471830","An Observational Study (Called RETAF-PS) Using a Patient Survey to Learn More About Treatment Outcomes in Patients With Irregular and Often Rapid Heartbeat (Atrial Fibrillation) Treated With Apixaban in a Real World Setting",[],"2022-11-30",[8646,21],[3943],{"nctId":24558,"briefTitle":24559,"status":107,"phases":24560,"primaryCompletion":4203,"completion":4203,"start":4204,"enrollment":24561,"conditions":24562,"interventions":24563},"NCT02687854","Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist",[],18591,[21],[3943,3763],{"nctId":4394,"briefTitle":4395,"status":107,"phases":24565,"primaryCompletion":4397,"completion":4397,"start":4398,"enrollment":4399,"conditions":24566,"interventions":24567},[],[21],[3542,3943,2202],{"nctId":4438,"briefTitle":4439,"status":107,"phases":24569,"primaryCompletion":4441,"completion":4442,"start":4443,"enrollment":4444,"conditions":24570,"interventions":24571},[],[3743],[3542,4002,3943],{"intervention":9669,"totalTrials":4620,"cells":24573},{"EARLY_PHASE1":24574,"PHASE1":24576,"PHASE2":24611,"PHASE3":24625,"PHASE4":24644,"NA":24653},{"trials":24575,"activeCount":101},[],{"trials":24577,"activeCount":101},[24578,24585,24591,24598,24604],{"nctId":24579,"briefTitle":24580,"status":107,"phases":24581,"primaryCompletion":4627,"completion":4627,"start":1506,"enrollment":1701,"conditions":24582,"interventions":24584},"NCT01538667","Study to Characterize Lung Deposition, Pharmacokinetics, Safety and Tolerability of Single Inhalations of Radiolabeled Ciprofloxacin Dry Powder in Healthy Subjects and Patients With Chronic Lung Diseases",[90],[24583],"Respiratory System",[9669,9669,9669,9669],{"nctId":24586,"briefTitle":24587,"status":107,"phases":24588,"primaryCompletion":8962,"completion":549,"start":3809,"enrollment":1081,"conditions":24589,"interventions":24590},"NCT01072942","To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD, GOLD II-III)",[90],[19802],[9669],{"nctId":24592,"briefTitle":24593,"status":107,"phases":24594,"primaryCompletion":3793,"completion":3793,"start":4587,"enrollment":411,"conditions":24595,"interventions":24597},"NCT00910351","Cipro Inhaler for Cystic Fibrosis Children Ages 6-12",[90],[24596],"Pseudomonas Infection",[9669],{"nctId":24599,"briefTitle":24600,"status":107,"phases":24601,"primaryCompletion":4596,"completion":4596,"start":1314,"enrollment":411,"conditions":24602,"interventions":24603},"NCT00961038","Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",[90],[19802],[9669,9669],{"nctId":24605,"briefTitle":24606,"status":107,"phases":24607,"primaryCompletion":3576,"completion":3576,"start":4700,"enrollment":2388,"conditions":24608,"interventions":24610},"NCT01052298","Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)",[90],[24609],"Disease, Pulmonary",[9669,9669,9669],{"trials":24612,"activeCount":101},[24613,24619],{"nctId":24614,"briefTitle":24615,"status":107,"phases":24616,"primaryCompletion":1569,"completion":1569,"start":4597,"enrollment":3023,"conditions":24617,"interventions":24618},"NCT00645788","Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis",[91],[1601],[9669,9669],{"nctId":24620,"briefTitle":24621,"status":107,"phases":24622,"primaryCompletion":2968,"completion":2968,"start":4736,"enrollment":6886,"conditions":24623,"interventions":24624},"NCT00930982","Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis",[91],[10004],[9669],{"trials":24626,"activeCount":101},[24627,24634,24638],{"nctId":24628,"briefTitle":24629,"status":107,"phases":24630,"primaryCompletion":3657,"completion":3657,"start":5395,"enrollment":1163,"conditions":24631,"interventions":24633},"NCT00668044","Ciprofloxacin on Burned Patients",[92],[24632,6541],"Burns",[9669,9669],{"nctId":9661,"briefTitle":9662,"status":107,"phases":24635,"primaryCompletion":3818,"completion":3818,"start":9664,"enrollment":9665,"conditions":24636,"interventions":24637},[92],[9667],[9669,9650],{"nctId":24639,"briefTitle":24640,"status":107,"phases":24641,"primaryCompletion":1486,"completion":1486,"start":1507,"enrollment":30,"conditions":24642,"interventions":24643},"NCT01561794","A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics\u002FPharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia",[92],[6718],[9669],{"trials":24645,"activeCount":101},[24646],{"nctId":24647,"briefTitle":24648,"status":107,"phases":24649,"completion":22617,"start":8451,"enrollment":24650,"conditions":24651,"interventions":24652},"NCT00669994","Trial to Evaluate the Efficacy and Safety of Cipro® XR in Treating Female Patients With Lower Urinary Tract Infections",[93],180,[6387],[9669],{"trials":24654,"activeCount":101},[24655],{"nctId":24656,"briefTitle":24657,"status":107,"phases":24658,"primaryCompletion":8962,"completion":3793,"start":445,"enrollment":24659,"conditions":24660,"interventions":24661},"NCT01670435","Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance",[],3274,[12370],[9669],{"intervention":24663,"totalTrials":4620,"cells":24664},"BAY987521",{"EARLY_PHASE1":24665,"PHASE1":24667,"PHASE2":24669,"PHASE3":24671,"PHASE4":24673,"NA":24675},{"trials":24666,"activeCount":101},[],{"trials":24668,"activeCount":101},[],{"trials":24670,"activeCount":101},[],{"trials":24672,"activeCount":101},[],{"trials":24674,"activeCount":101},[],{"trials":24676,"activeCount":101},[24677,24685,24692,24700,24706,24712,24718,24725,24732,24740,24746,24753],{"nctId":24678,"briefTitle":24679,"status":107,"phases":24680,"primaryCompletion":24681,"completion":24681,"start":24682,"enrollment":2316,"conditions":24683,"interventions":24684},"NCT02774252","18475 - Sun Protection Factor Assay",[94],"2015-09-03","2015-08-13",[18],[24663],{"nctId":24686,"briefTitle":24687,"status":107,"phases":24688,"primaryCompletion":23980,"completion":23980,"start":13475,"enrollment":3374,"conditions":24689,"interventions":24690},"NCT02995148","Sun Protection Factor Assay (343\u002F2016)",[94],[18],[24663,24691],"SPF Control",{"nctId":24693,"briefTitle":24694,"status":107,"phases":24695,"primaryCompletion":24696,"completion":24696,"start":24697,"enrollment":328,"conditions":24698,"interventions":24699},"NCT02936570","Sun Protection Factor Assay (SPF Assay 206\u002F2016)",[94],"2016-11-01","2016-10-26",[18],[24663],{"nctId":24701,"briefTitle":24702,"status":107,"phases":24703,"primaryCompletion":20729,"completion":20729,"start":24697,"enrollment":2041,"conditions":24704,"interventions":24705},"NCT02936544","Sun Protection Factor Assay (SPF Assay 204\u002F2016)",[94],[18],[24663],{"nctId":24707,"briefTitle":24708,"status":107,"phases":24709,"primaryCompletion":20729,"completion":20729,"start":24697,"enrollment":2041,"conditions":24710,"interventions":24711},"NCT02936557","Sun Protection Factor Assay (SPF Assay 205\u002F2016)",[94],[18],[24663],{"nctId":24713,"briefTitle":24714,"status":156,"phases":24715,"primaryCompletion":23980,"completion":23980,"start":23981,"enrollment":328,"conditions":24716,"interventions":24717},"NCT02995031","Sun Protection Factor Assay (318\u002F2016)",[94],[18],[24663,24691],{"nctId":24719,"briefTitle":24720,"status":107,"phases":24721,"primaryCompletion":1596,"completion":1596,"start":24722,"enrollment":3374,"conditions":24723,"interventions":24724},"NCT02995109","Sun Protection Factor Assay (338\u002F2016)",[94],"2017-01-04",[18],[24663,24691],{"nctId":24726,"briefTitle":24727,"status":107,"phases":24728,"primaryCompletion":24729,"completion":24729,"start":23981,"enrollment":2041,"conditions":24730,"interventions":24731},"NCT02995018","Sun Protection Factor Assay (317\u002F2016)",[94],"2017-01-25",[18],[24663,24691],{"nctId":24733,"briefTitle":24734,"status":107,"phases":24735,"primaryCompletion":24736,"completion":24736,"start":24736,"enrollment":1630,"conditions":24737,"interventions":24738},"NCT02854137","Evaluation of the Irritation Potential of Sunscreen Products in Human Eyes",[94],"2015-10-14",[18],[24663,24739],"Control",{"nctId":24741,"briefTitle":24742,"status":107,"phases":24743,"primaryCompletion":24696,"completion":24696,"start":24697,"enrollment":5220,"conditions":24744,"interventions":24745},"NCT02936583","Sun Protection Factor Assay (SPF Assay 207\u002F2016)",[94],[18],[24663],{"nctId":24747,"briefTitle":24748,"status":107,"phases":24749,"primaryCompletion":24722,"completion":24722,"start":13475,"enrollment":3374,"conditions":24750,"interventions":24751},"NCT02995161","Sun Protection Factor Assay (344\u002F2016)",[94],[18],[24663,24752],"SPF control",{"nctId":24754,"briefTitle":24755,"status":156,"phases":24756,"primaryCompletion":23980,"completion":23980,"start":24722,"enrollment":328,"conditions":24757,"interventions":24758},"NCT02995044","Sun Protection Factor Assay (319\u002F2016)",[94],[18],[24663,24691],{"intervention":6890,"totalTrials":2041,"cells":24760},{"EARLY_PHASE1":24761,"PHASE1":24763,"PHASE2":24781,"PHASE3":24783,"PHASE4":24801,"NA":24807},{"trials":24762,"activeCount":101},[],{"trials":24764,"activeCount":101},[24765,24771,24777],{"nctId":24766,"briefTitle":24767,"status":107,"phases":24768,"primaryCompletion":2366,"completion":2969,"start":1327,"enrollment":33,"conditions":24769,"interventions":24770},"NCT01388153","A 3-fold Crossover Bioequivalence Study Between Glucobay Orally Disintegrating Tablet (ODT) and Glucobay Standard Tablet",[90],[6888],[6890,6890,6890],{"nctId":24772,"briefTitle":24773,"status":107,"phases":24774,"primaryCompletion":1507,"completion":1507,"start":410,"enrollment":9115,"conditions":24775,"interventions":24776},"NCT01554631","A 3-fold Crossover Bioequivalence Study Between Glucobay ODT (Orally Disintegrating Tablet) 100 mg and Glucobay Standard Tablet 100 mg",[90],[6888],[6890,6890],{"nctId":17476,"briefTitle":17477,"status":107,"phases":24778,"primaryCompletion":4657,"completion":4657,"start":5052,"enrollment":1519,"conditions":24779,"interventions":24780},[90],[17480],[17460,6890,17482],{"trials":24782,"activeCount":101},[],{"trials":24784,"activeCount":101},[24785,24794],{"nctId":24786,"briefTitle":24787,"status":107,"phases":24788,"primaryCompletion":3091,"completion":24789,"start":24790,"enrollment":24791,"conditions":24792,"interventions":24793},"NCT03349684","Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients",[92],"2019-08-21","2018-03-05",287,[6888],[6890,17482],{"nctId":24795,"briefTitle":24796,"status":107,"phases":24797,"primaryCompletion":445,"completion":445,"start":24798,"enrollment":2408,"conditions":24799,"interventions":24800},"NCT01010100","Prevent\u002FDelay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care",[92],"2000-08",[8425],[6890],{"trials":24802,"activeCount":101},[24803],{"nctId":6883,"briefTitle":6884,"status":107,"phases":24804,"primaryCompletion":410,"completion":410,"start":1497,"enrollment":6886,"conditions":24805,"interventions":24806},[93],[6888],[6890,6870],{"trials":24808,"activeCount":101},[24809,24816,24823,24830,24839],{"nctId":24810,"briefTitle":24811,"status":107,"phases":24812,"primaryCompletion":4588,"completion":4588,"start":2970,"enrollment":24813,"conditions":24814,"interventions":24815},"NCT01612741","Diabetes Treatment With Glucobay in Combination With Metformin",[],19509,[749],[6890],{"nctId":24817,"briefTitle":24818,"status":107,"phases":24819,"primaryCompletion":4612,"completion":1423,"start":445,"enrollment":24820,"conditions":24821,"interventions":24822},"NCT01167231","Prevention of Postprandial Hyperglycemia by Acarbose May be a Promising Therapeutic Strategy for Reducing the Increased Risk for Cardiovascular Disease",[],3310,[8425],[6890],{"nctId":24824,"briefTitle":24825,"status":107,"phases":24826,"primaryCompletion":498,"completion":498,"start":2970,"enrollment":24827,"conditions":24828,"interventions":24829},"NCT01613105","Diabetes Treatment With Glucobay in Combination With Sulfonylurea",[],4564,[749],[6890],{"nctId":24831,"briefTitle":24832,"status":107,"phases":24833,"primaryCompletion":24834,"completion":24834,"start":24835,"enrollment":24836,"conditions":24837,"interventions":24838},"NCT00909051","GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups",[],"2010-12-31","2009-03-24",15729,[8425],[6890],{"nctId":24840,"briefTitle":24841,"status":107,"phases":24842,"completion":4627,"start":2968,"enrollment":5976,"conditions":24843,"interventions":24844},"NCT01248481","GlucoFriend-evaluation the Effectiveness of Glucobay When Combined With a Basal Insulin",[],[8425],[6890],{"intervention":1356,"totalTrials":3374,"cells":24846},{"EARLY_PHASE1":24847,"PHASE1":24849,"PHASE2":24867,"PHASE3":24895,"PHASE4":24913,"NA":24915},{"trials":24848,"activeCount":101},[],{"trials":24850,"activeCount":101},[24851,24855,24861],{"nctId":1348,"briefTitle":1349,"status":107,"phases":24852,"primaryCompletion":1351,"completion":1352,"start":1315,"enrollment":33,"conditions":24853,"interventions":24854},[90],[423,1354],[1356,1356,1357,1357,1357,1357,1358,1074],{"nctId":24856,"briefTitle":24857,"status":107,"phases":24858,"primaryCompletion":4736,"completion":4596,"start":3768,"enrollment":1599,"conditions":24859,"interventions":24860},"NCT00562913","Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin",[90],[219],[1356],{"nctId":24862,"briefTitle":24863,"status":107,"phases":24864,"primaryCompletion":4647,"completion":4292,"start":445,"enrollment":1081,"conditions":24865,"interventions":24866},"NCT00606125","Sorafenib\u002F Carboplatin\u002F Paclitaxel in Patients With Solid Tumors",[90],[29],[1356],{"trials":24868,"activeCount":101},[24869,24875,24882,24888],{"nctId":24870,"briefTitle":24871,"status":107,"phases":24872,"primaryCompletion":5472,"completion":5472,"start":3628,"enrollment":4285,"conditions":24873,"interventions":24874},"NCT00661375","BAY43-9006 Phase II Study for Renal Cell Carcinoma",[91],[2328],[1356],{"nctId":24876,"briefTitle":24877,"status":107,"phases":24878,"primaryCompletion":5946,"completion":5946,"start":3668,"enrollment":3374,"conditions":24879,"interventions":24881},"NCT00661180","Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec",[91],[24880],"Chronic Myelogenous Leukemia",[1356],{"nctId":24883,"briefTitle":24884,"status":156,"phases":24885,"primaryCompletion":3819,"completion":3819,"start":6270,"enrollment":233,"conditions":24886,"interventions":24887},"NCT00110344","Research Study for Patients With Metastatic Renal Cell Carcinoma",[91],[2328],[1356],{"nctId":24889,"briefTitle":24890,"status":107,"phases":24891,"primaryCompletion":3705,"completion":3705,"start":3658,"enrollment":4466,"conditions":24892,"interventions":24894},"NCT00657254","Extension Program for Bay 43-9006",[91],[19390,24893],"Metastasis",[1356],{"trials":24896,"activeCount":101},[24897,24906],{"nctId":24898,"briefTitle":24899,"status":107,"phases":24900,"primaryCompletion":3453,"completion":24901,"start":24902,"enrollment":24903,"conditions":24904,"interventions":24905},"NCT00692770","Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)",[92],"2014-11-28","2008-08-15",1114,[1009],[1356],{"nctId":24907,"briefTitle":24908,"status":107,"phases":24909,"primaryCompletion":3567,"completion":3567,"start":4789,"enrollment":24910,"conditions":24911,"interventions":24912},"NCT00492986","An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma",[92],1150,[2328],[1356],{"trials":24914,"activeCount":101},[],{"trials":24916,"activeCount":101},[24917],{"nctId":24918,"briefTitle":24919,"status":107,"phases":24920,"primaryCompletion":1587,"completion":1587,"start":1315,"enrollment":24921,"conditions":24922,"interventions":24923},"NCT00895674","Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar",[],2840,[2328,4936],[1356],{"intervention":23801,"totalTrials":3374,"cells":24925},{"EARLY_PHASE1":24926,"PHASE1":24928,"PHASE2":24934,"PHASE3":24943,"PHASE4":24983,"NA":24985},{"trials":24927,"activeCount":101},[],{"trials":24929,"activeCount":101},[24930],{"nctId":23796,"briefTitle":23797,"status":107,"phases":24931,"completion":6384,"start":3668,"enrollment":4934,"conditions":24932,"interventions":24933},[90],[5948],[23801,23801,23801,23801,1144],{"trials":24935,"activeCount":101},[24936],{"nctId":24937,"briefTitle":24938,"status":107,"phases":24939,"primaryCompletion":10250,"completion":10250,"start":3706,"enrollment":4620,"conditions":24940,"interventions":24942},"NCT00652418","Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography",[91],[23601,10298,24941],"Peripheral Arterial Diseases",[23801,23801],{"trials":24944,"activeCount":101},[24945,24952,24959,24966,24972,24979],{"nctId":24946,"briefTitle":24947,"status":107,"phases":24948,"completion":10250,"start":6113,"enrollment":8971,"conditions":24949,"interventions":24951},"NCT00310609","Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Aortic Arch and Cerebral Branches",[92],[24950],"Cardiovascular Abnormalities",[23801],{"nctId":24953,"briefTitle":24954,"status":107,"phases":24955,"completion":6363,"start":6113,"enrollment":10065,"conditions":24956,"interventions":24958},"NCT00310557","Magnevist® Injection-enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis of the Renal Arteries",[92],[24957],"Renal Artery Stenosis",[23801],{"nctId":24960,"briefTitle":24961,"status":107,"phases":24962,"completion":3628,"start":6113,"enrollment":3214,"conditions":24963,"interventions":24965},"NCT00309075","Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis in the Calf and\u002For Pedal Arteries",[92],[24964],"Stenosis",[23801],{"nctId":24967,"briefTitle":24968,"status":107,"phases":24969,"primaryCompletion":2968,"completion":2968,"start":3809,"enrollment":2345,"conditions":24970,"interventions":24971},"NCT00937391","Contrast-enhanced MRI in Children 2 Months to \u003C2 Years",[92],[6978],[23801],{"nctId":24973,"briefTitle":24974,"status":107,"phases":24975,"completion":6281,"start":6599,"enrollment":7124,"conditions":24976,"interventions":24978},"NCT00185276","Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries",[92],[24977],"Peripheral Vascular Disease",[23801,23801],{"nctId":23551,"briefTitle":23552,"status":107,"phases":24980,"primaryCompletion":2188,"completion":2188,"start":3809,"enrollment":1991,"conditions":24981,"interventions":24982},[92],[6978],[6980,23556],{"trials":24984,"activeCount":101},[],{"trials":24986,"activeCount":101},[24987,24994],{"nctId":24988,"briefTitle":24989,"status":107,"phases":24990,"primaryCompletion":3601,"completion":2406,"start":3567,"enrollment":20791,"conditions":24991,"interventions":24993},"NCT00744939","Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist",[],[23569,24992,16975],"Kidney Failure",[23801],{"nctId":24995,"briefTitle":24996,"status":107,"phases":24997,"primaryCompletion":8962,"completion":8962,"start":9022,"enrollment":24998,"conditions":24999,"interventions":25000},"NCT01376739","Magnevist Post-marketing Surveillance in Japan",[],2051,[8726],[23801],{"intervention":9124,"totalTrials":3374,"cells":25002},{"EARLY_PHASE1":25003,"PHASE1":25005,"PHASE2":25007,"PHASE3":25009,"PHASE4":25054,"NA":25063},{"trials":25004,"activeCount":101},[],{"trials":25006,"activeCount":101},[],{"trials":25008,"activeCount":101},[],{"trials":25010,"activeCount":101},[25011,25018,25025,25032,25039,25043,25047],{"nctId":25012,"briefTitle":25013,"status":107,"phases":25014,"primaryCompletion":1543,"completion":4880,"start":3601,"enrollment":25015,"conditions":25016,"interventions":25017},"NCT01892904","Comparative Study of BAY86-5300 With a Flexible Extended Regimen for Dysmenorrhea",[92],216,[6172],[9124],{"nctId":25019,"briefTitle":25020,"status":107,"phases":25021,"primaryCompletion":2917,"completion":3733,"start":408,"enrollment":8110,"conditions":25022,"interventions":25023},"NCT01697111","Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis",[92],[7793],[9124,25024],"Dienogest",{"nctId":25026,"briefTitle":25027,"status":464,"phases":25028,"primaryCompletion":4992,"completion":25029,"start":2407,"enrollment":101,"conditions":25030,"interventions":25031},"NCT02617537","To Investigate Efficacy of YAZ in the Treatment of Dysmenorrhea",[92],"2017-10",[6172],[9124],{"nctId":25033,"briefTitle":25034,"status":107,"phases":25035,"primaryCompletion":1497,"completion":1497,"start":6493,"enrollment":25036,"conditions":25037,"interventions":25038},"NCT00567164","Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ",[92],1887,[15,8191,8017],[9124,9124,9124],{"nctId":12075,"briefTitle":12076,"status":107,"phases":25040,"primaryCompletion":1352,"completion":1352,"start":1326,"enrollment":12078,"conditions":25041,"interventions":25042},[92],[9210],[9124,12064],{"nctId":9119,"briefTitle":9120,"status":464,"phases":25044,"primaryCompletion":3732,"completion":3732,"start":4250,"enrollment":101,"conditions":25045,"interventions":25046},[92],[15],[9124,9101,9101],{"nctId":25048,"briefTitle":25049,"status":107,"phases":25050,"primaryCompletion":1569,"completion":1569,"start":4588,"enrollment":7018,"conditions":25051,"interventions":25053},"NCT00824187","YAZ Premenstrual Dysphoric Disorder (PMDD) in China",[92],[25052],"Premenstrual Dysphoric Disorder ( PMDD)",[9124],{"trials":25055,"activeCount":101},[25056],{"nctId":25057,"briefTitle":25058,"status":107,"phases":25059,"primaryCompletion":2196,"completion":2196,"start":16411,"enrollment":25060,"conditions":25061,"interventions":25062},"NCT02710708","YAZ Post Authorization Safety Study (PASS)\u002FPost Authorization Efficacy Study (PAES) in China",[93],1921,[15],[9124],{"trials":25064,"activeCount":101},[25065,25074],{"nctId":25066,"briefTitle":25067,"status":107,"phases":25068,"primaryCompletion":5999,"completion":5999,"start":4587,"enrollment":25069,"conditions":25070,"interventions":25073},"NCT00998257","Regulatory Post Marketing Surveillance Study on YAZ",[],770,[15,25071,25072],"Premenstrual Syndrome","Acne",[9124],{"nctId":25075,"briefTitle":25076,"status":107,"phases":25077,"primaryCompletion":3222,"completion":25078,"start":24262,"enrollment":25079,"conditions":25080,"interventions":25081},"NCT01375998","YAZ Post-marketing Surveillance in Japan",[],"2018-03-08",3273,[6172],[9124],{"intervention":25083,"totalTrials":4466,"cells":25084},"Eylea",{"EARLY_PHASE1":25085,"PHASE1":25087,"PHASE2":25089,"PHASE3":25091,"PHASE4":25107,"NA":25123},{"trials":25086,"activeCount":101},[],{"trials":25088,"activeCount":101},[],{"trials":25090,"activeCount":101},[],{"trials":25092,"activeCount":101},[25093,25100],{"nctId":25094,"briefTitle":25095,"status":107,"phases":25096,"primaryCompletion":3502,"completion":3502,"start":4320,"enrollment":435,"conditions":25097,"interventions":25099},"NCT04015180","Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090",[92],[25098],"Retinopathy of Prematurity (ROP)",[25083],{"nctId":25101,"briefTitle":25102,"status":107,"phases":25103,"primaryCompletion":25104,"completion":25104,"start":12694,"enrollment":4424,"conditions":25105,"interventions":25106},"NCT04004208","Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy",[92],"2021-02-12",[25098],[25083],{"trials":25108,"activeCount":101},[25109,25117],{"nctId":25110,"briefTitle":25111,"status":107,"phases":25112,"primaryCompletion":25113,"completion":25113,"start":3639,"enrollment":25114,"conditions":25115,"interventions":25116},"NCT02581995","Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.",[93],"2017-08-09",560,[2953],[25083],{"nctId":25118,"briefTitle":25119,"status":107,"phases":25120,"primaryCompletion":3241,"completion":3241,"start":3639,"enrollment":24791,"conditions":25121,"interventions":25122},"NCT02581891","Managing Neovascular (Known as \"Wet\") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye",[93],[2922],[25083,25083],{"trials":25124,"activeCount":101},[25125,25134,25143,25151,25157],{"nctId":25126,"briefTitle":25127,"status":107,"phases":25128,"primaryCompletion":25129,"completion":25130,"start":7501,"enrollment":25131,"conditions":25132,"interventions":25133},"NCT03470103","A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America",[],"2020-09-21","2021-01-15",643,[2922],[25083],{"nctId":25135,"briefTitle":25136,"status":107,"phases":25137,"primaryCompletion":4952,"completion":25138,"start":23163,"enrollment":541,"conditions":25139,"interventions":25142},"NCT02585401","Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada",[],"2016-05-19",[25140,25141,3065],"Age-related Macular Degeneration (AMD)","Central Retinal Vein Occlusion (CRVO)",[25083],{"nctId":25144,"briefTitle":25145,"status":107,"phases":25146,"primaryCompletion":4117,"completion":25147,"start":23699,"enrollment":8849,"conditions":25148,"interventions":25149},"NCT02850263","A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema",[],"2020-11-23",[2953],[25083,25150,25150],"Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals \u002F Antineovascularisation agents",{"nctId":25152,"briefTitle":25153,"status":107,"phases":25154,"primaryCompletion":4266,"completion":4266,"start":2505,"enrollment":4462,"conditions":25155,"interventions":25156},"NCT03521895","An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies",[],[2922],[25083],{"nctId":25158,"briefTitle":25159,"status":107,"phases":25160,"primaryCompletion":25161,"completion":25161,"start":25162,"enrollment":10065,"conditions":25163,"interventions":25164},"NCT03411941","Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)",[],"2019-03-01","2018-02-28",[2922],[25083],{"intervention":6627,"totalTrials":4466,"cells":25166},{"EARLY_PHASE1":25167,"PHASE1":25169,"PHASE2":25175,"PHASE3":25177,"PHASE4":25197,"NA":25216},{"trials":25168,"activeCount":101},[],{"trials":25170,"activeCount":101},[25171],{"nctId":21602,"briefTitle":21603,"status":107,"phases":25172,"primaryCompletion":2969,"completion":1351,"start":2188,"enrollment":458,"conditions":25173,"interventions":25174},[90],[14368],[21595,6627],{"trials":25176,"activeCount":101},[],{"trials":25178,"activeCount":101},[25179,25185,25191],{"nctId":25180,"briefTitle":25181,"status":107,"phases":25182,"primaryCompletion":5999,"completion":1585,"start":2344,"enrollment":11,"conditions":25183,"interventions":25184},"NCT01294215","High Dose BAYA1040_Nifedipine: a Long Term Combination Study",[92],[6625],[6627],{"nctId":25186,"briefTitle":25187,"status":107,"phases":25188,"primaryCompletion":2969,"completion":2969,"start":1569,"enrollment":22747,"conditions":25189,"interventions":25190},"NCT01287260","High Dose BAYA1040_Nifedipine: a Dose-comparative Study",[92],[6625],[6627,6627],{"nctId":25192,"briefTitle":25193,"status":107,"phases":25194,"primaryCompletion":1351,"completion":1506,"start":1569,"enrollment":2126,"conditions":25195,"interventions":25196},"NCT01355367","High Dose BAYA1040 CR: a Long Term Extension Study",[92],[6625],[6627],{"trials":25198,"activeCount":101},[25199,25203,25207],{"nctId":6620,"briefTitle":6621,"status":107,"phases":25200,"primaryCompletion":4648,"completion":4648,"start":6384,"enrollment":6623,"conditions":25201,"interventions":25202},[93],[6625],[6627,6628,6607],{"nctId":7121,"briefTitle":7122,"status":107,"phases":25204,"primaryCompletion":2959,"completion":2959,"start":3809,"enrollment":7124,"conditions":25205,"interventions":25206},[93],[6625],[7108,6627,7127],{"nctId":25208,"briefTitle":25209,"status":107,"phases":25210,"primaryCompletion":25211,"completion":25211,"start":25212,"enrollment":25213,"conditions":25214,"interventions":25215},"NCT02413515","Blood Pressure Control of Nifedipine GITS 60mg Treatment in Chinese Hypertensive Subjects Uncontrolled on Starting-dose Mono-therapyo-therapy.",[93],"2016-08-08","2015-03-26",278,[6625],[6627],{"trials":25217,"activeCount":101},[25218,25225],{"nctId":25219,"briefTitle":25220,"status":107,"phases":25221,"completion":1351,"start":3809,"enrollment":25222,"conditions":25223,"interventions":25224},"NCT01118286","Treatment of Hypertension With Adalat® in Combination With Other Drugs",[],4497,[6625],[6627],{"nctId":25226,"briefTitle":25227,"status":107,"phases":25228,"primaryCompletion":2282,"completion":3601,"start":1497,"enrollment":25229,"conditions":25230,"interventions":25231},"NCT01363336","Post-marketing Surveillance for Hypertensive Patients With Diabetes and\u002For Chronic Kidney Disease",[],1882,[6625],[6627],{"intervention":6043,"totalTrials":4466,"cells":25233},{"EARLY_PHASE1":25234,"PHASE1":25236,"PHASE2":25238,"PHASE3":25251,"PHASE4":25260,"NA":25279},{"trials":25235,"activeCount":101},[],{"trials":25237,"activeCount":101},[],{"trials":25239,"activeCount":101},[25240,25244],{"nctId":15110,"briefTitle":15111,"status":107,"phases":25241,"primaryCompletion":3618,"completion":3618,"start":1587,"enrollment":11430,"conditions":25242,"interventions":25243},[91],[27],[15101,6043],{"nctId":25245,"briefTitle":25246,"status":107,"phases":25247,"primaryCompletion":1423,"completion":1423,"start":3778,"enrollment":229,"conditions":25248,"interventions":25250},"NCT00461123","Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy",[91],[25249],"Prostatic Hypertrophy, Benign",[6043],{"trials":25252,"activeCount":101},[25253],{"nctId":25254,"briefTitle":25255,"status":107,"phases":25256,"primaryCompletion":3668,"completion":3668,"start":22625,"enrollment":25257,"conditions":25258,"interventions":25259},"NCT00654680","Evaluating the Efficacy and Safety of Vardenafil in Patients Erectile Dysfunction Solely Secondary to Spinal Cord Injury",[92],418,[27],[6043],{"trials":25261,"activeCount":101},[25262,25268,25272],{"nctId":25263,"briefTitle":25264,"status":107,"phases":25265,"primaryCompletion":4707,"completion":4707,"start":6599,"enrollment":883,"conditions":25266,"interventions":25267},"NCT00668135","Assessment of Vardenafil in Patients With Erectile Dysfunction in Asia",[93],[27],[6043],{"nctId":6037,"briefTitle":6038,"status":107,"phases":25269,"completion":4666,"start":5946,"enrollment":112,"conditions":25270,"interventions":25271},[93],[6041],[1591,6043],{"nctId":25273,"briefTitle":25274,"status":107,"phases":25275,"primaryCompletion":2256,"completion":2256,"start":3567,"enrollment":1858,"conditions":25276,"interventions":25278},"NCT00738400","Study of Vardenafil in Patients Suffering From Erectile Dysfunction and Metabolic Syndrome",[93],[27,25277],"Metabolic Syndrome",[6043],{"trials":25280,"activeCount":101},[25281,25288,25295],{"nctId":25282,"briefTitle":25283,"status":107,"phases":25284,"primaryCompletion":4657,"completion":2187,"start":3809,"enrollment":25285,"conditions":25286,"interventions":25287},"NCT01106118","Therapeutic Effectiveness of Vardenafil in Patients With Erectile Dysfunction and Metabolic Syndrome in Daily Clinical Practice",[],2289,[27],[6043],{"nctId":25289,"briefTitle":25290,"status":107,"phases":25291,"primaryCompletion":4736,"completion":4596,"start":6493,"enrollment":25292,"conditions":25293,"interventions":25294},"NCT01207947","LEVITRA® Specific Drug Use Investigation. To Investigate the Safety Profile in Combination Use With Alpha-blockers",[],491,[27],[6043],{"nctId":25296,"briefTitle":25297,"status":156,"phases":25298,"primaryCompletion":3567,"completion":3567,"start":4691,"enrollment":25299,"conditions":25300,"interventions":25301},"NCT01215409","Real Life Safety and Efficacy of Vardenafil",[],372,[27],[6043],{"intervention":1428,"totalTrials":4466,"cells":25303},{"EARLY_PHASE1":25304,"PHASE1":25306,"PHASE2":25308,"PHASE3":25317,"PHASE4":25337,"NA":25339},{"trials":25305,"activeCount":101},[],{"trials":25307,"activeCount":101},[],{"trials":25309,"activeCount":101},[25310],{"nctId":25311,"briefTitle":25312,"status":107,"phases":25313,"primaryCompletion":498,"completion":498,"start":4648,"enrollment":25314,"conditions":25315,"interventions":25316},"NCT00185380","Dose-finding Study for the Ultralow-dose Levonorgestrel Intrauterine Contraceptive System (LCS)",[91],742,[15],[1428,1428,1428],{"trials":25318,"activeCount":101},[25319,25323,25330],{"nctId":1420,"briefTitle":1421,"status":107,"phases":25320,"primaryCompletion":1423,"completion":1423,"start":1315,"enrollment":1424,"conditions":25321,"interventions":25322},[92],[1426],[1428,1398],{"nctId":25324,"briefTitle":25325,"status":107,"phases":25326,"primaryCompletion":2282,"completion":2282,"start":4700,"enrollment":25327,"conditions":25328,"interventions":25329},"NCT00884260","GA Levonorgestrel Intrauterine Contraceptive System (LCS) Phase III Study China",[92],918,[15],[1428],{"nctId":25331,"briefTitle":25332,"status":107,"phases":25333,"primaryCompletion":25334,"completion":25334,"start":3020,"enrollment":9429,"conditions":25335,"interventions":25336},"NCT02985541","Mirena Extension Trial",[92],"2021-05-28",[15],[1428],{"trials":25338,"activeCount":101},[],{"trials":25340,"activeCount":101},[25341,25351,25358,25364,25372],{"nctId":25342,"briefTitle":25343,"status":107,"phases":25344,"primaryCompletion":25345,"completion":25346,"start":18518,"enrollment":25347,"conditions":25348,"interventions":25350},"NCT02475356","Prospective, Non-interventional, Multi-center Safety Study of Mirena for Heavy Menstrual Bleeding and Dysmenorrhea",[],"2019-01-18","2019-12-12",601,[25349],"Menorrhagia, Dysmenorrhea",[1428],{"nctId":25352,"briefTitle":25353,"status":107,"phases":25354,"primaryCompletion":3989,"completion":3989,"start":1629,"enrollment":25355,"conditions":25356,"interventions":25357},"NCT01958684","Bleeding Pattern Difference Between Levonorgestrel Intrauterine System (LNG-IUS) and Copper Intrauterine Devices (IUDs) Immediately Inserted After Abortion",[],512,[15],[1428],{"nctId":25359,"briefTitle":25360,"status":107,"phases":25361,"primaryCompletion":408,"completion":408,"start":445,"enrollment":6078,"conditions":25362,"interventions":25363},"NCT01414140","Mirena Post-marketing Surveillance in Japan",[],[15],[1428],{"nctId":25365,"briefTitle":25366,"status":107,"phases":25367,"primaryCompletion":5999,"completion":5999,"start":3818,"enrollment":25368,"conditions":25369,"interventions":25370},"NCT00931827","Acceptability of Long-term Progestin-only Contraception in Europe",[],436,[15],[1428,25371],"Implanon",{"nctId":25373,"briefTitle":25374,"status":107,"phases":25375,"primaryCompletion":3567,"completion":3567,"start":6281,"enrollment":25376,"conditions":25377,"interventions":25378},"NCT00868153","Mirena in Idiopathic Menorrhagia",[],1125,[24118],[1428],{"intervention":24691,"totalTrials":421,"cells":25380},{"EARLY_PHASE1":25381,"PHASE1":25383,"PHASE2":25385,"PHASE3":25387,"PHASE4":25389,"NA":25391},{"trials":25382,"activeCount":101},[],{"trials":25384,"activeCount":101},[],{"trials":25386,"activeCount":101},[],{"trials":25388,"activeCount":101},[],{"trials":25390,"activeCount":101},[],{"trials":25392,"activeCount":101},[25393,25397,25404,25408,25412,25416,25423,25427],{"nctId":24686,"briefTitle":24687,"status":107,"phases":25394,"primaryCompletion":23980,"completion":23980,"start":13475,"enrollment":3374,"conditions":25395,"interventions":25396},[94],[18],[24663,24691],{"nctId":25398,"briefTitle":25399,"status":107,"phases":25400,"primaryCompletion":23980,"completion":23980,"start":1667,"enrollment":3374,"conditions":25401,"interventions":25402},"NCT02995122","Sun Protection Factor Assay (339\u002F2016)",[94],[18],[25403,24691],"BAY987516",{"nctId":24713,"briefTitle":24714,"status":156,"phases":25405,"primaryCompletion":23980,"completion":23980,"start":23981,"enrollment":328,"conditions":25406,"interventions":25407},[94],[18],[24663,24691],{"nctId":24719,"briefTitle":24720,"status":107,"phases":25409,"primaryCompletion":1596,"completion":1596,"start":24722,"enrollment":3374,"conditions":25410,"interventions":25411},[94],[18],[24663,24691],{"nctId":24726,"briefTitle":24727,"status":107,"phases":25413,"primaryCompletion":24729,"completion":24729,"start":23981,"enrollment":2041,"conditions":25414,"interventions":25415},[94],[18],[24663,24691],{"nctId":25417,"briefTitle":25418,"status":107,"phases":25419,"primaryCompletion":20728,"completion":20728,"start":3020,"enrollment":4620,"conditions":25420,"interventions":25421},"NCT02994992","Sun Protection Factor Assay (316\u002F2016)",[94],[18],[25422,24691],"BAY 987516",{"nctId":24747,"briefTitle":24748,"status":107,"phases":25424,"primaryCompletion":24722,"completion":24722,"start":13475,"enrollment":3374,"conditions":25425,"interventions":25426},[94],[18],[24663,24752],{"nctId":24754,"briefTitle":24755,"status":156,"phases":25428,"primaryCompletion":23980,"completion":23980,"start":24722,"enrollment":328,"conditions":25429,"interventions":25430},[94],[18],[24663,24691],{"intervention":25024,"totalTrials":421,"cells":25432},{"EARLY_PHASE1":25433,"PHASE1":25435,"PHASE2":25444,"PHASE3":25452,"PHASE4":25464,"NA":25466},{"trials":25434,"activeCount":101},[],{"trials":25436,"activeCount":101},[25437],{"nctId":25438,"briefTitle":25439,"status":107,"phases":25440,"primaryCompletion":4587,"completion":3576,"start":7249,"enrollment":13111,"conditions":25441,"interventions":25443},"NCT00754871","Pharmacodynamic Characterization of Dienogest",[90],[25442],"Pharmacodynamics",[25024,25024,25024,25024],{"trials":25445,"activeCount":101},[25446],{"nctId":25447,"briefTitle":25448,"status":107,"phases":25449,"primaryCompletion":7061,"completion":1488,"start":5975,"enrollment":793,"conditions":25450,"interventions":25451},"NCT01283724","Visanne Study to Assess Safety in Adolescents",[91],[7793],[25024],{"trials":25453,"activeCount":101},[25454,25460],{"nctId":25455,"briefTitle":25456,"status":107,"phases":25457,"primaryCompletion":2290,"completion":2281,"start":7061,"enrollment":148,"conditions":25458,"interventions":25459},"NCT01822080","Phase 3 Study of Dienogest for the Treatment of Endometriosis in Chinese Patients",[92],[7793],[25024],{"nctId":25019,"briefTitle":25020,"status":107,"phases":25461,"primaryCompletion":2917,"completion":3733,"start":408,"enrollment":8110,"conditions":25462,"interventions":25463},[92],[7793],[9124,25024],{"trials":25465,"activeCount":101},[],{"trials":25467,"activeCount":101},[25468,25477,25487,25494],{"nctId":25469,"briefTitle":25470,"status":107,"phases":25471,"primaryCompletion":25472,"completion":25472,"start":25473,"enrollment":25474,"conditions":25475,"interventions":25476},"NCT04495855","A Study to Learn More About Using Dienogest to Treat Endometriosis in Chinese Participants",[],"2022-12-23","2020-10-28",968,[7793],[25024],{"nctId":25478,"briefTitle":25479,"status":107,"phases":25480,"primaryCompletion":25481,"completion":25482,"start":25483,"enrollment":22755,"conditions":25484,"interventions":25486},"NCT04808843","A Study to Learn More About How Safe Dienogest is and How Well it Works Under Real World Conditions in Indian Women With Endometriosis",[],"2024-02-05","2024-09-23","2022-05-13",[25485],"Endometriosis Associated Pelvic Pain",[25024],{"nctId":25488,"briefTitle":25489,"status":107,"phases":25490,"primaryCompletion":22991,"completion":22991,"start":23525,"enrollment":25491,"conditions":25492,"interventions":25493},"NCT01788722","Regulatory Post Marketing Surveillance Study in Korea",[],3223,[7793],[25024],{"nctId":25495,"briefTitle":25496,"status":107,"phases":25497,"primaryCompletion":21188,"completion":5240,"start":25498,"enrollment":25499,"conditions":25500,"interventions":25501},"NCT02425462","To Evaluate Effectiveness of Visanne in Improving Quality of Life in Asian Women With Endometriosis",[],"2015-04-28",895,[7793],[25024],{"intervention":3763,"totalTrials":480,"cells":25503},{"EARLY_PHASE1":25504,"PHASE1":25506,"PHASE2":25508,"PHASE3":25510,"PHASE4":25520,"NA":25522},{"trials":25505,"activeCount":101},[],{"trials":25507,"activeCount":101},[],{"trials":25509,"activeCount":101},[],{"trials":25511,"activeCount":101},[25512,25516],{"nctId":3754,"briefTitle":3755,"status":156,"phases":25513,"primaryCompletion":3221,"completion":3221,"start":1832,"enrollment":3757,"conditions":25514,"interventions":25515},[92],[3759],[3542,3761,3762,3542,3763],{"nctId":3824,"briefTitle":3825,"status":107,"phases":25517,"primaryCompletion":2367,"completion":2367,"start":408,"enrollment":3827,"conditions":25518,"interventions":25519},[92],[21],[3542,3763],{"trials":25521,"activeCount":101},[],{"trials":25523,"activeCount":101},[25524,25528,25535,25545,25549],{"nctId":3902,"briefTitle":3903,"status":107,"phases":25525,"primaryCompletion":3905,"completion":3905,"start":3906,"enrollment":3907,"conditions":25526,"interventions":25527},[],[3896],[3542,3899,3910,3911],{"nctId":25529,"briefTitle":25530,"status":107,"phases":25531,"primaryCompletion":4203,"completion":4203,"start":4204,"enrollment":25532,"conditions":25533,"interventions":25534},"NCT02687867","Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist",[],56039,[21],[4002,3763],{"nctId":25536,"briefTitle":25537,"status":107,"phases":25538,"primaryCompletion":25539,"completion":17274,"start":25540,"enrollment":25541,"conditions":25542,"interventions":25543},"NCT02610153","Subtherapeutic INR Levels in Patients With AVK: Incidence, Associated Factors, Prognosis and Control Strategies",[],"2018-06-30","2015-10-01",1013,[21],[25544],"Vitamin K Antagonist",{"nctId":4157,"briefTitle":4158,"status":107,"phases":25546,"primaryCompletion":4160,"completion":4160,"start":4107,"enrollment":4161,"conditions":25547,"interventions":25548},[],[4163],[3542,3763],{"nctId":24558,"briefTitle":24559,"status":107,"phases":25550,"primaryCompletion":4203,"completion":4203,"start":4204,"enrollment":24561,"conditions":25551,"interventions":25552},[],[21],[3943,3763],{"intervention":25554,"totalTrials":480,"cells":25555},"Iloprost",{"EARLY_PHASE1":25556,"PHASE1":25558,"PHASE2":25560,"PHASE3":25562,"PHASE4":25573,"NA":25575},{"trials":25557,"activeCount":101},[],{"trials":25559,"activeCount":101},[],{"trials":25561,"activeCount":101},[],{"trials":25563,"activeCount":101},[25564],{"nctId":25565,"briefTitle":25566,"status":107,"phases":25567,"primaryCompletion":25568,"completion":25569,"start":25570,"enrollment":701,"conditions":25571,"interventions":25572},"NCT01469169","Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study",[92],"2014-12-26","2016-12-14","2012-06-19",[1500],[25554],{"trials":25574,"activeCount":101},[],{"trials":25576,"activeCount":101},[25577,25585,25592,25598,25607,25614],{"nctId":25578,"briefTitle":25579,"status":107,"phases":25580,"primaryCompletion":3203,"completion":25581,"start":25582,"enrollment":2316,"conditions":25583,"interventions":25584},"NCT01894035","Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation",[],"2017-04-13","2013-09-23",[1589],[25554],{"nctId":25586,"briefTitle":25587,"status":107,"phases":25588,"primaryCompletion":25589,"completion":3979,"start":4390,"enrollment":36,"conditions":25590,"interventions":25591},"NCT03293407","Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension",[],"2019-10-09",[1500],[25554],{"nctId":25593,"briefTitle":25594,"status":107,"phases":25595,"primaryCompletion":4736,"completion":4736,"start":1315,"enrollment":2199,"conditions":25596,"interventions":25597},"NCT01062282","Hypertension Study of Ventavis® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension (VENIS)",[],[1589],[25554],{"nctId":25599,"briefTitle":25600,"status":107,"phases":25601,"primaryCompletion":25602,"completion":25603,"start":2211,"enrollment":25604,"conditions":25605,"interventions":25606},"NCT01971450","Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension",[],"2017-06-28","2018-04-18",89,[1500],[25554],{"nctId":25608,"briefTitle":25609,"status":107,"phases":25610,"primaryCompletion":5230,"completion":3733,"start":2969,"enrollment":3214,"conditions":25611,"interventions":25613},"NCT01458041","Iloprost Therapy in Patients With Critical Limb Ischemia",[],[25612],"Peripheral Arterial Disease",[25554],{"nctId":25615,"briefTitle":25616,"status":107,"phases":25617,"primaryCompletion":1506,"completion":4627,"start":4648,"enrollment":3990,"conditions":25618,"interventions":25619},"NCT00250640","Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years",[],[1500],[25554],{"intervention":25403,"totalTrials":5220,"cells":25621},{"EARLY_PHASE1":25622,"PHASE1":25624,"PHASE2":25626,"PHASE3":25628,"PHASE4":25630,"NA":25632},{"trials":25623,"activeCount":101},[],{"trials":25625,"activeCount":101},[],{"trials":25627,"activeCount":101},[],{"trials":25629,"activeCount":101},[],{"trials":25631,"activeCount":101},[],{"trials":25633,"activeCount":101},[25634,25641,25648,25654,25658,25664],{"nctId":25635,"briefTitle":25636,"status":107,"phases":25637,"primaryCompletion":5092,"completion":5092,"start":25638,"enrollment":1341,"conditions":25639,"interventions":25640},"NCT02930798","Sun Protection Factor Assay (SPF Assay 203\u002F2016)",[94],"2016-10-18",[18],[25403],{"nctId":25642,"briefTitle":25643,"status":107,"phases":25644,"primaryCompletion":25645,"completion":25645,"start":17761,"enrollment":1341,"conditions":25646,"interventions":25647},"NCT02930746","Sun Protection Factor Assay (SPF Assay 199\u002F2016)",[94],"2016-10-13",[18],[25403],{"nctId":25649,"briefTitle":25650,"status":107,"phases":25651,"primaryCompletion":25645,"completion":25645,"start":17761,"enrollment":1341,"conditions":25652,"interventions":25653},"NCT02930759","Sun Protection Factor Assay (SPF Assay 200\u002F2016)",[94],[18],[25403],{"nctId":25398,"briefTitle":25399,"status":107,"phases":25655,"primaryCompletion":23980,"completion":23980,"start":1667,"enrollment":3374,"conditions":25656,"interventions":25657},[94],[18],[25403,24691],{"nctId":25659,"briefTitle":25660,"status":107,"phases":25661,"primaryCompletion":4375,"completion":4375,"start":17761,"enrollment":2041,"conditions":25662,"interventions":25663},"NCT02930772","Sun Protection Factor Assay (SPF Assay 201\u002F2016)",[94],[18],[25403],{"nctId":25665,"briefTitle":25666,"status":107,"phases":25667,"primaryCompletion":25668,"completion":25668,"start":25669,"enrollment":2041,"conditions":25670,"interventions":25672},"NCT02885805","Sun Protection Factor (SPF) Efficacy Assay",[94],"2015-07-01","2015-06-26",[25671],"Sunscreen Agents",[25403,25673],"SPF 15 Control",{"intervention":7023,"totalTrials":5220,"cells":25675},{"EARLY_PHASE1":25676,"PHASE1":25678,"PHASE2":25680,"PHASE3":25686,"PHASE4":25688,"NA":25708},{"trials":25677,"activeCount":101},[],{"trials":25679,"activeCount":101},[],{"trials":25681,"activeCount":101},[25682],{"nctId":15336,"briefTitle":15337,"status":156,"phases":25683,"primaryCompletion":15339,"completion":12551,"start":15340,"enrollment":15341,"conditions":25684,"interventions":25685},[91],[15],[15327,15344,7023],{"trials":25687,"activeCount":101},[],{"trials":25689,"activeCount":101},[25690,25694,25701],{"nctId":7015,"briefTitle":7016,"status":107,"phases":25691,"primaryCompletion":2919,"completion":2919,"start":5975,"enrollment":7018,"conditions":25692,"interventions":25693},[93],[7020],[7002,7022,7023],{"nctId":25695,"briefTitle":25696,"status":107,"phases":25697,"completion":4836,"start":22645,"enrollment":1193,"conditions":25698,"interventions":25700},"NCT00696202","Mirena Efficiency and Tolerability During the First Year of Use",[93],[25699,15],"Medicated Intrauterine Devices",[7023],{"nctId":25702,"briefTitle":25703,"status":107,"phases":25704,"primaryCompletion":6493,"completion":6493,"start":6270,"enrollment":25705,"conditions":25706,"interventions":25707},"NCT00498784","HR-QoL and Sexuality in Mirena Inserted Contraception Users",[93],141,[15],[7023],{"trials":25709,"activeCount":101},[25710,25718],{"nctId":25711,"briefTitle":25712,"status":107,"phases":25713,"primaryCompletion":1423,"completion":1497,"start":1328,"enrollment":25714,"conditions":25715,"interventions":25717},"NCT00798980","Scandinavian Mirena Insertion Nulliparous Trial.",[],224,[25716],"Nulliparous",[7023],{"nctId":25719,"briefTitle":25720,"status":107,"phases":25721,"primaryCompletion":25722,"completion":25722,"start":25723,"enrollment":25724,"conditions":25725,"interventions":25727},"NCT02414919","Duration of Use of Highly Effective Reversible Contraception",[],"2016-03-28","2015-04-01",13880,[25726],"Pregnancy",[7023,25728,25729],"ParaGard","Implanon\u002FNexplanon",{"intervention":6847,"totalTrials":5220,"cells":25731},{"EARLY_PHASE1":25732,"PHASE1":25734,"PHASE2":25736,"PHASE3":25738,"PHASE4":25740,"NA":25746},{"trials":25733,"activeCount":101},[],{"trials":25735,"activeCount":101},[],{"trials":25737,"activeCount":101},[],{"trials":25739,"activeCount":101},[],{"trials":25741,"activeCount":101},[25742],{"nctId":6841,"briefTitle":6842,"status":107,"phases":25743,"primaryCompletion":4587,"completion":1314,"start":6493,"enrollment":6844,"conditions":25744,"interventions":25745},[93],[6625],[6828,6847,6848],{"trials":25747,"activeCount":101},[25748,25755,25762,25769,25776],{"nctId":25749,"briefTitle":25750,"status":107,"phases":25751,"primaryCompletion":2968,"completion":2968,"start":1497,"enrollment":25752,"conditions":25753,"interventions":25754},"NCT01071681","Survey to Assess Why People Are Not Responding to Treatment in Hypertension",[],1589,[12783],[6847],{"nctId":25756,"briefTitle":25757,"status":107,"phases":25758,"primaryCompletion":2968,"completion":2968,"start":3809,"enrollment":25759,"conditions":25760,"interventions":25761},"NCT01217879","COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-i Treatment Due to couGH in Slovakia",[],980,[6625],[6847],{"nctId":25763,"briefTitle":25764,"status":107,"phases":25765,"primaryCompletion":3809,"completion":3809,"start":6317,"enrollment":25766,"conditions":25767,"interventions":25768},"NCT00470886","Assessment of Compliance With Antihypertensive Telmisartan Therapy",[],3400,[6625],[6847],{"nctId":25770,"briefTitle":25771,"status":107,"phases":25772,"primaryCompletion":499,"completion":499,"start":3619,"enrollment":25773,"conditions":25774,"interventions":25775},"NCT01211171","COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-I Treatment Due to couGH in Poland",[],2498,[6625],[6847],{"nctId":25777,"briefTitle":25778,"status":107,"phases":25779,"primaryCompletion":1352,"completion":1352,"start":2970,"enrollment":25780,"conditions":25781,"interventions":25782},"NCT00927537","Therapy of Essential Hypertension With Kinzal®\u002F Kinzalplus®",[],2052,[6625],[6847,25783],"Telmisartan (Kinzal\u002FPritor, BAY68-9291) + Hydrochlorothiazide",{"intervention":1126,"totalTrials":328,"cells":25785},{"EARLY_PHASE1":25786,"PHASE1":25788,"PHASE2":25806,"PHASE3":25808,"PHASE4":25810,"NA":25812},{"trials":25787,"activeCount":101},[],{"trials":25789,"activeCount":101},[25790,25794,25798,25802],{"nctId":2598,"briefTitle":2599,"status":464,"phases":25791,"primaryCompletion":2601,"completion":2601,"start":2602,"enrollment":101,"conditions":25792,"interventions":25793},[90],[32],[2581,1115,1126],{"nctId":1944,"briefTitle":1945,"status":107,"phases":25795,"primaryCompletion":1947,"completion":1947,"start":1948,"enrollment":1949,"conditions":25796,"interventions":25797},[90],[1069,1932,1070,1124],[1919,1126,1115],{"nctId":1117,"briefTitle":1118,"status":107,"phases":25799,"primaryCompletion":1120,"completion":1121,"start":1122,"enrollment":97,"conditions":25800,"interventions":25801},[90],[1094,1103,1124],[52,1126],{"nctId":12680,"briefTitle":12681,"status":107,"phases":25803,"primaryCompletion":12683,"completion":3638,"start":12684,"enrollment":1949,"conditions":25804,"interventions":25805},[90],[187],[1126,1154,12687],{"trials":25807,"activeCount":101},[],{"trials":25809,"activeCount":101},[],{"trials":25811,"activeCount":101},[],{"trials":25813,"activeCount":101},[25814],{"nctId":3976,"briefTitle":3977,"status":156,"phases":25815,"primaryCompletion":3979,"completion":3979,"start":3980,"enrollment":3981,"conditions":25816,"interventions":25817},[],[3983],[3542,3943,1126,2202],{"intervention":25819,"totalTrials":328,"cells":25820},"Ventavis",{"EARLY_PHASE1":25821,"PHASE1":25823,"PHASE2":25825,"PHASE3":25835,"PHASE4":25844,"NA":25846},{"trials":25822,"activeCount":101},[],{"trials":25824,"activeCount":101},[],{"trials":25826,"activeCount":101},[25827],{"nctId":25828,"briefTitle":25829,"status":107,"phases":25830,"completion":25831,"start":25832,"enrollment":112,"conditions":25833,"interventions":25834},"NCT00414687","Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension",[91],"2001-05","1998-07",[1500],[25819],{"trials":25836,"activeCount":101},[25837],{"nctId":25838,"briefTitle":25839,"status":107,"phases":25840,"completion":4613,"start":25841,"enrollment":4934,"conditions":25842,"interventions":25843},"NCT00185315","Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension",[92],"2000-02",[1500],[25819],{"trials":25845,"activeCount":101},[],{"trials":25847,"activeCount":101},[25848,25856,25863],{"nctId":25849,"briefTitle":25850,"status":107,"phases":25851,"primaryCompletion":17986,"completion":25852,"start":14122,"enrollment":25853,"conditions":25854,"interventions":25855},"NCT02825160","Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)",[],"2023-09-27",282,[1500],[25819],{"nctId":25857,"briefTitle":25858,"status":107,"phases":25859,"primaryCompletion":15339,"completion":4943,"start":25860,"enrollment":4580,"conditions":25861,"interventions":25862},"NCT01781052","Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients",[],"2013-09-11",[1715],[25819],{"nctId":25864,"briefTitle":25865,"status":107,"phases":25866,"primaryCompletion":7249,"completion":7249,"start":3724,"enrollment":21297,"conditions":25867,"interventions":25869},"NCT00882947","Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)",[],[25868],"Primary Hypertension",[25819],{"intervention":25673,"totalTrials":328,"cells":25871},{"EARLY_PHASE1":25872,"PHASE1":25874,"PHASE2":25876,"PHASE3":25878,"PHASE4":25880,"NA":25882},{"trials":25873,"activeCount":101},[],{"trials":25875,"activeCount":101},[],{"trials":25877,"activeCount":101},[],{"trials":25879,"activeCount":101},[],{"trials":25881,"activeCount":101},[],{"trials":25883,"activeCount":101},[25884,25892,25898,25904,25912],{"nctId":25885,"briefTitle":25886,"status":107,"phases":25887,"primaryCompletion":18520,"completion":18520,"start":25888,"enrollment":5220,"conditions":25889,"interventions":25890},"NCT02872233","Sun Protection Factor (SPF) \u002F UVA Protection Factor (UVAPF) Assay",[94],"2015-05-26",[25671],[25891,25673],"BAY 987519",{"nctId":25893,"briefTitle":25894,"status":107,"phases":25895,"primaryCompletion":25668,"completion":25668,"start":25888,"enrollment":2041,"conditions":25896,"interventions":25897},"NCT02872246","Sun Protection Factor (SPF) \u002F UVA Protection Factor (UVAPF) - Assay",[94],[25671],[25422,25673],{"nctId":25899,"briefTitle":25900,"status":107,"phases":25901,"primaryCompletion":18520,"completion":18520,"start":25888,"enrollment":4620,"conditions":25902,"interventions":25903},"NCT02857738","Sun Protection Factor (SPF) - Static and Water Resistant Assay",[94],[25671],[25891,25673],{"nctId":25905,"briefTitle":25906,"status":107,"phases":25907,"primaryCompletion":3452,"completion":3452,"start":25908,"enrollment":4620,"conditions":25909,"interventions":25910},"NCT02857725","Sun Protection Factor (SPF) Assay",[94],"2015-05-18",[25671],[25911,25673],"BAY 987517",{"nctId":25665,"briefTitle":25666,"status":107,"phases":25913,"primaryCompletion":25668,"completion":25668,"start":25669,"enrollment":2041,"conditions":25914,"interventions":25915},[94],[25671],[25403,25673],{"intervention":3848,"totalTrials":328,"cells":25917},{"EARLY_PHASE1":25918,"PHASE1":25920,"PHASE2":25928,"PHASE3":25930,"PHASE4":25945,"NA":25953},{"trials":25919,"activeCount":101},[],{"trials":25921,"activeCount":101},[25922],{"nctId":25923,"briefTitle":25924,"status":107,"phases":25925,"primaryCompletion":1486,"completion":1486,"start":3594,"enrollment":160,"conditions":25926,"interventions":25927},"NCT02394093","To Evaluate the Bioavailability of a Single Oral Dose of the Acetylsalicylic Acid Containing Dry Powder 500 mg in Comparison to the Bioavailability of a Single Oral Dose of Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adults.",[90],[1511],[3848,3848,3848],{"trials":25929,"activeCount":101},[],{"trials":25931,"activeCount":101},[25932,25941],{"nctId":25933,"briefTitle":25934,"status":107,"phases":25935,"primaryCompletion":5081,"completion":5081,"start":25936,"enrollment":25937,"conditions":25938,"interventions":25940},"NCT00501059","A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease",[92],"2007-07-05",12546,[25939],"Moderate Risk of CVD",[3848],{"nctId":3838,"briefTitle":3839,"status":107,"phases":25942,"primaryCompletion":3841,"completion":3842,"start":3843,"enrollment":3844,"conditions":25943,"interventions":25944},[92],[3846],[3542,3542,3848,3849,3772,3850,3851],{"trials":25946,"activeCount":101},[25947],{"nctId":25948,"briefTitle":25949,"status":107,"phases":25950,"completion":3723,"start":4789,"enrollment":22738,"conditions":25951,"interventions":25952},"NCT01033526","Symptomatic Treatment of Common Cold Symptoms",[93],[6573],[3848],{"trials":25954,"activeCount":101},[25955],{"nctId":25956,"briefTitle":25957,"status":107,"phases":25958,"primaryCompletion":994,"completion":994,"start":1752,"enrollment":25959,"conditions":25960,"interventions":25961},"NCT03579732","EffectiveNess of Low Dose Aspirin in GastrointEstinal Cancer Prevention - Taiwan",[],4710504,[2249],[3848],{"intervention":2974,"totalTrials":328,"cells":25963},{"EARLY_PHASE1":25964,"PHASE1":25966,"PHASE2":25968,"PHASE3":25974,"PHASE4":25980,"NA":25982},{"trials":25965,"activeCount":101},[],{"trials":25967,"activeCount":101},[],{"trials":25969,"activeCount":101},[25970],{"nctId":15297,"briefTitle":15298,"status":156,"phases":25971,"primaryCompletion":4067,"completion":548,"start":3989,"enrollment":19,"conditions":25972,"interventions":25973},[91],[2922],[15288,2974],{"trials":25975,"activeCount":101},[25976],{"nctId":2965,"briefTitle":2966,"status":107,"phases":25977,"primaryCompletion":2968,"completion":2969,"start":2970,"enrollment":2971,"conditions":25978,"interventions":25979},[92],[2922],[2974,82,82,82],{"trials":25981,"activeCount":101},[],{"trials":25983,"activeCount":101},[25984,25992,26000],{"nctId":25985,"briefTitle":25986,"status":107,"phases":25987,"primaryCompletion":2969,"completion":2264,"start":4588,"enrollment":25988,"conditions":25989,"interventions":25991},"NCT01447043","Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)",[],2609,[25990],"Ophthalmology, Macular Degeneration",[2974],{"nctId":25993,"briefTitle":25994,"status":107,"phases":25995,"primaryCompletion":1543,"completion":2290,"start":4250,"enrollment":25996,"conditions":25997,"interventions":25999},"NCT01771081","Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy",[],911,[25998,2953,2922],"Ophthalmology",[2974],{"nctId":26001,"briefTitle":26002,"status":107,"phases":26003,"primaryCompletion":4250,"completion":4250,"start":9407,"enrollment":4693,"conditions":26004,"interventions":26005},"NCT01933152","Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration",[],[2922],[2974],{"intervention":26007,"totalTrials":328,"cells":26008},"Iopromide",{"EARLY_PHASE1":26009,"PHASE1":26011,"PHASE2":26013,"PHASE3":26015,"PHASE4":26017,"NA":26019},{"trials":26010,"activeCount":101},[],{"trials":26012,"activeCount":101},[],{"trials":26014,"activeCount":101},[],{"trials":26016,"activeCount":101},[],{"trials":26018,"activeCount":101},[],{"trials":26020,"activeCount":101},[26021,26030,26037,26045,26052],{"nctId":26022,"briefTitle":26023,"status":107,"phases":26024,"primaryCompletion":2939,"completion":2939,"start":26025,"enrollment":26026,"conditions":26027,"interventions":26029},"NCT03622801","Study on the Risk of Allergy-like Reactions After Intra-arterial or Intra-venous Injection of the Marketed X-ray Contrast Medium Iopromid",[],"2018-10-12",133331,[26028],"Contrast Medium",[26007],{"nctId":26031,"briefTitle":26032,"status":107,"phases":26033,"primaryCompletion":658,"completion":658,"start":4397,"enrollment":26034,"conditions":26035,"interventions":26036},"NCT04605471","A Study to Learn More About the Safety of Ultravist in Children and in the Elderly",[],132850,[8515],[26007],{"nctId":26038,"briefTitle":26039,"status":107,"phases":26040,"primaryCompletion":1351,"completion":1351,"start":1587,"enrollment":26041,"conditions":26042,"interventions":26044},"NCT01206257","The Safety and toleRability of UltraviSt in Patients Undergoing Cardiac CaTheterization (TRUST)",[],17513,[26043],"Angiocardiography",[26007],{"nctId":26046,"briefTitle":26047,"status":107,"phases":26048,"primaryCompletion":4627,"completion":2406,"start":1351,"enrollment":26049,"conditions":26050,"interventions":26051},"NCT01415414","Observational Study of Ultravist in Patients Requiring CECT",[],11660,[8726],[26007],{"nctId":26053,"briefTitle":26054,"status":107,"phases":26055,"primaryCompletion":26056,"completion":26057,"start":26058,"enrollment":26059,"conditions":26060,"interventions":26063},"NCT02840903","A Non-interventional Study to Observe the Computed Tomographic Angiography Image Quality With Different Contrast Media Injection Protocols Under Different Computed Tomography Machines Parameters Setting",[],"2017-07-28","2017-10-11","2016-07-26",1214,[26061,26062],"Angiography","Multidetector Computed Tomography",[26007],{"intervention":26065,"totalTrials":328,"cells":26066},"Gadoxetic Acid Disodium",{"EARLY_PHASE1":26067,"PHASE1":26069,"PHASE2":26071,"PHASE3":26073,"PHASE4":26082,"NA":26093},{"trials":26068,"activeCount":101},[],{"trials":26070,"activeCount":101},[],{"trials":26072,"activeCount":101},[],{"trials":26074,"activeCount":101},[26075],{"nctId":26076,"briefTitle":26077,"status":107,"phases":26078,"primaryCompletion":8109,"completion":8109,"start":9022,"enrollment":4888,"conditions":26079,"interventions":26081},"NCT00526188","Efficacy and Safety of Primovist in Chinese Patients",[92],[26080],"Known or Suspected Focal Liver Lesions",[26065],{"trials":26083,"activeCount":101},[26084],{"nctId":26085,"briefTitle":26086,"status":107,"phases":26087,"primaryCompletion":3601,"completion":3601,"start":3619,"enrollment":26088,"conditions":26089,"interventions":26091},"NCT00908596","Primovist \u002F Eovist in Renally Impaired Patients",[93],357,[26090],"Contrast Media",[26092],"Gadoxetic acid disodium",{"trials":26094,"activeCount":101},[26095,26103,26112],{"nctId":26096,"briefTitle":26097,"status":107,"phases":26098,"completion":3618,"start":6493,"enrollment":26099,"conditions":26100,"interventions":26102},"NCT00924248","Primovist Regulatory Post Marketing Surveillance (PMS)",[],4358,[26101],"Liver",[26092],{"nctId":26104,"briefTitle":26105,"status":107,"phases":26106,"primaryCompletion":24406,"completion":26107,"start":26108,"enrollment":26109,"conditions":26110,"interventions":26111},"NCT01411449","Primovist Post-marketing Surveillance in Japan",[],"2015-02-18","2008-03-11",2030,[8726],[26065],{"nctId":26113,"briefTitle":26114,"status":107,"phases":26115,"primaryCompletion":4250,"completion":4250,"start":499,"enrollment":19,"conditions":26116,"interventions":26119},"NCT01043523","Liver MRI With Primovist\u002FEovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.",[],[2541,26117,4829,26118],"Adenoma","Liver Abscess",[26065],{"intervention":4002,"totalTrials":855,"cells":26121},{"EARLY_PHASE1":26122,"PHASE1":26124,"PHASE2":26126,"PHASE3":26128,"PHASE4":26130,"NA":26132},{"trials":26123,"activeCount":101},[],{"trials":26125,"activeCount":101},[],{"trials":26127,"activeCount":101},[],{"trials":26129,"activeCount":101},[],{"trials":26131,"activeCount":101},[],{"trials":26133,"activeCount":101},[26134,26138,26142,26146],{"nctId":25529,"briefTitle":25530,"status":107,"phases":26135,"primaryCompletion":4203,"completion":4203,"start":4204,"enrollment":25532,"conditions":26136,"interventions":26137},[],[21],[4002,3763],{"nctId":3994,"briefTitle":3995,"status":107,"phases":26139,"primaryCompletion":3997,"completion":3997,"start":3998,"enrollment":3999,"conditions":26140,"interventions":26141},[],[21],[3542,3943,4002,2202],{"nctId":4124,"briefTitle":4125,"status":107,"phases":26143,"primaryCompletion":4127,"completion":4127,"start":2489,"enrollment":4097,"conditions":26144,"interventions":26145},[],[21],[3542,4072,4130],{"nctId":4438,"briefTitle":4439,"status":107,"phases":26147,"primaryCompletion":4441,"completion":4442,"start":4443,"enrollment":4444,"conditions":26148,"interventions":26149},[],[3743],[3542,4002,3943],{"intervention":26151,"totalTrials":855,"cells":26152},"BAY207543",{"EARLY_PHASE1":26153,"PHASE1":26155,"PHASE2":26157,"PHASE3":26159,"PHASE4":26161,"NA":26184},{"trials":26154,"activeCount":101},[],{"trials":26156,"activeCount":101},[],{"trials":26158,"activeCount":101},[],{"trials":26160,"activeCount":101},[],{"trials":26162,"activeCount":101},[26163,26170,26178],{"nctId":26164,"briefTitle":26165,"status":107,"phases":26166,"primaryCompletion":17447,"completion":17447,"start":23627,"enrollment":33,"conditions":26167,"interventions":26169},"NCT03853512","A Study to Gain Information How Well Dexpanthenol Dermal Spray Helps the Skin to Recover After a Peeling in the External Genital Area of Women",[93],[26168],"Skin Recovery",[26151],{"nctId":26171,"briefTitle":26172,"status":107,"phases":26173,"primaryCompletion":26174,"completion":26174,"start":26175,"enrollment":33,"conditions":26176,"interventions":26177},"NCT03853538","A Study to Gain Information How Well Dexpanthenol Dermal Spray Helps the Face Skin to Recover After Cosmetic Lasering",[93],"2019-03-06","2019-01-28",[14072,26168],[26151],{"nctId":26179,"briefTitle":26180,"status":107,"phases":26181,"primaryCompletion":20789,"completion":20789,"start":17242,"enrollment":16124,"conditions":26182,"interventions":26183},"NCT03853525","A Study to Gain Information How Well Dexpanthenol Dermal Spray Helps the Skin to Recover After Laser Hair Removal in the Groin and Intimate Area",[93],[26168],[26151],{"trials":26185,"activeCount":101},[26186],{"nctId":26187,"briefTitle":26188,"status":107,"phases":26189,"primaryCompletion":26190,"completion":26190,"start":5196,"enrollment":33,"conditions":26191,"interventions":26192},"NCT03852563","A Study to Gain Information How Well Dexpanthenol Derma Cream Helps the Face Skin to Recover After Cosmetic Lasering",[94],"2019-04-22",[14072,26168],[26151],{"intervention":17482,"totalTrials":855,"cells":26194},{"EARLY_PHASE1":26195,"PHASE1":26197,"PHASE2":26207,"PHASE3":26209,"PHASE4":26215,"NA":26217},{"trials":26196,"activeCount":101},[],{"trials":26198,"activeCount":101},[26199,26203],{"nctId":23623,"briefTitle":23624,"status":107,"phases":26200,"primaryCompletion":23626,"completion":23627,"start":23628,"enrollment":2316,"conditions":26201,"interventions":26202},[90],[1124],[7973,17482],{"nctId":17476,"briefTitle":17477,"status":107,"phases":26204,"primaryCompletion":4657,"completion":4657,"start":5052,"enrollment":1519,"conditions":26205,"interventions":26206},[90],[17480],[17460,6890,17482],{"trials":26208,"activeCount":101},[],{"trials":26210,"activeCount":101},[26211],{"nctId":24786,"briefTitle":24787,"status":107,"phases":26212,"primaryCompletion":3091,"completion":24789,"start":24790,"enrollment":24791,"conditions":26213,"interventions":26214},[92],[6888],[6890,17482],{"trials":26216,"activeCount":101},[],{"trials":26218,"activeCount":101},[26219],{"nctId":26220,"briefTitle":26221,"status":464,"phases":26222,"primaryCompletion":12881,"completion":26223,"start":4880,"enrollment":101,"conditions":26224,"interventions":26225},"NCT01961388","Study to Assess the Dietary Carbohydrate Content of Indian Diabetics With Special Therapeutic View on Effectiveness of Acarbose and Metformin Monotherapy",[],"2017-06",[8425],[26226,17482],"Bay G5421 Glucobay",{"intervention":26228,"totalTrials":855,"cells":26229},"Lanthanum Carbonate",{"EARLY_PHASE1":26230,"PHASE1":26232,"PHASE2":26234,"PHASE3":26243,"PHASE4":26255,"NA":26257},{"trials":26231,"activeCount":101},[],{"trials":26233,"activeCount":101},[],{"trials":26235,"activeCount":101},[26236],{"nctId":26237,"briefTitle":26238,"status":107,"phases":26239,"primaryCompletion":1498,"completion":1498,"start":3705,"enrollment":1181,"conditions":26240,"interventions":26242},"NCT00767637","Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone",[91],[8965,26241],"Dialysis",[26228],{"trials":26244,"activeCount":101},[26245,26251],{"nctId":26246,"briefTitle":26247,"status":107,"phases":26248,"primaryCompletion":1315,"completion":1315,"start":4675,"enrollment":1303,"conditions":26249,"interventions":26250},"NCT01518387","Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients",[92],[8965],[26228],{"nctId":11812,"briefTitle":11813,"status":107,"phases":26252,"primaryCompletion":444,"completion":444,"start":4675,"enrollment":11815,"conditions":26253,"interventions":26254},[92],[8965],[11818,11801],{"trials":26256,"activeCount":101},[],{"trials":26258,"activeCount":101},[26259],{"nctId":26260,"briefTitle":26261,"status":107,"phases":26262,"primaryCompletion":23163,"completion":26263,"start":26264,"enrollment":23496,"conditions":26265,"interventions":26267},"NCT01955876","Fosrenol Post-marketing Surveillance in Japan",[],"2016-08-05","2013-10-10",[8965,26266],"Kidney Disease",[26228],{"intervention":26269,"totalTrials":855,"cells":26270},"Kogenate",{"EARLY_PHASE1":26271,"PHASE1":26273,"PHASE2":26275,"PHASE3":26277,"PHASE4":26285,"NA":26300},{"trials":26272,"activeCount":101},[],{"trials":26274,"activeCount":101},[],{"trials":26276,"activeCount":101},[],{"trials":26278,"activeCount":101},[26279],{"nctId":26280,"briefTitle":26281,"status":107,"phases":26282,"completion":4770,"start":3706,"enrollment":1949,"conditions":26283,"interventions":26284},"NCT00606060","BAY14-2222 Continuous Infusion in Surgeries",[92],[17059],[26269],{"trials":26286,"activeCount":101},[26287,26293],{"nctId":26288,"briefTitle":26289,"status":156,"phases":26290,"completion":4666,"start":444,"enrollment":233,"conditions":26291,"interventions":26292},"NCT00621673","Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A",[93],[24],[26269],{"nctId":26294,"briefTitle":26295,"status":107,"phases":26296,"primaryCompletion":4612,"completion":4612,"start":3724,"enrollment":97,"conditions":26297,"interventions":26299},"NCT00586521","BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)",[93],[26298,24],"Hematologic Disease",[26269],{"trials":26301,"activeCount":101},[26302],{"nctId":26303,"briefTitle":26304,"status":107,"phases":26305,"completion":4571,"start":3658,"enrollment":864,"conditions":26306,"interventions":26307},"NCT00864552","International PMS Study - KOGENATE Bayer",[],[24],[26269],{"intervention":23932,"totalTrials":1341,"cells":26309},{"EARLY_PHASE1":26310,"PHASE1":26312,"PHASE2":26314,"PHASE3":26316,"PHASE4":26318,"NA":26320},{"trials":26311,"activeCount":101},[],{"trials":26313,"activeCount":101},[],{"trials":26315,"activeCount":101},[],{"trials":26317,"activeCount":101},[],{"trials":26319,"activeCount":101},[],{"trials":26321,"activeCount":101},[26322,26326,26335],{"nctId":23925,"briefTitle":23926,"status":107,"phases":26323,"primaryCompletion":23928,"completion":23928,"start":23929,"enrollment":13111,"conditions":26324,"interventions":26325},[94],[18],[23910,23932],{"nctId":26327,"briefTitle":26328,"status":107,"phases":26329,"primaryCompletion":26330,"completion":26330,"start":26331,"enrollment":8015,"conditions":26332,"interventions":26333},"NCT02779270","Test the Outdoor Usage for Sunscreen Products in Female Adults",[94],"2015-09-27","2015-09-26",[18],[26334,23932],"BAY987518",{"nctId":24031,"briefTitle":24032,"status":107,"phases":26336,"primaryCompletion":24034,"completion":24034,"start":24035,"enrollment":24036,"conditions":26337,"interventions":26338},[94],[23092],[23910,23932],{"intervention":26340,"totalTrials":1341,"cells":26341},"Selitrectinib",{"EARLY_PHASE1":26342,"PHASE1":26344,"PHASE2":26362,"PHASE3":26364,"PHASE4":26366,"NA":26368},{"trials":26343,"activeCount":101},[],{"trials":26345,"activeCount":101},[26346,26354],{"nctId":26347,"briefTitle":26348,"status":107,"phases":26349,"primaryCompletion":26350,"completion":419,"start":26351,"enrollment":16,"conditions":26352,"interventions":26353},"NCT03215511","A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer",[90],"2022-04-11","2017-07-03",[1826],[26340],{"nctId":26355,"briefTitle":26356,"status":107,"phases":26357,"primaryCompletion":26358,"completion":4116,"start":26359,"enrollment":1701,"conditions":26360,"interventions":26361},"NCT04275960","Study in Healthy Adult Male Participants to Gather Information How the Human Body Absorbs, Distributes and Excretes the Study Drug Selitrectinib Including the Effect of the Interaction of Food With the Study Drug on the Human Body",[90],"2020-10-01","2020-02-28",[1826],[26340],{"trials":26363,"activeCount":101},[],{"trials":26365,"activeCount":101},[],{"trials":26367,"activeCount":101},[],{"trials":26369,"activeCount":101},[26370],{"nctId":26371,"briefTitle":26372,"status":687,"phases":26373,"conditions":26374,"interventions":26375},"NCT03206931","Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion",[],[1826],[26340],{"intervention":25422,"totalTrials":1341,"cells":26377},{"EARLY_PHASE1":26378,"PHASE1":26380,"PHASE2":26382,"PHASE3":26384,"PHASE4":26386,"NA":26388},{"trials":26379,"activeCount":101},[],{"trials":26381,"activeCount":101},[],{"trials":26383,"activeCount":101},[],{"trials":26385,"activeCount":101},[],{"trials":26387,"activeCount":101},[],{"trials":26389,"activeCount":101},[26390,26398,26402],{"nctId":26391,"briefTitle":26392,"status":107,"phases":26393,"primaryCompletion":26394,"completion":26394,"start":26395,"enrollment":1519,"conditions":26396,"interventions":26397},"NCT02872207","Evaluation of the Stinging Potential in Human Eyes",[94],"2015-02-22","2015-02-21",[25671],[25422,25422,24739],{"nctId":25893,"briefTitle":25894,"status":107,"phases":26399,"primaryCompletion":25668,"completion":25668,"start":25888,"enrollment":2041,"conditions":26400,"interventions":26401},[94],[25671],[25422,25673],{"nctId":25417,"briefTitle":25418,"status":107,"phases":26403,"primaryCompletion":20728,"completion":20728,"start":3020,"enrollment":4620,"conditions":26404,"interventions":26405},[94],[18],[25422,24691],{"intervention":3963,"totalTrials":1341,"cells":26407},{"EARLY_PHASE1":26408,"PHASE1":26410,"PHASE2":26412,"PHASE3":26414,"PHASE4":26416,"NA":26418},{"trials":26409,"activeCount":101},[],{"trials":26411,"activeCount":101},[],{"trials":26413,"activeCount":101},[],{"trials":26415,"activeCount":101},[],{"trials":26417,"activeCount":101},[],{"trials":26419,"activeCount":101},[26420,26424,26428],{"nctId":3955,"briefTitle":3956,"status":107,"phases":26421,"primaryCompletion":3958,"completion":3958,"start":3959,"enrollment":3960,"conditions":26422,"interventions":26423},[],[21],[3963,3943,3542,3964],{"nctId":4141,"briefTitle":4142,"status":107,"phases":26425,"primaryCompletion":1542,"completion":3989,"start":2367,"enrollment":4144,"conditions":26426,"interventions":26427},[],[21],[3963,3542],{"nctId":4345,"briefTitle":4346,"status":107,"phases":26429,"primaryCompletion":4348,"completion":4348,"start":4349,"enrollment":4097,"conditions":26430,"interventions":26431},[],[21],[3542,3963],{"intervention":26433,"totalTrials":1341,"cells":26434},"SPF 50 Y65 110",{"EARLY_PHASE1":26435,"PHASE1":26437,"PHASE2":26439,"PHASE3":26441,"PHASE4":26443,"NA":26445},{"trials":26436,"activeCount":101},[],{"trials":26438,"activeCount":101},[],{"trials":26440,"activeCount":101},[],{"trials":26442,"activeCount":101},[],{"trials":26444,"activeCount":101},[],{"trials":26446,"activeCount":101},[26447,26458,26466],{"nctId":26448,"briefTitle":26449,"status":107,"phases":26450,"primaryCompletion":23701,"completion":23701,"start":26451,"enrollment":995,"conditions":26452,"interventions":26454},"NCT02872220","To Test for Photo Allergy Reaction of Sunscreens",[94],"2015-03-23",[26453],"Photoallergy",[26433,26455,26456,26457],"SPF 50 Y51 002","SPF 15 V27 104","Sodium chloride [NaCl]",{"nctId":26459,"briefTitle":26460,"status":107,"phases":26461,"primaryCompletion":26462,"completion":26462,"start":26463,"enrollment":1509,"conditions":26464,"interventions":26465},"NCT02802930","Test the Phototoxicity of Sunscreen Products",[94],"2015-04-26","2015-04-20",[25671],[26433,26455,26456,26457],{"nctId":26467,"briefTitle":26468,"status":107,"phases":26469,"primaryCompletion":26470,"completion":26471,"start":26472,"enrollment":13476,"conditions":26473,"interventions":26474},"NCT02803320","To Assess the Safety of a Sunscreen Product",[94],"2015-05-29","2015-05-31","2015-05-27",[18],[26433],{"intervention":26476,"totalTrials":1341,"cells":26477},"Testosterone Undeconate",{"EARLY_PHASE1":26478,"PHASE1":26480,"PHASE2":26482,"PHASE3":26484,"PHASE4":26486,"NA":26494},{"trials":26479,"activeCount":101},[],{"trials":26481,"activeCount":101},[],{"trials":26483,"activeCount":101},[],{"trials":26485,"activeCount":101},[],{"trials":26487,"activeCount":101},[26488],{"nctId":26489,"briefTitle":26490,"status":156,"phases":26491,"primaryCompletion":2366,"completion":2366,"start":2968,"enrollment":855,"conditions":26492,"interventions":26493},"NCT01092858","NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH)",[93],[7085],[26476],{"trials":26495,"activeCount":101},[26496,26505],{"nctId":26497,"briefTitle":26498,"status":107,"phases":26499,"primaryCompletion":3619,"completion":3619,"start":6396,"enrollment":124,"conditions":26500,"interventions":26504},"NCT00838838","Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis",[],[7085,26501,26502,26503],"Paraplegia","Bone Density","Osteoporosis",[26476],{"nctId":26506,"briefTitle":26507,"status":107,"phases":26508,"primaryCompletion":1498,"completion":1498,"start":3723,"enrollment":160,"conditions":26509,"interventions":26510},"NCT00847314","Efficacy and Tolerability of Testogel\u002FNebido in Combination With Exercise and Diet in Hypogonadal Male Patients",[],[7085],[26476],{"intervention":26512,"totalTrials":1341,"cells":26513},"BAY94-9027",{"EARLY_PHASE1":26514,"PHASE1":26516,"PHASE2":26518,"PHASE3":26520,"PHASE4":26539,"NA":26541},{"trials":26515,"activeCount":101},[],{"trials":26517,"activeCount":101},[],{"trials":26519,"activeCount":101},[],{"trials":26521,"activeCount":101},[26522,26530],{"nctId":26523,"briefTitle":26524,"status":107,"phases":26525,"primaryCompletion":26526,"completion":1191,"start":26527,"enrollment":11021,"conditions":26528,"interventions":26529},"NCT01580293","A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A",[91,92],"2014-06-13","2012-04-23",[24],[26512],{"nctId":26531,"briefTitle":26532,"status":107,"phases":26533,"primaryCompletion":26534,"completion":26535,"start":26536,"enrollment":3233,"conditions":26537,"interventions":26538},"NCT01775618","Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A",[92],"2015-03-19","2020-02-19","2013-05-29",[24],[26512,26512,26512],{"trials":26540,"activeCount":101},[],{"trials":26542,"activeCount":101},[26543],{"nctId":26544,"briefTitle":26545,"status":107,"phases":26546,"primaryCompletion":26547,"completion":1607,"start":26548,"enrollment":160,"conditions":26549,"interventions":26550},"NCT02971930","Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A",[],"2017-11-26","2017-06-20",[24],[26512],{"intervention":4072,"totalTrials":1341,"cells":26552},{"EARLY_PHASE1":26553,"PHASE1":26555,"PHASE2":26557,"PHASE3":26559,"PHASE4":26561,"NA":26563},{"trials":26554,"activeCount":101},[],{"trials":26556,"activeCount":101},[],{"trials":26558,"activeCount":101},[],{"trials":26560,"activeCount":101},[],{"trials":26562,"activeCount":101},[],{"trials":26564,"activeCount":101},[26565,26569,26573],{"nctId":4063,"briefTitle":4064,"status":107,"phases":26566,"primaryCompletion":4066,"completion":4066,"start":4067,"enrollment":4068,"conditions":26567,"interventions":26568},[],[4070],[3542,4072],{"nctId":4124,"briefTitle":4125,"status":107,"phases":26570,"primaryCompletion":4127,"completion":4127,"start":2489,"enrollment":4097,"conditions":26571,"interventions":26572},[],[21],[3542,4072,4130],{"nctId":4273,"briefTitle":4274,"status":107,"phases":26574,"primaryCompletion":4276,"completion":4276,"start":4277,"enrollment":4278,"conditions":26575,"interventions":26576},[],[21],[3542,4072],{"intervention":10171,"totalTrials":1341,"cells":26578},{"EARLY_PHASE1":26579,"PHASE1":26581,"PHASE2":26583,"PHASE3":26585,"PHASE4":26602,"NA":26604},{"trials":26580,"activeCount":101},[],{"trials":26582,"activeCount":101},[],{"trials":26584,"activeCount":101},[],{"trials":26586,"activeCount":101},[26587,26591],{"nctId":10163,"briefTitle":10164,"status":107,"phases":26588,"primaryCompletion":10166,"completion":10166,"start":10167,"enrollment":1744,"conditions":26589,"interventions":26590},[92],[10169],[10152,10171],{"nctId":26592,"briefTitle":26593,"status":107,"phases":26594,"primaryCompletion":26595,"completion":26596,"start":26597,"enrollment":26598,"conditions":26599,"interventions":26600},"NCT02066402","Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)",[92],"2016-03-06","2016-04-18","2014-03-04",598,[6541],[26601,10171],"Tedizolid",{"trials":26603,"activeCount":101},[],{"trials":26605,"activeCount":101},[26606],{"nctId":26607,"briefTitle":26608,"status":156,"phases":26609,"primaryCompletion":26610,"completion":26610,"start":26611,"enrollment":3688,"conditions":26612,"interventions":26614},"NCT02991131","Sivextro in Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global Observational Study",[],"2018-11-21","2016-12-17",[26613],"Skin Disease, Infectious",[26601,10171],{"intervention":26616,"totalTrials":1341,"cells":26617},"Xofigo",{"EARLY_PHASE1":26618,"PHASE1":26620,"PHASE2":26622,"PHASE3":26624,"PHASE4":26626,"NA":26628},{"trials":26619,"activeCount":101},[],{"trials":26621,"activeCount":101},[],{"trials":26623,"activeCount":101},[],{"trials":26625,"activeCount":101},[],{"trials":26627,"activeCount":101},[],{"trials":26629,"activeCount":101},[26630,26640,26649],{"nctId":26631,"briefTitle":26632,"status":107,"phases":26633,"primaryCompletion":26634,"completion":26634,"start":4049,"enrollment":1858,"conditions":26635,"interventions":26637},"NCT03419442","Multi-academic Center Study of Xofigo Patients",[],"2019-10-22",[26636],"Prostate Cancer, Castration Resistant",[26616,26638,26639],"Taxotere","Jevtana",{"nctId":26641,"briefTitle":26642,"status":107,"phases":26643,"primaryCompletion":24018,"completion":24018,"start":26644,"enrollment":26645,"conditions":26646,"interventions":26648},"NCT02729103","Treatment Patterns in Metastatic Prostate Cancer",[],"2016-10-31",565,[26647],"Prostatic Neoplasm",[26616],{"nctId":26650,"briefTitle":26651,"status":107,"phases":26652,"primaryCompletion":4337,"completion":4337,"start":26653,"enrollment":864,"conditions":26654,"interventions":26655},"NCT02899104","Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )",[],"2017-06-15",[672],[26616],{"intervention":26657,"totalTrials":1341,"cells":26658},"STW5",{"EARLY_PHASE1":26659,"PHASE1":26661,"PHASE2":26663,"PHASE3":26674,"PHASE4":26685,"NA":26687},{"trials":26660,"activeCount":101},[],{"trials":26662,"activeCount":101},[],{"trials":26664,"activeCount":101},[26665],{"nctId":26666,"briefTitle":26667,"status":107,"phases":26668,"primaryCompletion":26669,"completion":26669,"start":26670,"enrollment":447,"conditions":26671,"interventions":26673},"NCT04059900","Study in Patients Suffering From Heartburn and Backward Flow of Stomach Liquid Into the Esophagus",[91],"2013-05-03","2009-06-18",[26672],"Functional Gastrointestinal Disorders",[26657],{"trials":26675,"activeCount":101},[26676],{"nctId":26677,"briefTitle":26678,"status":107,"phases":26679,"primaryCompletion":26680,"completion":26680,"start":26681,"enrollment":573,"conditions":26682,"interventions":26684},"NCT01940848","Efficacy\u002FSafety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo",[92],"2017-10-25","2013-10-11",[26683],"Irritable Bowel Syndrome",[26657],{"trials":26686,"activeCount":101},[],{"trials":26688,"activeCount":101},[26689],{"nctId":26690,"briefTitle":26691,"status":107,"phases":26692,"primaryCompletion":26693,"completion":26694,"start":26695,"enrollment":26696,"conditions":26697,"interventions":26698},"NCT04059783","Study to Learn More About the Onset of Effect of Iberogast in Patients Suffering From Abnormal Stomach and Intestine Function",[],"2010-04-27","2011-02-20","2008-06-17",272,[26672],[26657],{"intervention":25911,"totalTrials":1341,"cells":26700},{"EARLY_PHASE1":26701,"PHASE1":26703,"PHASE2":26705,"PHASE3":26707,"PHASE4":26709,"NA":26711},{"trials":26702,"activeCount":101},[],{"trials":26704,"activeCount":101},[],{"trials":26706,"activeCount":101},[],{"trials":26708,"activeCount":101},[],{"trials":26710,"activeCount":101},[],{"trials":26712,"activeCount":101},[26713,26719,26723],{"nctId":26714,"briefTitle":26715,"status":107,"phases":26716,"primaryCompletion":23237,"completion":23237,"start":23104,"enrollment":3374,"conditions":26717,"interventions":26718},"NCT02760563","18611 - Sun Protection Factor Assay",[94],[18],[25911],{"nctId":25905,"briefTitle":25906,"status":107,"phases":26720,"primaryCompletion":3452,"completion":3452,"start":25908,"enrollment":4620,"conditions":26721,"interventions":26722},[94],[25671],[25911,25673],{"nctId":26724,"briefTitle":26725,"status":107,"phases":26726,"primaryCompletion":26727,"completion":26727,"start":26728,"enrollment":16124,"conditions":26729,"interventions":26730},"NCT02751372","18794 - Human Photo Toxicity Test",[94],"2016-05-06","2016-05-02",[18],[25911],{"intervention":26732,"totalTrials":1341,"cells":26733},"Visanne",{"EARLY_PHASE1":26734,"PHASE1":26736,"PHASE2":26738,"PHASE3":26740,"PHASE4":26754,"NA":26756},{"trials":26735,"activeCount":101},[],{"trials":26737,"activeCount":101},[],{"trials":26739,"activeCount":101},[],{"trials":26741,"activeCount":101},[26742,26748],{"nctId":26743,"briefTitle":26744,"status":107,"phases":26745,"primaryCompletion":4612,"completion":4612,"start":3706,"enrollment":20791,"conditions":26746,"interventions":26747},"NCT00225186","Safety and Efficacy of SH T00660AA in Treatment of Endometriosis",[92],[7793],[26732],{"nctId":26749,"briefTitle":26750,"status":107,"phases":26751,"completion":4750,"start":6384,"enrollment":2846,"conditions":26752,"interventions":26753},"NCT00225199","Efficacy and Safety of SH T00660AA in Treatment of Endometriosis",[92],[7793],[26732],{"trials":26755,"activeCount":101},[],{"trials":26757,"activeCount":101},[26758],{"nctId":26759,"briefTitle":26760,"status":107,"phases":26761,"primaryCompletion":1647,"completion":4067,"start":1507,"enrollment":26762,"conditions":26763,"interventions":26764},"NCT01595724","Daily Practice Treatment and Influence of Visanne on the Patient Assessment of Quality of Life",[],3006,[7793],[26732],{"intervention":26766,"totalTrials":1341,"cells":26767},"Cyproterone Acetate",{"EARLY_PHASE1":26768,"PHASE1":26770,"PHASE2":26772,"PHASE3":26774,"PHASE4":26776,"NA":26778},{"trials":26769,"activeCount":101},[],{"trials":26771,"activeCount":101},[],{"trials":26773,"activeCount":101},[],{"trials":26775,"activeCount":101},[],{"trials":26777,"activeCount":101},[],{"trials":26779,"activeCount":101},[26780,26789,26795],{"nctId":26781,"briefTitle":26782,"status":107,"phases":26783,"primaryCompletion":745,"completion":745,"start":12569,"enrollment":296,"conditions":26784,"interventions":26788},"NCT04925180","A Study to Learn About the Awareness and Knowledge That Doctors Have About the Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Treatments in Europe",[],[26785,26786,26787,307],"Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea","Hypersexuality in Men","Sexual Deviations in Men",[26766],{"nctId":26790,"briefTitle":26791,"status":156,"phases":26792,"completion":2969,"start":1314,"enrollment":680,"conditions":26793,"interventions":26794},"NCT00919022","Androcur Non-interventional Study Among Patients With Carcinoma of the Prostate",[],[307],[26766],{"nctId":26796,"briefTitle":26797,"status":107,"phases":26798,"primaryCompletion":3809,"completion":3809,"start":1423,"enrollment":26799,"conditions":26800,"interventions":26801},"NCT00908674","Androcur Effects on Quality of Life",[],245,[307],[26802],"Cyproterone acetate",{"intervention":3899,"totalTrials":175,"cells":26804},{"EARLY_PHASE1":26805,"PHASE1":26807,"PHASE2":26809,"PHASE3":26811,"PHASE4":26813,"NA":26815},{"trials":26806,"activeCount":101},[],{"trials":26808,"activeCount":101},[],{"trials":26810,"activeCount":101},[],{"trials":26812,"activeCount":101},[],{"trials":26814,"activeCount":101},[],{"trials":26816,"activeCount":101},[26817,26821],{"nctId":3889,"briefTitle":3890,"status":107,"phases":26818,"primaryCompletion":3892,"completion":3892,"start":3893,"enrollment":3894,"conditions":26819,"interventions":26820},[],[3896,3897],[3542,3899,3900],{"nctId":3902,"briefTitle":3903,"status":107,"phases":26822,"primaryCompletion":3905,"completion":3905,"start":3906,"enrollment":3907,"conditions":26823,"interventions":26824},[],[3896],[3542,3899,3910,3911],{"intervention":6081,"totalTrials":175,"cells":26826},{"EARLY_PHASE1":26827,"PHASE1":26829,"PHASE2":26831,"PHASE3":26833,"PHASE4":26839,"NA":26841},{"trials":26828,"activeCount":101},[],{"trials":26830,"activeCount":101},[],{"trials":26832,"activeCount":101},[],{"trials":26834,"activeCount":101},[26835],{"nctId":6072,"briefTitle":6073,"status":107,"phases":26836,"primaryCompletion":6075,"completion":6076,"start":6077,"enrollment":6078,"conditions":26837,"interventions":26838},[92],[15],[6081,5950],{"trials":26840,"activeCount":101},[],{"trials":26842,"activeCount":101},[26843],{"nctId":26844,"briefTitle":26845,"status":107,"phases":26846,"primaryCompletion":3732,"completion":4067,"start":2950,"enrollment":16124,"conditions":26847,"interventions":26849},"NCT01833793","Descriptive, Prospective, Non-interventional Study (NIS) to Describe Mirena and Amenorrhea Related Acceptability in Contraception Indication in Medical Practice",[],[26848],"Female Contraception",[6081],{"intervention":24739,"totalTrials":175,"cells":26851},{"EARLY_PHASE1":26852,"PHASE1":26854,"PHASE2":26856,"PHASE3":26858,"PHASE4":26860,"NA":26862},{"trials":26853,"activeCount":101},[],{"trials":26855,"activeCount":101},[],{"trials":26857,"activeCount":101},[],{"trials":26859,"activeCount":101},[],{"trials":26861,"activeCount":101},[],{"trials":26863,"activeCount":101},[26864,26868],{"nctId":26391,"briefTitle":26392,"status":107,"phases":26865,"primaryCompletion":26394,"completion":26394,"start":26395,"enrollment":1519,"conditions":26866,"interventions":26867},[94],[25671],[25422,25422,24739],{"nctId":24733,"briefTitle":24734,"status":107,"phases":26869,"primaryCompletion":24736,"completion":24736,"start":24736,"enrollment":1630,"conditions":26870,"interventions":26871},[94],[18],[24663,24739],{"intervention":26873,"totalTrials":175,"cells":26874},"Radium-223-dichloride",{"EARLY_PHASE1":26875,"PHASE1":26877,"PHASE2":26879,"PHASE3":26881,"PHASE4":26883,"NA":26885},{"trials":26876,"activeCount":101},[],{"trials":26878,"activeCount":101},[],{"trials":26880,"activeCount":101},[],{"trials":26882,"activeCount":101},[],{"trials":26884,"activeCount":101},[],{"trials":26886,"activeCount":101},[26887,26896],{"nctId":26888,"briefTitle":26889,"status":107,"phases":26890,"primaryCompletion":26891,"completion":26892,"start":26893,"enrollment":19388,"conditions":26894,"interventions":26895},"NCT02450812","Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany",[],"2020-06-30","2020-09-17","2015-05-28",[672],[26873],{"nctId":26897,"briefTitle":26898,"status":107,"phases":26899,"primaryCompletion":13254,"completion":13254,"start":26900,"enrollment":7849,"conditions":26901,"interventions":26902},"NCT04681144","A Study to Learn More About How Radium-223 Affects the Quality of Life of Colombian Patients With Prostate Cancer That Has Not Responded to Testosterone Lowering Treatment and Has Spread to the Bones, and to Better Understand Its Safety",[],"2021-04-08",[307],[26873],{"intervention":26904,"totalTrials":175,"cells":26905},"iodinated contrast agents",{"EARLY_PHASE1":26906,"PHASE1":26908,"PHASE2":26910,"PHASE3":26912,"PHASE4":26914,"NA":26916},{"trials":26907,"activeCount":101},[],{"trials":26909,"activeCount":101},[],{"trials":26911,"activeCount":101},[],{"trials":26913,"activeCount":101},[],{"trials":26915,"activeCount":101},[],{"trials":26917,"activeCount":101},[26918,26927],{"nctId":26919,"briefTitle":26920,"status":107,"phases":26921,"primaryCompletion":26922,"completion":26922,"start":23972,"enrollment":26923,"conditions":26924,"interventions":26926},"NCT02766283","Observational Study on Hypothyroidism in Young Children Following Iodine Contrast Exposure",[],"2016-08-30",843,[26925],"Hypothyroidism",[26904],{"nctId":26928,"briefTitle":26929,"status":107,"phases":26930,"primaryCompletion":26653,"completion":26653,"start":4349,"enrollment":26931,"conditions":26932,"interventions":26933},"NCT02959827","Iodinated Contrast Agents and Risk of Hypothyroidism in Young Children in the United States",[],2320,[26925],[26934],"Iodinated contrast agents",{"intervention":26455,"totalTrials":175,"cells":26936},{"EARLY_PHASE1":26937,"PHASE1":26939,"PHASE2":26941,"PHASE3":26943,"PHASE4":26945,"NA":26947},{"trials":26938,"activeCount":101},[],{"trials":26940,"activeCount":101},[],{"trials":26942,"activeCount":101},[],{"trials":26944,"activeCount":101},[],{"trials":26946,"activeCount":101},[],{"trials":26948,"activeCount":101},[26949,26953],{"nctId":26448,"briefTitle":26449,"status":107,"phases":26950,"primaryCompletion":23701,"completion":23701,"start":26451,"enrollment":995,"conditions":26951,"interventions":26952},[94],[26453],[26433,26455,26456,26457],{"nctId":26459,"briefTitle":26460,"status":107,"phases":26954,"primaryCompletion":26462,"completion":26462,"start":26463,"enrollment":1509,"conditions":26955,"interventions":26956},[94],[25671],[26433,26455,26456,26457],{"intervention":26456,"totalTrials":175,"cells":26958},{"EARLY_PHASE1":26959,"PHASE1":26961,"PHASE2":26963,"PHASE3":26965,"PHASE4":26967,"NA":26969},{"trials":26960,"activeCount":101},[],{"trials":26962,"activeCount":101},[],{"trials":26964,"activeCount":101},[],{"trials":26966,"activeCount":101},[],{"trials":26968,"activeCount":101},[],{"trials":26970,"activeCount":101},[26971,26975],{"nctId":26448,"briefTitle":26449,"status":107,"phases":26972,"primaryCompletion":23701,"completion":23701,"start":26451,"enrollment":995,"conditions":26973,"interventions":26974},[94],[26453],[26433,26455,26456,26457],{"nctId":26459,"briefTitle":26460,"status":107,"phases":26976,"primaryCompletion":26462,"completion":26462,"start":26463,"enrollment":1509,"conditions":26977,"interventions":26978},[94],[25671],[26433,26455,26456,26457],{"intervention":26457,"totalTrials":175,"cells":26980},{"EARLY_PHASE1":26981,"PHASE1":26983,"PHASE2":26985,"PHASE3":26987,"PHASE4":26989,"NA":26991},{"trials":26982,"activeCount":101},[],{"trials":26984,"activeCount":101},[],{"trials":26986,"activeCount":101},[],{"trials":26988,"activeCount":101},[],{"trials":26990,"activeCount":101},[],{"trials":26992,"activeCount":101},[26993,26997],{"nctId":26448,"briefTitle":26449,"status":107,"phases":26994,"primaryCompletion":23701,"completion":23701,"start":26451,"enrollment":995,"conditions":26995,"interventions":26996},[94],[26453],[26433,26455,26456,26457],{"nctId":26459,"briefTitle":26460,"status":107,"phases":26998,"primaryCompletion":26462,"completion":26462,"start":26463,"enrollment":1509,"conditions":26999,"interventions":27000},[94],[25671],[26433,26455,26456,26457],{"intervention":25891,"totalTrials":175,"cells":27002},{"EARLY_PHASE1":27003,"PHASE1":27005,"PHASE2":27007,"PHASE3":27009,"PHASE4":27011,"NA":27013},{"trials":27004,"activeCount":101},[],{"trials":27006,"activeCount":101},[],{"trials":27008,"activeCount":101},[],{"trials":27010,"activeCount":101},[],{"trials":27012,"activeCount":101},[],{"trials":27014,"activeCount":101},[27015,27019],{"nctId":25885,"briefTitle":25886,"status":107,"phases":27016,"primaryCompletion":18520,"completion":18520,"start":25888,"enrollment":5220,"conditions":27017,"interventions":27018},[94],[25671],[25891,25673],{"nctId":25899,"briefTitle":25900,"status":107,"phases":27020,"primaryCompletion":18520,"completion":18520,"start":25888,"enrollment":4620,"conditions":27021,"interventions":27022},[94],[25671],[25891,25673],{"intervention":27024,"totalTrials":175,"cells":27025},"Interferon-1beta",{"EARLY_PHASE1":27026,"PHASE1":27028,"PHASE2":27030,"PHASE3":27032,"PHASE4":27034,"NA":27036},{"trials":27027,"activeCount":101},[],{"trials":27029,"activeCount":101},[],{"trials":27031,"activeCount":101},[],{"trials":27033,"activeCount":101},[],{"trials":27035,"activeCount":101},[],{"trials":27037,"activeCount":101},[27038,27044],{"nctId":27039,"briefTitle":27040,"status":107,"phases":27041,"primaryCompletion":4736,"completion":1497,"start":445,"enrollment":2701,"conditions":27042,"interventions":27043},"NCT00461396","Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron",[],[35,6602],[27024],{"nctId":27045,"briefTitle":27046,"status":107,"phases":27047,"primaryCompletion":1569,"completion":1569,"start":6493,"enrollment":4649,"conditions":27048,"interventions":27049},"NCT00873340","Physical Disability in Patients Treated With Betaferon",[],[35],[27024],{"intervention":17473,"totalTrials":175,"cells":27051},{"EARLY_PHASE1":27052,"PHASE1":27054,"PHASE2":27060,"PHASE3":27062,"PHASE4":27064,"NA":27066},{"trials":27053,"activeCount":101},[],{"trials":27055,"activeCount":101},[27056],{"nctId":17467,"briefTitle":17468,"status":107,"phases":27057,"primaryCompletion":17470,"completion":420,"start":2335,"enrollment":1701,"conditions":27058,"interventions":27059},[90],[6888],[17460,17473,17474],{"trials":27061,"activeCount":101},[],{"trials":27063,"activeCount":101},[],{"trials":27065,"activeCount":101},[],{"trials":27067,"activeCount":101},[27068],{"nctId":27069,"briefTitle":27070,"status":107,"phases":27071,"primaryCompletion":1313,"completion":1313,"start":4597,"enrollment":27072,"conditions":27073,"interventions":27074},"NCT01333774","Influence of Different Approaches to Dietary Advising on the Effects of Acarbose Treatment in Obese Diabetic Patients Under Real-life Setting",[],423,[8425],[17473],{"intervention":26601,"totalTrials":175,"cells":27076},{"EARLY_PHASE1":27077,"PHASE1":27079,"PHASE2":27081,"PHASE3":27083,"PHASE4":27089,"NA":27091},{"trials":27078,"activeCount":101},[],{"trials":27080,"activeCount":101},[],{"trials":27082,"activeCount":101},[],{"trials":27084,"activeCount":101},[27085],{"nctId":26592,"briefTitle":26593,"status":107,"phases":27086,"primaryCompletion":26595,"completion":26596,"start":26597,"enrollment":26598,"conditions":27087,"interventions":27088},[92],[6541],[26601,10171],{"trials":27090,"activeCount":101},[],{"trials":27092,"activeCount":101},[27093],{"nctId":26607,"briefTitle":26608,"status":156,"phases":27094,"primaryCompletion":26610,"completion":26610,"start":26611,"enrollment":3688,"conditions":27095,"interventions":27096},[],[26613],[26601,10171],{"intervention":27098,"totalTrials":175,"cells":27099},"Cipro",{"EARLY_PHASE1":27100,"PHASE1":27102,"PHASE2":27104,"PHASE3":27106,"PHASE4":27108,"NA":27110},{"trials":27101,"activeCount":101},[],{"trials":27103,"activeCount":101},[],{"trials":27105,"activeCount":101},[],{"trials":27107,"activeCount":101},[],{"trials":27109,"activeCount":101},[],{"trials":27111,"activeCount":101},[27112,27120],{"nctId":27113,"briefTitle":27114,"status":107,"phases":27115,"primaryCompletion":13039,"completion":27116,"start":487,"enrollment":25,"conditions":27117,"interventions":27119},"NCT02555059","Special Drug Use Investigation of Ciproxan Injection in Pediatrics",[],"2019-06-13",[27118],"Cystitis \u002F Pyelonephritis \u002F Cystic Fibrosis \u002F Anthrax",[27098],{"nctId":27121,"briefTitle":27122,"status":107,"phases":27123,"primaryCompletion":1508,"completion":1508,"start":1326,"enrollment":13523,"conditions":27124,"interventions":27125},"NCT01690559","Ciprofloxacin Special Drug Use Investigation - To Investigate the Safety and Efficacy in Patients With Ciprofloxacin iv Administration Without Dilution",[],[12370],[27098],{"intervention":27127,"totalTrials":175,"cells":27128},"Standard shampoo mixture",{"EARLY_PHASE1":27129,"PHASE1":27131,"PHASE2":27133,"PHASE3":27135,"PHASE4":27137,"NA":27139},{"trials":27130,"activeCount":101},[],{"trials":27132,"activeCount":101},[],{"trials":27134,"activeCount":101},[],{"trials":27136,"activeCount":101},[],{"trials":27138,"activeCount":101},[],{"trials":27140,"activeCount":101},[27141,27152],{"nctId":27142,"briefTitle":27143,"status":107,"phases":27144,"primaryCompletion":27145,"completion":27145,"start":27146,"enrollment":1599,"conditions":27147,"interventions":27148},"NCT02872194","Evaluation of the Stinging Potential of Products in Human Eyes",[94],"2014-09-06","2014-09-05",[25671],[27149,27150,27151,27127],"BAY987516, Y55-170","BAY987516, X72-151","BAY987516, Y49-034",{"nctId":27153,"briefTitle":27154,"status":107,"phases":27155,"primaryCompletion":27156,"completion":27156,"start":13008,"enrollment":6678,"conditions":27157,"interventions":27158},"NCT02869113","Evaluation of the Stinging Potential of Sunscreen Products in Human Eyes",[94],"2015-01-24",[25671],[27159,27160,27160,27127],"BAY98751","BAY 98751",{"intervention":5201,"totalTrials":175,"cells":27162},{"EARLY_PHASE1":27163,"PHASE1":27165,"PHASE2":27167,"PHASE3":27169,"PHASE4":27171,"NA":27173},{"trials":27164,"activeCount":101},[],{"trials":27166,"activeCount":101},[],{"trials":27168,"activeCount":101},[],{"trials":27170,"activeCount":101},[],{"trials":27172,"activeCount":101},[],{"trials":27174,"activeCount":101},[27175,27179],{"nctId":5191,"briefTitle":5192,"status":107,"phases":27176,"primaryCompletion":5194,"completion":5195,"start":5196,"enrollment":5197,"conditions":27177,"interventions":27178},[],[5199],[5201,586,128],{"nctId":27180,"briefTitle":27181,"status":107,"phases":27182,"primaryCompletion":13505,"completion":13505,"start":12939,"enrollment":5121,"conditions":27183,"interventions":27184},"NCT03563014","A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223",[],[672],[5201],{"intervention":586,"totalTrials":175,"cells":27186},{"EARLY_PHASE1":27187,"PHASE1":27189,"PHASE2":27191,"PHASE3":27193,"PHASE4":27199,"NA":27201},{"trials":27188,"activeCount":101},[],{"trials":27190,"activeCount":101},[],{"trials":27192,"activeCount":101},[],{"trials":27194,"activeCount":101},[27195],{"nctId":577,"briefTitle":578,"status":107,"phases":27196,"primaryCompletion":580,"completion":581,"start":582,"enrollment":583,"conditions":27197,"interventions":27198},[92],[187],[72,586,587],{"trials":27200,"activeCount":101},[],{"trials":27202,"activeCount":101},[27203],{"nctId":5191,"briefTitle":5192,"status":107,"phases":27204,"primaryCompletion":5194,"completion":5195,"start":5196,"enrollment":5197,"conditions":27205,"interventions":27206},[],[5199],[5201,586,128],{"intervention":27208,"totalTrials":175,"cells":27209},"Iberogast",{"EARLY_PHASE1":27210,"PHASE1":27212,"PHASE2":27214,"PHASE3":27216,"PHASE4":27218,"NA":27220},{"trials":27211,"activeCount":101},[],{"trials":27213,"activeCount":101},[],{"trials":27215,"activeCount":101},[],{"trials":27217,"activeCount":101},[],{"trials":27219,"activeCount":101},[],{"trials":27221,"activeCount":101},[27222,27233],{"nctId":27223,"briefTitle":27224,"status":107,"phases":27225,"primaryCompletion":27226,"completion":27226,"start":27227,"enrollment":27228,"conditions":27229,"interventions":27232},"NCT05389709","A Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world Setting",[],"2023-05-11","2022-06-04",184,[27230,26683,27231],"Functional Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia","Functional Dyspepsia",[27208],{"nctId":27234,"briefTitle":27235,"status":107,"phases":27236,"primaryCompletion":25603,"completion":25603,"start":13975,"enrollment":26923,"conditions":27237,"interventions":27239},"NCT04993989","A Pharmacy-based Study to Learn More About How Well Iberogast Works, How it Affects the Body, How it is Used, and User Satisfaction in Patients With Functional and Motility-related (Stomach and Bowel Movement-related) Gastrointestinal Diseases, Including Irritable Bowel Syndrome",[],[27238],"Functional and Motility Related Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia",[27208],{"intervention":27241,"totalTrials":175,"cells":27242},"Adempas",{"EARLY_PHASE1":27243,"PHASE1":27245,"PHASE2":27247,"PHASE3":27249,"PHASE4":27251,"NA":27259},{"trials":27244,"activeCount":101},[],{"trials":27246,"activeCount":101},[],{"trials":27248,"activeCount":101},[],{"trials":27250,"activeCount":101},[],{"trials":27252,"activeCount":101},[27253],{"nctId":27254,"briefTitle":27255,"status":107,"phases":27256,"primaryCompletion":780,"completion":780,"start":2989,"enrollment":1163,"conditions":27257,"interventions":27258},"NCT02759419","A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.",[93],[1500],[27241],{"trials":27260,"activeCount":101},[27261],{"nctId":27262,"briefTitle":27263,"status":687,"phases":27264,"conditions":27265,"interventions":27266},"NCT01784562","Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)",[],[1500],[27241],{"intervention":27268,"totalTrials":175,"cells":27269},"radium Ra 223 dichloride",{"EARLY_PHASE1":27270,"PHASE1":27272,"PHASE2":27278,"PHASE3":27280,"PHASE4":27282,"NA":27284},{"trials":27271,"activeCount":101},[],{"trials":27273,"activeCount":101},[27274],{"nctId":16934,"briefTitle":16935,"status":107,"phases":27275,"primaryCompletion":468,"completion":468,"start":4880,"enrollment":1949,"conditions":27276,"interventions":27277},[90],[29,16938],[16940,16941],{"trials":27279,"activeCount":101},[],{"trials":27281,"activeCount":101},[],{"trials":27283,"activeCount":101},[],{"trials":27285,"activeCount":101},[27286],{"nctId":27287,"briefTitle":27288,"status":464,"phases":27289,"primaryCompletion":21188,"completion":21188,"start":24135,"enrollment":101,"conditions":27290,"interventions":27291},"NCT03325127","Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study",[],[672],[27268,27292,27293],"Zytiga","Xtandi",{"intervention":15180,"totalTrials":175,"cells":27295},{"EARLY_PHASE1":27296,"PHASE1":27298,"PHASE2":27300,"PHASE3":27306,"PHASE4":27308,"NA":27310},{"trials":27297,"activeCount":101},[],{"trials":27299,"activeCount":101},[],{"trials":27301,"activeCount":101},[27302],{"nctId":15173,"briefTitle":15174,"status":107,"phases":27303,"primaryCompletion":4736,"completion":4736,"start":4612,"enrollment":15176,"conditions":27304,"interventions":27305},[91],[15178],[15180,15180,15180,15180,15180,15164,15164],{"trials":27307,"activeCount":101},[],{"trials":27309,"activeCount":101},[],{"trials":27311,"activeCount":101},[27312],{"nctId":27313,"briefTitle":27314,"status":107,"phases":27315,"primaryCompletion":4657,"completion":4657,"start":3723,"enrollment":27316,"conditions":27317,"interventions":27320},"NCT01064453","Angeliq Regulatory Post Marketing Surveillance",[],4078,[27318,27319],"Postmenopausal Period","Osteoporosis, Postmenopausal",[15180],{"intervention":27322,"totalTrials":175,"cells":27323},"Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable",{"EARLY_PHASE1":27324,"PHASE1":27326,"PHASE2":27328,"PHASE3":27330,"PHASE4":27332,"NA":27334},{"trials":27325,"activeCount":101},[],{"trials":27327,"activeCount":101},[],{"trials":27329,"activeCount":101},[],{"trials":27331,"activeCount":101},[],{"trials":27333,"activeCount":101},[],{"trials":27335,"activeCount":101},[27336,27344],{"nctId":27337,"briefTitle":27338,"status":107,"phases":27339,"primaryCompletion":3873,"completion":12606,"start":27340,"enrollment":27341,"conditions":27342,"interventions":27343},"NCT01419327","Fosrenol Post-marketing Surveillance for Hemodialysis in Japan",[],"2009-03-23",3267,[8965],[27322],{"nctId":27345,"briefTitle":27346,"status":107,"phases":27347,"primaryCompletion":27348,"completion":3647,"start":27349,"enrollment":23537,"conditions":27350,"interventions":27351},"NCT01412398","Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan",[],"2014-04-08","2009-04-07",[8965],[27322],{"intervention":27353,"totalTrials":175,"cells":27354},"E2 transdermal",{"EARLY_PHASE1":27355,"PHASE1":27357,"PHASE2":27359,"PHASE3":27361,"PHASE4":27363,"NA":27365},{"trials":27356,"activeCount":101},[],{"trials":27358,"activeCount":101},[],{"trials":27360,"activeCount":101},[],{"trials":27362,"activeCount":101},[],{"trials":27364,"activeCount":101},[],{"trials":27366,"activeCount":101},[27367,27375],{"nctId":27368,"briefTitle":27369,"status":107,"phases":27370,"primaryCompletion":4639,"completion":4639,"start":27371,"enrollment":27372,"conditions":27373,"interventions":27374},"NCT01386281","Julina Post-marketing Surveillance for Climacteric Symptoms in Japan",[],"2008-10-20",506,[27319],[27353],{"nctId":27376,"briefTitle":27377,"status":107,"phases":27378,"primaryCompletion":2367,"completion":2229,"start":4588,"enrollment":2873,"conditions":27379,"interventions":27380},"NCT01397955","Julina Post-marketing Surveillance for Postmenopausal Osteoporosis in Japan",[],[27319],[27353],{"intervention":27382,"totalTrials":175,"cells":27383},"E2\u002FLNG",{"EARLY_PHASE1":27384,"PHASE1":27386,"PHASE2":27388,"PHASE3":27390,"PHASE4":27392,"NA":27394},{"trials":27385,"activeCount":101},[],{"trials":27387,"activeCount":101},[],{"trials":27389,"activeCount":101},[],{"trials":27391,"activeCount":101},[],{"trials":27393,"activeCount":101},[],{"trials":27395,"activeCount":101},[27396,27402],{"nctId":27397,"briefTitle":27398,"status":107,"phases":27399,"primaryCompletion":2918,"completion":1542,"start":1313,"enrollment":4251,"conditions":27400,"interventions":27401},"NCT01401114","Wellnara Post-marketing Surveillance in Japan",[],[27319],[27382],{"nctId":27403,"briefTitle":27404,"status":107,"phases":27405,"primaryCompletion":3619,"completion":3619,"start":9794,"enrollment":10252,"conditions":27406,"interventions":27407},"NCT00913926","Effects of Wellnara on Climacteric Symptoms",[],[6505],[27382],{"intervention":27409,"totalTrials":175,"cells":27410},"Darifenacin",{"EARLY_PHASE1":27411,"PHASE1":27413,"PHASE2":27415,"PHASE3":27424,"PHASE4":27426,"NA":27428},{"trials":27412,"activeCount":101},[],{"trials":27414,"activeCount":101},[],{"trials":27416,"activeCount":101},[27417],{"nctId":27418,"briefTitle":27419,"status":156,"phases":27420,"primaryCompletion":6493,"completion":6493,"start":1328,"enrollment":480,"conditions":27421,"interventions":27423},"NCT00845338","Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity",[91],[35,27422],"Overactive Detrusor",[27409],{"trials":27425,"activeCount":101},[],{"trials":27427,"activeCount":101},[],{"trials":27429,"activeCount":101},[27430],{"nctId":27431,"briefTitle":27432,"status":107,"phases":27433,"primaryCompletion":1498,"completion":4292,"start":3723,"enrollment":4466,"conditions":27434,"interventions":27435},"NCT00921245","FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period",[],[9474],[27409],{"intervention":27437,"totalTrials":175,"cells":27438},"EE30\u002FDRSP",{"EARLY_PHASE1":27439,"PHASE1":27441,"PHASE2":27443,"PHASE3":27445,"PHASE4":27447,"NA":27449},{"trials":27440,"activeCount":101},[],{"trials":27442,"activeCount":101},[],{"trials":27444,"activeCount":101},[],{"trials":27446,"activeCount":101},[],{"trials":27448,"activeCount":101},[],{"trials":27450,"activeCount":101},[27451,27458],{"nctId":27452,"briefTitle":27453,"status":107,"phases":27454,"primaryCompletion":1586,"completion":2187,"start":3768,"enrollment":27455,"conditions":27456,"interventions":27457},"NCT00923572","Yasmin Post Marketing Surveillance",[],777,[15],[27437],{"nctId":27459,"briefTitle":27460,"status":107,"phases":27461,"completion":2919,"start":4736,"enrollment":27462,"conditions":27463,"interventions":27464},"NCT00905684","Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (Yasmin® or Any Other Oral Contraceptives (OC)",[],5446,[15],[27437,27465],"Any other OC",{"intervention":27467,"totalTrials":175,"cells":27468},"Direct Oral Anticoagulant",{"EARLY_PHASE1":27469,"PHASE1":27471,"PHASE2":27473,"PHASE3":27475,"PHASE4":27477,"NA":27479},{"trials":27470,"activeCount":101},[],{"trials":27472,"activeCount":101},[],{"trials":27474,"activeCount":101},[],{"trials":27476,"activeCount":101},[],{"trials":27478,"activeCount":101},[],{"trials":27480,"activeCount":101},[27481,27489],{"nctId":27482,"briefTitle":27483,"status":107,"phases":27484,"primaryCompletion":5249,"completion":5964,"start":4067,"enrollment":27485,"conditions":27486,"interventions":27488},"NCT02470767","An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres",[],792,[3743,27487,21],"Prevention and Control",[27467],{"nctId":27490,"briefTitle":27491,"status":107,"phases":27492,"primaryCompletion":5249,"completion":5964,"start":4066,"enrollment":27493,"conditions":27494,"interventions":27495},"NCT02559232","An Observational Cross-sectional Study Evaluating the Use of Re-sources and the Sociodemographic and Clinical Characteristics of Patients Diagnosed With Non-valvular Atrial Fibrillation With a Risk of Stroke or Systemic Embolism on Anticoagulant Therapy and Treated in Primary Care Centers",[],247,[3743,27487,21],[27467],{"intervention":27497,"totalTrials":175,"cells":27498},"BAY86-4891",{"EARLY_PHASE1":27499,"PHASE1":27501,"PHASE2":27503,"PHASE3":27511,"PHASE4":27513,"NA":27515},{"trials":27500,"activeCount":101},[],{"trials":27502,"activeCount":101},[],{"trials":27504,"activeCount":101},[27505],{"nctId":27506,"briefTitle":27507,"status":107,"phases":27508,"primaryCompletion":1498,"completion":498,"start":4691,"enrollment":7849,"conditions":27509,"interventions":27510},"NCT00631124","A Study to Evaluate Inhibition of Ovulation of Two Oral Estrogen\u002FProgestogen Regimens in Healthy, Young Females Over a Period of 3 Treatment Cycles",[91],[15],[27497,27497],{"trials":27512,"activeCount":101},[],{"trials":27514,"activeCount":101},[],{"trials":27516,"activeCount":101},[27517],{"nctId":27518,"briefTitle":27519,"status":107,"phases":27520,"primaryCompletion":27521,"completion":12517,"start":2304,"enrollment":27522,"conditions":27523,"interventions":27524},"NCT03126773","A Prospective Multicenter Study on Patients'Satisfaction With Angeliq® Micro in Real Clinical Practice Conducted in Russia",[],"2019-11-30",1570,[1195],[27497],{"intervention":27526,"totalTrials":233,"cells":27527},"Olmesartan plus hydrochlorothiazide",{"EARLY_PHASE1":27528,"PHASE1":27530,"PHASE2":27532,"PHASE3":27534,"PHASE4":27536,"NA":27538},{"trials":27529,"activeCount":101},[],{"trials":27531,"activeCount":101},[],{"trials":27533,"activeCount":101},[],{"trials":27535,"activeCount":101},[],{"trials":27537,"activeCount":101},[],{"trials":27539,"activeCount":101},[27540],{"nctId":27541,"briefTitle":27542,"status":107,"phases":27543,"primaryCompletion":1508,"completion":2950,"start":1570,"enrollment":27544,"conditions":27545,"interventions":27546},"NCT01219556","Xirtam H Combination In the Treatment of Hypertension Evaluation Study.",[],8704,[6625],[27526],{"intervention":27548,"totalTrials":233,"cells":27549},"Oral anticoagulant",{"EARLY_PHASE1":27550,"PHASE1":27552,"PHASE2":27554,"PHASE3":27556,"PHASE4":27558,"NA":27560},{"trials":27551,"activeCount":101},[],{"trials":27553,"activeCount":101},[],{"trials":27555,"activeCount":101},[],{"trials":27557,"activeCount":101},[],{"trials":27559,"activeCount":101},[],{"trials":27561,"activeCount":101},[27562],{"nctId":27563,"briefTitle":27564,"status":107,"phases":27565,"primaryCompletion":27566,"completion":27566,"start":121,"enrollment":27567,"conditions":27568,"interventions":27569},"NCT04099238","Burden of Ischemic Stroke and Intake of Oral Anticoagulants in Patients With Atrial Fibrillation in the UK Primary Care",[],"2020-07-16",3739,[21],[27548],{"intervention":3900,"totalTrials":233,"cells":27571},{"EARLY_PHASE1":27572,"PHASE1":27574,"PHASE2":27576,"PHASE3":27578,"PHASE4":27580,"NA":27582},{"trials":27573,"activeCount":101},[],{"trials":27575,"activeCount":101},[],{"trials":27577,"activeCount":101},[],{"trials":27579,"activeCount":101},[],{"trials":27581,"activeCount":101},[],{"trials":27583,"activeCount":101},[27584],{"nctId":3889,"briefTitle":3890,"status":107,"phases":27585,"primaryCompletion":3892,"completion":3892,"start":3893,"enrollment":3894,"conditions":27586,"interventions":27587},[],[3896,3897],[3542,3899,3900],{"intervention":3911,"totalTrials":233,"cells":27589},{"EARLY_PHASE1":27590,"PHASE1":27592,"PHASE2":27594,"PHASE3":27596,"PHASE4":27598,"NA":27600},{"trials":27591,"activeCount":101},[],{"trials":27593,"activeCount":101},[],{"trials":27595,"activeCount":101},[],{"trials":27597,"activeCount":101},[],{"trials":27599,"activeCount":101},[],{"trials":27601,"activeCount":101},[27602],{"nctId":3902,"briefTitle":3903,"status":107,"phases":27603,"primaryCompletion":3905,"completion":3905,"start":3906,"enrollment":3907,"conditions":27604,"interventions":27605},[],[3896],[3542,3899,3910,3911],{"intervention":616,"totalTrials":233,"cells":27607},{"EARLY_PHASE1":27608,"PHASE1":27610,"PHASE2":27612,"PHASE3":27614,"PHASE4":27616,"NA":27618},{"trials":27609,"activeCount":101},[],{"trials":27611,"activeCount":101},[],{"trials":27613,"activeCount":101},[],{"trials":27615,"activeCount":101},[],{"trials":27617,"activeCount":101},[],{"trials":27619,"activeCount":101},[27620],{"nctId":607,"briefTitle":608,"status":107,"phases":27621,"primaryCompletion":610,"completion":610,"start":611,"enrollment":612,"conditions":27622,"interventions":27623},[],[614],[72,616],{"intervention":3921,"totalTrials":233,"cells":27625},{"EARLY_PHASE1":27626,"PHASE1":27628,"PHASE2":27630,"PHASE3":27632,"PHASE4":27634,"NA":27636},{"trials":27627,"activeCount":101},[],{"trials":27629,"activeCount":101},[],{"trials":27631,"activeCount":101},[],{"trials":27633,"activeCount":101},[],{"trials":27635,"activeCount":101},[],{"trials":27637,"activeCount":101},[27638],{"nctId":3913,"briefTitle":3914,"status":107,"phases":27639,"primaryCompletion":3916,"completion":3916,"start":3917,"enrollment":3918,"conditions":27640,"interventions":27641},[],[3631],[3542,3921],{"intervention":27643,"totalTrials":233,"cells":27644},"New FVIII products",{"EARLY_PHASE1":27645,"PHASE1":27647,"PHASE2":27649,"PHASE3":27651,"PHASE4":27653,"NA":27655},{"trials":27646,"activeCount":101},[],{"trials":27648,"activeCount":101},[],{"trials":27650,"activeCount":101},[],{"trials":27652,"activeCount":101},[],{"trials":27654,"activeCount":101},[],{"trials":27656,"activeCount":101},[27657],{"nctId":27658,"briefTitle":27659,"status":156,"phases":27660,"primaryCompletion":27661,"completion":27661,"start":27662,"enrollment":1341,"conditions":27663,"interventions":27664},"NCT03603275","Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry",[],"2020-05-14","2018-08-06",[24],[27643],{"intervention":27666,"totalTrials":233,"cells":27667},"Chronic hormonal treatment",{"EARLY_PHASE1":27668,"PHASE1":27670,"PHASE2":27672,"PHASE3":27674,"PHASE4":27676,"NA":27678},{"trials":27669,"activeCount":101},[],{"trials":27671,"activeCount":101},[],{"trials":27673,"activeCount":101},[],{"trials":27675,"activeCount":101},[],{"trials":27677,"activeCount":101},[],{"trials":27679,"activeCount":101},[27680],{"nctId":27681,"briefTitle":27682,"status":107,"phases":27683,"primaryCompletion":27684,"completion":20197,"start":27685,"enrollment":11339,"conditions":27686,"interventions":27687},"NCT03751800","A Study Run at Multiple Study Sites to Test Whether the SAMANTA Questionnaire That is Used to Diagnose Heavy Menstrual Bleeding (HMB), Can Also be Used to Assess Changes of Severity of HMB in Women With HMB Who Are Treated During 12 Months With a Chronic Hormonal Treatment",[],"2021-03-12","2018-12-12",[1426],[27666],{"intervention":2447,"totalTrials":233,"cells":27689},{"EARLY_PHASE1":27690,"PHASE1":27692,"PHASE2":27694,"PHASE3":27696,"PHASE4":27698,"NA":27700},{"trials":27691,"activeCount":101},[],{"trials":27693,"activeCount":101},[],{"trials":27695,"activeCount":101},[],{"trials":27697,"activeCount":101},[],{"trials":27699,"activeCount":101},[],{"trials":27701,"activeCount":101},[27702],{"nctId":2438,"briefTitle":2439,"status":107,"phases":27703,"primaryCompletion":2441,"completion":2441,"start":2442,"enrollment":2443,"conditions":27704,"interventions":27705},[],[2445],[1011,2447,1357],{"intervention":27707,"totalTrials":233,"cells":27708},"Sunscreen Sport Spray",{"EARLY_PHASE1":27709,"PHASE1":27711,"PHASE2":27713,"PHASE3":27715,"PHASE4":27717,"NA":27719},{"trials":27710,"activeCount":101},[],{"trials":27712,"activeCount":101},[],{"trials":27714,"activeCount":101},[],{"trials":27716,"activeCount":101},[],{"trials":27718,"activeCount":101},[],{"trials":27720,"activeCount":101},[27721],{"nctId":27722,"briefTitle":27723,"status":107,"phases":27724,"primaryCompletion":26727,"completion":26727,"start":26728,"enrollment":16124,"conditions":27725,"interventions":27726},"NCT02751541","Human Phototoxicity Test",[94],[18],[27707],{"intervention":3964,"totalTrials":233,"cells":27728},{"EARLY_PHASE1":27729,"PHASE1":27731,"PHASE2":27733,"PHASE3":27735,"PHASE4":27737,"NA":27739},{"trials":27730,"activeCount":101},[],{"trials":27732,"activeCount":101},[],{"trials":27734,"activeCount":101},[],{"trials":27736,"activeCount":101},[],{"trials":27738,"activeCount":101},[],{"trials":27740,"activeCount":101},[27741],{"nctId":3955,"briefTitle":3956,"status":107,"phases":27742,"primaryCompletion":3958,"completion":3958,"start":3959,"enrollment":3960,"conditions":27743,"interventions":27744},[],[21],[3963,3943,3542,3964],{"intervention":23854,"totalTrials":233,"cells":27746},{"EARLY_PHASE1":27747,"PHASE1":27749,"PHASE2":27751,"PHASE3":27753,"PHASE4":27755,"NA":27757},{"trials":27748,"activeCount":101},[],{"trials":27750,"activeCount":101},[],{"trials":27752,"activeCount":101},[],{"trials":27754,"activeCount":101},[],{"trials":27756,"activeCount":101},[],{"trials":27758,"activeCount":101},[27759],{"nctId":23846,"briefTitle":23847,"status":107,"phases":27760,"primaryCompletion":1313,"completion":1313,"start":23849,"enrollment":23850,"conditions":27761,"interventions":27762},[],[23852],[1144,23854],{"intervention":27764,"totalTrials":233,"cells":27765},"BAY86-5046_Interferon-beta-1b",{"EARLY_PHASE1":27766,"PHASE1":27768,"PHASE2":27770,"PHASE3":27772,"PHASE4":27774,"NA":27776},{"trials":27767,"activeCount":101},[],{"trials":27769,"activeCount":101},[],{"trials":27771,"activeCount":101},[],{"trials":27773,"activeCount":101},[],{"trials":27775,"activeCount":101},[],{"trials":27777,"activeCount":101},[27778],{"nctId":27779,"briefTitle":27780,"status":107,"phases":27781,"primaryCompletion":3576,"completion":3576,"start":11861,"enrollment":4790,"conditions":27782,"interventions":27783},"NCT01158183","Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis",[],[6602],[27764],{"intervention":27785,"totalTrials":233,"cells":27786},"Estradiol valerate\u002F Dienogest",{"EARLY_PHASE1":27787,"PHASE1":27789,"PHASE2":27791,"PHASE3":27793,"PHASE4":27795,"NA":27797},{"trials":27788,"activeCount":101},[],{"trials":27790,"activeCount":101},[],{"trials":27792,"activeCount":101},[],{"trials":27794,"activeCount":101},[],{"trials":27796,"activeCount":101},[],{"trials":27798,"activeCount":101},[27799],{"nctId":27800,"briefTitle":27801,"status":107,"phases":27802,"primaryCompletion":27803,"completion":27803,"start":12559,"enrollment":6000,"conditions":27804,"interventions":27806},"NCT04901377","A Study to Gather Information About User Satisfaction in Women in Russia Who Take Estradiol Valerate\u002FDienogest",[],"2023-04-20",[27805],"Oral Contraception",[27785],{"intervention":27808,"totalTrials":233,"cells":27809},"BAY14-2222_Kogenate-FS FVIII",{"EARLY_PHASE1":27810,"PHASE1":27812,"PHASE2":27814,"PHASE3":27816,"PHASE4":27818,"NA":27820},{"trials":27811,"activeCount":101},[],{"trials":27813,"activeCount":101},[],{"trials":27815,"activeCount":101},[],{"trials":27817,"activeCount":101},[],{"trials":27819,"activeCount":101},[],{"trials":27821,"activeCount":101},[27822],{"nctId":27823,"briefTitle":27824,"status":107,"phases":27825,"primaryCompletion":1487,"completion":1487,"start":3989,"enrollment":27826,"conditions":27827,"interventions":27828},"NCT02263066","Retrospective Study in Chinese Pediatric Hemophilia A Patients With rFⅧ Contained Regular Prophylaxis",[],181,[24],[27808],{"intervention":27830,"totalTrials":233,"cells":27831},"Kovaltry",{"EARLY_PHASE1":27832,"PHASE1":27834,"PHASE2":27836,"PHASE3":27838,"PHASE4":27840,"NA":27842},{"trials":27833,"activeCount":101},[],{"trials":27835,"activeCount":101},[],{"trials":27837,"activeCount":101},[],{"trials":27839,"activeCount":101},[],{"trials":27841,"activeCount":101},[],{"trials":27843,"activeCount":101},[27844],{"nctId":27845,"briefTitle":27846,"status":107,"phases":27847,"primaryCompletion":3335,"completion":27848,"start":5367,"enrollment":27849,"conditions":27850,"interventions":27851},"NCT02941783","Drug Use Investigation of Kovaltry in Hemophilia A Patients",[],"2025-09-16",230,[24],[27830],{"intervention":27853,"totalTrials":233,"cells":27854},"Sunscreening Sport Spray Rest",{"EARLY_PHASE1":27855,"PHASE1":27857,"PHASE2":27859,"PHASE3":27861,"PHASE4":27863,"NA":27865},{"trials":27856,"activeCount":101},[],{"trials":27858,"activeCount":101},[],{"trials":27860,"activeCount":101},[],{"trials":27862,"activeCount":101},[],{"trials":27864,"activeCount":101},[],{"trials":27866,"activeCount":101},[27867],{"nctId":27868,"briefTitle":27869,"status":107,"phases":27870,"primaryCompletion":2482,"completion":2482,"start":23944,"enrollment":2345,"conditions":27871,"interventions":27872},"NCT02751463","18850 - Human Photoallergy Test",[94],[18],[27853],{"intervention":886,"totalTrials":233,"cells":27874},{"EARLY_PHASE1":27875,"PHASE1":27877,"PHASE2":27879,"PHASE3":27881,"PHASE4":27883,"NA":27885},{"trials":27876,"activeCount":101},[],{"trials":27878,"activeCount":101},[],{"trials":27880,"activeCount":101},[],{"trials":27882,"activeCount":101},[],{"trials":27884,"activeCount":101},[],{"trials":27886,"activeCount":101},[27887],{"nctId":878,"briefTitle":879,"status":107,"phases":27888,"primaryCompletion":881,"completion":881,"start":882,"enrollment":883,"conditions":27889,"interventions":27890},[],[749,32],[62,886],{"intervention":27892,"totalTrials":233,"cells":27893},"Metronidazole\u002FMiconazole",{"EARLY_PHASE1":27894,"PHASE1":27896,"PHASE2":27898,"PHASE3":27900,"PHASE4":27902,"NA":27904},{"trials":27895,"activeCount":101},[],{"trials":27897,"activeCount":101},[],{"trials":27899,"activeCount":101},[],{"trials":27901,"activeCount":101},[],{"trials":27903,"activeCount":101},[],{"trials":27905,"activeCount":101},[27906],{"nctId":27907,"briefTitle":27908,"status":107,"phases":27909,"primaryCompletion":2919,"completion":2290,"start":3793,"enrollment":27910,"conditions":27911,"interventions":27915},"NCT01335373","Observational Program Neo-Penotran® Forte",[],13024,[27912,27913,27914],"Vaginal Candidiasis","Bacterial Vaginosis","Trichomonal Vaginitis",[27892],{"intervention":4013,"totalTrials":233,"cells":27917},{"EARLY_PHASE1":27918,"PHASE1":27920,"PHASE2":27922,"PHASE3":27924,"PHASE4":27926,"NA":27928},{"trials":27919,"activeCount":101},[],{"trials":27921,"activeCount":101},[],{"trials":27923,"activeCount":101},[],{"trials":27925,"activeCount":101},[],{"trials":27927,"activeCount":101},[],{"trials":27929,"activeCount":101},[27930],{"nctId":4004,"briefTitle":4005,"status":107,"phases":27931,"primaryCompletion":4007,"completion":4007,"start":4008,"enrollment":4009,"conditions":27932,"interventions":27933},[],[4011],[3542,4013],{"intervention":27935,"totalTrials":233,"cells":27936},"Betaferon, BAY86-5046",{"EARLY_PHASE1":27937,"PHASE1":27939,"PHASE2":27941,"PHASE3":27943,"PHASE4":27945,"NA":27947},{"trials":27938,"activeCount":101},[],{"trials":27940,"activeCount":101},[],{"trials":27942,"activeCount":101},[],{"trials":27944,"activeCount":101},[],{"trials":27946,"activeCount":101},[],{"trials":27948,"activeCount":101},[27949],{"nctId":27950,"briefTitle":27951,"status":107,"phases":27952,"primaryCompletion":27953,"completion":27954,"start":17065,"enrollment":21627,"conditions":27955,"interventions":27956},"NCT03808142","PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With Betaferon",[],"2020-04-20","2020-09-02",[35],[27935],{"intervention":27958,"totalTrials":233,"cells":27959},"Levonorgestrel IUD or Copper IUD",{"EARLY_PHASE1":27960,"PHASE1":27962,"PHASE2":27964,"PHASE3":27966,"PHASE4":27968,"NA":27970},{"trials":27961,"activeCount":101},[],{"trials":27963,"activeCount":101},[],{"trials":27965,"activeCount":101},[],{"trials":27967,"activeCount":101},[],{"trials":27969,"activeCount":101},[],{"trials":27971,"activeCount":101},[27972],{"nctId":27973,"briefTitle":27974,"status":107,"phases":27975,"primaryCompletion":3609,"completion":1647,"start":4627,"enrollment":1414,"conditions":27976,"interventions":27977},"NCT01731132","DIU-QoL. Quality of Life Evaluation in Intrauterine Device Users.",[],[15],[27958],{"intervention":27979,"totalTrials":233,"cells":27980},"Coppertone, BAY1183345",{"EARLY_PHASE1":27981,"PHASE1":27983,"PHASE2":27985,"PHASE3":27987,"PHASE4":27989,"NA":27991},{"trials":27982,"activeCount":101},[],{"trials":27984,"activeCount":101},[],{"trials":27986,"activeCount":101},[],{"trials":27988,"activeCount":101},[],{"trials":27990,"activeCount":101},[],{"trials":27992,"activeCount":101},[27993],{"nctId":27994,"briefTitle":27995,"status":107,"phases":27996,"primaryCompletion":27997,"completion":27997,"start":26175,"enrollment":16124,"conditions":27998,"interventions":28000},"NCT03841032","4 Week In-Use Study Evaluating How Well-Tolerated a Skin Care Product Is on Adults With Facial Redness",[94],"2019-02-25",[27999],"Rosacea",[27979],{"intervention":4494,"totalTrials":233,"cells":28002},{"EARLY_PHASE1":28003,"PHASE1":28005,"PHASE2":28007,"PHASE3":28009,"PHASE4":28011,"NA":28013},{"trials":28004,"activeCount":101},[],{"trials":28006,"activeCount":101},[],{"trials":28008,"activeCount":101},[],{"trials":28010,"activeCount":101},[],{"trials":28012,"activeCount":101},[],{"trials":28014,"activeCount":101},[28015],{"nctId":4485,"briefTitle":4486,"status":107,"phases":28016,"primaryCompletion":4488,"completion":4488,"start":4489,"enrollment":4490,"conditions":28017,"interventions":28018},[],[4492],[4494,3540],{"intervention":28020,"totalTrials":233,"cells":28021},"Ultravist",{"EARLY_PHASE1":28022,"PHASE1":28024,"PHASE2":28026,"PHASE3":28028,"PHASE4":28030,"NA":28032},{"trials":28023,"activeCount":101},[],{"trials":28025,"activeCount":101},[],{"trials":28027,"activeCount":101},[],{"trials":28029,"activeCount":101},[],{"trials":28031,"activeCount":101},[],{"trials":28033,"activeCount":101},[28034],{"nctId":28035,"briefTitle":28036,"status":107,"phases":28037,"primaryCompletion":3576,"completion":3576,"start":4612,"enrollment":28038,"conditions":28039,"interventions":28040},"NCT00876083","PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination",[],44920,[8726],[28020],{"intervention":26638,"totalTrials":233,"cells":28042},{"EARLY_PHASE1":28043,"PHASE1":28045,"PHASE2":28047,"PHASE3":28049,"PHASE4":28051,"NA":28053},{"trials":28044,"activeCount":101},[],{"trials":28046,"activeCount":101},[],{"trials":28048,"activeCount":101},[],{"trials":28050,"activeCount":101},[],{"trials":28052,"activeCount":101},[],{"trials":28054,"activeCount":101},[28055],{"nctId":26631,"briefTitle":26632,"status":107,"phases":28056,"primaryCompletion":26634,"completion":26634,"start":4049,"enrollment":1858,"conditions":28057,"interventions":28058},[],[26636],[26616,26638,26639],{"intervention":26639,"totalTrials":233,"cells":28060},{"EARLY_PHASE1":28061,"PHASE1":28063,"PHASE2":28065,"PHASE3":28067,"PHASE4":28069,"NA":28071},{"trials":28062,"activeCount":101},[],{"trials":28064,"activeCount":101},[],{"trials":28066,"activeCount":101},[],{"trials":28068,"activeCount":101},[],{"trials":28070,"activeCount":101},[],{"trials":28072,"activeCount":101},[28073],{"nctId":26631,"briefTitle":26632,"status":107,"phases":28074,"primaryCompletion":26634,"completion":26634,"start":4049,"enrollment":1858,"conditions":28075,"interventions":28076},[],[26636],[26616,26638,26639],{"intervention":25150,"totalTrials":233,"cells":28078},{"EARLY_PHASE1":28079,"PHASE1":28081,"PHASE2":28083,"PHASE3":28085,"PHASE4":28087,"NA":28089},{"trials":28080,"activeCount":101},[],{"trials":28082,"activeCount":101},[],{"trials":28084,"activeCount":101},[],{"trials":28086,"activeCount":101},[],{"trials":28088,"activeCount":101},[],{"trials":28090,"activeCount":101},[28091],{"nctId":25144,"briefTitle":25145,"status":107,"phases":28092,"primaryCompletion":4117,"completion":25147,"start":23699,"enrollment":8849,"conditions":28093,"interventions":28094},[],[2953],[25083,25150,25150],{"intervention":4090,"totalTrials":233,"cells":28096},{"EARLY_PHASE1":28097,"PHASE1":28099,"PHASE2":28101,"PHASE3":28103,"PHASE4":28105,"NA":28107},{"trials":28098,"activeCount":101},[],{"trials":28100,"activeCount":101},[],{"trials":28102,"activeCount":101},[],{"trials":28104,"activeCount":101},[],{"trials":28106,"activeCount":101},[],{"trials":28108,"activeCount":101},[28109],{"nctId":4084,"briefTitle":4085,"status":107,"phases":28110,"primaryCompletion":1486,"completion":2407,"start":499,"enrollment":4087,"conditions":28111,"interventions":28112},[],[3631],[3542,4090],{"intervention":28114,"totalTrials":233,"cells":28115},"[90]Y-ibritumomab tiuxetan",{"EARLY_PHASE1":28116,"PHASE1":28118,"PHASE2":28120,"PHASE3":28122,"PHASE4":28124,"NA":28126},{"trials":28117,"activeCount":101},[],{"trials":28119,"activeCount":101},[],{"trials":28121,"activeCount":101},[],{"trials":28123,"activeCount":101},[],{"trials":28125,"activeCount":101},[],{"trials":28127,"activeCount":101},[28128],{"nctId":28129,"briefTitle":28130,"status":107,"phases":28131,"primaryCompletion":3619,"completion":3619,"start":9022,"enrollment":160,"conditions":28132,"interventions":28135},"NCT01164696","A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin",[],[28133,28134],"Lymphoma, Follicular","Non-Hodgkin Lymphoma",[28114],{"intervention":4101,"totalTrials":233,"cells":28137},{"EARLY_PHASE1":28138,"PHASE1":28140,"PHASE2":28142,"PHASE3":28144,"PHASE4":28146,"NA":28148},{"trials":28139,"activeCount":101},[],{"trials":28141,"activeCount":101},[],{"trials":28143,"activeCount":101},[],{"trials":28145,"activeCount":101},[],{"trials":28147,"activeCount":101},[],{"trials":28149,"activeCount":101},[28150],{"nctId":4092,"briefTitle":4093,"status":107,"phases":28151,"primaryCompletion":3081,"completion":4095,"start":4096,"enrollment":4097,"conditions":28152,"interventions":28153},[],[4099,3560,3716,21],[3542,4101],{"intervention":28155,"totalTrials":233,"cells":28156},"FVIII products",{"EARLY_PHASE1":28157,"PHASE1":28159,"PHASE2":28161,"PHASE3":28163,"PHASE4":28165,"NA":28167},{"trials":28158,"activeCount":101},[],{"trials":28160,"activeCount":101},[],{"trials":28162,"activeCount":101},[],{"trials":28164,"activeCount":101},[],{"trials":28166,"activeCount":101},[],{"trials":28168,"activeCount":101},[28169],{"nctId":28170,"briefTitle":28171,"status":107,"phases":28172,"primaryCompletion":19285,"completion":19285,"start":28173,"enrollment":22755,"conditions":28174,"interventions":28175},"NCT03405337","Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies",[],"2018-02-14",[24],[28155,28176],"Conventional FVIII replacement therapies",{"intervention":28176,"totalTrials":233,"cells":28178},{"EARLY_PHASE1":28179,"PHASE1":28181,"PHASE2":28183,"PHASE3":28185,"PHASE4":28187,"NA":28189},{"trials":28180,"activeCount":101},[],{"trials":28182,"activeCount":101},[],{"trials":28184,"activeCount":101},[],{"trials":28186,"activeCount":101},[],{"trials":28188,"activeCount":101},[],{"trials":28190,"activeCount":101},[28191],{"nctId":28170,"briefTitle":28171,"status":107,"phases":28192,"primaryCompletion":19285,"completion":19285,"start":28173,"enrollment":22755,"conditions":28193,"interventions":28194},[],[24],[28155,28176],{"intervention":28196,"totalTrials":233,"cells":28197},"Insulin",{"EARLY_PHASE1":28198,"PHASE1":28200,"PHASE2":28202,"PHASE3":28204,"PHASE4":28206,"NA":28208},{"trials":28199,"activeCount":101},[],{"trials":28201,"activeCount":101},[],{"trials":28203,"activeCount":101},[],{"trials":28205,"activeCount":101},[],{"trials":28207,"activeCount":101},[],{"trials":28209,"activeCount":101},[28210],{"nctId":28211,"briefTitle":28212,"status":107,"phases":28213,"primaryCompletion":1629,"completion":2367,"start":9407,"enrollment":28214,"conditions":28215,"interventions":28216},"NCT01588639","To Evaluate Clinical Outcome and Injection Compliance of Scilin",[],2683,[6888],[28196,28217,28196],"Insulin (Scilin R _BAY81-9924",{"intervention":28217,"totalTrials":233,"cells":28219},{"EARLY_PHASE1":28220,"PHASE1":28222,"PHASE2":28224,"PHASE3":28226,"PHASE4":28228,"NA":28230},{"trials":28221,"activeCount":101},[],{"trials":28223,"activeCount":101},[],{"trials":28225,"activeCount":101},[],{"trials":28227,"activeCount":101},[],{"trials":28229,"activeCount":101},[],{"trials":28231,"activeCount":101},[28232],{"nctId":28211,"briefTitle":28212,"status":107,"phases":28233,"primaryCompletion":1629,"completion":2367,"start":9407,"enrollment":28214,"conditions":28234,"interventions":28235},[],[6888],[28196,28217,28196],{"intervention":24120,"totalTrials":233,"cells":28237},{"EARLY_PHASE1":28238,"PHASE1":28240,"PHASE2":28242,"PHASE3":28244,"PHASE4":28246,"NA":28248},{"trials":28239,"activeCount":101},[],{"trials":28241,"activeCount":101},[],{"trials":28243,"activeCount":101},[],{"trials":28245,"activeCount":101},[],{"trials":28247,"activeCount":101},[],{"trials":28249,"activeCount":101},[28250],{"nctId":24113,"briefTitle":24114,"status":107,"phases":28251,"completion":1327,"start":4700,"enrollment":24116,"conditions":28252,"interventions":28253},[],[24118],[6912,24120,24121],{"intervention":24121,"totalTrials":233,"cells":28255},{"EARLY_PHASE1":28256,"PHASE1":28258,"PHASE2":28260,"PHASE3":28262,"PHASE4":28264,"NA":28266},{"trials":28257,"activeCount":101},[],{"trials":28259,"activeCount":101},[],{"trials":28261,"activeCount":101},[],{"trials":28263,"activeCount":101},[],{"trials":28265,"activeCount":101},[],{"trials":28267,"activeCount":101},[28268],{"nctId":24113,"briefTitle":24114,"status":107,"phases":28269,"completion":1327,"start":4700,"enrollment":24116,"conditions":28270,"interventions":28271},[],[24118],[6912,24120,24121],{"intervention":4111,"totalTrials":233,"cells":28273},{"EARLY_PHASE1":28274,"PHASE1":28276,"PHASE2":28278,"PHASE3":28280,"PHASE4":28282,"NA":28284},{"trials":28275,"activeCount":101},[],{"trials":28277,"activeCount":101},[],{"trials":28279,"activeCount":101},[],{"trials":28281,"activeCount":101},[],{"trials":28283,"activeCount":101},[],{"trials":28285,"activeCount":101},[28286],{"nctId":4103,"briefTitle":4104,"status":107,"phases":28287,"primaryCompletion":4106,"completion":4106,"start":4107,"enrollment":4108,"conditions":28288,"interventions":28289},[],[21],[3542,4111],{"intervention":4122,"totalTrials":233,"cells":28291},{"EARLY_PHASE1":28292,"PHASE1":28294,"PHASE2":28296,"PHASE3":28298,"PHASE4":28300,"NA":28302},{"trials":28293,"activeCount":101},[],{"trials":28295,"activeCount":101},[],{"trials":28297,"activeCount":101},[],{"trials":28299,"activeCount":101},[],{"trials":28301,"activeCount":101},[],{"trials":28303,"activeCount":101},[28304],{"nctId":4113,"briefTitle":4114,"status":107,"phases":28305,"primaryCompletion":4116,"completion":4116,"start":4117,"enrollment":4118,"conditions":28306,"interventions":28307},[],[4120],[3542,3943,4122],{"intervention":28309,"totalTrials":233,"cells":28310},"Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973",{"EARLY_PHASE1":28311,"PHASE1":28313,"PHASE2":28315,"PHASE3":28317,"PHASE4":28319,"NA":28321},{"trials":28312,"activeCount":101},[],{"trials":28314,"activeCount":101},[],{"trials":28316,"activeCount":101},[],{"trials":28318,"activeCount":101},[],{"trials":28320,"activeCount":101},[],{"trials":28322,"activeCount":101},[28323],{"nctId":28324,"briefTitle":28325,"status":107,"phases":28326,"primaryCompletion":28327,"completion":28328,"start":28329,"enrollment":28330,"conditions":28331,"interventions":28333},"NCT02830477","Study Evaluating \"Real World\" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis",[],"2020-12-01","2021-03-01","2016-10-14",313,[28332],"Hemophilia A, Congenital",[28309],{"intervention":27149,"totalTrials":233,"cells":28335},{"EARLY_PHASE1":28336,"PHASE1":28338,"PHASE2":28340,"PHASE3":28342,"PHASE4":28344,"NA":28346},{"trials":28337,"activeCount":101},[],{"trials":28339,"activeCount":101},[],{"trials":28341,"activeCount":101},[],{"trials":28343,"activeCount":101},[],{"trials":28345,"activeCount":101},[],{"trials":28347,"activeCount":101},[28348],{"nctId":27142,"briefTitle":27143,"status":107,"phases":28349,"primaryCompletion":27145,"completion":27145,"start":27146,"enrollment":1599,"conditions":28350,"interventions":28351},[94],[25671],[27149,27150,27151,27127],{"intervention":27150,"totalTrials":233,"cells":28353},{"EARLY_PHASE1":28354,"PHASE1":28356,"PHASE2":28358,"PHASE3":28360,"PHASE4":28362,"NA":28364},{"trials":28355,"activeCount":101},[],{"trials":28357,"activeCount":101},[],{"trials":28359,"activeCount":101},[],{"trials":28361,"activeCount":101},[],{"trials":28363,"activeCount":101},[],{"trials":28365,"activeCount":101},[28366],{"nctId":27142,"briefTitle":27143,"status":107,"phases":28367,"primaryCompletion":27145,"completion":27145,"start":27146,"enrollment":1599,"conditions":28368,"interventions":28369},[94],[25671],[27149,27150,27151,27127],{"intervention":27151,"totalTrials":233,"cells":28371},{"EARLY_PHASE1":28372,"PHASE1":28374,"PHASE2":28376,"PHASE3":28378,"PHASE4":28380,"NA":28382},{"trials":28373,"activeCount":101},[],{"trials":28375,"activeCount":101},[],{"trials":28377,"activeCount":101},[],{"trials":28379,"activeCount":101},[],{"trials":28381,"activeCount":101},[],{"trials":28383,"activeCount":101},[28384],{"nctId":27142,"briefTitle":27143,"status":107,"phases":28385,"primaryCompletion":27145,"completion":27145,"start":27146,"enrollment":1599,"conditions":28386,"interventions":28387},[94],[25671],[27149,27150,27151,27127],{"intervention":23399,"totalTrials":233,"cells":28389},{"EARLY_PHASE1":28390,"PHASE1":28392,"PHASE2":28394,"PHASE3":28396,"PHASE4":28398,"NA":28400},{"trials":28391,"activeCount":101},[],{"trials":28393,"activeCount":101},[],{"trials":28395,"activeCount":101},[],{"trials":28397,"activeCount":101},[],{"trials":28399,"activeCount":101},[],{"trials":28401,"activeCount":101},[28402],{"nctId":23390,"briefTitle":23391,"status":107,"phases":28403,"primaryCompletion":2470,"completion":2470,"start":23155,"enrollment":23393,"conditions":28404,"interventions":28405},[],[23395,3743,23396,23397],[3761,23399],{"intervention":28407,"totalTrials":233,"cells":28408},"anti-VEGF treatment",{"EARLY_PHASE1":28409,"PHASE1":28411,"PHASE2":28413,"PHASE3":28415,"PHASE4":28417,"NA":28419},{"trials":28410,"activeCount":101},[],{"trials":28412,"activeCount":101},[],{"trials":28414,"activeCount":101},[],{"trials":28416,"activeCount":101},[],{"trials":28418,"activeCount":101},[],{"trials":28420,"activeCount":101},[28421],{"nctId":28422,"briefTitle":28423,"status":107,"phases":28424,"primaryCompletion":28425,"completion":28425,"start":28426,"enrollment":3529,"conditions":28427,"interventions":28428},"NCT06495203","A Study to Understand the Usage of an Artificial Intelligence Technology Called DARWEN for Eye Disorders and to Find Out the Factors Influencing Treatment Frequencies in People With nAMD and RVO",[],"2024-02-29","2023-11-02",[3053,2962],[28407],{"intervention":28430,"totalTrials":233,"cells":28431},"Iloprost,",{"EARLY_PHASE1":28432,"PHASE1":28434,"PHASE2":28436,"PHASE3":28438,"PHASE4":28440,"NA":28442},{"trials":28433,"activeCount":101},[],{"trials":28435,"activeCount":101},[],{"trials":28437,"activeCount":101},[],{"trials":28439,"activeCount":101},[],{"trials":28441,"activeCount":101},[],{"trials":28443,"activeCount":101},[28444],{"nctId":28445,"briefTitle":28446,"status":107,"phases":28447,"primaryCompletion":5081,"completion":28448,"start":28449,"enrollment":447,"conditions":28450,"interventions":28451},"NCT02826252","Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg\u002FmL (V10) to 20 μg\u002FmL (V20)",[],"2017-01-24","2016-09-15",[1500],[28430],{"intervention":28453,"totalTrials":233,"cells":28454},"Assigned pulmonary hypertension medication",{"EARLY_PHASE1":28455,"PHASE1":28457,"PHASE2":28459,"PHASE3":28461,"PHASE4":28463,"NA":28465},{"trials":28456,"activeCount":101},[],{"trials":28458,"activeCount":101},[],{"trials":28460,"activeCount":101},[],{"trials":28462,"activeCount":101},[],{"trials":28464,"activeCount":101},[],{"trials":28466,"activeCount":101},[28467],{"nctId":28468,"briefTitle":28469,"status":107,"phases":28470,"primaryCompletion":2407,"completion":2407,"start":28471,"enrollment":28472,"conditions":28473,"interventions":28474},"NCT02576002","Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)",[],"2015-10",2691,[1500],[28453],{"intervention":28476,"totalTrials":233,"cells":28477},"Cyproterone \u002F Ethinylestradiol (Diane-35, BAY86-5264) and its Generics",{"EARLY_PHASE1":28478,"PHASE1":28480,"PHASE2":28482,"PHASE3":28484,"PHASE4":28486,"NA":28488},{"trials":28479,"activeCount":101},[],{"trials":28481,"activeCount":101},[],{"trials":28483,"activeCount":101},[],{"trials":28485,"activeCount":101},[],{"trials":28487,"activeCount":101},[],{"trials":28489,"activeCount":101},[28490],{"nctId":28491,"briefTitle":28492,"status":107,"phases":28493,"primaryCompletion":4203,"completion":4203,"start":28494,"enrollment":28495,"conditions":28496,"interventions":28497},"NCT02349399","Drug Utilization Study on Diane-35 (and Generics) in Three European Healthcare Databases",[],"2015-05-01",26065,[8050],[28476],{"intervention":28499,"totalTrials":233,"cells":28500},"BAY86-5300_YAZ-Flex",{"EARLY_PHASE1":28501,"PHASE1":28503,"PHASE2":28505,"PHASE3":28507,"PHASE4":28509,"NA":28511},{"trials":28502,"activeCount":101},[],{"trials":28504,"activeCount":101},[],{"trials":28506,"activeCount":101},[],{"trials":28508,"activeCount":101},[],{"trials":28510,"activeCount":101},[],{"trials":28512,"activeCount":101},[28513],{"nctId":28514,"briefTitle":28515,"status":107,"phases":28516,"primaryCompletion":28517,"completion":28518,"start":28519,"enrollment":28520,"conditions":28521,"interventions":28523},"NCT03126747","Drug Use Investigation (DUI) of YazFlex for Endometriosis-associated Pelvic Pain and\u002For Dysmenorrhea",[],"2021-06-17","2021-11-17","2017-06-29",715,[28522],"Endometriosis and Dysmenorrhea",[28499],{"intervention":28525,"totalTrials":233,"cells":28526},"Levonogestrel IntraUterine System",{"EARLY_PHASE1":28527,"PHASE1":28529,"PHASE2":28531,"PHASE3":28533,"PHASE4":28535,"NA":28537},{"trials":28528,"activeCount":101},[],{"trials":28530,"activeCount":101},[],{"trials":28532,"activeCount":101},[],{"trials":28534,"activeCount":101},[],{"trials":28536,"activeCount":101},[],{"trials":28538,"activeCount":101},[28539],{"nctId":28540,"briefTitle":28541,"status":107,"phases":28542,"primaryCompletion":4116,"completion":28543,"start":28544,"enrollment":28545,"conditions":28546,"interventions":28547},"NCT03493295","Non-interventional, Real Life Study on Satisfaction With LNG-IUS in Spanish Young Women (18-30 Years Old) With Different Parity Status and Menstrual Bleeding Pattern",[],"2021-03-15","2018-04-25",587,[15],[28525],{"intervention":28549,"totalTrials":233,"cells":28550},"Interferon-beta-1b",{"EARLY_PHASE1":28551,"PHASE1":28553,"PHASE2":28555,"PHASE3":28557,"PHASE4":28559,"NA":28561},{"trials":28552,"activeCount":101},[],{"trials":28554,"activeCount":101},[],{"trials":28556,"activeCount":101},[],{"trials":28558,"activeCount":101},[],{"trials":28560,"activeCount":101},[],{"trials":28562,"activeCount":101},[28563],{"nctId":28564,"briefTitle":28565,"status":107,"phases":28566,"primaryCompletion":28567,"completion":13646,"start":20296,"enrollment":435,"conditions":28568,"interventions":28569},"NCT04356339","US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector",[],"2021-08-29",[35],[28549],{"intervention":28571,"totalTrials":233,"cells":28572},"Clotrimazole 1%",{"EARLY_PHASE1":28573,"PHASE1":28575,"PHASE2":28577,"PHASE3":28579,"PHASE4":28581,"NA":28583},{"trials":28574,"activeCount":101},[],{"trials":28576,"activeCount":101},[],{"trials":28578,"activeCount":101},[],{"trials":28580,"activeCount":101},[],{"trials":28582,"activeCount":101},[],{"trials":28584,"activeCount":101},[28585],{"nctId":28586,"briefTitle":28587,"status":107,"phases":28588,"primaryCompletion":28589,"completion":28590,"start":5889,"enrollment":28591,"conditions":28592,"interventions":28594},"NCT03599323","Study on the Safety of the Approved Product Empedic L Cream During Its Routine Use (Active Ingredient is Clotrimazole 1%)",[],"2021-07-07","2021-09-03",1033,[28593],"Vaginal Candida",[28571],{"intervention":28596,"totalTrials":233,"cells":28597},"SPF 50 Y49 091",{"EARLY_PHASE1":28598,"PHASE1":28600,"PHASE2":28602,"PHASE3":28604,"PHASE4":28606,"NA":28608},{"trials":28599,"activeCount":101},[],{"trials":28601,"activeCount":101},[],{"trials":28603,"activeCount":101},[],{"trials":28605,"activeCount":101},[],{"trials":28607,"activeCount":101},[],{"trials":28609,"activeCount":101},[28610],{"nctId":28611,"briefTitle":28612,"status":107,"phases":28613,"primaryCompletion":28614,"completion":28614,"start":24066,"enrollment":4649,"conditions":28615,"interventions":28616},"NCT02802917","To Evaluate Eye Installation-Tear Free",[94],"2015-05-24",[18],[28596,28617,28618,28619],"SPF 50 X15 158","SPF 50 X15 160","SPF 50 X57 162",{"intervention":28617,"totalTrials":233,"cells":28621},{"EARLY_PHASE1":28622,"PHASE1":28624,"PHASE2":28626,"PHASE3":28628,"PHASE4":28630,"NA":28632},{"trials":28623,"activeCount":101},[],{"trials":28625,"activeCount":101},[],{"trials":28627,"activeCount":101},[],{"trials":28629,"activeCount":101},[],{"trials":28631,"activeCount":101},[],{"trials":28633,"activeCount":101},[28634],{"nctId":28611,"briefTitle":28612,"status":107,"phases":28635,"primaryCompletion":28614,"completion":28614,"start":24066,"enrollment":4649,"conditions":28636,"interventions":28637},[94],[18],[28596,28617,28618,28619],{"intervention":28618,"totalTrials":233,"cells":28639},{"EARLY_PHASE1":28640,"PHASE1":28642,"PHASE2":28644,"PHASE3":28646,"PHASE4":28648,"NA":28650},{"trials":28641,"activeCount":101},[],{"trials":28643,"activeCount":101},[],{"trials":28645,"activeCount":101},[],{"trials":28647,"activeCount":101},[],{"trials":28649,"activeCount":101},[],{"trials":28651,"activeCount":101},[28652],{"nctId":28611,"briefTitle":28612,"status":107,"phases":28653,"primaryCompletion":28614,"completion":28614,"start":24066,"enrollment":4649,"conditions":28654,"interventions":28655},[94],[18],[28596,28617,28618,28619],{"intervention":28619,"totalTrials":233,"cells":28657},{"EARLY_PHASE1":28658,"PHASE1":28660,"PHASE2":28662,"PHASE3":28664,"PHASE4":28666,"NA":28668},{"trials":28659,"activeCount":101},[],{"trials":28661,"activeCount":101},[],{"trials":28663,"activeCount":101},[],{"trials":28665,"activeCount":101},[],{"trials":28667,"activeCount":101},[],{"trials":28669,"activeCount":101},[28670],{"nctId":28611,"briefTitle":28612,"status":107,"phases":28671,"primaryCompletion":28614,"completion":28614,"start":24066,"enrollment":4649,"conditions":28672,"interventions":28673},[94],[18],[28596,28617,28618,28619],{"intervention":28675,"totalTrials":233,"cells":28676},"BAY 987521",{"EARLY_PHASE1":28677,"PHASE1":28679,"PHASE2":28681,"PHASE3":28683,"PHASE4":28685,"NA":28687},{"trials":28678,"activeCount":101},[],{"trials":28680,"activeCount":101},[],{"trials":28682,"activeCount":101},[],{"trials":28684,"activeCount":101},[],{"trials":28686,"activeCount":101},[],{"trials":28688,"activeCount":101},[28689],{"nctId":28690,"briefTitle":28691,"status":107,"phases":28692,"primaryCompletion":28693,"completion":28693,"start":24736,"enrollment":3374,"conditions":28694,"interventions":28695},"NCT02760576","18612 - Sun Protection Factor Assay",[94],"2015-10-16",[18],[28675],{"intervention":28697,"totalTrials":233,"cells":28698},"Vardenafil,",{"EARLY_PHASE1":28699,"PHASE1":28701,"PHASE2":28703,"PHASE3":28705,"PHASE4":28707,"NA":28709},{"trials":28700,"activeCount":101},[],{"trials":28702,"activeCount":101},[],{"trials":28704,"activeCount":101},[],{"trials":28706,"activeCount":101},[],{"trials":28708,"activeCount":101},[],{"trials":28710,"activeCount":101},[28711],{"nctId":28712,"briefTitle":28713,"status":107,"phases":28714,"primaryCompletion":4596,"completion":2919,"start":9022,"enrollment":28715,"conditions":28716,"interventions":28717},"NCT00909233","LEVITRA® 20mg Special Drug Use Investigation (Long-term)",[],1221,[27],[28697],{"intervention":28719,"totalTrials":233,"cells":28720},"Low-dose levonorgestrel intrauterine systems",{"EARLY_PHASE1":28721,"PHASE1":28723,"PHASE2":28725,"PHASE3":28727,"PHASE4":28729,"NA":28731},{"trials":28722,"activeCount":101},[],{"trials":28724,"activeCount":101},[],{"trials":28726,"activeCount":101},[],{"trials":28728,"activeCount":101},[],{"trials":28730,"activeCount":101},[],{"trials":28732,"activeCount":101},[28733],{"nctId":28734,"briefTitle":28735,"status":107,"phases":28736,"primaryCompletion":28737,"completion":28738,"start":28739,"enrollment":2522,"conditions":28740,"interventions":28742},"NCT04785950","The Aim of This Study is to Estimate the Discontinuation Rate of Low-dose Levonorgestrel-releasing Intrauterine System Due to Self-reported Unacceptable Menstrual Bleeding Pattern in Spanish Women Who Are Using it for the First Time How Intrauterine System for Long Acting Contraception",[],"2023-01-12","2023-05-04","2021-02-21",[28741],"Hormonal Intrauterine Contraception",[28719],{"intervention":28744,"totalTrials":233,"cells":28745},"Any treatment for unresectable HCC as chosen by the physician",{"EARLY_PHASE1":28746,"PHASE1":28748,"PHASE2":28750,"PHASE3":28752,"PHASE4":28754,"NA":28756},{"trials":28747,"activeCount":101},[],{"trials":28749,"activeCount":101},[],{"trials":28751,"activeCount":101},[],{"trials":28753,"activeCount":101},[],{"trials":28755,"activeCount":101},[],{"trials":28757,"activeCount":101},[28758],{"nctId":28759,"briefTitle":28760,"status":464,"phases":28761,"primaryCompletion":2230,"completion":2230,"start":1570,"enrollment":101,"conditions":28762,"interventions":28763},"NCT01191385","GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study Start",[],[1009],[28744],{"intervention":27292,"totalTrials":233,"cells":28765},{"EARLY_PHASE1":28766,"PHASE1":28768,"PHASE2":28770,"PHASE3":28772,"PHASE4":28774,"NA":28776},{"trials":28767,"activeCount":101},[],{"trials":28769,"activeCount":101},[],{"trials":28771,"activeCount":101},[],{"trials":28773,"activeCount":101},[],{"trials":28775,"activeCount":101},[],{"trials":28777,"activeCount":101},[28778],{"nctId":27287,"briefTitle":27288,"status":464,"phases":28779,"primaryCompletion":21188,"completion":21188,"start":24135,"enrollment":101,"conditions":28780,"interventions":28781},[],[672],[27268,27292,27293],{"intervention":27293,"totalTrials":233,"cells":28783},{"EARLY_PHASE1":28784,"PHASE1":28786,"PHASE2":28788,"PHASE3":28790,"PHASE4":28792,"NA":28794},{"trials":28785,"activeCount":101},[],{"trials":28787,"activeCount":101},[],{"trials":28789,"activeCount":101},[],{"trials":28791,"activeCount":101},[],{"trials":28793,"activeCount":101},[],{"trials":28795,"activeCount":101},[28796],{"nctId":27287,"briefTitle":27288,"status":464,"phases":28797,"primaryCompletion":21188,"completion":21188,"start":24135,"enrollment":101,"conditions":28798,"interventions":28799},[],[672],[27268,27292,27293],{"intervention":23984,"totalTrials":233,"cells":28801},{"EARLY_PHASE1":28802,"PHASE1":28804,"PHASE2":28806,"PHASE3":28808,"PHASE4":28810,"NA":28812},{"trials":28803,"activeCount":101},[],{"trials":28805,"activeCount":101},[],{"trials":28807,"activeCount":101},[],{"trials":28809,"activeCount":101},[],{"trials":28811,"activeCount":101},[],{"trials":28813,"activeCount":101},[28814],{"nctId":23977,"briefTitle":23978,"status":107,"phases":28815,"primaryCompletion":23980,"completion":23980,"start":23981,"enrollment":3374,"conditions":28816,"interventions":28817},[94],[18],[23910,23984],{"intervention":28819,"totalTrials":233,"cells":28820},"Relief Pro cream",{"EARLY_PHASE1":28821,"PHASE1":28823,"PHASE2":28825,"PHASE3":28827,"PHASE4":28829,"NA":28831},{"trials":28822,"activeCount":101},[],{"trials":28824,"activeCount":101},[],{"trials":28826,"activeCount":101},[],{"trials":28828,"activeCount":101},[],{"trials":28830,"activeCount":101},[],{"trials":28832,"activeCount":101},[28833],{"nctId":28834,"briefTitle":28835,"status":107,"phases":28836,"primaryCompletion":28837,"completion":28837,"start":4266,"enrollment":4462,"conditions":28838,"interventions":28840},"NCT03757078","Study to Find Out How Symptoms Severity Changes During the Standard Course of Treatment With the Cream Relief Pro and Suppositories Relief Pro (Active Ingredients Are Fluocortolone + Lidocaine) in Patients Suffering From Twisted and Bulging Veins in the Rectal Area (Acute Hemorrhoids)",[],"2019-10-20",[28839],"Acute Hemorrhoids",[28819,28841],"Relief Pro rectal suppositories",{"intervention":28841,"totalTrials":233,"cells":28843},{"EARLY_PHASE1":28844,"PHASE1":28846,"PHASE2":28848,"PHASE3":28850,"PHASE4":28852,"NA":28854},{"trials":28845,"activeCount":101},[],{"trials":28847,"activeCount":101},[],{"trials":28849,"activeCount":101},[],{"trials":28851,"activeCount":101},[],{"trials":28853,"activeCount":101},[],{"trials":28855,"activeCount":101},[28856],{"nctId":28834,"briefTitle":28835,"status":107,"phases":28857,"primaryCompletion":28837,"completion":28837,"start":4266,"enrollment":4462,"conditions":28858,"interventions":28859},[],[28839],[28819,28841],{"intervention":28861,"totalTrials":233,"cells":28862},"Theraflex, BAY 874017",{"EARLY_PHASE1":28863,"PHASE1":28865,"PHASE2":28867,"PHASE3":28869,"PHASE4":28871,"NA":28873},{"trials":28864,"activeCount":101},[],{"trials":28866,"activeCount":101},[],{"trials":28868,"activeCount":101},[],{"trials":28870,"activeCount":101},[],{"trials":28872,"activeCount":101},[],{"trials":28874,"activeCount":101},[28875],{"nctId":28876,"briefTitle":28877,"status":107,"phases":28878,"primaryCompletion":4320,"completion":28879,"start":28880,"enrollment":28881,"conditions":28882,"interventions":28884},"NCT03330288","Prospective Multicenter Non-interventional Study in Patients With Knee or Hip Osteoarthritis Having a Theraflex Treatment",[],"2020-07-13","2017-11-20",1102,[28883],"Osteoarthritis",[28861],{"intervention":1883,"totalTrials":233,"cells":28886},{"EARLY_PHASE1":28887,"PHASE1":28889,"PHASE2":28891,"PHASE3":28893,"PHASE4":28895,"NA":28897},{"trials":28888,"activeCount":101},[],{"trials":28890,"activeCount":101},[],{"trials":28892,"activeCount":101},[],{"trials":28894,"activeCount":101},[],{"trials":28896,"activeCount":101},[],{"trials":28898,"activeCount":101},[28899],{"nctId":1876,"briefTitle":1877,"status":107,"phases":28900,"primaryCompletion":315,"completion":315,"start":1879,"enrollment":1880,"conditions":28901,"interventions":28902},[],[1826],[57,1883],{"intervention":24206,"totalTrials":233,"cells":28904},{"EARLY_PHASE1":28905,"PHASE1":28907,"PHASE2":28909,"PHASE3":28911,"PHASE4":28913,"NA":28915},{"trials":28906,"activeCount":101},[],{"trials":28908,"activeCount":101},[],{"trials":28910,"activeCount":101},[],{"trials":28912,"activeCount":101},[],{"trials":28914,"activeCount":101},[],{"trials":28916,"activeCount":101},[28917],{"nctId":24198,"briefTitle":24199,"status":107,"phases":28918,"primaryCompletion":24201,"completion":24201,"start":24202,"enrollment":24203,"conditions":28919,"interventions":28920},[],[3631],[24206,2202],{"intervention":923,"totalTrials":233,"cells":28922},{"EARLY_PHASE1":28923,"PHASE1":28925,"PHASE2":28927,"PHASE3":28929,"PHASE4":28931,"NA":28933},{"trials":28924,"activeCount":101},[],{"trials":28926,"activeCount":101},[],{"trials":28928,"activeCount":101},[],{"trials":28930,"activeCount":101},[],{"trials":28932,"activeCount":101},[],{"trials":28934,"activeCount":101},[28935],{"nctId":915,"briefTitle":916,"status":107,"phases":28936,"primaryCompletion":918,"completion":918,"start":919,"enrollment":920,"conditions":28937,"interventions":28938},[],[32,749],[62,923,924,925,926],{"intervention":924,"totalTrials":233,"cells":28940},{"EARLY_PHASE1":28941,"PHASE1":28943,"PHASE2":28945,"PHASE3":28947,"PHASE4":28949,"NA":28951},{"trials":28942,"activeCount":101},[],{"trials":28944,"activeCount":101},[],{"trials":28946,"activeCount":101},[],{"trials":28948,"activeCount":101},[],{"trials":28950,"activeCount":101},[],{"trials":28952,"activeCount":101},[28953],{"nctId":915,"briefTitle":916,"status":107,"phases":28954,"primaryCompletion":918,"completion":918,"start":919,"enrollment":920,"conditions":28955,"interventions":28956},[],[32,749],[62,923,924,925,926],{"intervention":925,"totalTrials":233,"cells":28958},{"EARLY_PHASE1":28959,"PHASE1":28961,"PHASE2":28963,"PHASE3":28965,"PHASE4":28967,"NA":28969},{"trials":28960,"activeCount":101},[],{"trials":28962,"activeCount":101},[],{"trials":28964,"activeCount":101},[],{"trials":28966,"activeCount":101},[],{"trials":28968,"activeCount":101},[],{"trials":28970,"activeCount":101},[28971],{"nctId":915,"briefTitle":916,"status":107,"phases":28972,"primaryCompletion":918,"completion":918,"start":919,"enrollment":920,"conditions":28973,"interventions":28974},[],[32,749],[62,923,924,925,926],{"intervention":926,"totalTrials":233,"cells":28976},{"EARLY_PHASE1":28977,"PHASE1":28979,"PHASE2":28981,"PHASE3":28983,"PHASE4":28985,"NA":28987},{"trials":28978,"activeCount":101},[],{"trials":28980,"activeCount":101},[],{"trials":28982,"activeCount":101},[],{"trials":28984,"activeCount":101},[],{"trials":28986,"activeCount":101},[],{"trials":28988,"activeCount":101},[28989],{"nctId":915,"briefTitle":916,"status":107,"phases":28990,"primaryCompletion":918,"completion":918,"start":919,"enrollment":920,"conditions":28991,"interventions":28992},[],[32,749],[62,923,924,925,926],{"intervention":27159,"totalTrials":233,"cells":28994},{"EARLY_PHASE1":28995,"PHASE1":28997,"PHASE2":28999,"PHASE3":29001,"PHASE4":29003,"NA":29005},{"trials":28996,"activeCount":101},[],{"trials":28998,"activeCount":101},[],{"trials":29000,"activeCount":101},[],{"trials":29002,"activeCount":101},[],{"trials":29004,"activeCount":101},[],{"trials":29006,"activeCount":101},[29007],{"nctId":27153,"briefTitle":27154,"status":107,"phases":29008,"primaryCompletion":27156,"completion":27156,"start":13008,"enrollment":6678,"conditions":29009,"interventions":29010},[94],[25671],[27159,27160,27160,27127],{"intervention":27160,"totalTrials":233,"cells":29012},{"EARLY_PHASE1":29013,"PHASE1":29015,"PHASE2":29017,"PHASE3":29019,"PHASE4":29021,"NA":29023},{"trials":29014,"activeCount":101},[],{"trials":29016,"activeCount":101},[],{"trials":29018,"activeCount":101},[],{"trials":29020,"activeCount":101},[],{"trials":29022,"activeCount":101},[],{"trials":29024,"activeCount":101},[29025],{"nctId":27153,"briefTitle":27154,"status":107,"phases":29026,"primaryCompletion":27156,"completion":27156,"start":13008,"enrollment":6678,"conditions":29027,"interventions":29028},[94],[25671],[27159,27160,27160,27127],{"intervention":4208,"totalTrials":233,"cells":29030},{"EARLY_PHASE1":29031,"PHASE1":29033,"PHASE2":29035,"PHASE3":29037,"PHASE4":29039,"NA":29041},{"trials":29032,"activeCount":101},[],{"trials":29034,"activeCount":101},[],{"trials":29036,"activeCount":101},[],{"trials":29038,"activeCount":101},[],{"trials":29040,"activeCount":101},[],{"trials":29042,"activeCount":101},[29043],{"nctId":4200,"briefTitle":4201,"status":107,"phases":29044,"primaryCompletion":4203,"completion":4203,"start":4204,"enrollment":4205,"conditions":29045,"interventions":29046},[],[21],[3542,4208],{"intervention":29048,"totalTrials":233,"cells":29049},"Iberogast®",{"EARLY_PHASE1":29050,"PHASE1":29052,"PHASE2":29054,"PHASE3":29056,"PHASE4":29058,"NA":29060},{"trials":29051,"activeCount":101},[],{"trials":29053,"activeCount":101},[],{"trials":29055,"activeCount":101},[],{"trials":29057,"activeCount":101},[],{"trials":29059,"activeCount":101},[],{"trials":29061,"activeCount":101},[29062],{"nctId":29063,"briefTitle":29064,"status":107,"phases":29065,"primaryCompletion":29066,"completion":29066,"start":29067,"enrollment":29068,"conditions":29069,"interventions":29070},"NCT04029376","Study to Learn More About the Stomach and Intestine Complaints of Children Aged From 3 to 14 Years",[],"2008-10-01","2007-04-01",1032,[26672],[29048],{"intervention":29072,"totalTrials":233,"cells":29073},"Glucobay M",{"EARLY_PHASE1":29074,"PHASE1":29076,"PHASE2":29078,"PHASE3":29080,"PHASE4":29082,"NA":29084},{"trials":29075,"activeCount":101},[],{"trials":29077,"activeCount":101},[],{"trials":29079,"activeCount":101},[],{"trials":29081,"activeCount":101},[],{"trials":29083,"activeCount":101},[],{"trials":29085,"activeCount":101},[29086],{"nctId":29087,"briefTitle":29088,"status":107,"phases":29089,"primaryCompletion":1508,"completion":4657,"start":3793,"enrollment":29090,"conditions":29091,"interventions":29092},"NCT01219582","GLucobay M OBservation Study for Efficacy and Safety in Treatment of Type-2 Diabetes Patients",[],9364,[944],[29072],{"intervention":29094,"totalTrials":233,"cells":29095},"Kinzal\u002FPritor",{"EARLY_PHASE1":29096,"PHASE1":29098,"PHASE2":29100,"PHASE3":29102,"PHASE4":29104,"NA":29106},{"trials":29097,"activeCount":101},[],{"trials":29099,"activeCount":101},[],{"trials":29101,"activeCount":101},[],{"trials":29103,"activeCount":101},[],{"trials":29105,"activeCount":101},[],{"trials":29107,"activeCount":101},[29108],{"nctId":29109,"briefTitle":29110,"status":107,"phases":29111,"primaryCompletion":1423,"completion":1314,"start":3768,"enrollment":29112,"conditions":29113,"interventions":29114},"NCT00932867","Surveillance of Efficacy and Safety of Drug PRITOR in patieNts With Arterial Hypertension, Who do Not Tolerate ACE inhibitoR Treatment",[],3114,[6625],[29094],{"intervention":29116,"totalTrials":233,"cells":29117},"Testosterone Product",{"EARLY_PHASE1":29118,"PHASE1":29120,"PHASE2":29122,"PHASE3":29124,"PHASE4":29126,"NA":29128},{"trials":29119,"activeCount":101},[],{"trials":29121,"activeCount":101},[],{"trials":29123,"activeCount":101},[],{"trials":29125,"activeCount":101},[],{"trials":29127,"activeCount":101},[],{"trials":29129,"activeCount":101},[29130],{"nctId":29131,"briefTitle":29132,"status":107,"phases":29133,"primaryCompletion":5517,"completion":5517,"start":29134,"enrollment":29135,"conditions":29136,"interventions":29137},"NCT03484260","Association Between the Prevalence of Cardiovascular Risk Factors and New Use of Testosterone",[],"2018-04-01",27778,[7085],[29116],{"intervention":29139,"totalTrials":233,"cells":29140},"Norethisterone enantate\u002Festradiol valerate",{"EARLY_PHASE1":29141,"PHASE1":29143,"PHASE2":29145,"PHASE3":29147,"PHASE4":29149,"NA":29151},{"trials":29142,"activeCount":101},[],{"trials":29144,"activeCount":101},[],{"trials":29146,"activeCount":101},[],{"trials":29148,"activeCount":101},[],{"trials":29150,"activeCount":101},[],{"trials":29152,"activeCount":101},[29153],{"nctId":29154,"briefTitle":29155,"status":107,"phases":29156,"primaryCompletion":29157,"completion":29158,"start":29159,"enrollment":29160,"conditions":29161,"interventions":29163},"NCT03901131","PROMES: A Clinical Study in Which Researchers Want to Learn More About the Safety Profile of MESIGYNA (Norethisterone Enantate 50 mg and Estradiol Valerate 5 mg) Used as a Medication to Prevent Pregnancy for Adult Women in Reproductive Age in the Peruvian Population at the Outpatient Clinic.",[],"2021-08-31","2022-02-17","2019-08-26",296,[29162],"Contraceptive",[29139],{"intervention":29165,"totalTrials":233,"cells":29166},"Non-VKA Oral Anticoagulants",{"EARLY_PHASE1":29167,"PHASE1":29169,"PHASE2":29171,"PHASE3":29173,"PHASE4":29175,"NA":29177},{"trials":29168,"activeCount":101},[],{"trials":29170,"activeCount":101},[],{"trials":29172,"activeCount":101},[],{"trials":29174,"activeCount":101},[],{"trials":29176,"activeCount":101},[],{"trials":29178,"activeCount":101},[29179],{"nctId":29180,"briefTitle":29181,"status":107,"phases":29182,"primaryCompletion":745,"completion":29183,"start":13627,"enrollment":7849,"conditions":29184,"interventions":29185},"NCT04722679","A Study to Collect Information on the Characteristics of Elderly Belgian Patients With NVAF That Are Treated With a NOAC for This Indication With a Special Focus on Their Fear of Bleeding While Using a NOAC vs the Clinical Benefit of a NOAC of Thrombosis\u002FStroke Prevention.",[],"2022-01-03",[4011],[29165],{"intervention":29187,"totalTrials":233,"cells":29188},"Interferon beta 1-b",{"EARLY_PHASE1":29189,"PHASE1":29191,"PHASE2":29193,"PHASE3":29195,"PHASE4":29197,"NA":29199},{"trials":29190,"activeCount":101},[],{"trials":29192,"activeCount":101},[],{"trials":29194,"activeCount":101},[],{"trials":29196,"activeCount":101},[],{"trials":29198,"activeCount":101},[],{"trials":29200,"activeCount":101},[29201],{"nctId":29202,"briefTitle":29203,"status":464,"phases":29204,"primaryCompletion":4657,"completion":4657,"start":1569,"enrollment":101,"conditions":29205,"interventions":29206},"NCT01071694","QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea",[],[6602],[29187],{"intervention":29208,"totalTrials":233,"cells":29209},"Sun screening Sport Lotion,",{"EARLY_PHASE1":29210,"PHASE1":29212,"PHASE2":29214,"PHASE3":29216,"PHASE4":29218,"NA":29220},{"trials":29211,"activeCount":101},[],{"trials":29213,"activeCount":101},[],{"trials":29215,"activeCount":101},[],{"trials":29217,"activeCount":101},[],{"trials":29219,"activeCount":101},[],{"trials":29221,"activeCount":101},[29222],{"nctId":29223,"briefTitle":29224,"status":107,"phases":29225,"primaryCompletion":2482,"completion":2482,"start":23944,"enrollment":2345,"conditions":29226,"interventions":29227},"NCT02750449","Human Photoallergy Test",[94],[18],[29208],{"intervention":29229,"totalTrials":233,"cells":29230},"BAY 987519, SPF 50, Y51-002",{"EARLY_PHASE1":29231,"PHASE1":29233,"PHASE2":29235,"PHASE3":29237,"PHASE4":29239,"NA":29241},{"trials":29232,"activeCount":101},[],{"trials":29234,"activeCount":101},[],{"trials":29236,"activeCount":101},[],{"trials":29238,"activeCount":101},[],{"trials":29240,"activeCount":101},[],{"trials":29242,"activeCount":101},[29243],{"nctId":29244,"briefTitle":29245,"status":107,"phases":29246,"primaryCompletion":29247,"completion":29247,"start":29248,"enrollment":24036,"conditions":29249,"interventions":29250},"NCT02857478","Supervised Outdoor-Use Test to Assess the Safety of a Sunscreen C-Spray on Sport Users",[94],"2015-06-28","2015-06-27",[25671],[29229,29251],"BAY 987519, SPF 50, P04-147",{"intervention":29251,"totalTrials":233,"cells":29253},{"EARLY_PHASE1":29254,"PHASE1":29256,"PHASE2":29258,"PHASE3":29260,"PHASE4":29262,"NA":29264},{"trials":29255,"activeCount":101},[],{"trials":29257,"activeCount":101},[],{"trials":29259,"activeCount":101},[],{"trials":29261,"activeCount":101},[],{"trials":29263,"activeCount":101},[],{"trials":29265,"activeCount":101},[29266],{"nctId":29244,"briefTitle":29245,"status":107,"phases":29267,"primaryCompletion":29247,"completion":29247,"start":29248,"enrollment":24036,"conditions":29268,"interventions":29269},[94],[25671],[29229,29251],{"intervention":29271,"totalTrials":233,"cells":29272},"ADT (Eligard®*) with or without treatment intensification",{"EARLY_PHASE1":29273,"PHASE1":29275,"PHASE2":29277,"PHASE3":29279,"PHASE4":29281,"NA":29283},{"trials":29274,"activeCount":101},[],{"trials":29276,"activeCount":101},[],{"trials":29278,"activeCount":101},[],{"trials":29280,"activeCount":101},[],{"trials":29282,"activeCount":101},[],{"trials":29284,"activeCount":101},[29285],{"nctId":29286,"briefTitle":29287,"status":107,"phases":29288,"primaryCompletion":29289,"completion":29289,"start":12579,"enrollment":29290,"conditions":29291,"interventions":29293},"NCT05149131","A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer",[],"2022-08-16",960,[29292],"Metastatic Castration-sensitive Prostate Cancer",[29271],{"intervention":26226,"totalTrials":233,"cells":29295},{"EARLY_PHASE1":29296,"PHASE1":29298,"PHASE2":29300,"PHASE3":29302,"PHASE4":29304,"NA":29306},{"trials":29297,"activeCount":101},[],{"trials":29299,"activeCount":101},[],{"trials":29301,"activeCount":101},[],{"trials":29303,"activeCount":101},[],{"trials":29305,"activeCount":101},[],{"trials":29307,"activeCount":101},[29308],{"nctId":26220,"briefTitle":26221,"status":464,"phases":29309,"primaryCompletion":12881,"completion":26223,"start":4880,"enrollment":101,"conditions":29310,"interventions":29311},[],[8425],[26226,17482],{"intervention":29313,"totalTrials":233,"cells":29314},"Testosterone Undecanoate",{"EARLY_PHASE1":29315,"PHASE1":29317,"PHASE2":29319,"PHASE3":29321,"PHASE4":29323,"NA":29325},{"trials":29316,"activeCount":101},[],{"trials":29318,"activeCount":101},[],{"trials":29320,"activeCount":101},[],{"trials":29322,"activeCount":101},[],{"trials":29324,"activeCount":101},[],{"trials":29326,"activeCount":101},[29327],{"nctId":29328,"briefTitle":29329,"status":107,"phases":29330,"primaryCompletion":549,"completion":549,"start":4666,"enrollment":29331,"conditions":29332,"interventions":29333},"NCT00410306","Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice",[],1493,[9368,7085],[29313],{"intervention":29335,"totalTrials":233,"cells":29336},"Bonefos",{"EARLY_PHASE1":29337,"PHASE1":29339,"PHASE2":29341,"PHASE3":29343,"PHASE4":29345,"NA":29347},{"trials":29338,"activeCount":101},[],{"trials":29340,"activeCount":101},[],{"trials":29342,"activeCount":101},[],{"trials":29344,"activeCount":101},[],{"trials":29346,"activeCount":101},[],{"trials":29348,"activeCount":101},[29349],{"nctId":29350,"briefTitle":29351,"status":107,"phases":29352,"primaryCompletion":4292,"completion":4292,"start":6317,"enrollment":29353,"conditions":29354,"interventions":29356},"NCT00909142","Bonefos and the Consumption of Analgesics",[],149,[29355],"Bone Neoplasms",[29335],{"intervention":4237,"totalTrials":233,"cells":29358},{"EARLY_PHASE1":29359,"PHASE1":29361,"PHASE2":29363,"PHASE3":29365,"PHASE4":29367,"NA":29369},{"trials":29360,"activeCount":101},[],{"trials":29362,"activeCount":101},[],{"trials":29364,"activeCount":101},[],{"trials":29366,"activeCount":101},[],{"trials":29368,"activeCount":101},[],{"trials":29370,"activeCount":101},[29371],{"nctId":4230,"briefTitle":4231,"status":107,"phases":29372,"primaryCompletion":3042,"completion":3042,"start":4233,"enrollment":4234,"conditions":29373,"interventions":29374},[],[3896],[3542,4237,4238],{"intervention":4238,"totalTrials":233,"cells":29376},{"EARLY_PHASE1":29377,"PHASE1":29379,"PHASE2":29381,"PHASE3":29383,"PHASE4":29385,"NA":29387},{"trials":29378,"activeCount":101},[],{"trials":29380,"activeCount":101},[],{"trials":29382,"activeCount":101},[],{"trials":29384,"activeCount":101},[],{"trials":29386,"activeCount":101},[],{"trials":29388,"activeCount":101},[29389],{"nctId":4230,"briefTitle":4231,"status":107,"phases":29390,"primaryCompletion":3042,"completion":3042,"start":4233,"enrollment":4234,"conditions":29391,"interventions":29392},[],[3896],[3542,4237,4238],{"intervention":29394,"totalTrials":233,"cells":29395},"Antithrombotic agents",{"EARLY_PHASE1":29396,"PHASE1":29398,"PHASE2":29400,"PHASE3":29402,"PHASE4":29404,"NA":29406},{"trials":29397,"activeCount":101},[],{"trials":29399,"activeCount":101},[],{"trials":29401,"activeCount":101},[],{"trials":29403,"activeCount":101},[],{"trials":29405,"activeCount":101},[],{"trials":29407,"activeCount":101},[29408],{"nctId":29409,"briefTitle":29410,"status":107,"phases":29411,"primaryCompletion":3440,"completion":3440,"start":13975,"enrollment":29412,"conditions":29413,"interventions":29414},"NCT03311139","Treatment and Outcomes of Atrial Fibrillation and Acute Coronary Syndrome in Sweden",[],14226,[21],[29394],{"intervention":29416,"totalTrials":233,"cells":29417},"Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG",{"EARLY_PHASE1":29418,"PHASE1":29420,"PHASE2":29422,"PHASE3":29424,"PHASE4":29426,"NA":29428},{"trials":29419,"activeCount":101},[],{"trials":29421,"activeCount":101},[],{"trials":29423,"activeCount":101},[],{"trials":29425,"activeCount":101},[],{"trials":29427,"activeCount":101},[],{"trials":29429,"activeCount":101},[29430],{"nctId":29431,"briefTitle":29432,"status":107,"phases":29433,"primaryCompletion":29434,"completion":29434,"start":26728,"enrollment":29435,"conditions":29436,"interventions":29437},"NCT02749396","EPID Multiple Sclerosis Pregnancy Study",[],"2018-08-14",2089,[35],[29416,29438,29439,29440,29441,29442],"Extavia (interferon beta-1b), Novartis Pharma AG","Rebif (interferon beta-1a), Merck Serono Europe Ltd","Plegridy (peginterferon beta-1a), Biogen Idec Ltd","Avonex (interferon beta-1a), Biogen Idec Ltd","MSDMDs other than Betaseron",{"intervention":29438,"totalTrials":233,"cells":29444},{"EARLY_PHASE1":29445,"PHASE1":29447,"PHASE2":29449,"PHASE3":29451,"PHASE4":29453,"NA":29455},{"trials":29446,"activeCount":101},[],{"trials":29448,"activeCount":101},[],{"trials":29450,"activeCount":101},[],{"trials":29452,"activeCount":101},[],{"trials":29454,"activeCount":101},[],{"trials":29456,"activeCount":101},[29457],{"nctId":29431,"briefTitle":29432,"status":107,"phases":29458,"primaryCompletion":29434,"completion":29434,"start":26728,"enrollment":29435,"conditions":29459,"interventions":29460},[],[35],[29416,29438,29439,29440,29441,29442],{"intervention":29439,"totalTrials":233,"cells":29462},{"EARLY_PHASE1":29463,"PHASE1":29465,"PHASE2":29467,"PHASE3":29469,"PHASE4":29471,"NA":29473},{"trials":29464,"activeCount":101},[],{"trials":29466,"activeCount":101},[],{"trials":29468,"activeCount":101},[],{"trials":29470,"activeCount":101},[],{"trials":29472,"activeCount":101},[],{"trials":29474,"activeCount":101},[29475],{"nctId":29431,"briefTitle":29432,"status":107,"phases":29476,"primaryCompletion":29434,"completion":29434,"start":26728,"enrollment":29435,"conditions":29477,"interventions":29478},[],[35],[29416,29438,29439,29440,29441,29442],{"intervention":29440,"totalTrials":233,"cells":29480},{"EARLY_PHASE1":29481,"PHASE1":29483,"PHASE2":29485,"PHASE3":29487,"PHASE4":29489,"NA":29491},{"trials":29482,"activeCount":101},[],{"trials":29484,"activeCount":101},[],{"trials":29486,"activeCount":101},[],{"trials":29488,"activeCount":101},[],{"trials":29490,"activeCount":101},[],{"trials":29492,"activeCount":101},[29493],{"nctId":29431,"briefTitle":29432,"status":107,"phases":29494,"primaryCompletion":29434,"completion":29434,"start":26728,"enrollment":29435,"conditions":29495,"interventions":29496},[],[35],[29416,29438,29439,29440,29441,29442],{"intervention":29441,"totalTrials":233,"cells":29498},{"EARLY_PHASE1":29499,"PHASE1":29501,"PHASE2":29503,"PHASE3":29505,"PHASE4":29507,"NA":29509},{"trials":29500,"activeCount":101},[],{"trials":29502,"activeCount":101},[],{"trials":29504,"activeCount":101},[],{"trials":29506,"activeCount":101},[],{"trials":29508,"activeCount":101},[],{"trials":29510,"activeCount":101},[29511],{"nctId":29431,"briefTitle":29432,"status":107,"phases":29512,"primaryCompletion":29434,"completion":29434,"start":26728,"enrollment":29435,"conditions":29513,"interventions":29514},[],[35],[29416,29438,29439,29440,29441,29442],{"intervention":29442,"totalTrials":233,"cells":29516},{"EARLY_PHASE1":29517,"PHASE1":29519,"PHASE2":29521,"PHASE3":29523,"PHASE4":29525,"NA":29527},{"trials":29518,"activeCount":101},[],{"trials":29520,"activeCount":101},[],{"trials":29522,"activeCount":101},[],{"trials":29524,"activeCount":101},[],{"trials":29526,"activeCount":101},[],{"trials":29528,"activeCount":101},[29529],{"nctId":29431,"briefTitle":29432,"status":107,"phases":29530,"primaryCompletion":29434,"completion":29434,"start":26728,"enrollment":29435,"conditions":29531,"interventions":29532},[],[35],[29416,29438,29439,29440,29441,29442],{"intervention":946,"totalTrials":233,"cells":29534},{"EARLY_PHASE1":29535,"PHASE1":29537,"PHASE2":29539,"PHASE3":29541,"PHASE4":29543,"NA":29545},{"trials":29536,"activeCount":101},[],{"trials":29538,"activeCount":101},[],{"trials":29540,"activeCount":101},[],{"trials":29542,"activeCount":101},[],{"trials":29544,"activeCount":101},[],{"trials":29546,"activeCount":101},[29547],{"nctId":937,"briefTitle":938,"status":107,"phases":29548,"primaryCompletion":940,"completion":940,"start":941,"enrollment":942,"conditions":29549,"interventions":29550},[],[32,944],[62,946],{"intervention":29552,"totalTrials":233,"cells":29553},"The physician's prescription in routine clinical practice",{"EARLY_PHASE1":29554,"PHASE1":29556,"PHASE2":29558,"PHASE3":29560,"PHASE4":29562,"NA":29564},{"trials":29555,"activeCount":101},[],{"trials":29557,"activeCount":101},[],{"trials":29559,"activeCount":101},[],{"trials":29561,"activeCount":101},[],{"trials":29563,"activeCount":101},[],{"trials":29565,"activeCount":101},[29566],{"nctId":29567,"briefTitle":29568,"status":107,"phases":29569,"primaryCompletion":25147,"completion":25147,"start":29570,"enrollment":29571,"conditions":29572,"interventions":29574},"NCT04445181","A Study Using the LMC Diabetes Registry to Learn More About Chronic Kidney Disease (CKD) in Canadian Patients With Type 2 Diabetes (T2D)",[],"2020-07-01",14873,[29573],"Chronic Kidney Disease in Type 2 Diabetes",[29552],{"intervention":29576,"totalTrials":233,"cells":29577},"GBCAs",{"EARLY_PHASE1":29578,"PHASE1":29580,"PHASE2":29582,"PHASE3":29584,"PHASE4":29586,"NA":29588},{"trials":29579,"activeCount":101},[],{"trials":29581,"activeCount":101},[],{"trials":29583,"activeCount":101},[],{"trials":29585,"activeCount":101},[],{"trials":29587,"activeCount":101},[],{"trials":29589,"activeCount":101},[29590],{"nctId":29591,"briefTitle":29592,"status":107,"phases":29593,"primaryCompletion":29594,"completion":29595,"start":29596,"enrollment":1858,"conditions":29597,"interventions":29598},"NCT06257277","An Observational Study to Collect Information on the Safety of Gadolinium-Based Contrast Agents in Patients in India",[],"2025-01-29","2025-05-26","2024-07-08",[8337],[29576],{"intervention":29600,"totalTrials":233,"cells":29601},"BAY81-9783",{"EARLY_PHASE1":29602,"PHASE1":29604,"PHASE2":29606,"PHASE3":29608,"PHASE4":29610,"NA":29612},{"trials":29603,"activeCount":101},[],{"trials":29605,"activeCount":101},[],{"trials":29607,"activeCount":101},[],{"trials":29609,"activeCount":101},[],{"trials":29611,"activeCount":101},[],{"trials":29613,"activeCount":101},[29614],{"nctId":29615,"briefTitle":29616,"status":107,"phases":29617,"primaryCompletion":29618,"completion":918,"start":13674,"enrollment":360,"conditions":29619,"interventions":29620},"NCT04665570","A Study to Learn More About How Acarbose and Metformin Work When Taken Together and How Safe They Are in Indian Patients Who Were Recently Diagnosed With Type 2 Diabetes (T2D)",[],"2023-09-09",[749],[29600],{"intervention":4296,"totalTrials":233,"cells":29622},{"EARLY_PHASE1":29623,"PHASE1":29625,"PHASE2":29627,"PHASE3":29629,"PHASE4":29631,"NA":29633},{"trials":29624,"activeCount":101},[],{"trials":29626,"activeCount":101},[],{"trials":29628,"activeCount":101},[],{"trials":29630,"activeCount":101},[],{"trials":29632,"activeCount":101},[],{"trials":29634,"activeCount":101},[29635],{"nctId":4289,"briefTitle":4290,"status":107,"phases":29636,"primaryCompletion":1327,"completion":4250,"start":4292,"enrollment":4293,"conditions":29637,"interventions":29638},[],[3631],[3542,4296],{"intervention":29640,"totalTrials":233,"cells":29641},"LEP",{"EARLY_PHASE1":29642,"PHASE1":29644,"PHASE2":29646,"PHASE3":29648,"PHASE4":29650,"NA":29652},{"trials":29643,"activeCount":101},[],{"trials":29645,"activeCount":101},[],{"trials":29647,"activeCount":101},[],{"trials":29649,"activeCount":101},[],{"trials":29651,"activeCount":101},[],{"trials":29653,"activeCount":101},[29654],{"nctId":29655,"briefTitle":29656,"status":107,"phases":29657,"primaryCompletion":909,"completion":909,"start":29658,"enrollment":16002,"conditions":29659,"interventions":29660},"NCT04607382","Survey on Menstrual Symptoms, Health Related Quality of Life and Work Productivity in Patients Suffering From Pain During Menstruation (Dysmenorrhea) in Japan",[],"2020-09-23",[6172],[29640,29661],"NSAIDs and\u002For Chinese medicine",{"intervention":29661,"totalTrials":233,"cells":29663},{"EARLY_PHASE1":29664,"PHASE1":29666,"PHASE2":29668,"PHASE3":29670,"PHASE4":29672,"NA":29674},{"trials":29665,"activeCount":101},[],{"trials":29667,"activeCount":101},[],{"trials":29669,"activeCount":101},[],{"trials":29671,"activeCount":101},[],{"trials":29673,"activeCount":101},[],{"trials":29675,"activeCount":101},[29676],{"nctId":29655,"briefTitle":29656,"status":107,"phases":29677,"primaryCompletion":909,"completion":909,"start":29658,"enrollment":16002,"conditions":29678,"interventions":29679},[],[6172],[29640,29661],{"intervention":29681,"totalTrials":233,"cells":29682},"Acarbose\u002FMetformin",{"EARLY_PHASE1":29683,"PHASE1":29685,"PHASE2":29687,"PHASE3":29689,"PHASE4":29691,"NA":29693},{"trials":29684,"activeCount":101},[],{"trials":29686,"activeCount":101},[],{"trials":29688,"activeCount":101},[],{"trials":29690,"activeCount":101},[],{"trials":29692,"activeCount":101},[],{"trials":29694,"activeCount":101},[29695],{"nctId":29696,"briefTitle":29697,"status":464,"phases":29698,"primaryCompletion":12881,"completion":29699,"start":4880,"enrollment":101,"conditions":29700,"interventions":29701},"NCT01915264","GLucobay M - Evaluation Of Safety and Effectiveness in Type 2 Diabetes Not Well Controlled on Monotherapy in Real Life Practice",[],"2017-03",[6888],[29681],{"intervention":29703,"totalTrials":233,"cells":29704},"Anti-VEGF injections",{"EARLY_PHASE1":29705,"PHASE1":29707,"PHASE2":29709,"PHASE3":29711,"PHASE4":29713,"NA":29715},{"trials":29706,"activeCount":101},[],{"trials":29708,"activeCount":101},[],{"trials":29710,"activeCount":101},[],{"trials":29712,"activeCount":101},[],{"trials":29714,"activeCount":101},[],{"trials":29716,"activeCount":101},[29717],{"nctId":29718,"briefTitle":29719,"status":107,"phases":29720,"primaryCompletion":2230,"completion":3609,"start":2969,"enrollment":3157,"conditions":29721,"interventions":29722},"NCT01448538","Non-Persistence\u002FNon-Adherence (NP\u002FNA) in Wet Age-related Macular Degeneration (wAMD) Patients in Germany",[],[3025],[29703],{"intervention":29724,"totalTrials":233,"cells":29725},"Lampit",{"EARLY_PHASE1":29726,"PHASE1":29728,"PHASE2":29730,"PHASE3":29732,"PHASE4":29734,"NA":29736},{"trials":29727,"activeCount":101},[],{"trials":29729,"activeCount":101},[],{"trials":29731,"activeCount":101},[],{"trials":29733,"activeCount":101},[],{"trials":29735,"activeCount":101},[],{"trials":29737,"activeCount":101},[29738],{"nctId":29739,"briefTitle":29740,"status":107,"phases":29741,"primaryCompletion":29742,"completion":29742,"start":5240,"enrollment":3062,"conditions":29743,"interventions":29744},"NCT03784391","Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina",[],"2020-04-06",[5259],[29724],{"intervention":29746,"totalTrials":233,"cells":29747},"PAH medication",{"EARLY_PHASE1":29748,"PHASE1":29750,"PHASE2":29752,"PHASE3":29754,"PHASE4":29756,"NA":29758},{"trials":29749,"activeCount":101},[],{"trials":29751,"activeCount":101},[],{"trials":29753,"activeCount":101},[],{"trials":29755,"activeCount":101},[],{"trials":29757,"activeCount":101},[],{"trials":29759,"activeCount":101},[29760],{"nctId":29761,"briefTitle":29762,"status":107,"phases":29763,"primaryCompletion":29764,"completion":29764,"start":29765,"enrollment":2701,"conditions":29766,"interventions":29767},"NCT03863990","Study Performed at Various Medical Centers to Learn More About Survival and Expected Course of Pulmonary Arterial Hypertension, a Type of High Blood Pressure in the Lungs Related to the Narrowing of the Small Blood Vessels in the Lungs",[],"2020-05-11","2019-07-15",[1715],[29746],{"intervention":24146,"totalTrials":233,"cells":29769},{"EARLY_PHASE1":29770,"PHASE1":29772,"PHASE2":29774,"PHASE3":29776,"PHASE4":29778,"NA":29780},{"trials":29771,"activeCount":101},[],{"trials":29773,"activeCount":101},[],{"trials":29775,"activeCount":101},[],{"trials":29777,"activeCount":101},[],{"trials":29779,"activeCount":101},[],{"trials":29781,"activeCount":101},[29782],{"nctId":24141,"briefTitle":24142,"status":107,"phases":29783,"primaryCompletion":1570,"completion":1570,"start":3567,"enrollment":4144,"conditions":29784,"interventions":29785},[],[1426],[6912,24146,24146],{"intervention":29787,"totalTrials":233,"cells":29788},"Qlaira or Yaz",{"EARLY_PHASE1":29789,"PHASE1":29791,"PHASE2":29793,"PHASE3":29795,"PHASE4":29797,"NA":29799},{"trials":29790,"activeCount":101},[],{"trials":29792,"activeCount":101},[],{"trials":29794,"activeCount":101},[],{"trials":29796,"activeCount":101},[],{"trials":29798,"activeCount":101},[],{"trials":29800,"activeCount":101},[29801],{"nctId":29802,"briefTitle":29803,"status":107,"phases":29804,"primaryCompletion":1570,"completion":1570,"start":8136,"enrollment":29805,"conditions":29806,"interventions":29807},"NCT01185678","Data on Oral Contraceptives Compliance in Non Stop Regimen",[],8416,[15],[29787],{"intervention":29809,"totalTrials":233,"cells":29810},"Telmisartan\u002Fhydrochlorothiazide",{"EARLY_PHASE1":29811,"PHASE1":29813,"PHASE2":29815,"PHASE3":29817,"PHASE4":29819,"NA":29821},{"trials":29812,"activeCount":101},[],{"trials":29814,"activeCount":101},[],{"trials":29816,"activeCount":101},[],{"trials":29818,"activeCount":101},[],{"trials":29820,"activeCount":101},[],{"trials":29822,"activeCount":101},[29823],{"nctId":29824,"briefTitle":29825,"status":107,"phases":29826,"primaryCompletion":5409,"completion":5409,"start":549,"enrollment":29827,"conditions":29828,"interventions":29829},"NCT01392534","Effects of Telmisartan\u002FHydrochlorothiazide Treatment in Hypertensive Patients Under Real-life Setting",[],1586,[25868],[29809],{"intervention":29831,"totalTrials":233,"cells":29832},"Clodronate",{"EARLY_PHASE1":29833,"PHASE1":29835,"PHASE2":29837,"PHASE3":29839,"PHASE4":29841,"NA":29843},{"trials":29834,"activeCount":101},[],{"trials":29836,"activeCount":101},[],{"trials":29838,"activeCount":101},[],{"trials":29840,"activeCount":101},[],{"trials":29842,"activeCount":101},[],{"trials":29844,"activeCount":101},[29845],{"nctId":29846,"briefTitle":29847,"status":107,"phases":29848,"primaryCompletion":8962,"completion":8962,"start":4588,"enrollment":1621,"conditions":29849,"interventions":29851},"NCT01198457","Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment",[],[521,187,470,29850],"Osteolysis",[29831],{"intervention":29853,"totalTrials":233,"cells":29854},"HF medication",{"EARLY_PHASE1":29855,"PHASE1":29857,"PHASE2":29859,"PHASE3":29861,"PHASE4":29863,"NA":29865},{"trials":29856,"activeCount":101},[],{"trials":29858,"activeCount":101},[],{"trials":29860,"activeCount":101},[],{"trials":29862,"activeCount":101},[],{"trials":29864,"activeCount":101},[],{"trials":29866,"activeCount":101},[29867],{"nctId":29868,"briefTitle":29869,"status":107,"phases":29870,"primaryCompletion":29871,"completion":29871,"start":29872,"enrollment":4462,"conditions":29873,"interventions":29874},"NCT05036967","A Study to Observe Treatment Patterns in Patients in Colombia Who Have Heart Failure",[],"2022-11-16","2021-08-01",[738],[29853],{"intervention":29876,"totalTrials":233,"cells":29877},"Interferon beta-1b,",{"EARLY_PHASE1":29878,"PHASE1":29880,"PHASE2":29882,"PHASE3":29884,"PHASE4":29886,"NA":29888},{"trials":29879,"activeCount":101},[],{"trials":29881,"activeCount":101},[],{"trials":29883,"activeCount":101},[],{"trials":29885,"activeCount":101},[],{"trials":29887,"activeCount":101},[],{"trials":29889,"activeCount":101},[29890],{"nctId":29891,"briefTitle":29892,"status":107,"phases":29893,"primaryCompletion":4596,"completion":1570,"start":445,"enrollment":6822,"conditions":29894,"interventions":29895},"NCT00928967","Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients",[],[35],[29876],{"intervention":5006,"totalTrials":233,"cells":29897},{"EARLY_PHASE1":29898,"PHASE1":29900,"PHASE2":29902,"PHASE3":29904,"PHASE4":29906,"NA":29908},{"trials":29899,"activeCount":101},[],{"trials":29901,"activeCount":101},[],{"trials":29903,"activeCount":101},[],{"trials":29905,"activeCount":101},[],{"trials":29907,"activeCount":101},[],{"trials":29909,"activeCount":101},[29910],{"nctId":4997,"briefTitle":4998,"status":107,"phases":29911,"primaryCompletion":5000,"completion":5001,"start":5002,"enrollment":5003,"conditions":29912,"interventions":29913},[],[4821],[42,5006],{"intervention":29915,"totalTrials":233,"cells":29916},"Hepatocellular Cancer (HCC) treatments including oral anti-cancer therapy [Nexavar (Sorafenib, BAY43-9006)]",{"EARLY_PHASE1":29917,"PHASE1":29919,"PHASE2":29921,"PHASE3":29923,"PHASE4":29925,"NA":29927},{"trials":29918,"activeCount":101},[],{"trials":29920,"activeCount":101},[],{"trials":29922,"activeCount":101},[],{"trials":29924,"activeCount":101},[],{"trials":29926,"activeCount":101},[],{"trials":29928,"activeCount":101},[29929],{"nctId":29930,"briefTitle":29931,"status":107,"phases":29932,"primaryCompletion":29933,"completion":29933,"start":23944,"enrollment":2126,"conditions":29934,"interventions":29936},"NCT02616692","HCC Patient Preferences in Japan",[],"2016-10-07",[29935],"Hepatocellular Cancer",[29915],{"intervention":29938,"totalTrials":233,"cells":29939},"EE\u002FDRSP",{"EARLY_PHASE1":29940,"PHASE1":29942,"PHASE2":29944,"PHASE3":29946,"PHASE4":29948,"NA":29950},{"trials":29941,"activeCount":101},[],{"trials":29943,"activeCount":101},[],{"trials":29945,"activeCount":101},[],{"trials":29947,"activeCount":101},[],{"trials":29949,"activeCount":101},[],{"trials":29951,"activeCount":101},[29952],{"nctId":29953,"briefTitle":29954,"status":107,"phases":29955,"primaryCompletion":4597,"completion":4597,"start":3768,"enrollment":29956,"conditions":29957,"interventions":29958},"NCT01198444","To Evaluate Compliance to Treatment Regimen (Rate of Deviations From the Prescribed Regimen) in Polish Females Treated With Different Low Dose Oral Contraceptives",[],11884,[15],[29938],{"intervention":4519,"totalTrials":233,"cells":29960},{"EARLY_PHASE1":29961,"PHASE1":29963,"PHASE2":29965,"PHASE3":29967,"PHASE4":29969,"NA":29971},{"trials":29962,"activeCount":101},[],{"trials":29964,"activeCount":101},[],{"trials":29966,"activeCount":101},[],{"trials":29968,"activeCount":101},[],{"trials":29970,"activeCount":101},[],{"trials":29972,"activeCount":101},[29973],{"nctId":4512,"briefTitle":4513,"status":107,"phases":29974,"primaryCompletion":3081,"completion":4095,"start":4515,"enrollment":4516,"conditions":29975,"interventions":29976},[],[3560,3716,21,4099],[4519,3540],{"intervention":29978,"totalTrials":233,"cells":29979},"Levonorgestrel- Intra Uterine System",{"EARLY_PHASE1":29980,"PHASE1":29982,"PHASE2":29984,"PHASE3":29986,"PHASE4":29988,"NA":29990},{"trials":29981,"activeCount":101},[],{"trials":29983,"activeCount":101},[],{"trials":29985,"activeCount":101},[],{"trials":29987,"activeCount":101},[],{"trials":29989,"activeCount":101},[],{"trials":29991,"activeCount":101},[29992],{"nctId":29993,"briefTitle":29994,"status":107,"phases":29995,"primaryCompletion":29996,"completion":29997,"start":29998,"enrollment":296,"conditions":29999,"interventions":30000},"NCT01961375","MIRENA for Contraception In InDian Subjects User continuAtion and Satisfaction Study: MIDAS Study",[],"2018-11-28","2023-09-21","2015-10-30",[15],[29978],{"intervention":30002,"totalTrials":233,"cells":30003},"Sunscreen Sport Lotion",{"EARLY_PHASE1":30004,"PHASE1":30006,"PHASE2":30008,"PHASE3":30010,"PHASE4":30012,"NA":30014},{"trials":30005,"activeCount":101},[],{"trials":30007,"activeCount":101},[],{"trials":30009,"activeCount":101},[],{"trials":30011,"activeCount":101},[],{"trials":30013,"activeCount":101},[],{"trials":30015,"activeCount":101},[30016],{"nctId":30017,"briefTitle":27723,"status":107,"phases":30018,"primaryCompletion":26727,"completion":26727,"start":26728,"enrollment":16124,"conditions":30019,"interventions":30020},"NCT02750475",[94],[18],[30002],{"intervention":30022,"totalTrials":233,"cells":30023},"Radium-223 dichloride,",{"EARLY_PHASE1":30024,"PHASE1":30026,"PHASE2":30028,"PHASE3":30030,"PHASE4":30032,"NA":30034},{"trials":30025,"activeCount":101},[],{"trials":30027,"activeCount":101},[],{"trials":30029,"activeCount":101},[],{"trials":30031,"activeCount":101},[],{"trials":30033,"activeCount":101},[],{"trials":30035,"activeCount":101},[30036],{"nctId":30037,"briefTitle":30038,"status":107,"phases":30039,"primaryCompletion":30040,"completion":30041,"start":26534,"enrollment":9365,"conditions":30042,"interventions":30044},"NCT02398526","Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases",[],"2020-05-20","2020-07-15",[30043],"Castration-Resistant Prostatic Cancer",[30022],{"intervention":30046,"totalTrials":233,"cells":30047},"Ivt. Aflibercept",{"EARLY_PHASE1":30048,"PHASE1":30050,"PHASE2":30052,"PHASE3":30054,"PHASE4":30056,"NA":30058},{"trials":30049,"activeCount":101},[],{"trials":30051,"activeCount":101},[],{"trials":30053,"activeCount":101},[],{"trials":30055,"activeCount":101},[],{"trials":30057,"activeCount":101},[],{"trials":30059,"activeCount":101},[30060],{"nctId":30061,"briefTitle":30062,"status":107,"phases":30063,"primaryCompletion":30064,"completion":30065,"start":26175,"enrollment":30066,"conditions":30067,"interventions":30068},"NCT03714308","Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.",[],"2023-03-06","2023-05-12",554,[2922],[30046],{"intervention":26334,"totalTrials":233,"cells":30070},{"EARLY_PHASE1":30071,"PHASE1":30073,"PHASE2":30075,"PHASE3":30077,"PHASE4":30079,"NA":30081},{"trials":30072,"activeCount":101},[],{"trials":30074,"activeCount":101},[],{"trials":30076,"activeCount":101},[],{"trials":30078,"activeCount":101},[],{"trials":30080,"activeCount":101},[],{"trials":30082,"activeCount":101},[30083],{"nctId":26327,"briefTitle":26328,"status":107,"phases":30084,"primaryCompletion":26330,"completion":26330,"start":26331,"enrollment":8015,"conditions":30085,"interventions":30086},[94],[18],[26334,23932],{"intervention":30088,"totalTrials":233,"cells":30089},"Stivarga",{"EARLY_PHASE1":30090,"PHASE1":30092,"PHASE2":30094,"PHASE3":30096,"PHASE4":30098,"NA":30100},{"trials":30091,"activeCount":101},[],{"trials":30093,"activeCount":101},[],{"trials":30095,"activeCount":101},[],{"trials":30097,"activeCount":101},[],{"trials":30099,"activeCount":101},[],{"trials":30101,"activeCount":101},[30102],{"nctId":30103,"briefTitle":30104,"status":107,"phases":30105,"primaryCompletion":30106,"completion":4983,"start":27348,"enrollment":30107,"conditions":30108,"interventions":30109},"NCT02042144","Safety and Effectiveness of Regorafenib",[],"2017-08-19",1034,[29],[30088],{"intervention":30111,"totalTrials":233,"cells":30112},"EE30-DRSP",{"EARLY_PHASE1":30113,"PHASE1":30115,"PHASE2":30117,"PHASE3":30119,"PHASE4":30121,"NA":30123},{"trials":30114,"activeCount":101},[],{"trials":30116,"activeCount":101},[],{"trials":30118,"activeCount":101},[],{"trials":30120,"activeCount":101},[],{"trials":30122,"activeCount":101},[],{"trials":30124,"activeCount":101},[30125],{"nctId":30126,"briefTitle":30127,"status":107,"phases":30128,"primaryCompletion":499,"completion":5409,"start":3818,"enrollment":30129,"conditions":30130,"interventions":30131},"NCT00988910","Effects of Drospirenone-containing or -Not Containing Combined Oral Contraceptives on General and Sexual Well-being",[],632,[15],[30111,30132],"Other combined oral contraceptives",{"intervention":30132,"totalTrials":233,"cells":30134},{"EARLY_PHASE1":30135,"PHASE1":30137,"PHASE2":30139,"PHASE3":30141,"PHASE4":30143,"NA":30145},{"trials":30136,"activeCount":101},[],{"trials":30138,"activeCount":101},[],{"trials":30140,"activeCount":101},[],{"trials":30142,"activeCount":101},[],{"trials":30144,"activeCount":101},[],{"trials":30146,"activeCount":101},[30147],{"nctId":30126,"briefTitle":30127,"status":107,"phases":30148,"primaryCompletion":499,"completion":5409,"start":3818,"enrollment":30129,"conditions":30149,"interventions":30150},[],[15],[30111,30132],{"intervention":30152,"totalTrials":233,"cells":30153},"Nifedipine controlled-release",{"EARLY_PHASE1":30154,"PHASE1":30156,"PHASE2":30158,"PHASE3":30160,"PHASE4":30162,"NA":30164},{"trials":30155,"activeCount":101},[],{"trials":30157,"activeCount":101},[],{"trials":30159,"activeCount":101},[],{"trials":30161,"activeCount":101},[],{"trials":30163,"activeCount":101},[],{"trials":30165,"activeCount":101},[30166],{"nctId":30167,"briefTitle":30168,"status":107,"phases":30169,"primaryCompletion":27661,"completion":13522,"start":30170,"enrollment":30171,"conditions":30172,"interventions":30173},"NCT03194633","Effectiveness and Tolerability of Long-Acting Nifedipine Gastrointestinal Therapeutic System in Chronic Kidney Disease With Uncontrolled Hypertension Patients, a Prospective, Multicenter, Observational Study",[],"2017-07-10",871,[6625],[30152],{"intervention":30175,"totalTrials":233,"cells":30176},"[111]In-ibritumomab tiuxetan",{"EARLY_PHASE1":30177,"PHASE1":30179,"PHASE2":30181,"PHASE3":30183,"PHASE4":30185,"NA":30187},{"trials":30178,"activeCount":101},[],{"trials":30180,"activeCount":101},[],{"trials":30182,"activeCount":101},[],{"trials":30184,"activeCount":101},[],{"trials":30186,"activeCount":101},[],{"trials":30188,"activeCount":101},[30189],{"nctId":30190,"briefTitle":30191,"status":107,"phases":30192,"completion":2344,"start":8109,"enrollment":11,"conditions":30193,"interventions":30195},"NCT01479387","Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan",[],[30194],"Non-Hodgkin's Lymphoma (NHL)",[30175],{"intervention":30197,"totalTrials":233,"cells":30198},"Standard of care in AF in Denmark",{"EARLY_PHASE1":30199,"PHASE1":30201,"PHASE2":30203,"PHASE3":30205,"PHASE4":30207,"NA":30209},{"trials":30200,"activeCount":101},[],{"trials":30202,"activeCount":101},[],{"trials":30204,"activeCount":101},[],{"trials":30206,"activeCount":101},[],{"trials":30208,"activeCount":101},[],{"trials":30210,"activeCount":101},[30211],{"nctId":30212,"briefTitle":30213,"status":107,"phases":30214,"primaryCompletion":5249,"completion":5249,"start":28471,"enrollment":30215,"conditions":30216,"interventions":30217},"NCT02615587","Burden of Illness in Atrial Fibrillation",[],107532,[21],[30197],{"intervention":30219,"totalTrials":233,"cells":30220},"Ventavis inhaled",{"EARLY_PHASE1":30221,"PHASE1":30223,"PHASE2":30225,"PHASE3":30227,"PHASE4":30229,"NA":30231},{"trials":30222,"activeCount":101},[],{"trials":30224,"activeCount":101},[],{"trials":30226,"activeCount":101},[],{"trials":30228,"activeCount":101},[],{"trials":30230,"activeCount":101},[],{"trials":30232,"activeCount":101},[30233],{"nctId":30234,"briefTitle":30235,"status":107,"phases":30236,"primaryCompletion":30237,"completion":1006,"start":30238,"enrollment":30239,"conditions":30240,"interventions":30241},"NCT01389271","Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years",[],"2017-03-08","2011-02-03",118,[1589],[30219],{"intervention":30243,"totalTrials":233,"cells":30244},"Multivitamins",{"EARLY_PHASE1":30245,"PHASE1":30247,"PHASE2":30249,"PHASE3":30251,"PHASE4":30253,"NA":30255},{"trials":30246,"activeCount":101},[],{"trials":30248,"activeCount":101},[],{"trials":30250,"activeCount":101},[],{"trials":30252,"activeCount":101},[],{"trials":30254,"activeCount":101},[],{"trials":30256,"activeCount":101},[30257],{"nctId":30258,"briefTitle":30259,"status":107,"phases":30260,"primaryCompletion":30261,"completion":1786,"start":30262,"enrollment":30263,"conditions":30264,"interventions":30266},"NCT05062044","A Study to Gather Information About the Progress and Outcomes of Pregnancy in Women Using Various Vitamin Support Plans Before and During Pregnancy",[],"2025-04-13","2021-12-01",1500,[30265],"Prevention of Vitamin Deficiency During and\u002For Before Pregnancy",[30243],{"intervention":30268,"totalTrials":233,"cells":30269},"VKA: Warfarin",{"EARLY_PHASE1":30270,"PHASE1":30272,"PHASE2":30274,"PHASE3":30276,"PHASE4":30278,"NA":30280},{"trials":30271,"activeCount":101},[],{"trials":30273,"activeCount":101},[],{"trials":30275,"activeCount":101},[],{"trials":30277,"activeCount":101},[],{"trials":30279,"activeCount":101},[],{"trials":30281,"activeCount":101},[30282],{"nctId":30283,"briefTitle":30284,"status":107,"phases":30285,"primaryCompletion":30286,"completion":30287,"start":30288,"enrollment":30289,"conditions":30290,"interventions":30291},"NCT02611635","Atrial Fibrillation Patient Preference Study",[],"2017-01-26","2017-02-16","2016-02-02",382,[21],[30268,30292,30293,30294,30295,30296],"NOAC: Rivaroxaban","NOAC: Dabigatran etexilate","NOAC: Apixaban","NOAC: Edoxaban","NOAC: Lixiana",{"intervention":30292,"totalTrials":233,"cells":30298},{"EARLY_PHASE1":30299,"PHASE1":30301,"PHASE2":30303,"PHASE3":30305,"PHASE4":30307,"NA":30309},{"trials":30300,"activeCount":101},[],{"trials":30302,"activeCount":101},[],{"trials":30304,"activeCount":101},[],{"trials":30306,"activeCount":101},[],{"trials":30308,"activeCount":101},[],{"trials":30310,"activeCount":101},[30311],{"nctId":30283,"briefTitle":30284,"status":107,"phases":30312,"primaryCompletion":30286,"completion":30287,"start":30288,"enrollment":30289,"conditions":30313,"interventions":30314},[],[21],[30268,30292,30293,30294,30295,30296],{"intervention":30293,"totalTrials":233,"cells":30316},{"EARLY_PHASE1":30317,"PHASE1":30319,"PHASE2":30321,"PHASE3":30323,"PHASE4":30325,"NA":30327},{"trials":30318,"activeCount":101},[],{"trials":30320,"activeCount":101},[],{"trials":30322,"activeCount":101},[],{"trials":30324,"activeCount":101},[],{"trials":30326,"activeCount":101},[],{"trials":30328,"activeCount":101},[30329],{"nctId":30283,"briefTitle":30284,"status":107,"phases":30330,"primaryCompletion":30286,"completion":30287,"start":30288,"enrollment":30289,"conditions":30331,"interventions":30332},[],[21],[30268,30292,30293,30294,30295,30296],{"intervention":30294,"totalTrials":233,"cells":30334},{"EARLY_PHASE1":30335,"PHASE1":30337,"PHASE2":30339,"PHASE3":30341,"PHASE4":30343,"NA":30345},{"trials":30336,"activeCount":101},[],{"trials":30338,"activeCount":101},[],{"trials":30340,"activeCount":101},[],{"trials":30342,"activeCount":101},[],{"trials":30344,"activeCount":101},[],{"trials":30346,"activeCount":101},[30347],{"nctId":30283,"briefTitle":30284,"status":107,"phases":30348,"primaryCompletion":30286,"completion":30287,"start":30288,"enrollment":30289,"conditions":30349,"interventions":30350},[],[21],[30268,30292,30293,30294,30295,30296],{"intervention":30295,"totalTrials":233,"cells":30352},{"EARLY_PHASE1":30353,"PHASE1":30355,"PHASE2":30357,"PHASE3":30359,"PHASE4":30361,"NA":30363},{"trials":30354,"activeCount":101},[],{"trials":30356,"activeCount":101},[],{"trials":30358,"activeCount":101},[],{"trials":30360,"activeCount":101},[],{"trials":30362,"activeCount":101},[],{"trials":30364,"activeCount":101},[30365],{"nctId":30283,"briefTitle":30284,"status":107,"phases":30366,"primaryCompletion":30286,"completion":30287,"start":30288,"enrollment":30289,"conditions":30367,"interventions":30368},[],[21],[30268,30292,30293,30294,30295,30296],{"intervention":30296,"totalTrials":233,"cells":30370},{"EARLY_PHASE1":30371,"PHASE1":30373,"PHASE2":30375,"PHASE3":30377,"PHASE4":30379,"NA":30381},{"trials":30372,"activeCount":101},[],{"trials":30374,"activeCount":101},[],{"trials":30376,"activeCount":101},[],{"trials":30378,"activeCount":101},[],{"trials":30380,"activeCount":101},[],{"trials":30382,"activeCount":101},[30383],{"nctId":30283,"briefTitle":30284,"status":107,"phases":30384,"primaryCompletion":30286,"completion":30287,"start":30288,"enrollment":30289,"conditions":30385,"interventions":30386},[],[21],[30268,30292,30293,30294,30295,30296],{"intervention":30388,"totalTrials":233,"cells":30389},"1% Hydrocortison cream",{"EARLY_PHASE1":30390,"PHASE1":30392,"PHASE2":30394,"PHASE3":30396,"PHASE4":30398,"NA":30400},{"trials":30391,"activeCount":101},[],{"trials":30393,"activeCount":101},[],{"trials":30395,"activeCount":101},[],{"trials":30397,"activeCount":101},[],{"trials":30399,"activeCount":101},[],{"trials":30401,"activeCount":101},[30402],{"nctId":30403,"briefTitle":30404,"status":464,"phases":30405,"primaryCompletion":2229,"completion":1488,"start":1629,"enrollment":101,"conditions":30406,"interventions":30408},"NCT01691209","Efficacy\u002FSafety Study to Explore a New Topical Formulation in Atopic Dermatitis",[94],[30407],"Dermatitis, Atopic",[30388],{"intervention":25371,"totalTrials":233,"cells":30410},{"EARLY_PHASE1":30411,"PHASE1":30413,"PHASE2":30415,"PHASE3":30417,"PHASE4":30419,"NA":30421},{"trials":30412,"activeCount":101},[],{"trials":30414,"activeCount":101},[],{"trials":30416,"activeCount":101},[],{"trials":30418,"activeCount":101},[],{"trials":30420,"activeCount":101},[],{"trials":30422,"activeCount":101},[30423],{"nctId":25365,"briefTitle":25366,"status":107,"phases":30424,"primaryCompletion":5999,"completion":5999,"start":3818,"enrollment":25368,"conditions":30425,"interventions":30426},[],[15],[1428,25371],{"intervention":4383,"totalTrials":233,"cells":30428},{"EARLY_PHASE1":30429,"PHASE1":30431,"PHASE2":30433,"PHASE3":30435,"PHASE4":30437,"NA":30439},{"trials":30430,"activeCount":101},[],{"trials":30432,"activeCount":101},[],{"trials":30434,"activeCount":101},[],{"trials":30436,"activeCount":101},[],{"trials":30438,"activeCount":101},[],{"trials":30440,"activeCount":101},[30441],{"nctId":4372,"briefTitle":4373,"status":107,"phases":30442,"primaryCompletion":4375,"completion":4376,"start":4377,"enrollment":4378,"conditions":30443,"interventions":30444},[],[4380,4381],[3542,4383],{"intervention":24022,"totalTrials":233,"cells":30446},{"EARLY_PHASE1":30447,"PHASE1":30449,"PHASE2":30451,"PHASE3":30453,"PHASE4":30455,"NA":30457},{"trials":30448,"activeCount":101},[],{"trials":30450,"activeCount":101},[],{"trials":30452,"activeCount":101},[],{"trials":30454,"activeCount":101},[],{"trials":30456,"activeCount":101},[],{"trials":30458,"activeCount":101},[30459],{"nctId":24015,"briefTitle":24016,"status":107,"phases":30460,"primaryCompletion":24018,"completion":24018,"start":24019,"enrollment":11,"conditions":30461,"interventions":30462},[94],[18],[23910,24022],{"intervention":30464,"totalTrials":233,"cells":30465},"Cyproterone acetate 2mg\u002Fethinylestradiol 35 μg",{"EARLY_PHASE1":30466,"PHASE1":30468,"PHASE2":30470,"PHASE3":30472,"PHASE4":30474,"NA":30476},{"trials":30467,"activeCount":101},[],{"trials":30469,"activeCount":101},[],{"trials":30471,"activeCount":101},[],{"trials":30473,"activeCount":101},[],{"trials":30475,"activeCount":101},[],{"trials":30477,"activeCount":101},[30478],{"nctId":30479,"briefTitle":30480,"status":107,"phases":30481,"primaryCompletion":30482,"completion":30482,"start":25669,"enrollment":6127,"conditions":30483,"interventions":30484},"NCT02410031","Risk Minimisation Study for Diane-35 and Its Generics",[],"2016-03-04",[8050],[30464],{"intervention":30486,"totalTrials":233,"cells":30487},"Radium 223 dichloride",{"EARLY_PHASE1":30488,"PHASE1":30490,"PHASE2":30492,"PHASE3":30494,"PHASE4":30496,"NA":30498},{"trials":30489,"activeCount":101},[],{"trials":30491,"activeCount":101},[],{"trials":30493,"activeCount":101},[],{"trials":30495,"activeCount":101},[],{"trials":30497,"activeCount":101},[],{"trials":30499,"activeCount":101},[30500],{"nctId":30501,"briefTitle":30502,"status":107,"phases":30503,"primaryCompletion":30504,"completion":30504,"start":30505,"enrollment":30506,"conditions":30507,"interventions":30508},"NCT04587427","A Study to Learn More About How Radium-223 is Being Used With Other Treatments in European Patients Who Have Not Received Radium-223 Before",[],"2023-05-30","2021-05-15",1067,[402],[30486],{"intervention":30510,"totalTrials":233,"cells":30511},"Kyleena",{"EARLY_PHASE1":30512,"PHASE1":30514,"PHASE2":30516,"PHASE3":30518,"PHASE4":30520,"NA":30522},{"trials":30513,"activeCount":101},[],{"trials":30515,"activeCount":101},[],{"trials":30517,"activeCount":101},[],{"trials":30519,"activeCount":101},[],{"trials":30521,"activeCount":101},[],{"trials":30523,"activeCount":101},[30524],{"nctId":30525,"briefTitle":30526,"status":107,"phases":30527,"primaryCompletion":30528,"completion":30529,"start":17103,"enrollment":30530,"conditions":30531,"interventions":30532},"NCT03182140","KYleena Satisfaction Study \u002F Observational Study on User Satisfaction With the Levonorgestrel Intrauterine Delivery System Kyleena (LNG-IUS 12) in New Contraceptive Users and After Switching From Another Contraceptive Method",[],"2019-12-19","2020-03-31",1134,[15],[30510],{"intervention":30534,"totalTrials":233,"cells":30535},"Inhaled iloprost",{"EARLY_PHASE1":30536,"PHASE1":30538,"PHASE2":30540,"PHASE3":30542,"PHASE4":30544,"NA":30546},{"trials":30537,"activeCount":101},[],{"trials":30539,"activeCount":101},[],{"trials":30541,"activeCount":101},[],{"trials":30543,"activeCount":101},[],{"trials":30545,"activeCount":101},[],{"trials":30547,"activeCount":101},[30548],{"nctId":30549,"briefTitle":30550,"status":107,"phases":30551,"primaryCompletion":30552,"completion":12463,"start":30553,"enrollment":6503,"conditions":30554,"interventions":30555},"NCT01355380","Efficacy of Ventavis Used in Real-life Setting.",[],"2016-04-28","2010-08-05",[1715],[30534],{"intervention":24494,"totalTrials":233,"cells":30557},{"EARLY_PHASE1":30558,"PHASE1":30560,"PHASE2":30562,"PHASE3":30564,"PHASE4":30566,"NA":30568},{"trials":30559,"activeCount":101},[],{"trials":30561,"activeCount":101},[],{"trials":30563,"activeCount":101},[],{"trials":30565,"activeCount":101},[],{"trials":30567,"activeCount":101},[],{"trials":30569,"activeCount":101},[30570],{"nctId":24488,"briefTitle":24489,"status":107,"phases":30571,"primaryCompletion":3609,"completion":3989,"start":3793,"enrollment":24491,"conditions":30572,"interventions":30573},[],[8017],[5939,24494],{"intervention":30575,"totalTrials":233,"cells":30576},"Available Recombinant, and Human Factor VIII products incl. Kogenate FS",{"EARLY_PHASE1":30577,"PHASE1":30579,"PHASE2":30581,"PHASE3":30583,"PHASE4":30585,"NA":30587},{"trials":30578,"activeCount":101},[],{"trials":30580,"activeCount":101},[],{"trials":30582,"activeCount":101},[],{"trials":30584,"activeCount":101},[],{"trials":30586,"activeCount":101},[],{"trials":30588,"activeCount":101},[30589],{"nctId":30590,"briefTitle":30591,"status":107,"phases":30592,"primaryCompletion":7840,"completion":17826,"start":30593,"enrollment":26696,"conditions":30594,"interventions":30595},"NCT02396862","Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment",[],"2015-12-09",[24],[30575],{"intervention":30597,"totalTrials":233,"cells":30598},"Glucobay ODT",{"EARLY_PHASE1":30599,"PHASE1":30601,"PHASE2":30603,"PHASE3":30605,"PHASE4":30607,"NA":30609},{"trials":30600,"activeCount":101},[],{"trials":30602,"activeCount":101},[],{"trials":30604,"activeCount":101},[],{"trials":30606,"activeCount":101},[],{"trials":30608,"activeCount":101},[],{"trials":30610,"activeCount":101},[30611],{"nctId":30612,"briefTitle":30613,"status":107,"phases":30614,"primaryCompletion":6677,"completion":2918,"start":1570,"enrollment":25285,"conditions":30615,"interventions":30616},"NCT01685502","Special Drug Use Investigation of Glucobay OD",[],[8425],[30597],{"intervention":4419,"totalTrials":233,"cells":30618},{"EARLY_PHASE1":30619,"PHASE1":30621,"PHASE2":30623,"PHASE3":30625,"PHASE4":30627,"NA":30629},{"trials":30620,"activeCount":101},[],{"trials":30622,"activeCount":101},[],{"trials":30624,"activeCount":101},[],{"trials":30626,"activeCount":101},[],{"trials":30628,"activeCount":101},[],{"trials":30630,"activeCount":101},[30631],{"nctId":4413,"briefTitle":4414,"status":107,"phases":30632,"primaryCompletion":4095,"completion":4095,"start":4258,"enrollment":4416,"conditions":30633,"interventions":30634},[],[3560,3716,21,4099],[3542,2202,4419],{"intervention":27465,"totalTrials":233,"cells":30636},{"EARLY_PHASE1":30637,"PHASE1":30639,"PHASE2":30641,"PHASE3":30643,"PHASE4":30645,"NA":30647},{"trials":30638,"activeCount":101},[],{"trials":30640,"activeCount":101},[],{"trials":30642,"activeCount":101},[],{"trials":30644,"activeCount":101},[],{"trials":30646,"activeCount":101},[],{"trials":30648,"activeCount":101},[30649],{"nctId":27459,"briefTitle":27460,"status":107,"phases":30650,"completion":2919,"start":4736,"enrollment":27462,"conditions":30651,"interventions":30652},[],[15],[27437,27465],{"intervention":25783,"totalTrials":233,"cells":30654},{"EARLY_PHASE1":30655,"PHASE1":30657,"PHASE2":30659,"PHASE3":30661,"PHASE4":30663,"NA":30665},{"trials":30656,"activeCount":101},[],{"trials":30658,"activeCount":101},[],{"trials":30660,"activeCount":101},[],{"trials":30662,"activeCount":101},[],{"trials":30664,"activeCount":101},[],{"trials":30666,"activeCount":101},[30667],{"nctId":25777,"briefTitle":25778,"status":107,"phases":30668,"primaryCompletion":1352,"completion":1352,"start":2970,"enrollment":25780,"conditions":30669,"interventions":30670},[],[6625],[6847,25783],{"intervention":30672,"totalTrials":233,"cells":30673},"Pritor",{"EARLY_PHASE1":30674,"PHASE1":30676,"PHASE2":30678,"PHASE3":30680,"PHASE4":30682,"NA":30684},{"trials":30675,"activeCount":101},[],{"trials":30677,"activeCount":101},[],{"trials":30679,"activeCount":101},[],{"trials":30681,"activeCount":101},[],{"trials":30683,"activeCount":101},[],{"trials":30685,"activeCount":101},[30686],{"nctId":30687,"briefTitle":30688,"status":107,"phases":30689,"primaryCompletion":1497,"completion":1497,"start":4750,"enrollment":30690,"conditions":30691,"interventions":30692},"NCT00471003","The Real-Life Efficacy and Safety of Telmisartan in Patients With Arterial Hypertension",[],5448,[6625],[30672],{"intervention":30694,"totalTrials":233,"cells":30695},"BAY98-7071_EE20\u002FDRSP\u002FL-5-MTHF",{"EARLY_PHASE1":30696,"PHASE1":30698,"PHASE2":30700,"PHASE3":30702,"PHASE4":30704,"NA":30706},{"trials":30697,"activeCount":101},[],{"trials":30699,"activeCount":101},[],{"trials":30701,"activeCount":101},[],{"trials":30703,"activeCount":101},[],{"trials":30705,"activeCount":101},[],{"trials":30707,"activeCount":101},[30708],{"nctId":30709,"briefTitle":30710,"status":107,"phases":30711,"primaryCompletion":30712,"completion":30712,"start":30713,"enrollment":30263,"conditions":30714,"interventions":30715},"NCT02159261","Assess Satisfaction of Patients and Physicians With Results of Yaz Plus Treatment for 13 Cycles",[],"2016-08-14","2014-07-15",[15],[30694],{"intervention":30717,"totalTrials":233,"cells":30718},"Darifenacin, Emselex",{"EARLY_PHASE1":30719,"PHASE1":30721,"PHASE2":30723,"PHASE3":30725,"PHASE4":30727,"NA":30729},{"trials":30720,"activeCount":101},[],{"trials":30722,"activeCount":101},[],{"trials":30724,"activeCount":101},[],{"trials":30726,"activeCount":101},[],{"trials":30728,"activeCount":101},[],{"trials":30730,"activeCount":101},[30731],{"nctId":30732,"briefTitle":30733,"status":107,"phases":30734,"primaryCompletion":3724,"completion":3724,"start":6048,"enrollment":30735,"conditions":30736,"interventions":30737},"NCT00786448","Post Marketing Surveillance Study on Emselex After Launch in Germany",[],5821,[9474],[30717],{"intervention":2572,"totalTrials":233,"cells":30739},{"EARLY_PHASE1":30740,"PHASE1":30742,"PHASE2":30744,"PHASE3":30746,"PHASE4":30748,"NA":30750},{"trials":30741,"activeCount":101},[],{"trials":30743,"activeCount":101},[],{"trials":30745,"activeCount":101},[],{"trials":30747,"activeCount":101},[],{"trials":30749,"activeCount":101},[],{"trials":30751,"activeCount":101},[30752],{"nctId":2561,"briefTitle":2562,"status":107,"phases":30753,"primaryCompletion":2564,"completion":2564,"start":2565,"enrollment":2566,"conditions":30754,"interventions":30755},[],[2568,2569,2570],[2572,2573,1011,42],{"intervention":2573,"totalTrials":233,"cells":30757},{"EARLY_PHASE1":30758,"PHASE1":30760,"PHASE2":30762,"PHASE3":30764,"PHASE4":30766,"NA":30768},{"trials":30759,"activeCount":101},[],{"trials":30761,"activeCount":101},[],{"trials":30763,"activeCount":101},[],{"trials":30765,"activeCount":101},[],{"trials":30767,"activeCount":101},[],{"trials":30769,"activeCount":101},[30770],{"nctId":2561,"briefTitle":2562,"status":107,"phases":30771,"primaryCompletion":2564,"completion":2564,"start":2565,"enrollment":2566,"conditions":30772,"interventions":30773},[],[2568,2569,2570],[2572,2573,1011,42],{"intervention":30775,"totalTrials":233,"cells":30776},"Aprotinin",{"EARLY_PHASE1":30777,"PHASE1":30779,"PHASE2":30781,"PHASE3":30783,"PHASE4":30785,"NA":30787},{"trials":30778,"activeCount":101},[],{"trials":30780,"activeCount":101},[],{"trials":30782,"activeCount":101},[],{"trials":30784,"activeCount":101},[],{"trials":30786,"activeCount":101},[],{"trials":30788,"activeCount":101},[30789],{"nctId":30790,"briefTitle":30791,"status":687,"phases":30792,"conditions":30793,"interventions":30794},"NCT00611845","Aprotinin US Special Access Protocol",[],[8247],[30775],{"intervention":25728,"totalTrials":233,"cells":30796},{"EARLY_PHASE1":30797,"PHASE1":30799,"PHASE2":30801,"PHASE3":30803,"PHASE4":30805,"NA":30807},{"trials":30798,"activeCount":101},[],{"trials":30800,"activeCount":101},[],{"trials":30802,"activeCount":101},[],{"trials":30804,"activeCount":101},[],{"trials":30806,"activeCount":101},[],{"trials":30808,"activeCount":101},[30809],{"nctId":25719,"briefTitle":25720,"status":107,"phases":30810,"primaryCompletion":25722,"completion":25722,"start":25723,"enrollment":25724,"conditions":30811,"interventions":30812},[],[25726],[7023,25728,25729],{"intervention":25729,"totalTrials":233,"cells":30814},{"EARLY_PHASE1":30815,"PHASE1":30817,"PHASE2":30819,"PHASE3":30821,"PHASE4":30823,"NA":30825},{"trials":30816,"activeCount":101},[],{"trials":30818,"activeCount":101},[],{"trials":30820,"activeCount":101},[],{"trials":30822,"activeCount":101},[],{"trials":30824,"activeCount":101},[],{"trials":30826,"activeCount":101},[30827],{"nctId":25719,"briefTitle":25720,"status":107,"phases":30828,"primaryCompletion":25722,"completion":25722,"start":25723,"enrollment":25724,"conditions":30829,"interventions":30830},[],[25726],[7023,25728,25729]]